{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"Nutrition &amp; Health Reference","text":"<p>Welcome to a comprehensive, evidence-based reference covering the full spectrum of human nutrition \u2014 from vitamins and minerals to neurotransmitter biochemistry.</p>"},{"location":"#whats-inside","title":"What's Inside","text":"Section Topics Vitamins All 13 vitamins \u2014 A, B1\u2013B12, C, D, E, K \u2014 with RDAs, deficiency signs, drug interactions Minerals 16 minerals \u2014 from calcium and magnesium to copper, zinc, selenium, and manganese Amino Acids 16 amino acids \u2014 essential and conditionally essential \u2014 with metabolism and clinical notes Neurotransmitters Serotonin, dopamine, GABA, glutamate, ACh, histamine, melatonin, endorphins + cofactor master reference Antioxidants Glutathione, CoQ10, resveratrol, lycopene, lutein, zeaxanthin, polyphenols, flavonoids Fatty Acids Omega-3 (EPA, DHA, ALA), Omega-6, Omega-9 \u2014 structure, function, and clinical use Gut Health Lactobacillus, Bifidobacterium, prebiotic fibers, and the gut-brain axis Phytonutrients Carotenoids, flavonoids, glucosinolates, and phytosterols Macronutrients Carbohydrates, proteins, dietary fats, and water Performance Creatine, beta-alanine, caffeine, L-carnitine, and workout nutrition Detox Pathways Phase 1\u20133 liver detox, methylation, glucuronidation, sulfation, and heavy metal detox Deep Dives COMT, MAO, Krebs cycle, and methylation pathway mechanics"},{"location":"#quick-reference-indices","title":"Quick Reference Indices","text":"<ul> <li>\ud83d\udd0d Deficiency Index \u2014 symptoms mapped to nutrient deficiencies</li> <li>\ud83e\udd66 Food Sources Index \u2014 nutrients mapped to food sources</li> <li>\u26a1 Interactions \u2014 nutrient-drug and nutrient-nutrient interactions</li> </ul>"},{"location":"#how-to-use-this-site","title":"How to Use This Site","text":"<p>Use the top navigation tabs to browse by category, or use the search bar (top right or press <code>/</code>) to find any nutrient, enzyme, pathway, or symptom instantly.</p>"},{"location":"content_roadmap/","title":"NutritionAndHealth \u2014 Content Roadmap","text":""},{"location":"content_roadmap/#completed","title":"\u2705 Completed","text":"Folder Contents <code>vitamins/</code> All 13 vitamins (A, B1, B2, B3, B5, B6, B7, B9, B12, C, D, E, K) <code>minerals/</code> All 16 essential minerals (Calcium, Chloride, Chromium, Copper, Fluoride, Iodine, Iron, Magnesium, Manganese, Molybdenum, Phosphorus, Potassium, Selenium, Sodium, Sulfur, Zinc) <code>amino_acids/</code> 9 essential (Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine) + 7 conditionally essential (Arginine, Cysteine, Glutamine, Glycine, Proline, Serine, Tyrosine) <code>fatty_acids/</code> Omega-3: ALA, EPA, DHA \u00b7 Omega-6: Linoleic Acid, Arachidonic Acid \u00b7 Omega-9: Oleic Acid <code>macronutrients/</code> Carbohydrates (types, GI, fibre), Proteins (complete vs incomplete, digestibility), Dietary Fats (saturated, unsaturated, trans), Water (requirements, electrolyte balance) <code>antioxidants/</code> Glutathione, CoQ10, Resveratrol, Lycopene, Lutein, Zeaxanthin, Beta-carotene, Polyphenols, Flavonoids (all 6 subclasses) <code>phytonutrients/</code> Carotenoids, Flavonoids, Glucosinolates, Phytosterols <code>gut_health/</code> Probiotics: Lactobacillus, Bifidobacterium \u00b7 Prebiotics: Inulin, FOS, Pectin \u00b7 Gut-brain axis <code>performance/</code> Creatine, Beta-alanine, Caffeine, L-Carnitine \u00b7 Pre/intra/post-workout nutrition <code>detox_pathways/</code> Overview \u00b7 Phase I (CYP450 biotransformation) \u00b7 Phase II (Glucuronidation, Sulfation, Glutathione conjugation, Methylation, Acetylation, Amino acid conjugation) \u00b7 Phase III (ABC transporters, biliary &amp; renal excretion) \u00b7 Methylation (one-carbon cycle, MTHFR, SAM) \u00b7 Glutathione pathway (Nrf2, GST, GPx) \u00b7 Sulfation (SULT enzymes, PAPS) \u00b7 Glucuronidation (UGT enzymes, EHC) \u00b7 Heavy metal detox (Hg, Pb, As, Cd, chelation) \u00b7 Gut microbiome detox (\u03b2-glucuronidase, TMAO, bile acids, SCFAs) \u00b7 Liver support nutrients <code>neuroscience/</code> Neuroplasticity (BDNF, LTP, NMDA, nutrients) \u00b7 HPA Axis (cortisol, ACTH, CRH, stress nutrient depletion, adrenal recovery) \u00b7 Sleep Architecture (adenosine, circadian rhythm, melatonin, nutrients per sleep stage) \u00b7 Kynurenine Pathway (tryptophan diversion, IDO/TDO, QUIN neurotoxicity, depression link) <p>| <code>deficiency_index.md</code> | Symptom \u2192 likely deficiency lookup table (by body system) | | <code>food_sources_index.md</code> | Food \u2192 nutrients provided (reverse lookup, with bioavailability notes) | | <code>interactions.md</code> | Nutrient synergies &amp; antagonisms, drug\u2013nutrient interactions, timing guide |</p>"},{"location":"content_roadmap/#planned","title":"\ud83d\udd1c Planned","text":""},{"location":"content_roadmap/#inflammation-immune","title":"Inflammation &amp; Immune","text":"Folder / File Contents <code>inflammation/eicosanoids.md</code> Prostaglandins, leukotrienes, thromboxanes; COX/LOX enzymes; omega-3 vs omega-6 balance <code>inflammation/cytokines_immunity.md</code> IL-6, TNF-\u03b1, NF-\u03baB; modulation by vitamin D, zinc, selenium <code>inflammation/mast_cell_histamine.md</code> MCAS, histamine overload, low-histamine diet; ties to DAO/HNMT content"},{"location":"content_roadmap/#genetics-biochemistry","title":"Genetics &amp; Biochemistry","text":"Folder / File Contents <code>genetics/snps_nutrigenomics.md</code> MTHFR, COMT, MAO-A, VDR, APOE; how variants change nutritional requirements <code>genetics/mitochondria_energy.md</code> ETC complexes I\u2013V; CoQ10, NAD\u207a/NADH, mitophagy; nutrients per complex (B2, B3, lipoic acid, Fe, Cu) <code>genetics/insulin_mtor.md</code> Chromium, vanadium, leucine; mTOR vs AMPK; caloric restriction mimetics"},{"location":"content_roadmap/#organ-system-specific","title":"Organ &amp; System-Specific","text":"Folder / File Contents <code>systems/bone_connective_tissue.md</code> Collagen synthesis (Vit C, Proline, Glycine, Cu); osteocalcin (K2, D); Ca-Mg-P balance <code>systems/thyroid_axis.md</code> T4\u2192T3 conversion (Se, Zn, Fe); iodine; thyroid-gut link; stress/fasting effects on T3 <code>systems/liver_physiology.md</code> Fatty liver (choline, inositol, betaine); bile production; cholesterol synthesis"},{"location":"content_roadmap/#clinical-applied","title":"Clinical &amp; Applied","text":"Folder / File Contents <code>clinical/therapeutic_protocols.md</code> Condition-specific nutrient stacks: depression, anxiety, ADHD, insomnia <code>clinical/lab_biomarkers.md</code> What to test and interpret: homocysteine, ferritin, 25-OH D, MMA, TMAO, organic acids <code>clinical/fasting_metabolic.md</code> Ketogenesis, beta-hydroxybutyrate signalling, autophagy, refeeding syndrome"},{"location":"content_roadmap/#adaptogens-botanicals","title":"Adaptogens &amp; Botanicals","text":"Folder / File Contents <code>botanicals/adaptogens.md</code> Ashwagandha (HPA), Rhodiola (MAO inhibition), Panax ginseng (cortisol/fatigue); mechanisms <code>botanicals/medicinal_mushrooms.md</code> Lion's Mane (NGF/BDNF), Reishi (immune), Cordyceps (mitochondria)"},{"location":"content_roadmap/#cross-cutting-indexes","title":"Cross-Cutting Indexes","text":"File Contents <code>bioavailability_guide.md</code> Nutrient forms ranked by absorption (e.g. Mg glycinate &gt; oxide; methylfolate &gt; folic acid) <code>timing_and_stacking.md</code> When to take what, with what, and why; extends <code>interactions.md</code> <code>conditions_index.md</code> Condition \u2192 relevant nutrient protocols (ADHD, depression, autoimmune, IBS, etc.)"},{"location":"deficiency_index/","title":"Deficiency Index \u2014 Symptom \u2192 Likely Deficiency","text":"<p>A quick-reference lookup table: start with a symptom or sign and find the likely nutrient deficiencies to investigate. Organised by body system.</p> <p>Usage note: Deficiency symptoms are rarely pathognomonic \u2014 multiple deficiencies often coexist, and symptoms overlap with non-nutritional causes. Use this as a starting point, not a diagnostic tool.</p>"},{"location":"deficiency_index/#neurological-cognitive","title":"Neurological &amp; Cognitive","text":"Symptom / Sign Likely Deficiency Key Notes Peripheral neuropathy (glove-and-stocking) B1 (Thiamine), B6, B12, E B12 most common; B6 excess also causes neuropathy Memory loss / dementia picture B1, B3, B12, B9 (Folate) B1 \u2192 Wernicke-Korsakoff; B12 \u2192 subacute combined degeneration Depression / low mood B9, B12, D, Omega-3 (EPA/DHA), Magnesium, Zinc, Tryptophan Folate/B12 \u2192 hyperhomocysteinaemia affecting methylation Anxiety / irritability B1, B3, B6, Magnesium, Zinc Magnesium deficiency is highly underdiagnosed Confusion / delirium B1 (Wernicke's), B3 (Pellagra), B12, Sodium (hyponatraemia) B1 deficiency most acute risk Poor concentration / brain fog B12, D, Iron, Omega-3, Iodine Iodine critical for thyroid-driven cognition Headaches Magnesium, B2 (Riboflavin), CoQ10 Magnesium + B2 used in migraine prophylaxis Seizures B6 (neonatal epilepsy), Calcium, Magnesium Pyridoxine-dependent epilepsy \u2014 rare but important Optic neuropathy B12, B1, Copper \"Nutritional amblyopia\" \u2014 bilateral visual loss"},{"location":"deficiency_index/#musculoskeletal","title":"Musculoskeletal","text":"Symptom / Sign Likely Deficiency Key Notes Muscle cramps / tetany Calcium, Magnesium, Potassium, B1 Check serum Ca\u00b2\u207a, Mg\u00b2\u207a, K\u207a Muscle weakness (proximal myopathy) D, Potassium, Magnesium, Selenium Vitamin D myopathy often misattributed to ageing Bone pain / tenderness D, Calcium, Phosphorus Osteomalacia \u2014 diffuse bone aching Rickets (children) D, Calcium, Phosphorus Bowing of weight-bearing bones Osteoporosis Calcium, D, K2, Magnesium, Protein Multifactorial \u2014 always multifactorial Joint pain D, Omega-3, Glucosinolates (anti-inflammatory) Poor wound healing C, Zinc, Vitamin A, Protein (Arginine/Glycine) C needed for hydroxylation of proline/lysine in collagen Growth stunting (children) Zinc, Protein (EAAs), Iodine, D Zinc most common single-nutrient cause globally"},{"location":"deficiency_index/#haematological","title":"Haematological","text":"Symptom / Sign Likely Deficiency Key Notes Macrocytic (megaloblastic) anaemia B12, B9 (Folate) Distinguish: B12 also has neurological signs Microcytic (hypochromic) anaemia Iron, B6, Copper Iron deficiency most common worldwide Normocytic anaemia Protein (EPO synthesis), Copper, B6 Pallor / fatigue / dyspnoea on exertion Iron, B12, B9, B6, Copper Easy bruising / petechiae C (Scurvy), K, Vitamin K2 Prolonged bleeding / clotting defect Vitamin K PT/INR elevated Haemolytic anaemia Vitamin E, Selenium, Copper E deficiency rare except in fat malabsorption"},{"location":"deficiency_index/#dermatological","title":"Dermatological","text":"Symptom / Sign Likely Deficiency Key Notes Dermatitis (pellagrous, sun-exposed areas) B3 (Niacin) Casal's necklace rash; the \"4 Ds\" of pellagra Seborrhoeic dermatitis / greasy scaly rash B2, B6, Biotin (B7), Zinc Periorificially distributed Angular cheilitis / cracked mouth corners B2, B3, B6, Iron, Zinc Glossitis (swollen smooth tongue) B2, B3, B9, B12, Iron Atrophic glossitis \u2014 magenta/beefy red tongue Perifollicular haemorrhages / follicular hyperkeratosis Vitamin C (Scurvy) Corkscrew hairs also typical Dry/scaly skin (ichthyosis-like) A, EFAs (Omega-3/6), Biotin Acne / poor skin healing Zinc, A, D Hair loss (diffuse) Iron, Zinc, Biotin (B7), Protein, D Biotin deficiency rare unless consuming raw egg whites (avidin) Nail changes (koilonychia = spoon nails) Iron Nail changes (Beau's lines or leukonychia) Zinc, Protein"},{"location":"deficiency_index/#ocular","title":"Ocular","text":"Symptom / Sign Likely Deficiency Key Notes Night blindness Vitamin A Earliest sign of A deficiency Xerophthalmia / Bitot's spots Vitamin A Severe deficiency; leading cause of preventable blindness Corneal vascularisation B2 (Riboflavin) Dry eyes Omega-3 (DHA/EPA), A Macular degeneration risk Lutein, Zeaxanthin, Omega-3, Zinc Cataracts (oxidative) C, E, Lutein, Riboflavin"},{"location":"deficiency_index/#cardiovascular","title":"Cardiovascular","text":"Symptom / Sign Likely Deficiency Key Notes Cardiomyopathy B1 (Wet Beri-beri), Selenium (Keshan disease), Carnitine Elevated homocysteine / CV risk B9, B12, B6 Methylation pathway impairment Hypertension Magnesium, Potassium, Calcium, D, Omega-3 Peripheral oedema B1 (wet beri-beri), Protein (hypoalbuminaemia) Arrhythmia Potassium, Magnesium, Calcium Hypomagnesaemia \u2192 digoxin toxicity risk"},{"location":"deficiency_index/#gastrointestinal","title":"Gastrointestinal","text":"Symptom / Sign Likely Deficiency Key Notes Diarrhoea B3, Zinc, Magnesium (excess), Probiotics imbalance \"3 Ds\" of pellagra include diarrhoea Constipation Magnesium (low intake), inadequate fibre, water Glossitis / stomatitis B2, B3, B12, Iron Anorexia / reduced appetite Zinc, B1, B3 Zinc deficiency impairs taste (hypogeusia) Dysphagia (in Plummer-Vinson) Iron Iron-deficiency associated oesophageal web Dysbiosis / altered gut flora Prebiotics (Inulin, FOS), Probiotics (Lactobacillus/Bifidobacterium)"},{"location":"deficiency_index/#endocrine-metabolic","title":"Endocrine &amp; Metabolic","text":"Symptom / Sign Likely Deficiency Key Notes Goitre / hypothyroidism Iodine, Selenium Selenium needed to convert T4 \u2192 T3 Poor insulin sensitivity Chromium, Magnesium, D, Omega-3 Adrenal fatigue / poor stress response B5 (Pantothenic acid), C, Magnesium B5 \u2192 CoA synthesis for adrenal steroidogenesis Low testosterone Zinc, D, Magnesium Dysmenorrhoea (painful periods) Magnesium, Omega-3, D, Iron"},{"location":"deficiency_index/#immune","title":"Immune","text":"Symptom / Sign Likely Deficiency Key Notes Frequent infections Zinc, Vitamins A, C, D, Selenium Zinc deficiency impairs T-cell function Poor vaccine response Zinc, D, Selenium Slow healing / recurrent ulcers Zinc, C, A, Protein (Arginine) Excessive inflammation Omega-3 (EPA/DHA), D, Polyphenols, Resveratrol"},{"location":"deficiency_index/#psychiatric-behavioural","title":"Psychiatric &amp; Behavioural","text":"Symptom / Sign Likely Deficiency Key Notes Psychosis (pellagra psychosis) B3 (Niacin) \"Dementia\" in pellagra is a psychiatric picture Neural tube defects (pregnancy) B9 (Folate) Supplementation must be pre-conception Pica (craving non-food items) Iron, Zinc Seasonal mood changes Vitamin D"},{"location":"deficiency_index/#reproductive","title":"Reproductive","text":"Symptom / Sign Likely Deficiency Key Notes Infertility (male) Zinc, Selenium, Antioxidants (CoQ10, E, C) Oxidative damage to sperm Infertility (female) Iron, B9, D, Iodine Neural tube defects (offspring) B9 (Folate) 400 \u00b5g/day pre-conception + first trimester Poor foetal growth / SGA Zinc, Iron, B12, Omega-3"},{"location":"deficiency_index/#three-ds-four-ds-mnemonic-summary","title":"Three Ds, Four Ds, Mnemonic Summary","text":"Condition Classic Mnemonic Nutrient Scurvy Bleeding gums, perifollicular haemorrhage, poor wound healing Vitamin C Rickets/Osteomalacia Bone pain, deformity, weakness Vitamin D + Calcium Pellagra Dermatitis, Diarrhoea, Dementia (Death) B3 (Niacin) / Tryptophan Beri-beri Dry (neuro) / Wet (cardiac + oedema) B1 (Thiamine) Wernicke-Korsakoff Confusion, Ophthalmoplegia, Ataxia \u2192 Korsakoff amnesia B1 (Thiamine) Ariboflavinosis Angular cheilitis, corneal vascularisation, seborrhoeic dermatitis B2 (Riboflavin) Hypocalcaemic tetany \"Bones, Stones, Groans, Moans\" (hypercalcaemia) / Chvostek &amp; Trousseau (hypocalcaemia) Calcium Keshan disease Cardiomyopathy (endemic China) Selenium <p>Cross-reference: food_sources_index.md \u00b7 interactions.md</p>"},{"location":"food_sources_index/","title":"Food Sources Index \u2014 Food \u2192 Nutrients Provided","text":"<p>A reverse-lookup index: start with a food and find which nutrients it contributes significantly to. Organised by food category. Bioavailability notes are included where relevant.</p> <p>Abbreviations: AA = amino acids \u00b7 EAA = essential amino acids \u00b7 MUFA = monounsaturated fatty acid \u00b7 PUFA = polyunsaturated fatty acid \u00b7 SFA = saturated fatty acid \u00b7 DV = % Daily Value (US, per serving)</p>"},{"location":"food_sources_index/#meat-poultry-eggs","title":"Meat, Poultry &amp; Eggs","text":"Food Key Nutrients Bioavailability Notes Beef (lean, cooked) B12, Zinc, Iron (haem), Selenium, B3, B6, Phosphorus, Creatine, all EAAs, Carnitine Haem iron absorbed at 15\u201335% vs 2\u201320% non-haem Chicken breast (cooked) B3, B6, Phosphorus, Selenium, all EAAs, Carnitine Complete protein; lower fat than red meat Chicken liver Vitamin A (retinol), B12, B2, B9 (Folate), Iron, Copper, Zinc, CoQ10, all EAAs Pre-formed retinol \u2014 very high; caution in pregnancy (teratogen above ~3,000 \u00b5g/day) Beef liver B12, Vitamin A, B2, B9, Iron, Copper, Zinc, B5, CoQ10, all EAAs Most nutrient-dense single food; Copper content among highest of any food Eggs (whole) B12, B2, B5, B7 (Biotin), D, K2 (MK-4), Selenium, Choline, Lutein, Zeaxanthin, all EAAs Raw avidin in egg white binds biotin \u2014 cook eggs to destroy avidin Egg yolk D, K2, A, B12, B2, B5, Choline, Lutein, Zeaxanthin, Phospholipids Choline: ~125 mg/yolk Turkey B3, B6, B12, Selenium, Tryptophan, Zinc, all EAAs High tryptophan \u2192 serotonin/melatonin precursor Lamb B12, Zinc, Iron (haem), Selenium, B3, Carnitine, all EAAs Similar profile to beef"},{"location":"food_sources_index/#seafood-fish","title":"Seafood &amp; Fish","text":"Food Key Nutrients Bioavailability Notes Salmon (wild, cooked) EPA, DHA (Omega-3), D, B12, B3, B6, Selenium, K1, Astaxanthin, all EAAs Wild &gt; farmed for Omega-3 ratio Sardines (canned, with bones) EPA, DHA, D, B12, Calcium (bones), Selenium, CoQ10, all EAAs Bones significantly boost calcium content Mackerel EPA, DHA, D, B12, Selenium, Magnesium, CoQ10 One of highest Omega-3 sources Herring EPA, DHA, D, B12, Selenium, CoQ10 Traditional source in Northern Europe Tuna (canned in water) B3, B12, Selenium, D, all EAAs Albacore higher in mercury than skipjack; limit in pregnancy Cod B12, B3, Selenium, Iodine, Phosphorus, all EAAs Low fat; good lean protein source Oysters Zinc (highest of any food), B12, Copper, Selenium, Iron, D 6 oysters can provide ~33 mg zinc (300% DV) Mussels B12, Iron, Selenium, Manganese, Omega-3, Zinc Excellent complete protein Shrimp/Prawns Iodine, Selenium, B12, Astaxanthin, Phosphorus, all EAAs Good low-calorie protein Seaweed (nori, kelp) Iodine, K1, B12 (in nori, though poorly bioavailable \u2014 caution), Calcium, Magnesium, Fucoidan B12 in seaweed is largely inactive analogue"},{"location":"food_sources_index/#dairy","title":"Dairy","text":"Food Key Nutrients Bioavailability Notes Milk (whole cow's) Calcium, D (fortified), B12, B2, B5, Phosphorus, Potassium, Iodine, all EAAs Highly bioavailable calcium; Iodine content varies with cow feed Yogurt (plain, full-fat) Calcium, B12, B2, Probiotics (Lactobacillus, Bifidobacterium), Iodine, complete protein Live cultures improve lactose digestion Cheese (hard, e.g. Parmesan) Calcium, B12, K2 (MK-4 in aged cheeses), Phosphorus, Selenium, Zinc, complete protein K2 highest in aged fermented cheeses Kefir Calcium, B12, B2, Probiotics (30+ strains), Phosphorus Broader probiotic diversity than yogurt Butter / Ghee Vitamins A, D, E, K2 (grass-fed), Butyrate (short-chain fatty acid) Grass-fed butter has ~5\u00d7 more K2 than grain-fed Whey protein All EAAs (highest BCAA content), B12, Calcium, Selenium Fastest-digesting complete protein; high leucine triggers MPS"},{"location":"food_sources_index/#legumes-pulses","title":"Legumes &amp; Pulses","text":"Food Key Nutrients Bioavailability Notes Lentils (cooked) B9 (Folate), Iron, Manganese, Molybdenum, B1, B6, Copper, Phosphorus, Fibre (prebiotic), Protein Non-haem iron \u2014 pair with Vitamin C to improve absorption Chickpeas (cooked) B9, Manganese, Copper, Iron, Phosphorus, B6, Zinc, Fibre, Protein Soaking / sprouting reduces phytates Black beans (cooked) B9, Manganese, Iron, Magnesium, Phosphorus, B1, Antioxidants, Fibre, Protein Fibre acts as prebiotic (FOS/inulin) Edamame (soybeans) All EAAs, Isoflavones (Phytoestrogens), B9, K1, Iron, Manganese, Copper Complete protein; isoflavones have mixed receptor effects Kidney beans (cooked) Iron, B9, Manganese, Phosphorus, Molybdenum, Fibre Raw kidney beans contain lectins (phytohaemagglutinin) \u2014 always cook thoroughly Peanuts B3, B7 (Biotin), Manganese, Magnesium, B1, Resveratrol, Protein, MUFA Technically a legume; also a tree-nut substitute"},{"location":"food_sources_index/#nuts-seeds","title":"Nuts &amp; Seeds","text":"Food Key Nutrients Bioavailability Notes Almonds Vitamin E, Magnesium, Calcium, B2, Manganese, MUFA, Fibre Soaking reduces phytates; blanched retain more E Walnuts ALA (Omega-3), Manganese, Copper, Gamma-tocopherol (E), Folate, Polyphenols Highest nut ALA content; convert ~5\u201310% to EPA/DHA Flaxseeds (ground) ALA (Omega-3), Lignans (phytoestrogens), B9, Magnesium, Manganese, Fibre Grinding required for bioavailability; whole seeds pass undigested Chia seeds ALA, Calcium, Manganese, Phosphorus, Fibre (prebiotic), Iron Good vegan omega-3 source Sunflower seeds Vitamin E (highest of seeds), B1, B5, B6, Magnesium, Selenium, Copper, Linoleic acid (Omega-6) Pumpkin seeds (pepitas) Zinc, Magnesium, Iron, Phosphorus, Manganese, Copper, Tryptophan One of best plant zinc sources (~2.5 mg/28g) Brazil nuts Selenium (highest of any food \u2014 1 nut = ~70\u201391 \u00b5g; UL = 400 \u00b5g/day), Magnesium, Copper Limit to 1\u20133 nuts/day; selenium toxicity (selenosis) possible Cashews Zinc, Copper, Magnesium, Iron, B1, MUFA Most iron-rich nut Hemp seeds All EAAs (complete protein), ALA, GLA (Omega-6), Magnesium, Zinc, Iron One of few plant complete proteins"},{"location":"food_sources_index/#vegetables","title":"Vegetables","text":"Food Key Nutrients Bioavailability Notes Spinach (cooked) B9, Vitamin K1, A (\u03b2-carotene), Iron, Manganese, Calcium High oxalate reduces Ca and Iron bioavailability; cooking reduces oxalate somewhat Kale (raw/cooked) K1, C, A (\u03b2-carotene), Calcium, Manganese, Glucosinolates, Flavonoids, Lutein, Zeaxanthin Low-oxalate green \u2192 better calcium absorption than spinach Broccoli C, K1, B9, Sulforaphane (from Glucoraphanin), Indole-3-carbinol, Calcium, Chromium Sulforaphane peaks when raw or lightly steamed; myrosinase destroyed by overcooking Sweet potato (baked) \u03b2-Carotene (Vitamin A), Manganese, Potassium, B6, B5, C, Fibre Fat improves \u03b2-carotene bioavailability (provitamin A \u2192 retinol conversion) Carrot \u03b2-Carotene, Biotin (B7), K1, B6, Potassium Cooking + fat increases \u03b2-carotene absorption Tomato (cooked) Lycopene (highest in cooked/processed), Vitamin C, K1, Potassium, Chromium Lycopene bioavailability greatly enhanced by cooking and oil Garlic Allicin, Selenium, B6, Allium polyphenols, FOS (prebiotic) Crush/chop 10 minutes before eating to maximise allicin Onion Quercetin, FOS/Inulin (prebiotic), B6, B9, Chromium, Flavonoids Cooking reduces quercetin; raw preferred for flavonoid content Red/yellow bell pepper Vitamin C (highest of any vegetable \u2014 ~150 mg/100g), B6, A (\u03b2-carotene), Flavonoids Better C source than oranges by weight Asparagus B9, K1, Inulin (prebiotic), B1, B2, Chromium Avocado K1, B5, B9, B6, Potassium, C, MUFA (Oleic acid), Lutein, Zeaxanthin, Fibre Healthy fat enhances absorption of fat-soluble nutrients in the meal Mushrooms (UV-exposed) Vitamin D2 (ergocalciferol), B2, B3, B5, Selenium, Copper, Ergothioneine Exposing gills to midday sun for 30 min generates 100s of IU D2 Brussels sprouts K1, C, B9, Glucosinolates, Sulforaphane Beetroot Nitrates, B9, Manganese, Potassium, Betaine, Iron, Fibre Nitrates \u2192 nitric oxide \u2192 vasodilation (athletic performance) Sea vegetables (kelp/nori) Iodine, Fucoxanthin, Fucoidan, Magnesium, Calcium Iodine highly variable; kelp can cause excess iodine"},{"location":"food_sources_index/#fruits","title":"Fruits","text":"Food Key Nutrients Bioavailability Notes Orange Vitamin C, B9, Potassium, Flavanones (Hesperidin, Naringenin), Fibre C enhances iron absorption from co-consumed foods Berries (blueberries, strawberries, raspberries) Vitamin C, Anthocyanins, Quercetin, Pterostilbene, Resveratrol (in grapes/berries), Manganese, Fibre Among highest ORAC (antioxidant capacity) foods Kiwi Vitamin C (92 mg/100g), K1, Actinidin (digestive enzyme), Folate, Potassium Banana Potassium, B6, B5, C, Manganese, resistant starch (prebiotic function) Underripe banana has more resistant starch Mango \u03b2-Carotene, C, B9, B6, Mannoheptulose, Polyphenols Pomegranate Punicalagins \u2192 Urolithin A (gut-derived), C, B9, K1, Potassium, Polyphenols Grapefruit C, Naringenin, Lycopene (pink/red grapefruit), B9, Potassium Inhibits CYP3A4 \u2192 dangerous interactions with many drugs (statins, CCBs, immunosuppressants) Papaya C, \u03b2-Carotene, B9, Papain (digestive enzyme), Lycopene, K1 Cherries (tart) Anthocyanins, Melatonin, Quercetin, Potassium, C Used in exercise recovery (anti-inflammatory) Grapes (red/purple) Resveratrol (skin), Quercetin, Anthocyanins, K1, B1 Resveratrol concentrated in skin; red wine is more bioavailable source (with risk)"},{"location":"food_sources_index/#grains-cereals","title":"Grains &amp; Cereals","text":"Food Key Nutrients Bioavailability Notes Oats (whole) B1, B5, Manganese, Phosphorus, Magnesium, Iron, Beta-glucan (prebiotic fibre), Zinc Beta-glucan lowers LDL-C; slows glucose absorption Brown rice Manganese, Selenium, Magnesium, B1, B3, B6, Fibre Milling removes bran \u2192 white rice loses most B vitamins Quinoa All EAAs (complete protein), Manganese, Magnesium, Iron, B9, Phosphorus, Fibre One of few plant complete proteins; gluten-free Wheat germ Vitamin E, B1, B9, B6, Manganese, Zinc, Selenium Concentrated nutritional fraction of wheat Fortified cereals B1, B2, B3, B9, B12 (rarely), Iron, D (some fortified) Check labels \u2014 significant variation; often manufactured folic acid (not natural folate) Buckwheat Rutin (Flavonoid), B9, Magnesium, Manganese, all EAAs Gluten-free; high in Rutin \u2192 capillary strengthening"},{"location":"food_sources_index/#oils-fats","title":"Oils &amp; Fats","text":"Food Key Nutrients Bioavailability Notes Extra-virgin olive oil MUFA (Oleic acid, Omega-9), Polyphenols (Oleocanthal, Hydroxytyrosol), Vitamin E, K1, Squalene Cold-pressed retains most polyphenols; high heat degrades them Coconut oil Lauric acid (C12 SFA), MCTs (medium-chain triglycerides) MCTs enter portal circulation directly; does not require lipoprotein transport Flaxseed oil ALA (Omega-3) ~57%, Lignans Highly perishable; store in fridge, away from light Fish oil (supplement) EPA, DHA (Omega-3) Ethyl ester vs triglyceride form \u2014 TG form ~70% better absorbed Palm oil (red) \u03b2-Carotene, Tocotrienols (Vitamin E), Vitamin K1 Red palm oil (unrefined) vs white (refined) \u2014 very different nutrient profiles"},{"location":"food_sources_index/#fermented-probiotic-foods","title":"Fermented &amp; Probiotic Foods","text":"Food Key Nutrients Bioavailability Notes Yogurt (live cultures) Probiotics (L. bulgaricus, S. thermophilus, L. acidophilus), Calcium, B12, B2 Check label for live culture CFU count Kefir Probiotics (30+ strains includig L. kefiri, L. reuteri), Calcium, Tryptophan, B12 Transient colonisation; daily intake needed for effect Kimchi Probiotics (Lactobacillus kimchii), Vitamin C, K1, Glucosinolates (from Baechu cabbage), Capsaicin, Fibre Fermentation enhances folate content Sauerkraut Probiotics (Lactobacillus plantarum), Vitamin C, K1, Glucosinolates, Isothiocyanates Unpasteurised only \u2014 pasteurisation kills probiotics Miso Probiotics, B12 (small amount), Zinc, Copper, Manganese, Isoflavones (from soy) Fermentation reduces anti-nutrient phytates Tempeh Probiotics, All EAAs (complete protein), Iron, Calcium, Manganese, Isoflavones, B12 (some) Fermentation increases bioavailability of iron and zinc vs unfermented soy Natto K2 (MK-7 \u2014 highest dietary source, ~800\u20131000 \u00b5g/100g), Probiotics (B. subtilis natto), All EAAs, Iron, Calcium MK-7 half-life ~70 hours; 1 serving can maintain K2 for several days Kombucha Probiotics, B vitamins, Organic acids (acetic, glucuronic) Alcohol content 0.5\u20133%; caution in pregnancy/alcohol sensitivity Apple cider vinegar (raw) Probiotics (mother), Acetic acid Evidence for health benefits largely anecdotal"},{"location":"food_sources_index/#herbs-spices-specialty-items","title":"Herbs, Spices &amp; Specialty Items","text":"Food Key Nutrients Bioavailability Notes Turmeric Curcumin (Polyphenol), Manganese Bioavailability very low alone; increases ~2000% with piperine (black pepper) + fat Green tea EGCG (Catechin Flavonoid), L-Theanine, Caffeine, Fluoride, K1 Catechin absorption inhibited by milk protein; best consumed alone Dark chocolate (\u226570%) Flavanols, Magnesium, Iron, Copper, Manganese, Theobromine, Fibre Dutching destroys flavanols \u2014 choose non-dutched cocoa Coffee Caffeine, Chlorogenic acids (Polyphenols), B3 (from trigonelline \u2192 niacin during roasting), Manganese Chlorogenic acids may reduce postprandial glucose Black pepper Piperine (Alkaloid \u2014 enhances bioavailability of many nutrients), Manganese Ginger Gingerols/Shogaols (phenolic compounds), Manganese, B6 Anti-nausea; anti-inflammatory via COX-2 pathway Cinnamon Chromium, Polyphenols, Cinnamaldehyde May improve insulin sensitivity; cassia variety contains coumarin \u2014 hepatotoxic in large amounts Cacao (raw, unsweetened) Flavanols, Magnesium, Iron, Zinc, Copper, Theobromine, Phenylethylamine Flavanol content highest in raw cacao vs processed chocolate Kelp / Spirulina (spirulina) Iodine (kelp), Phycocyanin (antioxidant), Iron, B12-analogues (not bioavailable), all EAAs (spirulina) B12 in spirulina largely inactive \u2014 not a reliable B12 source for vegans"},{"location":"food_sources_index/#vegan-plant-based-nutrient-map","title":"Vegan / Plant-Based Nutrient Map","text":"<p>A quick reference for common vegan nutrient gaps:</p> Nutrient Best Plant Sources Notes B12 Fortified foods (plant milk, nutritional yeast), Supplements No reliable plant source \u2014 supplementation essential Vitamin D UV-exposed mushrooms, Fortified foods, Sunlight D3 from lichen is the vegan form Omega-3 (EPA/DHA) Algae oil supplements, Walnuts/flaxseed (ALA only) Conversion ALA\u2192EPA/DHA is poor (~5%) in humans Iron Lentils, Tofu, Pumpkin seeds, Dark leafy greens Non-haem \u2014 always combine with Vitamin C Zinc Hemp seeds, Pumpkin seeds, Legumes, Whole grains Phytates reduce absorption; soaking helps Calcium Fortified plant milks, Tofu (calcium-set), Kale, Chia seeds Avoid relying on high-oxalate greens Iodine Iodised salt, Seaweed (variable), Supplements Seaweed unreliable \u2014 wide variability Complete Protein (all EAAs) Quinoa, Hemp seeds, Soy/Edamame, Tempeh, Buckwheat Most plant proteins are incomplete \u2014 combine grains + legumes Creatine Supplements only (vegan creatine monohydrate available) Muscle creatine lower in vegans at baseline Carnitine Small amounts in avocado; primarily synthesised endogenously Body can synthesise from Lysine + Methionine if adequate K2 (MK-7) Natto (only reliable plant source) Most plant K is K1; K2 conversion very limited Selenium Brazil nuts (1\u20133/day), Fortified foods Highly soil-dependent Choline Soy, Cruciferous vegetables, Quinoa Eggs and liver are superior sources <p>Cross-reference: deficiency_index.md \u00b7 interactions.md</p>"},{"location":"interactions/","title":"Nutrient Interactions \u2014 Synergies &amp; Antagonisms","text":"<p>A reference for how nutrients enhance or inhibit each other's absorption, metabolism, and function. Knowing these relationships is essential for optimising supplementation timing and food combinations.</p> <p>Key: \u2705 Synergy (beneficial co-administration) \u00b7 \u26d4 Antagonism (harmful, avoid co-administration) \u00b7 \u26a0\ufe0f Context-dependent</p>"},{"location":"interactions/#absorption-interactions-at-time-of-ingestion","title":"Absorption Interactions (At Time of Ingestion)","text":""},{"location":"interactions/#vitamins","title":"Vitamins","text":"Interaction Type Mechanism Practical Guidance Vitamin C + Iron (non-haem) \u2705 Synergy C reduces Fe\u00b3\u207a \u2192 Fe\u00b2\u207a (the absorbable form); also forms soluble chelate in intestine Take vitamin C with iron-rich plant meals; e.g., orange juice with lentils Vitamin D + Calcium \u2705 Synergy 1,25(OH)\u2082D\u2083 upregulates TRPV6 channel and calbindin-D \u2192 active Ca\u00b2\u207a absorption in duodenum Supplement calcium and D together; D deficiency makes Ca supplementation largely ineffective Vitamin D + Magnesium \u2705 Synergy Magnesium is required for all vitamin D hydroxylation steps (25-hydroxylase and 1\u03b1-hydroxylase) Concurrent Mg supplementation required for D activation; Mg deficiency makes high-dose D ineffective Vitamin D + K2 \u2705 Synergy D increases calcium absorption; K2 (MK-7) activates osteocalcin to incorporate Ca into bone matrix and activates Matrix Gla Protein (MGP) to prevent arterial calcification Co-administer D3 + K2 to direct calcium appropriately Fat-soluble vitamins (A, D, E, K) + Dietary Fat \u2705 Synergy Fat-soluble vitamins require bile salt-facilitated micelle formation for absorption Always consume fat-soluble vitamins with a fat-containing meal Vitamin A + Zinc \u2705 Synergy Zinc required for synthesis of retinol-binding protein (RBP) \u2014 the transport protein for Vitamin A Zinc deficiency can cause functional vitamin A deficiency even with adequate A intake Vitamin E + Vitamin C \u2705 Synergy Vitamin C regenerates oxidised (radical) Vitamin E (tocopheroxyl radical \u2192 tocopherol) Protective synergy \u2014 both are antioxidants operating at different compartments Beta-carotene + Fat \u2705 Synergy Carotenoid absorption requires lipid-rich micelles Add fat to carotene-rich meals (e.g., olive oil to cooked carrots) Vitamin K1 vs K2 \u26a0\ufe0f Context K1 (phylloquinone) primarily reaches liver for clotting factors; K2 (menaquinone) reaches peripheral tissues (bone, artery). They are not equivalent. For bone/cardiovascular benefit, specifically target K2 (MK-7 from natto/supplements) Vitamin B12 + Folate (B9) \u2705 Synergy B12 is required to regenerate methyltetrahydrofolate (active folate) from the methylfolate trap; both required for homocysteine remethylation Supplementing folate without B12 can mask B12 deficiency while neurological damage progresses"},{"location":"interactions/#minerals","title":"Minerals","text":"Interaction Type Mechanism Practical Guidance Calcium vs Iron \u26d4 Antagonism Ca\u00b2\u207a competitively inhibits both haem and non-haem iron absorption at shared transporter (DMT1) Do not take calcium supplements with iron-rich meals or iron supplements Calcium vs Zinc \u26d4 Antagonism High calcium intake decreases zinc absorption; both compete at intestinal level High-dose Ca supplements can worsen zinc status Calcium vs Magnesium \u26d4 Antagonism (high doses) At very high doses, Ca and Mg compete for shared transporters. At normal dietary intakes, they are somewhat interdependent. Ratio Ca:Mg ~2:1 generally recommended; avoid very high Ca without matching Mg Zinc vs Copper \u26d4 Antagonism High zinc induces metallothionein in intestinal cells, which preferentially sequesters copper \u2192 copper deficiency Long-term zinc supplementation (&gt;40 mg/day) should include 1\u20132 mg copper; therapeutic use of high zinc (Wilson's disease) intentionally uses this mechanism Iron vs Zinc \u26d4 Antagonism Competitive absorption at DMT1 Separate iron and zinc supplements by 2+ hours Iron vs Calcium \u26d4 Antagonism (see above) \u2014 \u2014 Iron vs Manganese \u26d4 Antagonism Both share DMT1 transporter Iron deficiency increases manganese absorption; excess manganese in iron-deficient children is a toxicity concern Magnesium + Potassium \u2705 Synergy Magnesium is required for Na/K-ATPase activity; Mg deficiency impairs the ability to restore intracellular potassium \u2192 refractory hypokalaemia In hospitalised patients, hypokalaemia not responding to K supplementation should prompt checking Mg status Selenium + Iodine \u2705 Synergy Selenium (as selenocysteine) is the active site of iodothyronine deiodinase, which converts T4 \u2192 T3. Selenium also protects thyroid from H\u2082O\u2082 damage during thyroid hormone synthesis Correct selenium deficiency alongside iodine deficiency; selenium alone without iodine can worsen autoimmune thyroiditis Iron + Hepcidin (inflammation) \u26a0\ufe0f Context Inflammation raises hepcidin \u2192 blocks ferroportin \u2192 traps iron in reticuloendothelial cells \u2192 anaemia of chronic disease. Oral iron is ineffective in active inflammation. IV iron bypasses hepcidin block; oral iron ineffective when CRP is high Oxalate vs Calcium, Iron, Magnesium \u26d4 Antagonism Oxalate forms insoluble complexes with Ca\u00b2\u207a, Fe\u00b2\u207a, Mg\u00b2\u207a \u2192 greatly reduces absorption High-oxalate foods (spinach, beet greens, rhubarb) are poor sources of calcium and iron; pair with low-oxalate sources Phytate vs Iron, Zinc, Calcium, Mg \u26d4 Antagonism Phytic acid (inositol hexaphosphate) chelates divalent cations \u2192 reduced absorption from legumes, grains Soaking, sprouting, fermenting, and cooking degrades phytate and significantly improves mineral bioavailability Tannins (tea/coffee) vs Iron \u26d4 Antagonism Polyphenolic tannins form insoluble complexes with non-haem iron Do not drink tea or coffee within 1 hour of an iron-rich meal or iron supplement"},{"location":"interactions/#metabolic-partnerships-functional-synergies","title":"Metabolic Partnerships (Functional Synergies)","text":"<p>These interactions occur at the level of metabolism rather than absorption.</p> Nutrients Relationship Mechanism B1 + B2 + B3 + B5 + Mg \u2705 Team All required for the TCA cycle / energy metabolism (pyruvate decarboxylase, \u03b1-ketoglutarate dehydrogenase, etc.) B6 + B9 + B12 \u2705 Team One-carbon (methyl) metabolism / methylation cycle; homocysteine remethylation requires all three B12 + Intrinsic Factor (IF) \u2705 Dependency Without gastric parietal cell-derived IF, oral B12 requires massive doses for passive absorption (~1% of dose) Tryptophan + B6 + B3 \u2705 Dependency B6 (as PLP) is required for conversion of tryptophan \u2192 niacin (kynurenine pathway, 60 mg Trp \u2192 ~1 mg niacin) Vitamin C + Iron (metabolic) \u2705 Synergy C is required as a cofactor for prolyl/lysyl hydroxylases (collagen cross-linking) \u2014 independently of absorption enhancement Selenium + Glutathione + Vitamin E \u2705 Team Selenium is the active site of Glutathione Peroxidase (GPx); E is the membrane-phase antioxidant; glutathione is the primary intracellular antioxidant Creatine + Carbohydrate (post-exercise) \u2705 Synergy Insulin stimulates muscle creatine transporter (SLC6A8) \u2014 carbohydrate co-ingestion enhances creatine uptake into muscle Beta-alanine \u2192 Carnosine (with Histidine) \u2705 Dependency Carnosine = Beta-alanine + Histidine; beta-alanine is rate-limiting in muscle; histidine availability also matters L-Carnitine (Lysine + Methionine + C + B6 + Fe + Niacin) \u2705 Team Carnitine biosynthesis requires Lysine, Methionine, Ascorbate (C), B6, Fe\u00b2\u207a, and niacin as cofactors CoQ10 + Selenium + Vitamin E \u2705 Team CoQ10 is regenerated from ubiquinol (reduced) to ubiquinone by Vitamin E and GPx (selenium) Omega-3 (EPA/DHA) + Vitamin E \u2705 Synergy PUFAs are highly susceptible to lipid peroxidation; Vitamin E protects cell membranes from oxidative damage Glucosinolates + Myrosinase \u2705 Dependency Glucosinolates (in cruciferous vegetables) are only converted to bioactive isothiocyanates (e.g., sulforaphane) by the enzyme myrosinase, which is destroyed by heat Curcumin + Piperine \u2705 Synergy Piperine inhibits CYP1A2/CYP3A4 and glucuronidation (Phase II metabolism) \u2192 bioavailability of curcumin increases ~20-fold Probiotics + Prebiotics (= Synbiotics) \u2705 Synergy Prebiotics (FOS, inulin, pectin) provide fermentable substrate for probiotic bacteria, enhancing their colonisation and effect"},{"location":"interactions/#drugnutrient-interactions","title":"Drug\u2013Nutrient Interactions","text":"<p>These interactions are clinically significant. Cross-reference with individual mineral/vitamin notes.</p>"},{"location":"interactions/#nutrient-levels-reduced-by-drugs","title":"Nutrient Levels Reduced by Drugs","text":"Drug Nutrient Depleted Mechanism Metformin B12 (significant), B9 Impairs ileal B12-IF complex absorption; reduces methylation Proton Pump Inhibitors (PPIs) B12, Magnesium, Iron, Zinc, Calcium Reduced gastric acid \u2192 impaired absorption of acid-dependent nutrients H2 Blockers (ranitidine, famotidine) B12 Reduced acid production reduces IF-mediated B12 absorption Oral Contraceptive Pill (OCP) B6, B9, B12, Riboflavin (B2), C, Zinc, Magnesium Estrogen affects B-vitamin metabolism Corticosteroids (long-term) Calcium, Vitamin D, Zinc, B6, K Induce renal Ca wasting; impair intestinal Ca absorption Cholestyramine / Colestipol (bile acid sequestrants) Vitamins A, D, E, K, Beta-carotene, B12 Bind bile acids \u2192 impair fat-soluble vitamin absorption Loop diuretics (furosemide) Potassium, Magnesium, Calcium, Thiamine (B1), Zinc Increase urinary excretion of divalent cations Thiazide diuretics Potassium, Magnesium, Zinc Increase K\u207a and Mg\u00b2\u207a excretion; decrease Ca excretion \u2192 hypercalcaemia risk Antiepileptics (phenytoin, phenobarbital, carbamazepine) Vitamin D, B9, B6, B12, K Induce CYP enzymes \u2192 accelerated catabolism of D and B vitamins Isoniazid (INH \u2014 TB drug) B6 (Pyridoxine) INH is a B6 antagonist \u2014 classic cause of drug-induced B6 deficiency neuropathy Statins (HMG-CoA reductase inhibitors) CoQ10 Block mevalonate pathway \u2192 CoQ10 synthesis (same pathway as cholesterol) Methotrexate B9 (Folate) Folic acid antagonist \u2014 inhibits dihydrofolate reductase (DHFR) Trimethoprim (antibiotic) B9 (Folate) Also DHFR inhibitor; folate supplementation may be needed"},{"location":"interactions/#nutrients-that-affect-drug-efficacy","title":"Nutrients That Affect Drug Efficacy","text":"Nutrient / Food Drug Affected Effect Vitamin K (high K1 foods) Warfarin / Acenocoumarol K1 reverses anticoagulant effect \u2014 maintain consistent K1 intake; do not rapidly change dietary K1 Calcium Fluoroquinolones, Tetracyclines, Levothyroxine, Bisphosphonates Forms insoluble chelate/complex \u2192 significantly reduced drug absorption Magnesium, Iron, Zinc Fluoroquinolones, Tetracyclines Same chelation mechanism as calcium Grapefruit / Grapefruit juice Statins (atorvastatin, simvastatin), Calcium channel blockers, Cyclosporine, some antiretrovirals Puranocoumarins in grapefruit irreversibly inhibit intestinal CYP3A4 \u2192 massive increase in drug bioavailability \u2192 toxicity St John's Wort (Hypericum) Warfarin, OCP, HIV antiretrovirals, Cyclosporine, Digoxin Potent CYP3A4 inducer \u2192 accelerated drug metabolism \u2192 treatment failure High-fat meal Fat-soluble drugs (e.g., Griseofulvin, Spironolactone, Isotretinoin) Increases bioavailability \u2192 take with food as directed High-protein diet Levodopa (Parkinson's) Large neutral amino acids compete with levodopa for intestinal and CNS transport \u2192 take 30 min before meals Caffeine Adenosine receptor drugs (e.g., Dipyridamole, Regadenoson, Adenosine) Caffeine is an adenosine receptor antagonist; invalidates pharmacological cardiac stress tests Tyramine-rich foods (aged cheese, cured meat, fermented) MAO Inhibitors (MAOIs \u2014 e.g., Phenelzine) MAOIs block tyramine breakdown \u2192 hypertensive crisis; strict dietary tyramine restriction essential"},{"location":"interactions/#supplementation-timing-guide","title":"Supplementation Timing Guide","text":"Supplement Best Time Reason Fat-soluble vitamins (A, D, E, K) With largest meal (containing fat) Require bile/micelles for absorption Calcium carbonate With meals Requires gastric acid for dissolution Calcium citrate Anytime (with or without food) Does not require stomach acid Iron On empty stomach (or with Vitamin C) Avoid taking with tea, coffee, calcium, dairy Magnesium (glycinate/malate) Evening Promotes relaxation; better sleep quality Zinc Away from meals (if nausea-tolerant); else with small amount of food Food reduces absorption but helps tolerance B vitamins complex Morning with food B vitamins are energising; evening use may affect sleep Vitamin B12 Morning May increase alertness / energy Probiotics (capsule form) With or just before a meal (not on empty stomach) Food buffers stomach acid, increasing probiotic survival Omega-3 fatty acids With meals containing fat Reduces fishy reflux; fat enhances absorption Creatine monohydrate Post-workout with carbohydrates Insulin enhances muscle creatine uptake Beta-alanine Pre-workout or split across day Minimise paraesthesia by using smaller more frequent doses Caffeine 30\u201360 min pre-exercise Ergogenic window; avoid within 6\u20138 h of sleep CoQ10 With fat-containing meal Fat-soluble; co-ingestion with fat improves absorption Vitamin C Split through the day (2\u20133 doses) Saturable transport \u2014 200 mg \u00d7 3 absorbed better than 1000 mg \u00d7 1 Curcumin With fat + black pepper Dramatically improves bioavailability Resveratrol Separate from Metformin by 2+ h Both activate SIRT1/AMPK \u2014 possible additive hypoglycaemia risk"},{"location":"interactions/#competitive-absorption-summary-quick-reference","title":"Competitive Absorption Summary (Quick Reference)","text":"<pre><code>At the intestinal transporter level, these nutrients compete:\n\nDMT1 (divalent metal transporter):  Fe\u00b2\u207a \u2190\u2192 Zn\u00b2\u207a \u2190\u2192 Cu\u00b2\u207a \u2190\u2192 Mn\u00b2\u207a \u2190\u2192 Cd\u00b2\u207a\n                                     (all inhibit each other at high doses)\n\nShared Ca\u00b2\u207a channel / passive diffusion:  Ca\u00b2\u207a \u2190\u2192 Mg\u00b2\u207a \u2190\u2192 Zn\u00b2\u207a\n\nFolate transporter (PCFT/RFC):  Folate antagonists (methotrexate, trimethoprim) block folate entry\n</code></pre> <p>Rule of thumb: Divalent cations (Fe\u00b2\u207a, Zn\u00b2\u207a, Cu\u00b2\u207a, Mg\u00b2\u207a, Ca\u00b2\u207a, Mn\u00b2\u207a) all compete at shared transporters. Do not mega-dose one without considering impact on others.</p>"},{"location":"interactions/#anti-nutrient-overview","title":"Anti-Nutrient Overview","text":"<p>Compounds in foods that reduce nutrient availability:</p> Anti-Nutrient Food Sources Nutrients Blocked Deactivation Method Phytic acid (Phytate) Grains, legumes, nuts, seeds Iron, Zinc, Calcium, Magnesium, Phosphorus Soaking, sprouting, fermenting, cooking Oxalic acid (Oxalate) Spinach, beet greens, rhubarb, Swiss chard Calcium, Iron, Magnesium Boiling (discarding water); pairing with low-oxalate sources Tannins Tea, coffee, red wine, sorghum Iron, Zinc, Protein Consume separately from mineral-rich meals Lectins Raw legumes (especially kidney beans), nightshades Protein digestion, gut lining integrity Full cooking (minimum 10 min boiling for kidney beans); pressure cooking Goitrogens Raw cruciferous (broccoli, kale, Brussels), millet, cassava Iodine absorption / thyroid hormone synthesis Cooking significantly reduces goitrogenic activity Avidin Raw egg white Biotin (B7) Cooking destroys avidin; biotin binds irreversibly to raw avidin Solanine Green/sprouted potatoes Cholinesterase inhibitor (not a nutrient antagonist, but toxic) Avoid green potatoes; don't eat sprouts"},{"location":"interactions/#synergy-cheat-sheet","title":"Synergy Cheat Sheet","text":"\"Stack\" Why Iron + Vitamin C Best non-haem iron absorption Calcium + Vitamin D + K2 + Magnesium Complete bone/cardiovascular calcium management B12 + B9 + B6 Homocysteine control; methylation Omega-3 + Vitamin E PUFA oxidation protection Zinc + Copper (balanced) Avoid copper deficiency from excess Zn Probiotics + Prebiotics (Synbiotics) Gut microbiome support Selenium + Iodine Thyroid function Turmeric + Piperine + Fat Curcumin bioavailability Creatine + Carbohydrate Muscle creatine loading Vitamin D + Magnesium Activate vitamin D <p>Cross-reference: deficiency_index.md \u00b7 food_sources_index.md</p>"},{"location":"amino_acids/arginine/","title":"Arginine","text":""},{"location":"amino_acids/arginine/#overview","title":"Overview","text":"<p>Arginine is a conditionally essential amino acid \u2014 it is synthesised endogenously from citrulline (via the urea cycle) in adults, but synthesis is insufficient during periods of rapid growth, critical illness, injury, or metabolic stress. Arginine is the direct precursor of nitric oxide (NO) \u2014 the principal mediator of vascular tone, immune killing, and cell signalling. It is also a central component of the urea cycle and a precursor of creatine, polyamines, and proline.</p> <ul> <li>Classification: Conditionally essential</li> <li>IUPAC abbreviation: Arg / R</li> <li>Side chain: Guanidinium group; strongly basic (pKa ~12.5); always positively charged at physiological pH</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 \u03b1-ketoglutarate via ornithine \u2192 glutamate pathway)</li> </ul>"},{"location":"amino_acids/arginine/#dietary-requirements","title":"Dietary Requirements","text":"Age / Group Estimated need Infants 161 mg/kg/day (essential at this age) Adults (endogenous synthesis adequate) ~5\u20136 g/day from mixed diet typical Critical illness / wound healing Greatly increased; supplemental doses 15\u201330 g/day studied <p>No established RDA or UL from food for adults under normal conditions. Preterm infants cannot synthesise sufficient arginine \u2014 considered essential in this group.</p>"},{"location":"amino_acids/arginine/#functions","title":"Functions","text":"<ul> <li>Nitric Oxide (NO) Synthesis: Arg + O\u2082 \u2192 NO + Citrulline (by nitric oxide synthase; NOS1/nNOS, NOS2/iNOS, NOS3/eNOS; requires BH4, NADPH, FAD, FMN, calmodulin)</li> <li>eNOS (endothelial): vasodilation, inhibits platelet aggregation, anti-atherosclerotic</li> <li>nNOS (neuronal): neurotransmission, learning and memory</li> <li>iNOS (inducible, macrophages): high-output NO for microbial killing (bactericidal, tumoricidal)</li> <li>Urea Cycle: Arginine \u2192 ornithine + urea (arginase) \u2014 the final, essential step in ammonia detoxification; ornithine then regenerates citrulline to sustain the cycle</li> <li>Creatine Synthesis: Arginine + Glycine \u2192 Guanidinoacetate (in kidney) \u2192 Creatine (SAM methylation in liver); creatine phosphate is the primary rapid-energy buffer in muscle</li> <li>Polyamine Synthesis: Ornithine \u2192 Putrescine \u2192 Spermidine \u2192 Spermine (polyamines; essential for cell proliferation, DNA stability, and apoptosis regulation)</li> <li>Proline Synthesis: Ornithine \u2192 proline (for collagen synthesis)</li> <li>Growth Hormone Secretion: Arginine stimulates pituitary GH release (by inhibiting somatostatin); used as a GH stimulation test</li> <li>Immune Function: iNOS-derived NO is a critical antimicrobial and antitumour effector; arginine availability governs macrophage killing capacity</li> </ul>"},{"location":"amino_acids/arginine/#metabolism","title":"Metabolism","text":"Step Details Endogenous synthesis Citrulline (from intestinal enterocytes; glutamine/proline origin) \u2192 Arginine (kidney, via ASS + ASL enzymes) Urea cycle Carbamoyl phosphate + Ornithine \u2192 Citrulline \u2192 Argininosuccinate \u2192 Arginine \u2192 Ornithine + Urea NO production Arg \u2192 NO + Citrulline (NOS isoforms) Creatine Arg + Gly \u2192 guanidinoacetate (AGAT) \u2192 creatine (GAMT + SAM) Key enzymes Arginase (Arg \u2192 Orn + Urea); NOS isoforms; AGAT; argininosuccinate synthase (ASS); lyase (ASL)"},{"location":"amino_acids/arginine/#food-sources","title":"Food Sources","text":"Food Serving Arginine (mg) Pumpkin seeds 28g ~1,400 mg Turkey (roasted) 85g ~1,650 mg Pork loin (cooked) 85g ~1,550 mg Chicken breast 85g ~1,500 mg Peanuts 28g ~950 mg Lentils (cooked) 200g ~1,240 mg Soybeans (cooked) 170g ~1,900 mg Walnuts 28g ~700 mg"},{"location":"amino_acids/arginine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/arginine/#urea-cycle-disorders","title":"Urea Cycle Disorders","text":"<ul> <li>Defects in urea cycle enzymes (OTC, CPS1, ASS \u2014 citrullinaemia, ASL \u2014 argininosuccinic aciduria, ARG \u2014 hyperargininaemia)</li> <li>Results in hyperammonaemia \u2014 encephalopathy, liver disease, developmental delay</li> <li>Arginine is supplemented in most urea cycle disorders (except ARG deficiency) to maintain urea cycle flux</li> <li>Treatment: low-protein diet, nitrogen scavengers (sodium benzoate, sodium phenylacetate), arginine supplementation, liver transplant</li> </ul>"},{"location":"amino_acids/arginine/#citrullinaemia-type-i-ass-deficiency","title":"Citrullinaemia Type I (ASS Deficiency)","text":"<ul> <li>Inability to convert citrulline \u2192 argininosuccinate \u2192 arginine; accumulates citrulline and ammonia</li> <li>Treated with arginine supplementation (bypasses the defect by providing arginine directly)</li> </ul>"},{"location":"amino_acids/arginine/#sepsis-and-critical-illness","title":"Sepsis and Critical Illness","text":"<ul> <li>NO-mediated vasodilation is pathological in septic shock (iNOS-generated NO causes uncontrolled vasodilation)</li> <li>Arginine supplementation in critically ill patients is controversial \u2014 may be harmful in septic shock (worsens vasodilation) but beneficial post-surgery (immune nutrition formulations)</li> </ul>"},{"location":"amino_acids/arginine/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Arginine \u2192 eNOS \u2192 NO \u2192 vasodilation \u2192 reduced blood pressure, reduced platelet aggregation, reduced LDL oxidation</li> <li>Arginine supplementation trials show modest BP reduction; conflicting CVD mortality data</li> <li>L-Arginine supplementation post-MI showed increased mortality in one trial (VINTAGE MI) \u2014 caution in acute MI</li> </ul>"},{"location":"amino_acids/arginine/#lysine-arginine-competition-herpes-simplex","title":"Lysine-Arginine Competition (Herpes Simplex)","text":"<ul> <li>HSV requires arginine for replication; high lysine intake competes with arginine at shared transporters \u2192 reduced intracellular arginine \u2192 inhibits viral replication (see Lysine note)</li> </ul>"},{"location":"amino_acids/arginine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect BH4 (Tetrahydrobiopterin) Essential NOS cofactor; BH4 deficiency \u2192 uncoupled NOS \u2192 superoxide instead of NO (oxidative stress) Lysine Competitive intestinal uptake (shared cationic transporter); high lysine lowers arginine availability Asymmetric dimethylarginine (ADMA) Endogenous NOS inhibitor; elevated in CKD, hypertension, diabetes \u2014 blocks NO from arginine Phosphodiesterase-5 inhibitors (sildenafil) Work downstream of NO (prevent cGMP breakdown); arginine \u2192 NO \u2192 cGMP \u2192 vasodilation \u2014 synergistic effect; risk of hypotension if combined with arginine supplements Creatine Arginine spares creatine synthesis need \u2014 high dietary creatine reduces arginine use for AGAT reaction"},{"location":"amino_acids/arginine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>L-Arginine (2\u20136 g/day): Used for erectile dysfunction (limited evidence), hypertension (modest effect), exercise performance (via NO-mediated muscle blood flow)</li> <li>Arginine + Citrulline: Citrulline often preferred \u2014 better oral bioavailability, fewer GI side effects, and effectively raises plasma arginine more than arginine itself (bypasses first-pass intestinal arginase)</li> <li>Immune nutrition (perioperative immunonutrition): Enteral formulas enriched with arginine, glutamine, omega-3 FAs \u2014 evidence supports better surgical outcomes in elective major surgery; controversial in sepsis</li> <li>Growth Hormone testing: IV arginine infusion (0.5 g/kg over 30 min) \u2014 standard GH stimulation test</li> <li>Avoid in: Septic shock (worsens vasodilation), herpes simplex outbreaks (arginine promotes HSV replication)</li> </ul>"},{"location":"amino_acids/cysteine/","title":"Cysteine","text":""},{"location":"amino_acids/cysteine/#overview","title":"Overview","text":"<p>Cysteine is a conditionally essential amino acid \u2014 it can be synthesised from methionine via the transsulphuration pathway (with adequate B6, folate, B12), but becomes essential when methionine intake is insufficient or in premature infants, individuals with liver disease, and critically ill patients. Cysteine is the rate-limiting precursor of glutathione (GSH) \u2014 the body's primary antioxidant tripeptide \u2014 and is a key component of proteins requiring structural disulphide bonds. Its thiol (\u2013SH) group is highly reactive and participates in redox chemistry, metal binding, and enzyme catalysis.</p> <ul> <li>Classification: Conditionally essential</li> <li>IUPAC abbreviation: Cys / C</li> <li>Side chain: Thiol (\u2013CH\u2082\u2013SH); pKa ~8.3; the most nucleophilic and oxidation-sensitive side chain</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 pyruvate)</li> </ul>"},{"location":"amino_acids/cysteine/#dietary-requirements","title":"Dietary Requirements","text":"Age / Group Notes Adults Can be synthesised from methionine; RDA expressed as combined Met + Cys (~19 mg/kg/day) Preterm infants Essential \u2014 limited transsulphuration capacity \u2192 must be provided in formula Liver disease / critically ill Hepatic transsulphuration impaired \u2192 dietary cysteine becomes essential <p>No established UL for food cysteine. Cysteine is unstable in solution (oxidises to cystine); parenteral nutrition formulas use N-acetylcysteine (NAC) to deliver cysteine.</p>"},{"location":"amino_acids/cysteine/#functions","title":"Functions","text":"<ul> <li>Glutathione (GSH) Synthesis: Cys is the rate-limiting precursor of GSH (\u03b3-glutamyl-cysteinyl-glycine). GSH is the cell's major antioxidant, detoxification agent (Phase II conjugation), and redox buffer. GSH levels critically depend on cysteine availability.</li> <li>Disulfide Bond Formation: Cys residues in proteins form S\u2013S bonds (oxidation; creating cystine) \u2014 essential for extracellular protein structure (immunoglobulins, albumin, elastin, insulin, keratin, receptor ligand-binding domains)</li> <li>Taurine Synthesis: Cys \u2192 cysteine sulphinic acid \u2192 hypotaurine \u2192 taurine (requires B6) \u2014 taurine is a conditionally essential compound critical in bile acid conjugation, cardiac function, vision (retinal), and neurological development (especially in infants)</li> <li>Coenzyme A (CoA) Synthesis: Pantothenic acid (B5) + cysteine \u2192 CoA \u2014 Cys sidechain provides the crucial thiol of CoA's active site</li> <li>Enzyme Catalysis: Cys is the active-site nucleophile in cysteine proteases (papain, calpain, caspases, cathepsins) and in many other thiol-catalysed enzymes</li> <li>Metal Binding/Sensing: Cys thiol groups coordinate Fe, Zn, Cu in metalloenzymes and metal-responsive transcription factors (e.g., MTF-1 responds to zinc via cys-containing zinc fingers)</li> <li>Redox Signalling: Reversible oxidation of protein cys thiols (to sulfenic acid, disulphide, glutathionylation) \u2014 key mechanism in redox-regulated signalling and oxidative stress sensing</li> <li>Ferroptosis Regulation: Cysteine (via system Xc\u207b glutamate/cystine antiporter) feeds GSH synthesis, which via GPx4 prevents lipid peroxidation \u2014 blockage of system Xc\u207b induces ferroptosis (cell death by lipid peroxidation)</li> <li>Keratin and Hair/Nail Structure: ~10\u201314% of keratin is cysteine \u2014 intermolecular disulphide bonds give hair strength and curling (chemical perms break these bonds)</li> </ul>"},{"location":"amino_acids/cysteine/#metabolism","title":"Metabolism","text":"Step Details Synthesis Homocysteine + Serine \u2192 Cystathionine (CBS; B6) \u2192 Cysteine + \u03b1-ketobutyrate (CTH; B6) GSH synthesis Glu + Cys \u2192 \u03b3-Glu-Cys (GCL; rate-limiting; inhibited by BSO) + Gly \u2192 GSH (GSS) Taurine Cys \u2192 cysteine sulphinic acid \u2192 taurine (CSADase; B6 cofactor) Catabolism Cys \u2192 pyruvate (glucogenic); also cys \u2192 H\u2082S (gasotransmitter) via CBS, CSE, MST enzymes H\u2082S production Cysteine \u2192 hydrogen sulphide (H\u2082S) \u2014 a gaseous signalling molecule; vasodilator, neuroprotectant"},{"location":"amino_acids/cysteine/#food-sources","title":"Food Sources","text":"Food Serving Cysteine (mg) Chicken breast (cooked) 85g ~350 mg Beef (lean, cooked) 85g ~330 mg Egg 1 large ~150 mg Sunflower seeds 28g ~230 mg Oats (dry) 40g ~155 mg Ricotta cheese 120g ~180 mg Brazil nuts 28g ~140 mg Lentils (cooked) 200g ~230 mg <p>N-Acetylcysteine (NAC) and whey protein are common supplemental sources of cysteine.</p>"},{"location":"amino_acids/cysteine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/cysteine/#paracetamol-acetaminophen-overdose","title":"Paracetamol (Acetaminophen) Overdose","text":"<ul> <li>Paracetamol \u2192 NAPQI (toxic reactive metabolite via CYP2E1/CYP3A4)</li> <li>NAPQI depletes hepatic glutathione \u2192 hepatocellular necrosis</li> <li>N-acetylcysteine (NAC) IV/oral is the antidote: replenishes cysteine \u2192 GSH \u2192 detoxifies remaining NAPQI</li> <li>NAC must be given within 8\u201316 hours of ingestion for maximum efficacy</li> </ul>"},{"location":"amino_acids/cysteine/#cystinuria","title":"Cystinuria","text":"<ul> <li>Defect in the rBAT-SLC7A9 dibasic amino acid transporter (also affects arginine, ornithine, lysine)</li> <li>Cystine (oxidised dimer of cysteine) is insoluble in urine \u2192 cystine kidney stones (recurrent, staghorn calculi)</li> <li>Treatment: high fluid intake (&gt;3 L/day), urine alkalinisation (cystine more soluble at pH &gt;7), D-penicillamine or tiopronin (form soluble complexes with cystine), dietary sodium and animal protein restriction</li> </ul>"},{"location":"amino_acids/cysteine/#cystinosis","title":"Cystinosis","text":"<ul> <li>Lysosomal cystine transporter (cystinosin) defect \u2192 cystine crystal accumulation in lysosomes of all tissues</li> <li>Most common cause of inherited Fanconi syndrome in children; progresses to chronic kidney disease</li> <li>Treatment: cysteamine (reacts with intralysosomal cystine \u2192 mixed disulphide that can exit lysosomes); renal replacement therapy; transplant</li> </ul>"},{"location":"amino_acids/cysteine/#homocystinuria-overlap-with-methionine-note","title":"Homocystinuria (Overlap with Methionine note)","text":"<ul> <li>CBS deficiency \u2192 impaired Hcy \u2192 cystathionine \u2192 cysteine \u2192 secondary cysteine deficiency</li> <li>Treated partly with cystine supplementation to compensate for inability to synthesise cysteine</li> </ul>"},{"location":"amino_acids/cysteine/#copd-pulmonary-mucus","title":"COPD / Pulmonary Mucus","text":"<ul> <li>NAC (600\u20131,200 mg/day) reduces mucus viscosity by breaking disulphide bonds in mucin glycoproteins \u2192 mucolytic; used in COPD and cystic fibrosis</li> </ul>"},{"location":"amino_acids/cysteine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Methionine Upstream precursor (transsulphuration) \u2014 cysteine can spare methionine requirements Vitamin B6 Required for CBS and CTH (both transsulphuration enzymes); deficiency impairs cysteine synthesis Folate + B12 Regulate homocysteine \u2192 methionine flux; deficiency pushes Hcy toward transsulphuration, increasing cysteine but also increasing demands on CBS Selenium Selenocysteine biosynthesis uses serine + selenophosphate analogously to cysteine biosynthesis Copper Excess copper oxidises cysteine thiols \u2192 may reduce enzyme thiol function; GSH chelates copper NAC + nitroglycerin NAC co-administration with nitroglycerin reduces nitrate tolerance; clinically relevant in chest pain management BSO (buthionine sulfoximine) Research tool \u2014 inhibits GCL \u2192 depletes GSH by blocking cysteine incorporation"},{"location":"amino_acids/cysteine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>NAC (N-Acetylcysteine, 600\u20132,400 mg/day):</li> <li>Mucolytic (COPD, CF, bronchitis)</li> <li>Antidote for paracetamol overdose (IV protocol)</li> <li>Antioxidant / GSH precursor</li> <li>Used in psychiatric research (OCD, schizophrenia, addiction \u2014 oxredox hypothesis)</li> <li>Modest evidence for reducing contrast-induced nephropathy (pretreatment)</li> <li>Whey protein: Rich in cysteine + branched-chain amino acids \u2014 effectively raises GSH levels in ageing adults</li> <li>Cystine (oxidised dimer): Poorly soluble; not effective as a supplement</li> <li>High-dose cysteine alone (unchelated) can be pro-oxidant at very high concentrations \u2014 NAC form is preferred for supplementation</li> </ul>"},{"location":"amino_acids/glutamine/","title":"Glutamine","text":""},{"location":"amino_acids/glutamine/#overview","title":"Overview","text":"<p>Glutamine is the most abundant free amino acid in the human body (plasma concentration ~500\u2013900 \u03bcmol/L; ~60% of the free amino acid pool in muscle). It is classified as conditionally essential \u2014 synthesised de novo from glutamate + ammonia (via glutamine synthetase), but demand exceeds synthesis capacity during catabolic states (surgery, trauma, burns, sepsis, prolonged exercise). Glutamine is a critical fuel for rapidly proliferating cells (enterocytes, lymphocytes) and is the principal vehicle for inter-organ nitrogen transport and ammoniagenesis in the kidney during acidosis.</p> <ul> <li>Classification: Conditionally essential</li> <li>IUPAC abbreviation: Gln / Q</li> <li>Side chain: Amide group (\u2013CONH\u2082); polar, uncharged at physiological pH</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 \u03b1-ketoglutarate \u2192 TCA cycle; or \u2192 glucose via gluconeogenesis)</li> </ul>"},{"location":"amino_acids/glutamine/#dietary-requirements","title":"Dietary Requirements","text":"Condition Notes Healthy adults Synthesised endogenously; no established RDA; ~3\u20136 g/day from dietary proteins Critical illness / trauma Conditionally essential; supplemental doses of 20\u201340 g/day studied Athletes (intense training) Plasma Gln falls after prolonged endurance exercise \u2192 increased demand <p>No established UL. High-dose glutamine (&gt;40 g/day) in critically ill patients without monitoring has been associated with adverse outcomes in some trials (REDOXS trial, AKI/MI context).</p>"},{"location":"amino_acids/glutamine/#functions","title":"Functions","text":"<ul> <li>Primary Fuel for Enterocytes: Small intestinal enterocytes preferentially oxidise glutamine (not glucose) for energy \u2014 via glutaminolysis (Gln \u2192 Glu \u2192 \u03b1-KG \u2192 TCA). Critical for mucosal integrity, villus structure, and gut barrier function.</li> <li>Lymphocyte &amp; Macrophage Fuel: Rapidly dividing immune cells rely heavily on glutamine as an oxidative and biosynthetic fuel \u2014 immune function declines in glutamine-depleted states (major surgery, critical illness)</li> <li>Nitrogen Shuttle (Inter-Organ Nitrogen Transport):</li> <li>Muscle releases glutamine (from glutamate + NH\u2084\u207a via glutamine synthetase) \u2192 liver and kidney take up glutamine</li> <li>Liver: Gln \u2192 glutamate \u2192 urea cycle (ammonia disposal) / gluconeogenesis</li> <li>Kidney: Gln \u2192 NH\u2084\u207a + glutamate \u2192 \u03b1-KG (renal ammoniagenesis; excretes acid during acidosis)</li> <li>Ammonia Homeostasis: Glutamine synthetase in astrocytes detoxifies NH\u2083 \u2192 Gln (critical in liver failure/hepatic encephalopathy \u2014 cerebral Gln accumulates \u2192 astrocyte dysfunction)</li> <li>Nucleotide Synthesis: Gln donates its amide nitrogen in purine and pyrimidine ring biosynthesis \u2014 essential for DNA/RNA synthesis in all dividing cells</li> <li>Gluconeogenesis Substrate: Major precursor for hepatic glucose production during fasting; muscle-derived glutamine \u2192 renal/hepatic gluconeogenesis</li> <li>Acid-Base Balance: Renal glutamine uptake \u2192 NH\u2084\u207a excretion in urine \u2192 net acid excretion \u2192 alkalinises blood during metabolic acidosis</li> <li>GSH Synthesis Substrate: Gln \u2192 Glu \u2192 one of three GSH precursors (with cysteine and glycine)</li> <li>mTORC1 Activation (indirect): Glutamine is required for leucine-induced mTORC1 activation via the SLC38A9/Ragulator/v-ATPase sensing system; glutamine also activates mTORC1 through GATOR2/FLCN pathway</li> <li>Neurotransmitter Cycle: Astrocytes convert synaptically released glutamate \u2192 Gln (via glutamine synthetase) \u2192 shuttle Gln to neurons \u2192 neurons release Glu (glutamate) or GABA; disruption of the glutamine-glutamate cycle is implicated in epilepsy and hepatic encephalopathy</li> </ul>"},{"location":"amino_acids/glutamine/#metabolism","title":"Metabolism","text":"Step Details Synthesis Glutamate + NH\u2084\u207a + ATP \u2192 Glutamine (glutamine synthetase; GS; ubiquitous, especially muscle + astrocytes) Catabolism Gln \u2192 Glu + NH\u2084\u207a (glutaminase; kidney, liver, lymphocytes, enterocytes) TCA entry Glu \u2192 \u03b1-ketoglutarate (GDH or transaminases) \u2192 Krebs cycle Gluconeogenesis Gln \u2192 Glu \u2192 \u03b1-KG \u2192 OAA \u2192 PEP \u2192 Glucose Nucleotide synthesis Gln amide N donates to PRPP \u2192 purine synthesis; to UMP \u2192 pyrimidine synthesis Renal ammoniagenesis Kidney glutaminase \u2192 NH\u2084\u207a (excreted) + Glu \u2192 \u03b1-KG \u2192 glucose"},{"location":"amino_acids/glutamine/#food-sources","title":"Food Sources","text":"Food Serving Glutamine (mg, approx.) Beef (lean, cooked) 85g ~1,200 mg Chicken (cooked) 85g ~1,100 mg Fish (cooked) 85g ~900\u20131,000 mg Eggs 1 large ~300 mg Milk (whole) 240 mL ~320 mg Tofu (firm) 100g ~550 mg Cabbage (raw) 90g ~170 mg Wheat germ 28g ~340 mg <p>Glutamine is labile \u2014 easily destroyed by heat and prolonged cooking. High-heat processing of protein foods significantly reduces free glutamine content.</p>"},{"location":"amino_acids/glutamine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/glutamine/#critical-illness-and-icu-nutrition","title":"Critical Illness and ICU Nutrition","text":"<ul> <li>Plasma glutamine falls dramatically after major surgery, burns, trauma, sepsis \u2192 \"glutamine debt\"</li> <li>Glutamine supplementation in parenteral nutrition (PN): 0.3\u20130.5 g/kg/day (usually as glutamine dipeptide alanine-glutamine or glycine-glutamine for stability)</li> <li>REDOXS Trial (2013): High-dose IV + enteral glutamine supplementation in MICU patients with multi-organ failure \u2192 increased 28-day mortality and AKI in sickest patients (MOF, AKI at baseline) \u2014 suggests glutamine supplementation is harmful in severe MOF</li> <li>Current ESPEN guidelines: glutamine supplementation may be beneficial in burns and elective surgery; avoid in unstable MOF/AKI</li> <li>Benefit confirmed in parenteral nutrition patients (reduces infections, hospital LOS in stable critically ill)</li> </ul>"},{"location":"amino_acids/glutamine/#gut-integrity-and-short-bowel-syndrome","title":"Gut Integrity and Short Bowel Syndrome","text":"<ul> <li>Short bowel syndrome (SBS): massively reduced absorptive surface \u2192 enterocyte glutamine deficiency \u2192 mucosal atrophy</li> <li>Glutamine supplementation (30 g/day) as part of bowel rehabilitation protocols; often combined with growth hormone and modified diet (the Byrne-Wilmore protocol)</li> </ul>"},{"location":"amino_acids/glutamine/#hepatic-encephalopathy","title":"Hepatic Encephalopathy","text":"<ul> <li>In liver failure, glutamine accumulates in astrocytes (liver cannot clear NH\u2084\u207a \u2192 peripherally converted to Gln via GS)</li> <li>Cerebral oedema and astrocyte swelling \u2192 HE symptoms</li> <li>Paradox: glutamine synthesis normally detoxifies ammonia (protective), but glutamine itself accumulates and is re-metabolised in mitochondria (glutaminase) \u2192 releases NH\u2083 intramitochondrially \u2192 oxidative stress (\"Trojan horse\" hypothesis)</li> </ul>"},{"location":"amino_acids/glutamine/#cancer-metabolism","title":"Cancer Metabolism","text":"<ul> <li>Many cancers are glutamine-addicted \u2014 rely on glutaminolysis to fuel TCA/anaplerosis, nucleotide synthesis, GSH, and reductive carboxylation for lipid synthesis in hypoxia</li> <li>Glutaminase inhibitors (CB-839, telaglenastat) in clinical trials for solid tumours</li> <li>The concept of \"glutamine depletion\" therapy \u2014 reduce tumour fuel supply</li> </ul>"},{"location":"amino_acids/glutamine/#sickle-cell-anaemia","title":"Sickle Cell Anaemia","text":"<ul> <li>Endari (L-glutamine oral powder, 10 g twice daily): FDA-approved for adults and paediatric patients \u22655 years with sickle cell disease</li> <li>Mechanism: Gln \u2192 NAD\u207a synthesis \u2192 reduces oxidative stress in sickle RBCs \u2192 fewer vaso-occlusive crises</li> <li>Reduces hospitalisation frequency by ~25%</li> </ul>"},{"location":"amino_acids/glutamine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Leucine (mTORC1) Glutamine is required for leucine-induced mTORC1 activation; glutamine depletion blunts mTOR signalling even with leucine Cysteine + Glycine All three are GSH precursors \u2014 glutamine\u2192glutamate feeds GSH first peptide step Methotrexate / Azathioprine Inhibit nucleotide synthesis (purine/pyrimidine) \u2014 pathways that require glutamine as N-donor; glutamine availability affects efficacy/toxicity Glucocorticoids Increase muscle glutamine release and whole-body glutamine flux; chronic use \u2192 muscle glutamine depletion and wasting Ammonia Glutamine synthesis removes NH\u2083; glutaminase releases NH\u2083 \u2014 the two reactions must be balanced; GS inhibitors (e.g., MSO) raise ammonia"},{"location":"amino_acids/glutamine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Powder form (5\u201315 g/day): Used by athletes post-exercise to replenish plasma glutamine; evidence for immune benefit is modest in recreational athletes; more relevant in intense military training or ultra-endurance athletes</li> <li>Bowel disease: Some use in IBD/IBS for mucosal support; evidence is limited (Crohn's trials negative; some benefit in IBS-D at 5 g three times daily)</li> <li>Cancer patients on chemotherapy: QoL support; some protocols include 10\u201330 g/day to reduce mucositis \u2014 mixed evidence; not standard of care</li> <li>Stability: Free L-glutamine powder is stable at room temperature but degrades in solution over time; alanyl-glutamine dipeptide is more stable for parenteral/enteral use</li> <li>Caution: Do not supplement at high doses (&gt;40 g/day) in patients with AKI, MOF, or hepatic encephalopathy</li> </ul>"},{"location":"amino_acids/glycine/","title":"Glycine","text":""},{"location":"amino_acids/glycine/#overview","title":"Overview","text":"<p>Glycine is the simplest amino acid \u2014 it is the only amino acid without a chiral centre, with a hydrogen atom as its side chain. It is classified as conditionally essential: synthesised from serine (primarily), threonine, and choline, but endogenous synthesis (~3 g/day) is insufficient to meet total body demands, especially for collagen synthesis (estimated need ~10\u201314 g/day). Glycine is the most abundant amino acid in collagen (~33% of all collagen residues), a key inhibitory neurotransmitter in the brainstem and spinal cord, and a primary conjugate for bile acid and xenobiotic detoxification.</p> <ul> <li>Classification: Conditionally essential (non-essential classically, but often insufficient endogenously)</li> <li>IUPAC abbreviation: Gly / G</li> <li>Side chain: Hydrogen (\u2013H); no chirality; smallest amino acid; allows unusual main-chain flexibility</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 serine \u2192 pyruvate)</li> </ul>"},{"location":"amino_acids/glycine/#dietary-requirements","title":"Dietary Requirements","text":"Condition Notes Healthy adults No RDA established; estimated total need ~10\u201314 g/day; endogenous synthesis ~3 g/day \u2192 dietary shortfall of ~7\u201310 g/day Collagen synthesis demand Collagen is ~33% glycine; growing children, pregnancy, wound healing, athletes significantly increase demand Critical illness Increased demand for detoxification, GSH synthesis (glycine is a GSH precursor), repair <p>No established UL. High doses (\u226590 g/day) may cause CNS depression via glycine receptor activation. Typical supplemental doses (3\u201315 g/day) are well-tolerated.</p>"},{"location":"amino_acids/glycine/#functions","title":"Functions","text":"<ul> <li>Collagen Structure: Every third residue in the collagen triple helix is glycine (Gly-X-Y repeating unit) \u2014 the small side chain is essential to fit inside the helix. Collagen is the most abundant protein in the body (~25% of total protein); glycine demand for collagen synthesis far exceeds endogenous synthesis capacity.</li> <li>Inhibitory Neurotransmitter (CNS): Glycine is a major inhibitory neurotransmitter in the brainstem, spinal cord, and retina \u2014 acts via strychnine-sensitive glycine receptors (GlyR; chloride channel). Inhibits motoneuron discharge \u2192 muscle relaxation and spinal reflex control.</li> <li>NMDA Receptor Co-agonist: Glycine (or D-serine) is a mandatory co-agonist at the glycine binding site of NMDA glutamate receptors \u2014 both glycine and glutamate must bind for NMDA receptor to open. Important in synaptic plasticity, learning, memory.</li> <li>Glutathione (GSH) Precursor: \u03b3-glutamyl-cysteinyl-glycine \u2014 glycine is the third tripeptide component of GSH; glycine availability can limit GSH synthesis (especially in elderly and critically ill).</li> <li>Bile Acid Conjugation: Glycine (and taurine) conjugate primary bile acids (cholate, chenodeoxycholate) in the liver \u2192 glycocholate, glycochenodeoxycholate \u2192 emulsify dietary fats; facilitate fat-soluble vitamin absorption.</li> <li>Creatine Synthesis: Arginine + Glycine \u2192 Guanidinoacetate (AGAT; kidney) + Ornithine \u2192 Creatine (GAMT; liver). Creatine synthesis is a major consumer of dietary glycine.</li> <li>One-Carbon Metabolism: Glycine \u2194 Serine (serine hydroxymethyltransferase; SHMT; B6, THF) \u2014 contributes one-carbon units to folate cycle for methylation and nucleotide synthesis.</li> <li>Porphyrin / Haem Synthesis: Glycine + Succinyl-CoA \u2192 \u03b4-aminolevulinic acid (ALA) \u2014 the first and rate-limiting step in haem biosynthesis (ALA synthase; B6-dependent).</li> <li>Purine Synthesis: Glycine is directly incorporated into the purine ring (as C4, C5, N7 of the imidazole ring) \u2014 essential for nucleotide biosynthesis.</li> <li>Detoxification (Conjugation): Glycine conjugates benzoate \u2192 hippurate (excreted in urine); conjugates xenobiotics and drug metabolites for urinary excretion.</li> <li>Anti-inflammatory Glycine Receptor (Gly-activated Cl\u207b channel on macrophages and hepatocytes): Glycine hyperpolarises macrophages and Kupffer cells via GlyR \u2192 reduces TNF-\u03b1, IL-1, NO release \u2192 anti-inflammatory. Active area in liver protection and surgery research.</li> </ul>"},{"location":"amino_acids/glycine/#metabolism","title":"Metabolism","text":"Step Details Synthesis Serine \u2192 Glycine (SHMT; B6, THF; reversible); Threonine aldolase (minor); Choline \u2192 betaine \u2192 glycine Degradation Glycine cleavage system (GCS/GLDC; P, H, T, L proteins; requires B2, B6, lipoic acid) \u2014 glycine \u2192 CO\u2082 + NH\u2084\u207a + methylene-THF Collagen pathway Gly incorporated into pro-collagen Gly-X-Y repeats; hydroxylation of X and Y (Pro, Lys) requires Vit C Haem synthesis Gly + Succinyl-CoA \u2192 ALA (ALA synthase; B6) \u2192 porphyrins \u2192 haem Creatine Gly + Arg \u2192 Guanidinoacetate (AGAT; kidney) \u2192 Creatine (GAMT; liver; SAM)"},{"location":"amino_acids/glycine/#food-sources","title":"Food Sources","text":"Food Serving Glycine (mg) Pork skin / gelatin 10g dry gelatin ~2,000\u20132,500 mg Beef (lean, cooked) 85g ~1,350 mg Chicken (cooked) 85g ~1,100 mg Collagen peptide powder 10g ~2,000\u20132,600 mg Salmon (cooked) 85g ~730 mg Pumpkin seeds 28g ~430 mg Lentils (cooked) 200g ~580 mg Egg 1 large ~200 mg <p>Collagen is the richest food source of glycine; muscle meat (fillets) is lower in glycine than connective tissue\u2013rich cuts (oxtail, bone broth, pig's trotters, skin). Bone broth provides significant glycine.</p>"},{"location":"amino_acids/glycine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/glycine/#non-ketotic-hyperglycinaemia-nkh-glycine-encephalopathy","title":"Non-Ketotic Hyperglycinaemia (NKH / Glycine Encephalopathy)","text":"<ul> <li>Defect in the glycine cleavage system (GCS); autosomal recessive</li> <li>Accumulation of glycine in blood and CSF \u2192 neonatal hypotonia, seizures, apnoea, severe intellectual disability or death</li> <li>Excess glycine over-activates NMDA receptors (co-agonist site) + glycine receptors \u2192 excitotoxicity paradoxically from an inhibitory amino acid at non-inhibitory receptors</li> <li>Treatment: sodium benzoate (conjugates glycine \u2192 hippurate, excreted), NMDA antagonists (dextromethorphan, ketamine) \u2014 outcomes are poor in severe forms</li> </ul>"},{"location":"amino_acids/glycine/#methylmalonic-acidaemia-propionic-acidaemia","title":"Methylmalonic Acidaemia / Propionic Acidaemia","text":"<ul> <li>Glycine conjugates propionyl-CoA \u2192 propionylglycine; urinary propionylglycine is a diagnostic marker</li> </ul>"},{"location":"amino_acids/glycine/#strychnine-poisoning","title":"Strychnine Poisoning","text":"<ul> <li>Strychnine blocks glycine receptors (GlyR) in spinal cord \u2192 loss of inhibitory interneuron function \u2192 violent tetanic convulsions (muscle hyperexcitability)</li> <li>Antidote: supportive care, benzodiazepines; highlights critical role of glycine in spinal inhibition</li> </ul>"},{"location":"amino_acids/glycine/#schizophrenia-nmda-hypofunction-hypothesis","title":"Schizophrenia (NMDA Hypofunction Hypothesis)","text":"<ul> <li>Glycine (3\u201380 g/day) and D-cycloserine (partial GlyR agonist) studied as adjuncts in schizophrenia to enhance NMDA receptor co-agonist activity</li> <li>Some trials show modest improvement in negative symptoms; not standard of care</li> </ul>"},{"location":"amino_acids/glycine/#metabolic-syndrome-and-insulin-resistance","title":"Metabolic Syndrome and Insulin Resistance","text":"<ul> <li>Low plasma glycine is consistently observed in obesity, insulin resistance, and T2DM</li> <li>Glycine supplementation (9 g/day) in one RCT improved insulin sensitivity in obese subjects; mechanism unclear (possibly improved mitochondrial function, reduced inflammation, improved GSH)</li> </ul>"},{"location":"amino_acids/glycine/#sleep-quality","title":"Sleep Quality","text":"<ul> <li>Glycine 3 g orally before bedtime: RCTs show improved subjective sleep quality, reduced daytime sleepiness, and reduced core body temperature (possibly via hypothalamic glycine receptors)</li> <li>One of the better-supported non-pharmacological sleep interventions</li> </ul>"},{"location":"amino_acids/glycine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Vitamin B6 SHMT (Gly\u2194Ser), ALA synthase (haem), and glycine cleavage H-protein all require PLP Folate (THF) SHMT reaction couples glycine-serine interconversion to the folate one-carbon cycle Vitamin C Required for prolyl/lysyl hydroxylation in collagen (acts on the X and Y positions adjacent to glycine) Zinc Supports ALA dehydratase (second step of haem synthesis, downstream of glycine entry); also binds metalloproteins where glycine-rich motifs are present Sodium benzoate Conjugates with glycine \u2192 hippurate (excreted in urine) \u2192 reduces plasma glycine; used therapeutically in NKH and urea cycle disorders NMDA receptor drugs Glycine co-agonist site is target for memantine (partial), D-cycloserine, and is relevant in ketamine mechanism of action"},{"location":"amino_acids/glycine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Collagen peptide supplements (5\u201315 g/day): Rich in glycine, proline, hydroxyproline; evidence supports joint pain reduction (knee OA), skin elasticity improvement, and reduction in exercise-related joint discomfort</li> <li>L-Glycine powder (3\u20135 g before bed): Well-supported for improving sleep quality (RCTs); also used for anxiety and GI comfort</li> <li>Glycine for metabolic health: Early evidence for insulin sensitivity, anti-inflammatory effects; larger trials needed</li> <li>Both glycine and taurine (another Cys/Met-derived compound) are essential for bile acid conjugation \u2014 together they ensure adequate fat-soluble vitamin absorption</li> <li>High-quality protein with organ meats, connective tissue, and bone broth increases dietary glycine significantly compared to a muscle-meat\u2013only diet</li> </ul>"},{"location":"amino_acids/histidine/","title":"Histidine","text":""},{"location":"amino_acids/histidine/#overview","title":"Overview","text":"<p>Histidine is an essential amino acid \u2014 it cannot be synthesised in adequate amounts by the body and must be obtained from the diet. It is unique among essential amino acids in that it was historically classified as \"semi-essential\" because adults can synthesise small amounts, but this is insufficient for normal function. It is the precursor of histamine, a key mediator of immune responses, gastric acid secretion, and neurotransmission. It also forms part of the active site of many enzymes (as the imidazole side chain acts as both a proton donor and acceptor near physiological pH).</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: His / H</li> <li>Side chain: Imidazole group; pKa ~6.0 \u2014 unique buffering capacity near physiological pH</li> <li>Glucogenic / Ketogenic: Glucogenic (converted to \u03b1-ketoglutarate)</li> </ul>"},{"location":"amino_acids/histidine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~36 mg/kg/day \u2014 Children 1\u20133 years ~22 mg/kg/day ~490 mg/day Adults 19+ ~14 mg/kg/day ~980 mg/day (70 kg adult) Pregnant Women Higher requirements ~1,000\u20131,100 mg/day <p>No established UL for histidine from food. High-dose supplements (&gt; 4 g/day) have been associated with adverse effects.</p>"},{"location":"amino_acids/histidine/#functions","title":"Functions","text":"<ul> <li>Histamine Precursor: Decarboxylated by histidine decarboxylase to form histamine \u2014 mediates allergic responses, gastric acid secretion (H2 receptors on parietal cells), vasodilation, wakefulness, and neurotransmission.</li> <li>Haemoglobin Buffering: The imidazole side chains of histidine residues in haemoglobin (the Bohr effect) facilitate CO\u2082 transport and O\u2082 release in tissues.</li> <li>Carnosine Synthesis: \u03b2-alanine + histidine \u2192 carnosine (dipeptide) \u2014 high concentrations in muscle and brain; buffers lactic acid during exercise, antioxidant, inhibits protein glycation.</li> <li>Enzyme Active Sites: Histidine residues are critical catalytic residues in serine proteases (trypsin, chymotrypsin, thrombin), kinases, and phosphatases.</li> <li>Metal Chelation: Imidazole ring coordinates zinc, copper, iron in metalloenzymes (e.g., carbonic anhydrase).</li> <li>Folate Metabolism: Histidine is catabolised through the formiminoglutamate (FIGLU) pathway, consuming tetrahydrofolate \u2014 FIGLU accumulates in folate deficiency (used in FIGLU excretion test for folate status).</li> <li>Immune Regulation: Histamine derived from histidine modulates innate and adaptive immune responses.</li> </ul>"},{"location":"amino_acids/histidine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport in the small intestine (SLC6A19, SLC36 transporters) Catabolism Histidine \u2192 urocanate \u2192 imidazolonepropionate \u2192 formimino-glutamate \u2192 glutamate \u2192 TCA cycle Key enzyme Histidase (HAL gene) \u2014 deficiency causes histidinaemia Histamine synthesis Histidine decarboxylase (HDC) \u2014 mast cells, enterochromaffin-like cells, neurons, macrophages"},{"location":"amino_acids/histidine/#food-sources","title":"Food Sources","text":"Food Serving Histidine (mg) Beef (lean, cooked) 85g ~880 mg Chicken breast (cooked) 85g ~800 mg Tuna (canned) 85g ~870 mg Salmon (cooked) 85g ~750 mg Parmesan cheese 28g ~440 mg Lentils (cooked) 200g ~530 mg Quinoa (cooked) 185g ~360 mg Egg 1 large ~295 mg"},{"location":"amino_acids/histidine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/histidine/#histidinaemia","title":"Histidinaemia","text":"<ul> <li>Autosomal recessive deficiency of histidase</li> <li>Accumulation of histidine and downstream metabolites (urocanate, imidazole pyruvate)</li> <li>Historically considered benign; surveillance continues but severe neurological effects are uncommon</li> </ul>"},{"location":"amino_acids/histidine/#histamine-intolerance-mast-cell-activation","title":"Histamine Intolerance / Mast Cell Activation","text":"<ul> <li>Excess dietary histidine or histamine (aged cheese, fermented foods, wine) \u2192 symptoms in individuals with reduced diamine oxidase (DAO) or histamine N-methyltransferase (HNMT) activity</li> <li>Symptoms: flushing, urticaria, rhinorrhoea, headache, palpitations</li> </ul>"},{"location":"amino_acids/histidine/#folate-deficiency-diagnosis","title":"Folate Deficiency Diagnosis","text":"<ul> <li>FIGLU excretion test: oral histidine load \u2192 measure urinary FIGLU</li> <li>Elevated FIGLU indicates folate deficiency (impaired FIGLU conversion requires tetrahydrofolate)</li> </ul>"},{"location":"amino_acids/histidine/#joint-conditions","title":"Joint Conditions","text":"<ul> <li>Histidine is depleted in rheumatoid arthritis (RA) patients \u2014 mechanism unclear; possibly due to elevated histaminase or increased demand</li> <li>Some trials have supplemented histidine in RA with modest benefit</li> </ul>"},{"location":"amino_acids/histidine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Folate (B9) Required for FIGLU \u2192 glutamate conversion; histidine loading reveals folate status Zinc / Copper Histidine chelates and aids transport of zinc and copper across intestinal epithelium Antihistamines (H1/H2 blockers) Block histamine receptors \u2014 do not affect histidine absorption but modulate downstream histamine effects Proton pump inhibitors Reduce gastric acid \u2014 same target pathway as histamine (H2 receptor on parietal cells)"},{"location":"amino_acids/histidine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Carnosine supplements provide histidine + \u03b2-alanine; used by athletes for intramuscular buffering</li> <li>High-dose isolated histidine supplementation (&gt;4 g/day) is not recommended without medical supervision</li> <li>Histidine-rich infant formulas are critical \u2014 infants have higher relative requirements than adults</li> </ul>"},{"location":"amino_acids/isoleucine/","title":"Isoleucine","text":""},{"location":"amino_acids/isoleucine/#overview","title":"Overview","text":"<p>Isoleucine is an essential amino acid and one of three branched-chain amino acids (BCAAs), alongside leucine and valine. While leucine is the dominant mTORC1 activator, isoleucine's primary metabolic role is in glucose transport and uptake in muscle \u2014 it independently stimulates GLUT4 translocation and glucose disposal. Isoleucine is both glucogenic and ketogenic, and its catabolism is tightly linked to energy metabolism in muscle.</p> <ul> <li>Classification: Essential; Branched-Chain Amino Acid (BCAA)</li> <li>IUPAC abbreviation: Ile / I</li> <li>Side chain: Branched aliphatic (methylethyl group); has two stereocentres</li> <li>Glucogenic / Ketogenic: Both (\u2192 succinyl-CoA [glucogenic] and acetyl-CoA [ketogenic])</li> </ul>"},{"location":"amino_acids/isoleucine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~58 mg/kg/day \u2014 Children 1\u20133 years ~36 mg/kg/day ~800 mg/day Adults 19+ ~19 mg/kg/day ~1,330 mg/day (70 kg adult) <p>No established UL for isoleucine from food. Taken in isolation, high-dose isoleucine may disturb BCAA balance by competing with leucine and valine at shared transporters.</p>"},{"location":"amino_acids/isoleucine/#functions","title":"Functions","text":"<ul> <li>Glucose Uptake in Muscle: Isoleucine independently stimulates GLUT4 translocation to the plasma membrane in skeletal muscle \u2014 increases glucose uptake even in the absence of insulin (via PI3K/Akt signalling). This is distinct from leucine's role and makes isoleucine important for post-exercise glucose disposal.</li> <li>Glycogen Synthesis: Promotes muscle glycogen resynthesis in the post-exercise window.</li> <li>mTORC1 Activation (minor): Contributes to mTOR signalling but is significantly less potent than leucine.</li> <li>Haemoglobin Structure: Isoleucine is a component of haemoglobin \u2014 the substitution Glu6\u2192Val (sickle cell) is adjacent; comparable mutations at other sites can affect stability.</li> <li>Immune Function: Supports synthesis of \u03b2-defensins (antimicrobial peptides produced by intestinal epithelium), contributing to innate mucosal immunity.</li> <li>Protein Synthesis Substrate: Essential structural component of muscle, connective tissue, and visceral proteins.</li> <li>Energy Supply: Catabolised in muscle during prolonged exercise, providing acetyl-CoA to the TCA cycle.</li> </ul>"},{"location":"amino_acids/isoleucine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport via LAT1 (SLC7A5) \u2014 shared transporter with leucine, valine, and aromatic amino acids First-pass metabolism Low hepatic extraction; preferentially taken up by muscle and adipose tissue Catabolism Ile \u2192 \u03b1-methylbutyryl-CoA \u2192 propionyl-CoA (\u2192 succinyl-CoA, glucogenic) + acetyl-CoA (ketogenic) Key enzyme Branched-Chain \u03b1-Keto Acid Dehydrogenase (BCKD) complex \u2014 same as leucine and valine Regulation Muscle exercise increases BCKD activity; insulin inhibits BCAA catabolism (promotes protein synthesis)"},{"location":"amino_acids/isoleucine/#food-sources","title":"Food Sources","text":"Food Serving Isoleucine (mg) Beef (lean, cooked) 85g ~1,100 mg Chicken breast (cooked) 85g ~1,050 mg Canned tuna 85g ~1,000 mg Egg 1 large ~340 mg Milk (whole) 240 mL ~450 mg Lentils (cooked) 200g ~700 mg Pumpkin seeds 28g ~380 mg Whey protein isolate 30g ~1,200 mg"},{"location":"amino_acids/isoleucine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/isoleucine/#maple-syrup-urine-disease-msud","title":"Maple Syrup Urine Disease (MSUD)","text":"<ul> <li>BCKD complex deficiency \u2014 isoleucine accumulates alongside leucine and valine</li> <li>Isoleucine is toxic in excess (neurological), but leucine is the primary driver of encephalopathy</li> <li>Management: BCAA-restricted diet; branched-chain keto acid\u2013supplemented medical formulas; liver transplant</li> </ul>"},{"location":"amino_acids/isoleucine/#isovaleric-acidaemia-not-isoleucine-specific","title":"Isovaleric Acidaemia (not isoleucine-specific)","text":"<ul> <li>Affects leucine catabolism (isovaleryl-CoA dehydrogenase); isoleucine catabolism is separate</li> </ul>"},{"location":"amino_acids/isoleucine/#post-exercise-glucose-disposal","title":"Post-Exercise Glucose Disposal","text":"<ul> <li>GLUT4 translocation by isoleucine is relevant in the context of post-workout nutrition \u2014 supports glycogen resynthesis and mirrors some insulin-like actions</li> </ul>"},{"location":"amino_acids/isoleucine/#bcaa-ratio-in-supplementation","title":"BCAA Ratio in Supplementation","text":"<ul> <li>Excess isolated leucine supplementation reduces isoleucine plasma concentration (transporter competition) \u2014 reinforces the importance of balanced BCAA ratios (2:1:1 Leu:Ile:Val)</li> </ul>"},{"location":"amino_acids/isoleucine/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Leucine + Valine Compete at LAT1; high leucine reduces isoleucine uptake; balanced BCAA ratios recommended B vitamins (B1, B2, B3, lipoic acid) Required cofactors for the BCKD complex \u2014 isoleucine catabolism depends on these Insulin Insulin suppresses BCAA (incl. isoleucine) catabolism \u2014 promotes protein anabolism Glucose Isoleucine-mediated GLUT4 upregulation is additive with insulin-stimulated glucose uptake"},{"location":"amino_acids/isoleucine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Sold as part of BCAA supplements (typically 2:1:1 Leu:Ile:Val)</li> <li>Rarely supplemented in isolation; imbalance without co-supplementation of leucine/valine is counterproductive</li> <li>Some evidence that BCAAs (including isoleucine) reduce exercise-induced muscle soreness and protect lean mass during caloric restriction</li> <li>Athletes consuming sufficient high-quality protein (\u22651.6 g/kg/day) are unlikely to need additional BCAA supplementation</li> </ul>"},{"location":"amino_acids/leucine/","title":"Leucine","text":""},{"location":"amino_acids/leucine/#overview","title":"Overview","text":"<p>Leucine is an essential amino acid and the most abundant branched-chain amino acid (BCAA) by proportion in muscle protein. It is the primary nutritional signal that activates mTORC1 (mechanistic target of rapamycin complex 1), making it the key anabolic trigger for muscle protein synthesis. Unlike other amino acids, leucine is catabolised primarily in skeletal muscle (not the liver), making its plasma level an important metabolic signal in the postprandial state.</p> <ul> <li>Classification: Essential; Branched-Chain Amino Acid (BCAA)</li> <li>IUPAC abbreviation: Leu / L</li> <li>Side chain: Isobutyl (aliphatic, hydrophobic)</li> <li>Glucogenic / Ketogenic: Exclusively ketogenic (\u2192 acetyl-CoA and acetoacetate; does not contribute to gluconeogenesis)</li> </ul>"},{"location":"amino_acids/leucine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~103 mg/kg/day \u2014 Children 1\u20133 years ~73 mg/kg/day ~1,600 mg/day Adults 19+ ~39 mg/kg/day ~2,730 mg/day (70 kg adult) Athletes / high protein need Higher 3,000\u20134,000 mg/day <p>No established UL from food sources. Leucine supplements at very high doses (&gt;10 g/day) may impair isoleucine and valine status and cause mild hyperammonaemia.</p>"},{"location":"amino_acids/leucine/#functions","title":"Functions","text":"<ul> <li>mTORC1 Activation (Master Anabolic Signal): Leucine directly activates mTORC1 via the Rag GTPase\u2013Ragulator complex and Sestrin2 sensor \u2014 initiates protein synthesis through phosphorylation of S6K1 and 4E-BP1. No other amino acid has this potency.</li> <li>Muscle Protein Synthesis: Acts as both a substrate and regulatory signal; the \"leucine threshold\" concept \u2014 a minimum intracellular leucine concentration must be reached to maximally stimulate MPS.</li> <li>Insulin Secretion: Stimulates pancreatic \u03b2-cell insulin secretion independently of glucose (via glutamate dehydrogenase activation).</li> <li>Protein Sparing: During energy restriction, leucine catabolism can generate ketone bodies and acetyl-CoA for energy substrate.</li> <li>Wound Healing: Provides substrate for tissue repair; upregulates protein synthesis in recovering tissues.</li> <li>Glucose Homeostasis: High leucine activates mTORC1 \u2192 S6K1 \u2192 IRS-1 serine phosphorylation, which can impair insulin signalling at high doses (mechanistic link between high BCAA diets and insulin resistance).</li> </ul>"},{"location":"amino_acids/leucine/#metabolism","title":"Metabolism","text":"Step Details Absorption Transported by LAT1 (SLC7A5) \u2014 shared with other BCAAs, tyrosine, phenylalanine First-pass metabolism Minimal hepatic extraction (~5%); primarily taken up by muscle Catabolism Leucine \u2192 \u03b1-ketoisocaproate (KIC) via BCAA aminotransferase \u2192 isovaleryl-CoA \u2192 acetyl-CoA + acetoacetate (via BCKD complex) Key enzyme Branched-Chain \u03b1-Keto Acid Dehydrogenase (BCKD) \u2014 requires B1, B2, B3, lipoic acid Regulation BCKD is inactivated by phosphorylation; activated by dephosphorylation in muscle with exercise"},{"location":"amino_acids/leucine/#food-sources","title":"Food Sources","text":"Food Serving Leucine (mg) Beef (lean, cooked) 85g ~2,150 mg Chicken breast (cooked) 85g ~2,090 mg Canned tuna 85g ~1,900 mg Milk (whole) 240 mL ~800 mg Whey protein isolate 30g ~2,900 mg Lentils (cooked) 200g ~1,300 mg Edamame (cooked) 155g ~1,200 mg Parmesan cheese 28g ~870 mg <p>Whey protein is notably leucine-rich (~10\u201311%) and rapidly absorbed, making it particularly effective for MPS stimulation.</p>"},{"location":"amino_acids/leucine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/leucine/#leucinosis-maple-syrup-urine-disease-msud","title":"Leucinosis / Maple Syrup Urine Disease (MSUD)","text":"<ul> <li>Autosomal recessive deficiency of the BCKD complex \u2014 all three BCAAs (leucine, isoleucine, valine) accumulate</li> <li>Leucine is the primary neurotoxin \u2014 causes encephalopathy, cerebral oedema</li> <li>Classic MSUD: neonatal onset; characteristic maple syrup odour in urine/cerumen</li> <li>Management: BCAA-restricted diet; leucine-reduced medical formulas; liver transplant (curative \u2014 restores hepatic BCKD activity)</li> </ul>"},{"location":"amino_acids/leucine/#sarcopenia-ageing","title":"Sarcopenia &amp; Ageing","text":"<ul> <li>Anabolic resistance \u2014 older muscle requires higher leucine doses to maximally activate MPS</li> <li>Leucine-enriched protein supplements (leucine \u2265 3g per meal) may partially overcome anabolic resistance in elderly</li> </ul>"},{"location":"amino_acids/leucine/#hyperleucinaemia-and-insulin-resistance","title":"Hyperleucinaemia and Insulin Resistance","text":"<ul> <li>Chronically elevated plasma BCAA (incl. leucine) \u2014 strong biomarker associated with insulin resistance and T2DM risk</li> <li>Mechanistic: S6K1 \u2192 IRS-1 Ser307 phosphorylation \u2192 impairs insulin signalling</li> </ul>"},{"location":"amino_acids/leucine/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Isoleucine + Valine BCAAs compete for the same transporter (LAT1); excess leucine can lower plasma isoleucine and valine \u2014 BCAA supplements should contain balanced ratios (typically 2:1:1 Leu:Ile:Val) B vitamins (B1, B2, B3, lipoic acid) Cofactors for the BCKD complex \u2014 deficiency slows leucine catabolism Insulin Leucine stimulates insulin; insulin drives leucine into muscle \u2014 synergistic for post-meal anabolism Rapamycin / mTOR inhibitors Block leucine's anabolic signalling \u2014 clinically relevant in transplant and oncology patients"},{"location":"amino_acids/leucine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>BCAA supplements: Most commonly 2:1:1 (Leu:Ile:Val) ratio; used peri-workout to limit muscle catabolism</li> <li>Leucine-enriched protein meals: Effective strategy for elderly or those with anabolic resistance</li> <li>HMB (\u03b2-hydroxy \u03b2-methylbutyrate): Metabolite of leucine (via KIC); marketed for anti-catabolic effects \u2014 evidence is stronger in untrained individuals and clinical muscle-wasting states</li> <li>Isolated high-dose leucine (&gt;10\u201315 g/day chronically) is not advised due to aminoaciduria and potential metabolic imbalances</li> </ul>"},{"location":"amino_acids/lysine/","title":"Lysine","text":""},{"location":"amino_acids/lysine/#overview","title":"Overview","text":"<p>Lysine is an essential amino acid and the most commonly limiting amino acid in cereal-grain\u2013based diets. It is critical for collagen synthesis and cross-linking, immune function, and carnitine biosynthesis. Lysine has a positively charged \u03b5-amino group that participates in key post-translational modifications (acetylation, methylation, ubiquitination) on histone proteins \u2014 directly linking lysine to epigenetic regulation of gene expression.</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: Lys / K</li> <li>Side chain: \u03b5-amino group (pKa ~10.5); positively charged at physiological pH</li> <li>Glucogenic / Ketogenic: Exclusively ketogenic (along with leucine \u2014 the only two strictly ketogenic essential amino acids; \u2192 acetyl-CoA and acetoacetate)</li> </ul>"},{"location":"amino_acids/lysine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~99 mg/kg/day \u2014 Children 1\u20133 years ~62 mg/kg/day ~1,365 mg/day Adults 19+ ~38 mg/kg/day ~2,660 mg/day (70 kg adult) Pregnant Women Higher ~3,100 mg/day <p>No established UL from food sources. Supplemental doses of 1\u20133 g/day are used clinically. Very high doses (&gt;15 g/day) have caused GI symptoms and tubulointerstitial nephritis in isolated case reports.</p>"},{"location":"amino_acids/lysine/#functions","title":"Functions","text":"<ul> <li>Collagen Synthesis: Lysine residues are hydroxylated by prolyl hydroxylase (requires vitamin C) to form hydroxylysine \u2014 essential for cross-linking collagen fibrils via lysyl oxidase (requires copper). Without adequate lysine or vitamin C \u2192 weakened connective tissue, poor wound healing.</li> <li>Carnitine Biosynthesis: Lysine (and methionine) \u2192 butyrobetaine \u2192 L-carnitine (requires vitamin C, B6, niacin, iron as cofactors). Carnitine is essential for long-chain fatty acid transport into mitochondria for \u03b2-oxidation.</li> <li>Calcium Absorption: Lysine increases intestinal calcium absorption and reduces urinary calcium excretion \u2014 may play a role in bone mineral density maintenance.</li> <li>Antiviral Activity (Herpes simplex): Arginine is required for HSV replication; lysine competes with arginine for intestinal absorption and intracellular uptake \u2014 lysine supplementation reduces HSV recurrence frequency and severity in clinical trials.</li> <li>Histone Modification: \u03b5-amino groups of histone lysine residues undergo:</li> <li>Acetylation (by HATs) \u2192 gene activation</li> <li>Methylation (by HMTs) \u2192 activation or repression depending on position (H3K4me3 = active; H3K27me3 = repressive)</li> <li>Ubiquitination \u2192 protein degradation (via proteasome) or signalling</li> <li>Enzyme Structure: Lysine residues form hydrogen bonds and ion pairs central to enzyme active site architecture.</li> <li>Antibody Production: Lysine availability supports immunoglobulin synthesis.</li> </ul>"},{"location":"amino_acids/lysine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport via b\u2070,\u207a transporter (SLC7A9 / BAT1) and rBAT \u2014 shared with arginine, ornithine, cystine Catabolism (main) Saccharopine pathway (liver): Lys \u2192 saccharopine \u2192 aminoadipate semialdehyde \u2192 \u03b1-ketoadipate \u2192 acetyl-CoA Alternative pathway Pipecolic acid pathway (active in brain and peroxisomes) Carnitine synthesis Lys \u2192 \u03b5-N-trimethyllysine \u2192 3-hydroxy-trimethyllysine \u2192 carnitine precursors Hydroxylation Prolyl hydroxylase-like enzymes \u2192 hydroxylysine in collagen"},{"location":"amino_acids/lysine/#food-sources","title":"Food Sources","text":"Food Serving Lysine (mg) Beef (lean, cooked) 85g ~2,300 mg Chicken breast (cooked) 85g ~2,200 mg Tuna (canned) 85g ~2,100 mg Eggs 1 large ~455 mg Milk (whole) 240 mL ~660 mg Parmesan cheese 28g ~780 mg Lentils (cooked) 200g ~1,240 mg Quinoa (cooked) 185g ~440 mg Seitan (wheat gluten) 100g very low \u2014 lysine-deficient <p>Wheat, corn, and most cereal grains are poor in lysine \u2014 the primary limiting amino acid in plant-based and cereal-dominant diets. Legumes compensate (high lysine, low methionine).</p>"},{"location":"amino_acids/lysine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/lysine/#lysinuric-protein-intolerance-lpi","title":"Lysinuric Protein Intolerance (LPI)","text":"<ul> <li>Defect in the y\u207aLAT1\u20134F2hc transporter (dibasic amino acid transporter)</li> <li>Impaired intestinal absorption and renal reabsorption of lysine, arginine, ornithine</li> <li>Results in urea cycle disruption (hyperammonaemia), protein intolerance, lung disease (PAP), haematological findings</li> <li>Treatment: low-protein diet, citrulline supplementation to bypass the defect, lysine supplementation (oral)</li> </ul>"},{"location":"amino_acids/lysine/#familial-hyperlysinaemia","title":"Familial Hyperlysinaemia","text":"<ul> <li>Bifunctional enzyme deficiency (aminoadipic semialdehyde synthase \u2014 AASS); generally benign</li> <li>Elevated plasma and urine lysine; usually an incidental amino acid screen finding</li> </ul>"},{"location":"amino_acids/lysine/#herpes-simplex-virus-hsv-recurrence","title":"Herpes Simplex Virus (HSV) Recurrence","text":"<ul> <li>Lysine supplementation (500\u20133,000 mg/day) reduces frequency and severity of HSV outbreaks</li> <li>Mechanism: competes with arginine (required for HSV replication) at shared intestinal and cellular transporters</li> <li>Evidence: meta-analyses support decreased recurrence; effect size is moderate</li> </ul>"},{"location":"amino_acids/lysine/#collagen-disorders-wound-healing","title":"Collagen Disorders / Wound Healing","text":"<ul> <li>Lysine deficiency \u2192 impaired collagen cross-linking \u2192 delayed healing, fragile connective tissue</li> <li>Relevant in severe malnutrition, elderly with protein-energy malnutrition</li> </ul>"},{"location":"amino_acids/lysine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Vitamin C Required for hydroxylysine formation (hydroxylation of lysine in collagen) and for carnitine synthesis Arginine Competitive antagonist \u2014 high arginine impairs lysine absorption; lysine:arginine ratio is relevant for HSV management Copper Lysyl oxidase (copper-dependent) forms collagen and elastin cross-links with hydroxylysine B6, B3, Iron Cofactors for carnitine biosynthesis from lysine and methionine Calcium Lysine enhances intestinal Ca\u00b2\u207a absorption; potential for co-supplementation in bone health protocols"},{"location":"amino_acids/lysine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>L-Lysine supplements (500\u20133,000 mg/day): Used for HSV recurrence prevention; widely available OTC</li> <li>Combined with Vitamin C: Sometimes co-supplemented for collagen synthesis / wound healing support</li> <li>Athletes: Lysine is rarely limiting if total protein intake is adequate with varied sources (meat, dairy, legumes)</li> <li>Vegan diets: Should ensure adequate lysine through legumes (lentils, chickpeas, soy, tofu) \u2014 cereal-only diets risk lysine insufficiency</li> </ul>"},{"location":"amino_acids/methionine/","title":"Methionine","text":""},{"location":"amino_acids/methionine/#overview","title":"Overview","text":"<p>Methionine is an essential amino acid and the only sulphur-containing essential amino acid (alongside the conditionally essential cysteine). It is the universal methyl group donor via its activated form S-adenosylmethionine (SAM), making it central to epigenetic regulation, neurotransmitter inactivation, creatine synthesis, and the transsulphuration pathway that produces cysteine and ultimately glutathione. All mammalian protein synthesis begins with methionine (start codon: AUG).</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: Met / M</li> <li>Side chain: Thioether (\u2013CH\u2082\u2013CH\u2082\u2013S\u2013CH\u2083); sulphur-containing, hydrophobic</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 succinyl-CoA via propionate)</li> </ul>"},{"location":"amino_acids/methionine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (combined Met + Cys, mg/kg/day) Approximate daily need Infants 0\u20136 months ~43 mg/kg/day \u2014 Children 1\u20133 years ~28 mg/kg/day ~615 mg/day Adults 19+ ~19 mg/kg/day ~1,330 mg/day (70 kg adult) <p>RDA is expressed as combined methionine + cysteine (cysteine can spare methionine). No established UL from food. High supplemental methionine (&gt;5 g/day) increases plasma homocysteine significantly.</p>"},{"location":"amino_acids/methionine/#functions","title":"Functions","text":"<ul> <li>S-Adenosylmethionine (SAM) \u2014 Universal Methyl Donor:</li> <li>Methionine + ATP \u2192 SAM (via methionine adenosyltransferase)</li> <li>SAM donates methyl groups to DNA (DNA methylation \u2192 gene silencing), histones, RNA, neurotransmitters, phospholipids, creatine, and dozens of other substrates</li> <li>SAM \u2192 S-adenosylhomocysteine (SAH) \u2192 homocysteine \u2192 re-methylated to methionine (requires folate, B12) or directed to transsulphuration</li> <li>Methionine Cycle (One-Carbon Metabolism):</li> <li>Remethylation: Homocysteine + 5-methylTHF \u2192 Methionine (requires B12 as cofactor for methionine synthase)</li> <li>Transsulphuration: Homocysteine \u2192 Cystathionine (CBS, B6-dependent) \u2192 Cysteine \u2192 Glutathione, taurine, sulphate</li> <li>Initiation of Protein Synthesis: All eukaryotic mRNAs are translated from AUG (methionine) start codon; the initiator Met is frequently co-translationally cleaved</li> <li>Creatine Synthesis: SAM donates a methyl group in guanidinoacetate \u2192 creatine conversion (in liver); creatine synthesis consumes ~40\u201345% of daily SAM methyl groups</li> <li>Phosphatidylcholine Synthesis: SAM methylates phosphatidylethanolamine (PE) \u2192 phosphatidylcholine (PC) \u2014 critical for cell membrane function and VLDL secretion from liver</li> <li>Epigenetic Regulation: DNA methylation (by DNMTs using SAM) controls gene expression across development, ageing, and disease</li> <li>Antioxidant Precursor: Via transsulphuration \u2192 Cysteine \u2192 Glutathione (GSH), taurine</li> </ul>"},{"location":"amino_acids/methionine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport (intestinal \u2013 SLC7A9, SLC6A19) Activation Met + ATP \u2192 SAM (methionine adenosyltransferase, MAT1A/MAT2A) Methylation SAM \u2192 SAH \u2192 Homocysteine Remethylation Hcy + 5-MTHF \u2192 Met (methionine synthase; B12-dependent) Transsulphuration Hcy \u2192 cystathionine (CBS; B6) \u2192 Cysteine Catabolism Cysteine \u2192 pyruvate / sulphate / taurine; Met \u2192 \u03b1-ketobutyrate \u2192 propionyl-CoA \u2192 succinyl-CoA"},{"location":"amino_acids/methionine/#food-sources","title":"Food Sources","text":"Food Serving Methionine (mg) Beef (lean, cooked) 85g ~680 mg Chicken breast (cooked) 85g ~650 mg Canned tuna 85g ~700 mg Egg 1 large ~210 mg Brazil nuts 28g ~640 mg Parmesan cheese 28g ~490 mg Lentils (cooked) 200g ~310 mg Sesame seeds 28g ~335 mg <p>Animal proteins are consistently high in methionine. Plant proteins (particularly legumes) tend to be methionine-limited (complemented by cereals which are methionine-rich but lysine-poor).</p>"},{"location":"amino_acids/methionine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/methionine/#homocystinuria-classical","title":"Homocystinuria (Classical)","text":"<ul> <li>Deficiency of cystathionine \u03b2-synthase (CBS); autosomal recessive</li> <li>Homocysteine accumulates to very high levels (plasma Hcy &gt;100 \u03bcmol/L)</li> <li>Features: Marfanoid habitus, ectopia lentis (downward lens dislocation \u2014 opposite of Marfan), intellectual disability, osteoporosis, thromboembolic events (DVT, stroke)</li> <li>Treatment: B6 (many are pyridoxine-responsive), methionine-restricted + cystine-supplemented diet, betaine (alternative methyl donor for remethylation), folate + B12</li> </ul>"},{"location":"amino_acids/methionine/#hyperhomocysteinaemia","title":"Hyperhomocysteinaemia","text":"<ul> <li>Mild-moderate elevation (15\u2013100 \u03bcmol/L): B12, folate, B6 deficiency; CKD; hypothyroidism; MTHFR C677T polymorphism</li> <li>Independent risk factor for cardiovascular disease, stroke, dementia</li> <li>Treatment: B12 + folate (\u00b1 B6) supplementation lowers Hcy levels; evidence for CVD risk reduction is mixed</li> </ul>"},{"location":"amino_acids/methionine/#methionine-restriction-longevity-research","title":"Methionine Restriction (Longevity Research)","text":"<ul> <li>Dietary methionine restriction extends lifespan in rodents \u2014 mechanism: reduced IGF-1, reduced mitochondrial ROS generation, altered methionine cycle flux</li> <li>Human relevance under investigation; not a current clinical recommendation</li> </ul>"},{"location":"amino_acids/methionine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Folate (B9) + B12 Required for remethylation of homocysteine \u2192 methionine; deficiency causes Hcy accumulation Pyridoxine (B6) CBS cofactor for transsulphuration; deficiency causes homocystinuria (partially reversible with B6) Riboflavin (B2) Cofactor for MTHFR (converts dietary folate to 5-MTHF); relevant especially with MTHFR C677T Cysteine Cysteine can spare methionine requirements by reducing the transsulphuration demand Betaine Alternative methyl donor remethylating homocysteine (BHMT pathway); used in homocystinuria management Nitrous oxide (N\u2082O) Irreversibly inactivates B12 \u2192 blocks methionine synthase \u2192 acute functional methionine cycle impairment"},{"location":"amino_acids/methionine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>SAMe (S-adenosylmethionine) supplements: Used for depression, osteoarthritis, liver disease; effective SAM precursor; doses 400\u20131,600 mg/day</li> <li>Methionine supplementation is rarely needed in individuals with adequate dietary protein</li> <li>High-protein diets elevate methionine intake and can raise homocysteine \u2014 especially relevant if B vitamin status is suboptimal</li> <li>NAC (N-acetylcysteine) provides cysteine, which can reduce the methionine burden on the transsulphuration pathway</li> </ul>"},{"location":"amino_acids/phenylalanine/","title":"Phenylalanine","text":""},{"location":"amino_acids/phenylalanine/#overview","title":"Overview","text":"<p>Phenylalanine is an essential amino acid and the metabolic precursor of tyrosine, dopamine, norepinephrine, epinephrine, melanin, and thyroid hormones. Its conversion to tyrosine by phenylalanine hydroxylase (PAH) is the most clinically significant reaction, and deficiency of PAH causes the well-known inborn error phenylketonuria (PKU). Phenylalanine exists as two enantiomers: L-phenylalanine (proteinogenic) and D-phenylalanine (inhibits enkephalin degradation).</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: Phe / F</li> <li>Side chain: Benzyl group (phenyl + methylene); large, hydrophobic, aromatic</li> <li>Glucogenic / Ketogenic: Both (glucogenic via fumarate; ketogenic via acetoacetate)</li> </ul>"},{"location":"amino_acids/phenylalanine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (combined Phe + Tyr, mg/kg/day) Approximate daily need Infants 0\u20136 months ~98 mg/kg/day \u2014 Children 1\u20133 years ~69 mg/kg/day ~1,500 mg/day Adults 19+ ~33 mg/kg/day ~2,300 mg/day (70 kg adult) <p>RDA is expressed as combined phenylalanine + tyrosine (since Phe \u2192 Tyr via PAH). Individuals with PKU must restrict Phe drastically and supplement with tyrosine.</p>"},{"location":"amino_acids/phenylalanine/#functions","title":"Functions","text":"<ul> <li>Tyrosine Synthesis: PAH + tetrahydrobiopterin (BH4) \u2192 hydroxylates Phe \u2192 Tyr; this is the rate-limiting step for catecholamine and thyroid hormone production</li> <li>Catecholamine Precursor Chain: Phe \u2192 Tyr \u2192 L-DOPA \u2192 Dopamine \u2192 Norepinephrine \u2192 Epinephrine</li> <li>Melanin Synthesis: Phe \u2192 Tyr \u2192 DOPA \u2192 eumelanin / pheomelanin (via tyrosinase)</li> <li>Thyroid Hormone Precursor: Tyr residues in thyroglobulin are iodinated \u2192 T3/T4 (requires PAH-generated tyrosine)</li> <li>Protein Structure: Aromatic side chain participates in hydrophobic core packing, \u03c0-stacking, and cation-\u03c0 interactions in protein folding</li> <li>Aspartame Metabolism: Aspartame (artificial sweetener) = Asp + Phe methyl ester; hydrolysis releases phenylalanine \u2014 critical PKU warning on all aspartame-containing products</li> <li>Enkephalin Degradation Inhibition (D-Phe): D-phenylalanine inhibits carboxypeptidase A and enkephalinase \u2192 prolongs endogenous opioid (enkephalin) activity \u2014 used in some analgesic formulations as DL-phenylalanine (DLPA)</li> </ul>"},{"location":"amino_acids/phenylalanine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport via LAT1 (SLC7A5); same transporter as BCAAs and tyrosine Hydroxylation Phe + O\u2082 + BH4 \u2192 Tyr + BH2 (phenylalanine hydroxylase, PAH; liver) BH4 regeneration DHPR enzyme (dihydropteridine reductase); requires NADH Catabolism Tyr \u2192 4-hydroxyphenylpyruvate \u2192 homogentisate \u2192 maleylacetoacetate \u2192 fumarate + acetoacetate Aromatic metabolites Phenylpyruvate, phenylacetate (PKU markers); trace amounts in normal catabolism"},{"location":"amino_acids/phenylalanine/#food-sources","title":"Food Sources","text":"Food Serving Phenylalanine (mg) Beef (lean, cooked) 85g ~1,000 mg Chicken breast (cooked) 85g ~980 mg Canned tuna 85g ~950 mg Egg 1 large ~340 mg Milk (whole) 240 mL ~420 mg Soy protein isolate 30g ~1,310 mg Pumpkin seeds 28g ~415 mg Parmesan cheese 28g ~630 mg"},{"location":"amino_acids/phenylalanine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/phenylalanine/#phenylketonuria-pku","title":"Phenylketonuria (PKU)","text":"<ul> <li>Cause: Autosomal recessive deficiency of PAH (or its cofactor BH4) \u2192 phenylalanine accumulates</li> <li>Classic PKU: PAH activity &lt;1%; plasma Phe &gt; 1,200 \u03bcmol/L</li> <li>Pathophysiology: Excess Phe competes with LAT1 for transport across the blood-brain barrier \u2192 reduces brain aromatic amino acids \u2192 decreased dopamine, serotonin, myelin synthesis \u2192 intellectual disability, seizures, musty odour (phenylacetate), eczema, fair skin/hair (reduced melanin)</li> <li>Newborn Screening: Universal in most countries (Guthrie test / tandem MS); treatment must begin within 3 weeks of birth to prevent irreversible neurological damage</li> <li>Treatment:</li> <li>Phe-restricted diet with amino acid formula (Phe-free) + supplemental tyrosine (lifelong)</li> <li>Sapropterin (Kuvan): Synthetic BH4; works in BH4-responsive PKU variants (~25\u201350% of patients) \u2014 lowers plasma Phe levels</li> <li>Pegvaliase (Palynziq): PEGylated phenylalanine ammonia lyase (bacterial enzyme) \u2014 metabolises Phe to ammonia + trans-cinnamic acid; for adults with uncontrolled PKU</li> <li>Maternal PKU: Women with PKU must maintain Phe &lt;360 \u03bcmol/L throughout pregnancy to prevent embryopathy</li> </ul>"},{"location":"amino_acids/phenylalanine/#bh4-deficiencies-non-classic-hyperphenylalaninaemia","title":"BH4 Deficiencies (Non-classic Hyperphenylalaninaemia)","text":"<ul> <li>Defects in BH4 synthesis/recycling (DHPR, PTPS, GCH1 deficiencies) \u2192 neurotransmitter deficiencies despite near-normal Phe levels (since BH4 is also cofactor for tyrosine and tryptophan hydroxylases)</li> <li>Treated with BH4 + neurotransmitter precursors (L-DOPA, 5-HTP)</li> </ul>"},{"location":"amino_acids/phenylalanine/#alkaptonuria","title":"Alkaptonuria","text":"<ul> <li>Deficiency of homogentisate 1,2-dioxygenase (downstream in phenylalanine/tyrosine catabolism)</li> <li>Accumulation of homogentisic acid \u2192 excreted in urine (darkens on standing), deposited in connective tissue (ochronosis) \u2192 arthritis, darkened sclerae and ear cartilage</li> </ul>"},{"location":"amino_acids/phenylalanine/#albinism-oculocutaneous","title":"Albinism (Oculocutaneous)","text":"<ul> <li>Tyrosinase deficiency \u2192 impaired melanin synthesis from Tyr (Phe/Tyr pathway intact; block is downstream)</li> </ul>"},{"location":"amino_acids/phenylalanine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Tetrahydrobiopterin (BH4) Essential PAH cofactor; riboflavin and NADH maintain BH4 in active form Tyrosine Product of Phe hydroxylation \u2014 spares Phe requirements; supplemented in PKU to prevent catecholamine deficiency LAT1 transporter competitors BCAAs (leucine, isoleucine, valine) share LAT1 \u2014 very high BCAA intake reduces Phe/Tyr brain transport (used experimentally to lower Phe in brain in PKU) Aspartame Releases Phe on hydrolysis \u2014 all aspartame products carry PKU warning MAOIs Block monoamine oxidase \u2014 excess tyramine/phenylalanine can cause hypertensive crisis with certain foods; Phe relevance is indirect via tyrosine/tyramine"},{"location":"amino_acids/phenylalanine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>DL-Phenylalanine (DLPA): Combination of L- and D-enantiomers; marketed for pain relief (D-form inhibits enkephalin degradation) and mood support \u2014 limited clinical evidence; avoid in PKU</li> <li>L-Phenylalanine: Rarely supplemented alone; used in some vitiligo protocols (with UVA therapy) to increase melanin synthesis</li> <li>Contraindicated in PKU \u2014 any phenylalanine supplement is dangerous for PKU patients</li> <li>Excess phenylalanine suppresses tryptophan and tyrosine brain uptake via LAT1 competition \u2014 relevant at very high supplement doses</li> </ul>"},{"location":"amino_acids/proline/","title":"Proline","text":""},{"location":"amino_acids/proline/#overview","title":"Overview","text":"<p>Proline is a conditionally essential amino acid with a unique cyclic structure \u2014 its side chain is bonded to both the \u03b1-carbon and the nitrogen, forming a pyrrolidine ring. This makes proline the only imino acid among the standard 20 amino acids and gives it exceptional conformational rigidity. Proline is the second most abundant amino acid in collagen (after glycine), essential for forming the collagen triple helix, and plays distinctive roles in protein folding, turn formation, and as a stress-responsive osmolyte in many organisms. It can be synthesised from glutamate or arginine.</p> <ul> <li>Classification: Conditionally essential</li> <li>IUPAC abbreviation: Pro / P</li> <li>Side chain: Pyrrolidine ring (cyclic \u2014 N is part of the ring); rigid; disrupts \u03b1-helices and \u03b2-sheets \u2192 introduces \u03b2-turns</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 glutamate \u2192 \u03b1-ketoglutarate)</li> </ul>"},{"location":"amino_acids/proline/#dietary-requirements","title":"Dietary Requirements","text":"Condition Notes Healthy adults Synthesised from glutamate; no established RDA; estimated 2\u20134 g/day from mixed diet Collagen synthesis / growth / healing Increased demand; connective tissue synthesis requires proline and hydroxyproline in large amounts Premature infants / severe illness Endogenous synthesis may be insufficient <p>No established UL. Proline supplementation in typical doses (1\u201310 g/day) is considered safe.</p>"},{"location":"amino_acids/proline/#functions","title":"Functions","text":"<ul> <li>Collagen Triple Helix Formation: Collagen Gly-X-Y repeating structure uses proline (Pro) frequently in the X position and hydroxyproline (Hyp) in the Y position. Hydroxylation of Pro \u2192 4-hydroxyproline (by prolyl 4-hydroxylase; requires vitamin C and iron) creates hydrogen bonds that stabilise the three-chain triple helix \u2014 without hydroxyproline, collagen unwinds and becomes non-functional (scurvy mechanism).</li> <li>Protein Structure and Folding: The cyclic ring prevents rotation around the N-C\u03b1 bond \u2192 induces \u03c3-turns, \u03b2-turns, poly-proline helices. Prolines break \u03b1-helices and redirect polypeptide chain direction \u2192 critical in signalling peptides and receptor binding regions.</li> <li>Collagen Post-Translational Processing: Pro is also 3-hydroxylated (by P3H1) in collagen \u2192 3-hydroxyproline; contributes to fibril architecture.</li> <li>Energy Substrate (especially in insects; lesser role in mammals): Proline \u2192 glutamate \u2192 \u03b1-KG \u2192 TCA cycle; serves as mobile fuel in flight muscle of insects; in humans provides gluconeogenic substrate during fasting.</li> <li>Antioxidant / Stress Osmolyte: Proline accumulates in plants under osmotic/salt/drought stress and protects macromolecules. In humans, elevated proline levels are found in certain stressed cells; role as osmolyte is minor compared to plants.</li> <li>Skin and Joint Integrity: Hydroxyproline is ~13% of collagen; dietary hydroxyproline (from collagen-rich foods) and proline availability are rate-limiting factors for de novo collagen synthesis in skin, cartilage, tendons, and bone matrix.</li> <li>Glutamate Metabolism: Proline \u2194 glutamate interconversion (via P5CS, PYCR, and PRODH enzymes) \u2014 connects the urea cycle, TCA cycle, and amino acid metabolism. Proline dehydrogenase (PRODH) in the mitochondria generates ROS (used to signal apoptosis in cancer cells).</li> <li>Gut Microbiome Metabolism: Proline-rich proteins (salivary proteins, collagen) are a substrate for gut bacteria; the microbiome modulates proline availability.</li> </ul>"},{"location":"amino_acids/proline/#metabolism","title":"Metabolism","text":"Step Details Synthesis from Glu Glu \u2192 Glu-5-semialdehyde (P5CS; ATP + NADPH) \u2192 \u0394\u00b9-pyrroline-5-carboxylate (P5C) \u2192 Proline (PYCR; NADPH) Synthesis from Arg Arg \u2192 Ornithine \u2192 P5C \u2192 Proline (PRODH/P5CR pathway in some tissues) Collagen hydroxylation Pro \u2192 4-hydroxyproline (prolyl 4-hydroxylase; O\u2082, \u03b1-KG, Fe\u00b2\u207a, ascorbate) Catabolism Pro \u2192 P5C (PRODH; mitochondria) \u2192 Glu \u2192 \u03b1-KG \u2192 TCA cycle Urea cycle connection Ornithine (from arginine/urea cycle) \u2192 P5C \u2192 Proline"},{"location":"amino_acids/proline/#food-sources","title":"Food Sources","text":"Food Serving Proline (mg) Gelatin / collagen peptide 10g ~2,100\u20132,800 mg Beef (lean, cooked) 85g ~800\u20131,000 mg Chicken (cooked) 85g ~750\u2013900 mg Bone broth (1 cup) 240 mL ~1,200 mg Egg white 1 large ~190 mg Whole wheat flour 30g ~400 mg Casein protein 30g ~800 mg Lentils (cooked) 200g ~540 mg <p>Animal connective tissue (skin, cartilage, tendons) and gelatin are the richest dietary sources. Collagen peptide supplements are primarily glycine + proline + hydroxyproline.</p>"},{"location":"amino_acids/proline/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/proline/#scurvy-vitamin-c-deficiency","title":"Scurvy (Vitamin C Deficiency)","text":"<ul> <li>Vitamin C is the cofactor for prolyl hydroxylase \u2192 without ascorbate, proline cannot be hydroxylated \u2192 immature collagen chains unfold (lack of hydroxyproline-mediated hydrogen bonds) \u2192 structurally weak collagen</li> <li>Results in: perifollicular haemorrhages, gingival disease, poor wound healing, corkscrew hairs, subperiosteal haemorrhages \u2192 clinically, this is primarily a proline hydroxylation failure</li> </ul>"},{"location":"amino_acids/proline/#hyperprolinaemia","title":"Hyperprolinaemia","text":"<ul> <li>Type I: PRODH deficiency \u2014 proline accumulates; associated with schizophrenia (PRODH gene at chromosome 22q11.2 \u2014 DiGeorge/velo-cardio-facial syndrome region); 22q11.2 deletion includes PRODH</li> <li>Type II: P5CDH deficiency \u2014 P5C and proline accumulate; more severe; intellectual disability, seizures, renal reabsorption defect; elevated plasma + urine proline; P5C accumulates and inactivates pyridoxal phosphate \u2192 secondary B6 deficiency</li> </ul>"},{"location":"amino_acids/proline/#cartilage-and-joint-disease","title":"Cartilage and Joint Disease","text":"<ul> <li>Hydroxyproline is the most abundant amino acid in cartilage collagen; joint tissue turnover depends on dietary proline availability</li> <li>Collagen peptide supplementation (5\u201315 g/day) \u2192 randomised trials show improvements in knee OA pain and function (WOMAC scores); evidence for athletes re: cartilage regeneration is building</li> </ul>"},{"location":"amino_acids/proline/#digeorge-syndrome-22q112-deletion","title":"DiGeorge Syndrome / 22q11.2 Deletion","text":"<ul> <li>PRODH (proline dehydrogenase) gene deletion \u2192 hyperprolinaemia type I</li> <li>PRODH links proline to mitochondrial ROS production and synaptic glutamate \u2192 neurodevelopmental effects; possible mechanism for psychiatric features of 22q11.2 deletion syndrome</li> </ul>"},{"location":"amino_acids/proline/#ehlersdanlos-syndrome-osteogenesis-imperfecta","title":"EhlersDanlos Syndrome / Osteogenesis Imperfecta","text":"<ul> <li>Genetic defects in collagen synthesis enzymes (prolyl hydroxylases, collagen chain genes) \u2192 structurally weak collagen despite adequate proline</li> <li>Demonstrates that proline availability alone is necessary but not sufficient; enzymatic machinery is equally critical</li> </ul>"},{"location":"amino_acids/proline/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Vitamin C Essential cofactor for prolyl 4-hydroxylase; deficiency \u2192 unhydroxylated collagen \u2192 unstable triple helix Iron (Fe\u00b2\u207a) Also a cofactor for prolyl hydroxylase; iron deficiency can impair collagen maturation (independent of Vit C) Glycine Co-dominant in collagen (Gly-Pro-Hyp is the canonical collagen tripeptide) \u2014 both must be co-adequate Glutamate / Arginine Upstream precursors of proline \u2014 adequate glutamate and arginine availability supports proline synthesis B6 (PLP) Type II hyperprolinaemia \u2014 accumulated P5C inactivates PLP \u2192 functional B6 deficiency, seizures"},{"location":"amino_acids/proline/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Collagen peptide supplements (5\u201315 g/day): Most widely used form; rich in glycine, proline, and hydroxyproline; bioavailable di/tripeptides (Pro-Hyp, Gly-Pro-Hyp) reach blood and joints intact</li> <li>Evidence base: Joint health (OA), skin elasticity (reduces wrinkles modestly), bone mineral density (combined with calcium)</li> <li>L-Proline powder: Available but less studied than collagen peptides; proline in collagen hydrolysate form is better absorbed and targeted than free L-proline</li> <li>Bone broth: Natural source of proline + hydroxyproline + glycine; variable amounts; flavourful but difficult to quantify exact content</li> <li>No documented toxicity at typical supplemental doses; extremely high doses not studied systematically</li> </ul>"},{"location":"amino_acids/serine/","title":"Serine","text":""},{"location":"amino_acids/serine/#overview","title":"Overview","text":"<p>Serine is a conditionally essential amino acid with a hydroxymethyl side chain, synthesised de novo primarily from 3-phosphoglycerate (a glycolytic intermediate) via the phosphoserine pathway. It is a metabolic crossroads amino acid: serine is the direct precursor of glycine, cysteine, sphingolipids, phosphatidylserine, D-serine, and it feeds one-carbon units into the folate cycle, nucleotide synthesis, and the methionine cycle. Serine is also the most common site of protein phosphorylation by serine/threonine kinases in cell signalling.</p> <ul> <li>Classification: Conditionally essential</li> <li>IUPAC abbreviation: Ser / S</li> <li>Side chain: Hydroxymethyl (\u2013CH\u2082\u2013OH); polar, uncharged, small \u2014 hydroxyl can participate in H-bonding and phosphorylation</li> <li>Glucogenic / Ketogenic: Glucogenic (\u2192 pyruvate)</li> </ul>"},{"location":"amino_acids/serine/#dietary-requirements","title":"Dietary Requirements","text":"Condition Notes Healthy adults Synthesised endogenously; no established RDA; ~2\u20133 g/day from typical diet Phosphoserine pathway defects Serine becomes fully essential in these rare inborn errors Neurological conditions / myelination High demand; CNS-specific serine synthesis (PHGDH) is particularly important in astrocytes <p>No established UL. Supplemental doses up to 10 g/day studied without significant adverse effects in certain conditions.</p>"},{"location":"amino_acids/serine/#functions","title":"Functions","text":"<ul> <li>Glycine Precursor: Serine \u2192 Glycine (serine hydroxymethyltransferase; SHMT1/2; PLP, THF) + 5,10-methylene-THF \u2014 the primary route of glycine production in the body and a major one-carbon donor to the folate cycle.</li> <li>Cysteine Precursor: Serine + Homocysteine \u2192 Cystathionine (CBS; PLP) \u2192 Cysteine \u2014 serine provides the carbon backbone for cysteine in the transsulphuration pathway.</li> <li>One-Carbon Metabolism / Folate Cycle: The SHMT reaction interconverts Ser \u2194 Gly and couples to the folate one-carbon cycle \u2014 supplies methylene-THF for thymidylate (dTMP) synthesis and formyl-THF for purine synthesis \u2192 links serine to DNA replication and methylation.</li> <li>Sphingolipid Synthesis: Serine + Palmitoyl-CoA \u2192 Sphinganine (serine palmitoyltransferase; SPT) \u2014 first and rate-limiting step in de novo sphingolipid synthesis. Sphingolipids (sphingomyelin, ceramide, gangliosides) are critical membrane components, especially in myelin, and act as bioactive lipid signalling molecules (ceramide \u2192 apoptosis; sphingosine-1-phosphate \u2192 survival/migration).</li> <li>Phosphatidylserine (PS) Synthesis: Serine head group is incorporated into phosphatidylserine in the endoplasmic reticulum (by PS synthase 1 and 2) \u2192 PS is a major inner-leaflet phospholipid of cell membranes. PS flips to outer leaflet during apoptosis (eat-me signal for phagocytes). Brain PS is abundant \u2014 modulates protein kinase C, AKT, and PLC signalling.</li> <li>D-Serine (NMDA Receptor Co-agonist): Serine is racemised to D-serine by serine racemase (SRR) in astrocytes and neurons \u2192 D-serine is the principal endogenous co-agonist at the glycine-binding site of NMDA receptors in the cerebral cortex and hippocampus (where it predominates over glycine). D-serine is critical for synaptic plasticity (LTP), learning, and memory.</li> <li>Protein Phosphorylation Site: The hydroxyl of serine is phosphorylated by serine/threonine kinases (PKA, PKC, AKT, mTOR, CDK, CK2, etc.) \u2192 phosphoserine is the most abundant form of protein phosphorylation in cells; regulates virtually all cellular signalling processes.</li> <li>Active Site Nucleophile (Serine Proteases): Serine is the catalytic nucleophile in the active-site triad of serine proteases (trypsin, chymotrypsin, elastase, thrombin, plasmin, complement proteases, subtilisins) and serine hydrolases (acetylcholinesterase, lipases) \u2014 arguably the most catalytically important amino acid in biology.</li> <li>Gluconeogenesis: Serine \u2192 pyruvate (serine dehydratase; PLP) \u2192 gluconeogenesis substrate</li> </ul>"},{"location":"amino_acids/serine/#metabolism","title":"Metabolism","text":"Step Details De novo synthesis 3-Phosphoglycerate (glycolysis) \u2192 3-Phosphoserine \u2192 Serine (phosphoserine pathway; 3 enzymes: PHGDH, PSAT1, PSPH) Serine \u2194 Glycine SHMT1 (cytosolic) + SHMT2 (mitochondrial); PLP + THF cofactors; reversible D-Serine synthesis Serine racemase (SRR) \u2192 D-serine (brain-enriched) Catabolism Serine \u2192 Pyruvate (serine dehydratase; PLP) \u2192 TCA / gluconeogenesis Collagen-linked Serine provides the initiating sugar-attachment site for glycosaminoglycans (O-xylosylation) in proteoglycans"},{"location":"amino_acids/serine/#food-sources","title":"Food Sources","text":"Food Serving Serine (mg) Beef (lean, cooked) 85g ~950 mg Chicken breast (cooked) 85g ~900 mg Canned tuna 85g ~880 mg Egg 1 large ~370 mg Milk (whole) 240 mL ~340 mg Pumpkin seeds 28g ~340 mg Lentils (cooked) 200g ~630 mg Soybeans (cooked) 170g ~820 mg"},{"location":"amino_acids/serine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/serine/#serine-deficiency-syndromes-phosphoserine-pathway-defects","title":"Serine Deficiency Syndromes (Phosphoserine Pathway Defects)","text":"<ul> <li>3-Phosphoglycerate Dehydrogenase (PHGDH) Deficiency: Most common and severe; presents with congenital microcephaly, intractable seizures (infantile onset), profound intellectual disability, peripheral neuropathy</li> <li>Phosphoserine Aminotransferase (PSAT1) Deficiency and Phosphoserine Phosphatase (PSPH) Deficiency: Similar but variable severity</li> <li>Treatment: Oral L-serine supplementation (200\u2013600 mg/kg/day) + glycine \u2014 dramatically improves seizure control and neurodevelopmental outcomes if started early; serine is the full therapeutic; one of the best examples of dietary amino acid as effective treatment for a neurological disorder</li> </ul>"},{"location":"amino_acids/serine/#neu-laxova-syndrome","title":"Neu-Laxova Syndrome","text":"<ul> <li>Severe lethal form of serine deficiency (PHGDH/PSAT1/PSPH defects) \u2014 multiple malformations including ichthyosis, limb abnormalities, brain anomalies; typically lethal perinatally</li> </ul>"},{"location":"amino_acids/serine/#schizophrenia-and-d-serine-hypofunction","title":"Schizophrenia and D-Serine Hypofunction","text":"<ul> <li>D-serine is the principal NMDA co-agonist in prefrontal cortex \u2192 D-serine depletion \u2192 NMDA hypofunction \u2192 psychosis-like symptoms (consistent with the glutamate hypothesis of schizophrenia)</li> <li>D-serine or L-serine (as D-serine precursor) supplementation trials in schizophrenia have shown improvement in negative and cognitive symptoms</li> <li>Sarcosine (N-methylglycine) inhibits glycine reuptake transporter (GlyT1) \u2192 increases glycine/D-serine levels at NMDA receptors \u2192 similar rationale</li> </ul>"},{"location":"amino_acids/serine/#cancer-metabolism-serine-synthesis-pathway","title":"Cancer Metabolism (Serine Synthesis Pathway)","text":"<ul> <li>Many cancers overexpress PHGDH (especially triple-negative breast cancer, melanoma, glioma) \u2014 divert glycolytic flux \u2192 serine synthesis \u2192 one-carbon metabolism \u2192 nucleotides and NADPH for proliferation and redox defence</li> <li>PHGDH inhibitors and serine restriction are active areas of cancer metabolism research</li> </ul>"},{"location":"amino_acids/serine/#lipid-disorders-spt-dysfunction","title":"Lipid Disorders (SPT dysfunction)","text":"<ul> <li>Serine palmitoyltransferase (SPT) mutations \u2192 hereditary sensory neuropathy type 1 (HSAN1) \u2014 toxic 1-deoxy-sphinganine (doxSA) accumulates (due to using alanine instead of serine as substrate for SPT)</li> <li>Oral L-serine supplementation competes with alanine at SPT \u2192 reduces doxSA \u2192 improves neuropathy in clinical trials</li> </ul>"},{"location":"amino_acids/serine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Vitamin B6 (PLP) Required for SHMT (Ser\u2194Gly), serine dehydratase, CBS (Ser + Hcy \u2192 cystathionine \u2192 cysteine); multiple serine-related enzymes need PLP Folate (THF) SHMT couples Ser\u2192Gly to methylene-THF generation \u2014 serine is effectively a one-carbon donor to the folate pool Methionine cycle Serine \u2192 Gly \u2192 methylene-THF \u2192 5-methyl-THF \u2192 methionine synthase \u2192 SAM \u2014 serine feeds into methylation capacity Glycine Interconvertible via SHMT; combined supplementation (Ser + Gly) is the standard treatment in serine deficiency disorders Palmitoyl-CoA Substrate partner in SPT reaction; dietary palmitate availability modulates ceramide and sphingolipid synthesis from serine D-Amino acid oxidase (DAAO) Degrades D-serine in the cerebellum/brainstem; DAAO inhibitors proposed as adjuncts for NMDA hypofunction conditions"},{"location":"amino_acids/serine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>L-Serine (200\u2013600 mg/kg/day) for serine deficiency disorders: The most evidence-based use \u2014 dramatic improvements in neuropaediatric outcomes; essentially a therapeutic amino acid</li> <li>L-Serine for HSAN1 (1-deoxy-sphingolipid neuropathy): Phase 2 RCT (Fridman et al.) showed reduction in doxSA and stabilisation of neuropathy; FDA Orphan Drug designation</li> <li>D-Serine supplements: Available; studied for schizophrenia and cognitive enhancement \u2014 clinical use is investigational; liver/kidney DAAO activity breaks down D-serine</li> <li>Phosphatidylserine (PS) soft gels (100\u2013300 mg/day): Related to serine but specifically the phospholipid form; FDA-qualified health claim for cognitive decline attenuation; cortisol blunting in athletes; some evidence for memory/focus in the elderly \u2014 though the PS on labels is soy-derived (plant PS \u2260 bovine cortex PS used in older studies)</li> <li>Dietary serine needs are typically met in protein-replete individuals; deficiency most relevant in metabolic disorders and rare genetic conditions</li> </ul>"},{"location":"amino_acids/threonine/","title":"Threonine","text":""},{"location":"amino_acids/threonine/#overview","title":"Overview","text":"<p>Threonine is an essential amino acid with a hydroxyl group on its side chain, making it a target for common post-translational modifications. It is one of the three hydroxyl-containing amino acids (alongside serine and tyrosine). Threonine is critical for mucin glycoprotein synthesis (intestinal mucosal barrier), collagen and elastin structure, and serves as a precursor for glycine and succinyl-CoA. It is the second most limiting amino acid in human diets after lysine in plant-protein\u2013based diets.</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: Thr / T</li> <li>Side chain: \u03b2-hydroxy group (\u2013CHOH\u2013CH\u2083); has two stereocentres; hydroxyl participates in H-bonding, phosphorylation, O-glycosylation</li> <li>Glucogenic / Ketogenic: Both (\u2192 glycine + acetyl-CoA [ketogenic]; \u2192 succinyl-CoA [glucogenic])</li> </ul>"},{"location":"amino_acids/threonine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~73 mg/kg/day \u2014 Children 1\u20133 years ~33 mg/kg/day ~730 mg/day Adults 19+ ~15 mg/kg/day ~1,050 mg/day (70 kg adult) <p>No established UL for threonine from food. IV threonine infusions at very high doses have caused motor dysfunction in animal models.</p>"},{"location":"amino_acids/threonine/#functions","title":"Functions","text":"<ul> <li>Mucin &amp; Glycoprotein Synthesis: Threonine is the most abundant amino acid in mucin-core proteins (MUC2, MUC5B, MUC5AC) \u2014 its hydroxyl group is the site of O-linked glycan attachment that gives mucins their gel-like properties. Critical for intestinal mucosal barrier integrity and respiratory tract protection.</li> <li>Collagen &amp; Connective Tissue: Threonine is incorporated into collagen and elastin where it contributes hydrogen bonds and \u03b2-sheet structures in fibrous proteins.</li> <li>Glycine Precursor: Threonine \u2192 glycine (via threonine aldolase) + acetaldehyde; provides ~10\u201320% of glycine requirements.</li> <li>Immune Function: Threonine depletion impairs T-cell proliferation and immunoglobulin synthesis; first-pass intestinal mucosal uptake is very high (gut uses ~50\u201370% of dietary threonine before systemic delivery).</li> <li>Central Nervous System: Glycine, derived from threonine, is an inhibitory neurotransmitter; levels of threonine affect CNS inhibitory tone. High threonine intake \u2192 increased spinal cord glycine levels (used in clinical trials for spasticity).</li> <li>Post-Translational Modifications:</li> <li>Phosphorylation (by serine/threonine kinases \u2014 e.g., PKA, PKC, AKT): Regulates enzyme/protein activity throughout cell signalling</li> <li>O-glycosylation (O-GlcNAcylation): Links cell metabolism (UDP-GlcNAc from glucose) to protein activity; competes with phosphorylation at the same residues</li> <li>Liver Function: Required for synthesis of fibronectin and plasma proteins; moderate deficiency \u2192 hepatic steatosis in animal models.</li> </ul>"},{"location":"amino_acids/threonine/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport (SLC6A19/B0AT1; SLC1A5/ASCT2) in small intestine First-pass gut utilisation Very high \u2014 intestinal epithelium and microbiome consume majority of dietary threonine Catabolism (main) Thr \u2192 2-oxobutyrate \u2192 propionyl-CoA \u2192 succinyl-CoA (glucogenic) Alternative pathway Thr \u2192 glycine + acetaldehyde (threonine aldolase); acetaldehyde \u2192 acetyl-CoA (ketogenic) Serine-glycine interplay Shares one-carbon metabolism with serine and glycine in the folate cycle"},{"location":"amino_acids/threonine/#food-sources","title":"Food Sources","text":"Food Serving Threonine (mg) Beef (lean, cooked) 85g ~1,050 mg Chicken breast (cooked) 85g ~1,000 mg Canned tuna 85g ~990 mg Egg 1 large ~295 mg Milk (whole) 240 mL ~360 mg Greek yoghurt 170g ~550 mg Lentils (cooked) 200g ~610 mg Wheat germ 28g ~310 mg"},{"location":"amino_acids/threonine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/threonine/#mucosal-barrier-and-gut-health","title":"Mucosal Barrier and Gut Health","text":"<ul> <li>Intestinal threonine utilisation is extremely high \u2014 up to 70% of absorbed threonine goes to gut epithelium</li> <li>Dietary threonine deficiency \u2192 reduced mucin synthesis \u2192 impaired mucosal barrier \u2192 increased intestinal permeability</li> <li>Relevant in: critical illness, inflammatory bowel disease, neonatal gut development, premature infants</li> </ul>"},{"location":"amino_acids/threonine/#threonine-and-spasticity","title":"Threonine and Spasticity","text":"<ul> <li>Intrathecal glycine has well-established muscle-relaxant / antispastic properties</li> <li>Oral L-threonine (4.5\u20136 g/day) increases CSF glycine \u2192 some studies show modest reduction in spasticity in multiple sclerosis and spinal cord injury patients</li> <li>Evidence is limited; not a first-line treatment</li> </ul>"},{"location":"amino_acids/threonine/#inborn-errors-rare","title":"Inborn Errors (Rare)","text":"<ul> <li>Isolated threonine catabolism defects are extremely rare; propionyl-CoA downstream defects (propionic acidaemia, methylmalonic acidaemia) affect the glucogenic arm of threonine catabolism</li> </ul>"},{"location":"amino_acids/threonine/#protein-quality-assessment","title":"Protein Quality Assessment","text":"<ul> <li>Threonine is the second most limiting essential amino acid in wheat-based diets (after lysine)</li> <li>The DIAAS (Digestible Indispensable Amino Acid Score) uses threonine as a reference amino acid for food quality comparative scoring</li> </ul>"},{"location":"amino_acids/threonine/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Glycine Threonine is a dietary precursor of glycine; glycine availability depends partly on threonine intake Folate cycle Glycine interconverts with serine in the folate one-carbon cycle \u2014 threonine\u2192glycine feeds into this Intestinal microbiome Gut bacteria utilise threonine as carbon/nitrogen source; large intestinal fermentation produces threonine-derived metabolites Mucin synthesis Adequate threonine is particularly critical in neonates and ICU patients requiring enteral nutrition \u2014 commercially formulated feeds account for intestinal extraction"},{"location":"amino_acids/threonine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Rarely supplemented in isolation in healthy adults</li> <li>Used in clinical research for spasticity (high-dose oral L-Thr to raise CSF glycine) \u2014 not standard of care</li> <li>Important in infant formula and neonatal parenteral nutrition design \u2014 high gut extraction means formulas need more threonine than systemic requirement models would predict</li> <li>Plant-based diets combining cereals (threonine-limited) with legumes (threonine-adequate) generally meet requirements</li> </ul>"},{"location":"amino_acids/tryptophan/","title":"Tryptophan","text":""},{"location":"amino_acids/tryptophan/#overview","title":"Overview","text":"<p>Tryptophan is an essential amino acid with the largest and most structurally complex aromatic side chain of any standard amino acid. It is the sole precursor of serotonin (5-HT), melatonin, and niacin (vitamin B3) in humans. Despite being the least abundant essential amino acid in most dietary proteins, it plays an outsized role in mood regulation, sleep, immune function, and cellular energy metabolism. Its metabolism branches into three major pathways: the kynurenine pathway (~95%), serotonin/melatonin pathway (~1\u20132%), and direct protein incorporation.</p> <ul> <li>Classification: Essential (9 essential amino acids)</li> <li>IUPAC abbreviation: Trp / W</li> <li>Side chain: Indole ring (benzene + pyrrole fused); most hydrophobic and bulky aromatic side chain</li> <li>Glucogenic / Ketogenic: Both (\u2192 acetoacetyl-CoA [ketogenic]; TCA intermediates via kynurenine pathway [glucogenic])</li> </ul>"},{"location":"amino_acids/tryptophan/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~17 mg/kg/day \u2014 Children 1\u20133 years ~12 mg/kg/day ~266 mg/day Adults 19+ ~5 mg/kg/day ~350 mg/day (70 kg adult) <p>Lowest absolute requirement of the essential amino acids. No established UL from food. Eosinophilia-myalgia syndrome (EMS) in 1989 was linked to a contaminated L-tryptophan batch, not tryptophan itself.</p>"},{"location":"amino_acids/tryptophan/#functions","title":"Functions","text":""},{"location":"amino_acids/tryptophan/#serotonin-melatonin-pathway-12-of-trp","title":"Serotonin / Melatonin Pathway (~1\u20132% of Trp)","text":"<ul> <li>Trp \u2192 5-hydroxytryptophan (5-HTP) (tryptophan hydroxylase; requires BH4, Fe\u00b2\u207a, O\u2082) \u2192 Serotonin (5-HT) (aromatic L-amino acid decarboxylase; requires B6)</li> <li>Serotonin \u2192 N-acetylserotonin \u2192 Melatonin (AANAT + ASMT enzymes; in pineal gland, regulated by darkness)</li> <li>Serotonin functions: mood, appetite, gut motility (90% of 5-HT is in enterochromaffin cells), platelet aggregation, vasoconstriction, sexual function, sleep</li> <li>Melatonin: circadian rhythm regulation, antioxidant, immune modulation</li> </ul>"},{"location":"amino_acids/tryptophan/#kynurenine-pathway-95-of-trp-catabolism","title":"Kynurenine Pathway (~95% of Trp catabolism)","text":"<ul> <li>Trp \u2192 Kynurenine (indoleamine 2,3-dioxygenase, IDO \u2014 major; or tryptophan 2,3-dioxygenase, TDO \u2014 liver-specific)</li> <li>Kynurenine branches:</li> <li>\u2192 Kynurenic acid (KYNA): NMDA receptor antagonist, neuroprotective (B6-dependent)</li> <li>\u2192 Quinolinic acid (QUIN): NMDA agonist, excitotoxic, pro-inflammatory; neurotoxic at high levels</li> <li>\u2192 Nicotinamide / NAD\u207a: ~60 mg Trp \u2192 ~1 mg niacin (very inefficient; requires thiamine, B2, B6, iron)</li> <li>\u2192 Picolinic acid: Zinc chelator; modulates immune function</li> <li>IDO is upregulated by interferons and inflammation \u2014 the body diverts Trp away from serotonin synthesis during infection/inflammation (mechanism of infection-related depression and fatigue)</li> </ul>"},{"location":"amino_acids/tryptophan/#niacin-synthesis","title":"Niacin Synthesis","text":"<ul> <li>Trp is the only endogenous source of niacin \u2014 though conversion is inefficient (60:1 ratio by weight)</li> <li>Protein-replete individuals can generate some niacin from Trp; pellagra occurs when both niacin and Trp are deficient (corn- and sorghum-dominant diets)</li> </ul>"},{"location":"amino_acids/tryptophan/#immune-regulation-ido-mediated","title":"Immune Regulation (IDO-mediated)","text":"<ul> <li>IDO in antigen-presenting cells depletes local Trp \u2192 starves T cells \u2192 immune tolerance</li> <li>Critical in: tumour immune evasion, maternal tolerance of fetus, transplant tolerance</li> <li>IDO inhibitors are in clinical trials as cancer immunotherapy adjuncts</li> </ul>"},{"location":"amino_acids/tryptophan/#metabolism","title":"Metabolism","text":"Step Details Absorption Active transport via LAT1 (SLC7A5) and B0AT1 (SLC6A19); competes with other large neutral amino acids Blood-brain barrier Transported by LAT1 \u2014 BCAAs reduce Trp brain uptake (competitive transport) Hydroxylation Tryptophan hydroxylase-1 (TPH1, periphery/gut) and TPH2 (brain) \u2014 rate-limiting for serotonin synthesis; requires BH4 Kynurenine pathway IDO (widespread, inducible by IFN-\u03b3) and TDO (liver, inducible by Trp itself and glucocorticoids) Half-life (plasma Trp) Relatively short; ~1\u20132 hours; plasma Trp is mostly albumin-bound (~80\u201390%)"},{"location":"amino_acids/tryptophan/#food-sources","title":"Food Sources","text":"Food Serving Tryptophan (mg) Turkey (roasted) 85g ~250 mg Chicken breast (cooked) 85g ~240 mg Tuna (canned) 85g ~290 mg Milk (whole) 240 mL ~110 mg Greek yoghurt 170g ~115 mg Egg 1 large ~75 mg Pumpkin seeds 28g ~170 mg Tofu (firm) 100g ~130 mg Chocolate (dark, 70%) 28g ~65 mg <p>The \"turkey makes you sleepy\" myth \u2014 turkey Trp is similar to other meats; the effect is more related to large carbohydrate meals (insulin lowers competing amino acids \u2192 relative Trp advantage at BBB).</p>"},{"location":"amino_acids/tryptophan/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/tryptophan/#carcinoid-syndrome","title":"Carcinoid Syndrome","text":"<ul> <li>Neuroendocrine tumours (carcinoid) produce large amounts of serotonin from Trp \u2014 up to 70% of Trp is diverted</li> <li>Results in niacin deficiency (pellagra-like) due to Trp diversion away from NAD\u207a synthesis</li> <li>Features: flushing, diarrhoea, bronchospasm, right heart valve disease</li> </ul>"},{"location":"amino_acids/tryptophan/#depression-and-the-serotonin-hypothesis","title":"Depression and the Serotonin Hypothesis","text":"<ul> <li>Tryptophan depletion (acute dietary Trp lowering) causes temporary depressive symptoms in recovered depressed individuals \u2014 evidence for the serotonin-Trp-mood link</li> <li>SSRIs work downstream of Trp (block 5-HT reuptake) \u2014 Trp availability is the upstream precursor constraint</li> <li>Dietary Trp alone does not reliably improve depression in unselected individuals</li> </ul>"},{"location":"amino_acids/tryptophan/#pellagra-and-niacin","title":"Pellagra and Niacin","text":"<ul> <li>Classic pellagra from corn-dominant diets (niacin in corn is bound, unavailable; corn is also Trp-poor)</li> <li>Treated with nicotinamide/niacin supplementation</li> <li>Occurs in Hartnup disease (Trp absorption disorder \u2014 see below)</li> </ul>"},{"location":"amino_acids/tryptophan/#hartnup-disease","title":"Hartnup Disease","text":"<ul> <li>Defect in SLC6A19 (B0AT1) \u2014 impaired intestinal and renal absorption of neutral amino acids including tryptophan</li> <li>Features: pellagra-like rash (photosensitive), cerebellar ataxia, psychiatric symptoms (intermittent)</li> <li>Treatment: high-protein diet + nicotinamide supplementation</li> </ul>"},{"location":"amino_acids/tryptophan/#ido-and-cancer-inflammation","title":"IDO and Cancer / Inflammation","text":"<ul> <li>IDO-high tumours deplete local Trp \u2192 suppress tumour-infiltrating T cells \u2192 immune evasion</li> <li>IDO inhibitors (epacadostat) in clinical trials for cancer immunotherapy; most have failed as monotherapy but combinations continue</li> <li>Chronic inflammation \u2192 high IDO \u2192 Trp\u2192Kynurenine shift \u2192 reduced serotonin, increased QUIN (neurotoxic) \u2014 proposed mechanism for depression in inflammatory diseases</li> </ul>"},{"location":"amino_acids/tryptophan/#interactions","title":"Interactions","text":"Nutrient / Drug Effect BCAAs (Leu, Ile, Val) Compete with Trp at LAT1 for BBB entry \u2014 high BCAA intake reduces brain serotonin synthesis Carbohydrates Insulin release lowers plasma BCAAs \u2192 relatively increases Trp brain ratio \u2192 increased 5-HT synthesis (post-meal effect) Vitamin B6 (PLP) Cofactor for 5-HTP \u2192 serotonin decarboxylation AND for kynurenine \u2192 kynurenic acid (KYAT) pathway Tetrahydrobiopterin (BH4) Cofactor for tryptophan hydroxylase \u2014 deficiency reduces 5-HT synthesis SSRIs Act downstream; patient response may be affected by baseline Trp availability MAOIs Block serotonin degradation (MAO-A); combining with high Trp or 5-HTP risks serotonin syndrome 5-HTP supplements Direct precursor to serotonin; bypasses tryptophan hydroxylase; should not be combined with MAOIs or SSRIs without medical supervision"},{"location":"amino_acids/tryptophan/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>L-Tryptophan (500 mg \u2013 2 g/day): Used for sleep, mild depression, premenstrual dysphoria; limited but positive evidence</li> <li>5-HTP (50\u2013300 mg/day): More readily crosses BBB and enters serotonin synthesis; better-studied than L-Trp for mood/sleep; don't combine with MAOIs/SSRIs (serotonin syndrome risk)</li> <li>Melatonin: Downstream product of Trp; 0.5\u20135 mg for sleep onset; shorter-acting than L-Trp supplementation</li> <li>Take Trp or 5-HTP with carbohydrates for best brain uptake (reduces competing amino acids)</li> </ul>"},{"location":"amino_acids/tyrosine/","title":"Tyrosine","text":""},{"location":"amino_acids/tyrosine/#overview","title":"Overview","text":"<p>Tyrosine is a conditionally essential amino acid \u2014 it is synthesised from phenylalanine by phenylalanine hydroxylase (PAH), but becomes dietary-essential when phenylalanine intake is insufficient or in phenylketonuria (PKU), where PAH is deficient. Tyrosine is the precursor to the catecholamines (dopamine, norepinephrine, epinephrine), thyroid hormones (T3, T4), and melanin. Its hydroxyl-containing phenol ring makes it a site of post-translational modifications including phosphorylation by receptor tyrosine kinases.</p> <ul> <li>Classification: Conditionally essential (essential in PKU)</li> <li>IUPAC abbreviation: Tyr / Y</li> <li>Side chain: Para-hydroxyphenyl (phenol); weakly acidic hydroxyl (pKa ~10.1); aromatic, partially hydrophobic</li> <li>Glucogenic / Ketogenic: Both (\u2192 fumarate [glucogenic] + acetoacetate [ketogenic])</li> </ul>"},{"location":"amino_acids/tyrosine/#dietary-requirements","title":"Dietary Requirements","text":"Age / Group RDA (combined Phe + Tyr, mg/kg/day) Adults ~33 mg/kg/day (combined); tyrosine spares ~50% of phenylalanine need PKU patients Tyrosine becomes fully essential; supplemented in all PKU formulas <p>No established UL for dietary tyrosine. Isolated supplemental tyrosine at high doses (&gt;7 g/day) may cause hyperthymia, anxiety, or headache in sensitive individuals.</p>"},{"location":"amino_acids/tyrosine/#functions","title":"Functions","text":""},{"location":"amino_acids/tyrosine/#catecholamine-synthesis","title":"Catecholamine Synthesis","text":"<p>Tyrosine \u2192 L-DOPA (tyrosine hydroxylase; TH; requires BH4, Fe\u00b2\u207a) \u2192 Dopamine (AADC; B6) \u2192 Norepinephrine (DBH; vitamin C, copper) \u2192 Epinephrine (PNMT; SAM methyl donor)</p> <ul> <li>Dopamine: Motor control (basal ganglia), reward/motivation, prolactin inhibition, cognition, mood</li> <li>Norepinephrine: Sympathetic nervous system tone, arousal, attention, fight-or-flight vasoconstriction</li> <li>Epinephrine: Adrenal medulla; systemic stress response, glycogenolysis, lipolysis, cardiac stimulation</li> </ul>"},{"location":"amino_acids/tyrosine/#thyroid-hormone-synthesis","title":"Thyroid Hormone Synthesis","text":"<ul> <li>Tyrosine residues in thyroglobulin are iodinated (TPO + I\u207b) \u2192 MIT and DIT \u2192 coupled \u2192 T4 and T3</li> <li>T4 is converted to active T3 by iodothyronine deiodinases (selenium-dependent)</li> </ul>"},{"location":"amino_acids/tyrosine/#melanin-synthesis","title":"Melanin Synthesis","text":"<ul> <li>Tyr \u2192 DOPA \u2192 dopaquinone \u2192 eumelanin (black-brown) / pheomelanin (red-yellow) via tyrosinase (copper-dependent)</li> <li>Determines skin, hair, and eye pigmentation</li> </ul>"},{"location":"amino_acids/tyrosine/#protein-post-translational-modifications","title":"Protein Post-Translational Modifications","text":"<ul> <li>Tyrosine phosphorylation by receptor tyrosine kinases (RTKs \u2014 EGFR, VEGFR, INSR, etc.) and non-receptor tyrosine kinases (Src, JAK family) \u2014 central to growth factor signalling, insulin signalling, immune receptor activation</li> <li>Tyrosine nitration (by peroxynitrite): oxidative stress marker on proteins</li> <li>Tyrosine sulfation (in Golgi): modifies extracellular proteins and GPCRs</li> </ul>"},{"location":"amino_acids/tyrosine/#cognitive-performance-under-stress","title":"Cognitive Performance Under Stress","text":"<ul> <li>Catecholamines in the prefrontal cortex (dopamine, NE) are consumed during acute stress \u2192 tyrosine replenishment may maintain cognitive performance under cold, noise, or sleep-deprivation stress</li> </ul>"},{"location":"amino_acids/tyrosine/#metabolism","title":"Metabolism","text":"Step Details Synthesis from Phe Phe + O\u2082 + BH4 \u2192 Tyr + BH2 (phenylalanine hydroxylase, PAH; liver) Catecholamine pathway Tyr \u2192 L-DOPA (TH; BH4) \u2192 Dopamine (AADC; B6) \u2192 NE (DBH; Vit C, Cu) \u2192 Epi (PNMT; SAM) Thyroid pathway Tyr in thyroglobulin \u2192 iodinated by TPO \u2192 T3/T4 Melanin pathway Tyr \u2192 DOPA \u2192 dopaquinone \u2192 melanin (tyrosinase; Cu) Catabolism Tyr \u2192 4-hydroxyphenylpyruvate \u2192 homogentisate \u2192 maleylacetoacetate \u2192 fumarate + acetoacetate"},{"location":"amino_acids/tyrosine/#food-sources","title":"Food Sources","text":"Food Serving Tyrosine (mg) Beef (lean, cooked) 85g ~955 mg Chicken breast (cooked) 85g ~900 mg Canned tuna 85g ~900 mg Parmesan cheese 28g ~770 mg Egg 1 large ~300 mg Milk (whole) 240 mL ~390 mg Edamame (cooked) 155g ~680 mg Almonds 28g ~215 mg"},{"location":"amino_acids/tyrosine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/tyrosine/#phenylketonuria-pku","title":"Phenylketonuria (PKU)","text":"<ul> <li>PAH deficiency \u2192 Phe accumulates \u2192 Tyr is depleted (cannot be made from Phe)</li> <li>PKU patients must supplement tyrosine as part of their Phe-restricted amino acid formula</li> <li>Tyr-deficient PKU \u2192 additional catecholamine and melanin deficiency (fair skin/hair, mood/cognitive issues)</li> </ul>"},{"location":"amino_acids/tyrosine/#alkaptonuria","title":"Alkaptonuria","text":"<ul> <li>Homogentisate 1,2-dioxygenase deficiency (downstream tyrosine catabolism)</li> <li>Accumulation of homogentisic acid \u2192 ochronosis (connective tissue darkening), arthritis, urine darkens on standing</li> </ul>"},{"location":"amino_acids/tyrosine/#tyrosinaemia-types-i-ii-iii","title":"Tyrosinaemia (Types I, II, III)","text":"<ul> <li>Type I (Fumarylacetoacetate hydrolase deficiency \u2014 FAH): Hepatorenal tyrosinaemia; severe liver disease, renal Fanconi syndrome, neurological crises, hepatocellular carcinoma risk; succinylacetone (marker) inhibits porphyrin synthesis \u2192 porphyria-like crises</li> <li>Treatment: Nitisinone (NTBC) \u2014 inhibits 4-hydroxyphenylpyruvate dioxygenase (upstream, prevents accumulation of toxic metabolites) + low Tyr/Phe diet + liver transplant</li> <li>Type II (Tyrosine aminotransferase deficiency): Ocular (corneal crystals), palmoplantar keratoderma, intellectual disability; treatment: low Tyr/Phe diet</li> <li>Type III (HPD deficiency, 4-HPPD): Mild; intermittent ataxia and intellectual disability</li> </ul>"},{"location":"amino_acids/tyrosine/#parkinsons-disease","title":"Parkinson's Disease","text":"<ul> <li>Loss of dopaminergic neurons in substantia nigra</li> <li>Treatment: L-DOPA (bypasses tyrosine hydroxylase rate-limiting step; given with carbidopa to prevent peripheral conversion)</li> <li>Tyrosine supplementation does not significantly boost CNS dopamine in established PD (TH is severely depleted)</li> </ul>"},{"location":"amino_acids/tyrosine/#interactions","title":"Interactions","text":"Nutrient / Drug Effect BH4 (Tetrahydrobiopterin) Rate-limiting cofactor for tyrosine hydroxylase (catecholamine synthesis) and phenylalanine hydroxylase Vitamin C Required for dopamine \u03b2-hydroxylase (NE synthesis); deficiency reduces NE production SAM (Methionine) Methyl donor for PNMT (epinephrine synthesis from NE) Copper DBH (NE synthesis), tyrosinase (melanin) \u2014 deficiency reduces NE and melanin Iodine + Selenium Required for thyroid hormone synthesis from tyrosine MAO inhibitors Block catecholamine/tyramine degradation \u2014 tyramine (from Tyr) in food can precipitate hypertensive crisis Levodopa (L-DOPA) Competes with tyrosine (and other large neutral amino acids) at LAT1 transporter; protein meals reduce L-DOPA absorption/efficacy Thyroid medications Levothyroxine is a synthetic form of T4 (tyrosine backbone + iodines)"},{"location":"amino_acids/tyrosine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>L-Tyrosine (500\u20132,000 mg, 30\u201360 min pre-stressor): Used for acute cognitive performance under stress (sleep deprivation, cold, noise exposure) \u2014 several RCTs show modest benefit; effect is short-lived (acute dosing)</li> <li>NALT (N-Acetyl-L-Tyrosine): More water-soluble but evidence for superior bioavailability is mixed; some studies show lower plasma Tyr conversion than L-Tyr</li> <li>Not effective for: Chronic mood disorders in the absence of catecholamine demand (baseline catecholamine-sufficient individuals); Parkinson's disease (TH enzyme is the absent bottleneck, not substrate)</li> <li>Caution: Avoid high-dose Tyr with MAOIs (tyramine accumulation risk); caution with hyperthyroidism (excess Tyr substrate for T3/T4 synthesis)</li> <li>PKU formula: All PKU amino acid formulas contain added tyrosine as an essential inclusion</li> </ul>"},{"location":"amino_acids/valine/","title":"Valine","text":""},{"location":"amino_acids/valine/#overview","title":"Overview","text":"<p>Valine is an essential amino acid and the smallest of the three branched-chain amino acids (BCAAs). It plays multiple roles in muscle protein synthesis, CNS function, and energy metabolism. Unlike leucine (purely ketogenic) and isoleucine (both), valine is exclusively glucogenic \u2014 it provides an important glucose-sparing or gluconeogenic contribution during prolonged exercise and fasting. Its catabolism takes place primarily in skeletal muscle, cardiac muscle, and brain.</p> <ul> <li>Classification: Essential; Branched-Chain Amino Acid (BCAA)</li> <li>IUPAC abbreviation: Val / V</li> <li>Side chain: Isopropyl (branched aliphatic, hydrophobic)</li> <li>Glucogenic / Ketogenic: Exclusively glucogenic (\u2192 succinyl-CoA via propionyl-CoA)</li> </ul>"},{"location":"amino_acids/valine/#dietary-requirements-rda","title":"Dietary Requirements (RDA)","text":"Age / Group RDA (mg/kg/day) Approximate daily need Infants 0\u20136 months ~87 mg/kg/day \u2014 Children 1\u20133 years ~43 mg/kg/day ~950 mg/day Adults 19+ ~24 mg/kg/day ~1,680 mg/day (70 kg adult) <p>No established UL. Excessive isolated valine supplementation without leucine/isoleucine can disrupt BCAA balance and impair the others' LAT1 transport.</p>"},{"location":"amino_acids/valine/#functions","title":"Functions","text":"<ul> <li>Muscle Protein Synthesis Substrate: Component of muscle structural proteins; contributes to mTORC1 activation alongside leucine (though less potently).</li> <li>Gluconeogenic Substrate: Valine is catabolised to succinyl-CoA, which feeds into the TCA cycle or can exit for gluconeogenesis \u2014 important fuel source during prolonged starvation or endurance exercise when muscle proteins are catabolised.</li> <li>Nitrogen Balance: Like all BCAAs, valine is transaminated in muscle (rather than liver) \u2014 the released amino group is transferred to pyruvate \u2192 alanine \u2192 exported to liver for urea synthesis (glucose-alanine cycle).</li> <li>Myelin Synthesis: Propionyl-CoA and succinyl-CoA from valine catabolism contribute to neuronal lipid synthesis; severe MSUD (with valine accumulation) contributes to white matter abnormalities.</li> <li>Haemoglobin Participation: Val6 in the \u03b2-globin chain \u2014 the canonical target of the sickle cell mutation (Glu\u2192Val substitution creates HbS).</li> <li>CNS Function: Valine competes with tryptophan and other large neutral amino acids at LAT1 for blood-brain barrier entry \u2014 high BCAA levels (including valine) reduce serotonin synthesis by limiting Trp brain uptake.</li> </ul>"},{"location":"amino_acids/valine/#metabolism","title":"Metabolism","text":"Step Details Absorption LAT1 (SLC7A5) \u2014 competitive with leucine, isoleucine, phenylalanine, tyrosine, tryptophan First-pass metabolism Minimal hepatic extraction; preferentially metabolised in skeletal muscle and brain Transamination Val \u2192 2-ketoisovalerate (KIV) by BCAA aminotransferase (BCAT1, BCAT2) \u2014 releases NH\u2082 to \u03b1-ketoglutarate \u2192 glutamate Oxidative decarboxylation KIV \u2192 isobutyryl-CoA (BCKD complex; requires B1, B2, B3, lipoic acid) Glucogenic end products Isobutyryl-CoA \u2192 methylmalonyl-CoA \u2192 succinyl-CoA \u2192 TCA / gluconeogenesis"},{"location":"amino_acids/valine/#food-sources","title":"Food Sources","text":"Food Serving Valine (mg) Beef (lean, cooked) 85g ~1,180 mg Chicken breast (cooked) 85g ~1,080 mg Canned tuna 85g ~1,050 mg Egg 1 large ~380 mg Milk (whole) 240 mL ~500 mg Lentils (cooked) 200g ~870 mg Edamame (cooked) 155g ~810 mg Whey protein isolate 30g ~1,450 mg"},{"location":"amino_acids/valine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"amino_acids/valine/#maple-syrup-urine-disease-msud","title":"Maple Syrup Urine Disease (MSUD)","text":"<ul> <li>Deficiency of the BCKD complex \u2014 all three BCAAs (leucine, isoleucine, valine) accumulate</li> <li>Valine and isoleucine contribute to general amino acid toxicity and osmotic effects; leucine is considered the primary neurotoxicant</li> <li>Classic presentation: failure to thrive, encephalopathy, alternating hypotonia and hypertonia, maple syrup odour (isovaleric acid)</li> <li>Management: BCAA-restricted diet using synthetic formula; leucine-lowered specifically; liver transplant (curative)</li> </ul>"},{"location":"amino_acids/valine/#sickle-cell-disease","title":"Sickle Cell Disease","text":"<ul> <li>Val6 in \u03b2-globin (Glu6Val mutation) \u2014 substituting a charged residue (glutamate) with hydrophobic valine creates a hydrophobic patch that promotes HbS polymerisation under low O\u2082 \u2192 sickling of erythrocytes</li> </ul>"},{"location":"amino_acids/valine/#methylmalonic-acidaemia-mma","title":"Methylmalonic Acidaemia (MMA)","text":"<ul> <li>Methylmalonyl-CoA mutase deficiency (or B12 deficiency of adenosylcobalamin form) \u2192 methylmalonyl-CoA accumulates \u2192 methylmalonic acid in blood/urine</li> <li>Valine, isoleucine, methionine, threonine all contribute propionyl-CoA \u2192 methylmalonyl-CoA (this pathway is affected)</li> <li>Treatment: protein restriction, high-carbohydrate diet, B12 supplementation (if responsive), organ transplant</li> </ul>"},{"location":"amino_acids/valine/#propionic-acidaemia","title":"Propionic Acidaemia","text":"<ul> <li>Propionyl-CoA carboxylase deficiency \u2192 propionyl-CoA accumulates (from valine, isoleucine, methionine, threonine, odd-chain fatty acids)</li> <li>Hyperammonaemia, metabolic acidosis, cardiomyopathy</li> <li>Treatment: low-protein diet, biotin supplementation (cofactor), liver/heart-liver transplant</li> </ul>"},{"location":"amino_acids/valine/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Leucine + Isoleucine Compete at LAT1 transporter; must be balanced in supplements (2:1:1 Leu:Ile:Val) B vitamins (B1, B2, B3, lipoic acid) Cofactors for the BCKD complex \u2014 valine catabolism depends on adequate B-vitamin status B12 (adenosylcobalamin) Methylmalonyl-CoA mutase requires adenosylcobalamin \u2014 B12 deficiency \u2192 methylmalonic acid accumulation from valine catabolism Tryptophan High valine (and BCAA) intakes reduce tryptophan CNS uptake via LAT1 competition \u2192 reduced serotonin synthesis Insulin Insulin drives BCAA uptake into muscle and suppresses catabolism \u2014 promotes protein anabolism"},{"location":"amino_acids/valine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Sold as part of BCAA supplements (2:1:1 Leu:Ile:Val ratio); rarely supplemented in isolation</li> <li>Isolated valine supplementation disrupts leucine/isoleucine balance and is not recommended</li> <li>BCAA supplements show modest evidence for:</li> <li>Reducing exercise-induced muscle damage and soreness (DOMS)</li> <li>Preserving lean mass during caloric restriction</li> <li>Reducing hepatic encephalopathy symptoms (high BCAA:aromatic amino acid ratio \u2014 Fischer ratio \u2014 used in hepatic encephalopathy nutrition protocols)</li> <li>Adequate dietary protein (\u22651.6 g/kg/day) from quality sources makes BCAA supplements unnecessary for most people</li> </ul>"},{"location":"antioxidants/beta_carotene/","title":"Beta-Carotene","text":""},{"location":"antioxidants/beta_carotene/#overview","title":"Overview","text":"<p>Beta-carotene is the most well-known provitamin A carotenoid \u2014 upon absorption, it can be cleaved by intestinal beta-carotene 15,15'-monooxygenase (BCMO1) into two molecules of retinal (vitamin A aldehyde), making it the most abundant dietary source of preformed-equivalent vitamin A globally, particularly in plant-based diets. It is an orange-yellow pigment synthesised by plants, algae, and fungi but not by animals; its characteristic colour reflects 9 conjugated double bonds that can absorb blue-violet light (~450 nm). Beyond its provitamin A role, beta-carotene functions as a membrane antioxidant and lipid-soluble free radical scavenger at normal physiological concentrations. However, two landmark clinical trials (ATBC and CARET) found that high-dose beta-carotene supplementation significantly increased lung cancer risk in smokers \u2014 a sobering example of how a nutrient's safety profile in food differs radically from pharmacological supplementation.</p> <ul> <li>Classification: Carotenoid; provitamin A (most potent dietary provitamin A); symmetric bicyclic carotene</li> <li>Structure: 40-carbon symmetric carotene; two \u03b2-ionone rings connected by a polyene chain; 9 conjugated double bonds (responsible for orange colour)</li> <li>Key property: 1 molecule \u03b2-carotene \u2192 theoretical maximum 2 molecules retinal (vitamin A); actual yield varies by conversion efficiency, food matrix, individual genetics (BCMO1 polymorphisms)</li> <li>Vitamin A equivalence: 12 \u00b5g dietary \u03b2-carotene from food = 1 \u00b5g retinol activity equivalent (RAE) [WHO]; 6 \u00b5g = 1 RAE for supplements</li> </ul>"},{"location":"antioxidants/beta_carotene/#provitamin-a-conversion","title":"Provitamin A Conversion","text":"Step Enzyme Details Intestinal cleavage BCMO1 (beta-carotene monooxygenase 1; symmetric cleavage) \u03b2-Carotene \u2192 2\u00d7 retinal (centric cleavage at 15,15' double bond); reaction requires O\u2082, FAD, Fe\u00b2\u207a Reduction Retinal reductase Retinal \u2192 retinol (vitamin A alcohol) in enterocytes Esterification LRAT (lecithin:retinol acyltransferase) Retinol \u2192 retinyl esters \u2192 incorporated into chylomicrons Hepatic storage Hepatic stellate cells (Ito cells) Retinyl esters stored as fat droplets; ~80\u201390% of body retinol stored in liver Eccentric cleavage BCMO2 (beta-carotene oxygenase 2) Alternative asymmetric cleavage \u2192 \u03b2-apo-carotenals (smaller fragments with antioxidant activity) <p>BCMO1 genetic polymorphisms: ~45% of women are poor converters due to common BCMO1 variants (R267S, A379V) \u2192 significantly lower vitamin A yield from plant foods \u2192 these individuals depend more on preformed vitamin A (liver, dairy, eggs); a concern for vegans with these polymorphisms.</p>"},{"location":"antioxidants/beta_carotene/#functions","title":"Functions","text":""},{"location":"antioxidants/beta_carotene/#provitamin-a-activity","title":"Provitamin A Activity","text":"<ul> <li>Provides vitamin A for all retinol-dependent functions: rhodopsin synthesis (night vision), retinoic acid signalling (cell differentiation, immune function, embryogenesis), mucosal integrity, immune competence</li> <li>In developing countries where preformed vitamin A is scarce (no liver, eggs, or dairy), beta-carotene from orange/yellow fruits and vegetables is the primary vitamin A source</li> </ul>"},{"location":"antioxidants/beta_carotene/#antioxidant-activity","title":"Antioxidant Activity","text":"<ul> <li>At physiological concentrations (pO\u2082 &lt;150 mmHg), beta-carotene is an effective singlet oxygen quencher and lipid peroxyl radical chain-breaking antioxidant in cell membranes</li> <li>pO\u2082-dependent behaviour: At high partial oxygen pressures (e.g., in lung tissue of smokers with supplemental oxygen or high-dose supplementation), beta-carotene can become a pro-oxidant rather than antioxidant \u2014 generating peroxyl radicals; this is the mechanistic explanation for the ATBC/CARET findings</li> </ul>"},{"location":"antioxidants/beta_carotene/#immune-function-via-vitamin-a","title":"Immune Function (via Vitamin A)","text":"<ul> <li>Vitamin A derived from beta-carotene supports:</li> <li>Mucosal barrier integrity (respiratory, GI)</li> <li>T-cell and B-cell differentiation</li> <li>NK cell and neutrophil function</li> <li>IgA production at mucosal surfaces</li> </ul>"},{"location":"antioxidants/beta_carotene/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Factor Effect Food matrix Dense chromoplast packaging in carrots and pumpkin significantly reduces bioaccessibility; cooking (particularly with fat) disrupts chromoplasts and increases bioavailability 5\u20136\u00d7 Dietary fat Required for micellar solubilisation and absorption; eating cooked carrots with butter/olive oil dramatically increases beta-carotene absorption Food processing Juicing &gt; blending &gt; cooking &gt; raw (for most vegetables); fine particle size aids release from cellular structures Absorption Passive diffusion via SR-BI and CD36; incorporated into chylomicrons as either intact beta-carotene or retinyl esters Regulatory absorption Unlike preformed vitamin A (which can accumulate toxically), beta-carotene absorption decreases at high intake \u2014 downregulation of SR-BI and upregulation of BCMO1 limits accumulation (safety mechanism that breaks down with very high-dose supplementation) Genetic variation (BCMO1) Poor converters absorb intact beta-carotene well but convert less to retinol; higher serum beta-carotene but lower vitamin A yield Intestinal conversion efficiency Highly variable: 3\u201328% of absorbed beta-carotene converted to retinol depending on vitamin A status, genetics, food matrix"},{"location":"antioxidants/beta_carotene/#dietary-sources","title":"Dietary Sources","text":"Food Serving Beta-carotene (mg) RAE (\u00b5g) Sweet potato (baked, flesh) 1 medium (114 g) 9.4 mg ~781 \u00b5g RAE Carrot (raw) 1 medium (61 g) 5.1 mg ~427 \u00b5g RAE Carrot juice 240 mL 22 mg ~1,830 \u00b5g RAE Pumpkin (canned) \u00bd cup (123 g) 8.5 mg ~708 \u00b5g RAE Butternut squash (cooked) 1 cup (205 g) 9.4 mg ~781 \u00b5g RAE Spinach (cooked) 1 cup (180 g) 8.7 mg ~730 \u00b5g RAE Kale (cooked) 1 cup (130 g) 5.3 mg ~440 \u00b5g RAE Cantaloupe melon 1 cup (160 g) 2.6 mg ~216 \u00b5g RAE Red sweet pepper (raw) 1 medium (119 g) 2.1 mg ~175 \u00b5g RAE Apricots (raw) 3 medium 1.1 mg ~92 \u00b5g RAE <p>RAE estimates assume 12 \u00b5g dietary \u03b2-carotene = 1 \u00b5g RAE (WHO/IOM), which is conservative; cooked vegetables with fat are approximately twice as efficient (~6 \u00b5g = 1 RAE per some guidelines).</p>"},{"location":"antioxidants/beta_carotene/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/beta_carotene/#vitamin-a-deficiency-global-burden","title":"Vitamin A Deficiency (Global Burden)","text":"<ul> <li>Vitamin A deficiency (VAD) affects ~190 million preschool children and 19 million pregnant women globally, primarily in sub-Saharan Africa and South/Southeast Asia</li> <li>Night blindness: The earliest clinical sign of VAD; reversible with adequate beta-carotene or retinol</li> <li>Xerophthalmia and corneal blindness: Advanced VAD; irreversible; leading cause of preventable childhood blindness</li> <li>Biofortification: Golden Rice (transgenic rice expressing \u03b2-carotene in the endosperm) and biofortified orange sweet potato are strategies to increase beta-carotene delivery in VAD-endemic regions</li> </ul>"},{"location":"antioxidants/beta_carotene/#the-atbc-and-caret-trials-landmark-cautionary-findings","title":"The ATBC and CARET Trials \u2014 Landmark Cautionary Findings","text":"<p>[!CAUTION] ATBC trial (1994): 29,133 male Finnish smokers; beta-carotene 20 mg/day for 5\u20138 years \u2192 18% increased lung cancer incidence, 8% increased overall mortality vs placebo. CARET trial (1996): 18,314 smokers/asbestos workers; 30 mg beta-carotene + 25,000 IU retinyl palmitate \u2192 28% increased lung cancer incidence, 17% increased overall mortality \u2192 trial stopped early. Neither supplement group showed benefit in any subgroup.</p> <ul> <li>Mechanism (proposed): In the oxidant-rich lung environment of smokers, pharmacological beta-carotene generates reactive beta-carotene radicals \u2192 propagate lipid peroxidation \u2192 carcinogenic arachidonic acid derivatives; also interferes with RA (retinoic acid) signalling \u2192 loss of tumour suppression</li> <li>Key lesson: Food-form beta-carotene is safe (associated with lower cancer risk in observational studies); isolated high-dose supplement beta-carotene is harmful in smokers and possibly in heavy exercisers (similar mechanism)</li> </ul>"},{"location":"antioxidants/beta_carotene/#beta-carotene-vs-luteinzeaxanthin-in-amd","title":"Beta-Carotene vs. Lutein/Zeaxanthin in AMD","text":"<ul> <li>AREDS1 formula contained 15 mg beta-carotene; AREDS2 replaced it with 10 mg lutein + 2 mg zeaxanthin: non-inferior for AMD protection, superior in smokers (beta-carotene concerns), and no competitive absorption issues for macular carotenoids</li> </ul>"},{"location":"antioxidants/beta_carotene/#carotenodermia-hypercarotenaemia","title":"Carotenodermia (Hypercarotenaemia)","text":"<ul> <li>Harmless orange-yellow discolouration of the skin (palms, soles, nasolabial folds) from very high dietary beta-carotene intake (&gt;30 mg beta-carotene/day from food, e.g., carrot juice drinkers); reversible on reducing intake; does not cause hypervitaminosis A (unlike retinol supplementation)</li> </ul>"},{"location":"antioxidants/beta_carotene/#interactions","title":"Interactions","text":"Factor Interaction Vitamin A (retinol) status When vitamin A stores are replete, BCMO1 activity decreases \u2192 less beta-carotene converted \u2192 more passes as intact carotenoid; when deficient, conversion upregulated Dietary fat Required for absorption; critical importance to consume with fat-containing foods Lutein and zeaxanthin Compete for intestinal absorption via shared SR-BI transporter; high-dose beta-carotene supplements reduce plasma lutein/zeaxanthin levels Iron and zinc Deficiencies impair beta-carotene conversion to retinol (iron: required by BCMO1; zinc: required for retinol mobilisation from liver via RBP) Vitamin E Both are fat-soluble antioxidants in membranes; synergistic antioxidant protection at physiological concentrations Alcohol Impairs retinol mobilisation from liver; combined with beta-carotene supplements, alcohol increases hepatotoxicity risk Orlistat (fat absorption blocker) Significantly reduces absorption of all fat-soluble nutrients including beta-carotene; patients on orlistat need vitamin A monitoring Smoking In smokers, beta-carotene supplementation is contraindicated; dietary beta-carotene from food remains safe; smoking directly depletes plasma carotenoids"},{"location":"antioxidants/beta_carotene/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>From food: safe and beneficial \u2014 high dietary beta-carotene from fruits and vegetables is consistently associated with lower cancer and CVD risk in epidemiological studies</li> <li>Supplemental beta-carotene:</li> <li>Contraindicated in smokers and asbestos-exposed individuals (ATBC/CARET evidence)</li> <li>Not recommended as an isolated supplement for general population (WCRF, WHO, ACS)</li> <li>Still present in some multivitamins \u2014 smokers should choose vitamin A as retinyl palmitate instead</li> <li>For vitamin A supplementation: Preformed retinyl palmitate (IU-dosed) is safer and more reliable than beta-carotene for people with BCMO1 polymorphisms, malabsorption, or significant VAD</li> <li>Natural mixed carotenoids (from algae: Dunaliella salina \u2014 contains alpha-carotene, beta-carotene, lutein, zeaxanthin together): may be safer than pure synthetic beta-carotene due to the antioxidant buffering of the other carotenoids; not definitively proven</li> <li>Note for vegans: Those following strict vegan diets should assess beta-carotene intake and, if BCMO1 poor-converter status is suspected (genetic testing available), consider preformed vitamin A from supplements or fortified foods</li> </ul>"},{"location":"antioxidants/coq10/","title":"Coenzyme Q10 (CoQ10 / Ubiquinone)","text":""},{"location":"antioxidants/coq10/#overview","title":"Overview","text":"<p>Coenzyme Q10 (CoQ10), also known as ubiquinone (from ubiquitous quinone), is a fat-soluble, vitamin-like compound found in every cell in the human body, with the highest concentrations in mitochondria-rich organs: heart, liver, kidney, and skeletal muscle. It is endogenously synthesised via the mevalonate pathway (shared with cholesterol synthesis), making it non-essential in healthy individuals. CoQ10 serves two fundamental roles: as a mobile electron carrier in the mitochondrial electron transport chain (ETC), and as the only endogenous lipid-soluble antioxidant generated by the body itself \u2014 protecting cell membranes and mitochondrial membranes from lipid peroxidation.</p> <ul> <li>Type: Fat-soluble quinone; endogenously synthesised; found in all cells</li> <li>Redox forms: Ubiquinone (CoQ; fully oxidised), Ubisemiquinone (CoQ\u2022; radical intermediate), Ubiquinol (CoQH\u2082; fully reduced, antioxidant form)</li> <li>Structure: Benzoquinone ring + isoprenoid side chain (10 isoprene units in humans; coenzyme Q10)</li> <li>Key fact: Biosynthesis uses the same mevalonate pathway as cholesterol; statins inhibit HMG-CoA reductase \u2192 reduce both cholesterol AND CoQ10 synthesis</li> </ul>"},{"location":"antioxidants/coq10/#biosynthesis","title":"Biosynthesis","text":"Stage Key Enzyme / Pathway Details Mevalonate pathway HMG-CoA reductase (HMGCR) \u2014 rate-limiting Acetyl-CoA \u2192 mevalonate \u2192 IPP \u2192 farnesyl-PP \u2192 (shared with cholesterol synthesis) \u2192 decaprenyl-PP (10-unit tail of CoQ10) Quinone ring synthesis Tyrosine \u2192 4-hydroxybenzoate (via PAH/ADCK3 pathway) Provides the benzoquinone ring head group Assembly COQ complex (COQ3\u2013COQ9 enzymes) Assembly of head group + tail \u2192 CoQ10 in the inner mitochondrial membrane <p>Statin effect: Statins inhibit HMGCR \u2192 reduce synthesis of both mevalonate-derived cholesterol AND the isoprenoid tail of CoQ10. CoQ10 plasma levels fall 16\u201354% with intensive statin therapy. This biochemical fact is mechanistically plausible as a contribution to statin-associated muscle symptoms (SAMS), though clinical evidence remains debated.</p>"},{"location":"antioxidants/coq10/#functions","title":"Functions","text":""},{"location":"antioxidants/coq10/#electron-transport-chain-primary-role","title":"Electron Transport Chain (Primary Role)","text":"<ul> <li>CoQ10 is the mobile hydrophobic electron shuttle between Complex I (NADH dehydrogenase) and Complex III (cytochrome bc1 complex) in the inner mitochondrial membrane</li> <li>Complex I \u2192 CoQ10 (ubiquinone + 2e\u207b + 2H\u207a \u2192 ubiquinol); Complex III \u2192 accepts electrons from ubiquinol \u2192 regenerates ubiquinone</li> <li>Net: CoQ10 cycling in ETC is essential for ~95% of cellular ATP through oxidative phosphorylation</li> </ul>"},{"location":"antioxidants/coq10/#antioxidant-functions","title":"Antioxidant Functions","text":"<ul> <li>Ubiquinol (CoQH\u2082) is the most potent known lipid-soluble antioxidant in biological membranes</li> <li>Directly quenches superoxide, lipid peroxyl radicals, peroxynitrite in the mitochondrial and cell membranes</li> <li>Regenerates vitamin E (tocopheryl radical \u2192 \u03b1-tocopherol) by donating electrons \u2014 CoQ10 is upstream of vitamin E in the membrane antioxidant hierarchy</li> <li>Prevents oxidative modification of LDL cholesterol (CoQ10-enriched LDL is more resistant to oxidation)</li> </ul>"},{"location":"antioxidants/coq10/#other-functions","title":"Other Functions","text":"<ul> <li>NF-\u03baB inhibition: Ubiquinol downregulates NF-\u03baB-mediated inflammatory gene expression (TNF-\u03b1, IL-6, IL-1\u03b2) at the transcriptional level</li> <li>Membrane integrity: Maintains mitochondrial membrane potential (\u0394\u03a8m); CoQ10 interacts with uncoupling proteins (UCPs) to regulate proton leak</li> <li>Sulphide oxidation: CoQ10 is the electron acceptor for sulphide:quinone oxidoreductase (SQR) \u2014 the enzyme that detoxifies hydrogen sulfide (H\u2082S) in mitochondria; relevant in gut bacterially-producing H\u2082S environments</li> </ul>"},{"location":"antioxidants/coq10/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Aspect Details Endogenous synthesis Produced in liver and other tissues via mevalonate pathway; peak production at age ~20, declines ~0.5%/year thereafter Dietary absorption Absorbed in the small intestine with dietary fat; incorporated into chylomicrons \u2192 lymph \u2192 plasma; fat-containing meals significantly improve CoQ10 absorption Plasma transport Primarily carried in LDL and HDL; oxidised to ubiquinol in plasma; plasma CoQ10 correlates with LDL particle number (not independent) Tissue distribution Heart &gt;&gt; liver &gt;&gt; kidney &gt;&gt; skeletal muscle &gt;&gt; brain &gt; lung &gt; plasma; cardiac CoQ10 declines significantly in heart failure Bioavailability of supplements Standard crystal form: poor (hydrophobic, poor dissolution); solubilised/soft-gel formulations (ubiquinol or solubilised ubiquinone) achieve 3\u20134\u00d7 higher plasma levels vs crystal powder Half-life in plasma ~33 hours; steady state achieved after ~3\u20134 weeks of supplementation"},{"location":"antioxidants/coq10/#dietary-sources","title":"Dietary Sources","text":"Food Serving CoQ10 Content (mg) Beef heart 100 g 11.3 mg Beef (lean) 100 g 3.1 mg Pork 100 g 2.4 mg Chicken (leg) 100 g 1.6 mg Sardines (tinned) 100 g 2.7 mg Salmon (cooked) 100 g 0.9 mg Soybean oil 1 tbsp 1.0 mg Sesame seeds 28 g 0.7 mg Broccoli 100 g 0.6 mg Cauliflower 100 g 0.6 mg <p>Dietary CoQ10 intake from typical Western diets is ~3\u20135 mg/day \u2014 far below therapeutic supplemental doses. Cooking destroys some CoQ10 (heat-labile). Heart and organ meats are richest sources.</p>"},{"location":"antioxidants/coq10/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/coq10/#heart-failure","title":"Heart Failure","text":"<ul> <li>Cardiac CoQ10 levels are inversely correlated with severity of heart failure (NYHA class)</li> <li>Q-SYMBIO trial (2014; n=420): CoQ10 300 mg/day for 2 years in heart failure \u2192 43% reduction in major adverse cardiovascular events (MACE), reduced all-cause mortality vs placebo \u2014 landmark trial, though awaiting replication at scale</li> <li>Proposed mechanism: improves mitochondrial ATP production in the energy-starved failing heart, reduces oxidative stress, improves endothelial function</li> </ul>"},{"location":"antioxidants/coq10/#statin-associated-muscle-symptoms-sams","title":"Statin-Associated Muscle Symptoms (SAMS)","text":"<ul> <li>5\u201310% of statin users experience myalgia; severe rhabdomyolysis rare but serious; statin-induced CoQ10 depletion is a proposed (but not confirmed) mechanism</li> <li>RCT evidence is mixed: Several RCTs failed to show CoQ10 (100\u2013600 mg/day) significantly reduces statin myalgia vs placebo; some positive trials exist; clinical practice varies; supplementation is low-risk and commonly recommended (100\u2013200 mg/day)</li> </ul>"},{"location":"antioxidants/coq10/#primary-coq10-deficiency","title":"Primary CoQ10 Deficiency","text":"<ul> <li>Rare autosomal recessive deficiency of CoQ10 biosynthesis enzymes (COQ2, COQ4, COQ6, COQ8A/ADCK3 etc.) \u2192 mitochondrial disease</li> <li>Spectrum: nephropathy, cerebellar ataxia, encephalopathy, exercise intolerance; often CoQ10-responsive (high-dose supplementation: 300\u20133,000 mg/day)</li> </ul>"},{"location":"antioxidants/coq10/#hypertension","title":"Hypertension","text":"<ul> <li>Meta-analyses: CoQ10 (100\u2013225 mg/day) reduces systolic BP by ~11 mmHg and diastolic BP by ~7 mmHg vs placebo \u2014 mechanism may involve improved endothelial NO bioavailability and reduced oxidative stress</li> <li>Evidence quality is moderate; not a primary antihypertensive treatment but potentially useful as adjunct</li> </ul>"},{"location":"antioxidants/coq10/#male-infertility","title":"Male Infertility","text":"<ul> <li>Seminal CoQ10 correlates with sperm motility and count; RCTs: CoQ10 300 mg/day for 3\u20136 months improves sperm motility and morphology in idiopathic male infertility (multiple trials, modest but consistent effect)</li> </ul>"},{"location":"antioxidants/coq10/#migraine-prophylaxis","title":"Migraine Prophylaxis","text":"<ul> <li>Several RCTs: CoQ10 300 mg/day reduces migraine frequency (~50% reduction in attack days vs baseline at 3 months) \u2014 included in European Headache Federation guidelines as an option for migraine prophylaxis</li> </ul>"},{"location":"antioxidants/coq10/#parkinsons-disease","title":"Parkinson's Disease","text":"<ul> <li>CoQ10 levels are reduced in substantia nigra mitochondria in PD; Complex I activity is impaired (a site of CoQ10 action)</li> <li>Large RCT (QE3 trial; n=600, CoQ10 1,200\u20132,400 mg/day): No benefit on PD progression vs placebo \u2014 definitive negative result; CoQ10 not recommended for PD treatment</li> </ul>"},{"location":"antioxidants/coq10/#interactions","title":"Interactions","text":"Factor Interaction Statins Deplete plasma and tissue CoQ10 by inhibiting mevalonate pathway; ubiquinol levels fall 16\u201354%; CoQ10 supplementation may partially compensate Warfarin CoQ10 has structural similarity to menaquinone (Vit K2); may modestly antagonise warfarin (reduce INR) in some patients; monitor INR if adding CoQ10 Beta-blockers Some beta-blockers (propranolol) inhibit CoQ10-dependent enzymes; CoQ10 may partially mitigate beta-blocker-induced fatigue Dietary fat Required for CoQ10 absorption \u2014 take with a fat-containing meal; defat/very low-fat diet impairs absorption Vitamin E CoQ10 regenerates vitamin E in membranes; synergistic lipid-soluble antioxidant system; CoQ10 + vitamin E provides broader membrane antioxidant protection than either alone Alpha-lipoic acid ALA regenerates CoQH\u2082 (ubiquinol); part of the integrated mitochondrial antioxidant network along with GSH Anticancer drugs (doxorubicin/anthracyclines) Anthracyclines cause cardiotoxicity partly via CoQ10 depletion in the heart; CoQ10 co-administration studied as cardioprotective strategy \u2014 evidence promising but not yet definitive"},{"location":"antioxidants/coq10/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dose: 100\u2013300 mg/day for general supplementation; 300\u2013600 mg/day for heart failure, migraines, male infertility; up to 3,000 mg/day for primary CoQ10 deficiency (under medical supervision)</li> <li>Form: Ubiquinol (reduced form) is preferred \u2014 better absorbed than ubiquinone, particularly in older adults (&gt;50) who have reduced ability to convert ubiquinone \u2192 ubiquinol; soft-gel or oil-based formulations are both superior to crystal powder</li> <li>Timing: Take with a fat-containing meal; twice-daily dosing produces more stable plasma levels vs once-daily</li> <li>Onset: Allow 3\u20134 weeks for plasma steady state; effects on tissue levels (heart, muscle) take longer</li> <li>Safety: Very well tolerated; rare GI side effects (nausea, diarrhoea) at high doses; no UL established; generally safe long-term; no significant adverse events reported in RCTs at doses up to 3,000 mg/day</li> <li>Drug interactions: Monitor INR in warfarin users; inform prescriber before adding high-dose CoQ10</li> </ul>"},{"location":"antioxidants/flavonoids/","title":"Flavonoids","text":""},{"location":"antioxidants/flavonoids/#overview","title":"Overview","text":"<p>Flavonoids are the largest and most studied subclass of polyphenols, with over 6,000 individual compounds identified in the plant kingdom. They share a common C6-C3-C6 backbone (two aromatic rings connected by a 3-carbon bridge forming a central pyranone ring), with structural variations in oxidation state, hydroxylation pattern, and glycosylation giving rise to six major subclasses. Flavonoids are responsible for the brilliant reds, blues, purples, and yellows of fruits and flowers, and serve plants as UV protectants, antimicrobials, and pollinator attractors. In human nutrition, flavonoids are among the most bioactive dietary components \u2014 with consistent epidemiological associations and a growing body of RCT evidence linking flavonoid intake to cardiovascular protection, metabolic health, cognitive preservation, and cancer prevention. The highest flavonoid intakes are associated with ~20\u201340% lower risk of CVD mortality across multiple large prospective cohort studies.</p> <ul> <li>Classification: Subclass of polyphenols; 6 major subclasses; C6-C3-C6 basic structure</li> <li>Key characteristic: Most naturally occur as glycosides (bound to sugars \u2014 primarily glucose, rhamnose, rutinose); hydrolysed in the gut to aglycones (free flavonoid) before/after absorption</li> <li>Bioavailability: Highly variable across subclasses and food matrices; gut microbiome is a critical determinant of metabolism and bioactivity</li> <li>Most studied subclass: Flavan-3-ols (catechins/epicatechins \u2014 in cocoa, green tea, apples) for cardiovascular effects; Flavonols (quercetin, kaempferol) for broad anti-inflammatory effects; Anthocyanins (berries) for neuroprotection and vascular health; Isoflavones (soy) for endocrine effects</li> </ul>"},{"location":"antioxidants/flavonoids/#the-six-subclasses","title":"The Six Subclasses","text":""},{"location":"antioxidants/flavonoids/#1-flavan-3-ols-catechins","title":"1. Flavan-3-ols (Catechins)","text":"Compound Source Key Properties Epicatechin (EC) Cocoa, apples, grapes, green tea Most studied; potent eNOS activator \u2192 NO production \u2192 vasodilation; anti-platelet Epigallocatechin-3-gallate (EGCG) Green tea (50\u201380% of green tea catechins) Strongest antioxidant among catechins; inhibits COX-2, NF-\u03baB, mTOR, VEGF-R; anti-proliferative; hepatotoxic at high supplemental doses Theaflavins Black tea (formed from catechin oxidation) LDL-C lowering; anti-inflammatory Proanthocyanidins (OPCs) Grape seed, cranberry, cacao Oligomers of catechins; strong antioxidants, anti-adhesion properties <p>Clinical evidence (flavan-3-ols): - Cocoa epicatechin: COSMOS-Heart RCT (n=21,442, 3.6 years, 500 mg/day cocoa extract \u2192 27% reduction in CVD deaths \u2014 one of the most significant dietary supplement RCTs) - Dose-response meta-analysis: 200 mg/day flavan-3-ols \u2192 \u22124 mmHg systolic BP; strong endothelial function improvement (FMD) - Green tea EGCG (600 mg/day catechins): Italian prostate cancer RCT \u2014 30% reduction in prostate cancer incidence in high-risk men over 1 year</p>"},{"location":"antioxidants/flavonoids/#2-flavonols","title":"2. Flavonols","text":"Compound Source Intake (typical Western diet) Quercetin Onions (highest), capers, kale, apples, berries ~25\u201350 mg/day Kaempferol Kale, endive, leek, broccoli, spinach ~10\u201320 mg/day Myricetin Berries, red wine, walnuts ~1\u20132 mg/day Fisetin Strawberries, apples, onions, cucumbers Trace <p>Quercetin \u2014 most studied flavonol: - Mechanism: NF-\u03baB inhibition, Nrf2 activation, AMPK activation, PI3K/mTOR inhibition, COX-2 inhibition, COMT inhibition (catecholamine metabolism) - Anti-inflammatory: Multiple RCTs confirm reduced CRP, IL-6, TNF-\u03b1 with quercetin supplementation (500\u20131,000 mg/day) - Blood pressure: Meta-analysis (n&gt;1,000): 153 mg/day quercetin \u2192 \u22122.6/\u22122.2 mmHg sys/dia BP reduction - Antihistamine / anti-allergy: Inhibits mast cell degranulation; clinical trial: quercetin equivalent to cromolyn sodium for pollen allergy symptom scores - Fisetin \u2014 senolytic activity: Emerging use as a \"senolytic\" (clears senescent cells); Mayo Clinic RCT: intermittent high-dose fisetin (20 mg/kg \u00d7 2 days/month) significantly reduced senescent cell burden markers in elderly; pipeline of senolytic trials ongoing</p>"},{"location":"antioxidants/flavonoids/#3-flavones","title":"3. Flavones","text":"Compound Source Key Properties Apigenin Parsley (richest), chamomile, celery, artichoke Anxiolytic (GABA-A receptor partial agonist); anti-inflammatory; NF-\u03baB inhibition; mild sedative (chamomile tea mechanism) Luteolin Celery, thyme, green pepper, broccoli Anti-inflammatory (potent COX-2 inhibitor); neuroprotective; anti-proliferative in cancer cell lines Nobiletin, Tangeretin Citrus peel Metabolic syndrome; anti-inflammatory; cognitive effects in animal models Baicalein Chinese skullcap (Scutellaria baicalensis) Anti-viral, anti-inflammatory; studied for SARS-CoV-2 inhibition"},{"location":"antioxidants/flavonoids/#4-flavanones","title":"4. Flavanones","text":"Compound Source Key Properties Hesperidin Orange, lemon peel Venous tone; capillary permeability; leg oedema; mild LDL-C reduction; diosmin+hesperidin (Daflon): approved in many countries for chronic venous insufficiency and haemorrhoids Naringenin / Naringin Grapefruit, orange CYP3A4 inhibitor \u2014 the \"grapefruit effect\" is primarily from naringenin + furanocoumarins; anti-inflammatory; improves insulin sensitivity Eriodictyol Lemons, other citrus Anti-inflammatory; antioxidant <p>Grapefruit drug interaction: Furanocoumarins (and to a lesser extent naringenin) in grapefruit irreversibly inhibit intestinal CYP3A4 for 12\u201324 hours \u2192 dramatically increases bioavailability of CYP3A4-metabolised drugs (contraindicated drugs: statins, cyclosporin, tacrolimus, some calcium channel blockers, certain benzodiazepines, many others). One glass of grapefruit juice can produce the same effect as multiple glasses over a day (enzyme recovery takes 24 h). A formal drug interaction check is mandatory when patients consume grapefruit.</p>"},{"location":"antioxidants/flavonoids/#5-anthocyanins","title":"5. Anthocyanins","text":"Compound Source Key Properties Cyanidin Cherries, blackcurrants, elderberry, red cabbage eNOS activation; anti-inflammatory; neuroprotective Delphinidin Blueberries, purple corn, bilberry VEGF inhibition; anti-angiogenic; retinal protection Pelargonidin Strawberries Antioxidant; bioavailable Malvidin Red wine, blueberries, bilberry Cardiovascular; eNOS; contributes to red wine anthocyanin activity Peonidin Blueberries, cherries Neuroprotective in animal models Petunidin Blueberries Anticancer models <p>Anthocyanins \u2014 standout clinical evidence: - Blood pressure and vascular function: Meta-analysis (25 RCTs, n&gt;1,500): anthocyanin supplementation \u2192 \u22123.72 mmHg systolic, \u22123.33 mmHg diastolic BP vs placebo - Cognitive function: BLUEBERRY RCT (University of Cincinnati): 24 weeks of wild blueberry supplementation significantly improved verbal memory in mild cognitive impairment (MCI); mechanism: eNOS-mediated cerebrovascular blood flow improvement - Tart cherry (cyanidin-3-glucoside): Multiple RCTs \u2192 reduces muscle soreness post-exercise, reduces uric acid (gout prevention), improves sleep (natural melatonin + anti-inflammatory) - Bilberry (delphinidin-predominant): Retinal blood flow and visual acuity in fatigue; historical WWII RAF pilots use (folklore supported by limited trial data) - Elderberry (Sambucus nigra): Meta-analysis: standardised elderberry extract reduced duration of cold/flu by ~2\u20134 days; inhibits viral neuraminidase and haemagglutinin; cytokine-stimulating effects (caution in cytokine storm conditions)</p>"},{"location":"antioxidants/flavonoids/#6-isoflavones","title":"6. Isoflavones","text":"Compound Source Key Properties Genistein Soy (primary); chickpeas, fava beans Phytoestrogen (ER\u03b2 agonist/ER\u03b1 weak); topoisomerase II inhibitor; angiogenesis inhibition Daidzein \u2192 Equol Soy \u2192 gut bacteria (only ~30% of Westerners produce equol) Equol has stronger estrogenic activity than daidzein; equol producers have better menopausal symptom response to soy Formononetin \u2192 Daidzein Red clover \u2192 gut Red clover isoflavones used for menopausal hot flushes; less evidence than estrogen therapy Biochanin A \u2192 Genistein Red clover, peanuts \u2192 gut Anti-proliferative <p>Isoflavones \u2014 clinical context: - Menopausal symptoms: Soy isoflavones (75\u2013150 mg/day) modestly reduce hot flush frequency (~15\u201320% reduction vs placebo), inferior to hormone therapy but safe option for those who cannot use HRT; effect dependent on equol-producer status - Bone health: Post-menopausal RCTs: isoflavones (&gt;54 mg/day for &gt;12 weeks) significantly reduce bone loss vs placebo in multiple meta-analyses - Breast cancer concern: No evidence soy isoflavones at food doses increase breast cancer risk in women; observational data from Asian cohorts suggests inverse association (early soy exposure may be protective); isoflavone supplementation in breast cancer survivors is not contraindicated by current evidence, but discuss with oncologist - Thyroid: May impair thyroid peroxidase activity at high doses; separate levothyroxine by \u22654 hours from soy intake</p>"},{"location":"antioxidants/flavonoids/#overall-dietary-sources-flavonoid-rich-foods","title":"Overall Dietary Sources \u2014 Flavonoid-Rich Foods","text":"Food Dominant Flavonoid Subclass Notable Compound Dark chocolate / cocoa Flavan-3-ols Epicatechin Green tea Flavan-3-ols EGCG Red wine Flavonols, Anthocyanins Quercetin, Malvidin Onions Flavonols Quercetin Blueberries Anthocyanins Delphinidin, Malvidin Apples Flavan-3-ols, Flavonols Epicatechin, Quercetin Oranges Flavanones Hesperidin, Naringenin Parsley Flavones Apigenin Soy (tofu, edamame) Isoflavones Genistein, Daidzein Kale Flavonols, Flavan-3-ols Kaempferol, Quercetin Chamomile tea Flavones Apigenin Tart cherries Anthocyanins Cyanidin-3-glucoside"},{"location":"antioxidants/flavonoids/#interactions","title":"Interactions","text":"Factor Interaction Non-haem iron absorption Quercetin, EGCG, hesperidin chelate Fe\u00b2\u207a and inhibit iron absorption; separate flavonoid-rich beverages (tea, coffee) from iron-rich meals by \u22651 hour for iron-deficient individuals Drug metabolism (CYP450) Grapefruit flavanones (naringenin + furanocoumarins): irreversible CYP3A4 inhibitor; EGCG: inhibits CYP3A4, P-glycoprotein; quercetin: inhibits CYP2C9 (warfarin metabolism) \u2014 warfarin INR monitoring Thyroid medications Soy isoflavones + levothyroxine: separate by \u22654 hours; may impair absorption Anticoagulants Multiple flavonoids have anti-platelet effects; potentiate warfarin/aspirin; monitor INR Gut microbiome Flavonoid effects are extensively modulated by gut bacteria; equol production from daidzein requires specific bacterial strains; lack of these strains reduces soy isoflavone efficacy Dietary fat Not strongly required for flavonoid absorption (unlike carotenoids) \u2014 most flavonoids are hydrophilic glycosides; but mild fat co-ingestion improves some aglycone absorption Zinc High doses of quercetin may chelate zinc; relevant only at supplemental doses"},{"location":"antioxidants/flavonoids/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Quercetin (500\u20131,000 mg/day): Most widely used flavonoid supplement; anti-inflammatory, antiviral, anti-allergy; generally well tolerated; headache and tingling at high doses; combine with bromelain or vitamin C for enhanced absorption; quercetin phytosome (QP) has significantly better bioavailability</li> <li>EGCG/Green tea extract (400\u2013800 mg/day EGCG): Weight management (modest, \u22121.2 kg in meta-analysis), antioxidant; hepatotoxicity risk &gt;800 mg/day EGCG on empty stomach \u2014 FDA safety warning; always take with food; decaffeinated extract available for caffeine-sensitive individuals</li> <li>Anthocyanin/berry extracts: Elderberry, bilberry, tart cherry, blueberry extracts \u2014 250\u20131,000 mg/day; cardiovascular, cognitive, exercise recovery benefits; generally very safe</li> <li>Cocoa flavanols (700 mg/day standardised): Best RCT evidence for cardiovascular endpoints; prefer products standardised to epicatechin; flavanol content in chocolate varies widely with processing (dark chocolate \u2260 high-flavanol; look for standardised extracts)</li> <li>Isoflavones (75\u2013150 mg/day): Menopausal symptom management, bone health in post-menopausal women; Red clover isoflavones (Promensil \u2014 40\u201380 mg/day isoflavones) have the most RCT data for hot flushes</li> <li>Fisetin (100\u2013500 mg/day; intermittent high-dose protocols being studied): Emerging senolytic; most antioxidant flavonoid (ORAC); very low oral bioavailability \u2014 nanoparticle/liposomal formulations in development</li> <li>Hesperidin/Diosmin (Daflon 500 mg twice daily): Clinically approved in many countries for chronic venous insufficiency and haemorrhoids; well tolerated; one of the most evidence-based flavonoid applications</li> </ul>"},{"location":"antioxidants/glutathione/","title":"Glutathione","text":""},{"location":"antioxidants/glutathione/#overview","title":"Overview","text":"<p>Glutathione (GSH) is the most abundant intracellular antioxidant in the human body, present in virtually every cell at millimolar concentrations. It is a tripeptide \u2014 \u03b3-L-glutamyl-L-cysteinyl-glycine \u2014 synthesised endogenously from three amino acids. Unlike dietary antioxidants, glutathione is not an essential nutrient: the body synthesises it continuously, making cellular GSH levels a product of substrate availability (particularly cysteine), enzyme capacity, and oxidative burden. GSH is the hub of the antioxidant network: it directly neutralises reactive oxygen species (ROS), regenerates vitamins C and E, powers the glutathione peroxidase and glutathione S-transferase enzyme families, and mediates detoxification of drugs, xenobiotics, and heavy metals.</p> <ul> <li>Type: Endogenous tripeptide antioxidant; non-essential (synthesised de novo)</li> <li>Structure: \u03b3-Glu\u2013Cys\u2013Gly; the unusual \u03b3-peptide bond (glutamate linked via its \u03b3-carboxyl) protects GSH from non-specific peptidases</li> <li>Active form: Reduced glutathione (GSH); oxidised form: GSSG (glutathione disulfide)</li> <li>Key property: The thiol (\u2013SH) group of cysteine is the reactive centre \u2014 donates electrons to neutralise ROS \u2192 forms GSSG; GSSG is reduced back to 2\u00d7GSH by glutathione reductase (GR) using NADPH</li> </ul>"},{"location":"antioxidants/glutathione/#biosynthesis","title":"Biosynthesis","text":"Step Enzyme Details Step 1 \u03b3-Glutamylcysteine synthetase (GCL; rate-limiting) Glutamate + Cysteine \u2192 \u03b3-Glutamylcysteine; rate-limited by cysteine availability and feedback-inhibited by GSH Step 2 Glutathione synthetase (GS) \u03b3-Glutamylcysteine + Glycine \u2192 GSH (reduced glutathione) <ul> <li>GCL is the committed, rate-limiting enzyme; cysteine is the limiting amino acid substrate</li> <li>Nrf2 pathway: Oxidative stress activates Nrf2 (nuclear factor erythroid 2-related factor 2) \u2192 binds ARE (antioxidant response element) \u2192 upregulates GCL, GS, glutathione reductase, thioredoxin \u2014 the master regulator of the cellular antioxidant response</li> <li>N-acetylcysteine (NAC) is the primary clinical means of replenishing GSH \u2014 NAC \u2192 cysteine \u2192 feeds GCL</li> </ul>"},{"location":"antioxidants/glutathione/#functions","title":"Functions","text":"<ul> <li>Direct ROS scavenging: GSH + H\u2082O\u2082 \u2192 GSSG + 2H\u2082O (via glutathione peroxidase, GPx); neutralises lipid hydroperoxides, peroxynitrite, hydroxyl radicals</li> <li>Regeneration of vitamins C and E: Vitamin C (dehydroascorbate) \u2192 ascorbate (via DHAR, using GSH); Vitamin E radical \u2192 Vitamin E (via Vitamin C, which GSH regenerates) \u2014 GSH is the electron donor at the base of the antioxidant hierarchy</li> <li>Xenobiotic and drug detoxification (Phase II): Glutathione S-transferase (GST) conjugates GSH to electrophilic compounds \u2192 glutathione conjugate \u2192 excreted via bile/urine (mercapturic acid pathway); substrates include paracetamol (NAPQI), heavy metals (arsenic, mercury), carcinogens</li> <li>Amino acid transport (\u03b3-glutamyl cycle): \u03b3-Glutamyl transpeptidase (GGT) transfers the glutamyl group of GSH to amino acids at the cell membrane \u2192 facilitates amino acid uptake; GGT is elevated in liver disease and alcohol excess (diagnostic marker)</li> <li>Protein thiol protection (S-glutathionylation): GSH forms mixed disulfides with protein cysteines during oxidative stress (S-glutathionylation) \u2192 protects thiol groups from irreversible oxidation; reversed by glutaredoxins</li> <li>Leukotriene synthesis: LTC4 synthase conjugates GSH to LTA4 \u2192 leukotriene C4 (LTC4) \u2014 a potent bronchoconstrictive eicosanoid; connects GSH to inflammatory signalling</li> <li>DNA synthesis: Ribonucleotide reductase (requires a glutaredoxin/GSH system) reduces ribonucleotides \u2192 deoxyribonucleotides; essential for DNA synthesis and repair</li> <li>Mitochondrial antioxidant defence: Mitochondrial GSH pool (mGSH) is separate and particularly critical \u2014 mitochondria produce ~90% of cellular ROS; mGSH depletion is closely linked to apoptosis and mitochondrial dysfunction</li> </ul>"},{"location":"antioxidants/glutathione/#metabolism","title":"Metabolism","text":"Step Details GSH utilisation GPx (glutathione peroxidase) uses GSH to reduce H\u2082O\u2082 and lipid hydroperoxides \u2192 GSSG GSSG reduction Glutathione reductase (GR) + NADPH \u2192 2\u00d7 GSH; NADPH supplied by G6PD (pentose phosphate pathway) GSH degradation GGT on extracellular cell surfaces cleaves GSH \u2192 CysGly + glutamate; dipeptidase cleaves CysGly \u2192 Cys + Gly; amino acids recycled via \u03b3-glutamyl cycle Kidney filtering Plasma GSH is primarily filtered and degraded by kidney tubular GGT; liver is the primary GSH exporter to plasma GSH:GSSG ratio Healthy cells maintain &gt;99% GSH (ratio ~100:1 to 300:1); under significant oxidative stress this falls; ratio is a clinical marker of redox status"},{"location":"antioxidants/glutathione/#food-sources-and-dietary-influences","title":"Food Sources and Dietary Influences","text":"<p>Glutathione itself is poorly absorbed intact from food \u2014 gut brush-border peptidases hydrolyse it; however dietary GSH in food may contribute to intestinal epithelial GSH and hepatic GSH via cysteine supply.</p> Factor Effect on Cellular GSH N-acetylcysteine (NAC) Most reliable means of raising cellular GSH \u2014 provides cysteine bypassing the rate-limiting GCL step Whey protein Highest dietary cysteine source (as cysteine + cystine); RCTs show whey protein raises lymphocyte GSH Cruciferous vegetables Glucosinolates \u2192 sulforaphane \u2192 activates Nrf2 \u2192 upregulates GCL and GS expression \u2192 raises cellular GSH capacity Alpha-lipoic acid Recycles GSSG \u2192 GSH; replenishes NADPH; raises GSH indirectly Selenium Cofactor for all GPx enzymes (GPx1\u20134, GPx6) \u2014 selenium deficiency reduces GPx activity \u2192 impairs GSH utilisation even if GSH levels are adequate Vitamin B2 (Riboflavin) FAD cofactor for glutathione reductase (GR) \u2014 B2 deficiency reduces GSSG \u2192 GSH recycling Dietary GSH (food) Asparagus, avocado, spinach, okra are highest food sources; bioavailability remains debated Oral GSH supplements Liposomal GSH shows improved bioavailability vs conventional oral GSH (limited trial evidence); sublingual GSH may also be better absorbed"},{"location":"antioxidants/glutathione/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/glutathione/#paracetamol-acetaminophen-overdose","title":"Paracetamol (Acetaminophen) Overdose","text":"<ul> <li>Paracetamol overdose is the prototypical GSH depletion injury: normal doses are detoxified by glucuronidation/sulfation (~90%); ~5% is oxidised by CYP2E1/CYP3A4 \u2192 NAPQI (N-acetyl-p-benzoquinone imine, highly reactive)</li> <li>Normal GSH conjugates NAPQI \u2192 mercapturic acid \u2192 safe excretion; in overdose, GSH is depleted faster than it can be replenished \u2192 NAPQI covalently binds hepatic proteins \u2192 centrilobular necrosis</li> <li>NAC is the antidote \u2014 provides cysteine to rapidly replenish GSH; most effective within 8\u201310 hours of ingestion</li> </ul>"},{"location":"antioxidants/glutathione/#oxidative-stress-diseases","title":"Oxidative Stress Diseases","text":"<ul> <li>Decreased GSH:GSSG ratios found in: HIV/AIDS, sepsis, ARDS, Parkinson's disease, Alzheimer's disease, type 2 diabetes, COPD, cystic fibrosis, rheumatoid arthritis, ALS</li> <li>Whether GSH depletion is causal or consequential varies by condition</li> </ul>"},{"location":"antioxidants/glutathione/#haemolytic-anaemia-g6pd-deficiency","title":"Haemolytic Anaemia (G6PD Deficiency)","text":"<ul> <li>G6PD (glucose-6-phosphate dehydrogenase) deficiency impairs pentose phosphate pathway \u2192 NADPH deficiency \u2192 glutathione reductase cannot recycle GSSG \u2192 GSH depletion \u2192 RBC oxidative damage \u2192 haemolysis</li> <li>Triggers: primaquine, dapsone, fava beans, infection; common in Mediterranean, African, Southeast Asian populations (protects against malaria)</li> </ul>"},{"location":"antioxidants/glutathione/#liver-disease","title":"Liver Disease","text":"<ul> <li>The liver is the primary GSH synthesis organ; hepatic GSH is critical for Phase II detoxification</li> <li>Alcoholic liver disease: ethanol \u2192 acetaldehyde (CYP2E1; NAD\u207a/NADH shift) \u2192 oxidative stress \u2192 GSH depletion; alcohol also specifically depletes mitochondrial GSH (mGSH) by impairing mitochondrial GSH transport</li> <li>NAC, SAMe (S-adenosylmethionine), silymarin (milk thistle) may partially support hepatic GSH in liver disease</li> </ul>"},{"location":"antioxidants/glutathione/#cystic-fibrosis","title":"Cystic Fibrosis","text":"<ul> <li>CF airways have depleted GSH due to impaired CFTR-mediated GSH secretion (CFTR transports GSH across epithelial membranes); oxidative stress in CF airways drives disease progression</li> <li>Inhaled GSH has been studied in CF (small trials \u2014 some symptomatic benefit)</li> </ul>"},{"location":"antioxidants/glutathione/#interactions","title":"Interactions","text":"Factor Interaction Selenium Essential cofactor for all GPx enzymes; GSH is ineffective without selenium-activated GPx; selenium deficiency \u2192 impaired GSH peroxidase activity Vitamin B2 (Riboflavin) FAD cofactor for GR; B2 deficiency \u2192 GSSG accumulates \u2192 GSH:GSSG ratio falls Vitamin C Regenerated by GSH (DHAR); synergistic antioxidant cycle: GSH\u2192C\u2192E\u2192direct ROS quenching; vitamin C also spares GSH Vitamin E Tocopheryl radical \u2192 regenerated by vitamin C \u2192 regenerated by GSH; fat-soluble ROS neutralisation depends on GSH Alpha-lipoic acid (ALA) Recycles GSH; raises intracellular cysteine via Nrf2 activation; also reduces GSSG via dihydrolipoate; strong synergy NAC (N-acetylcysteine) Bypasses rate-limiting GCL step \u2192 directly replenishes cysteine \u2192 raises GSH; used clinically in paracetamol overdose, contrast nephropathy prevention, COPD Alcohol Depletes hepatic and mitochondrial GSH; promotes oxidative stress via CYP2E1 induction Nrf2 activators Sulforaphane (cruciferous veg), curcumin, resveratrol activate Nrf2 \u2192 upregulate GCL, GS, GR expression \u2192 increase GSH synthesis capacity"},{"location":"antioxidants/glutathione/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Oral reduced glutathione (GSH): Historically poor bioavailability (GI tract hydrolysis); liposomal GSH (250\u2013500 mg/day) shows better plasma and lymphocyte GSH elevation in small RCTs; sublingual delivery also studied</li> <li>N-acetylcysteine (NAC) \u2014 most evidence-based: 600\u20131,800 mg/day; raises tissue GSH; approved for paracetamol overdose (IV) and as mucolytic in COPD; studied in COVID-19, PCOS, psychiatric conditions (OCD, bipolar), fertility</li> <li>Whey protein (30\u201340 g/day): Richest dietary cysteine source; several RCTs demonstrate raised lymphocyte and plasma GSH in elderly and HIV patients</li> <li>Alpha-lipoic acid (ALA; 300\u2013600 mg/day): Raises GSH via Nrf2 and GSSG reduction; used in diabetic neuropathy, metabolic syndrome; crosses blood-brain barrier \u2014 brain GSH support</li> <li>Selenium (55\u2013200 \u00b5g/day): Required for GPx activity; selenium supplementation in deficient individuals restores GPx activity and improves GSH utilisation</li> <li>Silymarin (milk thistle; 420 mg/day standardised extract): Hepatoprotective; raises hepatic GSH in animal models; some clinical evidence in alcoholic liver disease and NAFLD</li> </ul>"},{"location":"antioxidants/lutein/","title":"Lutein","text":""},{"location":"antioxidants/lutein/#overview","title":"Overview","text":"<p>Lutein is a xanthophyll carotenoid \u2014 a yellow-orange oxygenated carotene found in high concentrations in leafy green vegetables, egg yolks, and marigold flowers. Unlike beta-carotene, lutein has no provitamin A activity. Its most critical biological role is in the eye: lutein is selectively concentrated in the macula lutea of the retina (hence the name \u2014 lutea = yellow in Latin), where it and its stereoisomer zeaxanthin form the macular pigment that acts as a natural short-wavelength (blue-violet) light filter and antioxidant shield for the photoreceptors. Lutein is the subject of intense research for age-related macular degeneration (AMD) prevention and management \u2014 the leading cause of irreversible vision loss in adults over 65.</p> <ul> <li>Classification: Xanthophyll carotenoid (dihydroxy carotenoid); fat-soluble; no provitamin A activity</li> <li>Structure: 40-carbon carotenoid with two hydroxyl (\u2013OH) groups; \u03b5-ring at both ends; stereoisomer of zeaxanthin (differs in double bond position in one ring)</li> <li>Macular pigment optical density (MPOD): Measurable biomarker of macular lutein/zeaxanthin content; low MPOD = risk factor for AMD</li> <li>Key tissues: Macula (highest density of any tissue in body), lens, brain, skin</li> </ul>"},{"location":"antioxidants/lutein/#functions","title":"Functions","text":"<ul> <li>Blue light filtering (macular pigment): Lutein and zeaxanthin in the macula absorb high-energy blue-violet light (400\u2013500 nm) before it reaches the photoreceptors \u2014 acts as a biological internal UV filter; reduces photochemical damage to the photoreceptors and retinal pigment epithelium (RPE)</li> <li>Singlet oxygen and ROS quenching in the retina: The macula is metabolically hyperactive and exposed to high photon flux \u2192 very high local ROS generation; lutein quenches \u00b9O\u2082, lipid peroxyl radicals, and peroxynitrite in the highly unsaturated photoreceptor outer segment membranes (rich in DHA)</li> <li>Lens antioxidant protection: Lutein in the crystalline lens reduces photochemical oxidative damage \u2192 protective against nuclear cataract formation</li> <li>Neuroprotection (brain): Lutein is the most predominant carotenoid in the human brain (particularly in the frontal lobe, occipital cortex, cerebellum); associated with faster neural processing speed in observational studies; mechanism: membrane antioxidant protection, DHA conservation, anti-neuroinflammation</li> <li>Skin photoprotection: Lutein in skin absorbs UV-visible light \u2192 protects against UV-induced oxidative damage and matrix metalloproteinase (MMP) activation (collagen degradation)</li> <li>Anti-inflammatory signalling: Lutein reduces NF-\u03baB activation and inhibits COX-2 expression \u2192 reduces pro-inflammatory cytokines (IL-6, TNF-\u03b1) in vitro and in several animal models</li> </ul>"},{"location":"antioxidants/lutein/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Factor Effect Dietary fat co-ingestion Essential for lutein absorption (micellar solubilisation); an egg (with yolk fat) has better lutein bioavailability than spinach alone \u2014 fat in the egg yolk drives absorption Egg yolk vs. vegetables Egg yolk lutein has ~3\u20135\u00d7 higher bioavailability than lutein from dark leafy greens (spinach, kale) despite vegetables having more total lutein \u2014 due to protein-binding of lutein in chloroplasts; xanthophylls in eggs are in free (unbound) form in lipid droplets Cooking Moderate heating improves lutein bioavailability from vegetables (breaks down cell walls and protein complexes); overcooking destroys it Absorption SR-BI (scavenger receptor BI) and CD36 at enterocyte brush border mediate carotenoid uptake \u2192 incorporated into chylomicrons \u2192 lymph Plasma transport HDL is the primary plasma carrier of lutein (different from lycopene/\u03b2-carotene which preferentially associate with LDL) Retinal accumulation Lutein is selectively accumulated in the macula by GSTP1 (glutathione S-transferase Pi 1) \u2014 a lutein-binding protein that concentrates it from blood; meso-zeaxanthin in the fovea is derived from lutein conversion in situ by RPE Half-life Long plasma half-life (~10\u201320 days); tissue (retinal) half-life much longer; MPOD increases are sustained after supplementation stops"},{"location":"antioxidants/lutein/#dietary-sources","title":"Dietary Sources","text":"Food Serving Lutein + Zeaxanthin (mg) Kale (cooked) 1 cup (130 g) 23.7 mg Spinach (cooked) 1 cup (180 g) 20.4 mg Spinach (raw) 1 cup (30 g) 3.7 mg Collard greens (cooked) 1 cup (170 g) 14.6 mg Broccoli (cooked) 1 cup (91 g) 2.0 mg Peas (cooked) 1 cup (160 g) 4.1 mg Corn (cooked) 1 cup (154 g) 2.2 mg Egg yolk 1 large 0.25 mg (but 3\u20135\u00d7 more bioavailable than vegetable sources) Orange pepper 1 medium 1.0 mg Pistachios 28 g 0.8 mg"},{"location":"antioxidants/lutein/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/lutein/#age-related-macular-degeneration-amd","title":"Age-Related Macular Degeneration (AMD)","text":"<ul> <li>AMD is the leading cause of blindness in adults &gt;65; characterised by progressive degeneration of the macular photoreceptors and RPE; two forms: dry (geographic atrophy) and wet (neovascular)</li> <li>AREDS2 trial (n=4,203): supplementation with 10 mg lutein + 2 mg zeaxanthin replaced \u03b2-carotene in the AREDS formula \u2192 18% reduction in risk of AMD progression to advanced AMD; lutein/zeaxanthin superior to \u03b2-carotene (which had concerns in smokers); now the standard of care recommendation for intermediate AMD</li> <li>Mechanism: Restores MPOD; protects photoreceptor membranes and RPE from oxidative and phototoxic damage</li> <li>Low MPOD is an independent risk factor for AMD; MPOD can be measured clinically (heterochromatic flicker photometry)</li> </ul>"},{"location":"antioxidants/lutein/#cataract","title":"Cataract","text":"<ul> <li>Population studies (Nurses' Health Study, n=77,000+): highest quintile of dietary lutein+zeaxanthin intake associated with ~19\u201322% reduced risk of nuclear cataract</li> <li>Lutein in the lens absorbs UV and reduces photochemical cross-linking of lens proteins (the basis of nuclear cataract)</li> </ul>"},{"location":"antioxidants/lutein/#cognitive-function","title":"Cognitive Function","text":"<ul> <li>Lutein is the most abundant carotenoid in the human brain; brain lutein correlates with crystallised intelligence and processing speed in multiple cross-sectional studies (infants, adults, older adults)</li> <li>COGNI-SUN RCT: Lutein supplementation improved cognitive performance in healthy older women; mechanism likely via membrane antioxidant protection and anti-neuroinflammation</li> </ul>"},{"location":"antioxidants/lutein/#skin","title":"Skin","text":"<ul> <li>Oral lutein (10 mg/day) increases skin hydration, elasticity, and photoprotection against UV-induced erythema in RCTs; combination with topical lutein is synergistic</li> </ul>"},{"location":"antioxidants/lutein/#interactions","title":"Interactions","text":"Factor Interaction Zeaxanthin Zeaxanthin is the co-pigment of the macula; lutein predominates in the peripheral macula, zeaxanthin in the central fovea; the two are synergistic and always measured together (MPOD reflects both) DHA (Omega-3) DHA is the dominant fatty acid in photoreceptor outer segment membranes; lutein protects DHA from peroxidation; DHA+lutein supplementation shows additive benefits for AMD and MPOD vs. either alone Vitamin E Both are lipid-soluble antioxidants protecting membrane PUFAs; synergistic in retinal membranes Beta-carotene Competes with lutein for intestinal absorption via shared SR-BI transporter; high-dose beta-carotene supplementation may reduce plasma lutein; AREDS2 replaced beta-carotene with lutein+zeaxanthin partly for this reason Dietary fat Required for absorption; low-fat diets or fat malabsorption significantly reduces lutein bioavailability Smoking Smoking depletes plasma lutein and zeaxanthin; smokers at higher risk of AMD; smoking \u00d7 low lutein status = interactive risk"},{"location":"antioxidants/lutein/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>AREDS2 dose: 10 mg lutein + 2 mg zeaxanthin per day \u2014 evidence-based for intermediate AMD (AREDS2 RCT); this is the clinical standard</li> <li>General eye health: 6\u201320 mg/day lutein commonly used; 2 mg/day zeaxanthin; increases MPOD over 3\u201312 months</li> <li>Sources: Marigold flower extract (Tagetes erecta) is the primary commercial source; FloraGLO (DSM) and OmniXan are the major branded standardised forms used in research</li> <li>Form: Free lutein (as in egg yolk) vs. lutein esters (in supplements from marigold extracts); lutein esters must be hydrolysed in the gut; both have similar bioavailability when taken with fat</li> <li>Safety: No UL established; no adverse effects reported up to 20 mg/day in RCTs; no provitamin A activity \u2014 cannot cause hypervitaminosis A; no adverse effects in smokers (unlike beta-carotene)</li> <li>Dietary note: Eating eggs with leafy greens dramatically increases lutein absorption from greens \u2014 clinical-level dietary optimisation strategy</li> </ul>"},{"location":"antioxidants/lycopene/","title":"Lycopene","text":""},{"location":"antioxidants/lycopene/#overview","title":"Overview","text":"<p>Lycopene is a bright red carotenoid pigment responsible for the characteristic colour of tomatoes, watermelon, pink grapefruit, and guava. It is an acyclic carotene (no \u03b2-ionone ring), which distinguishes it structurally from \u03b2-carotene and renders it unable to be converted to vitamin A \u2014 making its health effects entirely independent of vitamin A activity. Lycopene is the most potent singlet oxygen quencher among all dietary carotenoids (2\u00d7 \u03b2-carotene, 10\u00d7 \u03b1-tocopherol), making it an exceptionally effective antioxidant. Lycopene accumulates preferentially in the testes, adrenal glands, and liver. Its most studied clinical association is with prostate cancer risk reduction, supported by epidemiological data, though large intervention trials have been mixed.</p> <ul> <li>Classification: Acyclic carotenoid; fat-soluble antioxidant; no vitamin A activity (no \u03b2-ionone ring)</li> <li>Structure: 40-carbon polyene with 11 conjugated double bonds (record among common carotenoids); highly unsaturated structure confers exceptional singlet oxygen quenching</li> <li>Forms: All-trans-lycopene (predominant in raw tomatoes); cis-lycopene (5-cis, 9-cis, 13-cis) \u2014 processing increases cis content; cis-lycopene has better bioavailability than trans</li> <li>Key property: Processing (heating, homogenising, pur\u00e9eing) dramatically increases bioavailability of lycopene from tomatoes \u2014 making tomato paste/sauce more bioavailable than raw tomatoes</li> </ul>"},{"location":"antioxidants/lycopene/#functions","title":"Functions","text":"<ul> <li>Singlet oxygen (\u00b9O\u2082) quenching: Lycopene's conjugated double bond system makes it the most efficient singlet oxygen quencher of dietary carotenoids \u2014 physically dissipates the excitation energy of \u00b9O\u2082 \u2192 returns to ground state without being consumed; the carotenoid is regenerated (unlike vitamin C or E which are consumed)</li> <li>Peroxyl radical scavenging: Lycopene interrupts lipid peroxidation chain reactions in cell membranes and LDL particles</li> <li>LDL oxidation protection: Lycopene incorporated into LDL reduces its susceptibility to oxidative modification \u2192 potentially reduces atherogenic ox-LDL formation</li> <li>Cell growth regulation: Inhibits cancer cell proliferation via gap junction communication enhancement (Cx43 connexin upregulation) \u2192 restores growth-suppressive cell-cell communication disrupted in cancer; independent of antioxidant activity</li> <li>Androgen receptor modulation: Downregulates androgen receptor (AR) signalling in prostate cells \u2192 potentially reduces prostate cell proliferation driven by androgens</li> <li>IGF-1 pathway inhibition: Lycopene reduces IGF-1 receptor signalling (a growth driver in prostate, breast, and colorectal cancers)</li> <li>Phase II enzyme induction: Activates Nrf2 \u2192 induces glutathione S-transferase, NQO1, heme oxygenase-1 \u2192 cellular antioxidant and detoxification capacity enhancement</li> </ul>"},{"location":"antioxidants/lycopene/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Factor Effect on Bioavailability Heating / processing Increases lycopene bioavailability: disrupts plant cell walls, releases lycopene from chromoplasts, isomerises trans \u2192 cis (more bioavailable); tomato paste/sauce \u2192 5\u00d7 higher plasma response vs raw tomato Dietary fat co-ingestion Fat is required: lycopene is incorporated into micelles via bile salts; adding olive oil to tomato sauce dramatically increases lycopene absorption (cook with oil) Food matrix Fine particle size (homogenisation, blending) and cooking increase bioaccessibility; whole tomato &lt; blended tomato &lt; tomato paste Cholesterol-lowering drugs (cholestyramine, ezetimibe) May impair carotenoid absorption (bile acid sequestrants impair micelle formation) Absorption Absorbed in small intestine in micelles \u2192 incorporated into chylomicrons \u2192 lymph \u2192 plasma \u2192 distributed to tissues Plasma distribution LDL (37%), HDL (14%), VLDL (14%), other lipoproteins; plasma lycopene is an excellent biomarker of tomato intake Tissue accumulation Testes (~4.3 nmol/g wet tissue), adrenal glands, liver \u2014 highest tissue concentrations; prostate accumulates significant lycopene Half-life ~12\u201333 days in plasma"},{"location":"antioxidants/lycopene/#dietary-sources","title":"Dietary Sources","text":"Food Serving Lycopene (mg) Tomato paste 2 tbsp (30 g) 9.5\u201314 mg Tomato sauce (canned) 100 mL 15\u201321 mg Tomatoes (raw) 1 medium (123 g) 3.2 mg Tomato juice 240 mL 22 mg Ketchup 1 tbsp (15 g) 2.5 mg Watermelon 1 cup (154 g) 12.7 mg Pink grapefruit \u00bd fruit 1.5\u20133 mg Guava (red flesh) 100 g 5.2 mg Papaya (pink) 100 g 1.8 mg <p>Cooking tip: Adding olive oil when making tomato sauce increases lycopene absorption by 2\u20133\u00d7 vs. oil-free preparation. Tomato paste is the most concentrated and bioavailable source. Watermelon provides lycopene with excellent bioavailability (already high cis-lycopene content, high water activity aids absorption).</p>"},{"location":"antioxidants/lycopene/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/lycopene/#prostate-cancer","title":"Prostate Cancer","text":"<ul> <li>The most extensively studied association: epidemiological data (Harvard NHS cohort, &gt;40,000 men) shows highest lycopene intake associated with ~21\u201335% lower risk of prostate cancer, particularly aggressive/advanced prostate cancer</li> <li>Lycopene accumulates in the prostate; men with prostate cancer have lower prostate lycopene than controls</li> <li>Mechanisms: AR downregulation, IGF-1 inhibition, cell cycle arrest (G\u2080/G\u2081), gap junction restoration, antioxidant protection of DNA</li> <li>Intervention trials: mixed. Several small RCTs show reduced PSA or improved histological outcomes; SELECT trial (selenium+vitamin E) found no benefit but did not test lycopene; definitive large RCT lacking</li> <li>WCRF/AICR: \"Limited, suggestive evidence\" for lycopene and prostate cancer \u2014 cannot make a firm recommendation based on current evidence</li> </ul>"},{"location":"antioxidants/lycopene/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Plasma lycopene is inversely associated with carotid intima-media thickness (cIMT), a marker of subclinical atherosclerosis, in multiple cross-sectional studies</li> <li>Lycopene inhibits HMG-CoA reductase (modestly) \u2192 may contribute to cholesterol lowering</li> <li>LYRIS trial (2019): 7 mg lycopene/day for 2 months in patients with CVD \u2192 significantly improved brachial artery flow-mediated dilation (FMD, a marker of endothelial function) vs placebo</li> </ul>"},{"location":"antioxidants/lycopene/#skin-photoprotection","title":"Skin Photoprotection","text":"<ul> <li>Lycopene in skin provides modest UV protection \u2014 acts as an endogenous sunscreen; higher skin lycopene levels \u2192 less UV-induced erythema</li> <li>Tomato paste (40 g/day; ~16 mg lycopene) for 10 weeks significantly reduced UV-induced skin erythema vs olive oil control</li> <li>Does not replace topical sunscreen (SPF effect is minor) but complements it</li> </ul>"},{"location":"antioxidants/lycopene/#fertility-male","title":"Fertility (Male)","text":"<ul> <li>Testes have the highest lycopene concentration of any tissue; oxidative stress is a major driver of male infertility</li> <li>Small RCTs suggest lycopene supplementation improves sperm count, motility, and morphology in oligospermic men; a systematic review confirmed modest benefit</li> </ul>"},{"location":"antioxidants/lycopene/#hypertension","title":"Hypertension","text":"<ul> <li>Meta-analysis: lycopene supplementation (&gt;12 mg/day in studies) modestly reduced systolic BP (~5 mmHg) vs placebo; effect appears threshold-dependent (above ~25 mg/day of dietary intake)</li> </ul>"},{"location":"antioxidants/lycopene/#interactions","title":"Interactions","text":"Factor Interaction Fat-soluble antioxidants (\u03b2-carotene, lutein, zeaxanthin) Carotenoids compete for intestinal absorption (shared SR-BI and CD36 transporters); very high supplemental \u03b2-carotene may reduce lycopene absorption and vice versa Cholesterol-lowering drugs Bile acid sequestrants (cholestyramine, colestipol) impair fat-soluble compound absorption including lycopene; ezetimibe (NPC1L1 inhibitor) may reduce carotenoid absorption Dietary fat Required for lycopene absorption (micelle formation); advise consumption of lycopene-rich foods with healthy fats (olive oil, avocado) Phytosterol supplements May reduce carotenoid absorption at high doses (shared micellar solubilisation pathway) Anticoagulants At very high doses, lycopene may have mild anti-platelet effects \u2014 clinically insignificant at food intake levels Finasteride/dutasteride (5-ARIs) Combined with prostate cancer-protective lifestyle including lycopene \u2014 no drug interaction data, but 5-ARIs and lycopene may complementarily reduce prostate cancer risk"},{"location":"antioxidants/lycopene/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dietary approach preferred: Processed tomato products (paste, sauce, juice) with olive oil are the most effective means of achieving high lycopene bioavailability \u2014 no need for supplements in most people</li> <li>Supplemental dose: 10\u201330 mg/day trans-lycopene or mixed isomers used in most RCTs; natural extracts (tomato oleoresin containing mixed isomers) may be preferable to pure all-trans-lycopene</li> <li>No RDA/AI established \u2014 no official dietary reference intake for lycopene in most countries</li> <li>Safety: No UL established; no toxicity at supplemental doses; lycopene does not cause hypervitaminosis A (no provitamin A activity); high intake may cause lycopenodermia (orange skin discolouration) \u2014 harmless and reversible</li> <li>Important note: Unlike \u03b2-carotene (which caused harm in smokers in ATBC and CARET trials), lycopene supplementation has not been associated with adverse effects in smokers; the absence of provitamin A activity may account for this safety difference</li> <li>Absorption optimisation: Take with a fat-containing meal; choose cis-lycopene-rich sources (cooked/processed tomatoes) or supplements containing mixed lycopene isomers</li> </ul>"},{"location":"antioxidants/polyphenols/","title":"Polyphenols","text":""},{"location":"antioxidants/polyphenols/#overview","title":"Overview","text":"<p>Polyphenols are the largest and most structurally diverse class of plant secondary metabolites, with over 8,000 identified structures. Defined by the presence of multiple phenolic hydroxyl groups (-OH) attached to aromatic rings, polyphenols serve plants as UV protectants, antimicrobial defences, and pigments. In the human diet, they are ubiquitous in fruits, vegetables, tea, coffee, cocoa, red wine, olive oil, and whole grains. Polyphenols are not classified as essential nutrients \u2014 no deficiency syndrome is described \u2014 but high polyphenol intake from plant-rich diets is consistently and strongly associated with reduced risk of cardiovascular disease, type 2 diabetes, neurodegenerative disease, and certain cancers across epidemiological studies.</p> <ul> <li>Classification: Secondary plant metabolites; non-essential bioactive compounds; 4 major structural classes + hundreds of subclasses</li> <li>Key property: Antioxidant via direct radical scavenging, metal chelation, and most importantly through modulation of antioxidant and inflammatory gene signalling (Nrf2, NF-\u03baB, MAPK pathways)</li> <li>Bioavailability challenge: Most polyphenols are extensively modified by gut microbiota and phase II metabolism; systemic bioavailability of parent compounds is often &lt;1\u20135%, but gut-derived metabolites have significant local intestinal effects and some are bioavailable systemically</li> <li>Food vs. supplement distinction: Whole food polyphenol effects are consistently stronger in trials than isolated polyphenol supplements \u2014 food matrix effects, polyphenol synergy, and gut microbiome interactions are critical</li> </ul>"},{"location":"antioxidants/polyphenols/#classification-and-major-subclasses","title":"Classification and Major Subclasses","text":"Class Subclass Examples Key Dietary Sources Flavonoids Flavonols, Flavones, Flavan-3-ols, Flavanones, Anthocyanins, Isoflavones See flavonoids document Phenolic acids Hydroxycinnamic acids (ferulic, caffeic, chlorogenic), Hydroxybenzoic acids (gallic, ellagic, protocatechuic) Coffee, whole grains, berries, artichokes Stilbenes Resveratrol, Pterostilbene Grapes, red wine, blueberries Lignans Secoisolariciresinol, Matairesinol, Enterolignans (gut-converted) Flaxseed, sesame, whole grains, cruciferous vegetables Tannins Ellagitannins (\u2192 urolithins), Proanthocyanidins (OPCs) Pomegranate, walnuts, berries, red wine, cranberry Curcuminoids Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin Turmeric Other phenols Hydroxytyrosol, oleuropein (olive), capsaicin (pepper), gingerol (ginger) Olive oil, peppers, ginger"},{"location":"antioxidants/polyphenols/#mechanisms-of-action-overview","title":"Mechanisms of Action \u2014 Overview","text":"Mechanism Details Direct antioxidant / radical scavenging Phenolic \u2013OH groups donate H\u2022 to quench lipid, hydroxyl, peroxyl, superoxide radicals; forms relatively stable phenoxyl radical; less important than once thought relative to signalling effects Metal chelation Polyphenols chelate Fe\u00b2\u207a and Cu\u00b2\u207a \u2192 inhibit Fenton reaction (Fe\u00b2\u207a + H\u2082O\u2082 \u2192 Fe\u00b3\u207a + OH\u2022 + OH\u207b) \u2192 reduce hydroxyl radical generation Nrf2 activation Many polyphenols activate Nrf2 (often via autoxidation to electrophilic quinones \u2192 Keap1 modification) \u2192 upregulate glutathione synthesis, heme-oxygenase-1, SOD, catalase NF-\u03baB inhibition Suppress I\u03baB kinase (IKK) phosphorylation \u2192 prevent NF-\u03baB nuclear translocation \u2192 reduce TNF-\u03b1, IL-6, IL-1\u03b2, COX-2, iNOS gene expression AMPK activation Multiple polyphenols mimic caloric restriction via AMPK activation (EGCG, quercetin, resveratrol) \u2192 improve insulin sensitivity, mitochondrial biogenesis eNOS upregulation Flavanols (especially epicatechin from cocoa) activate eNOS \u2192 increased NO production \u2192 vasodilation \u2192 blood pressure reduction; explains \"flavanol-mediated flow-mediated dilation\" Gut microbiome modulation Polyphenols are partly prebiotic \u2014 selectively feed beneficial gut bacteria (Lactobacillus, Bifidobacterium; Akkermansia); gut bacteria metabolise polyphenols to bioactive metabolites (urolithins from ellagitannins, equol from isoflavones) that have systemic effects"},{"location":"antioxidants/polyphenols/#major-classes-detailed-notes","title":"Major Classes \u2014 Detailed Notes","text":""},{"location":"antioxidants/polyphenols/#phenolic-acids","title":"Phenolic Acids","text":"<ul> <li>Chlorogenic acid (major coffee polyphenol): Abundant in green coffee beans (3\u20135 g per cup of instant coffee); inhibits hepatic glucose-6-phosphatase \u2192 reduces fasting glucose; improves insulin sensitivity; the primary mechanism behind coffee's well-documented protection against T2DM and liver disease</li> <li>Ferulic acid (major whole grain phenolic acid): Primarily in wheat bran (esterified to arabinoxylan); anti-inflammatory; crosses blood-brain barrier; studied for neuroprotection in Alzheimer's models</li> <li>Gallic acid (tannin monomer): Found in gallotannins; potent antioxidant; antimicrobial; prostate cancer apoptosis in vitro</li> <li>Ellagic acid and ellagitannins \u2192 colonic bacteria \u2192 urolithins (Urolithin A, B, C, D): Urolithin A has emerged as a significant postbiotic \u2014 activates mitophagy (mitochondrial recycling), extends lifespan in C. elegans and mice; clinical trial (TRIIM): Urolithin A supplement improved muscle mitochondrial health in older adults</li> </ul>"},{"location":"antioxidants/polyphenols/#tannins","title":"Tannins","text":"<ul> <li>Proanthocyanidins (OPCs): Oligomeric proanthocyanidins in grape seed extract, red wine, cranberry, cocoa; inhibit bacterial adhesion to uroepithelium (basis for cranberry and UTI prevention); potent free radical scavengers; modest LDL-C lowering</li> <li>Ellagitannins (pomegranate, walnuts, berries): Hydrolysed by gut bacteria to ellagic acid \u2192 urolithins; pomegranate juice (POJ) has strongest antioxidant capacity of commonly consumed juices (3\u00d7 red wine, 5\u00d7 green tea per gram)</li> <li>Hydrolysable tannins contribute significantly to the antioxidant capacity of pomegranate, strawberries, raspberries, and oak-barrel-aged red wine</li> </ul>"},{"location":"antioxidants/polyphenols/#lignans","title":"Lignans","text":"<ul> <li>Food sources: Flaxseed (richest \u2014 ~300 mg secoisolariciresinol diglucoside per 100 g), sesame seeds, whole grains, cruciferous vegetables</li> <li>Gut metabolism: Intestinal bacteria convert plant lignans \u2192 enterolignans (enterodiol, enterolactone) \u2014 phytoestrogenic activity via ER\u03b1/ER\u03b2; associated with reduced risk of hormone-sensitive cancers (breast, prostate) in epidemiological studies</li> <li>Cardiovascular: Flaxseed lignans reduce LDL-C and inflammatory markers in RCTs; enterolactone is inversely associated with cardiovascular mortality in cohort studies</li> </ul>"},{"location":"antioxidants/polyphenols/#curcumin","title":"Curcumin","text":"<ul> <li>Source: Turmeric (Curcuma longa), comprising ~2\u20135% of dry turmeric mass</li> <li>Bioavailability problem: Curcumin is extremely poorly absorbed (rapid conjugation and first-pass metabolism); typical plasma levels from 1 g curcumin are ~1\u20134 ng/mL (barely detectable); the vast majority of tested clinical benefits from dietary turmeric are limited by this</li> <li>Bioavailability solutions: Piperine (BioPerine, 5\u201320 mg) inhibits glucuronidation \u2192 increases bioavailability 20-fold; phospholipid complex (Meriva, Phytosome) \u2014 29-fold better; nanoparticle encapsulation; liposomal curcumin</li> <li>Mechanisms: EXTREMELY broad in vitro mechanistic targets (NF-\u03baB, Nrf2, STAT3, AP-1, p53, mTOR, Wnt, HDAC \u2014 nearly every cancer-relevant pathway); this breadth is sometimes called the \"curcumin promiscuity problem\" \u2014 it may be a PAINS (pan-assay interference) compound with artifactual results in many assays</li> <li>Clinical evidence: Promising for osteoarthritis pain (equivalent to NSAIDs in some trials at 500 mg 3\u00d7 daily of bioavailable forms); IBD and IBS remission maintenance; some cancer biomarker studies; no approved clinical indication</li> <li>Hydroxytyrosol (olive): A simpler phenol in EVOO; among the most potent antioxidants measured (ORAC); contributes to EVOO's cardiovascular benefits; EFSA approved health claim: \"Olive oil polyphenols contribute to the protection of blood lipids from oxidative stress\" (at \u22655 mg hydroxytyrosol + derivatives per 20 g EVOO)</li> </ul>"},{"location":"antioxidants/polyphenols/#dietary-sources-overall-polyphenol-richness","title":"Dietary Sources \u2014 Overall Polyphenol Richness","text":"Food Total Polyphenol Content (mg/100 g or 100 mL) Dark chocolate (100% cocoa) ~1,200 mg Dried rosemary ~3,000 mg Dried thyme ~1,200 mg Flaxseed meal ~1,500 mg Black elderberry ~1,950 mg Blackcurrant ~758 mg Blueberry ~560 mg Artichoke ~260 mg Black bean ~500 mg Extra-virgin olive oil ~200\u2013600 mg/100 mL Red wine ~1,200\u20132,000 mg/L Green tea ~200 mg per cup (240 mL) Coffee (brewed) ~200\u2013300 mg per cup"},{"location":"antioxidants/polyphenols/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/polyphenols/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Significant and consistent epidemiological evidence: Mediterranean and MIND diets (polyphenol-rich) reduce CVD incidence by 30\u201340% (PREDIMED, &gt;7,000 participants)</li> <li>Cocoa flavanols (700 mg/day): multiple RCTs \u2192 improved endothelial function (FMD), blood pressure reduction, platelet aggregation inhibition</li> <li>Olive oil polyphenols (hydroxytyrosol + oleuropein): EFSA-approved claim; reduce oxidised LDL</li> </ul>"},{"location":"antioxidants/polyphenols/#type-2-diabetes","title":"Type 2 Diabetes","text":"<ul> <li>3\u20134 cups/day coffee (polyphenol-rich): 25\u201330% lower T2DM risk in meta-analyses (both caffeinated and decaffeinated \u2014 chlorogenic acid is the active component, not caffeine)</li> <li>Berberine (an alkaloid polyphenol from Berberis plants; 500 mg 3\u00d7/day): clinically comparable to metformin for T2DM glucose management across multiple Chinese RCTs; activates AMPK, reduces hepatic glucose output</li> </ul>"},{"location":"antioxidants/polyphenols/#gut-microbiome-prebiotic-effects","title":"Gut Microbiome (Prebiotic Effects)","text":"<ul> <li>Polyphenols selectively increase Akkermansia muciniphila (associated with metabolic health), Lactobacillus, Bifidobacterium, and reduce Bacteroidetes overgrowth</li> <li>Red wine polyphenols (in &lt;250 mL/day amounts) significantly change gut microbiome composition within 4 weeks</li> </ul>"},{"location":"antioxidants/polyphenols/#cancer-chemoprevention","title":"Cancer Chemoprevention","text":"<ul> <li>Epidemiological associations for multiple cancers with polyphenol-rich diets; direct intervention evidence limited</li> <li>Green tea catechins (EGCG): reduce prostate cancer recurrence in high-risk men in a landmark Italian RCT (600 mg/day green tea catechins \u2192 30% prostate cancer incidence reduction vs control at 1 year)</li> </ul>"},{"location":"antioxidants/polyphenols/#interactions","title":"Interactions","text":"Factor Interaction Non-haem iron absorption Polyphenols (especially tannins, chlorogenic acid, caffeic acid) bind non-haem iron \u2192 inhibit absorption by up to 60\u201370%; avoid high-polyphenol beverages (tea, coffee) with iron-rich meals if iron-deficient Gut microbiome Polyphenol effects are largely microbiome-mediated; antibiotic use abolishes many polyphenol benefits; individual response to polyphenols is highly microbiome-dependent Drugs metabolised by CYP450 Grapefruit polyphenols (furanocoumarins \u2014 naringenin) strongly inhibit CYP3A4 \u2192 dangerous increases in many drug plasma levels (statins, calcium channel blockers, immunosuppressants) Warfarin Multiple polyphenols (quercetin, EGCG, resveratrol) have anticoagulant/anti-platelet effects; polyphenol-rich supplements may potentiate warfarin; monitor INR Thyroid medications Isoflavones (soy) may impair levothyroxine absorption \u2014 separate by at least 4 hours"},{"location":"antioxidants/polyphenols/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Whole food approach is strongly preferred \u2014 synergistic food matrix effects are repeatedly evident in trials vs. isolated polyphenols</li> <li>Cocoa flavanols (700 mg/day): Best evidence; CocoaVia and similar products provide standardised flavanol doses; CVD endpoint study (COSMOS-Heart: 21,442 people, 3.6 years): 500 mg/day cocoa extract \u2192 27% reduction in CVD death (major RCT)</li> <li>Green tea extract (EGCG; 400\u2013800 mg/day): Antioxidant and metabolic benefits; hepatotoxicity risk at &gt;800 mg/day EGCG on empty stomach \u2014 take with food; stimulant effects from caffeine</li> <li>Pomegranate extract (standardised to ellagitannins): 250\u20131,000 mg/day; prostate cancer interest, urolithin A production; no significant drug interactions at food doses</li> <li>Grape seed extract (OPCs; 100\u2013300 mg/day): Modest LDL-C reduction; anti-inflammatory; chronic venous insufficiency (CVI) \u2014 evidence-based in European guidelines</li> <li>Berberine (500 mg 3\u00d7/day with meals): Strong evidence for T2DM; also studied for NAFLD, lipid lowering (reduces LDL-C ~20%), PCOS; gastrointestinal side effects common; inhibits CYP3A4 \u2014 drug interaction monitoring required</li> <li>Urolithin A (500\u20131,000 mg/day): Emerging supplement for mitochondrial health and muscle function in elderly; Amazentis (Timeline Nutrition) is the primary commercial form; Phase II RCTs positive for muscle mitochondrial function</li> </ul>"},{"location":"antioxidants/resveratrol/","title":"Resveratrol","text":""},{"location":"antioxidants/resveratrol/#overview","title":"Overview","text":"<p>Resveratrol is a stilbene polyphenol produced by plants as a phytoalexin \u2014 a defence compound synthesised in response to infection, UV radiation, and injury. It was first isolated from the roots of Veratrum grandiflorum in 1939 and gained widespread scientific attention in 1997 when it was shown to inhibit cancer cell growth in multiple models. Resveratrol became the centrepiece of the \"French paradox\" hypothesis \u2014 the low cardiac mortality in southern France despite a high-saturated-fat diet was attributed in part to red wine consumption and its resveratrol content. However, epidemiological evidence linking resveratrol intake to health outcomes in humans is weak, and most dramatic mechanistic findings come from in vitro and animal studies using pharmacological doses. Human clinical trials with resveratrol have had mixed and generally modest results.</p> <ul> <li>Classification: Stilbene polyphenol; phytoalexin (plant defence compound)</li> <li>Chemical forms: trans-Resveratrol (active, more stable); cis-Resveratrol (less active); resveratrol glucoside = piceid (most abundant form in wine/grapes)</li> <li>Key targets: SIRT1 (sirtuin 1), AMPK, NF-\u03baB, COX-1/2, Nrf2, estrogen receptor \u03b2 (ER\u03b2), aryl hydrocarbon receptor (AhR)</li> <li>Bioavailability challenge: Rapidly metabolised and conjugated in gut wall and liver \u2192 very short half-life (~1 h); only ~1% reaches systemic circulation as free trans-resveratrol; most circulates as sulfate/glucuronide conjugates</li> </ul>"},{"location":"antioxidants/resveratrol/#mechanisms-of-action","title":"Mechanisms of Action","text":"Target Effect SIRT1 (Sirtuin 1) Resveratrol activates SIRT1 (NAD\u207a-dependent deacetylase) \u2192 deacetylates PGC-1\u03b1 \u2192 increases mitochondrial biogenesis, fatty acid oxidation, gluconeogenesis; FOXO3a deacetylation \u2192 stress resistance and autophagy; debate persists whether resveratrol activates SIRT1 directly or indirectly via AMPK AMPK Activates AMPK (AMP-activated protein kinase) \u2192 mimics caloric restriction; increases glucose uptake, fatty acid oxidation; inhibits mTOR \u2192 reduced anabolism, promotes autophagy NF-\u03baB Inhibits NF-\u03baB activation \u2192 reduces pro-inflammatory gene expression (TNF-\u03b1, IL-6, IL-1\u03b2, COX-2, iNOS) COX-1/2 (cyclooxygenase) Inhibits both COX-1 and COX-2 at high concentrations \u2192 reduces prostaglandin synthesis; anti-inflammatory, anti-platelet effects Nrf2 Activates Nrf2 \u2192 upregulates glutathione synthesis, heme oxygenase-1 (HO-1), catalase, SOD \u2014 broad antioxidant gene induction Estrogen receptor \u03b2 (ER\u03b2) Phytoestrogen activity \u2014 binds ER\u03b2 &gt; ER\u03b1; may have protective effects in ER-positive breast cancer (controversial) p53 activation Activates p53 tumour suppressor in cancer cell lines \u2192 apoptosis; demonstrated extensively in vitro"},{"location":"antioxidants/resveratrol/#dietary-sources","title":"Dietary Sources","text":"Source Resveratrol content Red wine 0.2\u201314 mg/L (highly variable; trans-resveratrol + piceid combined) Grape juice (red/purple) 0.4\u20132.0 mg/L Grapes (red skin) 0.16\u20133.54 mg/100 g skin Peanuts (raw) 0.01\u20130.26 mg/100 g Peanut butter 0.04\u20130.13 mg/100 g Japanese knotweed root (Polygonum cuspidatum) Most concentrated natural source; basis for most commercial resveratrol supplements (10\u201320% resveratrol extract) Blueberries 0.01\u20130.36 mg/100 g Dark chocolate (cocoa) Trace amounts <p>A typical glass of red wine contains ~1\u20133 mg trans-resveratrol. Most RCTs showing biological effects used 150\u20131,000 mg/day \u2014 50\u20131,000\u00d7 more than found in a glass of wine. The \"French paradox\" resveratrol intake explanation is biochemically implausible at dietary doses; overall Mediterranean lifestyle factors are better explanations.</p>"},{"location":"antioxidants/resveratrol/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Step Details Absorption trans-Resveratrol absorbed rapidly in small intestine; piceid (glucoside) hydrolysed by intestinal \u03b2-glucosidase \u2192 trans-resveratrol then absorbed First-pass metabolism Rapid conjugation in gut wall (sulfation, glucuronidation) and liver; only ~1% of oral dose reaches circulation as free (unconjugated) trans-resveratrol Plasma forms Resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide are the dominant plasma species; biological activity of conjugates vs. free resveratrol is debated Half-life ~1 hour (free resveratrol); ~4\u20139 hours (conjugates) Gut microbiome metabolism Colonic bacteria produce dihydroresveratrol and other metabolites; some metabolites (e.g., lunularin) may have biological activity; the gut microbiome significantly shapes resveratrol's effective dose Strategies to improve bioavailability Micronized resveratrol (40-fold increase in Cmax); nanoparticle encapsulation; liposomal formulations; piperine co-administration (inhibits UGT enzymes)"},{"location":"antioxidants/resveratrol/#clinical-evidence-in-humans","title":"Clinical Evidence in Humans","text":"Condition Evidence Summary Cardiovascular risk factors Mixed; some trials show modest reductions in blood pressure (systolic \u22123 to \u22125 mmHg), LDL-C oxidation, platelet aggregation at doses \u2265500 mg/day; no robust primary CVD outcome data Type 2 diabetes / insulin sensitivity Several RCTs show improved insulin sensitivity, fasting glucose, and HbA1c at 150\u2013500 mg/day; meta-analyses show modest benefit; not yet clinically recommended Cognitive / Alzheimer's COGNIAGE/REVIDA trials: no significant cognitive benefit vs placebo; one trial showed resveratrol slowed CSF biomarker changes in MCI Cancer prevention Promising in vitro and animal; no human RCT evidence of cancer prevention or treatment benefit; not recommended clinically Longevity / caloric restriction mimetic CALERIE and RESMENA trials: mixed; resveratrol activates SIRT1/AMPK in some studies; does not robustly replicate caloric restriction metabolic benefits in healthy humans PCOS Promising signal: 1,500 mg/day for 3 months reduced total testosterone and DHEAS, improved insulin sensitivity in a small RCT (n=30) Bone health RESHAW trial: 75 mg twice daily for 12 weeks improved bone turnover markers in postmenopausal women; small trial"},{"location":"antioxidants/resveratrol/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/resveratrol/#the-resveratrol-hype-vs-reality","title":"The \"Resveratrol Hype\" vs Reality","text":"<ul> <li>The initial explosion of interest stemmed from SIRT1-longevity work in yeast and mice. A key paper (Howitz et al., 2003, Nature) suggested resveratrol was a STAC (SIRT1-activating compound). Subsequent work showed the SIRT1 activation was partly a fluorescent assay artefact (Kaeberlein et al., 2005). David Sinclair and associates continued to report benefits, but an independent replication effort found most mouse longevity effects required pharmacological levels.</li> <li>Bottom line: Resveratrol has real biological targets and modest measurable effects in human trials at doses &gt;150 mg/day, but the \"longevity elixir\" narrative is not supported by current human clinical evidence.</li> </ul>"},{"location":"antioxidants/resveratrol/#interactions","title":"Interactions","text":"Factor Interaction Anticoagulants (warfarin, aspirin) Resveratrol inhibits COX-1 \u2192 anti-platelet effect; may potentiate anticoagulant/antiplatelet therapy \u2192 bleeding risk; monitor with warfarin use Cytochrome P450 (CYP450) Inhibits CYP3A4, CYP2C9, CYP2D6 \u2192 may increase plasma levels of drugs metabolised by these enzymes (warfarin, statins, some antidepressants, immunosuppressants) at high doses Quercetin Synergistic antioxidant and anti-inflammatory effects; co-found in many polyphenol-rich foods; quercetin may inhibit UGT conjugation of resveratrol \u2192 increases resveratrol bioavailability Piperine (black pepper) Inhibits UGT and sulfotransferase activity \u2192 significantly increases resveratrol bioavailability Oestrogens / hormone-sensitive cancers Phytoestrogenic activity via ER\u03b2 \u2014 theoretical concern in ER+ breast cancer; clinical significance at food doses is negligible; high-dose supplementation caution warranted in hormone-sensitive cancers Metformin Both activate AMPK; potentially additive effects on insulin sensitivity and mitochondrial function; resveratrol + metformin studied in T2DM; no significant interactions reported"},{"location":"antioxidants/resveratrol/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dose: Most human trials use 150\u20131,000 mg/day trans-resveratrol; no established RDA or UL</li> <li>Form: trans-Resveratrol is the biologically active isomer; typically derived from Polygonum cuspidatum (Japanese knotweed); avoid cis-resveratrol-dominant products</li> <li>Bioavailability strategies: Micronized resveratrol, liposomal formulations, or products including piperine (5\u201320 mg) for enhanced absorption</li> <li>Timing: No established optimal timing; with meals improves tolerability; some data suggest absorption is not significantly affected by food</li> <li>Safety: Well tolerated up to 1,000 mg/day; occasional GI side effects (nausea, diarrhoea) at higher doses; &gt;2,500 mg/day associated with GI intolerance in some subjects; no significant toxicity in human trials up to 5,000 mg/day over 29 days (only pharmacokinetic study)</li> <li>Who to avoid: Individuals on warfarin, CYP3A4-metabolised drugs, or hormone-sensitive cancers should use caution and consult a physician</li> <li>Overall assessment: Evidence suggests modest benefits for metabolic health markers at doses &gt;150 mg/day; insufficient evidence to recommend for disease treatment; relatively safe as a supplement; dietary sources (red wine, grapes) do not provide pharmacologically relevant doses</li> </ul>"},{"location":"antioxidants/zeaxanthin/","title":"Zeaxanthin","text":""},{"location":"antioxidants/zeaxanthin/#overview","title":"Overview","text":"<p>Zeaxanthin is a xanthophyll carotenoid that is the direct stereoisomer of lutein, differing only in the position of a double bond in one of its end-rings. Like lutein, zeaxanthin has no provitamin A activity and is classified as a non-essential nutrient. It is the dominant carotenoid of the fovea centralis \u2014 the centre of the macula responsible for high-acuity central vision \u2014 while lutein predominates in the peripheral macula. Together, lutein and zeaxanthin compose the macular pigment (MPOD), which serves as a blue-light filter and antioxidant shield for the photoreceptors. A third macular carotenoid, meso-zeaxanthin, is derived in situ from retinal lutein by the RPE and is not typically found in food \u2014 it is concentrated at the very centre of the fovea. Zeaxanthin is found in highest concentrations in orange/yellow peppers, maize, and egg yolks.</p> <ul> <li>Classification: Xanthophyll carotenoid (dihydroxy); fat-soluble; no provitamin A activity; stereoisomer of lutein</li> <li>Structure: 40-carbon symmetric carotenoid with \u2013OH groups on both \u03b5-rings; fully symmetric (unlike asymmetric lutein); 11 conjugated double bonds</li> <li>Key distinction from lutein: Zeaxanthin concentrates in the central fovea centralis; lutein in the peripheral macula; zeaxanthin is the higher singlet oxygen quencher per molecule (fully symmetric conjugation)</li> <li>Meso-zeaxanthin: The (3R,3'S) stereoisomer of zeaxanthin; not in food; made in the fovea from retinal lutein \u2192 highest antioxidant capacity at the centre of vision</li> </ul>"},{"location":"antioxidants/zeaxanthin/#functions","title":"Functions","text":"<ul> <li>Blue light filtering (fovea): Zeaxanthin is at highest density in the very centre of the fovea \u2014 where visual acuity is sharpest and phototoxic risk is greatest (focused light beam converges here); absorbs 400\u2013500 nm blue-violet light before it reaches the photoreceptors</li> <li>Superior singlet oxygen quenching: Zeaxanthin has a higher \u00b9O\u2082 quenching rate constant than lutein (due to its fully symmetric conjugated system) \u2014 most effective carotenoid antioxidant at the foveal centre</li> <li>Photoreceptor membrane protection: The outer segments of cone photoreceptors in the fovea contain very high concentrations of DHA (70\u201380% of fatty acids), making them exquisitely vulnerable to lipid peroxidation; zeaxanthin quenches peroxyl radicals in these membranes</li> <li>Visual processing and contrast sensitivity: Higher MPOD (reflecting higher zeaxanthin+lutein) is associated with better photostress recovery, glare tolerance, and contrast sensitivity \u2014 particularly relevant under high-glare conditions (driving, digital screens)</li> <li>Brain: Present in brain tissue (similar to lutein); associated with cognitive performance; less well-studied than lutein in neurological contexts</li> <li>Retinal ganglion cell protection: In vitro and animal models: zeaxanthin protects retinal ganglion cells (damaged in glaucoma) from oxidative stress</li> </ul>"},{"location":"antioxidants/zeaxanthin/#metabolism-and-bioavailability","title":"Metabolism and Bioavailability","text":"Factor Details Absorption Same pathway as lutein: micellar solubilisation \u2192 SR-BI/CD36 uptake in enterocytes \u2192 chylomicrons \u2192 lymph \u2192 plasma Dietary fat Required; take zeaxanthin-rich foods or supplements with fat Egg yolk bioavailability Egg yolk zeaxanthin (free form, in lipid droplets) is significantly more bioavailable than zeaxanthin in peppers (protein/fibre bound); proportion of zeaxanthin in egg yolk lutein+zeaxanthin: ~15\u201330% (more lutein than zeaxanthin in eggs) Plasma transport Primarily in HDL (like lutein); transferred to various tissues including macula Retinal accumulation GSTP1 (at macula periphery) binds lutein; GSTP1-related protein at the foveal centre may concentrate zeaxanthin; meso-zeaxanthin derived from lutein by RPE isomerase activity MPOD measurement Measures combined lutein + zeaxanthin (including meso-zeaxanthin) at the macula; normal MPOD ~0.3\u20130.5 OD; AMD patients typically have low MPOD Supplementation response MPOD increases over 3\u201312 months with supplementation; meso-zeaxanthin supplements specifically raise central foveal carotenoid density"},{"location":"antioxidants/zeaxanthin/#dietary-sources","title":"Dietary Sources","text":"Food Serving Zeaxanthin (mg) Note Orange sweet pepper 1 medium (119 g) 5.1 mg Richest food source of zeaxanthin Yellow sweet pepper 1 medium 1.3 mg Corn / maize (cooked) 1 cup (154 g) 0.9 mg Both lutein + zeaxanthin Egg yolk 1 large ~0.05\u20130.2 mg High bioavailability; ratio of zeaxanthin in egg varies by hen feed Orange (mandarin) 1 medium 0.15 mg Goji berries (wolfberries) 28 g 1.0\u20133.6 mg Rich source of zeaxanthin specifically Saffron 1 g (culinary dose) 2\u201312 mg (as zeaxanthin esters) Highest zeaxanthin concentration of any food by weight Kale, spinach See lutein table Predominantly lutein (~6:1 ratio) <p>Goji berries (Lycium barbarum) are uniquely rich in zeaxanthin dipalmitate (zeaxanthin ester) \u2014 a major traditional food in Chinese medicine with claimed vision benefits; human trials support MPOD improvement with goji supplementation.</p>"},{"location":"antioxidants/zeaxanthin/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"antioxidants/zeaxanthin/#age-related-macular-degeneration-amd","title":"Age-Related Macular Degeneration (AMD)","text":"<ul> <li>Zeaxanthin is the co-active carotenoid in the AREDS2 formulation alongside lutein (10 mg lutein + 2 mg zeaxanthin daily)</li> <li>Zeaxanthin at the fovea is specifically protective of central vision \u2014 the type of vision most critical for reading and face recognition (lost in advanced AMD)</li> <li>CREST trial and MOST study: Supplementation including meso-zeaxanthin (10 mg) + lutein + zeaxanthin showed greater MPOD improvement and functional vision gains (contrast sensitivity, reading speed) than lutein+zeaxanthin without meso-zeaxanthin</li> </ul>"},{"location":"antioxidants/zeaxanthin/#glaucoma-emerging-evidence","title":"Glaucoma (Emerging Evidence)","text":"<ul> <li>Zeaxanthin may protect retinal ganglion cells (the cell type damaged in glaucoma); animal models consistently show benefit; human RCTs sparse; early signal in the literature</li> </ul>"},{"location":"antioxidants/zeaxanthin/#diabetic-retinopathy","title":"Diabetic Retinopathy","text":"<ul> <li>Diabetic retinopathy involves significant oxidative stress and neovascularisation in the retina; low plasma zeaxanthin is associated with higher DR severity in T2DM patients; intervention trials limited</li> </ul>"},{"location":"antioxidants/zeaxanthin/#cognitive-function","title":"Cognitive Function","text":"<ul> <li>Zeaxanthin is present in brain tissue; higher plasma zeaxanthin associated with better verbal fluency and memory in older adults (Observational studies); limited interventional data for zeaxanthin specifically vs. lutein</li> </ul>"},{"location":"antioxidants/zeaxanthin/#saffron-and-macular-health","title":"Saffron and Macular Health","text":"<ul> <li>Saffron (Crocus sativus) supplementation (20\u201330 mg/day of saffron extract \u2248 1.5\u20133 mg zeaxanthin equivalents) was studied in AMD \u2014 Italian RCT (Falsini et al.): 20 mg/day saffron for 3 months improved retinal function (ERG) vs placebo in early AMD; mechanism attributed to crocin/zeaxanthin content; very small trial, needs replication</li> </ul>"},{"location":"antioxidants/zeaxanthin/#interactions","title":"Interactions","text":"Factor Interaction Lutein Synergistic macular partner; lutein and zeaxanthin are always measured together (MPOD); supplements should contain both; AREDS2 ratio: 5:1 (lutein:zeaxanthin); CREST added meso-zeaxanthin Meso-zeaxanthin The third macular carotenoid; derived from lutein in the fovea; supplements including all three provide more complete foveal coverage; meso-zeaxanthin not obtainable from common foods Omega-3 DHA Synergistic with zeaxanthin in protecting the DHA-rich photoreceptor outer segments; DHA + zeaxanthin combined supplementation studied in AMD with additive effects Beta-carotene Competes for intestinal absorption; high-dose beta-carotene may reduce zeaxanthin absorption; AREDS2 deliberately replaced beta-carotene with lutein+zeaxanthin Dietary fat Required for absorption; low-fat meals significantly reduce zeaxanthin bioavailability Smoking Significantly depletes plasma and macular carotenoids; smoking is the strongest modifiable AMD risk factor; smokers especially benefit from lutein+zeaxanthin intake"},{"location":"antioxidants/zeaxanthin/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>AMD prevention/treatment (AREDS2 standard): 10 mg lutein + 2 mg zeaxanthin per day; use with AREDS2 full vitamin/mineral formula for intermediate AMD</li> <li>Enhanced MPOD formula: 10 mg lutein + 2 mg zeaxanthin + 10 mg meso-zeaxanthin (e.g., MacuShield Gold formula) \u2014 additional improvement in central foveal MPOD vs standard AREDS2; particularly relevant for patients with low MPOD in central fovea</li> <li>General vision/blue light health: 6 mg zeaxanthin/day + 10\u201320 mg lutein supports MPOD; beneficial for high-screen-time users, pilots, and athletes requiring acute visual performance</li> <li>Goji berry extract: Contains zeaxanthin dipalmitate esters; 15 g/day dried goji or standardised extract shown to increase plasma zeaxanthin and MPOD</li> <li>Safety: No UL; no toxicity; no provitamin A activity; safe in smokers; well tolerated at all studied doses</li> <li>Saffron: Culinary use (~0.5\u20131 g/day in cooking) is safe; supplemental saffron (15\u201320 mg/day standardised extract) being studied in AMD \u2014 promising but not yet standard of care</li> </ul>"},{"location":"detox_pathways/glucuronidation/","title":"Glucuronidation Pathway","text":""},{"location":"detox_pathways/glucuronidation/#overview","title":"Overview","text":"<p>Glucuronidation is quantitatively the most important Phase II conjugation pathway in humans, accounting for the metabolism of roughly 35\u201340% of all drugs that undergo conjugation. It is performed by the UDP-glucuronosyltransferase (UGT) enzyme family, which attaches glucuronic acid to nucleophilic atoms (\u2013OH, \u2013NH\u2082, \u2013COOH, \u2013SH) on substrates.</p> <p>The resulting glucuronide conjugates are highly polar, water-soluble, and typically pharmacologically inactive, making them ideal for biliary or urinary excretion.</p>"},{"location":"detox_pathways/glucuronidation/#enzymology","title":"Enzymology","text":""},{"location":"detox_pathways/glucuronidation/#udp-glucuronosyltransferases-ugts","title":"UDP-Glucuronosyltransferases (UGTs)","text":"<ul> <li>Location: Endoplasmic reticulum membrane (lumenal face)</li> <li>Human isoforms: 22 functional genes in two families \u2014 UGT1 (UGT1A1\u20131A13) and UGT2 (UGT2A1\u20132A3, UGT2B4\u20132B28)</li> <li>Cofactor: UDP-glucuronic acid (UDPGA), synthesised from glucose-1-phosphate + UDP-glucose</li> </ul>"},{"location":"detox_pathways/glucuronidation/#udpga-synthesis","title":"UDPGA Synthesis","text":"<pre><code>Glucose-1-phosphate + UTP  \u2192  UDP-glucose (UGK enzyme)\nUDP-glucose + 2 NAD\u207a  \u2192  UDP-glucuronic acid + 2 NADH  (UGDH enzyme)\n</code></pre> <p>Availability of UDPGA depends on adequate glucose (energy substrate) and NAD\u207a (from niacin, B3). Fasting or prolonged low-carbohydrate states can modestly impair UDPGA availability.</p>"},{"location":"detox_pathways/glucuronidation/#key-ugt-isoforms-and-their-substrates","title":"Key UGT Isoforms and Their Substrates","text":"Isoform Primary Substrates Clinical Notes UGT1A1 Bilirubin, oestrogens, irinotecan (SN-38), etoposide Most clinically studied; UGT1A128* variant \u2192 Gilbert's/CN syndrome UGT1A3 Bile acids, carboxylic acid drugs, T3 \u2014 UGT1A4 Lamotrigine, trifluoperazine, androgens Induced by rifampicin, carbamazepine UGT1A6 Small planar phenols: serotonin, acetaminophen, aspirin \u2014 UGT1A9 Propofol, mycophenolic acid, furosemide \u2014 UGT2B7 Morphine \u2192 M6G (active), codeine, valproic acid, AZT M6G is more potent than morphine; accumulates in renal failure UGT2B15 Oxazepam, testosterone, DHT, S-lorazepam Androgen inactivation UGT2B17 Testosterone, DHT, androsterone Individual variability; gene copy number varies widely"},{"location":"detox_pathways/glucuronidation/#endogenous-substrates","title":"Endogenous Substrates","text":"<p>Beyond xenobiotics, glucuronidation is essential for normal physiology:</p> Endogenous Compound Result of Glucuronidation Bilirubin Bilirubin diglucuronide \u2192 water-soluble; excreted in bile Oestradiol (E2) E2-3G, E2-17G \u2192 inactivated; biliary excretion Oestrone (E1) E1-3G \u2192 excreted; reversible via gut \u03b2-glucuronidase T3/T4 (thyroid) Glucuronide conjugates \u2192 biliary excretion; enterohepatic cycling Testosterone/DHT Androgen glucuronides \u2192 urinary excretion (sport doping detection) Retinoic acid Retinyl \u03b2-glucuronide \u2192 excreted Serotonin Minor glucuronide pathway"},{"location":"detox_pathways/glucuronidation/#ugt1a128-gilberts-syndrome","title":"UGT1A1*28 \u2014 Gilbert's Syndrome","text":"<p>The most common UGT variant in clinical practice:</p> <ul> <li>Variant: Extra TA repeat in UGT1A1 promoter (7 TA repeats vs. normal 6) \u2014 UGT1A128*</li> <li>Frequency: ~10% homozygous, ~40% heterozygous in Western populations</li> <li>Effect: 70\u201375% reduction in UGT1A1 expression \u2192 impaired bilirubin glucuronidation</li> <li>Clinical: Mild unconjugated hyperbilirubinaemia, typically benign; yellowing with fasting/illness/fever</li> </ul> <p>Practical implications: - Increased GI toxicity with irinotecan (UGT1A1 glucuronidates active metabolite SN-38) - Potentially enhanced oestrogen levels (reduced E2 glucuronidation) - Consider lower dose irinotecan in 28/28 patients (FDA recommends genotyping)</p>"},{"location":"detox_pathways/glucuronidation/#enterohepatic-recirculation-ehc-of-glucuronides","title":"Enterohepatic Recirculation (EHC) of Glucuronides","text":"<p>EHC is the major \"escape\" route that can nullify glucuronidation \u2014 see <code>phase_3_transport.md</code> for the full mechanism.</p> <p>Key clinical examples:</p> Compound EHC Consequence Oestrogens Prolonged oestrogen exposure; relevant to HRT, contraceptives Morphine-6-glucuronide Prolonged opioid effect (particularly in renal impairment) Bilirubin (neonates) Neonatal jaundice \u2014 immature UGT1A1 + active intestinal \u03b2-glucuronidase NSAIDs (acyl glucuronides) Reactive acyl glucuronides re-released \u2192 GI mucosal damage Irinotecan (SN-38-G) SN-38 re-released in colon \u2192 colonic toxicity <p>Reducing EHC: - Calcium D-glucarate (Ca-D-glucarate): Hydrolysed to D-glucaric acid \u2192 inhibits \u03b2-glucuronidase; studied for oestrogen modulation and cancer chemoprevention - Dietary fibre (inulin, psyllium, cellulose): Binds deconjugated compounds in gut - Probiotic strains with low \u03b2-glucuronidase activity</p>"},{"location":"detox_pathways/glucuronidation/#inducers-and-inhibitors-of-ugts","title":"Inducers and Inhibitors of UGTs","text":""},{"location":"detox_pathways/glucuronidation/#inducers-increase-glucuronidation","title":"Inducers (increase glucuronidation)","text":"Inducer Mechanism/Source Cruciferous vegetables (sulforaphane, DIM) Activate Nrf2 and AhR \u2192 UGT1A1, 1A6 upregulation St. John's Wort PXR activation \u2192 UGT induction Rifampicin (antibiotic) Strong PXR agonist Phenobarbital CAR receptor activation Alcohol (chronic) Variable UGT induction"},{"location":"detox_pathways/glucuronidation/#inhibitors-decrease-glucuronidation","title":"Inhibitors (decrease glucuronidation)","text":"Inhibitor Effect Valproic acid Competes for UGT2B7 (morphine, lamotrigine interactions) Probenecid Competes for UGT and renal transporters Ketoconazole Broad inhibition High bilirubin load Competitive inhibition of UGT1A1"},{"location":"detox_pathways/glucuronidation/#nutritional-and-lifestyle-support","title":"Nutritional and Lifestyle Support","text":"Compound Effect on Glucuronidation Cruciferous vegetables (broccoli, Brussels sprouts, kale) Induce UGT1A1/1A6 via DIM and sulforaphane Niacin (B3) NAD\u207a for UDPGA synthesis Adequate glucose (carbohydrates) UDPGA precursor (not a reason to overeat; normal diet sufficient) Magnesium Cofactor in UDP-glucose metabolism Calcium D-glucarate Inhibits \u03b2-glucuronidase \u2192 reduces EHC Probiotics Reduce intestinal \u03b2-glucuronidase activity Dietary fibre Binds reabsorbable aglycones Avoid excessive alcohol Chronic alcohol disrupts UGT activity and increases EHC"},{"location":"detox_pathways/glutathione_pathway/","title":"Glutathione Pathway","text":""},{"location":"detox_pathways/glutathione_pathway/#overview","title":"Overview","text":"<p>Glutathione (GSH) is often called the \"master antioxidant\" of the cell. It is a tripeptide \u2014 glutamate\u2013cysteine\u2013glycine \u2014 present in virtually all mammalian cells in millimolar concentrations, highest in the liver (5\u201310 mM). It is central to both Phase II conjugation (glutathione-S-transferases) and the direct neutralisation of reactive oxygen species.</p>"},{"location":"detox_pathways/glutathione_pathway/#structure-and-properties","title":"Structure and Properties","text":"<pre><code>\u03b3-Glu \u2014 Cys \u2014 Gly\n           |\n           SH  \u2190 thiol group (reactive)\n</code></pre> <ul> <li>Reduced form (GSH): Active antioxidant; has a free \u2013SH group</li> <li>Oxidised form (GSSG): Glutathione disulfide; two GSH molecules joined by S\u2013S bond</li> <li>The GSH:GSSG ratio reflects cellular redox status (healthy ratio &gt; 100:1 in liver)</li> </ul>"},{"location":"detox_pathways/glutathione_pathway/#biosynthesis","title":"Biosynthesis","text":""},{"location":"detox_pathways/glutathione_pathway/#step-1-glutamylcysteine-synthesis","title":"Step 1 \u2014 \u03b3-Glutamylcysteine Synthesis","text":"<ul> <li>Enzyme: Glutamate-cysteine ligase (GCL), also called \u03b3-GCS</li> <li>Reaction: Glutamate + Cysteine + ATP \u2192 \u03b3-Glutamylcysteine + ADP + Pi</li> <li>Rate-limiting step: Cysteine availability is the primary constraint</li> <li>Regulation: Feedback-inhibited by GSH; upregulated by Nrf2 transcription factor</li> </ul>"},{"location":"detox_pathways/glutathione_pathway/#step-2-gsh-synthesis","title":"Step 2 \u2014 GSH Synthesis","text":"<ul> <li>Enzyme: Glutathione synthetase (GSS)</li> <li>Reaction: \u03b3-Glutamylcysteine + Glycine + ATP \u2192 GSH + ADP + Pi</li> </ul>"},{"location":"detox_pathways/glutathione_pathway/#substrate-availability","title":"Substrate Availability","text":"Amino Acid Primary Dietary Sources Cysteine (rate-limiting) Eggs, poultry, meat, dairy, NAC (supplement), whey protein Glutamate Ubiquitous; glutamine \u2192 glutamate (abundant) Glycine Collagen-rich foods, bone broth, gelatin, glycine supplement"},{"location":"detox_pathways/glutathione_pathway/#the-glutathione-cycle-redox-recycling","title":"The Glutathione Cycle (Redox Recycling)","text":"<pre><code>2 GSH  +  H\u2082O\u2082  \u2500\u2500\u2500 GPx (selenium) \u2500\u2500\u2500\u2192  GSSG  +  2 H\u2082O\n                                               \u2502\n                                     Glutathione reductase\n                                      (requires NADPH, FAD/B2)\n                                               \u2502\n                                           2 GSH  \u2190\u2500\u2500\u2500\u2500\u2500\u2500\n</code></pre>"},{"location":"detox_pathways/glutathione_pathway/#key-enzymes","title":"Key Enzymes","text":"Enzyme Function Cofactor Glutathione peroxidase (GPx) (GPx1\u20138) Reduces H\u2082O\u2082 and lipid peroxides; converts 2 GSH \u2192 GSSG Selenium (selenocysteine) Glutathione reductase (GR) Regenerates GSH from GSSG NADPH (from B2/FAD, Niacin/NADPH) Glutaredoxin (Grx) Reduces protein mixed disulfides using GSH \u2014 Thioredoxin reductase (TrxR) Parallel antioxidant system Selenium, NADPH <p>If GSSG cannot be reduced (e.g., selenium or B2 deficiency), GSSG accumulates \u2192 exported from cell \u2192 net GSH depletion.</p>"},{"location":"detox_pathways/glutathione_pathway/#glutathione-s-transferases-gsts-phase-ii-role","title":"Glutathione-S-Transferases (GSTs) \u2014 Phase II Role","text":"<p>GSTs catalyse the conjugation of GSH to a wide range of electrophilic substrates:</p> <pre><code>GSH  +  Electrophile (R\u2013X)  \u2500\u2500\u2192  GS\u2013R  +  HX\n</code></pre> <p>The resulting glutathione conjugate is processed: 1. GSH conjugate transported out (MRP1/2) 2. \u03b3-glutamyl transpeptidase (GGT) cleaves glutamate \u2192 cysteinylglycine conjugate 3. Dipeptidase cleaves glycine \u2192 cysteine conjugate 4. N-acetyltransferase acetylates \u2192 mercapturic acid (excreted in urine)</p>"},{"location":"detox_pathways/glutathione_pathway/#gst-isoforms-and-their-substrates","title":"GST Isoforms and Their Substrates","text":"Isoform Family Key Substrates GSTA (alpha) Steroid hormones, lipid peroxidation products (4-HNE, acrolein) GSTM (mu) Aromatic hydrocarbons (benzypyrene epoxides), aflatoxin GSTP (pi) Chemotherapy agents (cisplatin, doxorubicin) \u2014 overexpressed in many cancers \u2192 drug resistance GSTT (theta) Halogenated compounds, ethylene oxide"},{"location":"detox_pathways/glutathione_pathway/#genetic-null-variants","title":"Genetic Null Variants","text":"<ul> <li>GSTM1 null (~50% of Europeans): Complete absence of GSTM1 \u2192 reduced clearance of PAHs, aflatoxin, benzene</li> <li>GSTT1 null (~20% Europeans, ~50% East Asians): Reduced clearance of small haloalkanes</li> <li>Double null (both GSTM1 + GSTT1) significantly increases xenobiotic burden</li> </ul>"},{"location":"detox_pathways/glutathione_pathway/#nrf2-the-master-regulator-of-gsh-and-antioxidant-genes","title":"Nrf2 \u2014 The Master Regulator of GSH and Antioxidant Genes","text":"<p>Nuclear factor erythroid 2-related factor 2 (Nrf2) is the key transcription factor that upregulates the antioxidant response element (ARE), inducing expression of:</p> <ul> <li>GCL (GSH synthesis enzymes)</li> <li>GSTs</li> <li>NQO1 (quinone oxidoreductase)</li> <li>Heme oxygenase-1 (HO-1)</li> <li>Thioredoxin</li> <li>Ferritin</li> </ul>"},{"location":"detox_pathways/glutathione_pathway/#natural-nrf2-activators","title":"Natural Nrf2 Activators","text":"Compound Source Sulforaphane Cruciferous vegetables (highest in broccoli sprouts) Curcumin Turmeric Resveratrol Grapes, red wine EGCG Green tea Quercetin Apples, onions, capers Lipoic acid (ALA) Meat, organ meats; supplement Lycopene Tomatoes, cooked &gt; raw Baicalein Scutellaria (Chinese skullcap) <p>Under normal conditions, Nrf2 is sequestered by Keap1 and targeted for ubiquitin-proteosomal degradation. Electrophiles and oxidants modify Keap1 cysteines \u2192 Nrf2 released \u2192 nuclear translocation \u2192 ARE gene activation.</p>"},{"location":"detox_pathways/glutathione_pathway/#gsh-across-the-body","title":"GSH Across the Body","text":"Tissue GSH Concentration Key Role Liver 5\u201310 mM Phase II conjugation, antioxidant defence Red blood cells 2 mM Prevents oxidative haemolysis (via GPx/GR) Lungs 100\u2013500 \u00b5M Protects alveolar cells from inhaled toxins, ozone Mitochondria 10\u201315% total GSH Critical for mitochondrial redox balance Brain 1\u20133 mM Neuronal protection; low GSH in Parkinson's disease Gut epithelium Moderate First-pass detox and mucosal barrier protection"},{"location":"detox_pathways/glutathione_pathway/#causes-of-gsh-depletion","title":"Causes of GSH Depletion","text":"Factor Mechanism Acetaminophen overdose NAPQI (Phase I metabolite) rapidly depletes hepatic GSH Chronic alcohol Impairs GSH synthesis; displaces GSH from mitochondria Malnutrition (cysteine, glycine deficiency) Substrate limitation Selenium deficiency GPx cannot regenerate GSH from GSSG Riboflavin (B2) deficiency GR cannot reduce GSSG Ageing Progressive decline in GCL activity Oxidative stress / chronic illness Consumption exceeds synthesis rate Heavy metal exposure Mercury and arsenic bind \u2013SH groups; deplete GSH HIV / sepsis Massive ROS \u2192 GSH depletion"},{"location":"detox_pathways/glutathione_pathway/#supplementation-strategies","title":"Supplementation Strategies","text":"Approach Evidence Notes N-acetylcysteine (NAC) Strong Replenishes cysteine; used IV for paracetamol poisoning; increases GSH in liver, lungs Liposomal GSH Moderate Better absorption than unprotected oral GSH; some hepatic uptake Whey protein Moderate Rich in cysteine and \u03b3-glutamylcysteine peptides; raises blood GSH Glycine Moderate Rate-limiting in elderly (cysteine less limiting) Alpha-lipoic acid Moderate Independently scavenges ROS; regenerates GSH from GSSG Selenium Essential GPx activity requires selenocysteine Vitamin C Supportive Spares GSH by directly scavenging radicals; regenerates tocopherol Undenatured oral GSH Poor Rapidly hydrolysed in gut to amino acids before absorption"},{"location":"detox_pathways/gut_microbiome_detox/","title":"Gut Microbiome and Detoxification","text":""},{"location":"detox_pathways/gut_microbiome_detox/#overview","title":"Overview","text":"<p>The gut microbiome \u2014 the ~38 trillion microorganisms inhabiting the human gastrointestinal tract \u2014 plays a substantial and bidirectional role in detoxification. Gut bacteria can activate, inactivate, transform, or regenerate xenobiotics and endogenous waste products. They are both allies and adversaries in hepatic detoxification, depending on microbial community composition.</p>"},{"location":"detox_pathways/gut_microbiome_detox/#key-microbial-detoxification-reactions","title":"Key Microbial Detoxification Reactions","text":""},{"location":"detox_pathways/gut_microbiome_detox/#1-glucuronidase-activity-enterohepatic-recirculation-ehc","title":"1. \u03b2-Glucuronidase Activity \u2014 Enterohepatic Recirculation (EHC)","text":"<p>This is the most clinically significant microbial detox-related enzyme:</p> <ul> <li>Enzyme: \u03b2-Glucuronidase (many species produce it)</li> <li>Reaction: Cleaves glucuronide conjugates \u2192 free aglycone + glucuronic acid</li> <li>Main producing genera: Clostridium, Bacteroides, Bifidobacterium, Escherichia coli, Ruminococcus</li> </ul> <p>Consequences:</p> Compound Affected Consequence of EHC Oestrogens (E1, E2) Deconjugated \u2192 reabsorbed \u2192 elevated circulating oestrogen Bilirubin Urobilinogen formation; in neonates \u2192 jaundice contribution Morphine-6-glucuronide Prolonged opioid effect Irinotecan (SN-38-G) Colonic toxicity (diarrhoea) BPA glucuronide Reactivation of endocrine disruptor NSAIDs Acyl glucuronide re-release \u2192 GI inflammation <p>Reducing \u03b2-Glucuronidase: - Calcium D-glucarate (oral supplement): Converted in vivo to D-glucaric acid \u2192 inhibits \u03b2-glucuronidase; studied in cancer chemoprevention - Probiotic supplementation: Lactobacillus acidophilus, Bifidobacterium longum \u2014 associated with lower \u03b2-glucuronidase activity - High-fibre diet: Shifts microbiome toward Firmicutes/Bacteroidetes ratio associated with lower enzyme activity - Antibiotics: Non-absorbable antibiotics (rifaximin) reduce microbial EHC in specific conditions (e.g., hepatic encephalopathy)</p>"},{"location":"detox_pathways/gut_microbiome_detox/#2-bile-acid-transformation","title":"2. Bile Acid Transformation","text":"<p>Primary bile acids (cholic acid, chenodeoxycholic acid) are conjugated in the liver (with glycine or taurine) and secreted into bile. In the gut:</p> <pre><code>Hepatocyte \u2192 conjugated primary bile acids \u2192 bile canaliculi \u2192 duodenum\n\nIn colon:\nConjugated PBA \u2192 deconjugated by bile salt hydrolase (BSH)\n                   (Lactobacillus, Bifidobacterium, Clostridium)\n                          \u2193\nDehydroxylation (7\u03b1-dehydroxylase of Clostridium, Ruminococcus)\n                          \u2193\nSecondary bile acids (deoxycholic acid, lithocholic acid)\n\n~95% reabsorbed via ASBT in terminal ileum \u2192 EHC\n~5% excreted in faeces\n</code></pre> <p>Dysbiosis consequence: Altered bile acid pool \u2192 impaired fat digestion, altered FXR/TGR5 signalling, increased LCA (lithocholic acid \u2014 hepatotoxic, potentially carcinogenic).</p> <p>Beneficial: Tauro-ursodeoxycholic acid (TUDCA) and its precursor UDCA are produced or augmented by specific bacteria \u2014 hepatoprotective and anti-ER-stress properties.</p>"},{"location":"detox_pathways/gut_microbiome_detox/#3-trimethylamine-metabolism-tmao","title":"3. Trimethylamine Metabolism \u2192 TMAO","text":"<p>Choline, phosphatidylcholine, L-carnitine, betaine \u2192 gut bacteria produce trimethylamine (TMA)</p> <pre><code>Dietary choline/carnitine\n        \u2502\n  Gut bacterial TMA lyases (flavin-containing TMA lyase)\n  [Prevotella copri, Escherichia fergusonii, Anaerococcus hydrogenalis]\n        \u2502\n        \u25bc\n  TMA (trimethylamine) \u2014 absorbed into portal blood\n        \u2502\n  Hepatic FMO3 (flavin-containing monooxygenase 3)\n        \u2502\n        \u25bc\n  TMAO (trimethylamine N-oxide) \u2014 urinary excretion\n</code></pre> <p>TMAO is associated with: - Increased cardiovascular risk (promotes foam cell formation, platelet aggregation) - Kidney disease - Glucose intolerance</p> <p>Protective factors: - Dietary resveratrol (reduces TMAO via FMO3 suppression in mice) - DMSO (dimethylsulfoxide) administration - Mediterranean diet composition shifts microbiome away from TMA producers - 3,3-Dimethyl-1-butanol (DMB) \u2014 TMA lyase inhibitor (experimental, found in balsamic vinegar, olive oil)</p>"},{"location":"detox_pathways/gut_microbiome_detox/#4-short-chain-fatty-acid-scfa-production-indirect-detox-support","title":"4. Short-Chain Fatty Acid (SCFA) Production \u2014 Indirect Detox Support","text":"<p>Microbiome fermentation of dietary fibre \u2192 butyrate, propionate, acetate:</p> SCFA Main Producer Detox-Relevant Effect Butyrate Faecalibacterium prausnitzii, Roseburia, Clostridia Colonocyte fuel; maintains mucosal barrier (prevents leaky gut); inhibits inflammatory NF-\u03baB; induces apoptosis in cancer cells Propionate Bacteroidetes Hepatic gluconeogenesis substrate; HDAC inhibitor (epigenetic); reduces hepatic lipogenesis Acetate Bifidobacterium, Akkermansia Peripheral energy; precursor for cholesterol and lipid synthesis; modulates appetite via GPR41/43 <p>Leaky gut (intestinal permeability) and toxin translocation: Low SCFA production \u2192 impaired tight junctions \u2192 lipopolysaccharide (LPS) from gram-negative bacteria translocates into portal blood \u2192 hepatic endotoxin burden \u2192 Kupffer cell activation \u2192 liver inflammation \u2192 impaired Phase I/II capacity.</p>"},{"location":"detox_pathways/gut_microbiome_detox/#5-polyphenol-biotransformation","title":"5. Polyphenol Biotransformation","text":"<p>Dietary polyphenols (~90%) are not absorbed in the small intestine; they reach the colon and are fermented by bacteria into smaller, bioavailable metabolites:</p> Polyphenol Microbial Metabolite Enhanced Activity Ellagitannins (pomegranate, walnuts) Urolithins (A, B, C) Mitophagy induction; Nrf2 activation; anti-inflammatory Lignans (flaxseed) Enterolactone, enterodiol Oestrogen receptor modulation; weaker phytooestrogen activity Isoflavones (soy \u2014 daidzein) Equol More potent oestrogenic/anti-androgenic in equol producers (~25\u201330% of Western adults) Curcumin Tetrahydrocurcumin More bioavailable; anti-oxidant Quercetin 3,4-dihydroxyphenylacetic acid Anti-inflammatory"},{"location":"detox_pathways/gut_microbiome_detox/#6-hepatic-encephalopathy-ammonia-detox","title":"6. Hepatic Encephalopathy \u2014 Ammonia Detox","text":"<p>The gut microbiome is the primary source of systemic ammonia:</p> <pre><code>Dietary protein + urea \u2192 gut bacteria (urease-producing)\n\u2192 Ammonia (NH\u2083) \u2192 absorbed \u2192 portal blood\n\u2192 Liver: ornithine cycle \u2192 urea \u2192 urinary excretion\n\nLiver failure \u2192 impaired urea cycle \u2192 NH\u2083 accumulates \u2192 encephalopathy\n</code></pre> <p>Clinical interventions: - Lactulose (osmotic laxative) \u2192 reduces colonic pH \u2192 traps NH\u2084\u207a; reduces transit time - Rifaximin (non-absorbable antibiotic) \u2192 reduces urease-producing bacteria - Zinc \u2014 essential ureacycle enzyme cofactor; often deficient in cirrhosis - BCAA supplementation \u2014 competes with aromatic amino acids (tyrosine, tryptophan) for BBB transport \u2192 reduces \"false neurotransmitter\" production</p>"},{"location":"detox_pathways/gut_microbiome_detox/#dysbiosis-patterns-and-detoxification-impairment","title":"Dysbiosis Patterns and Detoxification Impairment","text":"Dysbiosis Pattern Detox Consequence Overgrowth of \u03b2-glucuronidase-producing bacteria Elevated EHC \u2192 oestrogen excess, toxin reabsorption Low Akkermansia muciniphila Weakened mucosal barrier \u2192 LPS translocation SIBO (small intestinal bacterial overgrowth) Early deconjugation of bile acids \u2192 fat malabsorption; D-lactic acidosis High TMA-producing organisms Elevated TMAO \u2192 cardiovascular risk Low butyrate producers Leaky gut; reduced colonocyte fuel; impaired Nrf2 signalling Candida overgrowth Acetaldehyde production (competing with liver ADH)"},{"location":"detox_pathways/gut_microbiome_detox/#supporting-the-gut-microbiome-for-detoxification","title":"Supporting the Gut Microbiome for Detoxification","text":"Intervention Benefit High-fibre diet (30 g/day target) SCFA production; microbiome diversity; reduced \u03b2-glucuronidase Polyphenol-rich foods Microbiome diversity; urolithin production; Nrf2 activation Probiotic supplementation Lactobacillus and Bifidobacterium spp. \u2192 reduce \u03b2-glucuronidase; improve barrier Prebiotic fibres (inulin, FOS, arabinoxylan) Feed butyrate producers Fermented foods (kefir, kimchi, sauerkraut) Live microorganism delivery; barrier support Avoid chronic antibiotic overuse Preserve microbial diversity Adequate hydration Prevents constipation \u2192 reduces transit time and reabsorption of waste Calcium D-glucarate Inhibits microbial \u03b2-glucuronidase; oestrogen clearance support"},{"location":"detox_pathways/heavy_metal_detox/","title":"Heavy Metal Detoxification","text":""},{"location":"detox_pathways/heavy_metal_detox/#overview","title":"Overview","text":"<p>Heavy metals are dense metallic elements that can accumulate in biological tissues and cause significant toxicity. Unlike organic xenobiotics, they cannot be metabolised (chemically broken down) \u2014 they can only be transformed between oxidation states or chelated and excreted intact.</p> <p>The body manages heavy metal burden through: 1. Metallothionein \u2014 metal-binding proteins that sequester and buffer metals 2. Glutathione conjugation \u2014 GSH coordinates metals for export 3. Methylation (arsenic only) \u2014 changes speciation and solubility 4. Chelation \u2014 endogenous or exogenous ligands bind metals \u2192 urinary/biliary excretion</p>"},{"location":"detox_pathways/heavy_metal_detox/#the-four-most-clinically-significant-heavy-metals","title":"The Four Most Clinically Significant Heavy Metals","text":""},{"location":"detox_pathways/heavy_metal_detox/#1-mercury-hg","title":"1. Mercury (Hg)","text":""},{"location":"detox_pathways/heavy_metal_detox/#forms","title":"Forms","text":"Form Main Source Organ Targeting Elemental Hg (Hg\u2070) Dental amalgam vapour, broken thermometers CNS (lipophilic, crosses BBB) Inorganic Hg\u00b2\u207a Industrial exposure, some skin-lightening creams Kidneys (proximal tubule) Methylmercury (MeHg) Large fatty fish (tuna, shark, swordfish, tilefish) CNS, foetal brain"},{"location":"detox_pathways/heavy_metal_detox/#mechanism-of-toxicity","title":"Mechanism of Toxicity","text":"<ul> <li>Binds to thiol (\u2013SH) groups on enzymes, structural proteins, and glutathione</li> <li>Inhibits glutathione peroxidase, thioredoxin reductase, Na/K-ATPase</li> <li>Displaces zinc and selenium from metalloenzymes</li> <li>Neurotoxic: disrupts microtubule assembly, induces excitotoxicity (NMDA receptor sensitisation)</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#detoxification-mechanisms","title":"Detoxification Mechanisms","text":"<pre><code>MeHg  \u2192  demethylation in gut/liver  \u2192  Hg\u00b2\u207a\n                                              \u2502\n               \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2524\n               \u2502                              \u2502\n         GSH conjugation              Metallothionein sequestration\n         (Hg\u2013SG complex)                (MT-Hg; especially kidney)\n               \u2502\n               \u25bc\n        Biliary excretion \u2192 faeces (major route for organic forms)\n        Urinary excretion \u2192 urine (minor; inorganic forms)\n</code></pre> <p>Selenium protects against mercury by: - Forming inert Hg\u2013Se complexes (HgSe, tiemannite) \u2192 trapped in tissues (not excreted but inactivated) - High seafood selenium:mercury ratios (e.g., most tuna) suggest protective effect</p>"},{"location":"detox_pathways/heavy_metal_detox/#testing","title":"Testing","text":"<ul> <li>Acute exposure: Blood mercury (half-life ~70 days for inorganic; ~50 days for MeHg)</li> <li>Chronic exposure: Urine mercury (inorganic); hair mercury (MeHg \u2014 1 cm = ~1 month)</li> <li>Normal: blood &lt; 5 \u00b5g/L; urine &lt; 5 \u00b5g/g creatinine</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#2-lead-pb","title":"2. Lead (Pb)","text":""},{"location":"detox_pathways/heavy_metal_detox/#sources","title":"Sources","text":"<ul> <li>Historical: leaded petrol (phased out), lead paint (pre-1978 in USA)</li> <li>Current: lead pipes and plumbing solder, imported ceramics, some cosmetics, contaminated soil near smelters, imported herbal supplements</li> <li>Occupational: battery manufacturing, radiator repair, shooting ranges</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#mechanism-of-toxicity_1","title":"Mechanism of Toxicity","text":"<ul> <li>Mimics calcium, zinc, and iron at biological binding sites</li> <li>Inhibits ALAD (aminolaevulinic acid dehydratase) \u2192 disrupts haem synthesis \u2192 anaemia</li> <li>Inhibits NMDA receptors and voltage-gated Ca\u00b2\u207a channels \u2192 neurotoxicity</li> <li>Inhibits ferrochelatase \u2192 iron not inserted into protoporphyrin \u2192 elevated blood FEP</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#storage-and-redistribution","title":"Storage and Redistribution","text":"<pre><code>Blood (half-life ~35 days)\n\u2192 Soft tissue (half-life few weeks)\n\u2192 Bone (half-life 10\u201320 years) \u2190 95% of body lead burden stored here\n</code></pre> <p>Bone dissolution during pregnancy, lactation, osteoporosis, or calcium deficiency can remobilise lead.</p>"},{"location":"detox_pathways/heavy_metal_detox/#detoxification-and-chelation","title":"Detoxification and Chelation","text":"Chelator Route Comments EDTA (CaNa\u2082-EDTA) IV or IM Used in acute/severe lead poisoning; mobilises bone lead DMSA (succimer, meso-2,3-DMSA) Oral First-line for children; removes blood and soft tissue lead Penicillamine Oral Second-line; more side-effect prone DMPS IV or oral (Europe) Also chelates mercury <p>Nutritional support (preventive/adjunctive): - Calcium, zinc, iron compete with lead at absorption \u2014 adequate status is protective - Vitamin C supports ALAD enzyme; may reduce lead retention (limited data) - Pectin and other soluble fibres bind lead in gut</p>"},{"location":"detox_pathways/heavy_metal_detox/#reference-values","title":"Reference Values","text":"Level Classification &lt; 3.5 \u00b5g/dL Below CDC reference value (UK: &lt; 10 \u00b5g/dL action level) 5 \u00b5g/dL CDC level of concern in children &gt; 45 \u00b5g/dL Chelation therapy indicated in children &gt; 70 \u00b5g/dL Medical emergency"},{"location":"detox_pathways/heavy_metal_detox/#3-arsenic-as","title":"3. Arsenic (As)","text":""},{"location":"detox_pathways/heavy_metal_detox/#sources_1","title":"Sources","text":"<ul> <li>Contaminated groundwater (Bangladesh, parts of India, Chile, Argentina)</li> <li>Rice (bioaccumulates inorganic arsenic)</li> <li>Seafood (mainly organic arsenobetaine \u2014 much less toxic)</li> <li>Treated timber (CCA, chromated copper arsenate \u2014 legacy exposure)</li> <li>Coal combustion fly ash</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#speciation-and-methylation","title":"Speciation and Methylation","text":"<p>Arsenic undergoes reductive methylation in the liver \u2014 a Phase II-like detox step:</p> <pre><code>As\u2075\u207a (arsenate)  \u2192  As\u00b3\u207a (arsenite)  \u2192  MMA (monomethylarsonic acid)  \u2192  DMA (dimethylarsinic acid)\n                 [GSTO1A reductase]   [AS3MT + SAM]                    [AS3MT + SAM]\n                                      \u2190 requires glutathione at each step \u2192\n</code></pre> <ul> <li>DMA is the primary urinary form (~60\u201380% of total arsenic in urine)</li> <li>Individuals with AS3MT (arsenic methyltransferase) variants or low GSH have more MMA \u2014 which is more toxic than DMA</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#mechanism-of-toxicity_2","title":"Mechanism of Toxicity","text":"<ul> <li>Binds vicinal dithiols (Cys\u2013Cys pairs) \u2192 inhibits pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase</li> <li>Substitutes for phosphate (arsenate) in ATP synthesis</li> <li>Epigenetic effects: alters DNA methylation patterns</li> <li>Carcinogen (Group 1, IARC): skin, lung, bladder, kidney cancers</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#protection-and-detoxification","title":"Protection and Detoxification","text":"Approach Mechanism Folate, B12, SAM Methyl groups for AS3MT-mediated methylation \u2192 DMA Glutathione (NAC, whey) Required at every methylation step Selenium Increases arsenic methylation rate; forms inert As\u2013Se complexes Zinc Induces metallothionein; competes at absorption DMSA (succimer) Chelates arsenic; used in acute poisoning"},{"location":"detox_pathways/heavy_metal_detox/#4-cadmium-cd","title":"4. Cadmium (Cd)","text":""},{"location":"detox_pathways/heavy_metal_detox/#sources_2","title":"Sources","text":"<ul> <li>Cigarette smoke (tobacco accumulates cadmium from soil \u2014 smokers have 3\u20135\u00d7 higher body burden)</li> <li>Contaminated soil near smelters, phosphate fertilisers</li> <li>Certain foods: shellfish (oysters especially), organ meats, some leafy vegetables on contaminated soil</li> <li>Rechargeable batteries (NiCd)</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#mechanism-of-toxicity_3","title":"Mechanism of Toxicity","text":"<ul> <li>Kidneys: Proximal tubular damage (\"Itai-itai disease\" \u2014 Japan; cadmium-induced osteoporosis + renal failure)</li> <li>Binds metallothionein in liver \u2192 Cd\u2013MT complex \u2192 delivered to kidney \u2192 kidney accumulates Cd\u2013MT</li> <li>Inhibits calcium, zinc, and iron absorption (competes at DMT-1 transporter)</li> <li>Endocrine disruptor: agonises oestrogen receptor</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#metallothionein-mt-and-cadmium","title":"Metallothionein (MT) and Cadmium","text":"<p>Metallothionein (MT-1, MT-2) are cysteine-rich proteins (~20 cysteines in 61 residues) that bind up to 7 divalent metal ions per molecule. They are induced by: - Heavy metals (Cd, Zn, Cu, Hg) - Glucocorticoids - Cytokines - Oxidative stress</p> <p>MT binding limits free metal toxicity but prolongs retention; cadmium half-life in the liver is ~10\u201330 years.</p>"},{"location":"detox_pathways/heavy_metal_detox/#reference-values_1","title":"Reference Values","text":"<ul> <li>Urine cadmium &lt; 1 \u00b5g/g creatinine (below action level in most guidelines)</li> <li>Blood cadmium: &lt; 0.5 \u00b5g/L (non-smokers)</li> </ul>"},{"location":"detox_pathways/heavy_metal_detox/#general-heavy-metal-detoxification-support","title":"General Heavy Metal Detoxification Support","text":"Nutrient / Strategy Mechanism Glutathione / NAC Chelation partner for mercury, arsenic; replenishes depleted GSH Selenium Forms metal\u2013selenium complexes; GPx protection against ROS Zinc Induces MT synthesis; competes with Cd and Pb at absorption Vitamin C Antioxidant; mild chelating activity; lowers blood lead in some studies Alpha-lipoic acid Chelates mercury and arsenic (crosses BBB); regenerates GSH Chlorella Marine algae; binds heavy metals in gut (absorption barrier) High-fibre diet Reduces gut transit \u2192 less time for metal reabsorption Calcium and iron Compete with lead and cadmium at intestinal absorption sites Medical chelation (DMSA, DMPS, EDTA) Prescribed; required for significant toxicity; must be administered by clinicians"},{"location":"detox_pathways/liver_support_nutrients/","title":"Liver Support Nutrients","text":""},{"location":"detox_pathways/liver_support_nutrients/#overview","title":"Overview","text":"<p>The liver performs the vast majority of Phase I and Phase II detoxification. It is extraordinary energy-demanding (accounting for ~20% of resting metabolic rate) and requires a constant supply of specific cofactors, amino acids, minerals, and antioxidants. This file details \u2014 per detox phase \u2014 the key nutrients required and their biochemical rationale.</p>"},{"location":"detox_pathways/liver_support_nutrients/#phase-i-cyp450-nutrient-requirements","title":"Phase I \u2014 CYP450 Nutrient Requirements","text":"Nutrient Role Deficiency Consequence Iron (Fe\u00b2\u207a) Haem group of all CYP450 enzymes; must cycle Fe\u00b3\u207a/Fe\u00b2\u207a during catalytic cycle Reduced CYP450 activity; impaired drug and toxin metabolism Riboflavin (B2) FAD cofactor for NADPH-cytochrome P450 reductase (the electron donor to CYP) Slowed CYP450 electron transfer Niacin (B3) NADPH (from pentose phosphate pathway) \u2014 electron carrier for CYP450 reductase Reduced NADPH pool; CYP450 uncoupling Magnesium ATPase function; electron transport chain; co-factor for CYP-associated reactions Broad reduction in energy-dependent Phase I reactions Copper Cytochrome b5 (another CYP450 electron donor), CuZn-SOD (antioxidant) Impaired antioxidant defence alongside Phase I Zinc CYP450 structural integrity; CuZn-SOD Reduced CYP450 protein stability; oxidative vulnerability Molybdenum Aldehyde oxidase (Phase I enzyme metabolising purines, aldehydes) Reduced xenobiotic aldehyde clearance; elevated aldehydes Antioxidants (C, E, glutathione) Quench ROS produced during CYP450 catalytic cycling Compounding oxidative damage during Phase I activity"},{"location":"detox_pathways/liver_support_nutrients/#phase-ii-conjugation-nutrient-requirements","title":"Phase II Conjugation \u2014 Nutrient Requirements","text":""},{"location":"detox_pathways/liver_support_nutrients/#glucuronidation-ugt-enzymes","title":"Glucuronidation (UGT Enzymes)","text":"Nutrient Role Niacin (B3) NAD\u207a \u2192 UDP-glucose \u2192 UDP-glucuronic acid (UDPGA synthesis) Magnesium UDP-glucose dehydrogenase cofactor B-complex (general) Energy input for UDPGA synthesis Cruciferous vegetables Sulforaphane and DIM \u2192 Nrf2 and AhR \u2192 UGT1A1/1A6 upregulation"},{"location":"detox_pathways/liver_support_nutrients/#sulfation-sult-enzymes","title":"Sulfation (SULT Enzymes)","text":"Nutrient Role Sulfur amino acids (methionine, cysteine \u2014 from eggs, meat, dairy) Dietary sulfur \u2192 inorganic sulfate \u2192 PAPS (cofactor for all SULT reactions) MSM (methylsulfonylmethane) Provides bioavailable sulfur directly; well-absorbed Taurine Synthesised from cysteine; bile acid conjugation and alternate sulfur pathway Molybdenum Sulfite oxidase: converts sulfite \u2192 sulfate (essential for final PAPS-available sulfate) B6 (pyridoxal-5-phosphate) CBS (cystathionine beta-synthase) cofactor \u2192 cysteine from homocysteine Magnesium ATP required for both ATP sulfurylase and APS kinase in PAPS synthesis"},{"location":"detox_pathways/liver_support_nutrients/#glutathione-conjugation-gsts","title":"Glutathione Conjugation (GSTs)","text":"Nutrient Role Cysteine (from NAC, whey, eggs, poultry) Rate-limiting substrate for glutathione biosynthesis (GCL step) Glycine Third residue of GSH tripeptide (increasingly limiting in ageing) Glutamate First residue; glutamine \u2192 glutamate (abundant) Selenium Selenocysteine in GPx active site; recycles GSSG \u2192 GSH Riboflavin (B2) FAD for glutathione reductase (GSSG \u2192 GSH regeneration) Niacin (B3) NADPH production (required by glutathione reductase) Sulforaphane Nrf2 inducer \u2192 upregulates GCL (rate-limiting GSH synthesis enzyme)"},{"location":"detox_pathways/liver_support_nutrients/#methylation-comt-hnmt-dnmt","title":"Methylation (COMT, HNMT, DNMT)","text":"Nutrient Role Methylcobalamin (B12) MTR cofactor; remethylates homocysteine \u2192 methionine L-methylfolate (5-MTHF) MTHFR product; provides methyl group to B12 for MTR Riboflavin (B2) FAD for MTHFR and MTRR enzymes Pyridoxal-5-phosphate (B6) CBS cofactor \u2192 transsulfuration pathway Betaine (TMG) BHMT-mediated alternative remethylation (liver, kidney) Choline Converted to betaine; phosphatidylcholine synthesis (SAM consumer) Zinc Methionine synthase structural cofactor Magnesium MAT cofactor (SAM synthesis)"},{"location":"detox_pathways/liver_support_nutrients/#amino-acid-conjugation","title":"Amino Acid Conjugation","text":"Nutrient Role Glycine Substrate for hippurate pathway (benzoate \u2192 hippuric acid); bile acid conjugation Taurine Taurine-bile acid conjugation (BAAT enzyme); supports sulfation Glutamine Substrate for phenylacetylglutamine pathway; glutamate donor Adequate protein intake Maintains all amino acid conjugation substrate pools"},{"location":"detox_pathways/liver_support_nutrients/#acetylation-nat1nat2","title":"Acetylation (NAT1/NAT2)","text":"Nutrient Role Pantothenic acid (B5) Coenzyme A (CoA) synthesis \u2192 Acetyl-CoA (nitrogen acetylation cofactor) B-vitamins (general) Energy metabolism for CoA recycling"},{"location":"detox_pathways/liver_support_nutrients/#general-hepatoprotective-nutrients","title":"General Hepatoprotective Nutrients","text":"<p>Beyond Phase-specific requirements, these nutrients protect hepatocytes and maintain overall liver function:</p> Compound Mechanism Evidence Level Silymarin (milk thistle) Antioxidant; inhibits CYP2E1 (reduces NAPQI); inhibits TNF-\u03b1; regenerates GSH; Nrf2 activation Moderate-strong (particularly paracetamol hepatotoxicity and NAFLD) N-acetylcysteine (NAC) GSH precursor; anti-inflammatory; direct antioxidant Strong (clinical use in paracetamol poisoning; NAFLD; pulmonary fibrosis) Alpha-lipoic acid (ALA) Recycling of Vitamins C and E; GSH regeneration; heavy metal chelation Moderate (diabetic neuropathy; NAFLD) Choline Phosphatidylcholine synthesis (essential for VLDL export from liver); prevents hepatic steatosis Strong (dietary choline deficiency causes NAFLD) Vitamin E (tocopherols + tocotrienols) Lipid peroxidation prevention; proven to reduce liver inflammation in NAFLD (PIVENS trial: 800 IU/day) Strong for NASH/NAFLD; possibly prostate cancer concern at high doses Betaine BHMT-mediated remethylation; osmoprotectant; reduces hepatic fat (2 g/day in NAFLD trials) Moderate TUDCA (tauroursodeoxycholic acid) Reduces ER stress; anti-apoptotic; stimulates bile flow; used in cholestasis Moderate (FDA-approved for primary biliary cholangitis) Artichoke leaf extract Choleretic (stimulates bile production); hepatoprotective via luteolin Moderate Curcumin NF-\u03baB inhibition; anti-fibrotic; CYP modulation; Nrf2 activation Moderate (limited by bioavailability \u2014 use phospholipid complex or piperine) Zinc Alcohol dehydrogenase, CuZn-SOD, MT induction; anti-fibrotic Moderate Selenium GPx; reduces liver fibrosis markers; low in cirrhosis Moderate Vitamin D Anti-fibrotic via VDR on hepatic stellate cells; deficiency common in NAFLD Moderate Coffee (chlorogenic acids, kahweol) Inverse association with cirrhosis, hepatocellular carcinoma, liver fibrosis Strong epidemiological evidence"},{"location":"detox_pathways/liver_support_nutrients/#practical-summary-daily-liver-support-framework","title":"Practical Summary \u2014 Daily Liver Support Framework","text":""},{"location":"detox_pathways/liver_support_nutrients/#food-first-priorities","title":"Food-First Priorities","text":"Food Category Benefit Cruciferous vegetables (broccoli, kale, Brussels sprouts) \u2014 daily Sulforaphane \u2192 Nrf2 \u2192 Phase II induction Eggs (2\u20133/day) Cysteine, choline (phosphatidylcholine) High-quality protein (100\u2013130 g/day) All amino acid conjugation substrates Alliums (garlic, onion, leeks) Organic sulfur compounds; glutathione induction Colourful fruits/vegetables Polyphenols (Nrf2 activators) Coffee (2\u20133 cups/day) Liver protective; reduces fibrosis risk Green tea EGCG; Nrf2; UGT induction Fermented foods Microbiome support; reduces \u03b2-glucuronidase Adequate water (2\u20133 L/day) Renal excretion of water-soluble conjugates"},{"location":"detox_pathways/liver_support_nutrients/#key-supplements-where-diet-falls-short","title":"Key Supplements (Where Diet Falls Short)","text":"Supplement Typical Dose Primary Benefit NAC 600\u20131200 mg/day GSH support; Phase II; liver protection Methylated B-complex (5-MTHF, methyl-B12, B6, B2) Per product Methylation support; homocysteine reduction Magnesium glycinate 300\u2013400 mg/day Multi-pathway cofactor Milk thistle (silymarin 70\u201380%) 140\u2013420 mg/day Hepatoprotection; Nrf2; CYP2E1 modulation Zinc 15\u201325 mg/day CYP450 support; MT induction; antioxidant Selenium (as selenomethionine) 100\u2013200 \u00b5g/day GPx; thyroid; GSH regeneration Calcium D-glucarate 500\u20131500 mg/day \u03b2-Glucuronidase inhibition; oestrogen clearance"},{"location":"detox_pathways/methylation/","title":"Methylation \u2014 The One-Carbon Cycle","text":""},{"location":"detox_pathways/methylation/#overview","title":"Overview","text":"<p>Methylation is a universal biochemical reaction in which a methyl group (\u2013CH\u2083) is transferred from S-adenosylmethionine (SAM) to a target molecule, altering its activity, solubility, or stability. It is essential for detoxification of hormones, neurotransmitters, and heavy metals, and underpins DNA and histone epigenetic regulation.</p> <p>Methylation is not exclusively a detox pathway \u2014 it is one of the most fundamental cellular regulatory mechanisms. It is covered here in the context of detoxification.</p>"},{"location":"detox_pathways/methylation/#the-one-carbon-cycle-folatemethionine-cycle","title":"The One-Carbon Cycle (Folate\u2013Methionine Cycle)","text":"<pre><code>Dietary Methionine\n        \u2502\n        \u25bc\n    SAM (S-adenosylmethionine)  \u2190\u2500\u2500 major methyl donor\n        \u2502\n        \u2502  methylation reaction (COMT, HNMT, PNMT, TPMT, DNMT, etc.)\n        \u2502  transfers \u2013CH\u2083 to substrate\n        \u25bc\n    SAH (S-adenosylhomocysteine)\n        \u2502\n        \u25bc\n    Homocysteine \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n        \u2502                                                  \u2502\n      [Remethylation \u2014 via MTHFR + MTR]           [Transsulfuration \u2014 via CBS]\n        \u2502                                                  \u2502\n   Methionine \u2190 (needs 5-MTHF + B12)               Cystathionine\n                                                          \u2502\n                                                        Cysteine\n                                                          \u2502\n                                                     Glutathione / Taurine / Sulfate\n</code></pre>"},{"location":"detox_pathways/methylation/#key-steps","title":"Key Steps","text":"Enzyme Function Cofactors MAT (methionine adenosyltransferase) Converts methionine \u2192 SAM ATP, Mg\u00b2\u207a MTHFR Converts 5,10-methyleneTHF \u2192 5-MTHF (active folate) Riboflavin (FAD) MTR (methionine synthase) Remethylates homocysteine \u2192 methionine Methylcobalamin (B12), 5-MTHF MTRR Regenerates methyl-B12 (keeps MTR active) Riboflavin CBS (cystathionine \u03b2-synthase) Diverts homocysteine \u2192 transsulfuration Pyridoxal-5-phosphate (B6) BHMT Alternative remethylation using betaine (liver, kidney only) Betaine (trimethylglycine)"},{"location":"detox_pathways/methylation/#detoxification-roles-of-methylation","title":"Detoxification Roles of Methylation","text":""},{"location":"detox_pathways/methylation/#catecholamine-and-oestrogen-metabolism-comt","title":"Catecholamine and Oestrogen Metabolism (COMT)","text":"<p>Catechol-O-methyltransferase (COMT) inactivates: - Dopamine \u2192 3-methoxytyramine - Adrenaline \u2192 metanephrine - Noradrenaline \u2192 normetanephrine - 2-OH and 4-OH oestrogen catechols \u2192 methoxy-oestrogens (less genotoxic)</p> <p>The COMT V158M SNP (rs4680) reduces enzyme activity by ~40% in Met/Met homozygotes, lengthening oestrogen catechol half-life and potentially increasing breast cancer risk.</p>"},{"location":"detox_pathways/methylation/#heavy-metal-methylation","title":"Heavy Metal Methylation","text":"<p>Arsenic undergoes reductive methylation in the liver: - Arsenate (As\u2075\u207a) \u2192 arsenite (As\u00b3\u207a) \u2192 monomethylarsonic acid (MMA) \u2192 dimethylarsinic acid (DMA) - Methylated forms are less toxic and more water-soluble \u2192 excreted in urine - Requires: SAM + glutathione</p> <p>Mercury: - Inorganic Hg\u00b2\u207a can be methylated by gut bacteria \u2192 methylmercury (MORE toxic) - Hepatic demethylation (minor) \u2192 inorganic form \u2192 biliary excretion</p>"},{"location":"detox_pathways/methylation/#histamine-inactivation-hnmt","title":"Histamine Inactivation (HNMT)","text":"<p>Histamine N-methyltransferase converts histamine \u2192 N-methylhistamine (inactive) inside cells, primarily in the CNS, lungs, and liver. Impaired HNMT (via genetic variant or SAM depletion) contributes to histamine intolerance.</p>"},{"location":"detox_pathways/methylation/#mthfr-gene-variants","title":"MTHFR Gene Variants","text":"<p>MTHFR (methylenetetrahydrofolate reductase) is the most studied methylation gene variant in clinical nutrition:</p> Variant Frequency Effect on enzyme C677T (rs1801133) \u2014 T/T homozygous ~10% general population, up to 20% Italians/Mexicans ~70% reduced MTHFR activity, elevated homocysteine A1298C (rs1801131) ~10% ~40% reduced activity (compound het with C677T = significant impairment) <p>Consequences of impaired MTHFR: - Reduced 5-MTHF \u2192 reduced SAM \u2192 reduced methylation capacity across all pathways - Elevated homocysteine \u2192 endothelial damage, thrombosis risk - Impaired DNA methylation \u2192 epigenetic dysregulation - Increased susceptibility to oestrogen-dominant conditions</p> <p>Management: - Supplement with L-methylfolate (5-MTHF) \u2014 bypasses the MTHFR block - Methylcobalamin (methyl-B12) rather than cyanocobalamin - Riboflavin (B2) \u2014 stabilises thermolabile MTHFR enzyme - Avoid high-dose synthetic folic acid (may compete with 5-MTHF at receptors)</p>"},{"location":"detox_pathways/methylation/#homocysteine","title":"Homocysteine","text":"<p>Homocysteine is the pivotal intersection of the methylation cycle. Elevated homocysteine (&gt;10 \u00b5mol/L) is both a marker of methylation insufficiency and an independent cardiovascular risk factor.</p>"},{"location":"detox_pathways/methylation/#causes-of-elevated-homocysteine","title":"Causes of Elevated Homocysteine","text":"Cause Mechanism Folate deficiency Insufficient 5-MTHF for MTR remethylation B12 deficiency MTR requires methylcobalamin B6 deficiency CBS transsulfuration requires PLP Riboflavin deficiency MTHFR needs FAD MTHFR C677T T/T Reduced 5-MTHF production Renal insufficiency Reduced homocysteine clearance Hypothyroidism Reduced MTR activity Ageing Progressive decline in methylation capacity"},{"location":"detox_pathways/methylation/#reference-ranges","title":"Reference Ranges","text":"Level Category &lt; 7 \u00b5mol/L Optimal 7\u201310 \u00b5mol/L Borderline 10\u201315 \u00b5mol/L Mild hyperhomocysteinaemia &gt; 15 \u00b5mol/L Moderate-severe (significant cardiovascular/cognitive risk)"},{"location":"detox_pathways/methylation/#sam-the-universal-methyl-donor","title":"SAM \u2014 The Universal Methyl Donor","text":"<p>SAM is consumed in every methylation reaction and must be continuously regenerated via the folate\u2013methionine cycle. SAM is also involved in: - Synthesis of creatine (40% of SAM consumption) - Synthesis of phosphatidylcholine (PC) from PE - Synthesis of polyamines (spermine, spermidine) - Melatonin synthesis (ASMT enzyme)</p> <p>SAM depletion impairs all downstream methylation, including Phase II detoxification of oestrogens, catecholamines, and heavy metals.</p>"},{"location":"detox_pathways/methylation/#nutritional-support-for-methylation","title":"Nutritional Support for Methylation","text":"Nutrient Role Methyl-B12 (methylcobalamin) MTR cofactor; remethylates homocysteine L-methylfolate (5-MTHF) Active folate; bypasses MTHFR Pyridoxal-5-phosphate (B6) CBS cofactor; drives transsulfuration Riboflavin (B2) FAD \u2014 MTHFR and MTRR cofactor Betaine (TMG) BHMT-dependent alternative remethylation (liver only) Choline Converted to betaine; phosphatidylcholine synthesis Methionine (from protein) SAM precursor Zinc Methionine synthetase cofactor Magnesium MAT cofactor; SAM synthesis"},{"location":"detox_pathways/overview/","title":"Detoxification Pathways \u2014 Overview","text":""},{"location":"detox_pathways/overview/#what-is-detoxification","title":"What Is Detoxification?","text":"<p>Detoxification is the body's intrinsic, multi-organ process of transforming and eliminating endogenous waste products (hormones, bilirubin, ammonia) and exogenous xenobiotics (drugs, environmental toxins, food contaminants, alcohol). Far from being a marketing term, detox is a set of rigorously characterised biochemical reactions shared across virtually all living organisms.</p> <p>Key insight \u2014 \"Detox\" is not a product. It is a continuous biological function performed primarily by the liver, with support from the kidneys, lungs, gut, skin, and lymphatic system.</p>"},{"location":"detox_pathways/overview/#primary-organs-involved","title":"Primary Organs Involved","text":"Organ Primary Role Liver Phase I &amp; II biotransformation of nearly all xenobiotics Kidneys Filtration and urinary excretion of water-soluble conjugates Gut / Intestines First-pass metabolism, Phase III efflux transporters, gut microbiome transformation Lungs Exhalation of volatile compounds (e.g., acetone, ethanol vapour) Skin Minor sweating of some heavy metals and BPA Lymphatic system Immune-mediated removal of cellular debris and pathogens"},{"location":"detox_pathways/overview/#the-three-phase-model","title":"The Three-Phase Model","text":"<p>Hepatic detoxification is classically described in three phases:</p> <pre><code>Lipophilic toxin\n      \u2502\n      \u25bc\n [Phase I] Oxidation / Reduction / Hydrolysis  \u2500\u2500\u2500\u2500 CYP450 enzymes\n      \u2502  (adds reactive functional group)\n      \u2502  \u26a0 May create MORE reactive / toxic intermediate\n      \u25bc\n [Phase II] Conjugation  \u2500\u2500\u2500\u2500 GSTs, UGTs, SULTs, NATs, COMT, MAT\n      \u2502  (adds large polar group \u2192 water-soluble)\n      \u25bc\n [Phase III] Transport &amp; Excretion  \u2500\u2500\u2500\u2500 MRP2, P-gp, BCRP\n      \u2502  (moves conjugates out of cells into bile or urine)\n      \u25bc\nEliminated via faeces or urine\n</code></pre>"},{"location":"detox_pathways/overview/#why-all-three-phases-must-be-balanced","title":"Why All Three Phases Must Be Balanced","text":"<p>Phase I generates reactive intermediates. If Phase II is overwhelmed or nutrient-deficient, these intermediates accumulate and cause oxidative DNA damage. A diet rich in Phase II inducers (e.g., cruciferous vegetables) without adequate Phase I support can create \"functional blocks.\"</p>"},{"location":"detox_pathways/overview/#supporting-pathways-systems","title":"Supporting Pathways &amp; Systems","text":"<p>Beyond the classical hepatic phases, several additional systems contribute:</p> Pathway Location Key Function Methylation Liver, brain, all cells Inactivates hormones, neurotransmitters, heavy metals Sulfation Liver, gut, adrenals Conjugates hormones, phenols, neurotransmitters Glucuronidation Liver, intestinal wall Largest Phase II pathway by volume Glutathione conjugation Liver, kidneys, lungs Neutralises reactive electrophiles and free radicals Amino acid conjugation Liver, kidneys Glycine, taurine, glutamine bind bile acids and benzoates Acetylation Liver, lungs, spleen Metabolises drugs (e.g., isoniazid, sulfonamides)"},{"location":"detox_pathways/overview/#key-nutrients-required","title":"Key Nutrients Required","text":"Nutrient Phases Supported B-vitamins (B2, B3, B6, B9, B12) Phase I (CYP cofactors), Methylation Magnesium Phase I, II Glutathione / NAC Phase II (GST) Glycine Amino acid conjugation Sulfur (MSM, NAC, taurine) Sulfation, glutathione synthesis Zinc, Selenium Antioxidant enzymes (SOD, GPx) Iron CYP450 haem group Molybdenum Aldehyde oxidase (Phase I)"},{"location":"detox_pathways/overview/#contents-of-this-folder","title":"Contents of This Folder","text":"File Topic <code>phase_1_biotransformation.md</code> CYP450 enzymes, oxidation, reduction, hydrolysis <code>phase_2_conjugation.md</code> All six major conjugation reactions <code>phase_3_transport.md</code> ABC transporters, efflux pumps, biliary and renal excretion <code>methylation.md</code> One-carbon cycle, SAM/SAH, MTHFR, HPA axis <code>sulfation.md</code> SULT enzymes, PAPS, phenol &amp; hormone sulfation <code>glucuronidation.md</code> UGT enzymes, enterohepatic recirculation <code>glutathione_pathway.md</code> GSH synthesis, glutathione cycle, GPx, Nrf2 <code>liver_support_nutrients.md</code> Detailed nutrient requirements for all phases <code>heavy_metal_detox.md</code> Chelation, metallothionein, specific metals (Hg, Pb, As, Cd) <code>gut_microbiome_detox.md</code> Beta-glucuronidase, TMAO, bile acid transformation"},{"location":"detox_pathways/phase_1_biotransformation/","title":"Phase I Biotransformation","text":""},{"location":"detox_pathways/phase_1_biotransformation/#overview","title":"Overview","text":"<p>Phase I is the first line of hepatic detoxification. It chemically modifies lipophilic xenobiotics by introducing or unmasking a reactive polar functional group (\u2013OH, \u2013NH\u2082, \u2013SH, \u2013COOH), making the molecule slightly more water-soluble and, critically, creating a \"handle\" for Phase II conjugation enzymes.</p> <p>\u26a0\ufe0f Important caveat \u2014 Phase I reactions can transiently produce more toxic reactive intermediates (e.g., epoxides, quinones, free radicals) than the parent compound. This is why Phase II capacity must keep pace with Phase I activity.</p>"},{"location":"detox_pathways/phase_1_biotransformation/#the-cytochrome-p450-superfamily-cyp450","title":"The Cytochrome P450 Superfamily (CYP450)","text":"<p>The dominant Phase I enzymes are the cytochrome P450 monooxygenases, a superfamily of ~57 functional genes in humans. They are haem-containing proteins embedded in the smooth endoplasmic reticulum (and inner mitochondrial membrane for some isoforms).</p>"},{"location":"detox_pathways/phase_1_biotransformation/#reaction-mechanism-simplified","title":"Reaction Mechanism (Simplified)","text":"<pre><code>Substrate (RH) + O\u2082 + NADPH + H\u207a  \u2192  Product (ROH) + H\u2082O + NADP\u207a\n</code></pre> <p>The CYP450 iron centre cycles between Fe\u00b3\u207a and Fe\u00b2\u207a, binding molecular oxygen and donating one oxygen atom to the substrate while reducing the other to water.</p>"},{"location":"detox_pathways/phase_1_biotransformation/#major-isoforms-and-their-substrates","title":"Major Isoforms and Their Substrates","text":"Isoform Abundance (liver) Key Substrates / Inducers / Inhibitors CYP1A1 Low (inducible) PAHs from grilled food, cigarette smoke \u00b7 Induced by cruciferous vegetables (indole-3-carbinol), charred meat CYP1A2 ~13% of total Caffeine, melatonin, theophylline \u00b7 Induced by smoking \u00b7 Inhibited by fluvoxamine CYP2B6 ~3% Bupropion, efavirenz, cyclophosphamide CYP2C9 ~20% Warfarin, ibuprofen, phenytoin \u00b7 Polymorphic (poor metabolisers at higher bleeding risk) CYP2C19 ~7% Omeprazole, clopidogrel, diazepam \u00b7 Poor metaboliser allele common in East Asians (~20%) CYP2D6 ~3% but critical Codeine \u2192 morphine, metoprolol, tramadol \u00b7 Ultra-rapid metabolisers at overdose risk CYP2E1 ~7% Ethanol, acetaminophen, benzene, CCl\u2084 \u00b7 Induced by fasting, alcohol \u00b7 Generates ROS and NAPQI CYP3A4/5 ~40% Statins, cyclosporine, testosterone, cortisol, &gt;50% of all drugs \u00b7 Induced by St. John's wort, rifampicin"},{"location":"detox_pathways/phase_1_biotransformation/#genetic-polymorphisms","title":"Genetic Polymorphisms","text":"<p>CYP450 genes are highly polymorphic. Single nucleotide polymorphisms (SNPs) categorise individuals as:</p> <ul> <li>Poor metabolisers (PM) \u2014 reduced or absent enzyme activity; drug accumulates</li> <li>Intermediate metabolisers (IM) \u2014 one functional allele</li> <li>Extensive metabolisers (EM) \u2014 normal</li> <li>Ultra-rapid metabolisers (UM) \u2014 multiple gene copies; drug cleared too fast</li> </ul>"},{"location":"detox_pathways/phase_1_biotransformation/#types-of-phase-i-reactions","title":"Types of Phase I Reactions","text":""},{"location":"detox_pathways/phase_1_biotransformation/#1-oxidation-most-common","title":"1. Oxidation (Most Common)","text":"Reaction Type Example Aliphatic hydroxylation Testosterone \u2192 androstanediol Aromatic hydroxylation Benzene \u2192 phenol N-oxidation Trimethylamine \u2192 TMAO S-oxidation Dimethyl sulfoxide \u2192 DMSO Epoxidation Benzo[a]pyrene \u2192 benzo[a]pyrene-7,8-epoxide (carcinogenic) Dealkylation (N-, O-, S-) Codeine \u2192 morphine (O-demethylation via CYP2D6)"},{"location":"detox_pathways/phase_1_biotransformation/#2-reduction","title":"2. Reduction","text":"<p>Less common; occurs under low-oxygen (anaerobic) conditions:</p> <ul> <li>Nitroreduction \u2014 Metronidazole activated to toxic radical anion</li> <li>Azo-reduction \u2014 Gut microbiome reduces azo dyes (e.g., tartrazine)</li> <li>Carbonyl reduction \u2014 Ketones \u2192 secondary alcohols via carbonyl reductases</li> </ul>"},{"location":"detox_pathways/phase_1_biotransformation/#3-hydrolysis","title":"3. Hydrolysis","text":"<p>Esterases and amidases cleave ester and amide bonds:</p> <ul> <li>Aspirin (acetylsalicylic acid) \u2192 salicylic acid (plasma esterases)</li> <li>Cocaine \u2192 benzoylecgonine (pseudo-cholinesterase)</li> <li>Procaine \u2192 PABA + diethylaminoethanol</li> </ul>"},{"location":"detox_pathways/phase_1_biotransformation/#key-cofactors-and-nutrients-required","title":"Key Cofactors and Nutrients Required","text":"Nutrient Role in Phase I Iron Core of haem in CYP450 active site Magnesium CYP450 electron transport support Riboflavin (B2) FAD cofactor for NADPH-cytochrome P450 reductase Niacin (B3) NADPH production via pentose phosphate pathway Copper Cytochrome oxidase, antioxidant defence Zinc CYP450 protein structure Molybdenum Aldehyde oxidase (Phase I xanthine oxidase family) Antioxidants Buffer ROS produced during CYP450 cycling"},{"location":"detox_pathways/phase_1_biotransformation/#flavonoids-and-cyp450-interaction","title":"Flavonoids and CYP450 Interaction","text":"<p>Many dietary phytochemicals modulate CYP450:</p> Phytochemical Effect Grapefruit furanocoumarins Irreversibly inhibit CYP3A4 (major drug interaction risk) Indole-3-carbinol (cruciferous) Induces CYP1A1/1A2 Quercetin Inhibits CYP3A4, CYP2C9 Curcumin Inhibits CYP1A2; variable effect on CYP3A4 Resveratrol Inhibits CYP1B1 St. John's Wort Strong CYP3A4 inducer (clinically significant)"},{"location":"detox_pathways/phase_1_biotransformation/#reactive-oxygen-species-ros-production","title":"Reactive Oxygen Species (ROS) Production","text":"<p>The CYP450 catalytic cycle is inherently \"leaky\" \u2014 oxygen can escape as superoxide (O\u2082\u2022\u207b) rather than being used for hydroxylation. This oxidative uncoupling is exacerbated by:</p> <ul> <li>Alcohol consumption (CYP2E1 is especially ROS-prone)</li> <li>Xenobiotic overload</li> <li>Nutrient deficiencies (inadequate antioxidants)</li> </ul> <p>Resulting ROS can damage: - Mitochondrial DNA - Lipid membranes (lipid peroxidation) - Proteins (carbonylation) - Phase II enzyme capacity itself</p>"},{"location":"detox_pathways/phase_1_biotransformation/#clinical-relevance","title":"Clinical Relevance","text":"Scenario Mechanism Acetaminophen hepatotoxicity CYP2E1 converts paracetamol \u2192 NAPQI, depletes glutathione Alcohol-drug interactions Ethanol inhibits CYP2E1 acutely; chronic use induces it Grapefruit warnings on statins CYP3A4 inhibition \u2192 statin accumulation \u2192 myopathy Slow acetylator phenotype (NAT2) Isoniazid accumulates \u2192 peripheral neuropathy Codeine in CYP2D6 ultra-metabolisers Rapid conversion to morphine \u2192 overdose in children"},{"location":"detox_pathways/phase_2_conjugation/","title":"Phase II Conjugation","text":""},{"location":"detox_pathways/phase_2_conjugation/#overview","title":"Overview","text":"<p>Phase II reactions are biosynthetic (conjugation) reactions that attach large, polar, endogenous molecules to the reactive intermediates produced by Phase I (or directly to some parent compounds). The result is a large, highly water-soluble conjugate that can be readily excreted in bile or urine.</p> <p>Phase II is generally considered detoxifying in the truest sense \u2014 it neutralises reactivity and flags compounds for elimination.</p>"},{"location":"detox_pathways/phase_2_conjugation/#the-six-major-phase-ii-conjugation-pathways","title":"The Six Major Phase II Conjugation Pathways","text":""},{"location":"detox_pathways/phase_2_conjugation/#1-glucuronidation-ugt-enzymes","title":"1. Glucuronidation (UGT Enzymes)","text":"<p>The largest Phase II pathway by volume.</p> <ul> <li>Enzymes: UDP-glucuronosyltransferases (UGTs), 22 isoforms (UGT1A1\u2013UGT2B28)</li> <li>Cofactor: UDP-glucuronic acid (UDPGA), derived from glucose \u2192 glucuronate</li> <li>Location: Liver (primary), intestinal epithelium, kidneys, brain</li> <li>Functional groups conjugated: \u2013OH, \u2013COOH, \u2013NH\u2082, \u2013SH</li> </ul> <p>Substrates glucuronidated:</p> Category Examples Endogenous Bilirubin, steroid hormones, thyroid hormones, bile acids Drugs Morphine, paracetamol, NSAIDs, valproic acid, lamotrigine Xenobiotics BPA, phthalates, environmental oestrogens <p>Enterohepatic Recirculation (EHC): Glucuronide conjugates excreted into bile can be cleaved by gut bacterial \u03b2-glucuronidase, releasing the free aglycone for reabsorption \u2014 a significant issue with oestrogen, bilirubin, and some drugs. Calcium D-glucarate and probiotic modulation can reduce \u03b2-glucuronidase activity.</p> <p>Key inducers: Cruciferous vegetables (sulforaphane), St. John's Wort, rifampicin Key inhibitors/competitors: High bilirubin load, alcohol, probenecid</p>"},{"location":"detox_pathways/phase_2_conjugation/#2-sulfation-sult-enzymes","title":"2. Sulfation (SULT Enzymes)","text":"<ul> <li>Enzymes: Sulfotransferases (SULTs), 13 cytosolic isoforms</li> <li>Cofactor: PAPS (3'-phosphoadenosine-5'-phosphosulfate), synthesised from ATP + inorganic sulfate</li> <li>Location: Liver, intestinal mucosa, brain, adrenal glands, platelets</li> <li>Functional groups: \u2013OH (phenols, alcohols), \u2013NH\u2082, \u2013NH</li> </ul> <p>Substrates sulfated:</p> Category Examples Hormones Oestrogens (E1-SO\u2084, E2-SO\u2084), DHEA-S, testosterone-S Neurotransmitters Dopamine sulphate, serotonin, adrenaline Drugs Paracetamol (minor pathway), minoxidil (activation step) Dietary compounds Quercetin, resveratrol, flavonoids Thyroid T4 \u2192 T4-sulfate (inactivation step) <p>Rate-limiting factor: PAPS availability, which depends on inorganic sulfate (from dietary sulfur amino acids: cysteine, methionine, NAC, taurine; and MSM).</p> <p>Competition: High phenol or oestrogenic load depletes PAPS rapidly \u2192 \"sulfation saturation.\" Individuals with CBS gene variants may have reduced sulfate production.</p>"},{"location":"detox_pathways/phase_2_conjugation/#3-glutathione-conjugation-gst-enzymes","title":"3. Glutathione Conjugation (GST Enzymes)","text":"<ul> <li>Enzymes: Glutathione-S-transferases (GSTs, cytosolic and microsomal), multiple families (\u03b1, \u03bc, \u03b8, \u03c0, \u03c3)</li> <li>Cofactor: Glutathione (GSH) \u2014 a tripeptide of glutamate + cysteine + glycine</li> <li>Location: Liver, kidneys, lungs, intestine, red blood cells</li> </ul> <p>Key reactions: - Nucleophilic attack of GSH on electrophilic substrates (epoxides, quinones, activated alkyl halides) - Peroxidase activity (GSH peroxidase, GPx) \u2014 reduces H\u2082O\u2082 and lipid peroxides</p> <p>Critical substrates:</p> Substrate Source NAPQI (N-acetyl-p-benzoquinone imine) Paracetamol overdose via CYP2E1 Benzo[a]pyrene epoxides Cigarette smoke, charred meat Acrolein Cigarette smoke, fried foods 4-HNE (4-hydroxynonenal) Lipid peroxidation product Mercury, arsenic Heavy metals (via MerB) <p>GSH regeneration cycle: GSH (reduced) \u2192 GSSG (oxidised) \u2192 GSH (regenerated by glutathione reductase using NADPH). Selenium-dependent GPx is also part of this cycle.</p> <p>Depletion risk factors: Malnutrition, chronic illness, heavy metal exposure, alcohol, ageing.</p>"},{"location":"detox_pathways/phase_2_conjugation/#4-methylation-comt-tpmt-hnmt-gnmt","title":"4. Methylation (COMT, TPMT, HNMT, GNMT)","text":"<p>See dedicated file: <code>methylation.md</code> for full detail.</p> <ul> <li>Cofactor: S-adenosylmethionine (SAM), the universal methyl donor</li> <li>Enzymes: Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT), histamine methyltransferase (HNMT), others</li> <li>Substrates: Catecholamines, oestrogens, histamine, arsenic, heavy metals, drugs (6-mercaptopurine)</li> </ul>"},{"location":"detox_pathways/phase_2_conjugation/#5-acetylation-nat1-nat2","title":"5. Acetylation (NAT1, NAT2)","text":"<ul> <li>Enzymes: N-acetyltransferases (NAT1, NAT2)</li> <li>Cofactor: Acetyl-CoA</li> <li>Location: Liver, intestinal epithelium, red blood cells</li> </ul> <p>Genetic polymorphism \u2014 \"acetylator status\":</p> Phenotype Frequency Consequence Fast acetylator ~50% (varies by ethnicity) Rapid drug clearance; may generate more carcinogenic arylamines Slow acetylator ~50% Drugs accumulate; isoniazid \u2192 neuropathy; hydralazine \u2192 lupus-like syndrome <p>Key substrates: Isoniazid, hydralazine, sulfonamides, procainamide, arylamines (carcinogens from cooked meat \u2014 heterocyclic amines).</p>"},{"location":"detox_pathways/phase_2_conjugation/#6-amino-acid-conjugation-glycine-taurine-glutamine","title":"6. Amino Acid Conjugation (Glycine, Taurine, Glutamine)","text":"<ul> <li>Enzymes: Acyl-CoA ligases + aminoacyl transferases</li> <li>Location: Hepatic mitochondria (primarily)</li> </ul> <p>Substrates and conjugates:</p> Substrate Amino Acid Used Product Benzoic acid Glycine Hippuric acid (urinary excretion) Bile acids (chenodeoxycholic) Glycine or Taurine Glyco- or tauro-bile acids Salicylate Glycine Salicyluric acid Quinolinic acid Glycine Kynurenic acid (minor) Phenylacetic acid Glutamine Phenylacetylglutamine <p>Taurine conjugation of bile acids keeps bile acids in solution and prevents cholestasis. This pathway is limited by dietary glycine and taurine availability.</p>"},{"location":"detox_pathways/phase_2_conjugation/#factors-that-impair-phase-ii","title":"Factors That Impair Phase II","text":"Factor Effect Low-protein diet Depletes amino acid conjugation substrates and GSH precursors Selenium deficiency Reduces GPx activity \u2192 oxidised glutathione accumulates Magnesium deficiency Impairs PAPS synthesis (sulfation) and UDP-glucuronate production B12 / folate / B6 deficiency Impairs SAM regeneration \u2192 methylation failure Chronic alcohol Depletes GSH, disrupts methylation, saturates glucuronidation Gut dysbiosis Elevated \u03b2-glucuronidase \u2192 EHC amplified Genetic variants GSTM1/GSTT1 null, UGT1A1*28 (Gilbert's), COMT V158M, NAT2 slow allele"},{"location":"detox_pathways/phase_2_conjugation/#phase-ii-support-dietary-nutritional","title":"Phase II Support \u2014 Dietary &amp; Nutritional","text":"Compound Mechanism N-acetylcysteine (NAC) GSH precursor (rate-limiting cysteine) Cruciferous vegetables Induce UGTs, GSTs via Nrf2 (sulforaphane, indole-3-carbinol) Calcium D-glucarate Inhibits \u03b2-glucuronidase \u2192 prevents EHC of oestrogens Glycine Substrate for bile acid conjugation and hippurate pathway Taurine Bile acid conjugation; assists sulfation Riboflavin (B2) Regenerates GSH via glutathione reductase (FAD-dependent) Methyl donors SAM, betaine, choline, folate, B12 \u2192 methylation Magnesium Cofactor for PAPS synthesis Selenium Selenocysteine in GPx active site Rosemary, turmeric, green tea EGCG Nrf2 activators \u2192 upregulate Phase II suite"},{"location":"detox_pathways/phase_3_transport/","title":"Phase III \u2014 Transport &amp; Excretion","text":""},{"location":"detox_pathways/phase_3_transport/#overview","title":"Overview","text":"<p>Phase III is the final step in hepatic detoxification: the active transport of Phase II conjugates (and some Phase I intermediates) out of hepatocytes into bile canaliculi, or out of renal tubular cells into urine, for elimination from the body.</p> <p>Without efficient Phase III transport, water-soluble conjugates would accumulate inside cells and cause toxicity despite having undergone Phase II modification.</p>"},{"location":"detox_pathways/phase_3_transport/#transporters-involved","title":"Transporters Involved","text":"<p>Phase III relies on ATP-binding cassette (ABC) transporters \u2014 a superfamily of active, energy-dependent efflux pumps. They operate against concentration gradients, using ATP hydrolysis.</p>"},{"location":"detox_pathways/phase_3_transport/#key-efflux-transporters","title":"Key Efflux Transporters","text":"Transporter Gene Location Primary Substrates MRP2 (ABCC2) ABCC2 Hepatocyte canalicular membrane, kidney, intestine Glucuronides, glutathione conjugates, sulphate conjugates, bilirubin diglucuronide P-glycoprotein (P-gp, MDR1) ABCB1 Hepatocyte, intestinal epithelium, BBB, kidney Hydrophobic drugs, steroids, xenobiotics (prevents brain entry) BCRP (MXR) ABCG2 Liver, intestine, mammary gland, placenta Sulphate conjugates, folate, drugs (imatinib, methotrexate) MRP3 (ABCC3) ABCC3 Basolateral (sinusoidal) hepatocyte Glucuronides, bile acids (efflux to sinusoid \u2192 blood \u2192 kidney) BSEP ABCB11 Canalicular membrane Bile salts (primary bile acid secretion) OAT1/3 SLC22A family Renal proximal tubule Glucuronides, organic anions (Phase II products from bloodstream \u2192 urine)"},{"location":"detox_pathways/phase_3_transport/#routes-of-elimination","title":"Routes of Elimination","text":""},{"location":"detox_pathways/phase_3_transport/#1-biliary-excretion-faeces","title":"1. Biliary Excretion (\u2192 Faeces)","text":"<p>Large conjugates (MW &gt; ~500 Da) are preferentially excreted into bile via MRP2 and then travel to the duodenum. Gut flora can:</p> <ul> <li>Deconjugate them (via \u03b2-glucuronidase) \u2192 enterohepatic recirculation (EHC) \u2192 reabsorption</li> <li>Further transform them (e.g., bile acid modification by Bacteroides, Clostridium)</li> <li>Excrete them intact in faeces (if deconjugation is suppressed)</li> </ul> <p>Compounds primarily eliminated via bile: - Bilirubin diglucuronide - Large drug glucuronides (morphine-6G) - Heavy metal complexes - Steroid sulphates and glucuronides</p>"},{"location":"detox_pathways/phase_3_transport/#2-renal-excretion-urine","title":"2. Renal Excretion (\u2192 Urine)","text":"<p>Smaller conjugates (MW &lt; ~300\u2013500 Da) return to the bloodstream via basolateral transporters (MRP3, MRP4) and are filtered at the kidney glomerulus or actively secreted by renal tubular OAT transporters.</p> <p>Compounds primarily eliminated via urine: - Paracetamol glucuronide and sulfate - Hippuric acid (glycine conjugate of benzoate) - Many drug metabolites - Water-soluble heavy metal chelates</p>"},{"location":"detox_pathways/phase_3_transport/#3-pulmonary-excretion","title":"3. Pulmonary Excretion","text":"<p>Volatile compounds diffuse across the alveolar membrane into exhaled air:</p> <ul> <li>Ethanol (~5% exhaled \u2014 basis of breathalyser)</li> <li>Acetone (elevated in ketosis and diabetic ketoacidosis)</li> <li>Acetaldehyde (intermediate of ethanol metabolism)</li> <li>Volatile organic compounds (VOCs) from industrial exposure</li> </ul>"},{"location":"detox_pathways/phase_3_transport/#4-skin-sweat","title":"4. Skin / Sweat","text":"<p>Minor pathway for: - Heavy metals: arsenic, mercury, cadmium (detectable in sweat research) - BPA (bisphenol A) - Urea and small nitrogenous waste</p> <p>Saunas may modestly increase elimination of lipophilic xenobiotics through sweat and sebum, though the evidence is limited.</p>"},{"location":"detox_pathways/phase_3_transport/#enterohepatic-recirculation-ehc-the-recycling-loop","title":"Enterohepatic Recirculation (EHC) \u2014 The \"Recycling Loop\"","text":"<pre><code>    Liver conjugates compound\n            \u2502\n            \u25bc\n    Secreted into bile (MRP2)\n            \u2502\n            \u25bc\n    Small intestine (duodenum)\n            \u2502\n        \u03b2-glucuronidase\n        (gut bacteria)\n            \u2502\n            \u25bc\n    Free (unconjugated) compound\n            \u2502\n            \u25bc\n    Reabsorbed \u2192 portal circulation \u2192 liver \u2192 re-conjugated\n</code></pre> <p>Clinically problematic EHC occurs with: - Oestrogens: Deconjugated E1/E2 re-enter circulation \u2192 higher oestrogen exposure - Bilirubin: Neonatal jaundice management requires interrupting EHC (phototherapy, cholestyramine) - Morphine-6-glucuronide: Prolonged opioid effect - NSAIDs: GI toxicity partly from EHC of NSAID acyl glucuronides</p> <p>Strategies to reduce EHC: - Dietary fibre \u2192 binds deconjugated compounds in gut - Calcium D-glucarate \u2192 inhibits \u03b2-glucuronidase enzyme - Probiotic strains that downregulate \u03b2-glucuronidase (L. acidophilus, B. longum)</p>"},{"location":"detox_pathways/phase_3_transport/#genetic-variants-affecting-phase-iii","title":"Genetic Variants Affecting Phase III","text":"Gene Variant Effect ABCC2 c.3972C&gt;T, c.-24C&gt;T Reduced MRP2 \u2192 impaired bilirubin and drug conjugate excretion \u2192 Dubin\u2013Johnson syndrome (homozygous null) ABCB1 C3435T Altered P-gp expression/function; affects drug bioavailability ABCG2 Q141K Reduced BCRP \u2192 increased plasma drug levels (rosuvastatin, gout risk from elevated urate) ABCB11 Various BSEP deficiency \u2192 progressive familial intrahepatic cholestasis type 2 (PFIC2)"},{"location":"detox_pathways/phase_3_transport/#nutrients-and-compounds-supporting-phase-iii","title":"Nutrients and Compounds Supporting Phase III","text":"Compound Mechanism Dietary fibre (soluble) Binds deconjugated toxins in gut \u2192 reduces EHC Probiotics Downregulate microbial \u03b2-glucuronidase Artichoke extract Stimulates bile flow (choleretic) \u2192 enhanced biliary excretion Dandelion root Mild cholagogue (increases bile release from gallbladder) Taurine Supports bile acid conjugation \u2192 maintains bile fluidity Adequate hydration Essential for renal tubular filtration of conjugates Magnesium ATPase function (ABC transporter activity)"},{"location":"detox_pathways/sulfation/","title":"Sulfation Pathway","text":""},{"location":"detox_pathways/sulfation/#overview","title":"Overview","text":"<p>Sulfation is a major Phase II conjugation reaction in which a sulfonate group (\u2013SO\u2083\u207b) is transferred from the activated sulfate donor PAPS (3'-phosphoadenosine-5'-phosphosulfate) to hydroxyl (\u2013OH) or amino (\u2013NH\u2082) groups on a substrate. This renders the molecule highly water-soluble and negatively charged, facilitating renal or biliary excretion.</p> <p>Sulfation is particularly critical for the metabolism of steroid hormones, thyroid hormones, neurotransmitters, and dietary phenols.</p>"},{"location":"detox_pathways/sulfation/#enzymes-sulfotransferases-sults","title":"Enzymes \u2014 Sulfotransferases (SULTs)","text":"<p>Sulfotransferases are cytosolic enzymes (as opposed to UGTs, which are microsomal). Humans have 13 SULT isoforms, grouped into families:</p> Family Key Members Primary Function SULT1A SULT1A1, 1A2, 1A3 Broad phenol sulfation; catecholamines (1A3); dietary polyphenols SULT1B SULT1B1 Thyroid hormones, iodothyronines SULT1E SULT1E1 Oestrogens (very high affinity for E2 at low concentrations) SULT2A SULT2A1 DHEA, androstenediol, bile acids SULT2B SULT2B1 Cholesterol, oxysterols"},{"location":"detox_pathways/sulfation/#the-cofactor-paps","title":"The Cofactor: PAPS","text":"<p>PAPS (3'-phosphoadenosine-5'-phosphosulfate) is synthesised in two steps:</p> <pre><code>ATP + SO\u2084\u00b2\u207b  \u2500\u2500\u2500 ATP sulfurylase \u2500\u2500\u2500\u2192  APS (adenosine-5'-phosphosulfate)\nAPS + ATP    \u2500\u2500\u2500 APS kinase \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2192  PAPS + ADP\n</code></pre> <p>Rate-limiting factors for PAPS: - Inorganic sulfate availability \u2014 from dietary sulfur amino acids (cysteine, methionine), MSM (methylsulfonylmethane), or direct sulfate intake - ATP availability \u2014 mitochondrial energy production - Magnesium \u2014 required for ATP sulfurylase and APS kinase</p> <p>Depletion of PAPS is common when the sulfation pathway is overwhelmed by high phenol intake or hormonal load.</p>"},{"location":"detox_pathways/sulfation/#key-substrates-sulfated","title":"Key Substrates Sulfated","text":""},{"location":"detox_pathways/sulfation/#steroid-hormones","title":"Steroid Hormones","text":"Hormone Sulfated Form Purpose DHEA DHEA-sulfate (DHEA-S) Inactive storage form; major circulating adrenal androgen Oestradiol (E2) E2-3-sulfate Inactivation; excretion; reservoir Oestrone (E1) E1-sulfate Circulating pool; reversible by STS (steroid sulfatase) Testosterone Testosterone-sulfate Minor inactivation pathway Cholesterol Cholesterol-sulfate Membrane stability; coagulation <p>Steroid sulfatase (STS) can hydrolyse these sulfate esters back to active steroids \u2014 an important axis in hormone-sensitive cancers (particularly breast cancer). SULT1E1/STS balance determines intratissue oestrogen activity.</p>"},{"location":"detox_pathways/sulfation/#thyroid-hormones","title":"Thyroid Hormones","text":"<ul> <li>T4 \u2192 T4-sulfate (SULT1B1) \u2014 inactivation; also substrate for type 1 deiodinase in gut</li> <li>T3 \u2192 T3-sulfate \u2014 rapid inactivation</li> <li>Fetal thyroid hormone buffering relies heavily on sulfation</li> </ul>"},{"location":"detox_pathways/sulfation/#neurotransmitters-sult1a3","title":"Neurotransmitters (SULT1A3)","text":"<ul> <li>Dopamine \u2192 dopamine sulfate (major circulating form of dopamine)</li> <li>Serotonin \u2192 serotonin sulfate</li> <li>Adrenaline \u2192 adrenaline sulfate</li> <li>High amine intake (e.g., from fermented foods, wine) competes for SULT1A3 \u2192 may exacerbate sulfation saturation</li> </ul>"},{"location":"detox_pathways/sulfation/#dietary-phenols","title":"Dietary Phenols","text":"<ul> <li>Quercetin, resveratrol, EGCG, ferulic acid \u2192 sulfated conjugates (major fate in intestinal wall)</li> <li>Paracetamol (acetaminophen) \u2192 paracetamol sulfate (primary route at therapeutic doses; limited capacity)</li> <li>Phenol (gut-derived from protein fermentation by Clostridia) \u2192 phenyl sulfate</li> </ul>"},{"location":"detox_pathways/sulfation/#sulfation-saturation","title":"Sulfation Saturation","text":"<p>The sulfation pathway can be easily saturated due to limited PAPS availability, unlike glucuronidation or amino acid conjugation.</p> <p>Consequence of saturation: - Substrates shift to glucuronidation (which may undergo EHC) or remain unconjugated (toxic) - Paracetamol at high doses saturates sulfation \u2192 overflow to CYP2E1 \u2192 NAPQI \u2192 hepatotoxicity</p> <p>Signs of sulfation insufficiency (clinical/functional): - Sensitivity to dietary phenols (wine, coffee, chocolate) - Adverse reactions to high-phenol foods (garlic, onion, citrus) - Impaired oestrogen clearance - Elevated phenols on organic acid testing</p>"},{"location":"detox_pathways/sulfation/#genetic-variants","title":"Genetic Variants","text":"Gene Variant Effect SULT1A1 R213H (rs9282861) ~30\u201340% reduced enzyme activity; associated with increased breast cancer risk in some populations SULT1E1 Promoter polymorphisms Altered oestrogen sulfation capacity CBS Various Reduced transsulfuration \u2192 lower inorganic sulfate from cysteine \u2192 PAPS limitation"},{"location":"detox_pathways/sulfation/#nutritional-support-for-sulfation","title":"Nutritional Support for Sulfation","text":"Nutrient / Compound Role Sulfur amino acids (methionine, cysteine from protein foods, eggs) Dietary source of sulfate via transsulfuration MSM (methylsulfonylmethane) Provides inorganic sulfur directly; well-tolerated Taurine Alternative sulfur sink; bile acid conjugation; may spare sulfate for PAPS Magnesium Cofactor for PAPS synthesis enzymes Molybdenum Sulfite oxidase \u2192 converts sulfite \u2192 sulfate B6 (pyridoxal-5-phosphate) CBS cofactor \u2192 drives cysteine production Epsom salt baths (MgSO\u2084) Transdermal sulfate absorption (limited but used clinically in some protocols) Avoiding excessive phenol load Reduces competition for PAPS; particularly during recovery from GI conditions"},{"location":"fatty_acids/ala/","title":"Alpha-Linolenic Acid (ALA) \u2014 Omega-3","text":""},{"location":"fatty_acids/ala/#overview","title":"Overview","text":"<p>Alpha-linolenic acid (ALA) is an essential omega-3 polyunsaturated fatty acid (PUFA) \u2014 the body cannot synthesise it de novo, so it must be obtained from the diet. It is an 18-carbon fatty acid with three double bonds in the cis configuration (18:3 n-3; \u03949,12,15). ALA is the plant-kingdom precursor of the longer-chain omega-3s EPA (20:5 n-3) and DHA (22:6 n-3), though conversion efficiency is low in humans. It serves primarily as an energy substrate and an elongation/desaturation precursor, and has independent roles in reducing cardiovascular risk.</p> <ul> <li>Classification: Essential fatty acid; Omega-3 (n-3) PUFA</li> <li>IUPAC shorthand: 18:3 (\u03949,12,15) or 18:3 n-3</li> <li>Melting point: \u221211 \u00b0C (liquid at room temperature and body temperature)</li> <li>Key characteristic: Most abundant omega-3 in the plant kingdom; prone to oxidation (3 double bonds)</li> </ul>"},{"location":"fatty_acids/ala/#dietary-requirements","title":"Dietary Requirements","text":"Population AI (Adequate Intake) Adult men (\u226519 yrs) 1.6 g/day Adult women (\u226519 yrs) 1.1 g/day Pregnancy 1.4 g/day Lactation 1.3 g/day <p>No established UL for ALA. Very high intakes from food sources not associated with toxicity. Supplemental flaxseed oil at high doses may cause GI upset and loose stools.</p>"},{"location":"fatty_acids/ala/#functions","title":"Functions","text":"<ul> <li>Precursor to EPA and DHA: ALA undergoes elongation and desaturation (\u03946-desaturase \u2192 \u03945-desaturase pathway) to yield EPA and then DHA. This is the only endogenous route to omega-3 EPA/DHA in humans. However, conversion is inefficient: only ~5\u201310% of ALA converts to EPA and &lt;1% to DHA in healthy adults.</li> <li>Energy substrate: The majority (~70\u201385%) of ingested ALA is \u03b2-oxidised for energy in mitochondria and peroxisomes; it is a normal fuel.</li> <li>Cell membrane phospholipids: Incorporated into phospholipids (mainly phosphatidylcholine, phosphatidylethanolamine) in cell membranes, influencing membrane fluidity and receptor function \u2014 though to a lesser extent than EPA/DHA.</li> <li>Anti-inflammatory precursor: EPA derived from ALA competes with arachidonic acid (AA) for cyclooxygenase (COX) and lipoxygenase (LOX), reducing pro-inflammatory eicosanoid (prostaglandin E2, leukotriene B4) production.</li> <li>Cardiovascular protection: Epidemiological studies associate higher ALA intake with reduced risk of fatal coronary heart disease; proposed mechanisms include reduced platelet aggregation, antiarrhythmic effects, and modest LDL-lowering.</li> <li>Gene regulation (PPAR\u03b1/\u03b3): ALA and its metabolites are ligands for peroxisome proliferator-activated receptors (PPAR-\u03b1, PPAR-\u03b3), influencing fatty acid oxidation, adipogenesis, and inflammation.</li> </ul>"},{"location":"fatty_acids/ala/#metabolism","title":"Metabolism","text":"Step Details Absorption Absorbed from the small intestine as free fatty acid or within TAG micelles; packaged into chylomicrons \u2192 lymph \u2192 circulation \u03b2-Oxidation ~70\u201385% undergoes mitochondrial/peroxisomal \u03b2-oxidation for energy Elongation ALA (18:3 n-3) + elongase \u2192 20:3 n-3 (ETE) \u03946-Desaturation (rate-limiting) ALA \u2192 18:4 n-3 (stearidonic acid; SDA) via \u03946-desaturase (FADS2); rate-limiting step; competes with LA (\u03946-desaturation of omega-6) \u03945-Desaturation 20:4 n-3 \u2192 EPA (20:5 n-3) via \u03945-desaturase (FADS1) Further elongation \u2192 DHA EPA \u2192 24:5 n-3 \u2192 24:6 n-3 (\u03946-desaturation in peroxisomes) \u2192 DHA (22:6 n-3) via retroconversion (Sprecher pathway) Key limiting factors High omega-6 (LA) competitively inhibits \u03946-desaturase; alcohol, trans fats, zinc deficiency, ageing reduce FADS2 activity"},{"location":"fatty_acids/ala/#food-sources","title":"Food Sources","text":"Food Serving ALA (g) Flaxseed (ground) 1 tbsp (7 g) ~1.6 g Flaxseed oil 1 tbsp (14 ml) ~7.3 g Chia seeds 28 g ~5.1 g Walnuts (English) 28 g ~2.6 g Hemp seeds 28 g ~1.0 g Canola (rapeseed) oil 1 tbsp ~1.3 g Soybean oil 1 tbsp ~0.9 g Edamame (cooked) 100 g ~0.3 g <p>Flaxseed oil and chia seeds are the most concentrated plant sources. Ground flaxseed is preferred over whole (improved bioavailability). ALA in plant foods degrades with heat and prolonged storage (oxidation).</p>"},{"location":"fatty_acids/ala/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/ala/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>The PREDIMED and CARDIOFIT cohort data associate higher ALA intake with lower risk of fatal MI and cardiac arrhythmia.</li> <li>ALA does not raise LDL; may modestly lower triglycerides and blood pressure at doses &gt;3 g/day.</li> <li>The benefit appears partly independent of EPA/DHA conversion \u2014 likely via antiarrhythmic membrane effects and reduced platelet aggregation.</li> </ul>"},{"location":"fatty_acids/ala/#ala-vs-preformed-epadha","title":"ALA vs. Preformed EPA/DHA","text":"<ul> <li>Strictly vegan/vegetarian individuals relying solely on ALA for omega-3 status often have suboptimal DHA levels (brain/retina DHA is almost entirely dependent on dietary preformed DHA or very efficient conversion).</li> <li>Algal oil (direct DHA source from microalgae \u2014 the original producers of marine omega-3s) is the recommended DHA supplement for vegans.</li> <li>Stearidonic acid (SDA)-enriched soybean oil converts to EPA more efficiently than ALA (~3\u00d7 the conversion rate) and may be a more effective plant-based omega-3 source.</li> </ul>"},{"location":"fatty_acids/ala/#6-desaturase-polymorphisms-fads2","title":"\u03946-Desaturase Polymorphisms (FADS2)","text":"<ul> <li>Common variants in FADS1/FADS2 genes significantly affect ALA\u2192EPA\u2192DHA conversion efficiency; some individuals are poor converters requiring preformed EPA/DHA.</li> </ul>"},{"location":"fatty_acids/ala/#prostate-cancer-controversy","title":"Prostate Cancer Controversy","text":"<ul> <li>Older epidemiological studies suggested high ALA may increase prostate cancer risk; subsequent meta-analyses have not confirmed this relationship. Current evidence does not support restricting ALA for this reason.</li> </ul>"},{"location":"fatty_acids/ala/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Linoleic acid (LA, Omega-6) Competes with ALA for \u03946-desaturase; high LA:ALA ratio (typical Western diet ~15\u201320:1) substantially suppresses ALA conversion to EPA/DHA; optimal ratio ~4:1 Zinc Cofactor for \u03946-desaturase; zinc deficiency impairs ALA\u2192EPA conversion Vitamin B6 Required for elongase and desaturase steps in fatty acid metabolism Magnesium Cofactor for FADS enzymes Trans fatty acids Inhibit \u03946-desaturase; high trans fat intake reduces ALA\u2192EPA/DHA conversion Alcohol Inhibits \u03946-desaturase; chronic alcohol use reduces EPA/DHA synthesis from ALA Vitamin E Protects ALA from peroxidation; foods high in ALA (flax, chia) and ALA supplements should be accompanied by adequate vitamin E"},{"location":"fatty_acids/ala/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Flaxseed oil (1\u20132 tbsp/day): Most common ALA supplement; prone to rancidity \u2014 store refrigerated in dark bottles; consume within 6 weeks of opening</li> <li>Ground flaxseed (2 tbsp/day): More stable than oil; also provides lignans (phytoestrogenic antioxidants) and fibre; superior for most uses</li> <li>Chia seeds: Stable shelf life; good ALA source plus fibre and calcium</li> <li>ALA does not reliably raise DHA levels \u2014 vegans should also supplement with algal DHA (200\u2013400 mg/day) for neurological and retinal health</li> <li>Cooking with ALA-rich oils at high heat should be avoided \u2014 use for cold dressings; use more heat-stable oils (avocado, coconut) for frying</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/","title":"Arachidonic Acid (AA) \u2014 Omega-6","text":""},{"location":"fatty_acids/arachidonic_acid/#overview","title":"Overview","text":"<p>Arachidonic acid (AA) is a long-chain omega-6 PUFA with 20 carbons and 4 double bonds (20:4 n-6; \u03945,8,11,14). It is classified as conditionally essential: synthesised from linoleic acid (LA) via \u03946-desaturase \u2192 elongase \u2192 \u03945-desaturase, but synthesis may be insufficient in preterm infants or those with FADS gene variants. AA is the dominant precursor to pro-inflammatory eicosanoids (Series 2 PGs, TXA2, Series 4 leukotrienes) and also to anti-inflammatory lipoxins. It is a critical structural lipid in muscle and brain and is required for infant brain development.</p> <ul> <li>Classification: Long-chain omega-6 PUFA; conditionally essential</li> <li>IUPAC shorthand: 20:4 (\u03945,8,11,14) or 20:4 n-6</li> <li>Primary dietary source: Animal products (meat, eggs, fish)</li> <li>Key characteristic: Central hub of eicosanoid biology; substrate for COX, LOX, and CYP450 pathways; precursor to endocannabinoids</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#dietary-requirements","title":"Dietary Requirements","text":"Population Notes Healthy adults No RDA; dietary intake ~150\u2013500 mg/day in omnivores Infants (0\u201312 months) Required in formula at \u22650.5% of total fatty acids (FDA, EFSA); critical for brain and retinal development Preterm infants Particularly dependent on preformed dietary AA \u2014 endogenous synthesis from LA is inadequate <p>No established UL. Very high supplemental doses (&gt;1.5 g/day) may theoretically increase pro-inflammatory eicosanoid production.</p>"},{"location":"fatty_acids/arachidonic_acid/#functions","title":"Functions","text":"<ul> <li>Pro-inflammatory eicosanoid precursor (major function):</li> <li>COX-1/COX-2 pathway: AA \u2192 PGH2 \u2192 PGE2 (pain, fever), PGI2 (vasodilation), TXA2 (vasoconstriction, platelet aggregation)</li> <li>5-LOX pathway: AA \u2192 LTB4 (neutrophil chemoattractant), LTC4/LTD4/LTE4 (cysteinyl leukotrienes; bronchoconstriction in asthma)</li> <li>CYP epoxygenases: AA \u2192 EETs (vasodilatory, anti-inflammatory; cardioprotective)</li> <li>Lipoxin precursor (anti-inflammatory): AA + 15-LOX (or aspirin-acetylated COX-2) \u2192 LXA4/LXB4 \u2014 specialised pro-resolving mediators (SPMs) that terminate inflammation and promote macrophage efferocytosis.</li> <li>Structural lipid \u2014 brain: AA is the most abundant omega-6 in the CNS; concentrated at sn-2 of PI and PE in synaptosomal membranes; critical for lipid raft structure and PIP2/DAG/IP3 second-messenger cascades.</li> <li>Endocannabinoid precursor: AA \u2192 anandamide (AEA) and 2-AG \u2014 the primary endocannabinoids; relevant in pain modulation and appetite regulation.</li> <li>Muscle anabolism (via PGF2\u03b1): COX-2\u2013derived PGF2\u03b1 activates mTOR \u2192 muscle protein synthesis; AA supplementation increases this signalling.</li> <li>Infant neurodevelopment: AA and DHA are both required for brain and retinal growth; AA:DHA ratio in breast milk ~1.5:1; ARA added to preterm infant formula.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#metabolism","title":"Metabolism","text":"Step Details Synthesis from LA LA (18:2) \u2192 GLA (18:3; FADS2) \u2192 DGLA (20:3; ELOVL5) \u2192 AA (20:4; FADS1) Dietary absorption Absorbed from meat/eggs as free FA or phospholipid; highly bioavailable Membrane incorporation Selectively incorporated at sn-2 of PI, PE, PC (Lands cycle); serves as membrane reservoir Release cPLA\u2082 (Ca\u00b2\u207a-activated) releases free AA on inflammatory stimuli \u2192 eicosanoid synthesis COX pathway AA \u2192 PGH2 (COX-1/2; NSAID target) \u2192 synthases \u2192 PGE2, TXA2, PGI2 5-LOX pathway AA \u2192 5-HPETE \u2192 LTA4 \u2192 LTB4 or LTC4 (glutathione conjugation) Lipoxin pathway AA + 15-LOX \u2192 LXA4/LXB4 (pro-resolving) Endocannabinoid pathway AA esterified in sn-2 of 2-AG or NAPE \u2192 AEA (anandamide) via NAPE-PLD"},{"location":"fatty_acids/arachidonic_acid/#food-sources","title":"Food Sources","text":"Food Serving AA (mg) Salmon (cooked) 85 g ~350 mg Tuna (cooked) 85 g ~300 mg Chicken (cooked) 85 g ~120\u2013160 mg Pork (cooked) 85 g ~190 mg Beef (lean, cooked) 85 g ~60\u2013100 mg Liver (beef, cooked) 85 g ~180 mg Egg yolk 1 large ~60 mg <p>AA is found exclusively in animal products. Vegans rely entirely on LA\u2192AA conversion; plasma AA is modestly lower in vegans but typically maintained by upregulated endogenous synthesis.</p>"},{"location":"fatty_acids/arachidonic_acid/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/arachidonic_acid/#aspirin-and-nsaids","title":"Aspirin and NSAIDs","text":"<ul> <li>Aspirin irreversibly acetylates COX-1 (platelet) and COX-2 \u2192 blocks AA\u2192PGH2 \u2192 reduces TXA2 (antiplatelet), PGE2 (anti-pyretic/analgesic).</li> <li>COX-2 selective inhibitors (celecoxib) spare GI COX-1 but eliminate endothelial PGI2 (vasodilatory/antiplatelet) without blocking platelet TXA2 \u2192 net prothrombotic \u2192 increased MI risk (as seen with rofecoxib/Vioxx).</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#asthma-and-allergic-disease","title":"Asthma and Allergic Disease","text":"<ul> <li>Cysteinyl leukotrienes (LTC4, LTD4, LTE4) cause bronchoconstriction and eosinophil recruitment \u2014 major mediators of allergic asthma.</li> <li>Montelukast: Leukotriene receptor antagonist (LTD4 receptor).</li> <li>Zileuton: 5-LOX inhibitor; blocks all leukotrienes upstream.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#aspirin-exacerbated-respiratory-disease-aerd-samters-triad","title":"Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad)","text":"<ul> <li>COX inhibition by aspirin/NSAIDs shunts AA preferentially through the 5-LOX pathway \u2192 massive leukotriene surge \u2192 severe bronchoconstriction. Treatment: leukotriene antagonists + aspirin desensitisation.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#infant-nutrition","title":"Infant Nutrition","text":"<ul> <li>Preterm infants cannot synthesise adequate AA from LA; breast milk AA is essential.</li> <li>ARA (from fungal ARASCO) added to formula at 0.5\u20131% total FA; AA:DHA ratio ~1.5:1 mirrors breast milk.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#dysmenorrhoea","title":"Dysmenorrhoea","text":"<ul> <li>PGE2 (AA-derived) sensitises uterine/peripheral nociceptors \u2192 menstrual pain.</li> <li>NSAIDs (ibuprofen, naproxen) are first-line treatment \u2014 act by blocking AA\u2192PGE2 synthesis.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#sports-performance-supplement","title":"Sports Performance Supplement","text":"<ul> <li>AA supplementation (~1.5 g/day): Small RCTs show increased muscular hypertrophy and strength (via PGF2\u03b1 \u2192 mTOR \u2192 muscle protein synthesis); used as a bodybuilding supplement; evidence base limited.</li> </ul>"},{"location":"fatty_acids/arachidonic_acid/#interactions","title":"Interactions","text":"Nutrient / Drug Effect EPA (omega-3) Competes with AA for COX and LOX; EPA:AA membrane ratio determines inflammatory eicosanoid balance DGLA Competes with AA for COX \u2192 produces anti-inflammatory PGE1; GLA supplementation boosts DGLA Aspirin / NSAIDs Downstream COX inhibitors \u2014 block AA\u2192PGH2 Corticosteroids Upregulate lipocortin/annexin A1 \u2192 inhibit PLA2 \u2192 prevent AA release from membranes; most upstream pharmacological target in the AA pathway Zileuton 5-LOX inhibitor; blocks LTA4/LTB4/LTC4 from AA Vitamin E Indirect COX/PLA2 inhibitory effect; reduces AA-mediated lipid peroxidation Zinc Required for FADS1 (\u03945-desaturase) and FADS2 (\u03946-desaturase); zinc deficiency reduces AA synthesis from LA"},{"location":"fatty_acids/arachidonic_acid/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>AA is not typically supplemented by the general population \u2014 omnivore diets provide adequate amounts</li> <li>ARA supplements (1\u20131.5 g/day): Used by bodybuilders for muscle hypertrophy via COX-2/PGF2\u03b1/mTOR signalling; combine cautiously with high EPA intake (EPA competitively reduces AA-derived PGF2\u03b1)</li> <li>Infant formula ARA: Added as ARASCO (from Mortierella alpina fungus) to meet developmental requirements; DHA co-supplemented at ~1:1.5 DHA:ARA ratio</li> <li>Anti-inflammatory strategies targeting AA pathway:</li> <li>Increase EPA/DHA \u2192 displaces AA from membranes</li> <li>Reduce LA-rich seed oil intake \u2192 less AA precursor</li> <li>GLA supplementation \u2192 DGLA\u2191, PGE1\u2191, competitive reduction of AA-derived eicosanoids</li> </ul>"},{"location":"fatty_acids/dha/","title":"Docosahexaenoic Acid (DHA) \u2014 Omega-3","text":""},{"location":"fatty_acids/dha/#overview","title":"Overview","text":"<p>Docosahexaenoic acid (DHA) is a long-chain omega-3 polyunsaturated fatty acid (LC-PUFA) with 22 carbons and 6 double bonds in the cis configuration (22:6 n-3). It is the most structurally complex and functionally critical omega-3 in the human body \u2014 the dominant structural lipid of the brain and retina. DHA constitutes ~30\u201340% of total fatty acids in retinal photoreceptor membranes and ~15\u201320% of dry weight of the cerebral cortex. It is classified as conditionally essential: synthesised from ALA via the Sprecher pathway, but conversion is so inefficient (&lt;1% of ALA\u2192DHA) that preformed dietary DHA is effectively essential for adequate brain and retinal function, particularly during pregnancy, lactation, and infancy.</p> <ul> <li>Classification: Long-chain omega-3 PUFA; conditionally essential</li> <li>IUPAC shorthand: 22:6 (\u03944,7,10,13,16,19) or 22:6 n-3</li> <li>Primary dietary source: Marine fatty fish, microalgae (original producers)</li> <li>Key characteristic: Dominant structural lipid of the CNS and retina; essential for neurodevelopment; precursor to D-series resolvins and neuroprotectins</li> </ul>"},{"location":"fatty_acids/dha/#dietary-requirements","title":"Dietary Requirements","text":"Population Recommendation General adults No official RDA; most authorities recommend 250\u2013500 mg/day EPA+DHA Pregnancy 200\u2013300 mg/day DHA minimum (EFSA, WHO) Lactation 200\u2013300 mg/day DHA; breast milk DHA content reflects maternal intake Infants (0\u201312 months) ~100 mg/day DHA (from breast milk/formula) Vegans/Vegetarians Algal DHA 200\u2013400 mg/day recommended (no marine intake) <p>No established UL. High doses (&gt;3 g/day EPA+DHA) may increase bleeding time. Doses used in clinical trials reach 2\u20134 g DHA/day without serious adverse effects.</p>"},{"location":"fatty_acids/dha/#functions","title":"Functions","text":"<ul> <li>Structural lipid \u2014 brain (primary function): DHA is the most abundant PUFA in the CNS. It is concentrated in the sn-2 position of phosphatidylserine (PS) and phosphatidylethanolamine (PE) in neuronal cell membranes, synaptic vesicle membranes, and myelin sheaths. DHA's unique structure (6 double bonds) imparts exceptional membrane fluidity and curvature, critical for synaptic transmission, receptor-coupled signalling (rhodopsin, GPCR), and vesicle fusion.</li> <li>Structural lipid \u2014 retina: DHA constitutes ~30\u201340% of fatty acids in photoreceptor outer segment membranes; essential for rhodopsin function and phototransduction cascade efficiency. Low DHA is associated with impaired dark adaptation and visual acuity.</li> <li>Neurodevelopment: DHA accumulates rapidly in fetal brain and retina during the third trimester and the first 2 years of postnatal life. Inadequate maternal DHA is associated with lower IQ, impaired visual acuity, and increased risk of ADHD in offspring. Critical \"programmable\" window cannot be compensated for later.</li> <li>Neuroprotectin D1 (NPD1) / Protectin D1: DHA is the precursor to neuroprotectin D1 (also called protectin D1) \u2014 a potent SPM (specialised pro-resolving mediator) that inhibits oxidative stress-induced neuronal apoptosis, reduces A\u03b242 amyloid secretion, and protects against ischaemia-reperfusion injury.</li> <li>D-series resolvins (RvD1\u2013RvD6): DHA \u2192 D-series resolvins (via aspirin-acetylated COX-2 or 15-LOX) \u2192 actively resolve inflammation; reduce neutrophil infiltration, promote macrophage phagocytosis of apoptotic cells.</li> <li>Gene regulation (PPAR\u03b3, RXR): DHA activates PPAR\u03b3 and retinoid X receptor (RXR) \u2014 influences adipogenesis, insulin sensitisation, and anti-inflammatory gene expression.</li> <li>Serotonin and dopamine modulation: DHA influences serotonin receptor density and dopamine signalling in the prefrontal cortex (relevant in ADHD, depression, schizophrenia research).</li> <li>Anti-arrhythmic: Incorporated into cardiomyocyte membranes \u2192 modulates sodium and calcium channel kinetics \u2192 reduces cardiac arrhythmia risk (particularly ventricular fibrillation).</li> <li>Triglyceride reduction: DHA, like EPA, activates PPAR\u03b1 and inhibits DGAT \u2192 lowers plasma TG; DHA may raise LDL-C slightly more than EPA (clinically relevant difference primarily at pharmacological doses).</li> </ul>"},{"location":"fatty_acids/dha/#metabolism","title":"Metabolism","text":"Step Details Dietary absorption Absorbed in small intestine (as TG, PL or free FA) \u2192 chylomicrons \u2192 lymph \u2192 plasma Sprecher pathway (synthesis from EPA) EPA (20:5) \u2192 22:5 n-3 (DPA; elongation) \u2192 24:5 n-3 (elongation) \u2192 24:6 n-3 (\u03946-desaturation; FADS2) \u2192 DHA (22:6; peroxisomal retroconversion/chain shortening); the rate-limiting \u03946-desaturation step is shared with ALA conversion \u2014 making ALA\u2192DHA conversion very inefficient Phospholipid remodelling DHA preferentially incorporated at sn-2 position of PS and PE via Lands cycle; full membrane enrichment takes 4\u20138 weeks Retroconversion DHA \u2192 DPA (22:5 n-3) \u2192 EPA: a minor retroconversion pathway Peroxisomal \u03b2-oxidation Excess DHA and the 24:6 n-3 intermediate are processed in peroxisomes; peroxisomal function essential for DHA synthesis and metabolism Brain DHA dynamics Once in brain, DHA turnover is slow; brain preferentially takes up DHA via a specific transport system (MFSD2A transporter in blood-brain barrier endothelial cells) \u2014 essential for brain DHA retention"},{"location":"fatty_acids/dha/#food-sources","title":"Food Sources","text":"Food Serving DHA (mg) Wild salmon (cooked) 85 g ~1,000\u20131,200 mg Atlantic mackerel (cooked) 85 g ~900 mg Herring (cooked) 85 g ~850 mg Sardines (canned in oil) 85 g ~400\u2013500 mg Anchovies (canned) 85 g ~400 mg Rainbow trout (farmed, cooked) 85 g ~700 mg Tuna (canned light) 85 g ~180 mg Algal oil supplement 1 serving ~200\u2013400 mg Eggs (DHA-enriched) 1 large ~100\u2013150 mg <p>Plant foods contain virtually no DHA. Microalgae are the original producers \u2014 marine EPA/DHA enters the food chain via algae \u2192 zooplankton \u2192 small fish \u2192 large fish. Algal oil allows vegans to access preformed DHA directly from the biological source.</p>"},{"location":"fatty_acids/dha/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/dha/#neurodevelopment-and-pregnancy","title":"Neurodevelopment and Pregnancy","text":"<ul> <li>Maternal DHA deficiency during pregnancy is associated with lower offspring IQ (measured at 4 years), impaired visual development, and increased risk of neurodevelopmental disorders.</li> <li>DIAMOND trial and DINO trial: DHA supplementation in infants and during lactation improves visual acuity and cognitive outcomes, particularly in preterm infants.</li> <li>DHA supplementation during pregnancy (600 mg/day; DORIS trial) reduced rate of early preterm birth (&lt;34 weeks) by ~40% in women with low DHA status.</li> <li>Recommendation: Pregnant women should consume \u2265200\u2013300 mg/day DHA; if fish intake is limited, supplement with algal DHA.</li> </ul>"},{"location":"fatty_acids/dha/#alzheimers-disease-and-cognitive-decline","title":"Alzheimer's Disease and Cognitive Decline","text":"<ul> <li>Epidemiological studies consistently associate higher DHA intake/status with lower risk of dementia.</li> <li>MFSD2A transporter: Mutations in MFSD2A reduce brain DHA uptake \u2192 microcephaly and intellectual disability (rare); underscores DHA's structural necessity in the brain.</li> <li>ADRN trial (Alzheimer's Disease Cooperative Study): DHA 2 g/day for 18 months did not slow decline in established Alzheimer's \u2014 suggesting DHA's role may be primarily preventive (structural) rather than therapeutic in advanced disease.</li> <li>DHA reduces A\u03b2 peptide generation (via neuroprotectin D1) and tau hyperphosphorylation in animal models.</li> </ul>"},{"location":"fatty_acids/dha/#adhd","title":"ADHD","text":"<ul> <li>Children with ADHD have consistently lower plasma DHA levels vs. controls.</li> <li>Supplementation trials (DHA 500\u20131,200 mg/day) show modest but statistically significant improvements in attention, hyperactivity, and impulsivity.</li> </ul>"},{"location":"fatty_acids/dha/#age-related-macular-degeneration-amd","title":"Age-Related Macular Degeneration (AMD)","text":"<ul> <li>Higher dietary DHA+EPA associated with ~40% lower risk of advanced AMD (AREDS2 data).</li> <li>AREDS2 trial: Omega-3 (EPA+DHA) supplementation did not independently reduce AMD progression beyond the AREDS formula (lutein/zeaxanthin), but dietary EPA+DHA remained a protective association.</li> </ul>"},{"location":"fatty_acids/dha/#dha-vs-epa-for-depression","title":"DHA vs. EPA for Depression","text":"<ul> <li>In contrast to EPA (which appears more active in MDD), DHA alone is less effective for depressive symptoms; combined EPA+DHA preparations with EPA predominance are preferred.</li> </ul>"},{"location":"fatty_acids/dha/#interactions","title":"Interactions","text":"Nutrient / Drug Effect EPA Closely linked in metabolism and function; most benefits attributed to \"EPA+DHA\" \u2014 optimal ratios differ by clinical goal (higher EPA:DHA for inflammation/depression; DHA focus for cognition/neurodevelopment) Vitamin E Antioxidant protection against DHA peroxidation \u2014 DHA's 6 double bonds make it highly susceptible to lipid peroxidation; adequate vitamin E is critical with high PUFA diets Phosphatidylserine (PS) DHA is preferentially esterified in brain PS; PS supplements and DHA likely synergise for neurological function Choline Choline is the head group of PC (phosphatidylcholine) \u2014 DHA-enriched PC is the preferred delivery form for brain DHA; krill oil provides both DHA-PC and choline Vitamin D Synergistic in anti-inflammatory and neurodevelopmental contexts; share gene regulatory pathways Warfarin / Anticoagulants Mild additive anticoagulant effect at high doses; monitor INR Alcohol Promotes DHA peroxidation and disrupts brain DHA incorporation MFSD2A transporter Brain DHA uptake via MFSD2A is lysophosphatidylcholine (LPC-DHA) form dependent; DHA in phospholipid form (krill, LPC supplements) may have superior brain uptake"},{"location":"fatty_acids/dha/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Fish oil (EPA+DHA): Most used omega-3 supplement globally; DHA content typically lower than EPA in standard fish oil (2:1 EPA:DHA); select products with specific DHA amounts</li> <li>Algal DHA oil: Recommended for vegans/vegetarians; growing evidence supports efficacy equivalent to fish oil; also appropriate during pregnancy (avoids potential fish mercury concern)</li> <li>Krill oil: DHA delivered as phospholipids \u2192 superior brain bioavailability; contains astaxanthin and choline; smaller doses required; more expensive per gram DHA</li> <li>DHA-enriched eggs: A practical, food-based way to increase DHA; from hens fed marine algae or flaxseed (not as high as fish)</li> <li>During pregnancy: Algal DHA 200\u2013600 mg/day is safe, evidence-based, and avoids methyl-mercury concern</li> <li>Storage: DHA-rich oils highly susceptible to oxidation \u2014 store fish/algal oils refrigerated, consume promptly; check for off-smells indicating rancidity</li> <li>Form bioavailability ranking: rTG &gt; krill phospholipid \u2248 natural TG &gt; ethyl ester (EE) when taken fasted; EE form approaches TG bioavailability when consumed with a fat-containing meal</li> </ul>"},{"location":"fatty_acids/epa/","title":"Eicosapentaenoic Acid (EPA) \u2014 Omega-3","text":""},{"location":"fatty_acids/epa/#overview","title":"Overview","text":"<p>Eicosapentaenoic acid (EPA) is a long-chain omega-3 polyunsaturated fatty acid (LC-PUFA) with 20 carbons and 5 double bonds in the cis configuration (20:5 n-3). It is classified as conditionally essential: synthesised from ALA via \u03946-desaturation/elongation, but conversion from ALA is highly inefficient (&lt;10%), making dietary preformed EPA from marine sources effectively essential for most people. EPA is the primary anti-inflammatory eicosanoid precursor (Series 3 prostaglandins, Series 5 leukotrienes, E-series resolvins) and competes directly with arachidonic acid (AA) for cyclooxygenase and lipoxygenase enzymes. It is clinically established for hypertriglyceridaemia and is a major area in cardiovascular medicine.</p> <ul> <li>Classification: Long-chain omega-3 PUFA; conditionally essential</li> <li>IUPAC shorthand: 20:5 (\u03945,8,11,14,17) or 20:5 n-3</li> <li>Primary source: Marine fatty fish, krill, microalgae</li> <li>Key characteristic: The dominant anti-inflammatory omega-3; competes with AA for eicosanoid synthesis; precursor to E-series resolvins</li> </ul>"},{"location":"fatty_acids/epa/#dietary-requirements","title":"Dietary Requirements","text":"Population Recommendation General adults No official RDA; most authorities recommend 250\u2013500 mg/day EPA+DHA combined Cardiovascular disease ACC/AHA: \u22651 g/day EPA+DHA for patients with established CVD Hypertriglyceridaemia FDA-approved prescription EPA (icosapentaenoyl ethyl ester; Vascepa): 4 g/day EPA Pregnancy/Lactation 200\u2013300 mg/day DHA minimum; EPA typically included <p>No established UL for EPA from food. FDA considers up to 3 g/day from supplements Generally Recognised As Safe (GRAS). Doses &gt;3 g/day may modestly increase bleeding time.</p>"},{"location":"fatty_acids/epa/#functions","title":"Functions","text":"<ul> <li>Anti-inflammatory eicosanoid production (primary function): EPA serves as substrate for COX-1/COX-2 and 5-LOX to produce Series 3 prostaglandins (PGE3, TXA3) and Series 5 leukotrienes (LTB5) \u2014 both dramatically less pro-inflammatory than the AA-derived Series 2 (PGE2, TXA2) and Series 4 (LTB4) counterparts. TXA3 is a weaker platelet aggregant than TXA2.</li> <li>Resolvin E-series synthesis: EPA is the precursor to E-series resolvins (RvE1, RvE2) and E-series protectins \u2014 specialised pro-resolving mediators (SPMs) that actively terminate inflammation and promote return to tissue homeostasis.</li> <li>Competitive inhibition of AA pathways: EPA competes with AA for COX and LOX enzymes \u2014 increased EPA:AA ratio in cell membranes reduces the quantity of pro-inflammatory AA-derived eicosanoids produced upon cellular activation.</li> <li>Triglyceride reduction: EPA reduces hepatic VLDL-TG secretion by inhibiting diacylglycerol acyltransferase (DGAT) and stimulating \u03b2-oxidation via PPAR\u03b1 activation \u2192 reduces plasma triglycerides by 20\u201350% at pharmacological doses.</li> <li>Platelet function: EPA reduces platelet aggregation and thromboxane A2 production \u2192 antithrombotic effect.</li> <li>Endothelial function: Increases nitric oxide (NO) bioavailability; reduces VCAM-1 and ICAM-1 expression; improves arterial compliance.</li> <li>Gene regulation (PPAR\u03b1/\u03b3/\u03b4): EPA is a potent PPAR\u03b1 ligand \u2192 upregulates mitochondrial \u03b2-oxidation of fatty acids; downregulates SREBP-1c (reduces lipogenesis).</li> <li>Neurological: EPA has mood-stabilising effects in depression; high EPA (vs DHA) fish oil preparations outperform placebo in MDD trials; mechanism may relate to anti-inflammatory action (reducing neuroinflammation) rather than direct neuronal membrane effects.</li> </ul>"},{"location":"fatty_acids/epa/#metabolism","title":"Metabolism","text":"Step Details Dietary absorption Absorbed as TAG, phospholipid, or free FA from small intestine \u2192 packaged in chylomicrons \u2192 lymph \u2192 plasma Integration into phospholipids EPA replaces AA/DHA in sn-2 position of membrane phospholipids (PL remodelling; Lands cycle); enrichment of cell membranes occurs over 4\u20138 weeks of supplementation Eicosanoid synthesis Membrane EPA released by phospholipase A2 (PLA2) \u2192 COX (\u2192 Series 3 PGs/TXs) or 5-LOX (\u2192 Series 5 LTs) Resolvin synthesis EPA + aspirin-acetylated COX-2 \u2192 18-HEPE \u2192 RvE1/RvE2 (also via cytochrome P450 or 5-LOX) Retroconversion EPA can be retroconverted to ALA (minor pathway) Elongation to DHA EPA \u2192 22:5 n-3 (DPA) \u2192 24:5 n-3 \u2192 24:6 n-3 (\u03946-desaturation) \u2192 DHA (peroxisomal \u03b2-oxidation; Sprecher pathway); rate-limited and inefficient \u03b2-Oxidation Excess EPA undergoes mitochondrial \u03b2-oxidation for energy"},{"location":"fatty_acids/epa/#food-sources","title":"Food Sources","text":"Food Serving EPA (mg) Atlantic mackerel (cooked) 85 g ~1,000 mg Wild salmon (cooked) 85 g ~600\u20131,000 mg Herring (cooked) 85 g ~900 mg Sardines (canned in oil) 85 g ~450 mg Anchovies (canned) 85 g ~700 mg Rainbow trout (cooked) 85 g ~400 mg Oysters (cooked) 85 g ~400 mg Tuna (canned light) 85 g ~170 mg Krill oil (supplement) 1 g ~150 mg <p>Fatty cold-water fish are the most concentrated EPA source. Farmed salmon EPA content varies with feed composition (declining in recent years as fishmeal is replaced with plant oils). Wild-caught fish generally have higher EPA:DHA ratios. Plant foods contain negligible EPA.</p>"},{"location":"fatty_acids/epa/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/epa/#hypertriglyceridaemia","title":"Hypertriglyceridaemia","text":"<ul> <li>Prescription-grade EPA (icosapentaenoyl ethyl ester; IPE; Vascepa\u00ae): FDA-approved at 4 g/day for adults with serum TG \u2265150 mg/dL; lowers TG by 20\u201330% in statin-treated patients.</li> <li>REDUCE-IT trial (2018): 4 g/day IPE added to statin therapy in patients with elevated TG and established CVD or high CV risk \u2192 25% relative reduction in major adverse cardiovascular events (MACE) including CV death, non-fatal MI, stroke. Landmark trial; mechanism debated (anti-inflammatory vs. direct membrane stabilisation vs. plaque stabilisation vs. benefit from mineral oil comparator).</li> </ul>"},{"location":"fatty_acids/epa/#major-depressive-disorder-mdd","title":"Major Depressive Disorder (MDD)","text":"<ul> <li>Multiple meta-analyses show EPA-predominant formulations (EPA:DHA ratio &gt;2:1, typically 1\u20132 g EPA/day) significantly reduce depressive symptoms in MDD.</li> <li>APA and ISSFAL guidelines support EPA+DHA as adjunctive treatment for MDD; EPA may be the more pharmacologically active component for mood.</li> <li>Mechanism: reduces neuroinflammation (IL-6, TNF-\u03b1, CRP); restores HPA axis regulation; may modulate serotonin signalling.</li> </ul>"},{"location":"fatty_acids/epa/#inflammation-and-autoimmune-disease","title":"Inflammation and Autoimmune Disease","text":"<ul> <li>EPA reduces inflammatory markers (CRP, IL-6, TNF-\u03b1) in rheumatoid arthritis; fish oil supplementation (~3 g/day EPA+DHA) modestly reduces joint pain and morning stiffness \u2014 may allow NSAID dose reduction.</li> <li>Evidence in IBD, lupus, and psoriasis is mixed.</li> </ul>"},{"location":"fatty_acids/epa/#bleeding-risk","title":"Bleeding Risk","text":"<ul> <li>At doses &gt;3 g/day EPA+DHA: modestly prolongs bleeding time and reduces platelet aggregation. Clinically significant bleeding is rare but relevant in patients on anticoagulants (warfarin, DOACs) or antiplatelet agents.</li> </ul>"},{"location":"fatty_acids/epa/#interactions","title":"Interactions","text":"Nutrient / Drug Effect Arachidonic acid (AA, Omega-6) EPA:AA ratio in membranes determines eicosanoid balance; high dietary AA blunts anti-inflammatory effects of EPA Aspirin Aspirin-acetylated COX-2 preferentially converts EPA \u2192 18-HEPE \u2192 RvE1 (resolvin); aspirin + EPA is synergistic for anti-inflammatory resolvin production Warfarin / DOACs EPA reduces platelet aggregation and TXA2; mild additive anticoagulant effect; monitor INR at high EPA doses Statins Synergistic for cardiovascular risk reduction (REDUCE-IT trial); statin+EPA recommended in high TG patients on statin therapy Vitamin D Synergistic anti-inflammatory; vitamin D receptors and EPA-derived resolvins share downstream inflammatory gene targets Vitamin E Protects EPA from peroxidation in the gut and in food storage; fish oil supplements should be stabilised with vitamin E (tocopherols) Alcohol Inhibits \u03946-desaturase (reduces ALA\u2192EPA conversion); also promotes oxidative stress that degrades EPA"},{"location":"fatty_acids/epa/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Standard fish oil: Most common source; look for products certified for purity (IFOS, NSF); typical dose 1\u20134 g/day for EPA+DHA combined</li> <li>Ethyl ester (EE) vs. triglyceride (TG) form: EE forms (most prescription and many OTC products) have lower bioavailability unless taken with a fatty meal; rTG (re-esterified triglyceride) forms have superior bioavailability. TG forms are more bioavailable but more expensive.</li> <li>Krill oil: EPA in phospholipid form \u2014 higher bioavailability per gram vs. fish oil TG; also provides choline and astaxanthin (antioxidant); smaller doses needed</li> <li>Algal oil: Vegan EPA source (some algal oils now provide EPA, not just DHA); recommended for vegans/vegetarians</li> <li>Stability: Store in opaque containers, refrigerated or frozen; fish oil goes rancid quickly \u2014 rancid oil may be harmful (avoid oil with fishy/metallic taste beyond fresh ocean smell)</li> <li>Enteric-coated capsules: Reduce fish burps; may slightly reduce bioavailability</li> </ul>"},{"location":"fatty_acids/linoleic_acid/","title":"Linoleic Acid (LA) \u2014 Omega-6","text":""},{"location":"fatty_acids/linoleic_acid/#overview","title":"Overview","text":"<p>Linoleic acid (LA) is an essential omega-6 polyunsaturated fatty acid (PUFA) \u2014 the parent omega-6 fatty acid that the body cannot synthesise, making dietary intake mandatory. It is an 18-carbon fatty acid with two double bonds (18:2 n-6; \u03949,12). LA is the most abundant PUFA in the human diet and the metabolic precursor to all omega-6 PUFA derivatives, most importantly arachidonic acid (AA; 20:4 n-6). Through AA, LA is the ultimate precursor to pro-inflammatory eicosanoids (Series 2 prostaglandins, Series 4 leukotrienes, thromboxane A2). LA is absolutely required for: skin barrier integrity (structural ceramide acylation), immune function, and cell membrane composition.</p> <ul> <li>Classification: Essential fatty acid; Omega-6 (n-6) PUFA</li> <li>IUPAC shorthand: 18:2 (\u03949,12) or 18:2 n-6</li> <li>Most abundant PUFA in the Western diet</li> <li>Key characteristic: Parent omega-6; sole precursor to arachidonic acid; critical for skin barrier integrity</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#dietary-requirements","title":"Dietary Requirements","text":"Population AI (Adequate Intake) Adult men (\u226519 yrs) 17 g/day Adult women (\u226519 yrs) 12 g/day Pregnancy 13 g/day Lactation 13 g/day <p>The Western diet provides ~15\u201325 g/day LA \u2014 well above AI. No established UL. Very high intakes (&gt;10% of energy from LA) may theoretically increase oxidative stress and promote pro-inflammatory AA production, though this is debated.</p>"},{"location":"fatty_acids/linoleic_acid/#functions","title":"Functions","text":"<ul> <li>Skin barrier integrity (uniquely essential): LA is incorporated via ester linkage into ceramide-1-acylceramide (acylceramide) \u2014 the specific ceramide species in the stratum corneum responsible for the water-impermeable lamellar membrane of the skin. No other fatty acid can substitute in this role. LA deficiency \u2192 scaly skin, increased transepidermal water loss (TEWL), and impaired skin barrier \u2014 the classic cutaneous LA deficiency syndrome.</li> <li>Cell membrane structural lipid: LA and AA (its derivative) are major components of the sn-2 position of membrane phospholipids; determine membrane fluidity and microdomain (lipid raft) properties.</li> <li>Precursor to arachidonic acid (AA): LA \u2192 \u03b3-Linolenic acid (GLA; 18:3 n-6; via \u03946-desaturase) \u2192 AA (20:4 n-6); AA is the substrate for Series 2 prostaglandins (PGE2, PGI2, TXA2), Series 4 leukotrienes (LTB4, LTC4), and 12-HETE \u2014 predominantly pro-inflammatory mediators critical for immune activation, platelet aggregation, and vascular tone.</li> <li>Precursor to DGLA: LA \u2192 GLA \u2192 DGLA (dihomo-\u03b3-linolenic acid; 20:3 n-6) \u2192 Series 1 prostaglandins (PGE1) \u2014 anti-inflammatory; DGLA competes with AA for COX; GLA/DGLA supplementation (evening primrose oil, borage oil) exploits this to reduce inflammation.</li> <li>Eicosanoid source via AA: AA-derived PGE2, TXA2, and LTB4 are essential mediators of the inflammatory response, pain sensitisation, platelet aggregation, and bronchoconstriction \u2014 functions that require tightly regulated omega-6 AA-eicosanoid signalling.</li> <li>Lipoxin precursor: AA is also the precursor to lipoxins (LXA4, LXB4) \u2014 specialised pro-resolving mediators (SPMs) that signal anti-inflammatory resolution; LA\u2192AA pathway thus participates in both initiation and resolution of inflammation.</li> <li>Gene regulation (PPAR\u03b3): LA and its metabolites activate PPAR\u03b3 \u2192 adipogenesis, insulin sensitisation; LA-rich diets associated with modest insulin sensitivity improvements vs. saturated fat\u2013rich diets.</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#metabolism","title":"Metabolism","text":"Step Details Dietary absorption Absorbed in small intestine as free FA or within TAG/PL; packaged in chylomicrons \u03946-Desaturation (rate-limiting) LA (18:2 n-6) \u2192 GLA (18:3 n-6) via \u03946-desaturase (FADS2); competes with ALA for the same enzyme; the dominant pathway (LA &gt;&gt; ALA in typical Western diet) Elongation GLA (18:3 n-6) \u2192 DGLA (20:3 n-6) via elongase (ELOVL5) \u03945-Desaturation DGLA (20:3 n-6) \u2192 AA (20:4 n-6) via \u03945-desaturase (FADS1) Membrane incorporation AA preferentially esterified at sn-2 position of PC, PE, PI in cell membranes; serves as AA reservoir Eicosanoid liberation Phospholipase A2 (PLA2) releases AA from membranes on inflammatory stimulus \u2192 COX/LOX \u2192 eicosanoids Skin ceramide pathway LA esterified to \u03c9-hydroxy fatty acid \u2192 acylceramide (EOS ceramide class) \u2192 lamellar body secretion \u2192 stratum corneum \u03b2-Oxidation Excess LA oxidised for energy via mitochondrial \u03b2-oxidation"},{"location":"fatty_acids/linoleic_acid/#food-sources","title":"Food Sources","text":"Food Serving LA (g) Sunflower oil (high-LA) 1 tbsp ~9 g Safflower oil 1 tbsp ~10 g Corn oil 1 tbsp ~7 g Soybean oil 1 tbsp ~7 g Walnuts 28 g ~10.8 g Sunflower seeds 28 g ~6.5 g Pine nuts 28 g ~9.4 g Peanut butter 2 tbsp ~4.4 g Chicken (dark meat, cooked) 85 g ~1.8 g Tofu 100 g ~2.2 g <p>LA is ubiquitous in modern diets \u2014 vegetable/seed oils (sunflower, corn, soybean) are dominant sources and have dramatically increased LA intake over the 20th century (estimated 2\u20133\u00d7 increase in total Western LA consumption). This shift has increased the omega-6:omega-3 ratio from ~4:1 (traditional diets) to ~15\u201320:1.</p>"},{"location":"fatty_acids/linoleic_acid/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/linoleic_acid/#la-deficiency","title":"LA Deficiency","text":"<ul> <li>Classic presentation: scaly, ichthyotic skin, increased TEWL, alopecia, poor wound healing, impaired growth \u2014 caused by failure to form the essential acylceramide skin barrier ceramide.</li> <li>Occurs primarily in: patients on long-term fat-free parenteral nutrition, very-low-fat enteral formulas, rare fat malabsorption disorders (cystic fibrosis, short bowel syndrome), and historically in infants fed LA-deficient formula.</li> <li>Treatment: topical or dietary LA (even cutaneous application of sunflower oil can correct skin barrier defects in deficient patients).</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#omega-6omega-3-ratio","title":"Omega-6:Omega-3 Ratio","text":"<ul> <li>The extremely high LA intake in modern Western diets (~15\u201325 g/day) vs. modest omega-3 intake suppresses ALA\u2192EPA/DHA conversion (competitive \u03946-desaturase inhibition) and floods the eicosanoid system with pro-inflammatory AA-derived mediators.</li> <li>Current consensus: Rather than avoid LA, the most effective strategy is increasing omega-3 intake to improve the balance; lowering LA intake is secondary and harder to achieve.</li> <li>There is active debate on whether high LA intake per se is pro-inflammatory or whether it is simply neutral in the context of adequate omega-3 ingestion.</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#conjugated-linoleic-acid-cla","title":"Conjugated Linoleic Acid (CLA)","text":"<ul> <li>CLA is a group of LA isomers produced by bacterial biohydrogenation in ruminant animals; found in beef fat and dairy.</li> <li>CLA (specifically c9,t11-CLA and t10,c12-CLA) studied for effects on body composition (modest anti-obesity effect), anticancer properties, and insulin resistance. Evidence is mixed and doses required (3\u20136 g/day) exceed dietary amounts.</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#gla-supplementation-evening-primrose-borage-oil","title":"GLA Supplementation (Evening Primrose / Borage Oil)","text":"<ul> <li>GLA (LA metabolite) \u2192 DGLA \u2192 PGE1 (anti-inflammatory) with less conversion to AA</li> <li>Used for: atopic dermatitis/eczema (mixed evidence), PMS and mastalgia (modest benefit), rheumatoid arthritis (modest joint pain reduction at 2\u20133 g/day GLA).</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Replacing saturated fat with LA (polyunsaturated fat) reduces LDL-C and total:HDL ratio \u2192 associated with reduced CVD risk in meta-analyses.</li> <li>AHA recommends replacing saturated fat with PUFA (primarily LA-rich oils) \u2014 projected to reduce CVD risk by ~20% for each 5% energy substitution.</li> </ul>"},{"location":"fatty_acids/linoleic_acid/#interactions","title":"Interactions","text":"Nutrient / Drug Effect ALA (Omega-3) Competitive substrate for \u03946-desaturase; high LA blunts ALA conversion to EPA/DHA; ideal LA:ALA ratio ~4:1 (typical Western diet is 15\u201320:1) Zinc Cofactor for \u03946-desaturase; zinc deficiency reduces DGLA and AA synthesis from LA Vitamin B6 PLP required for fatty acid desaturation/elongation steps Aspirin / NSAIDs Inhibit COX, reducing prostaglandin synthesis from AA \u2014 target of anti-inflammatory drugs downstream of LA pathway Corticosteroids Inhibit PLA2 \u2192 reduce AA release from membrane PL \u2192 broad suppression of AA-derived eicosanoids GLA supplements Increase DGLA; shifts AA:DGLA balance toward anti-inflammatory PGE1; theoretically synergistic with omega-3 EPA (both reduce pro-inflammatory AA eicosanoid output)"},{"location":"fatty_acids/linoleic_acid/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>LA itself is not typically supplemented \u2014 it is over-abundant in the typical Western diet</li> <li>GLA supplements (evening primrose oil, borage oil, black currant oil): Used to bypass the rate-limiting \u03946-desaturation step; doses of 2\u20133 g/day GLA for inflammatory conditions; generally safe; may modestly increase AA production at very high doses \u2014 combining with EPA may mitigate this</li> <li>CLA supplements (2\u20134 g/day): Mixed evidence for body composition; c9,t11-CLA isomer considered safer than t10,c12-CLA (the latter linked to insulin resistance at high doses)</li> <li>Reducing excess LA: For those on seed oil\u2013heavy diets, switching to olive oil (monosaturated), avocado oil, or reducing processed foods can substantially lower LA intake and improve omega-6:omega-3 balance</li> <li>Skin applications: LA-rich oils (rosehip oil, sunflower oil, evening primrose oil) topically applied improve acne-prone skin (acne lesions have low LA in surface sebum) and eczema (TEWL reduction)</li> </ul>"},{"location":"fatty_acids/oleic_acid/","title":"Oleic Acid \u2014 Omega-9","text":""},{"location":"fatty_acids/oleic_acid/#overview","title":"Overview","text":"<p>Oleic acid is the most abundant monounsaturated fatty acid (MUFA) in nature and in the human diet. It is an 18-carbon fatty acid with a single double bond in the cis configuration at the \u03949 position (18:1 n-9; \u03949). It is non-essential: the body synthesises oleic acid from stearic acid (18:0) via stearoyl-CoA desaturase-1 (SCD-1; \u03949-desaturase), and it is abundantly available from olive oil, avocado, and nuts. Oleic acid is the primary fatty acid of the Mediterranean diet and is associated with cardiovascular protection, improved insulin sensitivity, and anti-inflammatory effects. Unlike the physiologically polar essential fatty acids (omega-3/6), oleic acid's roles are primarily structural, metabolic, and energetic with important regulatory effects.</p> <ul> <li>Classification: Non-essential monounsaturated fatty acid (MUFA); Omega-9 (n-9)</li> <li>IUPAC shorthand: 18:1 (\u03949) or 18:1 n-9 or cis-9-octadecenoic acid</li> <li>Most abundant MUFA in the human diet and body</li> <li>Key characteristic: Predominant fatty acid of olive oil (~70\u201380%); cornerstone of the Mediterranean diet; endogenously synthesised</li> </ul>"},{"location":"fatty_acids/oleic_acid/#dietary-requirements","title":"Dietary Requirements","text":"Population Notes All adults No AI or RDA established \u2014 not dietary-essential; endogenous synthesis is sufficient General recommendation Replacing saturated and trans fats with MUFAs (including oleic acid) is recommended by AHA and EFSA <p>No established UL. Oleic acid is considered one of the most benign dietary fatty acids. Very high intakes may contribute to excess caloric intake (all fatty acids: 9 kcal/g).</p>"},{"location":"fatty_acids/oleic_acid/#functions","title":"Functions","text":"<ul> <li>Energy substrate: Oleic acid undergoes \u03b2-oxidation in mitochondria \u2014 a highly efficient fuel (yileds 146 ATP per molecule). MUFAs are the preferred fuel source for the heart and oxidative muscle fibres under aerobic conditions.</li> <li>Cell membrane structural component: Oleic acid is the most abundant MUFA in cell membrane phospholipids. Incorporated at both sn-1 and sn-2 positions of PC, PE, PI \u2014 influences membrane fluidity: more fluid than saturated FA but less fluid than PUFAs. Oleic acid incorporation displaces saturated FA and helps prevent over-rigidification of membranes.</li> <li>LDL remodelling \u2014 atherosclerosis protection: Oleic acid-enriched LDL particles are more resistant to oxidation than LA-enriched LDL. Ox-LDL is the initiating event in atherosclerotic plaque formation; MUFA-enriched membranes have fewer oxidisable double bonds. Oleic acid replaces saturated FA (lowers LDL-C) and omega-6 PUFA (reduces LDL oxidisability) simultaneously.</li> <li>PPAR\u03b1/\u03b3 ligand (gene regulation): Oleic acid activates PPAR\u03b1 (hepatic fat oxidation, VLDL reduction) and PPAR\u03b3 (adipogenesis, insulin sensitisation) \u2014 contributing to its metabolic effects on lipid homeostasis and insulin signalling.</li> <li>NF-\u03baB inhibition (anti-inflammatory): Oleic acid inhibits NF-\u03baB activation in endothelial cells and macrophages \u2192 reduces expression of VCAM-1, ICAM-1 (adhesion molecules), MCP-1, and IL-6 \u2192 reduces monocyte adhesion to endothelium (an early step in atherosclerosis).</li> <li>HER2/neu downregulation: In vitro, oleic acid downregulates the HER2/neu oncogene through a mechanism that potentiates trastuzumab (Herceptin) efficacy \u2014 suggests dietary oleic acid may have modest anti-tumour context in HER2+ breast cancer (human relevance unconfirmed).</li> <li>SCD-1 product (lipid homeostasis): SCD-1 maintains the ratio of saturated to monounsaturated FA in tissues. SCD-1 activity produces oleic acid from stearate and palmitoleic acid (16:1 n-7) from palmitate \u2014 critical for membrane fluidity homeostasis; excess dietary saturated FA without adequate SCD-1 activity \u2192 cell membrane rigidity, ER stress.</li> <li>Cholesterol esterification (LCAT substrate): Oleic acid is the primary fatty acid used by LCAT (lecithin-cholesterol acyltransferase) to esterify free cholesterol on HDL \u2192 cholesteryl oleate \u2014 the main cholesterol ester form transported in plasma; relevant to reverse cholesterol transport.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#metabolism","title":"Metabolism","text":"Step Details Endogenous synthesis Stearic acid (18:0) \u2192 Oleic acid (18:1 n-9) via SCD-1 (stearoyl-CoA desaturase-1; \u03949-desaturase); requires NADH, cytochrome b5, O\u2082; located in ER membrane Dietary absorption Absorbed as free FA or within TAG micelles; incorporated into chylomicrons \u2192 lymph \u2192 plasma; very high bioavailability TAG storage Major component of adipose triacylglycerol; adipose MUFA:PUFA ratio reflects dietary MUFA intake Membrane incorporation Incorporated at sn-1 and sn-2 of phospholipids; Lands cycle remodelling continuously adjusts composition \u03b2-Oxidation 18:1 requires one additional step (enoyl-CoA isomerase for the cis double bond) vs. saturated FA; net yield: ~146 ATP; slightly less efficient per unit vs. stearate per \u03b2-oxidation cycle due to isomerase step Elongation Oleic acid can be elongated to eicosenoic acid (20:1 n-9; gondoic acid) \u2014 minor pathway Mead acid (stress pathway) In PUFA deficiency, \u03946/\u03945-desaturase converts oleic acid \u2192 Mead acid (20:3 n-9); elevated Mead acid (and elevated Mead acid:AA ratio, the \"triene:tetraene ratio\") is a biochemical marker of essential fatty acid deficiency"},{"location":"fatty_acids/oleic_acid/#food-sources","title":"Food Sources","text":"Food Serving Oleic Acid (g) Olive oil (extra virgin) 1 tbsp (14 ml) ~10 g Avocado oil 1 tbsp ~10 g Hazelnut oil 1 tbsp ~10.6 g Avocado (whole) 1 medium (150 g) ~10 g Hazelnuts 28 g ~9 g Almonds 28 g ~8.5 g Macadamia nuts 28 g ~16.5 g Peanuts / peanut butter 28 g ~7 g Canola/rapeseed oil 1 tbsp ~8 g Beef fat (tallow) 1 tbsp ~5 g Eggs (whole) 1 large ~2 g <p>Olive oil is the richest and most studied source of oleic acid \u2014 extra-virgin olive oil (EVOO) also provides polyphenols (oleocanthal, oleuropein, hydroxytyrosol) that synergise with oleic acid's cardiovascular effects. Macadamia nuts are the richest whole-food source per gram.</p>"},{"location":"fatty_acids/oleic_acid/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"fatty_acids/oleic_acid/#mediterranean-diet-and-cardiovascular-disease","title":"Mediterranean Diet and Cardiovascular Disease","text":"<ul> <li>The PREDIMED trial (7,447 high-CV-risk adults; Spain): Mediterranean diet supplemented with EVOO (\u22654 tbsp/day) reduced MACE (MI, stroke, CV death) by 30% relative to low-fat control diet \u2014 one of the landmark dietary RCTs.</li> <li>Oleic acid + olive oil polyphenols together appear to drive the cardiovascular benefit (oleic acid alone vs. EVOO shows attenuation of some benefits in mechanistic studies).</li> <li>Mechanism: LDL oxidation resistance, NF-\u03baB inhibition, reduced platelet aggregation, improved endothelial function, blood pressure reduction, HDL raising.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#lipid-profile-effects","title":"Lipid Profile Effects","text":"<ul> <li>Replacing dietary saturated fat with oleic acid-rich MUFA:</li> <li>Lowers LDL-C (similar magnitude to omega-6 PUFA substitution)</li> <li>Raises or maintains HDL-C (better than PUFA substitution, which can lower HDL)</li> <li>Lowers TG (vs. carbohydrate substitution)</li> <li>Net result: improved total:HDL cholesterol ratio</li> </ul>"},{"location":"fatty_acids/oleic_acid/#insulin-sensitivity-and-type-2-diabetes","title":"Insulin Sensitivity and Type 2 Diabetes","text":"<ul> <li>Oleic acid-rich diets improve insulin sensitivity and reduce fasting glucose vs. saturated fat diets in multiple RCTs.</li> <li>Mediterranean diet (MUFA-rich) reduces T2DM incidence and improves glycaemic control in established T2DM.</li> <li>Mechanism: PPAR\u03b3 activation, reduced ER stress, improved adipocyte function.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#oleocanthal-evoo-phenolic-companion-to-oleic-acid","title":"Oleocanthal (EVOO Phenolic Companion to Oleic Acid)","text":"<ul> <li>Oleocanthal (a phenolic in EVOO) is a non-selective COX-1/COX-2 inhibitor \u2014 mimics ibuprofen's anti-inflammatory mechanism; the throat irritation from EVOO is the \"oleocanthal sensation\" (shared with oral ibuprofen).</li> <li>Synergises with oleic acid's anti-inflammatory (NF-\u03baB) effects \u2192 EVOO has broader anti-inflammatory action than refined oleic acid alone.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#essential-fatty-acid-deficiency-mead-acid-as-biomarker","title":"Essential Fatty Acid Deficiency (Mead Acid as Biomarker)","text":"<ul> <li>In PUFA deficiency (fat-free parenteral nutrition, malabsorption), \u03946-desaturase converts oleic acid \u2192 Mead acid (20:3 n-9).</li> <li>Triene:tetraene ratio = Mead acid (20:3 n-9) : AA (20:4 n-6) &gt;0.2 is the biochemical criterion for essential fatty acid deficiency \u2014 oleic acid metabolite elevates as PUFAs deplete.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#blood-pressure","title":"Blood Pressure","text":"<ul> <li>High MUFA diets (olive oil-based Mediterranean diet) reduce systolic and diastolic blood pressure in multiple RCTs; oleic acid may enhance endothelial NO production and reduce vascular smooth muscle cell signalling via NF-\u03baB.</li> </ul>"},{"location":"fatty_acids/oleic_acid/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Saturated fatty acids (SFA) Oleic acid replaced SFA in diet \u2192 lowers LDL-C; SFA and MUFA compete for membrane incorporation \u2014 higher MUFA:SFA diet improves membrane fluidity Omega-6 PUFA (LA) Both LA and oleic acid lower LDL-C; oleic acid raises HDL better than LA; LA-enriched LDL is more oxidisable than oleic acid\u2013enriched LDL EVOO polyphenols (oleocanthal, oleuropein, hydroxytyrosol) Synergistic anti-inflammatory and antioxidant effects with oleic acid; cardiovascular benefit of EVOO exceeds that of refined oleic acid alone Vitamin E (tocopherols) Olive oil naturally contains vitamin E (\u03b1-tocopherol); antioxidant protection for MUFA against peroxidation; although MUFAs are much more resistant to oxidation than PUFAs SCD-1 activity High carbohydrate/fructose intake upregulates SCD-1 \u2192 increases endogenous oleic acid synthesis (de novo lipogenesis \u2192 palmitate 16:0 \u2192 palmitoleate 16:1, and stearate \u2192 oleate); relevant in metabolic syndrome/NAFLD pathogenesis Trans oleic acid (elaidic acid; 18:1 t9) The trans isomer of oleic acid (18:1 t9; found in partially hydrogenated oils/industrial trans fats) has opposite cardiovascular effects \u2014 raises LDL, lowers HDL, promotes inflammation; completely distinct from cis oleic acid"},{"location":"fatty_acids/oleic_acid/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Oleic acid is not typically supplemented in isolation \u2014 olive oil, avocado oil, and nuts provide abundant dietary oleic acid</li> <li>Extra-virgin olive oil (\u22654 tbsp/day): The most evidence-based \"supplemental\" MUFA intervention; used at this dose in PREDIMED; provides oleic acid + polyphenols + vitamin E</li> <li>High-oleic sunflower/safflower oils: Bred varieties with &gt;80% oleic acid; very heat-stable (due to low PUFA, less prone to oxidative degradation); useful cooking oil alternative to seed oils; lacks the polyphenols of EVOO</li> <li>Avocado oil: High oleic acid + stable at high heat (smoke point ~270 \u00b0C) \u2192 excellent for cooking; lacks EVOO polyphenols</li> <li>For cooking: EVOO is appropriate for low-to-medium heat (saut\u00e9, roast); high-oleic sunflower or avocado oil for high-heat cooking</li> <li>Storing olive oil: Keep in dark glass, cool storage; oleic acid itself is oxidation-resistant but minor PUFAs and polyphenols in EVOO degrade with light, heat, and oxygen exposure</li> </ul>"},{"location":"gut_health/bifidobacterium/","title":"Bifidobacterium (Probiotic Genus)","text":""},{"location":"gut_health/bifidobacterium/#overview","title":"Overview","text":"<p>Bifidobacterium is a genus of Gram-positive, anaerobic, branched rod-shaped bacteria that are among the most abundant and clinically important members of the human gut microbiome. They are the dominant bacteria in the gut of breast-fed infants (comprising up to 90% of the colonic microbiome), where they play critical roles in immune education, colonisation resistance, and metabolism of human milk oligosaccharides (HMOs). Abundance declines with age, antibiotic use, and Western diet. Bifidobacterium ferments complex polysaccharides via the \"bifid shunt\" (fructose-6-phosphate phosphoketolase pathway), producing acetate and lactate without gas production \u2014 unlike many other fermenters.</p> <ul> <li>Classification: Actinobacteria \u2192 Actinomycetales \u2192 Bifidobacteriaceae</li> <li>Key species: B. longum, B. breve, B. infantis, B. bifidum, B. adolescentis, B. animalis subsp. lactis (DN-173 010, BB-12)</li> <li>Natural habitats: Large intestine (primary residence), breast milk (unique source for neonates), vagina</li> <li>Unique metabolism: Bifid shunt produces 3 mol acetate + 2 mol lactate per mol glucose \u2014 highly efficient, no CO\u2082/H\u2082 gas production</li> </ul>"},{"location":"gut_health/bifidobacterium/#mechanisms-of-action","title":"Mechanisms of Action","text":"Mechanism Details HMO / prebiotic fermentation B. infantis and B. longum encode glycoside hydrolase gene clusters for HMO degradation \u2192 acetate production \u2192 colonic acidification \u2192 colonisation resistance against pathogens Acetate production Acetate is the primary SCFA produced; crosses blood-brain barrier; protects against enteropathogenic E. coli O157:H7 by upregulating intestinal epithelial cell defence genes IgA stimulation Bifidobacterium uniquely enhances secretory IgA production \u2192 first-line mucosal immune defence; critical for neonatal immune education Regulatory T-cell induction Certain strains (B. infantis 35624) induce Tregs and IL-10 production \u2192 systemic anti-inflammatory effect Tight junction upregulation Increase claudin-1, occludin \u2192 reduce intestinal permeability; B. longum BB536 reduces LPS translocation Tryptophan metabolism B. longum produces indole-3-aldehyde and indole-3-lactic acid from tryptophan \u2192 AhR activation \u2192 mucosal homeostasis; serotonin precursor pathway GABA synthesis B. longum 1714 produces GABA \u2192 implicated in gut-brain axis effects on anxiety and stress"},{"location":"gut_health/bifidobacterium/#key-strains-and-evidence-base","title":"Key Strains and Evidence Base","text":"Strain Key Indications Evidence Level B. infantis 35624 (Align) IBS (all subtypes \u2014 pain, bloating, bowel habits), normalises IL-10/IL-12 ratio Strong \u2014 multiple RCTs vs. placebo B. animalis subsp. lactis DN-173 010 Constipation (transit time), IBS-C; found in Activia yogurt Strong for transit time B. animalis subsp. lactis BB-12 Infant diarrhoea, AAD, immune function, vaginal health Moderate\u2013Strong B. longum BB536 Seasonal allergies (pollen), IBS, upper respiratory infections Moderate B. longum 1714 Stress, anxiety, sleep quality (psychobiotic) Emerging \u2014 phase II RCT B. breve M-16V Preterm infant gut colonisation, NEC prevention Moderate B. longum + L. helveticus R0175* + R0052 Depression and anxiety scores (HADS) \u2014 \"psychobiotic\" combination Emerging"},{"location":"gut_health/bifidobacterium/#dietary-sources","title":"Dietary Sources","text":"Source Notes Yogurt with specific strains B. animalis subsp. lactis (Activia), B. longum (various labelled products); check strain labelling Kefir Multiple Bifidobacterium spp. present alongside Lactobacillus; fermentation varies by culture Breast milk Not a dietary source per se, but the primary natural vehicle for B. infantis EVC001 to neonates Cheese (soft fermented) Some aged cheeses contain viable Bifidobacterium if not heat-treated Supplements Most reliable source for therapeutic doses; single-strain or combination products widely available <p>Note: Bifidobacteria are strict anaerobes \u2014 they are more sensitive to oxygen and stomach acid than Lactobacillus; encapsulation technology significantly affects viability.</p>"},{"location":"gut_health/bifidobacterium/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"gut_health/bifidobacterium/#irritable-bowel-syndrome-ibs","title":"Irritable Bowel Syndrome (IBS)","text":"<ul> <li>B. infantis 35624 (Align): Landmark RCT (Whorwell et al., 2006) showed significant improvement in composite IBS symptoms vs. placebo at 10\u2078 dose; effect on pain, bloating, bowel habit normalisation</li> <li>Mechanism: normalises the IL-10/IL-12 ratio (immune dysregulation marker in IBS)</li> </ul>"},{"location":"gut_health/bifidobacterium/#infant-health-and-nec-prevention","title":"Infant Health and NEC Prevention","text":"<ul> <li>Dominant gut bacterium in breast-fed infants; formula-fed infants have substantially less Bifidobacterium, with consequences for immune development</li> <li>B. breve and B. infantis reduce the risk of necrotising enterocolitis (NEC) in preterm infants \u2014 one of the strongest probiotic evidence bases (Cochrane review)</li> </ul>"},{"location":"gut_health/bifidobacterium/#allergic-disease-and-atopy","title":"Allergic Disease and Atopy","text":"<ul> <li>B. longum BB536 (2 \u00d7 10\u2079 CFU/day): reduces nasal symptoms and medication use in Japanese cedar pollinosis (hay fever) \u2014 RCT evidence</li> <li>Colonisation with Bifidobacterium in early infancy (first month of life) associated with lower risk of atopic eczema and food allergy at 2 years</li> </ul>"},{"location":"gut_health/bifidobacterium/#psychobiotic-evidence-gut-brain-axis","title":"Psychobiotic Evidence (Gut-Brain Axis)","text":"<ul> <li>B. longum 1714: reduced cortisol and self-reported stress in healthy adults (NutraMed trial)</li> <li>Produces GABA and modulates HPA axis response; vagal nerve signalling implicated</li> </ul>"},{"location":"gut_health/bifidobacterium/#antibiotic-associated-diarrhoea","title":"Antibiotic-Associated Diarrhoea","text":"<ul> <li>B. animalis BB-12 in combination with LGG reduces AAD risk significantly in children</li> </ul>"},{"location":"gut_health/bifidobacterium/#interactions","title":"Interactions","text":"Factor Interaction Antibiotics Highly susceptible to most antibiotics \u2014 Bifidobacterium populations collapse during broad-spectrum antibiotic courses; supplementation during and after helps restore populations Prebiotic fibres (inulin, FOS, lactulose, GOS) Selectively fermented by Bifidobacterium \u2192 bifidogenic effect; key prebiotic partnership Human milk oligosaccharides (HMOs) B. infantis is uniquely adapted to metabolise HMOs via dedicated transport and enzyme systems \u2014 explains breast-fed infant gut dominance High animal protein diet Reduces Bifidobacterium abundance; high dietary fibre from plant foods restores it Proton pump inhibitors (PPIs) May increase survival of orally ingested bifidobacteria through stomach (reduced acid kill) Immunosuppressants Caution in severely immunocompromised (risk of bacterial translocation, though extremely rare)"},{"location":"gut_health/bifidobacterium/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dose: Clinical trials use 10\u2078\u201310\u00b9\u2070 CFU/day; B. infantis 35624 shows effect at 10\u2078 CFU (Align dose); higher doses are not necessarily more effective</li> <li>Stability: Obligate anaerobes \u2014 more oxygen-sensitive than Lactobacillus; microencapsulation or nitrogen-flushed packaging important; refrigeration generally required</li> <li>Strain specificity: B. infantis \u2260 B. longum \u2260 B. animalis; clinical indications are strain-specific; generic \"bifidobacterium\" labelling is inadequate for therapeutic use</li> <li>Synbiotic pairing: Prebiotic fibres (FOS, GOS, inulin) significantly enhance Bifidobacterium activity \u2014 combination products (synbiotics) show improved outcomes vs. probiotic alone in several trials</li> <li>Colonisation: Like Lactobacillus, Bifidobacterium supplementation does not lead to permanent colonisation in most adults; ongoing supplementation or prebiotic support required</li> <li>Neonatal use: B. infantis EVC001 with lactoferrin in breast milk supplementation protocol has shown near-complete restoration of healthy infant microbiome composition in formula-fed neonates</li> </ul>"},{"location":"gut_health/gut_brain_axis/","title":"The Gut-Brain Axis","text":""},{"location":"gut_health/gut_brain_axis/#overview","title":"Overview","text":"<p>The gut-brain axis (GBA) is a bidirectional, multi-channel communication network linking the central nervous system (CNS) with the enteric nervous system (ENS) and the gut microbiome. The ENS \u2014 an intrinsic neural network of approximately 500 million neurons embedded in the walls of the gastrointestinal tract \u2014 is often called the \"second brain.\" The GBA integrates neural, endocrine, immune, and microbial signals across the gut-brain highway, influencing mood, cognition, stress responses, appetite, pain perception, and gut motility. Disruptions in GBA signalling are increasingly implicated in psychiatric disorders (depression, anxiety), neurodegenerative diseases (Parkinson's, Alzheimer's), and functional GI disorders (IBS).</p> <ul> <li>Components: CNS (brain + spinal cord), ENS (myenteric + submucosal plexuses), vagus nerve (cranial nerve X), HPA axis, immune cells (gut-associated lymphoid tissue, GALT), gut microbiome</li> <li>Key neurotransmitters produced in gut: Serotonin (~90% of body's total), GABA, dopamine, norepinephrine, acetylcholine, neuropeptide Y, substance P</li> <li>Signalling directions: Bottom-up (gut \u2192 brain: vagal afferents carry ~80% of vagal fibres upward) and top-down (brain \u2192 gut: ANS efferents control motility, secretion, immune function)</li> </ul>"},{"location":"gut_health/gut_brain_axis/#communication-pathways","title":"Communication Pathways","text":""},{"location":"gut_health/gut_brain_axis/#1-neural-pathway-vagus-nerve","title":"1. Neural Pathway \u2014 Vagus Nerve","text":"<ul> <li>The vagus nerve (cranial nerve X) is the primary physical highway of the GBA; ~80% of its fibres are afferent (gut \u2192 brain) \u2014 conveying sensory information about luminal pH, distension, nutrient composition, and microbial metabolites</li> <li>Gut epithelial enteroendocrine cells (EECs) \u2014 especially enterochromaffin cells (ECCs) \u2014 act as chemosensors; they release serotonin (5-HT) \u2192 activates 5-HT\u2083 receptors on submucosal vagal afferent terminals \u2192 signals transmitted to nucleus tractus solitarius (NTS) in brainstem \u2192 thalamus \u2192 insula/cortex</li> <li>Vagotomy studies show that many probiotic-induced anxiolytic effects (e.g., L. rhamnosus JB-1) are abolished when the vagus nerve is severed \u2014 confirming its essential role</li> </ul>"},{"location":"gut_health/gut_brain_axis/#2-neuroendocrine-pathway-hpa-axis","title":"2. Neuroendocrine Pathway \u2014 HPA Axis","text":"<ul> <li>Hypothalamic-Pituitary-Adrenal (HPA) axis: Brain stress signals \u2192 CRH release from hypothalamic PVN \u2192 ACTH from anterior pituitary \u2192 cortisol from adrenal cortex \u2192 systemic stress response</li> <li>Cortisol affects gut permeability (increases \"leaky gut\"), reduces mucus production, alters microbiome composition (reduces Lactobacillus, increases gram-negative bacteria \u2192 more LPS)</li> <li>Gut microbiome modulates HPA axis: Germ-free (GF) animals show exaggerated HPA responses to stress; colonisation early in life normalises HPA axis reactivity (\"critical window\" hypothesis)</li> <li>Microbiome signals reach the HPA axis via vagal pathways, immune mediators (cytokines), and microbially-produced hormones/metabolites</li> </ul>"},{"location":"gut_health/gut_brain_axis/#3-immune-pathway-cytokines-and-galt","title":"3. Immune Pathway \u2014 Cytokines and GALT","text":"<ul> <li>The gut contains 70% of the body's immune cells (GALT: Peyer's patches, mesenteric lymph nodes, lamina propria lymphocytes, IELs)</li> <li>Gut dysbiosis \u2192 increased intestinal permeability \u2192 LPS (lipopolysaccharide) translocation \u2192 systemic endotoxaemia \u2192 activation of toll-like receptor 4 (TLR4) on macrophages \u2192 pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6) \u2192 cross BBB \u2192 activate microglia \u2192 neuroinflammation</li> <li>Neuroinflammation is now considered a core mechanism in depression, anxiety, and neurodegenerative diseases; vagus nerve has anti-inflammatory role (cholinergic anti-inflammatory pathway via \u03b17-nicotinic acetylcholine receptors on macrophages)</li> </ul>"},{"location":"gut_health/gut_brain_axis/#4-microbial-metabolite-pathway","title":"4. Microbial Metabolite Pathway","text":"Metabolite Source Brain Effect Short-chain fatty acids (SCFAs) Fermentation of dietary fibre by Bacteroides, Firmicutes, Bifidobacterium Butyrate: maintains BBB integrity (tight junction proteins), reduces neuroinflammation; propionate: appetite regulation (hypothalamus); acetate: crosses BBB, reduces appetite via hypothalamic signalling Indoles / Tryptophan metabolites Lactobacillus, Bifidobacterium \u2192 tryptophan \u2192 indole-3-aldehyde, ILA, IAA AhR activation in gut \u2192 IDO1 regulation \u2192 kynurenine pathway modulation \u2192 serotonin/quinolinic acid balance GABA B. longum, L. brevis, L. rhamnosus \u2192 GABA synthesis Vagal transmission of GABA signals (GABA itself poorly crosses BBB), but enteric GABA modulates local ENS-vagal signalling \u2192 anxiolytic effects Serotonin (5-HT) Gut ECCs (stimulated by microbiota SCFAs and bile acids) produce 90% of body's total serotonin Gut serotonin: regulates motility, nausea, pain; limited direct CNS entry, but gut-ENS serotonergic signalling drives vagal afferent input \u2192 mood-relevant CNS pathways D-lactic acid Certain strains of Lactobacillus In excess: encephalopathy in short bowel syndrome patients; not an issue at normal microbiome levels LPS (endotoxin) Gram-negative bacteria die/turnover Low-grade systemic LPS \u2192 TLR4 \u2192 cytokine storm \u2192 BBB disruption \u2192 neuroinflammation; \"metabolic endotoxaemia\""},{"location":"gut_health/gut_brain_axis/#5-enteroendocrine-signalling","title":"5. Enteroendocrine Signalling","text":"<ul> <li>GLP-1 (glucagon-like peptide-1): Released from L-cells in ileum/colon in response to nutrients and SCFAs \u2192 stimulates insulin secretion, reduces glucagon, slows gastric emptying, acts centrally to reduce appetite; GLP-1 receptors in vagus nerve and brainstem</li> <li>PYY (peptide YY): Released from L-cells \u2192 satiety signal via hypothalamic Y2 receptors; decreased in obesity</li> <li>Ghrelin: Produced in gastric fundus \u2192 hunger signal to hypothalamus (orexigenic); suppressed by feeding; altered by microbiome composition</li> <li>Cholecystokinin (CCK): Released from I-cells in duodenum in response to fat/protein \u2192 signals satiety via vagal CCK-A receptors</li> </ul>"},{"location":"gut_health/gut_brain_axis/#microbiome-mood-cognition-connection","title":"Microbiome-Mood-Cognition Connection","text":""},{"location":"gut_health/gut_brain_axis/#depression-and-anxiety","title":"Depression and Anxiety","text":"<ul> <li>Epidemiological: IBS patients have 2\u20133\u00d7 higher rates of depression/anxiety; treatment of gut dysbiosis sometimes improves psychiatric symptoms</li> <li>Mechanistic: Depressed patients show altered microbiome (reduced Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii; increased Alistipes, Blautia); serum kynurenine/tryptophan ratio elevated (IDO activation by chronic inflammation \u2192 serotonin depletion)</li> <li>Psychobiotic trials:</li> <li>L. helveticus R0052 + B. longum R0175 (3 \u00d7 10\u2079 CFU/day \u00d7 30 days): reduced HADS anxiety and depression scores, reduced urinary cortisol, improved memory (Messaoudi et al., 2011)</li> <li>B. longum 1714 \u00d7 4 weeks: reduced self-reported stress and anxiety in healthy volunteers; improved visuospatial memory; reduced cortisol awakening response</li> <li>B. infantis 35624: normalises IL-10/IL-12 ratio in healthy animals; reduces depressive-like behaviour in maternal separation model</li> </ul>"},{"location":"gut_health/gut_brain_axis/#the-gut-brain-skin-axis-extension","title":"The Gut-Brain-Skin Axis (Extension)","text":"<ul> <li>Emerging evidence: gut dysbiosis \u2192 systemic inflammation \u2192 skin conditions (acne, psoriasis, eczema)</li> <li>Probiotics \u2192 reduced skin inflammation via microbiome-immune-skin signalling cascade</li> <li>\"Gut-skin axis\" is under active research; not fully characterised</li> </ul>"},{"location":"gut_health/gut_brain_axis/#gut-brain-axis-in-disease-states","title":"Gut-Brain Axis in Disease States","text":"Disease/Condition GBA Relevance Parkinson's Disease \u03b1-synuclein aggregates found first in ENS (Braak staging); constipation precedes motor symptoms by 10\u201315 years; vagotomy reduces PD risk (retrograde Braak spread hypothesis) Alzheimer's Disease Altered microbiome (reduced SCFA-producing bacteria, increased LPS-producing gram-negatives); LPS found in amyloid plaques; GLP-1 receptor agonists (originally gut drugs) show neuroprotection in AD mouse models Multiple Sclerosis Gut Akkermansia muciniphila and Bacteroides fragilis reduced; increased gut permeability; immunomodulatory role of microbiome in MS progression under study Autism Spectrum Disorder (ASD) 30\u201370% of ASD children have GI symptoms; altered microbiome (reduced Bifidobacterium, elevated Clostridium); maternal Microbiome transfer models alter social behaviour in mice; mechanism not established in humans IBS Bidirectional: visceral hypersensitivity driven by aberrant CNS pain processing + dysbiosis + gut permeability; psychological stress exacerbates IBS via corticotropin-releasing factor (CRF) \u2192 mast cell activation \u2192 serotonin release \u2192 altered motility"},{"location":"gut_health/gut_brain_axis/#therapeutic-targets","title":"Therapeutic Targets","text":"Intervention Mechanism Evidence Psychobiotics (specific probiotic strains) Restore microbiome \u2192 normalise HPA axis, reduce neuroinflammation, modulate NTs Phase II RCTs; small effect sizes; promising but not clinical standard of care Prebiotics (FOS, inulin, GOS) Enhance SCFA-producing bacteria \u2192 BBB integrity, vagal signalling, anti-inflammatory Growing evidence; GOS reduces anxiety in healthy adults (Schmidt et al., 2015) Low-FODMAP diet Reduces fermentation substrates \u2192 reduces visceral distension and pain in IBS; may reduce Bifidobacterium short-term Strong for IBS symptom relief; microbiome consequences need monitoring Mediterranean diet High fibre, polyphenols, olive oil \u2192 promotes Faecalibacterium prausnitzii, Akkermansia, reduces systemic inflammation Associated with lower depression risk; PREDIMED-Plus sub-studies ongoing Vagus nerve stimulation (VNS) Non-invasive or implanted; activates cholinergic anti-inflammatory pathway FDA-approved for epilepsy, depression; transcutaneous VNS under investigation for IBS, IBD, depression Faecal Microbiota Transplant (FMT) Donor microbiome reshapes recipient GBA Established for recurrent CDI; emerging evidence for IBS, IBD, and even psychiatric outcomes (phase I)"},{"location":"gut_health/gut_brain_axis/#key-research-figures","title":"Key Research Figures","text":"<ul> <li>John Cryan &amp; Ted Dinan (University College Cork): Coined \"psychobiotic\"; major RCTs on gut-brain-mood connection</li> <li>Emeran Mayer (UCLA): Pioneered brain imaging in IBS; author of The Mind-Gut Connection</li> <li>Rob Knight (UCSD): American Gut Project; population-level microbiome-mood correlations</li> </ul>"},{"location":"gut_health/gut_brain_axis/#interactions-and-modulators","title":"Interactions and Modulators","text":"Factor Effect on GBA Psychological stress Activates HPA axis \u2192 cortisol \u2192 altered motility, increased permeability, dysbiosis; bidirectional with gut symptoms Sleep deprivation Alters microbiome composition within 2 days; reduces Lactobacillus; increases inflammatory markers Exercise Increases Akkermansia muciniphila and F. prausnitzii abundance; SCFA production\u2191; anti-neuroinflammatory via BDNF upregulation Antibiotics Devastate microbiome diversity \u2192 impaired SCFA production \u2192 BBB vulnerability, increased neuroinflammation risk; recovery takes 6\u201312 months Proton pump inhibitors (PPIs) Increase gastric pH \u2192 altered duodenal/jejunal microbiome \u2192 dysbiosis cascade; associated with increased C. difficile risk Dietary emulsifiers (CMC, polysorbate-80) Disturb mucus layer \u2192 dysbiosis \u2192 increased intestinal permeability and low-grade inflammation in mouse and human studies Fermented foods 10-week high-fermented food diet (Sonnenburg lab, Cell 2021) \u2192 increased microbiome diversity, reduced 19 inflammatory proteins (including IL-17A, IL-6) \u2192 supports GBA homeostasis"},{"location":"gut_health/lactobacillus/","title":"Lactobacillus (Probiotic Genus)","text":""},{"location":"gut_health/lactobacillus/#overview","title":"Overview","text":"<p>Lactobacillus is a genus of Gram-positive, facultatively anaerobic, rod-shaped bacteria that produce lactic acid as their primary fermentation end-product. They are among the most clinically studied and commercially used probiotics. Historically a single large genus, Lactobacillus was reclassified in 2020 into 23 genera; many familiar species now belong to renamed genera (e.g., Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus), though the old names remain in widespread use. Lactobacillus species are naturally found in the human gastrointestinal tract, vagina, and oral cavity, and are major components of fermented foods.</p> <ul> <li>Classification: Firmicutes \u2192 Bacilli \u2192 Lactobacillales \u2192 Lactobacillaceae</li> <li>Key species: L. acidophilus, L. rhamnosus GG (LGG), L. plantarum, L. casei, L. reuteri, L. fermentum, L. helveticus, L. brevis</li> <li>Natural habitats: Small intestine (especially L. acidophilus), colon, vagina, oral cavity, fermented foods</li> <li>GRAS / QPS status: Generally Recognized As Safe (FDA) / Qualified Presumption of Safety (EFSA) for most food-grade strains</li> </ul>"},{"location":"gut_health/lactobacillus/#mechanisms-of-action","title":"Mechanisms of Action","text":"Mechanism Details Competitive exclusion Adhere to intestinal epithelium via surface proteins (S-layer, pili, mucus-binding proteins) \u2192 occupy receptor sites \u2192 prevent pathogen colonisation Lactic acid production Lower intestinal pH \u2192 inhibits acid-sensitive pathogens (Salmonella, Clostridium, E. coli) \u2192 creates selective environment for commensal bacteria Bacteriocin production Produce narrow-spectrum antimicrobial peptides (nisin, lactacin, reuterin) targeting closely related Gram-positive pathogens Short-chain fatty acid production Ferment dietary fibre \u2192 acetate, propionate, butyrate \u2192 local colonocyte fuel, anti-inflammatory signalling, gut barrier maintenance Epithelial barrier reinforcement Upregulate tight junction proteins (claudin-1, occludin, ZO-1) \u2192 reduce paracellular permeability (\"leaky gut\") Immune modulation Interact with Toll-like receptors (TLR2, TLR4) on dendritic cells and macrophages \u2192 shift Th1/Th2 balance; strain-specific regulatory T-cell induction (LGG \u2192 IL-10, TGF-\u03b2) Mucin stimulation Upregulate MUC2 and MUC3 gene expression \u2192 thickened mucus layer \u2192 additional pathogen exclusion barrier"},{"location":"gut_health/lactobacillus/#key-strains-and-evidence-base","title":"Key Strains and Evidence Base","text":"Strain Key Indications Evidence Level L. rhamnosus GG (LGG) Acute diarrhoea, antibiotic-associated diarrhoea (AAD), rotavirus diarrhoea in children, C. difficile prevention Strong \u2014 multiple RCTs, meta-analyses; NNT ~7 for AAD L. acidophilus NCFM Lactose intolerance (produces \u03b2-galactosidase), IBS-D, vaginal microbiome support Moderate L. plantarum 299v IBS (bloating, flatulence, pain), post-antibiotic gut restoration Moderate \u2014 several RCTs L. reuteri DSM 17938 Infant colic (significant reduction in crying time), H. pylori eradication adjunct, bone density (produces reuterin) Moderate\u2013Strong L. casei Shirota Traveller's diarrhoea prevention, immune function in elderly Moderate L. helveticus R0052 Anxiety and mood (combined with B. longum R0175), bone mineral density Emerging"},{"location":"gut_health/lactobacillus/#dietary-sources","title":"Dietary Sources","text":"Source Notable Strains/Notes Yogurt L. bulgaricus, L. acidophilus, L. casei (added cultures); labelled \"live and active cultures\" if \u226510\u2077 CFU/g Kefir Diverse cocktail including multiple Lactobacillus spp. + yeasts; higher probiotic density than yogurt Sauerkraut L. plantarum, L. brevis, L. fermenti; heat-treatment destroys bacteria \u2014 choose unpasteurised Kimchi L. kimchii, L. plantarum, L. brevis; rich probiotic diversity Miso L. acidophilus, L. casei (lactic acid fermentation); note high sodium Tempeh Fermented soy; primarily Rhizopus mold but may contain lactobacilli Sourdough bread L. sourdoughii, L. sanfranciscensis; baking kills bacteria \u2014 benefit is from metabolites (organic acids, pre-digested gluten)"},{"location":"gut_health/lactobacillus/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"gut_health/lactobacillus/#antibiotic-associated-diarrhoea-aad","title":"Antibiotic-Associated Diarrhoea (AAD)","text":"<ul> <li>Meta-analyses (Cochrane 2019): Lactobacilli (especially LGG and L. acidophilus) reduce AAD risk by ~60%; NNT \u2248 7</li> <li>Best started concurrently with antibiotic course; take 2 hours apart from antibiotic dose</li> <li>Evidence strongest in children; also significant in adults</li> </ul>"},{"location":"gut_health/lactobacillus/#clostridioides-difficile-infection-cdi","title":"Clostridioides difficile Infection (CDI)","text":"<ul> <li>LGG and L. casei reduce primary CDI risk; insufficient evidence for recurrent CDI treatment</li> <li>Not a replacement for vancomycin/fidaxomicin; used as adjunct</li> </ul>"},{"location":"gut_health/lactobacillus/#irritable-bowel-syndrome-ibs","title":"Irritable Bowel Syndrome (IBS)","text":"<ul> <li>Effect is strain-specific; L. plantarum 299v and LGG have the most RCT support</li> <li>Global symptom improvement, particularly bloating and flatulence; effects modest vs. placebo</li> </ul>"},{"location":"gut_health/lactobacillus/#vaginal-health","title":"Vaginal Health","text":"<ul> <li>L. crispatus, L. jensenii, L. gasseri dominate a healthy vaginal microbiome (Lactobacillus-dominated CST I, II, III)</li> <li>Depletion associated with bacterial vaginosis (BV); oral and vaginal L. rhamnosus GR-1 + L. reuteri RC-14 reduce BV recurrence</li> </ul>"},{"location":"gut_health/lactobacillus/#infant-health","title":"Infant Health","text":"<ul> <li>L. reuteri DSM 17938 reduces crying time in colic by ~1 hour/day (Cochrane meta-analysis)</li> <li>LGG reduces incidence of atopic eczema when given to mothers in late pregnancy (NEJM 2001 and replication studies)</li> </ul>"},{"location":"gut_health/lactobacillus/#interactions","title":"Interactions","text":"Factor Interaction Antibiotics Most antibiotics can kill Lactobacillus strains; separate dosing by 2 hours (take probiotic mid-meal interval); resume full course after antibiotic completion Prebiotic fibres (FOS, inulin) Selectively stimulate Lactobacillus growth (synbiotic effect) \u2192 enhanced colonisation and metabolic activity Immunosuppressive drugs Exercise caution in severely immunocompromised patients (transplant, high-dose steroids, haematological malignancy) \u2014 rare risk of bacteraemia Acid-suppressing drugs (PPIs) Higher gastric pH may improve Lactobacillus survival through stomach transit Dietary fat High saturated fat diet reduces Lactobacillus abundance; Mediterranean diet supports it"},{"location":"gut_health/lactobacillus/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dose: Most clinical trials use 10\u2078\u201310\u00b9\u2070 CFU/day (1\u201310 billion CFU); higher is not necessarily better \u2014 strain-specificity matters more than dose</li> <li>Viability: Check for \"live and active cultures at time of consumption\" labelling \u2014 not just manufacture date</li> <li>Refrigeration: Many Lactobacillus supplements require refrigeration; some microencapsulated formulations are shelf-stable</li> <li>Duration: Benefits are typically transient \u2014 colonisation is not permanent; continuous use required for sustained effects</li> <li>Strain specificity: Do not extrapolate findings from LGG to other Lactobacillus products; effects are strain- and dose-specific</li> <li>Safety: Extremely safe in healthy individuals; rare adverse events (bacteraemia) confined to critically ill or severely immunocompromised patients</li> </ul>"},{"location":"gut_health/prebiotic_fibers/","title":"Prebiotic Fibers: Inulin, FOS &amp; Pectin","text":""},{"location":"gut_health/prebiotic_fibers/#overview","title":"Overview","text":"<p>Prebiotics are selectively fermented dietary components that confer a health benefit on the host through modulation of the gut microbiota composition and/or activity. The term was formally defined by Gibson &amp; Roberfroid (1995) and updated by the ISAPP (2017) to encompass non-digestible compounds beyond just fibre. The three major prebiotic fibers covered here \u2014 Inulin, Fructooligosaccharides (FOS), and Pectin \u2014 are the best-characterised and most clinically studied. All three resist digestion in the small intestine and are fermented in the colon, but they differ substantially in structure, fermentation kinetics, and microbiome effects.</p> <ul> <li>Classification: Non-digestible dietary fibers (soluble fiber category)</li> <li>Shared mechanism: Escape small intestine absorption \u2192 reach colon intact \u2192 fermented by specific bacteria \u2192 produce SCFAs and other metabolites \u2192 confer health benefits</li> <li>Key fermentation products: Butyrate, propionate, acetate (short-chain fatty acids)</li> <li>Selectivity criteria (ISAPP): Must selectively stimulate specific beneficial bacteria (not all colonic bacteria equally)</li> </ul>"},{"location":"gut_health/prebiotic_fibers/#inulin","title":"Inulin","text":""},{"location":"gut_health/prebiotic_fibers/#structure-and-sources","title":"Structure and Sources","text":"<p>Inulin is a polysaccharide composed of fructose chains (\u03b2-1,2 linkages) terminated by a glucose residue; chain length (degree of polymerisation, DP) ranges from DP 2 to &gt;60. It is extracted primarily from chicory root (the main commercial source, 41\u201348% of dry weight). Inulin-type fructans are also found in Jerusalem artichoke, dahlia tubers, globe artichoke, garlic, leek, onion, asparagus, and banana.</p> Property Details Chain length Long-chain inulin: DP 10\u201360 + (slower fermentation, more distal colon) Fermentation rate Slower than FOS \u2192 ferments more distally \u2192 more even butyrate distribution across colon Bifidogenic effect Strongly and selectively stimulates Bifidobacterium and Faecalibacterium prausnitzii Commercial forms Orafti HP, Fibersol-2; widely used in functional food industry Caloric value ~1.5 kcal/g (vs. 4 kcal/g for digestible carbohydrates) \u2014 useful in calorie-reduced products"},{"location":"gut_health/prebiotic_fibers/#health-effects","title":"Health Effects","text":"<ul> <li>Laxation: Increases stool frequency and bulk; evidence stronger than for short-chain FOS at equal doses</li> <li>Calcium absorption: Long-chain inulin (8\u201315 g/day) significantly enhances colonic calcium absorption \u2014 meta-analysis confirms 20% increase in Ca absorption; relevant for bone health</li> <li>Lipid metabolism: Modest reductions in fasting TG and total cholesterol in RCTs with doses \u226510 g/day; likely via propionate-mediated hepatic lipogenesis inhibition</li> <li>Glucose control: Reduces postprandial glucose (GLP-1 secretion via L-cell stimulation); modest effect at 8\u201315 g/day</li> </ul>"},{"location":"gut_health/prebiotic_fibers/#fructooligosaccharides-fos-oligofructose","title":"Fructooligosaccharides (FOS / Oligofructose)","text":""},{"location":"gut_health/prebiotic_fibers/#structure-and-sources_1","title":"Structure and Sources","text":"<p>FOS are short-chain inulin-type fructans with DP 2\u20138 (most commonly DP 3\u20135). Oligofructose refers to the inulin fraction with DP 2\u20138 produced by partial enzymatic hydrolysis of inulin. FOS can also be synthesised from sucrose using fructosyltransferases. Found naturally in: onion (~2\u20136% fw), leek, asparagus, garlic, artichoke, banana; chicory root produces both inulin and FOS.</p> Property Details Chain length Short (DP 2\u20138) \u2192 rapid fermentation, primarily in proximal colon Fermentation rate Fast \u2192 significant gas production (H\u2082, CO\u2082) \u2192 flatulence and bloating dose-dependently Bifidogenic effect Potent Bifidobacterium and Lactobacillus stimulator; classic \"prebiotic substrate\" Sweetness ~30\u201350% sweetness of sucrose \u2192 used as sugar replacer in functional foods Tolerance threshold GI symptoms begin at ~5\u20138 g/day in sensitive individuals; well tolerated up to 4\u20135 g/day"},{"location":"gut_health/prebiotic_fibers/#health-effects_1","title":"Health Effects","text":"<ul> <li>Microbiome modulation: Most consistent bifidogenic effect of any prebiotic; even 4 g/day for 2 weeks significantly increases Bifidobacterium counts</li> <li>Immune function: Bifidobacterium stimulation \u2192 increased sIgA; reduced frequency of respiratory infections in elderly (6 g/day FOS RCT)</li> <li>Bowel function: Softens stool, increases frequency; useful in functional constipation</li> <li>Glycaemic index: Low GI (\u22481); blunts postprandial glucose response when used as sucrose replacer</li> </ul>"},{"location":"gut_health/prebiotic_fibers/#pectin","title":"Pectin","text":""},{"location":"gut_health/prebiotic_fibers/#structure-and-sources_2","title":"Structure and Sources","text":"<p>Pectin is a complex heteropolysaccharide primarily composed of galacturonic acid residues (\u03b1-1,4 linked), with regions of rhamnogalacturonan decorated with arabinose, galactose, and other sugars. It is found in the cell walls and middle lamella of terrestrial plants. Commercially extracted from apple pomace and citrus peel. Two major forms: high-methoxyl pectin (HM, &gt;50% methylated, forms gels at low pH with sugar) and low-methoxyl pectin (LM, gels with Ca\u00b2\u207a ions, preferred for food and pharmaceutical applications).</p> Property Details Molecular weight 50,000\u2013150,000 Da (high MW forms more viscous gels) Fermentation rate Moderate-to-slow; fermented throughout the colon; promotes diverse microbiota Microbiome effect Less strictly bifidogenic than inulin/FOS; promotes Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides spp. \u2014 associated with gut barrier integrity Viscosity Forms highly viscous gel in GI lumen \u2192 physical cholesterol-lowering mechanism Key sources Apples, citrus peel, apricot, plum, guava; apple pectin from highest DRI consideration"},{"location":"gut_health/prebiotic_fibers/#health-effects_2","title":"Health Effects","text":"<ul> <li>Cholesterol reduction: ~10\u201315% LDL reduction with 6\u201315 g/day citrus/apple pectin; mechanism: bile acid sequestration (similar to cholestyramine but much weaker), reduced micellar cholesterol absorption \u2014 FDA approved \"may reduce risk of heart disease\" claim</li> <li>Postprandial glycaemia: Viscous gel slows gastric emptying \u2192 blunts glucose and insulin spikes; 10 g pectin reduces postprandial glucose by ~20% in T2DM patients</li> <li>Satiety: Reduces gastric emptying rate \u2192 prolonged satiety; PYY and GLP-1 secretion stimulates</li> <li>Colon cancer: Galacturonic acid residues and SCFA production from pectin fermentation; in vitro studies show pectin-derived oligomers bind and inhibit galectin-3 (metastasis promoter) \u2014 phase I/II clinical trial data emerging</li> <li>Diarrhoea: High-pectin apple sauce historically used for diarrhoea (BRAT diet rationale); absorbs water, adds bulk, mild antimicrobial effect</li> </ul>"},{"location":"gut_health/prebiotic_fibers/#comparison-table","title":"Comparison Table","text":"Feature Inulin FOS/Oligofructose Pectin Chain length Long (DP 10\u201360+) Short (DP 2\u20138) Heteropolymer (MW 50\u2013150 kDa) Primary fermentation site Distal colon Proximal colon Throughout colon Bifidogenic selectivity High Very high Moderate (Akkermansia, F. prausnitzii) Flatulence potential Moderate High Low\u2013moderate Cholesterol effect Modest Modest Strong (bile acid sequestration) Calcium absorption Significant \u2191 Moderate \u2191 Minimal Commercial dose studied 5\u201315 g/day 4\u201310 g/day 6\u201315 g/day Key food sources Chicory, artichoke Onion, garlic, leek Apples, citrus peel"},{"location":"gut_health/prebiotic_fibers/#clinical-interactions","title":"Clinical Interactions","text":"Interaction Details Probiotic synergy (synbiotics) FOS/inulin + Bifidobacterium or Lactobacillus = synbiotic \u2192 better colonisation and metabolic activity than either alone Medications (sulfonylureas, metformin) Prebiotic-mediated GLP-1 increase + glucose lowering \u2192 may potentiate hypoglycaemic drugs; monitor blood glucose Anticoagulants Pectin may slightly reduce warfarin bioavailability by viscous-gel-mediated bile sequestration; monitor INR if high-dose pectin supplementation begun FODMAP sensitivity FOS and inulin are high-FODMAP \u2014 contraindicated during low-FODMAP elimination phase for IBS; reintroduced in FODMAP rechallenge phase Phenolic absorption Pectin and inulin reduce absorption of some polyphenols in the small intestine but may increase colonic availability; net effect on antioxidant status unclear"},{"location":"gut_health/prebiotic_fibers/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Inulin: 5\u201315 g/day; start low (3 g/day) and titrate up over 2\u20133 weeks to minimise flatulence; long-chain HP inulin better tolerated and more distal than short-chain Orafti GR</li> <li>FOS: 4\u20138 g/day for bifidogenic effect; split dose across meals reduces GI symptoms; taste is mildly sweet \u2014 can replace 30\u201350% sugar</li> <li>Pectin: 6\u201315 g/day for cholesterol reduction; gel-forming in liquid \u2014 mix thoroughly; apple pectin supplements (450 mg capsules) provide lower doses requiring multiple servings</li> <li>Tolerability tip: Any fermentable fibre taken rapidly in high doses causes bloating/flatulence; always introduce gradually</li> <li>FODMAP note: Avoid high-dose FOS/inulin during IBS symptom management; pectin is generally better tolerated in IBS</li> </ul>"},{"location":"macronutrients/carbohydrates/","title":"Carbohydrates","text":""},{"location":"macronutrients/carbohydrates/#overview","title":"Overview","text":"<p>Carbohydrates are the body's primary and most readily available energy source, providing 4 kcal per gram. They are organic compounds composed of carbon, hydrogen, and oxygen (CH\u2082O)\u2099, synthesised by plants through photosynthesis and consumed as starches, sugars, and non-digestible fibres. The brain is almost entirely dependent on glucose derived from carbohydrates, consuming ~120 g/day at rest. Carbohydrates drive metabolic processes, spare protein from catabolism, regulate fat metabolism, and serve as the substrate for glycogen synthesis in liver and muscle.</p> <ul> <li>Classification: Macronutrient; 4 kcal/g</li> <li>Storage form: Glycogen (liver ~100 g, muscle ~400 g)</li> <li>Primary fuel for: Brain, red blood cells (obligate glucose users), renal medulla, exercising muscle</li> <li>Key property: Only macronutrient that can fuel anaerobic (glycolytic) metabolism; fastest ATP production rate of the three macronutrients</li> </ul>"},{"location":"macronutrients/carbohydrates/#classification-of-carbohydrates","title":"Classification of Carbohydrates","text":"Category Examples Digestibility Monosaccharides Glucose, Fructose, Galactose Immediate absorption Disaccharides Sucrose (glu+fru), Lactose (glu+gal), Maltose (glu+glu) Digested at brush border Oligosaccharides FOS, GOS, Raffinose Mostly fermented (prebiotic) Polysaccharides \u2014 starchy Amylose, Amylopectin, Glycogen Digested by amylases Polysaccharides \u2014 non-starchy (fibre) Cellulose, Pectin, Inulin, Beta-glucan Not digested; fermented or excreted"},{"location":"macronutrients/carbohydrates/#dietary-requirements","title":"Dietary Requirements","text":"Population Recommended Carbohydrate Intake Adults (general) 130 g/day (EAR; minimum to sustain brain glucose needs without gluconeogenesis) Acceptable Macronutrient Distribution Range (AMDR) 45\u201365% of total energy intake (DRI, IOM) Athletes (moderate exercise) 5\u20137 g/kg/day Athletes (high-intensity/endurance) 6\u201310 g/kg/day Dietary fibre (adults) AI: 25 g/day (women), 38 g/day (men); most adults consume &lt;15 g/day <p>No established UL for carbohydrates, but excess added sugar intake is associated with obesity, dyslipidaemia (hypertriglyceridaemia), dental caries, and non-alcoholic fatty liver disease (NAFLD). WHO recommends free sugars &lt;10% of energy (ideally &lt;5%).</p>"},{"location":"macronutrients/carbohydrates/#glycemic-index-and-glycemic-load","title":"Glycemic Index and Glycemic Load","text":"Concept Definition Range Glycemic Index (GI) Rate at which 50 g available carbohydrate raises blood glucose relative to pure glucose (GI=100) Low: &lt;55, Medium: 55\u201369, High: \u226570 Glycemic Load (GL) GI \u00d7 (carbohydrate content per serving \u00f7 100); accounts for portion size Low: &lt;10, Medium: 11\u201319, High: \u226520 <p>GL is more clinically meaningful than GI: A watermelon has a high GI (~72) but a low GL (~4 per typical serving) because a standard portion has little actual carbohydrate. White rice: GI ~72, GL ~29 per cup \u2014 a high-GL food.</p> <p>Factors that lower GI: - Presence of fat, protein, or fibre (slows gastric emptying) - Intact grain structure (whole grains vs. flour) - Acidity (vinegar, sourdough fermentation) - Resistant starch (cooked-and-cooled potato/rice) - Al dente cooking (less gelatinised starch = slower digestion)</p>"},{"location":"macronutrients/carbohydrates/#dietary-fibre","title":"Dietary Fibre","text":"Type Examples Primary Action Soluble fibre Pectin, beta-glucan, inulin, psyllium Viscous gel formation \u2192 slows glucose absorption \u2192 lowers LDL-C; fermented by gut microbiota \u2192 SCFAs Insoluble fibre Cellulose, wheat bran, lignin Increases stool bulk; accelerates colonic transit; reduces colorectal cancer risk Resistant starch (RS) Cooked-and-cooled potato/rice, unripe banana, legumes Behaves as prebiotic fibre; produces butyrate \u2192 colonocyte fuel <p>Short-chain fatty acids (SCFAs) from fibre fermentation: - Butyrate: Primary fuel for colonocytes; anti-inflammatory; may protect against colorectal cancer - Propionate: Hepatic gluconeogenesis substrate; reduces hepatic lipogenesis - Acetate: Systemic energy substrate; may suppress appetite via GPR43</p>"},{"location":"macronutrients/carbohydrates/#metabolism","title":"Metabolism","text":"Step Details Digestion Salivary and pancreatic \u03b1-amylase hydrolyse starch \u2192 maltose, maltotriose; brush-border enzymes (maltase, sucrase, lactase) hydrolyse disaccharides \u2192 monosaccharides Absorption Glucose and galactose: SGLT1 (sodium-glucose cotransporter 1, active); Fructose: GLUT5 (passive facilitated diffusion); all exit basolateral side via GLUT2 \u2192 portal vein Hepatic processing Fructose \u2192 fructose-1-phosphate \u2192 trioses (DHAP, glyceraldehyde) \u2192 glycolysis/de novo lipogenesis/gluconeogenesis; Galactose \u2192 galactose-1-phosphate \u2192 UDP-galactose \u2192 glycogen Glycolysis Glucose \u2192 2\u00d7 pyruvate; net yield 2 ATP (anaerobic) or entry into TCA cycle via acetyl-CoA \u2192 30\u201332 ATP (aerobic) Glycogen synthesis Liver: glucose \u2192 glycogen (glycogenesis); regulated by insulin (activates glycogen synthase); Muscle: stores glycogen exclusively for local use Glycogen breakdown Glucagon, epinephrine \u2192 glycogenolysis \u2192 glucose-1-phosphate \u2192 glucose-6-phosphate (muscle cannot release free glucose; liver can via glucose-6-phosphatase) Gluconeogenesis When glycogen depleted: liver/kidney synthesise glucose from lactate, alanine, glycerol \u2014 preserves brain glucose during fasting"},{"location":"macronutrients/carbohydrates/#food-sources","title":"Food Sources","text":"Food Serving Total Carbs (g) Fibre (g) GI White rice (cooked) 1 cup (186 g) 45 0.6 72 Brown rice (cooked) 1 cup (195 g) 45 3.5 50 Oats (rolled, dry) 40 g 27 4 55 Whole wheat bread 1 slice (30 g) 15 1.9 69 Lentils (cooked) 1 cup (198 g) 40 15.6 32 Banana (medium) 118 g 27 3.1 51 Apple 182 g 25 4.4 36 Sweet potato (baked) 130 g 26 3.8 63 White potato (baked) 173 g 37 3.8 78 Quinoa (cooked) 1 cup (185 g) 39 5.2 53"},{"location":"macronutrients/carbohydrates/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"macronutrients/carbohydrates/#diabetes-and-glycaemic-control","title":"Diabetes and Glycaemic Control","text":"<ul> <li>In type 2 diabetes, impaired insulin-mediated GLUT4 translocation in muscle and adipose tissue leads to hyperglycaemia. Dietary carbohydrate type and amount are primary modulators of postprandial glucose.</li> <li>Low-carbohydrate diets (&lt;26% energy from CHO) consistently reduce HbA1c in T2DM; very low-carbohydrate (ketogenic, &lt;50 g/day) diets can achieve near-normal glycaemia but require careful medication adjustment.</li> <li>Fructose overconsumption: High fructose intake (especially from HFCS in SSBs) bypasses PFK-1 regulation \u2192 unregulated hepatic lipogenesis \u2192 hypertriglyceridaemia, hepatic steatosis (NAFLD), hyperuricaemia.</li> </ul>"},{"location":"macronutrients/carbohydrates/#metabolic-syndrome","title":"Metabolic Syndrome","text":"<ul> <li>Excess refined carbohydrate intake raises postprandial insulin \u2192 promotes fat storage, suppresses lipolysis \u2192 central adiposity, insulin resistance cycle.</li> <li>High-carbohydrate, low-fat diets consistently raise triglycerides and lower HDL-C (particularly when refined CHO replaces dietary fat).</li> </ul>"},{"location":"macronutrients/carbohydrates/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Soluble fibre (beta-glucan, psyllium): Binds bile acids \u2192 increases hepatic LDL-receptor expression \u2192 lowers LDL-C. 3 g/day oat beta-glucan is sufficient for a clinically significant LDL-C reduction (~5\u201310%).</li> <li>Whole grain consumption is associated with reduced CVD risk in epidemiological studies.</li> </ul>"},{"location":"macronutrients/carbohydrates/#athletic-performance","title":"Athletic Performance","text":"<ul> <li>Glycogen depletion (after ~90\u2013120 min high-intensity exercise) causes fatigue; carbohydrate loading pre-race (supercompensation) maximises glycogen stores.</li> <li>Intra-exercise carbohydrate (30\u201360 g/hour): glucose+fructose mixture at a 2:1 ratio uses both SGLT1 and GLUT5 transporters \u2192 total intestinal absorption up to 90 g/hour vs 60 g/hour with glucose alone.</li> </ul>"},{"location":"macronutrients/carbohydrates/#lactose-intolerance","title":"Lactose Intolerance","text":"<ul> <li>Deficiency of brush-border lactase \u2192 undigested lactose reaches colon \u2192 fermentation \u2192 gas (H\u2082, CO\u2082, CH\u2084), bloating, diarrhoea. Prevalence: ~65\u201370% of adults globally; highest in East Asian, West African, and Middle Eastern populations.</li> </ul>"},{"location":"macronutrients/carbohydrates/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Insulin Carbohydrate (especially high-GI) is the primary insulin secretagogue; glycaemic index, fibre content, and portion size all modulate insulin response Dietary fat Fat slows gastric emptying \u2192 blunts postprandial glucose and insulin peaks; fat + CHO combination lowers the GI of the overall meal Protein Protein independently stimulates insulin secretion (particularly leucine, BCAAs); protein + CHO at a meal \u2192 greater insulin response than CHO alone (useful post-exercise for glycogen resynthesis) Dietary fibre Soluble fibre: lowers glycaemic response of co-ingested carbohydrates; insoluble fibre: negligible effect on glycaemic response Chromium Chromium potentiates insulin signalling (component of chromodulin); deficiency impairs glucose tolerance Magnesium Required for all phosphate-transfer reactions in glycolysis and glycogen synthesis; magnesium deficiency is associated with insulin resistance Vitamin B1 (Thiamine) Rate-limiting cofactor for pyruvate dehydrogenase (pyruvate \u2192 acetyl-CoA) and \u03b1-ketoglutarate dehydrogenase; thiamine deficiency blocks aerobic carbohydrate metabolism \u2192 lactic acidosis Resistant starch (cooled) Retrograded (resistant) starch increases after cooking and cooling \u2014 lower glycaemic response than freshly cooked starch; enhances colonic fermentation and SCFA production"},{"location":"macronutrients/carbohydrates/#supplementation-practical-notes","title":"Supplementation / Practical Notes","text":"<ul> <li>No supplement needed for most people \u2014 dietary carbohydrates are universally available; focus should be on food quality (whole grains, legumes, fruits, vegetables) rather than supplementation</li> <li>Sports carbohydrate supplements: Glucose polymers (maltodextrin) + fructose gels/drinks during endurance events; rapid gastric emptying; useful when solid food is impractical</li> <li>Psyllium husk (5\u201310 g/day with water): Evidence-based soluble fibre supplement for LDL-C reduction and glycaemic improvement; start low to avoid flatulence</li> <li>Inulin/FOS (3\u20138 g/day): Prebiotic fibre supplement for gut microbiome support; excessive doses cause GI discomfort</li> <li>Resistant starch (raw potato/banana starch): Emerging interest as prebioitc; 15\u201330 g/day studied for SCFA-mediated gut health benefits; tolerance varies</li> <li>Very low carbohydrate / ketogenic diets: Below ~50 g/day, hepatic ketogenesis produces ketone bodies (\u03b2-hydroxybutyrate, acetoacetate) \u2192 brain adapts over 3\u20134 weeks to ketone oxidation; reduces need for gluconeogenesis; medical supervision warranted for T2DM patients on insulin/sulfonylureas</li> </ul>"},{"location":"macronutrients/dietary_fats/","title":"Dietary Fats","text":""},{"location":"macronutrients/dietary_fats/#overview","title":"Overview","text":"<p>Dietary fats (lipids) are the most energy-dense macronutrient at 9 kcal per gram \u2014 more than double carbohydrates or protein. They are essential for fat-soluble vitamin absorption (A, D, E, K), cell membrane integrity, hormone synthesis (steroid hormones, eicosanoids), thermal insulation, and organ cushioning. Fats are classified by the degree of saturation of their fatty acid chains \u2014 a fundamental determinant of their physical properties, metabolic fate, and health effects. The narrative around dietary fat has shifted dramatically: dietary fat quality (type) matters far more than total fat quantity.</p> <ul> <li>Classification: Macronutrient; 9 kcal/g</li> <li>Storage form: Triacylglycerols (TAGs) in adipose tissue \u2014 essentially unlimited energy reserve</li> <li>Essential fats: Linoleic acid (LA; 18:2 n-6, Omega-6) and Alpha-linolenic acid (ALA; 18:3 n-3, Omega-3) are the only truly essential dietary fats \u2014 all others can be synthesised</li> <li>Fat-soluble vitamin carrier: Required for absorption, transport, and storage of vitamins A, D, E, and K</li> </ul>"},{"location":"macronutrients/dietary_fats/#classification-of-dietary-fats","title":"Classification of Dietary Fats","text":"Category Structure Sources Primary Health Effect Saturated fatty acids (SFA) No double bonds; straight-chain (solid at room temp) Butter, ghee, lard, coconut oil, palm oil, fatty meat, full-fat dairy Raise LDL-C (primarily LDL-P); neutral to slightly positive on HDL-C; heterogeneous by chain length Monounsaturated fatty acids (MUFA) One double bond (cis); liquid at room temp Olive oil, avocado, nuts (hazelnuts, almonds, cashews), canola oil Lower LDL-C; neutral or raise HDL-C; anti-inflammatory Polyunsaturated fatty acids (PUFA) \u2014 n-6 2+ double bonds; Omega-6 family Sunflower, corn, soybean, safflower oils; seeds Lower LDL-C; pro- and anti-inflammatory (LA); n-6:n-3 ratio matters Polyunsaturated fatty acids (PUFA) \u2014 n-3 2+ double bonds; Omega-3 family Fatty fish (EPA/DHA), flaxseed, chia, walnuts (ALA) Anti-inflammatory; lower TG; reduce CVD events Trans fatty acids (TFA) Double bonds in trans configuration Partially hydrogenated oils (industrial TFA); ruminant TFA (CLA in dairy, beef) Industrial TFA: raise LDL-C, lower HDL-C, strongly pro-inflammatory; ruminant TFA (CLA): neutral to beneficial"},{"location":"macronutrients/dietary_fats/#saturated-fatty-acids-chain-length-differences","title":"Saturated Fatty Acids \u2014 Chain-Length Differences","text":"Chain length Example Effect on lipids Short-chain (C4\u2013C8) Butyric (C4), Caprylic (C8) Minimal LDL effect; absorbed via portal vein (not chylomicron); energy use \u2248 carbohydrate Medium-chain (C10\u2013C12) Capric (C10), Lauric (C12) Lauric acid raises both LDL-C and HDL-C; large component of coconut oil; raises TC:HDL ratio vs MUFA Long-chain (C14\u2013C18) Myristic (C14), Palmitic (C16), Stearic (C18) Palmitic: most LDL-raising SFA; Stearic: neutral (rapidly converted to oleic acid via SCD-1); Myristic: strongly raises LDL-C Very long-chain (&gt;C18) Arachidic (C20) Minor dietary amounts; minor LDL-raising effect <p>Stearic acid (C18:0) is a notable exception \u2014 it does not raise LDL-C because it is efficiently desaturated to oleic acid (18:1) via SCD-1 in the liver. Basis for interest in high-stearate dark chocolate (cocoa butter is ~34% stearate).</p>"},{"location":"macronutrients/dietary_fats/#dietary-requirements","title":"Dietary Requirements","text":"Population Fat Recommendation Adults (AMDR) 20\u201335% of total energy (IOM/DRI) Saturated fat &lt;10% of energy (WHO, AHA, EFSA); AHA recommends &lt;7% for CV risk Trans fat (industrial) &lt;1% of energy (WHO); ideally as low as possible; many countries have mandated elimination Omega-6 (LA) AI 11\u201312 g/day (women), 14\u201317 g/day (men) Omega-3 (ALA) AI 1.1 g/day (women), 1.6 g/day (men) EPA + DHA (omega-3) No formal RDA; 250\u2013500 mg/day EPA+DHA recommended by AHA, EFSA, and WHO for cardiovascular health Minimum fat intake &lt;20% fat risks inadequate fat-soluble vitamin absorption; very low-fat diets not recommended"},{"location":"macronutrients/dietary_fats/#metabolism","title":"Metabolism","text":"Step Details Digestion Lingual and gastric lipase initiate TAG hydrolysis; pancreatic lipase (with colipase) is the primary TAG hydrolase in the duodenum; bile salts emulsify fat \u2192 micelles \u2192 lipase access Absorption Free fatty acids (FFA) + monoacylglycerols + cholesterol absorbed into enterocytes; long-chain FA \u2192 re-esterified into TAG \u2192 chylomicrons \u2192 lymph (thoracic duct \u2192 subclavian vein); medium-chain FA (C8\u2013C12) \u2192 portal vein directly Chylomicron processing Lipoprotein lipase (LPL) on capillary walls hydrolyses chylomicron TAG \u2192 FFA released to adipose/muscle; chylomicron remnants \u2192 liver VLDL/LDL/HDL cycle Liver packages TAG + cholesterol \u2192 VLDL \u2192 IDL \u2192 LDL (cholesterol-rich); LDL-R (LDL receptor) on liver/peripheral cells clears LDL; HDL participates in reverse cholesterol transport \u03b2-Oxidation FA activated to acyl-CoA \u2192 carnitine shuttle into mitochondria \u2192 \u03b2-oxidation \u2192 acetyl-CoA \u2192 TCA cycle; long-chain FA requires carnitine (CACT/CPT1/CPT2 system) Ketogenesis In fasting/low-carb: excess acetyl-CoA \u2192 HMG-CoA \u2192 \u03b2-hydroxybutyrate + acetoacetate (ketone bodies) \u2014 alternative fuel for brain, heart, skeletal muscle Steroid hormone synthesis Cholesterol \u2192 pregnenolone \u2192 all steroid hormones (cortisol, aldosterone, testosterone, oestrogen, progesterone, vitamin D) Eicosanoid synthesis AA (n-6) \u2192 COX \u2192 prostaglandins, thromboxanes (pro-inflammatory); EPA (n-3) \u2192 COX \u2192 3-series prostaglandins (less active); DHA \u2192 resolvins, protectins (anti-inflammatory resolution)"},{"location":"macronutrients/dietary_fats/#food-sources","title":"Food Sources","text":"Food Serving Total Fat (g) SFA (g) MUFA (g) PUFA (g) Olive oil (EVOO) 1 tbsp (14 g) 14 2 10 1.5 Coconut oil 1 tbsp (14 g) 14 12 0.8 0.2 Butter 1 tbsp (14 g) 11.5 7.3 3 0.4 Avocado (1 medium) 150 g 22 3.2 14.7 2.7 Salmon (cooked) 100 g 13 3 4 5 (incl. 2 EPA+DHA) Walnuts 28 g 18.5 1.7 2.5 13.4 (mainly ALA) Almonds 28 g 14 1.1 9 3.5 Egg (whole) 1 large 5 1.6 2 0.7 Cheddar cheese 30 g 9.4 5.9 2.7 0.3 Ground beef (80% lean) 100 g 20 7.7 8.7 0.8"},{"location":"macronutrients/dietary_fats/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"macronutrients/dietary_fats/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>The relationship between dietary fat and CVD is complex: replacing SFA with PUFA (especially n-6 LA) reduces CVD events (strong RCT evidence; PREDIMED, DELTA, Finnish Mental Hospital Study). The composition of the replacement matters \u2014 PUFA &gt; MUFA &gt; refined carbohydrate for CVD risk reduction when replacing SFA.</li> <li>Trans fatty acids (industrial): Strongest dietary predictor of CHD; raise LDL-C, lower HDL-C, increase Lp(a), increase markers of inflammation. Industrial TFA have been effectively eliminated from most food supplies (FDA GRAS status revoked 2015; WHO REPLACE initiative).</li> <li>LDL-C vs LDL particle number (LDL-P): SFAs primarily raise small dense LDL particles (most atherogenic); polyunsaturated fats shift LDL to larger, more buoyant particles; LDL particle number is a more powerful CVD predictor than LDL-C alone (NMR lipoprofile).</li> </ul>"},{"location":"macronutrients/dietary_fats/#omega-3-and-cardiovascular-risk","title":"Omega-3 and Cardiovascular Risk","text":"<ul> <li>EPA + DHA (preformed marine omega-3s): Reduce TG by 20\u201350% at 2\u20134 g/day (approved indication for icosapentaenoic acid \u2014 Vascepa \u2014 at 4 g/day for hypertriglyceridaemia in REDUCE-IT trial: 25% reduction in MACE).</li> <li>Mechanism: Reduces VLDL synthesis, increases TG clearance via LPL, anti-inflammatory, antiarrhythmic, reduces platelet aggregation.</li> <li>ALA (plant-based omega-3): Conversion to EPA is ~5\u201310%; to DHA ~0\u20134% \u2014 insufficient to meet needs without marine sources or supplementation.</li> </ul>"},{"location":"macronutrients/dietary_fats/#fat-soluble-vitamin-malabsorption","title":"Fat-Soluble Vitamin Malabsorption","text":"<ul> <li>Dietary fat intake &lt;20 g/day impairs absorption of vitamins A, D, E, and K; fat malabsorption (Crohn's, cystic fibrosis, cholestatic liver disease, short bowel syndrome) \u2192 clinical deficiencies of all four fat-soluble vitamins.</li> <li>Adding fat to meals with fat-soluble supplements/foods significantly improves absorption (e.g., vitamin D with a fat-containing meal doubles absorption vs. fasting).</li> </ul>"},{"location":"macronutrients/dietary_fats/#non-alcoholic-fatty-liver-disease-nafld","title":"Non-Alcoholic Fatty Liver Disease (NAFLD)","text":"<ul> <li>Excess fructose (via de novo lipogenesis) and excess saturated fat are the primary dietary drivers of hepatic fat accumulation.</li> <li>Mediterranean diet (high MUFA/n-3, low SFA, high fibre) is the most evidence-based dietary intervention for NAFLD.</li> <li>Omega-3 supplementation reduces hepatic fat content in NAFLD (multiple RCTs) but does not consistently improve fibrosis scores.</li> </ul>"},{"location":"macronutrients/dietary_fats/#gallstone-disease","title":"Gallstone Disease","text":"<ul> <li>Very low-fat diets paradoxically increase gallstone risk \u2014 gallbladder requires fat stimulation (via CCK) to contract and empty; stasis \u2192 cholesterol gallstone formation.</li> <li>Moderate fat intake (especially MUFA) stimulates adequate gallbladder motility.</li> </ul>"},{"location":"macronutrients/dietary_fats/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Fat-soluble vitamins (A, D, E, K) Dietary fat required for micelle formation and absorption; inadequate dietary fat \u2192 deficiencies even with adequate vitamin intake; fat-rich meals improve vitamin D absorption 2-fold Omega-6:Omega-3 ratio Western diet ratio ~15\u201320:1 (excess n-6); optimal estimated at 4:1 or below for anti-inflammatory balance; excess n-6 competes with n-3 for \u03946-desaturase and membrane incorporation Bile acids Bile (from cholesterol) essential for fat digestion; enterohepatic recycling; dietary fibre binds bile acids \u2192 excretion \u2192 increased LDL-receptor expression (LDL-C lowering) Carbohydrates (refined) Replacing dietary fat with refined carbohydrate raises TG, lowers HDL-C, raises small dense LDL particles \u2014 net adverse effect on lipid profile despite lowering total LDL-C Vitamin E Tocopherols protect PUFAs from oxidation in membranes and food; high PUFA diets increase vitamin E requirement; sunflower, safflower oils (high LA) naturally contain \u03b1-tocopherol Carnitine Transports long-chain FA across inner mitochondrial membrane for \u03b2-oxidation; carnitine deficiency impairs fat oxidation (clinical carnitine deficiency is rare, primarily in haemodialysis patients) Lipoprotein lipase (LPL) Insulin activates LPL \u2192 clears TG from circulation; LPL activity is reduced in insulin resistance \u2192 hypertriglyceridaemia; omega-3 FA and fibrates increase LPL activity Cholesterol absorption (dietary) Dietary cholesterol has modest effect on blood cholesterol in most people (hyperresponders: ~25% of population); phytosterols (plant sterols) competitively inhibit cholesterol absorption \u2192 lower LDL-C by 8\u201310% at 2 g/day"},{"location":"macronutrients/dietary_fats/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Fish oil (EPA+DHA): Most evidence-based omega-3 supplement; 1\u20134 g EPA+DHA/day; reduces TG; reduces CVD risk in high-risk patients; prescription-grade icosapentaenoic acid (Vascepa) at 4 g/day has RCT evidence for MACE reduction; common side effect: fishy burps (mitigated by enteric-coated formulas, taking with meals, freezing capsules)</li> <li>Algal oil (DHA): Vegan alternative, derived from the marine algae that fish consume; provides preformed DHA (~250\u2013500 mg/serve); less EPA than fish oil; appropriate for vegans/vegetarians</li> <li>MCT oil (medium-chain triglycerides): C8 (caprylic) and C10 (capric) glycerides; rapidly absorbed via portal vein, do not require carnitine for mitochondrial entry; used in ketogenic diets and as an easily digested fat for malabsorption; C8 most ketogenic; GI intolerance at doses &gt;30 g/day when titrated rapidly</li> <li>Conjugated linoleic acid (CLA): Ruminant-derived TFA (natural); modestly reduces body fat in RCTs (~0.09 kg/week at 3.2 g/day vs placebo \u2014 small but consistent); found naturally in dairy and beef</li> <li>Phytosterol/stanol supplements: 2 g/day reduces LDL-C by 8\u201310%; available in fortified margarines, capsules; most effective when taken with fat-containing meals; do not use in phytosterolaemia (rare genetic condition) or in children except under medical supervision</li> <li>Krill oil: Contains EPA+DHA in phospholipid form (potentially better bioavailability vs ethyl ester fish oil); also contains astaxanthin (antioxidant carotenoid); smaller capsule; higher cost per gram EPA+DHA vs fish oil</li> </ul>"},{"location":"macronutrients/proteins/","title":"Proteins","text":""},{"location":"macronutrients/proteins/#overview","title":"Overview","text":"<p>Proteins are the most structurally diverse macronutrient, serving as the building blocks for virtually every functional and structural component in the body \u2014 from enzymes and hormones to immune antibodies and contractile muscle fibres. They are polymers of amino acids linked by peptide bonds, providing 4 kcal/gram. Unlike carbohydrates and fats, the body has no dedicated protein storage depot \u2014 \"stored\" protein exists functionally (as muscle, organ tissue, enzymes), making adequate daily intake essential. Dietary protein quality depends on both amino acid composition (completeness) and digestibility.</p> <ul> <li>Classification: Macronutrient; 4 kcal/g</li> <li>Building blocks: 20 standard amino acids (9 essential, 7 conditionally essential, 4 non-essential)</li> <li>Key roles: Structural (collagen, actin, myosin), catalytic (enzymes), regulatory (hormones, receptors), immune (antibodies, complement), transport (haemoglobin, albumin), signalling (growth factors, cytokines)</li> <li>Nitrogen balance: Unique among macronutrients in containing nitrogen (~16% by mass); nitrogen balance is the index of protein adequacy</li> </ul>"},{"location":"macronutrients/proteins/#complete-vs-incomplete-proteins","title":"Complete vs Incomplete Proteins","text":"Category Definition Examples Complete protein Provides all 9 essential amino acids in sufficient amounts relative to needs Eggs, meat, poultry, fish, dairy, soy, quinoa, buckwheat Incomplete protein Low in one or more essential amino acids (limiting amino acid) Most plant proteins: wheat (low Lys), rice (low Lys), legumes (low Met/Cys), corn (low Lys, Trp) Complementary proteins Two or more incomplete proteins that together supply all EAAs Rice + legumes (classic combination); wheat + dairy <p>The concept of \"protein combining at every meal\" is outdated \u2014 the body maintains an amino acid pool; complementary proteins consumed within the same day are sufficient. However, whole-day adequacy of all EAAs matters.</p>"},{"location":"macronutrients/proteins/#protein-quality-metrics","title":"Protein Quality Metrics","text":"Metric Description Strengths / Weaknesses DIAAS (Digestible Indispensable Amino Acid Score) Score for each EAA: (digestible dietary AA / reference AA pattern) \u00d7 100; uses ileal digestibility Current gold standard (WHO 2013); accounts for intestinal bacterial use of AA PDCAAS (Protein Digestibility-Corrected Amino Acid Score) Older version; uses faecal digestibility, scores capped at 1.0 Can overestimate plant protein quality; being replaced by DIAAS BV (Biological Value) Proportion of absorbed nitrogen retained by the body Measures utilisation, not digestibility; rarely used clinically now <p>High DIAAS foods (&gt;100% = exceeds reference): Eggs (~113), whey protein (~109), whole milk (~114), beef (~111) Moderate DIAAS: Soy protein isolate (~98), pea protein (~75\u201382) Lower DIAAS: Wheat (~40\u201345), rice (~59), most plant proteins</p>"},{"location":"macronutrients/proteins/#dietary-requirements","title":"Dietary Requirements","text":"Population Protein Requirement Adults (sedentary) 0.8 g/kg/day (RDA; minimum to prevent deficiency in 97.5% of population) AMDR 10\u201335% of total energy intake Older adults (&gt;65 years) 1.0\u20131.2 g/kg/day (PROT-AGE recommendation); anabolic resistance requires higher EAA to stimulate MPS Resistance training athletes 1.6\u20132.2 g/kg/day for muscle accretion (meta-analytic ceiling ~1.62 g/kg/day for MPS; higher intakes during caloric restriction may prevent muscle loss) Endurance athletes 1.2\u20131.6 g/kg/day Pregnancy Add ~25 g/day above baseline (RDA ~1.1 g/kg/day) Lactation Add ~25 g/day above baseline Critical illness / trauma 1.2\u20132.0 g/kg/day (ASPEN/SCCM guidelines)"},{"location":"macronutrients/proteins/#metabolism","title":"Metabolism","text":"Step Details Digestion \u2014 stomach Pepsinogen \u2192 pepsin (HCl activation); pepsin cleaves Phe, Tyr, Trp peptide bonds \u2192 polypeptides; denatures proteins (exposing peptide bonds) Digestion \u2014 small intestine Pancreatic proteases: trypsin, chymotrypsin, elastase (endopeptidases); carboxypeptidases A and B (exopeptidases); brush-border peptidases \u2192 di/tripeptides and free AAs Absorption Free AAs: specific transporters (e.g., EAAT for acidic, CAT-1 for basic, SNAT for neutral AAs); Di/tripeptides: PepT1 cotransporter (H\u207a-dependent) \u2014 more efficient than free AA uptake Amino acid pool Absorbed AAs \u2192 portal vein \u2192 liver \u2192 distributed to systemic AA pool; liver extracts ~60% of first-pass AAs for hepatic protein synthesis Muscle protein synthesis (MPS) Leucine is the primary anabolic signal \u2192 activates mTORC1 \u2192 phosphorylates S6K1 and 4E-BP1 \u2192 increased ribosomal translation of muscle proteins; ~3 g leucine per meal is the threshold dose Muscle protein breakdown (MPB) Ubiquitin-proteasome system (main); autophagy-lysosome pathway; regulated by insulin (suppresses MPB), IGF-1, testosterone, cortisol (promotes MPB during stress/fasting) Transamination Excess AAs: amino group transferred to \u03b1-keto acids (via ALT, AST); produces glutamate + new \u03b1-keto acid; carbon skeletons enter glycolysis or TCA Urea cycle Ammonia (toxic) \u2192 carbamoyl phosphate \u2192 citrulline \u2192 argininosuccinate \u2192 arginine \u2192 urea; urea excreted renally; requires adequate hydration Glucogenic vs ketogenic Glucogenic AAs (Ala, Gln, Asp, Pro, etc.): carbon skeletons \u2192 glucose precursors; Ketogenic AAs (Leu, Lys): \u2192 acetyl-CoA/acetoacetate \u2192 ketone bodies; Both (Phe, Tyr, Trp, Ile): yield both"},{"location":"macronutrients/proteins/#food-sources","title":"Food Sources","text":"Food Serving Protein (g) DIAAS / Notes Chicken breast (cooked) 100 g 31 ~110; complete, high leucine Eggs (whole) 2 large 13 ~113; reference standard protein Greek yoghurt (plain, full-fat) 200 g 17 ~114 (milk-based); high in casein Whey protein (powder) 30 g 24\u201325 ~109; fast-digesting; ideal post-exercise Tuna (canned in water) 100 g 26 ~120; high BV, complete Salmon (cooked) 100 g 25 Complete; EPA/DHA bonus Tofu (firm) 100 g 8 ~79 (soy); complete but lower digestibility Lentils (cooked) 200 g 18 Low Met; incomplete; high fibre Quinoa (cooked) 185 g 8 ~76; complete plant protein; all EAAs Black beans (cooked) 1 cup (172 g) 15 Low Met; pair with grains Pea protein (powder) 30 g 21 ~75\u201382; low Met; better than older estimates"},{"location":"macronutrients/proteins/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"macronutrients/proteins/#sarcopenia-and-ageing","title":"Sarcopenia and Ageing","text":"<ul> <li>Muscle mass peaks in the 3rd decade; loss accelerates after age 60 at ~1\u20132%/year. Anabolic resistance in older adults means more protein (and especially leucine) is needed per meal to achieve the same MPS response as younger adults.</li> <li>Leucine threshold rises in ageing \u2014 0.4 g leucine per kg (vs ~0.24 g/kg in young adults) to maximally stimulate MPS.</li> <li>Practical threshold: 30\u201340 g high-quality protein per meal in older adults; 3\u20134 meals/day; combined with resistance exercise.</li> </ul>"},{"location":"macronutrients/proteins/#protein-and-bone-health","title":"Protein and Bone Health","text":"<ul> <li>The \"acid-ash hypothesis\" (protein acidifies urine and leaches calcium from bones) is largely refuted. Higher protein intakes are protective of bone density, particularly in older adults (reduces risk of hip fracture).</li> <li>IGF-1 (stimulated by dietary protein) promotes osteoblast activity; calcium absorption from the gut is enhanced by protein.</li> </ul>"},{"location":"macronutrients/proteins/#kidney-disease","title":"Kidney Disease","text":"<ul> <li>In established CKD (eGFR &lt;30 mL/min without dialysis), protein restriction (0.6\u20130.8 g/kg/day) may slow progression by reducing urea load and glomerular hyperfiltration. Dietitian-supervised management required.</li> <li>In dialysis patients, protein requirements increase to 1.2\u20131.4 g/kg/day to compensate for dialysate losses.</li> <li>High protein intake does not cause CKD in healthy individuals with normal kidneys \u2014 epidemiological and RCT evidence does not support this concern in the absence of existing renal disease.</li> </ul>"},{"location":"macronutrients/proteins/#weight-management","title":"Weight Management","text":"<ul> <li>Protein has the highest thermic effect of food (TEF): 20\u201330% of ingested protein energy is expended in digestion, absorption, and metabolism (vs ~5\u201310% for CHO, ~0\u20133% for fat).</li> <li>Protein is the most satiating macronutrient per calorie \u2014 increases GLP-1, PYY, CCK secretion; suppresses ghrelin.</li> <li>High-protein hypocaloric diets preferentially preserve lean mass during weight loss.</li> </ul>"},{"location":"macronutrients/proteins/#phenylketonuria-pku","title":"Phenylketonuria (PKU)","text":"<ul> <li>Autosomal recessive deficiency of phenylalanine hydroxylase (PAH) \u2192 phenylalanine accumulates \u2192 neurotoxicity (intellectual disability, seizures).</li> <li>Management: lifelong low-phenylalanine diet + tyrosine supplementation (becomes essential); sapropterin (BH4 cofactor) for BH4-responsive PKU.</li> </ul>"},{"location":"macronutrients/proteins/#interactions","title":"Interactions","text":"Nutrient / Factor Effect Leucine Primary trigger of mTORC1-mediated MPS; 2.5\u20133 g leucine per meal recommended to maximise MPS (present in ~30 g whey or ~3 eggs) Carbohydrates (post-exercise) CHO + protein together post-exercise: CHO raises insulin (suppresses MPB) while protein supplies AAs (raises MPS); combined &gt; either alone for net protein balance in initial recovery Vitamin B6 (Pyridoxine) Cofactor for all aminotransferases (transamination) and amino acid decarboxylases; B6 requirement scales with protein intake (~0.016 mg per gram protein) Iron Animal protein enhances non-haem iron absorption (the \"meat factor\" / flesh factor); haem iron in meat is absorbed via separate pathway (HCP-1) independently of pH Zinc Phytate in plant proteins chelates zinc \u2192 lower bioavailability from plant sources; animal protein increases zinc absorption; protein intake correlates with zinc status Calcium Protein increases urinary calcium excretion (hypercalciuria) \u2014 historically misinterpreted as bone loss; net effect on bone is neutral to positive (protein raises IGF-1 and intestinal calcium absorption) Insulin / IGF-1 Protein (especially BCAAs, Arg) stimulates insulin secretion; dietary protein correlates with IGF-1 \u2014 IGF-1 mediates anabolic effects on muscle and bone Kidney function (CKD) In CKD, restrict protein to reduce urea/creatinine load and slow progression; in dialysis, increase protein to compensate for losses"},{"location":"macronutrients/proteins/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Whey protein: Derived from milk (cheese-making byproduct); fast-digesting (~90 min to peak plasma AA); highest DIAAS food protein; ideal post-exercise; ~24 g protein/30 g serve; contains \u03b2-lactoglobulin (high leucine), \u03b1-lactalbumin, lactoferrin</li> <li>Casein protein: Slow-digesting (clots in stomach \u2192 sustained AA release over 5\u20137 h); ideal pre-sleep protein (40 g casein pre-sleep increases overnight MPS in RCTs); lower leucine/g vs whey</li> <li>Soy protein isolate: Closest plant protein to animal protein in quality (DIAAS ~98); complete AA profile; contains isoflavones (weak oestrogen-like activity \u2014 not a clinical concern at food amounts)</li> <li>Pea protein: Popular vegan alternative; DIAAS ~75\u201382; low in Met/Cys; usually combined with rice protein to complete the AA profile; well tolerated</li> <li>Creatine (related): Not a protein supplement but supports protein synthesis indirectly by enhancing phosphocreatine resynthesis \u2192 more training volume \u2192 greater MPS stimulus</li> <li>EAA/BCAA supplements: Useful in clinical settings (pre/post-operative, cancer cachexia) or for those unable to meet protein targets through food; whole protein foods are superior for muscle-building in healthy individuals (contain micronutrients, phytonutrients, varied AAs)</li> <li>Protein timing: Post-exercise protein (within ~2 h) is beneficial; total daily protein intake is the strongest determinant of MPS over time; \"anabolic window\" is wider than once thought</li> </ul>"},{"location":"macronutrients/water/","title":"Water","text":""},{"location":"macronutrients/water/#overview","title":"Overview","text":"<p>Water is the most abundant compound in the human body, comprising ~60% of body weight in adult men and ~55% in adult women (varies by body composition \u2014 lean tissue is ~73% water, adipose tissue ~10%). Although not a source of calories, water is universally classified as an essential nutrient: survival without it is limited to days, compared to weeks without food. Water serves as the universal biological solvent, enabling all biochemical reactions, nutrient transport, thermoregulation, joint lubrication, waste elimination, and cellular homeostasis. Hydration status profoundly affects cognitive function, physical performance, kidney function, and gut health.</p> <ul> <li>Classification: Essential nutrient; 0 kcal; sometimes classified as the \"forgotten macronutrient\"</li> <li>Body distribution: Intracellular fluid (ICF) ~60% of total body water (TBW); Extracellular fluid (ECF) ~40% TBW (plasma ~7.5%, interstitial fluid ~25%, transcellular fluids ~7.5%)</li> <li>Regulatory hormones: ADH (vasopressin), aldosterone, ANP (atrial natriuretic peptide), renin-angiotensin-aldosterone system (RAAS)</li> <li>Unique property: High heat capacity (4.18 J/g\u00b7\u00b0C) and heat of vaporisation (2,430 J/g) makes it an ideal thermoregulatory medium via sweat evaporation</li> </ul>"},{"location":"macronutrients/water/#daily-water-balance","title":"Daily Water Balance","text":""},{"location":"macronutrients/water/#inputs","title":"Inputs","text":"Source Volume (approximate) Beverages (all fluids) 1,400\u20132,000 mL/day Water in food 700\u20131,000 mL/day Metabolic water (oxidative metabolism) 200\u2013300 mL/day Total intake ~2,300\u20133,300 mL/day (typical sedentary adult)"},{"location":"macronutrients/water/#outputs","title":"Outputs","text":"Route Volume (approximate) Urine 1,000\u20131,500 mL/day (regulated by ADH) Insensible losses \u2014 skin (diffusion) ~350\u2013400 mL/day Sweat (active evaporation) 0\u2013several litres/hour (highly variable) Respiratory losses 250\u2013350 mL/day Faecal losses 100\u2013200 mL/day Total output ~2,100\u20132,500 mL/day (non-exercise, temperate) <p>Metabolic water is produced by oxidative phosphorylation: oxidation of 100 g fat \u2192 ~107 g water; 100 g carbohydrate \u2192 ~55 g water; 100 g protein \u2192 ~41 g water. Camels exploit this (fatty hump) \u2014 but humans cannot meaningfully rely on it for hydration.</p>"},{"location":"macronutrients/water/#dietary-requirements-adequate-intakes","title":"Dietary Requirements (Adequate Intakes)","text":"Population Total Water AI (all sources) Adult men (19\u201350 yr) 3.7 L/day (IOM) Adult women (19\u201350 yr) 2.7 L/day Pregnancy +0.3 L/day (3.0 L total) Lactation +0.7 L/day (3.8 L total) Children 1\u20133 yr 1.3 L/day Children 9\u201313 yr (boys) 2.4 L/day Older adults (&gt;65 yr) Same or higher need; impaired thirst sensation increases dehydration risk Athletes / hot climate Highly individual \u2014 0.5\u20131.0 L sweat per hour during exercise; replace based on body weight change <p>The \"8\u00d78 rule\" (8 glasses \u00d7 8 oz = ~1.9 L/day) has no scientific basis \u2014 the IOM AIs above are evidence-based. Needs vary by body size, activity, climate, diet composition (high fruit/vegetable intake provides significant water), and health status. Pale yellow urine is the practical indicator of adequate hydration.</p>"},{"location":"macronutrients/water/#physiological-functions","title":"Physiological Functions","text":"Function Mechanism Universal solvent Water's polarity (dipole moment) enables dissolution of ionic compounds (electrolytes), polar molecules (glucose, amino acids, vitamins), and protein hydration shells \u2014 prerequisite for all biochemical reactions Thermoregulation Sweating: ~580 kcal removed per litre of sweat evaporated; core temp maintained within a narrow range (36.5\u201337.5\u00b0C); without this, core temperature would rise ~1\u00b0C per 5\u20138 min during moderate exercise Nutrient and oxygen transport Plasma (blood = 55% plasma by volume; plasma = ~92% water) carries O\u2082 (dissolved + haemoglobin-bound), glucose, fatty acids, amino acids, hormones, immune cells, vitamins Waste elimination Kidneys filter ~180 L plasma/day \u2192 excrete ~1\u20132 L urine containing urea, creatinine, uric acid, drug metabolites; minimum urine output ~500 mL/day to excrete daily solute load Digestion and absorption Saliva (~1.5 L/day), gastric juice (~2 L/day), pancreatic secretions (~1.5 L/day), bile (~1 L/day), intestinal secretions (~1 L/day) \u2014 ~7 L secreted into GI tract daily, almost entirely reabsorbed Lubricant and cushion Synovial fluid (joint lubrication \u2014 predominantly water + hyaluronan); cerebrospinal fluid (cushions brain/spinal cord); pleural, pericardial, amniotic fluids Cellular volume regulation Osmotic pressure drives water between ICF and ECF; AQP (aquaporins \u2014 water channels) regulate trans-membrane water movement; cell swelling/shrinkage alters enzyme activity and gene expression Hydrolysis reactions Water is a reactant in hydrolytic cleavage of peptide bonds, ester bonds, glycosidic bonds \u2014 fundamental to digestion and many metabolic pathways Acid-base equilibrium Water acts as both acid (donates H\u207a) and base (accepts H\u207a); H\u2082CO\u2083/HCO\u2083\u207b buffering system (Henderson-Hasselbalch); maintains blood pH 7.35\u20137.45"},{"location":"macronutrients/water/#electrolyte-balance-and-osmolality","title":"Electrolyte Balance and Osmolality","text":"Electrolyte Compartment Normal Serum Range Key Role Sodium (Na\u207a) ECF dominant 135\u2013145 mEq/L Principal ECF osmole; determines plasma osmolality; regulated by ADH and aldosterone Potassium (K\u207a) ICF dominant 3.5\u20135.0 mEq/L Resting membrane potential, action potentials, cardiac rhythm Chloride (Cl\u207b) ECF 98\u2013106 mEq/L Charge balance for Na\u207a; HCl production in stomach Bicarbonate (HCO\u2083\u207b) ECF 22\u201329 mEq/L Primary blood buffer Calcium (Ca\u00b2\u207a) ECF (ionised) 1.1\u20131.4 mmol/L Neuromuscular excitability, cardiac function, clotting Magnesium (Mg\u00b2\u207a) ICF 0.7\u20131.0 mmol/L Enzyme cofactor; cardiac and neuromuscular stability <p>Plasma osmolality = 2\u00d7[Na\u207a] + [Glucose]/18 + [BUN]/2.8 \u2248 285\u2013295 mOsm/kg - ADH released when osmolality rises &gt;290 or volume drops &gt;10% \u2192 renal water retention \u2192 dilutes osmolality - Aldosterone released (via RAAS) when Na\u207a low or volume low \u2192 renal Na\u207a retention \u2192 water follows osmotically</p>"},{"location":"macronutrients/water/#dehydration","title":"Dehydration","text":"Level % Body Weight Lost as Water Signs and Symptoms Mild 1\u20132% Thirst, slight reduction in cognitive performance, ~10% decrease in aerobic capacity Moderate 3\u20135% Headache, dry mouth, reduced urine output, irritability, impaired attention, \u226520% aerobic capacity decrease Severe 6\u20138% Muscle cramps, rapid heart rate, dizziness, confusion, oliguria Critical &gt;10% Delirium, organ failure, death if untreated <p>Thirst lags dehydration by 1\u20132% \u2014 by the time you feel thirsty, performance is already mildly impaired. Athletes and older adults should drink proactively, not reactively. However, drinking to thirst is appropriate for most sedentary people and for preventing overhydration.</p>"},{"location":"macronutrients/water/#overhydration-and-hyponatraemia","title":"Overhydration and Hyponatraemia","text":"Condition Mechanism Clinical Significance Exercise-associated hyponatraemia (EAH) Excess hypotonic fluid intake (outpaces renal excretion) + ADH non-suppression during exercise dilutes plasma Na\u207a Can occur in slow endurance athletes overdrinking plain water; prevents by drinking to thirst or using electrolyte drinks; Na\u207a &lt;135 mEq/L \u2192 cerebral oedema \u2192 seizures (severe) Psychogenic polydipsia Compulsive water drinking (often in psychiatric illness); &gt;1 L/hour overwhelms renal max clearance (~0.8\u20131 L/hour) Chronic dilutional hyponatraemia SIADH Inappropriate ADH secretion \u2192 excessive renal water retention \u2192 dilutional hyponatraemia Caused by CNS disease, pulmonary disease, drugs (SSRIs, carbamazepine, cyclophosphamide, NSAIDs)"},{"location":"macronutrients/water/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"macronutrients/water/#kidney-stones","title":"Kidney Stones","text":"<ul> <li>Adequate hydration is the most effective preventive measure for all kidney stone types; target urine output &gt;2 L/day (requires total fluid intake ~2.5\u20133 L/day).</li> <li>Dilute urine reduces calcium oxalate, uric acid, and calcium phosphate supersaturation.</li> <li>Lemon juice (citric acid \u2192 urinary citrate) is specifically beneficial for calcium oxalate stones (citrate chelates calcium, inhibits crystallisation).</li> </ul>"},{"location":"macronutrients/water/#urinary-tract-infections-utis","title":"Urinary Tract Infections (UTIs)","text":"<ul> <li>Increased water intake (1.5 additional litres/day over baseline) reduces UTI recurrence by ~50% in women with recurrent UTIs (JAMA 2018 RCT).</li> <li>Mechanism: More frequent urination flushes bacteria from the urethra.</li> </ul>"},{"location":"macronutrients/water/#constipation","title":"Constipation","text":"<ul> <li>Adequate fluid intake combined with dietary fibre is required for fibre to have its stool-bulking effect; fibre without water can worsen constipation.</li> <li>Carbonated water marginally superior to still water for constipation relief in some trials.</li> </ul>"},{"location":"macronutrients/water/#cognitive-function-and-mood","title":"Cognitive Function and Mood","text":"<ul> <li>Dehydration of 1\u20132% body weight impairs attention, working memory, and psychomotor speed \u2014 particularly in the elderly and in heat; relevant for academic performance and occupational safety.</li> <li>Headache is a common symptom of mild dehydration.</li> </ul>"},{"location":"macronutrients/water/#cardiovascular-and-renal-disease-management","title":"Cardiovascular and Renal Disease Management","text":"<ul> <li>In heart failure, free water may need restriction (&lt;1.5 L/day) to prevent volume overload and dilutional hyponatraemia.</li> <li>In CKD, fluid management is individualised \u2014 early CKD benefits from high fluid intake (reduces progression); advanced CKD or anuria requires restriction.</li> </ul>"},{"location":"macronutrients/water/#interactions","title":"Interactions","text":"Factor Effect Sodium Na\u207a is the primary osmotic determinant of ECF volume; high sodium intake proportionally increases water requirement and retention; WHO recommends &lt;5 g NaCl/day Caffeine Mild diuretic effect at high doses (&gt;250 mg/day); at habitual intake levels, coffee and tea contribute to net hydration (the diuresis is less than the fluid delivered); tolerance develops rapidly Alcohol Suppresses ADH release \u2192 diuresis \u2192 net dehydration effect; drinks above ~4% ABV cause net fluid loss; explains post-alcohol dehydration/headache (exacerbated by vasodilation) Dietary fibre Soluble fibre absorbs water in the gut \u2192 requires adequate water intake to maintain GI motility; insoluble fibre absorbs water \u2192 stool bulking; fibre + inadequate water \u2192 constipation Protein (high intake) Increases renal urea load \u2192 obligatory water needed for urea excretion; high-protein diets may slightly increase water requirement (~0.5\u20131 mL/kcal from protein = ~300\u2013500 mL extra/day) Exercise / heat Sweat losses highly variable: 0.5\u20132.5 L/hour depending on intensity, heat, humidity, acclimatisation state; sodium losses 0.5\u20132 g/L sweat; electrolyte replacement essential during prolonged exercise (&gt;1 hour) ADH / vasopressin Antidiuretic hormone is the central bottleneck of water regulation; many drugs and conditions impair ADH regulation (lithium causes nephrogenic DI; SSRI \u2192 SIADH) Diuretics Loop diuretics (furosemide), thiazides, acetazolamide \u2014 all increase urinary water and electrolyte losses; careful monitoring of hydration and electrolytes required"},{"location":"macronutrients/water/#practical-and-supplementation-notes","title":"Practical and Supplementation Notes","text":"<ul> <li>Plain water remains the optimal hydration beverage for most people; no supplement is needed for routine sedentary hydration</li> <li>Electrolyte drinks / oral rehydration salts (ORS): WHO ORS formula for diarrhoeal dehydration: 75 mEq/L Na\u207a, 75 mmol/L glucose, 20 mEq/L K\u207a \u2014 isotonicity drives active co-transport absorption via SGLT1; superior to plain water for rehydration in significant diarrhoea/vomiting</li> <li>Sports drinks (isotonic, 6% CHO + electrolytes): Evidence-based for endurance exercise &gt;60\u201390 min; replenish glycogen + sodium + fluid simultaneously; unnecessary for &lt;60 min exercise or casual activity</li> <li>IV fluids (clinical use): Normal saline (0.9% NaCl), Lactated Ringer's, Hartmann's solution for volume resuscitation; 5% dextrose for hypoglycaemia/energy; choice depends on clinical context</li> <li>Coconut water: Natural hypotonic beverage; moderate K\u207a, low Na\u207a; insufficient Na\u207a for prolonged exercise rehydration (add a pinch of salt); suitable casual hydration alternative</li> <li>Hydration monitoring: Urine colour (pale yellow = adequate; dark yellow = dehydrated; clear = possibly over-hydrated); urine specific gravity 1.010\u20131.025 (adequate range); body weight pre/post exercise (1 kg loss \u2248 ~1 L fluid deficit)</li> <li>Carbonated water: Safe; does not damage tooth enamel with normal consumption (very low carbonic acid concentration); some evidence of slight constipation benefit; may increase satiety marginally; does not impair hydration</li> <li>Hydrogen-rich water: No credible clinical evidence of benefit beyond ordinary water; classified as a dubious wellness product</li> </ul>"},{"location":"minerals/calcium/","title":"Calcium (Ca)","text":""},{"location":"minerals/calcium/#overview","title":"Overview","text":"<p>Calcium is the most abundant mineral in the human body, with approximately 99% stored in bones and teeth as hydroxyapatite crystals, and the remaining 1% in blood, muscles, and extracellular fluid. This 1% is metabolically vital \u2014 calcium is a universal intracellular second messenger and is essential for muscle contraction, nerve signalling, enzyme activation, and blood coagulation.</p> <ul> <li>Atomic number: 20; divalent cation (Ca\u00b2\u207a)</li> <li>Category: Macromineral (required in hundreds of mg/day)</li> <li>Body content: ~1,000\u20131,200 g in average adult</li> <li>Bone reservoir: Acts as a dynamic calcium buffer \u2014 constantly remodelled to maintain serum calcium within a tight range (2.1\u20132.6 mmol/L)</li> </ul>"},{"location":"minerals/calcium/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 200 mg/day (AI) Infants 7\u201312 months 260 mg/day (AI) Children 1\u20133 years 700 mg/day Children 4\u20138 years 1,000 mg/day Children 9\u201318 years 1,300 mg/day Adults 19\u201350 1,000 mg/day Adult Men 51\u201370 1,000 mg/day Adult Women 51\u201370 1,200 mg/day Adults 71+ 1,200 mg/day Pregnant / Breastfeeding Women 1,000 mg/day (1,300 if &lt;19 yrs) <p>Tolerable Upper Intake Level (UL): 2,500 mg/day for adults 19\u201350; 2,000 mg/day for adults 51+.</p>"},{"location":"minerals/calcium/#functions","title":"Functions","text":"<ul> <li>Bone and Teeth Mineralisation: Forms structural hydroxyapatite [Ca\u2081\u2080(PO\u2084)\u2086(OH)\u2082] in skeletal tissue; critical for peak bone mass development in adolescence.</li> <li>Muscle Contraction: Ca\u00b2\u207a binds troponin C in cardiac and skeletal muscle, initiating actin-myosin cross-bridge cycling. Required for smooth muscle tone.</li> <li>Nerve Impulse Transmission: Regulates neurotransmitter vesicle release at synaptic terminals via Ca\u00b2\u207a-driven exocytosis.</li> <li>Blood Clotting: Multiple coagulation factors (II, VII, IX, X) require Ca\u00b2\u207a as a cofactor; essential in the clotting cascade.</li> <li>Enzyme Activation: Activates calmodulin-dependent protein kinases, phospholipases, and protease calpain.</li> <li>Cell Signalling: Acts as a second messenger in cell proliferation, apoptosis, and gene expression.</li> <li>Hormone Secretion: Stimulates insulin release from beta cells; regulates parathyroid hormone (PTH) secretion inversely.</li> <li>Vascular Function: Involved in contraction and dilation of blood vessels.</li> </ul>"},{"location":"minerals/calcium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Vitamin D (1,25-dihydroxyvitamin D\u2083) Upregulates intestinal TRPV6 calcium channel and calbindin-D9k; essential for active absorption Parathyroid Hormone (PTH) Increases renal calcium reabsorption, stimulates bone resorption, activates vitamin D Vitamin K2 (MK-7) Activates osteocalcin and matrix Gla protein \u2014 directs calcium into bones and away from arteries Magnesium Required for PTH secretion and vitamin D activation; deficiency impairs calcium metabolism Phosphorus Forms Ca:P ratio in bone; ratio of 2:1 (Ca:P) is optimal"},{"location":"minerals/calcium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Active (duodenum/jejunum, vitamin D-dependent) and passive (throughout intestine); overall 25\u201335% of intake absorbed Factors increasing absorption Vitamin D sufficiency, acidic gastric pH, lactose, low calcium intake Factors decreasing absorption High oxalate (spinach), high phytate (bran), achlorhydria, excess phosphorus, high caffeine or sodium Distribution 99% bone/teeth; 0.9% intracellular; 0.1% extracellular fluid Regulation PTH, calcitonin, and 1,25-(OH)\u2082D\u2083 tightly maintain serum Ca\u00b2\u207a at 2.1\u20132.6 mmol/L Excretion Primarily renal (~200 mg/day); some faecal; renal reabsorption enhanced by PTH and vitamin D; increased by high sodium intake"},{"location":"minerals/calcium/#effects-of-deficiency-hypocalcaemia","title":"Effects of Deficiency (Hypocalcaemia)","text":"<p>Acute hypocalcaemia is a medical emergency (serum Ca\u00b2\u207a &lt;2.1 mmol/L corrected).</p> <p>Symptoms: - Neuromuscular: Tetany, muscle cramps, paraesthesiae (tingling in extremities and perioral area) - Neurological: Seizures (hypocalcaemic), carpopedal spasm, Chvostek's sign (facial twitch), Trousseau's sign (carpal spasm with blood pressure cuff) - Cardiac: Prolonged QT interval \u2192 arrhythmias; cardiac failure in severe cases - Skeletal (chronic): Rickets (children), osteomalacia (adults), osteoporosis (long-term inadequacy) - Dental: Enamel hypoplasia, impaired dental development</p> <p>At-Risk Populations: - Vitamin D-deficient individuals - Post-menopausal women (oestrogen loss accelerates bone resorption) - Elderly (reduced intestinal absorption, less sun exposure) - Hypoparathyroidism and post-thyroidectomy patients - Those with malabsorption (coeliac, Crohn's, short bowel syndrome) - Vegans (especially if avoiding fortified foods)</p>"},{"location":"minerals/calcium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Acute severe hypocalcaemia IV calcium gluconate (10 ml of 10% solution) over 10 minutes; ECG monitoring Hypoparathyroidism Oral calcium carbonate 1\u20133 g/day + calcitriol (active vitamin D) 0.25\u20131 \u00b5g/day Dietary deficiency / osteoporosis prevention 1,000\u20131,200 mg/day dietary + supplement if needed; co-administer vitamin D 800\u20132,000 IU/day Rickets / Osteomalacia High-dose vitamin D + calcium (regimen depends on cause) Post-menopausal osteoporosis Calcium + vitamin D + bisphosphonates (e.g., alendronate) <p>Calcium carbonate is cheapest but requires stomach acid; calcium citrate is better absorbed in achlorhydria or with PPIs.</p>"},{"location":"minerals/calcium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Bisphosphonates (e.g., alendronate) Calcium impairs absorption \u2014 separate by \u22652 hours Fluoroquinolone / tetracycline antibiotics Calcium chelates drug \u2192 reduced antibiotic absorption Levothyroxine Calcium reduces absorption \u2014 separate by \u22654 hours Thiazide diuretics Reduce urinary calcium excretion \u2192 may cause hypercalcaemia if calcium intake is high Loop diuretics (e.g., furosemide) Increase urinary calcium loss Corticosteroids Impair intestinal calcium absorption; increase bone resorption Proton pump inhibitors (PPIs) Reduce gastric acid \u2192 impair calcium carbonate absorption Calcium channel blockers High-dose calcium supplements may blunt their antihypertensive effect"},{"location":"minerals/calcium/#food-sources","title":"Food Sources","text":"Food Serving Calcium (mg) Parmesan cheese 28g ~336 mg Milk (cow, whole) 240 ml ~300 mg Plain yogurt (low-fat) 245g ~415 mg Canned sardines (with bones) 85g ~325 mg Fortified plant milk (soy, almond) 240 ml ~300 mg Tofu (set with calcium sulfate) 85g ~250 mg Kale (cooked) 90g ~95 mg White beans (cooked) 90g ~80 mg Bok choy (cooked) 85g ~79 mg Broccoli (cooked) 90g ~60 mg <p>Note: Calcium from high-oxalate foods (spinach, beet greens, Swiss chard) has poor bioavailability (~5%) due to oxalate binding. Low-oxalate greens (kale, bok choy) offer much better absorption (~50%).</p>"},{"location":"minerals/calcium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Calcium itself is a mineral element \u2014 it is not degraded by cooking, light, or storage.</li> <li>Bioavailability from food can be affected by cooking methods (e.g., boiling greens reduces oxalate content, improving Ca absorption).</li> <li>Calcium in supplements is stable indefinitely when stored dry.</li> </ul>"},{"location":"minerals/calcium/#toxicity-hypercalcaemia","title":"Toxicity (Hypercalcaemia)","text":"Cause Details Primary hyperparathyroidism Most common cause; excess PTH increases bone resorption and renal Ca reabsorption Excessive supplementation UL of 2,000\u20132,500 mg/day may be exceeded by over-supplementation Vitamin D toxicity Excess 1,25-(OH)\u2082D\u2083 drives intestinal hyperabsorption Granulomatous diseases Sarcoidosis, TB produce excess active vitamin D <p>Symptoms of Hypercalcaemia: \"Bones, stones, groans, moans\" \u2014 bone pain, nephrolithiasis (kidney stones), abdominal pain/constipation, fatigue/confusion. Severe cases: cardiac arrhythmia, renal failure, coma.</p> <p>Milk-Alkali Syndrome: Excessive calcium carbonate intake (antacids) combined with milk \u2192 hypercalcaemia, metabolic alkalosis, and renal impairment.</p>"},{"location":"minerals/chloride/","title":"Chloride (Cl)","text":""},{"location":"minerals/chloride/#overview","title":"Overview","text":"<p>Chloride is the principal intracellular and extracellular anion. In the extracellular fluid, it is the main counter-ion to sodium, playing a critical role in maintaining osmotic balance, blood volume, and electrical neutrality. Chloride also participates directly in gastric acid production, carbon dioxide transport, and cell volume regulation.</p> <ul> <li>Atomic number: 17; monovalent anion (Cl\u207b)</li> <li>Category: Macromineral / Electrolyte</li> <li>Body content: ~115 g in average adult</li> <li>Normal serum range: 98\u2013106 mmol/L</li> <li>Key fact: Consumed almost entirely as sodium chloride (table salt) and other chloride salts in food.</li> </ul>"},{"location":"minerals/chloride/#requirements-ai","title":"Requirements (AI)","text":"Age / Group Adequate Intake (AI) Infants 0\u20136 months 180 mg/day Infants 7\u201312 months 570 mg/day Children 1\u20133 years 1,500 mg/day Children 4\u20138 years 1,900 mg/day Children 9\u201313 years 2,300 mg/day Adolescents 14\u201318 years 2,300 mg/day Adults 19\u201350 2,300 mg/day Adults 51\u201370 2,000 mg/day Adults 71+ 1,800 mg/day Pregnant Women 2,300 mg/day Breastfeeding Women 2,300 mg/day <p>No Tolerable Upper Intake Level (UL) is established for chloride separately \u2014 the AI reflects combined intake as NaCl (sodium chloride), and sodium UL governs clinical guidance.</p>"},{"location":"minerals/chloride/#functions","title":"Functions","text":"<ul> <li>Extracellular Osmolality: Along with Na\u207a, Cl\u207b is the primary determinant of extracellular fluid tonicity and volume.</li> <li>Gastric Acid Production: Cl\u207b is secreted by gastric parietal cells via H\u207a/K\u207a-ATPase combined with apical Cl\u207b channels to form hydrochloric acid (HCl, pH 1.5\u20133.5). Essential for protein digestion and pathogen killing.</li> <li>Carbon Dioxide Transport (Chloride Shift): In RBCs, CO\u2082 is hydrated to bicarbonate (HCO\u2083\u207b) by carbonic anhydrase; HCO\u2083\u207b exits the cell in exchange for Cl\u207b (the Hamburger/chloride shift) \u2014 moves CO\u2082 from tissues to lungs.</li> <li>Nerve and Muscle Excitability: GABA_A receptors are Cl\u207b channels; Cl\u207b influx hyperpolarises neurons (inhibitory post-synaptic potential). Glycine receptors also operate via Cl\u207b.</li> <li>Cell Volume Regulation: Cl\u207b influx/efflux with Na\u207a or K\u207a regulates cell swelling and shrinkage.</li> <li>Electrical Neutrality: Balances cation charge across cell membranes and in plasma.</li> <li>Bile and Pancreatic Secretion: Component of digestive secretions; CFTR (cystic fibrosis transmembrane conductance regulator) is a Cl\u207b channel essential for mucus and secretion hydration.</li> </ul>"},{"location":"minerals/chloride/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Sodium Principal paired cation (NaCl) \u2014 chloride excretion/retention shadows sodium handling by kidneys Hydrogen (H\u207a) / Carbonic anhydrase Drives chloride shift in RBCs and gastric acid formation CFTR (cystic fibrosis transmembrane conductance regulator) Cl\u207b channel required for secretion hydration in lungs, pancreas, GI tract Potassium K\u207a/Cl\u207b co-transporters (KCC) regulate cell volume and neuronal inhibition"},{"location":"minerals/chloride/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Nearly completely absorbed in the small intestine; passive paracellular and active transport Distribution ~70% extracellular fluid; 20% intracellular; 10% bone Regulation Closely linked to sodium regulation via kidneys (RAAS, aldosterone); follows sodium reabsorption in most nephron segments Excretion Primarily renal; can be conserved below 1 mmol/day under severe restriction Sweat Significant losses in excessive sweating; cystic fibrosis patients have abnormally high sweat Cl\u207b (&gt;60 mmol/L \u2014 diagnostic)"},{"location":"minerals/chloride/#effects-of-deficiency-hypochloraemia","title":"Effects of Deficiency (Hypochloraemia)","text":"<p>Serum Cl\u207b &lt;98 mmol/L. Usually secondary to sodium depletion, vomiting, or excessive diuresis.</p> <p>Causes: Prolonged vomiting (loss of HCl), prolonged nasogastric suction, loop/thiazide diuretics, metabolic alkalosis, SIADH.</p> <p>Symptoms: - Metabolic alkalosis (most characteristic consequence \u2014 loss of HCl leaves net bicarbonate excess) - Muscle weakness, cramps, tetany - Respiratory compensation (hypoventilation \u2014 retains CO\u2082 to buffer alkalosis) - Confusion, lethargy in severe cases</p> <p>At-Risk Groups: Patients with recurrent vomiting (eating disorders, hyperemesis gravidarum), prolonged NG tube drainage, high-dose diuretic users.</p>"},{"location":"minerals/chloride/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild hypochloraemia Oral NaCl (dietary salt restoration or saline tablets); treat underlying cause Hypochloraemic metabolic alkalosis IV 0.9% NaCl (isotonic saline) to provide Cl\u207b and correct volume; KCl added if hypokalaemic Severe alkalosis refractory to saline Acetazolamide (promotes HCO\u2083\u207b excretion); rarely HCl infusion via central venous line"},{"location":"minerals/chloride/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Loop diuretics Promote urinary Cl\u207b loss \u2192 hypochloraemia and metabolic alkalosis Thiazide diuretics Renal Cl\u207b loss; less pronounced than loop diuretics Proton pump inhibitors Reduce gastric HCl secretion \u2014 clinically, not a major factor in serum Cl\u207b Acetazolamide Promotes HCO\u2083\u207b excretion \u2192 relatively increases serum Cl\u207b (hyperchloraemic acidosis)"},{"location":"minerals/chloride/#food-sources","title":"Food Sources","text":"<p>Chloride is consumed almost exclusively as sodium chloride (salt) and potassium chloride (salt substitute). Most natural foods contain minimal amounts.</p> Food Serving Approximate Chloride (mg) Table salt (NaCl) 1 tsp ~3,550 mg Canned soup 240 ml ~450\u2013900 mg Processed deli meats 85g ~500\u20131,000 mg Soy sauce 1 tbsp ~950 mg Sea vegetables (seaweed, kelp) 28g ~400\u2013600 mg Milk 240 ml ~170 mg Bread (white) 1 slice ~100\u2013200 mg"},{"location":"minerals/chloride/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Chloride (as a mineral anion) is not degraded by cooking, heat, light, or storage.</li> <li>Content in food is directly tied to added salt (NaCl) during processing or cooking.</li> </ul>"},{"location":"minerals/chloride/#toxicity-hyperchloraemia","title":"Toxicity (Hyperchloraemia)","text":"<p>Serum Cl\u207b &gt;106 mmol/L. Usually associated with hyperchloraemic metabolic acidosis.</p> <p>Causes: Excessive normal saline (0.9% NaCl has supraphysiological Cl\u207b at 154 mmol/L); renal tubular acidosis; diarrhoea (HCO\u2083\u207b loss proportionally raises Cl\u207b); acetazolamide; ammonium chloride.</p> <p>Clinical significance: Hyperchloraemic acidosis is associated with renal vasoconstriction and reduced GFR. Balanced crystalloids (Ringer's lactate, Plasma-Lyte) reduce hyperchloraemia risk vs. normal saline in critical care.</p>"},{"location":"minerals/chromium/","title":"Chromium (Cr)","text":""},{"location":"minerals/chromium/#overview","title":"Overview","text":"<p>Chromium is an essential trace mineral that potentiates the action of insulin and plays a role in the metabolism of carbohydrates, fats, and proteins. It exists in biological systems as trivalent chromium (Cr\u00b3\u207a) \u2014 the only biologically relevant and nutritionally important form. The function of chromium in insulin action has been attributed to a low-molecular-weight chromium-binding oligopeptide (LMWCr or chromodulin).</p> <ul> <li>Atomic number: 24; biologically active as Cr\u00b3\u207a (trivalent); Cr\u2076\u207a (hexavalent) is industrial/toxic</li> <li>Category: Trace mineral</li> <li>Body content: ~4\u20136 mg in average adult; widely distributed, highest in liver, kidney, muscle, spleen</li> <li>Key fact: Chromium requirements are among the smallest of all essential minerals; deficiency in healthy free-living adults is rare.</li> </ul>"},{"location":"minerals/chromium/#requirements-ai","title":"Requirements (AI)","text":"Age / Group Adequate Intake (AI) Infants 0\u20136 months 0.2 \u00b5g/day Infants 7\u201312 months 5.5 \u00b5g/day Children 1\u20133 years 11 \u00b5g/day Children 4\u20138 years 15 \u00b5g/day Males 9\u201313 years 25 \u00b5g/day Females 9\u201313 years 21 \u00b5g/day Males 14\u201350 years 35 \u00b5g/day Females 14\u201318 years 24 \u00b5g/day Adult Women 19\u201350 25 \u00b5g/day Adult Men 51+ 30 \u00b5g/day Adult Women 51+ 20 \u00b5g/day Pregnant Women 29\u201330 \u00b5g/day Breastfeeding Women 44\u201345 \u00b5g/day <p>No Tolerable Upper Intake Level (UL) has been established for trivalent chromium from food or supplements due to low toxicity and poor absorption. Cr\u2076\u207a (hexavalent) has a separate UL of 0.1 mg/day from water.</p>"},{"location":"minerals/chromium/#functions","title":"Functions","text":"<ul> <li>Insulin Sensitisation (Chromodulin): Chromium is incorporated into chromodulin (LMWCr) \u2014 an oligopeptide consisting of glycine, cysteine, aspartate, and glutamate that binds 4 Cr\u00b3\u207a ions. Upon insulin receptor activation, chromodulin is released from stores and amplifies insulin receptor tyrosine kinase activity.</li> <li>Glucose Uptake: By potentiating insulin signalling, chromium facilitates GLUT4 translocation to cell membranes \u2192 enhanced cellular glucose uptake.</li> <li>Lipid Metabolism: Chromium supplementation has been associated with modest improvements in triglyceride and HDL profiles in some studies, attributed to improved insulin sensitivity.</li> <li>Protein Metabolism: Chromium was used in livestock for muscle protein accretion \u2014 evidence in humans is weak.</li> <li>Chromium and Exercise: Claims about chromium picolinate for muscle building are largely not supported by robust human trials.</li> </ul>"},{"location":"minerals/chromium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Insulin receptor Chromium amplifies insulin receptor tyrosine kinase activity \u2014 functional only when insulin pathway is intact Transferrin Primary chromium transport protein in plasma (alongside albumin) Nicotinic acid (B3) Early hypothesis that chromium formed a \"glucose tolerance factor\" (GTF) complex with niacin and amino acids \u2014 subsequently disproved; separate processes"},{"location":"minerals/chromium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Very low: 0.5\u20132% of dietary Cr\u00b3\u207a; organic chromium (picolinate, nicotinate) slightly higher ~2\u20135% Absorbed as Cr\u00b3\u207a transported via transferrin in blood Distribution Liver, kidney, muscle, bone, spleen Excretion Primarily urinary; renal excretion increases with high carbohydrate intake and strenuous exercise Half-life Varies by tissue \u2014 short (~1 day) in plasma, longer in tissues"},{"location":"minerals/chromium/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>The evidence base for chromium essentiality is less robust than for other trace minerals.</p> <p>Clinical deficiency (documented only in patients on total parenteral nutrition without chromium): - Impaired glucose tolerance resembling type 2 diabetes - Elevated fasting glucose and insulin - Impaired lipid metabolism - Peripheral neuropathy</p> <p>In free-living populations: Chromium deficiency based on dietary intake is not well-documented; it is difficult to measure chromium status accurately (contamination confounds blood/urine measurements).</p>"},{"location":"minerals/chromium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Proven TPN-associated deficiency IV chromium 10\u201315 \u00b5g/day in TPN formulation Standard TPN maintenance 10\u201315 \u00b5g/day IV (optimal long-term may be lower \u2014 reassessed given potential nephrotoxicity risk) Type 2 diabetes / insulin resistance (controversial) Chromium picolinate 200\u20131,000 \u00b5g/day studied; modest, inconsistent evidence; not a standard of care"},{"location":"minerals/chromium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect NSAIDs (aspirin, ibuprofen) May increase chromium absorption (mechanism unclear) Antacids Alkaline pH reduces Cr\u00b3\u207a absorption Iron supplements Compete with chromium for transferrin binding; high iron may reduce chromium transport Insulin / hypoglycaemic agents Theoretical potentiation \u2014 monitor blood glucose if combining chromium supplements with insulin therapy"},{"location":"minerals/chromium/#food-sources","title":"Food Sources","text":"Food Serving Chromium (\u00b5g) Broccoli (cooked) 90g ~22 \u00b5g Grape juice 240 ml ~8 \u00b5g English muffin (whole wheat) 1 muffin ~4 \u00b5g Potatoes (mashed) 1 cup ~3 \u00b5g Garlic (dried) 1 tsp ~3 \u00b5g Turkey breast 85g ~2 \u00b5g Beef (ground) 85g ~2 \u00b5g Orange juice 240 ml ~2 \u00b5g Apple (with peel) 1 medium ~1.4 \u00b5g Green beans 90g ~1.1 \u00b5g <p>Note: Chromium content of foods is poorly characterised \u2014 values in databases have high variability due to soil and analytical contamination issues.</p>"},{"location":"minerals/chromium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Chromium mineral content is stable to cooking and storage.</li> <li>Stainless steel cookware (which contains chromium) can leach small amounts of Cr\u00b3\u207a into acidic foods \u2014 generally considered safe and may contribute to intake.</li> </ul>"},{"location":"minerals/chromium/#toxicity","title":"Toxicity","text":"<p>Trivalent Cr\u00b3\u207a (dietary/supplemental forms): - Very low toxicity; no UL established from food sources - Chromium picolinate at high doses (&gt;1,000 \u00b5g/day) has theoretical concerns \u2014 picolinic acid may enhance cellular uptake beyond regulation; very rare reports of renal failure and rhabdomyolysis</p> <p>Hexavalent Cr\u2076\u207a (industrial form \u2014 NOT dietary): - Potent carcinogen and mutagen; classified as IARC Group 1 (lung carcinogen via inhalation) - Causes DNA strand breaks and oxidative damage - Found in industrial settings (chrome plating, tanning, welding on stainless steel) and contaminated groundwater</p>"},{"location":"minerals/copper/","title":"Copper (Cu)","text":""},{"location":"minerals/copper/#overview","title":"Overview","text":"<p>Copper is an essential trace mineral and a transition metal that functions as a redox cofactor, cycling between Cu\u207a (cuprous) and Cu\u00b2\u207a (cupric) states. It is a key component of several critical enzymes involved in energy production, iron metabolism, antioxidant defence, neurotransmitter synthesis, and connective tissue formation. Total body copper is approximately 75\u2013150 mg, distributed primarily in muscle, bone, liver, brain, and blood.</p> <ul> <li>Atomic number: 29; cycles Cu\u207a \u2194 Cu\u00b2\u207a</li> <li>Category: Trace mineral</li> <li>Normal serum range: 70\u2013140 \u00b5g/dL (increases in pregnancy and inflammation as copper is an acute-phase reactant)</li> </ul>"},{"location":"minerals/copper/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 200 \u00b5g/day (AI) Infants 7\u201312 months 220 \u00b5g/day (AI) Children 1\u20133 years 340 \u00b5g/day Children 4\u20138 years 440 \u00b5g/day Children 9\u201313 years 700 \u00b5g/day Adolescents 14\u201318 years 890 \u00b5g/day Adults 19+ 900 \u00b5g/day Pregnant Women 1,000 \u00b5g/day Breastfeeding Women 1,300 \u00b5g/day <p>Tolerable Upper Intake Level (UL): 10,000 \u00b5g/day (10 mg/day) for adults.</p>"},{"location":"minerals/copper/#functions","title":"Functions","text":"<ul> <li>Cytochrome c Oxidase (Complex IV): Copper is essential in this terminal enzyme of the ETC \u2014 transfers electrons to O\u2082 to form water; critical for aerobic ATP synthesis.</li> <li>Iron Metabolism (Ceruloplasmin): Ceruloplasmin (a copper-containing ferroxidase) oxidises Fe\u00b2\u207a to Fe\u00b3\u207a, enabling iron loading onto transferrin for transport. Copper deficiency \u2192 functional iron deficiency anaemia.</li> <li>Antioxidant Defence (SOD1): Cu/Zn-superoxide dismutase (SOD1) dismutates superoxide radicals (O\u2082\u207b) to H\u2082O\u2082; found in cytoplasm. SOD2 (manganese-dependent) in mitochondria.</li> <li>Connective Tissue Crosslinking (Lysyl Oxidase): Copper enzyme crosslinks collagen and elastin fibres; deficiency causes aortic aneurysm, joint laxity, and fragile bone (Menkes-like effects).</li> <li>Neurotransmitter Synthesis (Dopamine \u03b2-Hydroxylase): Converts dopamine to norepinephrine; copper deficiency can impair the sympathetic nervous system.</li> <li>Tyrosinase: Copper enzyme required for melanin synthesis from tyrosine \u2014 deficiency \u2192 hypopigmentation.</li> <li>Peptidylglycine \u03b1-Amidating Monooxygenase (PAM): Activates neuropeptides (substance P, vasoactive intestinal peptide) and peptide hormones.</li> <li>Mitochondrial Biogenesis and ETC assembly: Copper chaperone proteins (COX17, SCO1) are required for Complex IV assembly.</li> </ul>"},{"location":"minerals/copper/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Zinc Copper and zinc compete for absorption via metallothionein; balance is critical (Cu:Zn ratio normally ~1:10 in serum) Iron Operates downstream of copper in iron metabolism; functional iron deficiency occurs in copper deficiency Albumin and ceruloplasmin Copper transport proteins in plasma; ceruloplasmin carries ~95% of plasma copper Vitamin C (high dose) Can reduce copper absorption when taken in very high doses (&gt;1,500 mg)"},{"location":"minerals/copper/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 25\u201345% of dietary copper absorbed in stomach and proximal small intestine; via Ctr1 transporter Absorbed as Cu\u207a (cuprous); dietary Cu\u00b2\u207a reduced by stomach acid Distribution Liver (primary hub); bound to ceruloplasmin (~95% plasma copper); also albumin and macroglobulin (~5%) Metabolism Liver \u2014 excreted in bile (~95% of body copper turnover); ATP7B transporter essential for biliary copper export Excretion Primarily biliary/faecal; urinary copper minimal (&lt;60 \u00b5g/day) unless chelation therapy Half-life ~2\u20135 weeks for hepatic copper pool"},{"location":"minerals/copper/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Copper deficiency is uncommon but clinically important.</p> <p>Causes: Prolonged high-dose zinc supplementation (most common \u2014 zinc induces metallothionein which preferentially binds Cu), malabsorption (bariatric surgery, coeliac disease), excess formula-based feeding without copper supplementation.</p> <p>Symptoms: - Haematological: Anaemia (normocytic or macrocytic, sideroblastic \u2014 iron can not be loaded onto transferrin), neutropenia - Neurological: Myelopathy (copper deficiency myelopathy \u2014 demyelination of posterior and lateral spinal columns, mimics subacute combined degeneration of vitamin B12 deficiency), peripheral neuropathy, ataxia, cognitive impairment - Connective tissue: Weakened collagen and elastin \u2014 aortic aneurysm risk, skeletal abnormalities - Immunological: Lymphopenia, increased infection susceptibility - Hypopigmentation: Reduced melanin production</p>"},{"location":"minerals/copper/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild copper deficiency Copper gluconate or copper sulfate 2 mg/day oral Neurological copper deficiency 2\u20134 mg/day elemental copper; may require IV copper initially Zinc-induced copper deficiency Stop or reduce zinc; copper 2 mg/day; neurological recovery partial Wilson's disease (copper overload) Penicillamine chelation (D-Pen), trientine, or zinc therapy (50 mg elemental TID blocks Cu absorption) Menkes disease (Cu transporter defect) SC copper-histidine injections (bypasses defective intestinal Ctr1)"},{"location":"minerals/copper/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Zinc (&gt;50 mg elemental/day) Induces intestinal metallothionein \u2192 sequesters copper \u2192 deficiency Penicillamine Chelates copper: used therapeutically in Wilson's; causes deficiency with long-term use Vitamin C (&gt;1,500 mg/day) May reduce copper absorption and ceruloplasmin activity Antacids Alkaline pH may reduce Cu\u00b2\u207a absorption partially"},{"location":"minerals/copper/#food-sources","title":"Food Sources","text":"Food Serving Copper (\u00b5g) Beef liver (cooked) 85g ~12,400 \u00b5g Oysters (cooked) 85g ~4,850 \u00b5g Crab (Dungeness, cooked) 85g ~630 \u00b5g Cashews 28g ~620 \u00b5g Sunflower seeds 28g ~519 \u00b5g Hazelnuts 28g ~496 \u00b5g Dark chocolate (70\u201385%) 28g ~501 \u00b5g Baked potato (flesh + skin) 1 medium ~610 \u00b5g Mushrooms (shiitake, cooked) 86g ~650 \u00b5g Lentils (cooked) 90g ~249 \u00b5g"},{"location":"minerals/copper/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Copper content in foods is stable to cooking and storage.</li> <li>Copper can leach from copper pipes into drinking water \u2014 particularly in households with new copper plumbing and acidic water.</li> </ul>"},{"location":"minerals/copper/#toxicity","title":"Toxicity","text":"Condition Details Acute copper toxicity Accidental ingestion of copper salts \u2192 nausea, vomiting, haemolytic anaemia, hepatic necrosis Wilson's disease Autosomal recessive (ATP7B mutation) \u2014 impaired biliary copper excretion \u2192 copper deposits in liver (cirrhosis), brain (neuropsychiatric symptoms), cornea (Kayser-Fleischer rings), kidneys Indian childhood cirrhosis High copper intake from brass vessel-stored milk \u2192 severe early hepatic copper overload Chronic supplemental excess (&gt;10 mg/day UL) Hepatic injury, GI symptoms, haemolysis <p>Serum markers: Ceruloplasmin and serum copper are usually low in deficiency (except in inflammation/pregnancy where they rise); 24-hour urine copper &gt;100 \u00b5g/day + low ceruloplasmin + Kayser-Fleischer rings = Wilson's disease triad.</p>"},{"location":"minerals/fluoride/","title":"Fluoride (F)","text":""},{"location":"minerals/fluoride/#overview","title":"Overview","text":"<p>Fluoride (the ionised form of fluorine) is a trace mineral that is unique in that its primary biological function is prevention of dental caries rather than acting as an enzyme cofactor. It is incorporated into the crystalline structure of tooth enamel and bone, enhancing resistance to acid dissolution. Fluoride is found naturally in water, soil, and some foods; it is also widely added to drinking water and toothpaste as a public health intervention.</p> <ul> <li>Atomic number: 9 (fluorine); exists in biological systems as fluoride ion (F\u207b)</li> <li>Category: Trace mineral</li> <li>Body content: ~2.6 g in average adult; primary storage in bone and teeth (as fluorapatite)</li> <li>Key fact: Water fluoridation is one of the ten greatest public health achievements of the 20th century (CDC); optimal concentration is 0.7 mg/L.</li> </ul>"},{"location":"minerals/fluoride/#requirements-ai","title":"Requirements (AI)","text":"Age / Group Adequate Intake (AI) Infants 0\u20136 months 0.01 mg/day Infants 7\u201312 months 0.5 mg/day Children 1\u20133 years 0.7 mg/day Children 4\u20138 years 1.0 mg/day Children 9\u201313 years 2.0 mg/day Adolescents 14\u201318 years 3.0 mg/day Adult Men 19+ 4.0 mg/day Adult Women 19+ 3.0 mg/day Pregnant Women 3.0 mg/day Breastfeeding Women 3.0 mg/day <p>Tolerable Upper Intake Level (UL): 10 mg/day for adults; 1.3\u20132.2 mg/day for children (age-dependent), based on dental/skeletal fluorosis prevention.</p>"},{"location":"minerals/fluoride/#functions","title":"Functions","text":"<ul> <li>Dental Caries Prevention: F\u207b incorporates into hydroxyapatite of tooth enamel \u2192 forms fluorapatite (Ca\u2081\u2080(PO\u2084)\u2086F\u2082) which is more resistant to acid (pH threshold 4.5 vs. 5.5 for hydroxyapatite). Fluoride also inhibits glycolysis by mutans streptococci, reducing acid production.</li> <li>Remineralisation: Fluoride enhances remineralisation of early carious lesions by promoting mineral deposition from saliva.</li> <li>Bone Structure: Fluoride in bone (as fluorapatite) increases crystal size and density; high-dose therapeutic use briefly explored for osteoporosis (limited due to adverse effects on bone quality).</li> <li>Enzyme Inhibition: At high concentrations, F\u207b inhibits enolase (glycolytic enzyme) \u2014 basis for its antibacterial effect; at toxic concentrations, inhibits multiple enzymes in human cells.</li> </ul>"},{"location":"minerals/fluoride/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Calcium Required for fluorapatite formation ([Ca\u2081\u2080(PO\u2084)\u2086F\u2082]) Phosphate Co-structural in fluorapatite Saliva Provides calcium and phosphate for remineralisation promoted by fluoride"},{"location":"minerals/fluoride/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption ~80\u201390% of soluble fluoride absorbed rapidly in stomach and small intestine Absorption reduced by Calcium, aluminium, and magnesium (form insoluble complexes) Distribution 99% in mineralised tissues (bone and teeth); rapid initial distribution to hard tissues Plasma peak ~30\u201360 minutes after ingestion Excretion Primarily renal (~50\u201360% within 24 hours); remainder deposited in bone; sweat and faeces minor Half-life (plasma) ~2\u20139 hours"},{"location":"minerals/fluoride/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Fluoride deficiency is not associated with essential biochemical dysfunction beyond dental effects.</p> <p>Manifestations: Increased susceptibility to dental caries (cavities) \u2014 the primary and most clinically important consequence. Communities without water fluoridation or fluoride in diet have significantly higher caries rates.</p> <p>Note: Unlike other minerals, fluoride deficiency does not cause a characteristic clinical syndrome beyond dental caries \u2014 it is therefore often termed a \"conditional essential\" mineral with primary dental rather than metabolic essentiality.</p>"},{"location":"minerals/fluoride/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Caries prevention (community) Water fluoridation at 0.7 mg/L; fluoride toothpaste (1,000\u20131,500 ppm for adults, 1,000 ppm ages 3\u20136) Caries prevention (high-risk child) Fluoride varnish (22,600 ppm NaF) applied 2\u20134\u00d7/year by dental professional Children in non-fluoridated areas Fluoride supplements prescribed by dentist (0.25\u20131 mg/day based on age and water fluoride level) Severe acute fluoride ingestion Induce vomiting; calcium gluconate or milk to bind fluoride; IV calcium gluconate for hypocalcaemia"},{"location":"minerals/fluoride/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Calcium antacids / milk Reduce fluoride absorption (form insoluble CaF\u2082) \u2014 avoid co-ingestion with fluoride supplements Aluminium and magnesium antacids Similarly reduce fluoride absorption Ciprofloxacin and fluoroquinolones Contain fluorine but not fluoride \u2014 unrelated to dietary fluoride toxicology"},{"location":"minerals/fluoride/#food-sources","title":"Food Sources","text":"Food Serving Fluoride (mg) Fluoridated tap water 1 L ~0.7 mg Tea (black, brewed) 240 ml 0.1\u20130.6 mg Canned sardines (with bones) 85g ~0.2 mg Shrimp 85g ~0.17 mg Crab 85g ~0.21 mg Grape juice / raisins 240 ml / 145g ~0.07\u20130.17 mg Potatoes (boiled in fluoridated water) 1 medium ~0.05\u20130.10 mg <p>Most dietary fluoride comes from fluoridated drinking water and beverages made with it. Foods prepared with fluoridated water also contribute.</p>"},{"location":"minerals/fluoride/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Fluoride is not degraded by cooking or storage. However, foods cooked in fluoridated water absorb additional fluoride.</li> <li>Fluoride concentrations in tea increase with steeping time.</li> </ul>"},{"location":"minerals/fluoride/#toxicity","title":"Toxicity","text":"Type Detail Dental fluorosis Exposure during tooth development (0\u20138 years) \u2192 white spots, pitting, or brown staining of enamel; primarily cosmetic at mild\u2013moderate levels Skeletal fluorosis Chronic very high intake (&gt;10 mg/day for years) \u2192 bone pain, increased density, calcification of ligaments, osteosclerosis; seen in areas with naturally high fluoride water (&gt;4 mg/L) Acute toxicity ~5 mg/kg body weight is lethal; as low as 1 mg/kg causes GI symptoms; symptoms: nausea, vomiting, hypocalcaemia, tetany, cardiac arrhythmia Thyroid Controversy exists; very high endemic fluoride areas associated with altered thyroid function in some studies; not established at public health fluoridation levels"},{"location":"minerals/iodine/","title":"Iodine (I)","text":""},{"location":"minerals/iodine/#overview","title":"Overview","text":"<p>Iodine is an essential trace mineral required exclusively for the synthesis of thyroid hormones \u2014 thyroxine (T4) and triiodothyronine (T3). Thyroid hormones regulate metabolism in virtually every cell in the body, making iodine indispensable for normal growth, development, and metabolic rate. Iodine deficiency is the world's leading preventable cause of brain damage and intellectual disability.</p> <ul> <li>Atomic number: 53; biologically active as iodide (I\u207b)</li> <li>Category: Trace mineral</li> <li>Body content: ~15\u201320 mg; ~70\u201380% in the thyroid gland</li> <li>Key fact: Iodine deficiency affects approximately 2 billion people globally; iodisation of salt is one of the most cost-effective public health interventions.</li> </ul>"},{"location":"minerals/iodine/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 110 \u00b5g/day (AI) Infants 7\u201312 months 130 \u00b5g/day (AI) Children 1\u20138 years 90 \u00b5g/day Children 9\u201313 years 120 \u00b5g/day Adolescents 14\u201318 years 150 \u00b5g/day Adults 19+ 150 \u00b5g/day Pregnant Women 220 \u00b5g/day Breastfeeding Women 290 \u00b5g/day <p>Tolerable Upper Intake Level (UL): 1,100 \u00b5g/day for adults (includes all sources).</p>"},{"location":"minerals/iodine/#functions","title":"Functions","text":"<ul> <li>Thyroid Hormone Synthesis: Iodide is actively transported into thyroid follicular cells (via NIS \u2014 sodium-iodide symporter), oxidised to iodine by thyroid peroxidase (TPO) (selenium-dependent enzyme), incorporated into thyroglobulin at tyrosine residues to form monoiodotyrosine (MIT) and diiodotyrosine (DIT), coupled to form T4 and T3.</li> <li>Metabolic Rate Regulation: T3 binds nuclear thyroid hormone receptors \u2192 regulates transcription of genes controlling basal metabolic rate, thermogenesis, and oxidative phosphorylation capacity.</li> <li>Growth and Development: Essential for normal linear growth, bone maturation, and organ development.</li> <li>Brain Development: Critical in fetal and neonatal periods \u2014 T3 is required for neuronal migration, myelination, synaptic development, and dendritic growth. Deficiency \u2192 cretinism.</li> <li>Cardiac Function: T3 regulates heart rate and cardiac contractility.</li> <li>Reproductive Function: Required for ovulation and pregnancy maintenance.</li> <li>Antimicrobial Properties: Topical iodine (Lugol's, povidone-iodine) has direct bactericidal, virucidal, and fungicidal activity.</li> </ul>"},{"location":"minerals/iodine/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Selenium (deiodinases) DIO1 and DIO2 convert T4 \u2192 active T3; selenium deficiency impairs T3 production Iron (thyroid peroxidase) TPO is a haem-containing enzyme; iron deficiency reduces its activity and impairs thyroid hormone synthesis Zinc Required for thyroid hormone receptor function and T3 binding Tyrosine Amino acid substrate for iodination (thyroglobulin tyrosine residues)"},{"location":"minerals/iodine/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Essentially 100% of dietary iodide absorbed in stomach and small intestine NIS (sodium-iodide symporter) Concentrates iodide 20\u201340\u00d7 in thyroid tissue against gradient; also in breast and salivary glands Thyroid uptake Radioiodine uptake (RAIU) is ~10\u201330% of administered dose normally; used diagnostically and therapeutically Thyroid hormone half-life T4: 5\u20137 days; T3: 1\u20132 days; rT3: 4 hours Excretion Primarily urinary (&gt;90%); 24-hour urinary iodine is the best population-level marker of iodine status"},{"location":"minerals/iodine/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Iodine Deficiency Disorders (IDD) \u2014 a spectrum by life stage:</p> Stage Manifestation Fetal / neonatal Cretinism (intellectual disability, deafness, spastic diplegia, short stature), stillbirth, miscarriage Neonatal / infant Neonatal hypothyroidism; impaired brain development Child Goitre, impaired mental and physical development, poor school performance Adult Goitre (compensatory thyroid enlargement), hypothyroidism, fatigue, weight gain, cold intolerance, constipation Pregnancy Foetal brain damage; increased perinatal and neonatal mortality"},{"location":"minerals/iodine/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary iodine deficiency Iodised salt; potassium iodide supplementation 150\u2013300 \u00b5g/day; Lugol's iodine where necessary Pregnancy iodine deficiency 220 \u00b5g/day via iodine-containing prenatal supplement Neonatal hypothyroidism IV levothyroxine initiated immediately; iodine supplementation if cause is deficiency Thyroid storm (emergency) Potassium iodide (SSKI) given 1+ hour after thionamide to block thyroid hormone release (Wolff-Chaikoff effect) Radiation emergency (nuclear fallout) Potassium iodide tablets to saturate thyroid NIS and block radioiodine uptake: 130 mg KI for adults"},{"location":"minerals/iodine/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Amiodarone Contains 37% iodine by weight; causes drug-induced thyrotoxicosis (excess iodine \u2192 Jod-Basedow effect) or hypothyroidism (Wolff-Chaikoff) Lithium Inhibits thyroidal iodide uptake and thyroid hormone secretion \u2192 hypothyroidism Goitrogens (thiouracil, propylthiouracil, methimazole) Block TPO \u2192 reduce thyroid hormone synthesis; used therapeutically in hyperthyroidism Perchlorate / thiocyanate Compete with iodide at NIS \u2192 reduce thyroid uptake (cigarette smoke contains thiocyanate) Radioiodine (\u00b9\u00b3\u00b9I) Used therapeutically for hyperthyroidism and thyroid cancer; requires stopping interfering medications Soy isoflavones High doses may interfere with iodine absorption and thyroid hormone synthesis"},{"location":"minerals/iodine/#food-sources","title":"Food Sources","text":"Food Serving Iodine (\u00b5g) Seaweed (nori, dried) 10g 116\u20132,984 \u00b5g (highly variable) Cod (baked) 85g ~99 \u00b5g Iodised salt 1/4 tsp ~71 \u00b5g Milk (cow, whole) 240 ml ~56 \u00b5g Plain yogurt 245g ~75 \u00b5g Shrimp 85g ~35 \u00b5g Eggs 1 large ~24 \u00b5g Canned tuna 85g ~17 \u00b5g Prunes (dried) 5 prunes ~13 \u00b5g <p>Note: Non-iodised sea salt and gourmet salts do not contain meaningful iodine. Seaweed can provide dangerous iodine excess \u2014 excess iodine paradoxically inhibits thyroid (Wolff-Chaikoff effect).</p>"},{"location":"minerals/iodine/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Iodine in food is relatively stable. Cooking causes some losses (10\u201350% depending on method).</li> <li>Iodised salt loses iodine gradually when exposed to air, moisture, and light \u2014 store covered and dry.</li> </ul>"},{"location":"minerals/iodine/#toxicity","title":"Toxicity","text":"Intake Effect &gt;1,100 \u00b5g/day (UL exceeded) May trigger hypothyroidism or hyperthyroidism (Jod-Basedow) in susceptible individuals Wolff-Chaikoff effect Acute iodine load transiently inhibits thyroid organification \u2014 normally escaped; failure in neonates / diseased glands Jod-Basedow phenomenon Iodine excess \u2192 hyperthyroidism in glands with autonomous nodules or Graves' disease Seaweed-induced thyrotoxicosis Reported from excessive seaweed consumption (particularly kelp supplements)"},{"location":"minerals/iron/","title":"Iron (Fe)","text":""},{"location":"minerals/iron/#overview","title":"Overview","text":"<p>Iron is the most abundant trace mineral in the human body, with approximately 2.5\u20134 g in average adults. It exists in two functional pools: functional iron (in haemoglobin, myoglobin, cytochromes, and iron-containing enzymes) and storage iron (ferritin and haemosiderin in liver, spleen, and bone marrow). Iron's primary biological role is oxygen transport and electron transfer, enabled by its reversible Fe\u00b2\u207a \u2194 Fe\u00b3\u207a redox cycling.</p> <ul> <li>Atomic number: 26; exists as ferrous (Fe\u00b2\u207a) and ferric (Fe\u00b3\u207a) forms</li> <li>Category: Trace mineral</li> <li>Key fact: Iron deficiency is the most prevalent nutritional deficiency worldwide, affecting ~2 billion people.</li> </ul>"},{"location":"minerals/iron/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 0.27 mg/day (AI) Infants 7\u201312 months 11 mg/day Children 1\u20133 years 7 mg/day Children 4\u20138 years 10 mg/day Children 9\u201313 years 8 mg/day Adolescents 14\u201318 (male) 11 mg/day Adolescents 14\u201318 (female) 15 mg/day Adult Men 19\u201350 8 mg/day Adult Women 19\u201350 18 mg/day Adults 51+ (both sexes) 8 mg/day Pregnant Women 27 mg/day Breastfeeding Women 9\u201310 mg/day <p>Tolerable Upper Intake Level (UL): 45 mg/day for adults.</p>"},{"location":"minerals/iron/#functions","title":"Functions","text":"<ul> <li>Oxygen Transport (Haemoglobin): Fe\u00b2\u207a in haem of haemoglobin binds O\u2082 reversibly \u2014 each haemoglobin carries 4 Fe atoms and 4 O\u2082 molecules. ~70% of body iron is in RBCs.</li> <li>Oxygen Storage (Myoglobin): Iron in myoglobin stores and releases O\u2082 in muscle cells during exercise.</li> <li>Electron Transport Chain: Iron-sulfur proteins (Complexes I, II, III) and cytochrome c oxidase (Complex IV) require iron for electron transfer \u2014 fundamental to ATP synthesis.</li> <li>DNA Synthesis: Ribonucleotide reductase (converts ribonucleotides to deoxyribonucleotides) is an iron-dependent enzyme.</li> <li>Catalase and Peroxidases: Haem-iron enzymes that decompose hydrogen peroxide \u2014 antioxidant defence.</li> <li>Neurotransmitter Synthesis: Tyrosine hydroxylase (dopamine, norepinephrine) and tryptophan hydroxylase (serotonin) are iron-dependent.</li> <li>Thyroid Hormone Synthesis: Thyroid peroxidase (iodination of thyroglobulin) is a haem enzyme.</li> <li>Immune Function: Required for neutrophil bactericidal activity (myeloperoxidase) and T-cell proliferation.</li> </ul>"},{"location":"minerals/iron/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Vitamin C Reduces Fe\u00b3\u207a to Fe\u00b2\u207a in gut lumen \u2192 enhances non-haem iron absorption (2\u20134\u00d7 increase) Gastric acid / pepsin Releases iron from food matrix; reduces Fe\u00b3\u207a to Fe\u00b2\u207a Copper (ceruloplasmin) Ceruloplasmin oxidises Fe\u00b2\u207a to Fe\u00b3\u207a for transferrin binding; copper deficiency \u2192 functional iron deficiency Vitamin A Mobilises iron from ferritin stores; deficiency impairs iron utilisation Ferritin / transferrin Storage and transport proteins; iron loading requires these apoprotein backbones"},{"location":"minerals/iron/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Forms absorbed Haem iron (Fe\u00b2\u207a, from meat/fish) \u2014 absorbed ~25%; non-haem iron (mainly Fe\u00b3\u207a, plant foods) \u2014 absorbed 2\u201320% Absorption site Duodenum and proximal jejunum; DMT1 (divalent metal transporter) for non-haem; separate receptor-mediated for haem iron Enhancers Vitamin C, meat factor, acidic pH Inhibitors Phytate, polyphenols/tannins (tea, coffee), calcium, oxalate, egg yolk phosphoproteins Distribution ~70% haemoglobin; ~10% myoglobin + enzymes; ~20% stored as ferritin/haemosiderin Regulation Hepcidin (liver-derived hormone) is the master regulator \u2014 blocks ferroportin export from enterocytes and macrophages Excretion Minimal \u2014 1\u20132 mg/day lost via gut cell sloughing, sweat, menstruation; no active excretion mechanism"},{"location":"minerals/iron/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Iron deficiency progresses through three stages: 1. Iron depletion: Ferritin falls, no anaemia 2. Iron-deficient erythropoiesis: Low transferrin saturation, elevated TIBC, microcytosis emerging 3. Iron deficiency anaemia (IDA): Microcytic, hypochromic anaemia \u2014 Hb &lt;12 g/dL (women) or &lt;13 g/dL (men)</p> <p>Symptoms: - Fatigue, pallor, exertional dyspnoea, palpitations - Glossitis, angular cheilitis, koilonychia (spoon nails) - Pica (craving non-food items \u2014 ice, clay, dirt) - Restless leg syndrome - Impaired cognitive development (especially children &lt;2 years) - Impaired thyroid hormone synthesis \u2192 secondary hypothyroidism</p> <p>Diagnosis: Serum ferritin (best early marker), transferrin saturation, TIBC, reticulocyte haemoglobin content, peripheral smear.</p>"},{"location":"minerals/iron/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild-moderate IDA Ferrous sulfate 200 mg (65 mg elemental Fe) oral 3\u00d7/day; alternate-day dosing may reduce GI side effects Alternate oral agents Ferrous gluconate, ferrous fumarate, ferric maltol (better GI tolerance) Poor oral tolerance / severe IDA IV iron \u2014 ferric carboxymaltose, iron sucrose, low-molecular-weight iron dextran Functional iron deficiency (CKD, inflammation) IV iron + erythropoiesis-stimulating agents (ESAs) Iron deficiency in pregnancy 27 mg/day dietary + 30\u2013120 mg/day supplemental as indicated <p>Take oral iron with vitamin C, on an empty stomach if tolerated. Separate from calcium, tea, and coffee by \u22652 hours.</p>"},{"location":"minerals/iron/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Antacids / PPIs Reduce gastric acid \u2192 impair non-haem iron reduction and absorption Tetracycline / fluoroquinolone antibiotics Iron chelates drug \u2192 reduced antibiotic absorption; separate by \u22652 hours Levothyroxine Iron reduces absorption \u2014 separate by \u22654 hours Bisphosphonates Iron reduces absorption \u2014 separate by \u22652 hours Calcium supplements Compete at DMT1 transporter \u2192 reduce iron absorption Deferoxamine / deferasirox Iron chelators \u2014 used in iron overload Methyldopa Iron reduces absorption Cholestyramine Binds iron in gut; impairs absorption"},{"location":"minerals/iron/#food-sources","title":"Food Sources","text":"Food Serving Iron (mg) Type Beef liver (cooked) 85g ~5.2 mg Haem (~40%) Oysters (cooked) 85g ~8 mg Haem White beans (cooked) 90g ~3.9 mg Non-haem Fortified breakfast cereal 1 cup 2\u201318 mg Non-haem Dark chocolate (70\u201385%) 28g ~3.4 mg Non-haem Lentils (cooked) 90g ~3.3 mg Non-haem Beef (ground, 85% lean, cooked) 85g ~2.2 mg Haem (~40%) Tofu (firm) 85g ~2.0 mg Non-haem Kidney beans (cooked) 90g ~2.0 mg Non-haem Spinach (cooked) 90g ~3.2 mg Non-haem (low bioavailability)"},{"location":"minerals/iron/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Iron mineral content in food is not degraded by cooking.</li> <li>Cast-iron cookware can increase iron content of acidic foods significantly.</li> <li>Vitamin C in the same meal significantly improves non-haem iron absorption.</li> </ul>"},{"location":"minerals/iron/#toxicity-iron-overload","title":"Toxicity (Iron Overload)","text":"<ul> <li>Acute toxicity (children): Adult iron supplement ingestion is a leading cause of poisoning in children; &gt;20 mg/kg elemental iron can cause GI haemorrhage, metabolic acidosis, liver failure.</li> <li>Hereditary haemochromatosis: Autosomal recessive (HFE gene mainly) \u2014 unregulated iron absorption leads to systemic iron deposition (liver cirrhosis, cardiomyopathy, bronze diabetes, arthropathy, hypogonadism). Treatment: phlebotomy.</li> <li>Transfusional iron overload: Frequent transfusions in haemoglobin disorders \u2192 chelation with deferoxamine or deferasirox.</li> <li>Serum markers: Elevated ferritin (&gt;300 \u00b5g/L men, &gt;200 \u00b5g/L women) + transferrin saturation &gt;45% suggests overload; liver biopsy or MRI liver iron quantification for confirmation.</li> </ul>"},{"location":"minerals/magnesium/","title":"Magnesium (Mg)","text":""},{"location":"minerals/magnesium/#overview","title":"Overview","text":"<p>Magnesium is the fourth most abundant mineral in the body and the second most abundant intracellular cation after potassium. It is a cofactor for over 300 enzymatic reactions, including all reactions involving ATP (which must be complexed as Mg-ATP to be biologically active). Approximately 60% of body magnesium is in bone, 39% in soft tissues, and less than 1% in serum.</p> <ul> <li>Atomic number: 12; divalent cation (Mg\u00b2\u207a)</li> <li>Category: Macromineral</li> <li>Body content: ~25 g in average adult</li> <li>Key fact: Serum magnesium accounts for &lt;1% of total body magnesium \u2014 serum levels are a poor marker of total body status.</li> </ul>"},{"location":"minerals/magnesium/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 30 mg/day (AI) Infants 7\u201312 months 75 mg/day (AI) Children 1\u20133 years 80 mg/day Children 4\u20138 years 130 mg/day Children 9\u201313 years 240 mg/day Adolescents 14\u201318 (male) 410 mg/day Adolescents 14\u201318 (female) 360 mg/day Adult Men 19\u201330 400 mg/day Adult Men 31+ 420 mg/day Adult Women 19\u201330 310 mg/day Adult Women 31+ 320 mg/day Pregnant Women 19\u201330 350 mg/day Pregnant Women 31+ 360 mg/day Breastfeeding Women 310\u2013320 mg/day <p>Tolerable Upper Intake Level (UL): 350 mg/day from supplements only (food magnesium has no established UL). The UL applies to non-food sources only due to osmotic laxative effect.</p>"},{"location":"minerals/magnesium/#functions","title":"Functions","text":"<ul> <li>ATP Activation: Mg\u00b2\u207a chelates ATP to form the biologically active Mg-ATP complex required by all ATPases, kinases, and energy-transducing enzymes.</li> <li>DNA Synthesis and Repair: Cofactor for DNA polymerases, ligases, and repair enzymes; essential for RNA transcription.</li> <li>Protein Synthesis: Required by ribosomes for ternary complex formation during translation.</li> <li>Glycolysis: Cofactor for phosphoglycerate kinase, phosphoglycerate mutase, pyruvate kinase, and enolase.</li> <li>Bone Mineralisation: Incorporated into bone hydroxyapatite; stimulates osteoblast activity and regulates bone crystal size.</li> <li>Calcium Channel Blockade: Acts as a physiological antagonist of voltage-gated calcium channels \u2014 the basis for its anticonvulsant and antiarrhythmic effects.</li> <li>Neuromuscular Transmission: Regulates pre-synaptic calcium entry and inhibits acetylcholine release; magnesium deficiency causes neuromuscular hyperexcitability.</li> <li>Cardiovascular: Vasodilation; inhibits platelet aggregation; antiarrhythmic (prolonged refractory period).</li> <li>Insulin Signalling: Required for insulin receptor tyrosine kinase activity; deficiency associated with insulin resistance.</li> <li>PTH and Vitamin D Metabolism: Required for PTH secretion and for hydroxylation steps in vitamin D activation.</li> </ul>"},{"location":"minerals/magnesium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Vitamin B6 Needed for magnesium transport into cells (PLP-dependent processes) Vitamin D Reciprocal: magnesium is required for vitamin D activation, and vitamin D may improve Mg absorption Potassium Hypomagnesaemia causes potassium wasting; both deficiencies often co-occur ATP Required target for Mg\u00b2\u207a complexation \u2014 linked in all enzymatic activity"},{"location":"minerals/magnesium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 30\u201340% of dietary intake absorbed; primarily paracellular in ileum and colon; TRPM6/TRPM7 channels for active transport Absorption increases Low dietary intake, vitamin D sufficiency, protein intake, fermentable fibre Absorption decreases High phytate, oxalate, high calcium intake, alcohol, chronic PPI use Distribution ~60% bone; ~39% muscles/soft tissue; &lt;1% serum (0.75\u20130.95 mmol/L normal) Excretion Kidneys are principal regulators; ~120 mg/day filtered; reabsorbed primarily in thick ascending loop of Henle Renal conservation Deficiency triggers up to 95% tubular reabsorption (highly efficient) Half-life (serum) Not applicable \u2014 serum levels reflect renal handling, not true stores"},{"location":"minerals/magnesium/#effects-of-deficiency-hypomagnesaemia","title":"Effects of Deficiency (Hypomagnesaemia)","text":"<p>Serum Mg &lt;0.75 mmol/L. Often concurrent with hypokalaemia and hypocalcaemia.</p> <p>Causes: - Excessive alcohol consumption (major cause) - Poorly controlled type 2 diabetes (urinary Mg wasting) - Chronic diarrhoea, malabsorption syndromes - Loop/thiazide diuretics - Prolonged PPI use - Post-surgery (refeeding, bowel resection) - Medications: cisplatin, amphotericin B, aminoglycosides</p> <p>Symptoms: - Early: Anorexia, nausea, fatigue, weakness - Neuromuscular: Tremor, muscle cramps, tetany (Trousseau's/Chvostek's sign) - Cardiac: Prolonged PR/QT intervals, arrhythmias (PVCs, VT, VF) \u2014 especially dangerous - Neurological: Confusion, depression, personality changes; seizures in severe deficiency - Bone: Hypomagnesaemia \u2192 hypocalcaemia (impairs PTH secretion and action) - Electrolyte: Refractory hypokalaemia and hypocalcaemia that cannot be corrected until Mg is replete</p>"},{"location":"minerals/magnesium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild deficiency (asymptomatic) Oral magnesium glycinate/citrate/malate 200\u2013400 mg/day (better tolerated than oxide) Moderate deficiency Oral 400\u2013800 mg/day elemental Mg; correct underlying cause Severe / symptomatic IV magnesium sulfate (MgSO\u2084) 1\u20134 g over 15\u201360 minutes; repeat as needed Eclampsia/pre-eclampsia IV MgSO\u2084 4\u20136 g loading dose then 1\u20132 g/hour maintenance (gold standard) Torsades de pointes IV MgSO\u2084 2 g over 1\u20132 minutes (regardless of serum Mg level) Severe asthma (acute) IV MgSO\u2084 2 g over 20 minutes (bronchodilator effect) Migraine prophylaxis Oral 400\u2013600 mg/day \u2014 evidence-supported"},{"location":"minerals/magnesium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Loop diuretics (furosemide) Increase urinary Mg excretion \u2192 hypomagnesaemia Thiazide diuretics Increase urinary Mg wasting Proton pump inhibitors (PPIs) Long-term use impairs intestinal Mg absorption \u2192 clinically significant hypomagnesaemia Cisplatin Nephrotoxic magnesium wasting (tubular damage) Amphotericin B Renal Mg wasting Aminoglycosides Tubular damage \u2192 Mg loss Digoxin Hypomagnesaemia increases digoxin toxicity risk Bisphosphonates Mg may reduce absorption; separate by \u22652 hours Calcium channel blockers Magnesium potentiates hypotensive effects Magnesium antacids/laxatives + antibiotics (quinolones, tetracyclines) Chelation reduces antibiotic absorption \u2014 separate by \u22652 hours"},{"location":"minerals/magnesium/#food-sources","title":"Food Sources","text":"Food Serving Magnesium (mg) Pumpkin seeds (roasted) 28g ~150 mg Chia seeds 28g ~111 mg Almonds 28g ~80 mg Cooked spinach 90g ~78 mg Cashews 28g ~74 mg Black beans (cooked) 90g ~60 mg Edamame (cooked) 90g ~50 mg Whole wheat bread 2 slices ~46 mg Dark chocolate (70\u201385% cacao) 28g ~65 mg Avocado \u00bd medium ~22 mg Banana 1 medium ~32 mg"},{"location":"minerals/magnesium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>As a mineral, magnesium is not degraded by cooking, light, or storage.</li> <li>Refining of grains removes magnesium-rich bran and germ \u2014 white flour provides &lt;30% the Mg of whole wheat flour.</li> <li>Processing and boiling (and discarding cooking water) reduce Mg in vegetables.</li> </ul>"},{"location":"minerals/magnesium/#toxicity-hypermagnesaemia","title":"Toxicity (Hypermagnesaemia)","text":"<p>Almost exclusively occurs in renal failure or with excessive supplemental/therapeutic use.</p> Serum Level Clinical Effect &gt;1.1 mmol/L Nausea, flushing, hypotension &gt;2.5 mmol/L Loss of deep tendon reflexes, somnolence &gt;5 mmol/L Respiratory paralysis, heart block &gt;7.5 mmol/L Cardiac arrest <p>Treatment: IV calcium gluconate (antagonises Mg\u00b2\u207a at calcium channels), hydration, and haemodialysis in renal failure.</p> <p>Oral magnesium supplement toxicity: Causes osmotic diarrhoea long before systemic toxicity \u2014 self-limiting in normal renal function.</p>"},{"location":"minerals/manganese/","title":"Manganese (Mn)","text":""},{"location":"minerals/manganese/#overview","title":"Overview","text":"<p>Manganese is an essential trace mineral that functions as both a direct enzyme cofactor and as a structural component of metalloenzymes. Total body manganese is approximately 10\u201320 mg, concentrated in bone, liver, kidney, and brain. Its most critical role in humans is as a cofactor for manganese superoxide dismutase (MnSOD, SOD2) \u2014 the primary mitochondrial antioxidant enzyme.</p> <ul> <li>Atomic number: 25; exists primarily as Mn\u00b2\u207a and Mn\u00b3\u207a in biological systems</li> <li>Category: Trace mineral</li> <li>Body content: ~10\u201320 mg in average adult</li> </ul>"},{"location":"minerals/manganese/#requirements-ai","title":"Requirements (AI)","text":"Age / Group Adequate Intake (AI) Infants 0\u20136 months 0.003 mg/day Infants 7\u201312 months 0.6 mg/day Children 1\u20133 years 1.2 mg/day Children 4\u20138 years 1.5 mg/day Males 9\u201313 years 1.9 mg/day Females 9\u201313 years 1.6 mg/day Males 14\u201318 years 2.2 mg/day Females 14\u201318 years 1.6 mg/day Adult Men 19+ 2.3 mg/day Adult Women 19+ 1.8 mg/day Pregnant Women 2.0 mg/day Breastfeeding Women 2.6 mg/day <p>Tolerable Upper Intake Level (UL): 11 mg/day for adults from all sources.</p>"},{"location":"minerals/manganese/#functions","title":"Functions","text":"<ul> <li>Mitochondrial Antioxidant (MnSOD / SOD2): Manganese superoxide dismutase is the primary O\u2082\u207b scavenger in mitochondria; converts superoxide to H\u2082O\u2082 \u2192 further reduced by glutathione peroxidase or catalase.</li> <li>Gluconeogenesis (Pyruvate Carboxylase): Manganese activates pyruvate carboxylase (or is present in magnesium's place), catalysing pyruvate \u2192 oxaloacetate \u2014 the first step in gluconeogenesis.</li> <li>Glycosaminoglycan Synthesis: Manganese activates glycosyltransferases involved in chondroitin sulphate and heparan sulphate synthesis \u2014 essential for cartilage and extracellular matrix formation.</li> <li>Urea Cycle (Arginase): Mn-containing arginase converts arginine \u2192 urea + ornithine; essential for nitrogen disposal.</li> <li>Glutamine Synthesis (Glutamine Synthetase): Mn-dependent enzyme recycles glutamate + NH\u2083 \u2192 glutamine; important in the brain and liver.</li> <li>Bone Formation: Mn activates glycosyltransferases for osteocalcin and proteoglycan synthesis; low manganese \u2192 impaired bone formation.</li> <li>Carbohydrate Metabolism: Activates various kinases and phosphatases in carbohydrate pathways.</li> <li>Coagulation: Mn activates some clotting factors and cofactor for prothrombin synthesis.</li> </ul>"},{"location":"minerals/manganese/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Iron Iron and manganese share intestinal absorptive transporters (DMT1); excess iron reduces Mn absorption Calcium High calcium reduces manganese absorption Magnesium Mg can substitute Mn in some enzyme-binding sites"},{"location":"minerals/manganese/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 1\u20135% of dietary intake; absorbed in small intestine via DMT1 (shared with iron); transferrin can bind Mn Absorption inversely related Higher body iron stores \u2192 lower manganese absorption Distribution Bone (~40%), liver, kidney, pancreas, brain; transported by transferrin and \u03b1\u2082-macroglobulin Homeostasis Primarily controlled by biliary excretion (not renal); bile secretion is the main regulatory mechanism Half-life ~37\u201339 days"},{"location":"minerals/manganese/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>True dietary manganese deficiency in humans is extremely rare and has not been documented naturally outside of experimental settings.</p> <p>Experimentally induced deficiency (Doisy 1972): dermatitis, hypocholesterolaemia, impaired glucose tolerance, reduced coagulation factor activity, impaired growth.</p> <p>Marginal deficiency associations: Reduced bone density, impaired glycosaminoglycan synthesis (cartilage), altered glucose metabolism, impaired reproductive function.</p>"},{"location":"minerals/manganese/#treatment-protocols","title":"Treatment Protocols","text":"<p>Manganese deficiency resolves with adequate dietary intake or supplementation at the AI level. No established therapeutic protocol for acquired deficiency due to its rarity.</p> Condition Protocol Parenteral nutrition without Mn Include 55\u2013100 \u00b5g/day Mn in TPN formulations TPN-associated deficiency Supplement 0.2\u20130.3 mg/day IV"},{"location":"minerals/manganese/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Iron supplements High iron reduces Mn absorption (shared DMT1 transporter) Calcium / magnesium supplements High intake can reduce Mn absorption Antacids May impair Mn absorption in the gut Antipsychotics Manganese may modulate dopamine neurotransmission"},{"location":"minerals/manganese/#food-sources","title":"Food Sources","text":"Food Serving Manganese (mg) Mussels (cooked) 85g ~5.8 mg Hazelnuts 28g ~1.7 mg Pecans 28g ~1.1 mg Brown rice (cooked) 195g ~1.8 mg Pineapple (chunks) 165g ~1.5 mg Oatmeal (cooked) 234g ~1.4 mg Tempeh 85g ~1.0 mg Soybeans (roasted) 85g ~1.7 mg Spinach (cooked) 90g ~0.8 mg Tea (black, brewed) 240 ml ~0.5 mg"},{"location":"minerals/manganese/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Manganese in food is stable to heat and storage. Refining removes significant manganese \u2014 whole grains contain much more than refined flours.</li> </ul>"},{"location":"minerals/manganese/#toxicity-manganism","title":"Toxicity (Manganism)","text":"<p>Dietary toxicity from food alone is essentially unknown. Toxicity is largely from occupational/environmental inhalation (mining, welding, battery manufacturing).</p> Source Effect Inhalation (occupational) Manganism \u2014 Parkinson-like syndrome (tremor, rigidity, bradykinesia, psychiatric symptoms); manganese preferentially accumulates in basal ganglia Chronic TPN with excess Mn Brain manganese accumulation \u2192 neurological symptoms (T1-bright basal ganglia on MRI) Well water contamination Elevated Mn in drinking water linked to cognitive deficits in children Dietary excess (supplements) UL 11 mg/day \u2014 chronic &gt;11 mg/day associated with neurotoxic risk <p>Mn neurotoxicity is distinct from Parkinson's disease \u2014 involves globus pallidus and has specific clinical features.</p>"},{"location":"minerals/molybdenum/","title":"Molybdenum (Mo)","text":""},{"location":"minerals/molybdenum/#overview","title":"Overview","text":"<p>Molybdenum is an essential trace mineral that forms part of the molybdenum cofactor (Moco) \u2014 a complex with molybdopterin that is required by four human enzymes (molybdoenzymes). These enzymes catalyse oxidation-reduction reactions involved in the metabolism of purines, sulfur-containing amino acids, and certain heterocyclic compounds. Molybdenum deficiency is extraordinarily rare in the general population.</p> <ul> <li>Atomic number: 42; functions as Mo\u2074\u207a/Mo\u2075\u207a/Mo\u2076\u207a in redox cycling within Moco</li> <li>Category: Trace mineral</li> <li>Body content: ~9 mg in average adult; distributed in liver, kidney, adrenal glands, bone</li> <li>Key fact: Molybdenum has the highest UL relative to dietary intake of any essential mineral \u2014 typical dietary intake is well within safe limits.</li> </ul>"},{"location":"minerals/molybdenum/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 2 \u00b5g/day (AI) Infants 7\u201312 months 3 \u00b5g/day (AI) Children 1\u20133 years 17 \u00b5g/day Children 4\u20138 years 22 \u00b5g/day Children 9\u201313 years 34 \u00b5g/day Adolescents 14\u201318 years 43 \u00b5g/day Adults 19+ 45 \u00b5g/day Pregnant Women 50 \u00b5g/day Breastfeeding Women 50 \u00b5g/day <p>Tolerable Upper Intake Level (UL): 2,000 \u00b5g/day (2 mg/day) for adults.</p>"},{"location":"minerals/molybdenum/#functions","title":"Functions","text":"<p>Molybdenum functions via four molybdoenzymes in humans:</p> Enzyme Reaction Significance Xanthine oxidase / XDH Hypoxanthine \u2192 xanthine \u2192 uric acid (purine catabolism) Uric acid is an important plasma antioxidant; excess causes gout Aldehyde oxidase Oxidises aromatic aldehydes (e.g., retinaldehyde \u2192 retinoic acid), pyrimidines, purine metabolites, drugs Drug metabolism (phase I) in liver Sulfite oxidase Sulfite (SO\u2083\u00b2\u207b) \u2192 sulfate (SO\u2084\u00b2\u207b) \u2014 final step in cysteine and methionine catabolism Detoxifies sulfite from protein catabolism and food preservation Mitochondrial amidoxime reducing component (mARC) Reduces N-hydroxylated bases and amidoximes; reduces nitrite to NO Prodrug activation; nitric oxide metabolism"},{"location":"minerals/molybdenum/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Molybdopterin (MPT) Organic scaffold complexed with Mo to form Moco; synthesised from GTP in a multi-step pathway FAD (riboflavin) Electron carrier in xanthine oxidase reaction Iron (Fe-S clusters) Xanthine oxidase contains both Moco and Fe-S clusters for electron transfer Copper At very high intakes, molybdenum forms thiomolybdate \u2192 binds copper \u2192 can cause copper deficiency (interaction in ruminants; clinically relevant in Wilson's disease treatment research)"},{"location":"minerals/molybdenum/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 88\u201393% of dietary molybdenum absorbed, primarily in upper GI tract Transport Circulates as molybdate (MoO\u2084\u00b2\u207b) in plasma; loosely bound to red blood cells and albumin Distribution Liver and kidney (highest concentrations); bone Excretion Primarily urinary molybdate; kidneys are the primary homeostatic regulators Half-life ~50\u201396 hours (short; rapid renal handling)"},{"location":"minerals/molybdenum/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Naturally occurring molybdenum deficiency has been documented in only one known case \u2014 a patient on long-term total parenteral nutrition without molybdenum supplementation.</p> <p>That case (1981): Tachycardia, tachypnoea, night blindness, irritability \u2192 progressed to coma; elevated plasma methionine and low sulfate; resolved with IV ammonium molybdate supplementation.</p> <p>Confirmed genetic disorder \u2014 Molybdenum Cofactor Deficiency (MoCD): Autosomal recessive, loss of Moco biosynthesis enzymes \u2192 combined deficiency of all four molybdoenzymes. Presents in neonates with intractable seizures, severe intellectual disability, and elevated urinary sulfite. Formerly uniformly fatal; now treated with cyclic pyranopterin monophosphate (cPMP) substitution therapy for Type A (MOCODA gene).</p>"},{"location":"minerals/molybdenum/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol TPN-induced deficiency IV ammonium molybdate 163 \u00b5g/day Standard TPN supplementation 5\u201320 \u00b5g/day (for adults on TPN per ASPEN guidelines) Molybdenum cofactor deficiency (Type A) cPMP (fosdenopterin) substitution \u2014 IV daily; approved by FDA 2021 Excess molybdenum (copper-Mo antagonism) Reduce molybdenum intake; copper supplementation"},{"location":"minerals/molybdenum/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Allopurinol Inhibits xanthine oxidase (same enzyme molybdenum supports) \u2014 used for gout; reduces uric acid Febuxostat Also inhibits xanthine oxidase; additive with Mo restriction considerations Copper supplements Very high molybdenum \u2192 forms thiomolybdate \u2192 chelates copper \u2192 copper deficiency (theoretical in humans; demonstrated in ruminants) Ammonium molybdate (therapeutic) Used as molybdenum source in TPN"},{"location":"minerals/molybdenum/#food-sources","title":"Food Sources","text":"Food Serving Molybdenum (\u00b5g) Legumes (black-eyed peas, cooked) 90g ~288 \u00b5g Lima beans (boiled) 90g ~104 \u00b5g Chickpeas (cooked) 90g ~66 \u00b5g Oats (rolled, dry) 40g ~22 \u00b5g Beef liver (cooked) 85g ~138 \u00b5g Whole wheat bread 2 slices ~32 \u00b5g Milk 240 ml ~8 \u00b5g Eggs 1 large ~14 \u00b5g Pork (cooked) 85g ~15 \u00b5g <p>Note: Molybdenum content of plant foods varies significantly with soil molybdenum levels; legumes are universally the richest sources.</p>"},{"location":"minerals/molybdenum/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Molybdenum in food is stable to cooking and storage.</li> <li>High-Mo foods (legumes) retain their molybdenum content well even after prolonged boiling.</li> </ul>"},{"location":"minerals/molybdenum/#toxicity","title":"Toxicity","text":"<p>Molybdenum has very low toxicity in humans; the UL (2,000 \u00b5g/day) is more than 40\u00d7 typical dietary intake (45\u201380 \u00b5g/day).</p> Intake / Scenario Effect High endemic intake (Armenian highlands, Iraq \u2014 10\u201315 mg/day from plant foods) Gout-like symptoms (elevated uric acid from excess XO activity), diarrhoea, growth depression Industrial exposure Occupational exposure to molybdenum dust \u2192 respiratory effects; not typically from dietary intake Animal studies (high doses) Copper deficiency via thiomolybdate formation; anaemia, weight loss <p>Gout connection: Molybdenum excess \u2192 overactive xanthine oxidase \u2192 excess uric acid \u2192 gout. This is the most clinically relevant adverse effect. Conversely, xanthine oxidase inhibitors (allopurinol, febuxostat) are first-line gout treatments.</p>"},{"location":"minerals/phosphorus/","title":"Phosphorus (P)","text":""},{"location":"minerals/phosphorus/#overview","title":"Overview","text":"<p>Phosphorus is the second most abundant mineral in the body, with approximately 85% stored in bones and teeth as hydroxyapatite. The remaining 15% is distributed throughout every cell and in extracellular fluid, where it plays central roles in energy metabolism, nucleic acid synthesis, and membrane structure. Phosphorus exists in the body primarily as phosphate (PO\u2084\u00b3\u207b) in various ionisation states.</p> <ul> <li>Atomic number: 15; forms phosphate anion (H\u2082PO\u2084\u207b, HPO\u2084\u00b2\u207b, PO\u2084\u00b3\u207b) at physiological pH</li> <li>Category: Macromineral</li> <li>Body content: ~700\u2013800 g in average adult</li> <li>Key fact: Phosphorus exists almost entirely as organic or inorganic phosphate \u2014 elemental phosphorus is not found in biological systems.</li> </ul>"},{"location":"minerals/phosphorus/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 100 mg/day (AI) Infants 7\u201312 months 275 mg/day (AI) Children 1\u20133 years 460 mg/day Children 4\u20138 years 500 mg/day Children 9\u201318 years 1,250 mg/day Adults 19+ 700 mg/day Pregnant / Breastfeeding Women 700 mg/day <p>Tolerable Upper Intake Level (UL): 4,000 mg/day for adults 19\u201370; 3,000 mg/day for adults 70+.</p>"},{"location":"minerals/phosphorus/#functions","title":"Functions","text":"<ul> <li>Bone and Teeth Mineralisation: Forms structural hydroxyapatite with calcium; phosphorus:calcium weight ratio in bone \u2248 1:2.</li> <li>Energy Metabolism (ATP): Core component of adenosine triphosphate (ATP) \u2014 the universal cellular energy currency. Also in ADP, AMP, GTP, and creatine phosphate.</li> <li>Nucleic Acid Backbone: Phosphate groups form the sugar-phosphate backbone of DNA and RNA.</li> <li>Phospholipid Membranes: Phosphatidylcholine, phosphatidylserine, and other phospholipids form all biological membranes.</li> <li>Enzyme Regulation: Protein phosphorylation/dephosphorylation is the most ubiquitous cellular signalling mechanism; kinases and phosphatases control virtually all cellular processes.</li> <li>Acid-Base Buffer: Inorganic phosphate (H\u2082PO\u2084\u207b/HPO\u2084\u00b2\u207b) is a major intracellular and urinary buffer (pKa \u2248 6.8).</li> <li>Oxygen Delivery: 2,3-BPG (bisphosphoglycerate) in red blood cells regulates haemoglobin's oxygen affinity.</li> <li>B Vitamins Activation: Forms the phosphorylated active coenzyme forms of B1 (TPP), B2 (FMN, FAD), B3 (NAD, NADP), B6 (PLP).</li> </ul>"},{"location":"minerals/phosphorus/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Vitamin D Promotes intestinal phosphate absorption via NaPi-IIb transporter; increases renal reabsorption Parathyroid Hormone (PTH) Decreases renal tubular phosphate reabsorption (phosphaturic effect) FGF-23 (Fibroblast Growth Factor-23) Bone-derived hormone that increases phosphate excretion; important in CKD Calcium Maintains proper Ca:P ratio; excess phosphorus impairs calcium metabolism"},{"location":"minerals/phosphorus/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Primarily in jejunum; 55\u201370% of dietary phosphorus absorbed; inorganic phosphate (from additives) absorbed at ~90% Bioavailability Reduced by phytate in plant foods (bound form absorbed poorly without phytase); high bioavailability from animal sources Distribution 85% bone/teeth; 14% soft tissue (mainly intracellular); &lt;1% extracellular fluid Normal serum range 0.8\u20131.45 mmol/L (2.5\u20134.5 mg/dL) Regulation PTH, vitamin D, FGF-23, and calcitonin regulate serum phosphate Excretion Primarily renal; renal tubular reabsorption modulated by PTH and FGF-23"},{"location":"minerals/phosphorus/#effects-of-deficiency-hypophosphataemia","title":"Effects of Deficiency (Hypophosphataemia)","text":"<p>Serum phosphate &lt;0.8 mmol/L. True dietary deficiency is rare given phosphorus abundance in food; occurs mainly in clinical settings.</p> <p>Causes: - Refeeding syndrome (high insulin drives phosphate intracellularly) - Antacid overuse (aluminium/magnesium hydroxide binds dietary phosphate) - Hyperparathyroidism - Malabsorption syndromes - Severe alcoholism - Diabetic ketoacidosis treatment</p> <p>Symptoms: - Musculoskeletal: Proximal muscle weakness, bone pain, fractures; rickets (children), osteomalacia (adults) - Haematological: Haemolytic anaemia (low 2,3-BPG impairs RBC membrane), impaired platelet function - Neurological: Confusion, irritability, paraesthesiae, seizures, coma in severe cases - Respiratory: Diaphragmatic weakness \u2192 ventilatory failure (life-threatening in ICU patients) - Cardiac: Reduced cardiac output, cardiomyopathy in severe cases</p>"},{"location":"minerals/phosphorus/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild-moderate hypophosphataemia Oral phosphate supplementation (e.g., sodium/potassium phosphate salts) 1\u20132 g/day Severe / symptomatic hypophosphataemia IV sodium phosphate or potassium phosphate; rate \u22647.5 mmol/hour under ECG monitoring Refeeding syndrome prevention Gradual caloric reintroduction; monitor and supplement electrolytes before re-feeding X-linked hypophosphataemic rickets Oral phosphate + calcitriol; or burosumab (anti-FGF-23 monoclonal antibody)"},{"location":"minerals/phosphorus/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Aluminium/magnesium antacids Bind dietary phosphate \u2192 hypophosphataemia with chronic use Calcium supplements (high dose) Form calcium-phosphate complexes \u2192 reduced phosphate absorption Sevelamer / lanthanum carbonate Phosphate binders used in chronic kidney disease (intended effect) Calcimimetics (cinacalcet) Reduce PTH \u2192 increase renal phosphate reabsorption Furosemide Promotes renal phosphate excretion"},{"location":"minerals/phosphorus/#food-sources","title":"Food Sources","text":"Food Serving Phosphorus (mg) Baked salmon 85g ~315 mg Chicken breast (cooked) 85g ~220 mg Low-fat milk 240 ml ~240 mg Lentils (cooked) 180g ~360 mg Whole wheat bread 2 slices ~136 mg Sunflower seeds 28g ~330 mg Almonds 28g ~136 mg Plain yogurt 245g ~385 mg Canned tuna 85g ~230 mg <p>Important: Phosphoric acid used as an additive in carbonated soft drinks (especially cola beverages) provides highly bioavailable phosphate (~250 mg/350 ml can) and, with high intake, may adversely affect the Ca:P ratio and bone health.</p>"},{"location":"minerals/phosphorus/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Phosphorus as a mineral is element-level stable \u2014 not degraded by cooking or storage.</li> <li>Phytate-bound phosphorus in plant foods can be released by soaking, fermenting, or sprouting (activates endogenous phytase).</li> </ul>"},{"location":"minerals/phosphorus/#toxicity-hyperphosphataemia","title":"Toxicity (Hyperphosphataemia)","text":"<p>Serum phosphate &gt;1.45 mmol/L. Most common in chronic kidney disease (CKD) when renal phosphate excretion is impaired.</p> Effect Details Secondary hyperparathyroidism Excess phosphate suppresses calcitriol, raises PTH \u2192 bone resorption Vascular calcification Calcium-phosphate deposits in vessel walls \u2192 cardiovascular disease Hypocalcaemia Phosphate binds serum calcium \u2192 tetany risk Soft tissue calcification Deposition in joints, skin (calcinosis cutis), organs <p>In individuals with normal kidney function, dietary excess is efficiently excreted and toxicity from food alone is rare. UL is set at 4,000 mg/day.</p>"},{"location":"minerals/potassium/","title":"Potassium (K)","text":""},{"location":"minerals/potassium/#overview","title":"Overview","text":"<p>Potassium is the principal intracellular cation, with approximately 98% of total body potassium located inside cells at a concentration of ~150 mmol/L \u2014 nearly 40 times the extracellular concentration. This gradient, maintained by the Na\u207a/K\u207a-ATPase pump, is fundamental to membrane potential, nerve conduction, and muscle contractility.</p> <ul> <li>Atomic number: 19; monovalent cation (K\u207a)</li> <li>Category: Macromineral / Electrolyte</li> <li>Body content: ~140 g in average adult (98% intracellular)</li> <li>Normal serum range: 3.5\u20135.0 mmol/L</li> </ul>"},{"location":"minerals/potassium/#requirements-ai","title":"Requirements (AI)","text":"Age / Group Adequate Intake (AI) Infants 0\u20136 months 400 mg/day Infants 7\u201312 months 860 mg/day Children 1\u20133 years 2,000 mg/day Children 4\u20138 years 2,300 mg/day Adolescents 14\u201318 (male) 3,000 mg/day Adolescents 14\u201318 (female) 2,300 mg/day Adult Men 19+ 3,400 mg/day Adult Women 19+ 2,600 mg/day Pregnant Women 2,900 mg/day Breastfeeding Women 2,800 mg/day <p>Most Western diets provide well below the AI \u2014 approximately 2,500 mg/day for men and 2,000 mg/day for women.</p>"},{"location":"minerals/potassium/#functions","title":"Functions","text":"<ul> <li>Resting Membrane Potential: K\u207a is the primary determinant of resting membrane potential (~\u221270 mV in neurons); the K\u207a outward diffusion gradient creates cell excitability.</li> <li>Na\u207a/K\u207a-ATPase Pump: Pumps 3 Na\u207a out and 2 K\u207a in per ATP cycle \u2014 maintains electrochemical gradients in every cell.</li> <li>Cardiac Rhythm: K\u207a channels govern phase 3 repolarisation of the cardiac action potential; serum K\u207a critically affects arrhythmia risk.</li> <li>Muscle Contraction: Required for skeletal, smooth, and cardiac muscle function.</li> <li>Blood Pressure Regulation: Potassium promotes vasodilation and natriuresis \u2014 higher K\u207a intake is consistently associated with lower blood pressure.</li> <li>Renal Acid-Base Balance: K\u207a and H\u207a exchange in renal tubules; hypokalaemia causes metabolic alkalosis.</li> <li>Insulin Secretion: KATP channel closure in pancreatic \u03b2 cells triggers insulin release after glucose uptake.</li> </ul>"},{"location":"minerals/potassium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Magnesium Required for Na\u207a/K\u207a-ATPase; hypomagnesaemia causes refractory hypokalaemia Aldosterone Increases renal K\u207a excretion in exchange for Na\u207a reabsorption Insulin Drives K\u207a into cells acutely \u2014 used therapeutically in hyperkalaemia \u03b2\u2082-agonists Shift K\u207a intracellularly \u2014 used in acute hyperkalaemia management"},{"location":"minerals/potassium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption ~85\u201390% absorbed in small intestine via passive and active transport Distribution 98% intracellular (muscle ~75\u201380% of total body K\u207a) Excretion ~90% renal (aldosterone-regulated in collecting duct); ~10% faecal Renal conservation Less efficient than Na\u207a \u2014 obligatory urinary loss of 5\u201320 mEq/day minimum"},{"location":"minerals/potassium/#effects-of-deficiency-hypokalaemia","title":"Effects of Deficiency (Hypokalaemia)","text":"<p>Serum K\u207a &lt;3.5 mmol/L.</p> <p>Causes: Loop/thiazide diuretics (most common), vomiting, diarrhoea, laxative abuse, mineralocorticoid excess, insulin overdose, \u03b2\u2082-agonist therapy, refeeding syndrome, amphotericin B, cisplatin.</p> <p>Symptoms: - Cardiac: Flat T waves, prominent U waves, PVCs, VT, VF \u2014 life-threatening - Musculoskeletal: Weakness, muscle cramps, paralysis, rhabdomyolysis - GI: Constipation, ileus - Renal: Nephrogenic diabetes insipidus, metabolic alkalosis - Neurological: Paraesthesiae, restless legs</p>"},{"location":"minerals/potassium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild hypokalaemia (3.0\u20133.5) Oral KCl 40\u201380 mEq/day; increase dietary K\u207a Moderate (2.5\u20133.0) Oral KCl 100\u2013160 mEq/day; ECG monitoring Severe / symptomatic (&lt;2.5 or cardiac) IV KCl via central line, max 20 mEq/hour; continuous ECG monitoring Concurrent hypomagnesaemia Correct Mg first \u2014 K\u207a replacement will fail without it <p>Never give IV potassium as a bolus \u2014 fatal cardiac arrest risk.</p>"},{"location":"minerals/potassium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Loop diuretics Major cause of K\u207a wasting \u2192 hypokalaemia Thiazide diuretics Significant urinary K\u207a loss ACE inhibitors / ARBs Reduce aldosterone \u2192 increase serum K\u207a \u2192 hyperkalaemia risk Potassium-sparing diuretics Block K\u207a excretion \u2192 hyperkalaemia risk Digoxin Hypokalaemia dramatically increases toxicity risk Insulin Drives K\u207a into cells; diabetics on high-dose insulin at risk NSAIDs Can cause hyperkalaemia especially with ACEi/ARBs Amphotericin B Renal K\u207a and Mg wasting"},{"location":"minerals/potassium/#food-sources","title":"Food Sources","text":"Food Serving Potassium (mg) Baked potato (with skin) 1 medium ~926 mg Sweet potato (baked) 1 medium ~542 mg White beans (cooked) 90g ~502 mg Avocado \u00bd medium ~487 mg Salmon (cooked) 85g ~414 mg Banana 1 medium ~422 mg Spinach (cooked) 90g ~419 mg Tomato paste 60 ml ~549 mg Orange juice 240 ml ~496 mg Milk (cow, whole) 240 ml ~366 mg"},{"location":"minerals/potassium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Potassium is a mineral \u2014 not degraded by cooking or storage.</li> <li>Food processing reduces potassium content; cooking and discarding water removes significant potassium from vegetables.</li> </ul>"},{"location":"minerals/potassium/#toxicity-hyperkalaemia","title":"Toxicity (Hyperkalaemia)","text":"<p>Serum K\u207a &gt;5.0 mmol/L. Can be fatal.</p> <p>Causes: Renal failure (most common), ACE inhibitors/ARBs, potassium-sparing diuretics, IV K\u207a overdose, massive haemolysis, rhabdomyolysis, Addison's disease, acidosis.</p> <p>ECG progression: Peaked T waves \u2192 wide PR \u2192 wide QRS \u2192 sine wave \u2192 VF/asystole.</p> <p>Treatment: 1. Membrane stabilisation: IV calcium gluconate (immediate cardiac protection) 2. Transcellular shift: Insulin + glucose IV, nebulised salbutamol, sodium bicarbonate (if acidotic) 3. K\u207a removal: Sodium zirconium cyclosilicate or patiromer (oral binders), loop diuretics, haemodialysis</p>"},{"location":"minerals/selenium/","title":"Selenium (Se)","text":""},{"location":"minerals/selenium/#overview","title":"Overview","text":"<p>Selenium is an essential trace mineral that is incorporated into proteins as the unusual amino acid selenocysteine \u2014 referred to as the \"21st amino acid.\" Selenoproteins are the biologically active forms of selenium in humans; the human genome encodes 25 selenoproteins, many of which serve critical antioxidant and thyroid hormone regulatory functions. Selenium content in food is highly variable and reflects soil selenium levels.</p> <ul> <li>Atomic number: 34; biologically active as selenocysteine (Sec, U) in selenoproteins; inorganic forms: selenite (SeO\u2083\u00b2\u207b), selenate (SeO\u2084\u00b2\u207b)</li> <li>Category: Trace mineral</li> <li>Body content: ~13\u201321 mg in average adult; highest concentrations in thyroid, liver, kidneys, testes</li> <li>Key fact: Marginal selenium deficiency and toxicity (selenosis) occur in narrow intake ranges \u2014 the therapeutic window is relatively small.</li> </ul>"},{"location":"minerals/selenium/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 15 \u00b5g/day (AI) Infants 7\u201312 months 20 \u00b5g/day (AI) Children 1\u20133 years 20 \u00b5g/day Children 4\u20138 years 30 \u00b5g/day Children 9\u201313 years 40 \u00b5g/day Adolescents 14\u201318 years 55 \u00b5g/day Adults 19+ 55 \u00b5g/day Pregnant Women 60 \u00b5g/day Breastfeeding Women 70 \u00b5g/day <p>Tolerable Upper Intake Level (UL): 400 \u00b5g/day for adults.</p>"},{"location":"minerals/selenium/#functions","title":"Functions","text":"<ul> <li>Antioxidant Defence (Glutathione Peroxidases, GPx): Four major GPx isoforms (GPx1\u20134) reduce hydrogen peroxide and lipid hydroperoxides using glutathione as electron donor \u2014 protect cellular membranes and DNA from oxidative damage. GPx4 specifically protects against ferroptosis.</li> <li>Thyroid Hormone Activation: Iodothyronine deiodinases (DIO1, DIO2, DIO3) are selenoproteins that convert T4 (thyroxine) to active T3 (triiodothyronine) or inactive rT3 \u2014 selenium deficiency directly impairs thyroid hormone metabolism.</li> <li>Thioredoxin Reductases (TrxR1, TrxR2, TGR): Reduce thioredoxin, maintaining cellular redox balance; essential for ribonucleotide synthesis (via ribonucleotide reductase), vitamin C recycling, and defence against reactive nitrogen species.</li> <li>Selenoprotein P (SELENOP): Major selenium transport protein in plasma (accounts for ~50\u201360% of plasma Se); delivers selenium to brain, testes, and other organs preferentially.</li> <li>Sperm Motility (GPx5, SELENOT): Selenoproteins are essential for sperm flagella structure and function \u2014 selenium deficiency can cause male infertility.</li> <li>Cancer Prevention (mechanistic): Selenium metabolites (methylselenol) may induce apoptosis in cancer cells and reduce angiogenesis; epidemiological association but supplementation trials have not consistently shown benefit in selenium-replete populations.</li> <li>Immune Function: Supports NK cell activity, T-cell proliferation, and antibody production.</li> <li>Muscle Integrity (SEPN1): ER-resident selenoprotein; mutations cause rigid spine muscular dystrophy.</li> </ul>"},{"location":"minerals/selenium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Glutathione (GSH) Electron donor for GPx reactions; requires cysteine, glutamate, glycine Vitamin E Synergistic antioxidant \u2014 works alongside GPx to prevent lipid peroxidation; deficiency of either amplifies effects of the other Iodine Selenium-dependent DIO2 converts T4 \u2192 T3; iodine and selenium deficiency together cause myxoedematous cretinism Sulphur amino acids Selenocysteine biosynthesis depends on serine and selenophosphate"},{"location":"minerals/selenium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 50\u201390%; organic selenium (selenomethionine from plant proteins) absorbed at ~90%; inorganic selenite ~50% Best form Selenomethionine (organic) \u2014 highest bioavailability; incorporated non-specifically into body protein Distribution Selenoprotein P transports plasma selenium; concentrated in thyroid, testes, liver, kidney, brain Excreted as Trimethylselenonium, selenosugar in urine; garlic breath (dimethylselenide) at very high doses Half-life ~100 days (varies by tissue)"},{"location":"minerals/selenium/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Dietary deficiency is common in areas with selenium-poor soil (parts of China, Europe, New Zealand, Africa).</p> <p>Clinical syndromes: - Keshan Disease: Selenium-deficient cardiomyopathy (dilated cardiomyopathy, arrhythmias, cardiac failure) \u2014 described in Keshan district, China; considered a selenium deficiency + coxsackievirus B cofactor. Preventable with supplementation. - Kashin-Beck Disease: Osteoarthropathy (endemic to selenium-poor areas) \u2014 cartilage necrosis, joint deformity; multifactorial with selenium deficiency as a component. - Myxoedematous Cretinism: Combined selenium + iodine deficiency in pregnancy \u2192 irreversible neurological damage in offspring. - Generalised: Muscle pain/weakness, cardiomyopathy, hypothyroidism symptoms, immune suppression, male infertility. - Critical care (ICU): Low selenium associated with worse outcomes; selenium-depleted in prolonged ICU stays.</p>"},{"location":"minerals/selenium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Keshan disease / frank deficiency 100\u2013200 \u00b5g/day selenium (as selenomethionine) orally General supplementation (low-intake population) 55\u2013200 \u00b5g/day (do not exceed UL of 400 \u00b5g/day) Selenium-deficient ICU patient IV sodium selenite 1,000 \u00b5g/day loading then 250\u2013500 \u00b5g/day (evidence mixed; used in many European protocols) Autoimmune thyroid disease (Hashimoto's) 200 \u00b5g/day selenium \u2013 modest evidence for reducing TPO antibody titres"},{"location":"minerals/selenium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Chemotherapy (cisplatin) Selenium may reduce nephrotoxicity and oxidative damage; some evidence selenium status affects cisplatin metabolism Clozapine Clozapine-induced agranulocytosis risk may be modified by selenium status Statins May reduce selenium-dependent CoQ10 pathway (minor interaction) Valproic acid Reported to reduce plasma selenium levels"},{"location":"minerals/selenium/#food-sources","title":"Food Sources","text":"<p>Selenium content varies greatly based on soil selenium:</p> Food Serving Selenium (\u00b5g) Brazil nuts 1 nut (5g) 68\u201391 \u00b5g (can exceed UL with 6+ nuts) Yellowfin tuna (cooked) 85g ~92 \u00b5g Halibut (cooked) 85g ~47 \u00b5g Sardines (canned in oil) 85g ~45 \u00b5g Ham (roasted) 85g ~42 \u00b5g Shrimp (cooked) 85g ~40 \u00b5g Beef (lean, cooked) 85g ~33 \u00b5g Whole wheat bread 2 slices ~16 \u00b5g Egg 1 large ~15 \u00b5g Enriched pasta (cooked) 140g ~33 \u00b5g <p>Caution: Brazil nuts vary enormously in selenium content \u2014 1\u20132 per day is adequate; daily consumption of handfuls can easily exceed the UL.</p>"},{"location":"minerals/selenium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Organic selenium (selenomethionine) in food is stable to moderate heat and storage.</li> <li>Inorganic selenite in food may be partially lost during prolonged cooking or high-heat processing.</li> </ul>"},{"location":"minerals/selenium/#toxicity-selenosis","title":"Toxicity (Selenosis)","text":"Intake Level Effect &gt;400 \u00b5g/day (UL) Hair and nail brittleness/loss (classic early sign), garlic breath odour (exhaled dimethylselenide) &gt;750 \u00b5g/day GI disturbance, fatigue, neurological abnormalities (irritability, numbness) &gt;900 \u00b5g/day chronically Selenosis \u2014 alopecia, nail changes, peripheral neuropathy, dermatitis Acute poisoning Vomiting, diarrhoea, respiratory distress, renal failure <p>SELECT trial note: High-dose selenium supplementation (200 \u00b5g/day of selenomethionine) in selenium-replete men (US population) increased type 2 diabetes risk \u2014 supplementation beyond the RDA in replete populations is not recommended.</p>"},{"location":"minerals/sodium/","title":"Sodium (Na)","text":""},{"location":"minerals/sodium/#overview","title":"Overview","text":"<p>Sodium is the principal extracellular cation and is the primary determinant of extracellular fluid (ECF) volume and osmolality. It is essential for maintaining fluid balance, blood pressure, nerve impulse generation, and nutrient absorption. Sodium is tightly regulated by the kidneys, aldosterone, ADH (vasopressin), and natriuretic peptides.</p> <ul> <li>Atomic number: 11; monovalent cation (Na\u207a)</li> <li>Category: Macromineral / Electrolyte</li> <li>Body content: ~92 g in average adult; ~40% in bone (bound), ~55% in ECF, ~10% in intracellular fluid</li> <li>Normal serum range: 136\u2013145 mmol/L (hypernatraemia &gt;145; hyponatraemia &lt;135)</li> </ul>"},{"location":"minerals/sodium/#requirements-ai-chronic-disease-risk-limit","title":"Requirements (AI / Chronic Disease Risk Limit)","text":"<p>Note: No RDA is established for sodium as deficiency is extremely rare. Adequate Intake (AI) levels and chronic disease risk guidelines are provided.</p> Age / Group Adequate Intake (AI) Chronic Disease Risk Reduction (CDRR) Infants 0\u20136 months 110 mg/day \u2014 Infants 7\u201312 months 370 mg/day \u2014 Children 1\u20133 years 800 mg/day \u22641,200 mg/day Children 4\u20138 years 1,000 mg/day \u22641,500 mg/day Children 9\u201313 years 1,200 mg/day \u22641,800 mg/day Adolescents 14\u201318 years 1,500 mg/day \u22642,300 mg/day Adults 19\u201350 1,500 mg/day \u22642,300 mg/day Adults 51\u201370 1,300 mg/day \u22642,300 mg/day Adults 71+ 1,200 mg/day \u22642,300 mg/day <p>WHO recommendation: &lt;2,000 mg/day sodium (&lt;5 g salt) to reduce cardiovascular disease risk. Average intake in Western diets: 3,400\u20135,000 mg/day \u2014 roughly double the upper recommended limit.</p>"},{"location":"minerals/sodium/#functions","title":"Functions","text":"<ul> <li>Extracellular Fluid Volume Regulation: Sodium is the primary osmotic determinant of ECF; sodium retention \u2192 water retention \u2192 blood pressure.</li> <li>Resting Membrane Potential: Na\u207a/K\u207a-ATPase pump (3 Na\u207a out : 2 K\u207a in, per cycle) maintains cell electrochemical gradient crucial for excitability.</li> <li>Action Potential Generation: Voltage-gated Na\u207a channels open during depolarisation \u2014 the fundamental mechanism of nerve impulse conduction and muscle contraction.</li> <li>Nutrient Transport: Na\u207a-coupled co-transporters absorb glucose (SGLT1/2), amino acids, phosphate, and water in gut epithelium.</li> <li>Acid-Base Balance: Na\u207a-H\u207a exchangers help regulate pH in renal tubules.</li> <li>Saliva and Gastric Secretion: Na\u207a is a key component of secretory fluids.</li> <li>Blood Pressure Regulation: Sodium excess expands ECF volume \u2192 increased cardiac output and blood pressure.</li> </ul>"},{"location":"minerals/sodium/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Potassium Maintains intracellular-to-extracellular Na\u207a/K\u207a gradient; high potassium intake helps offset sodium-driven hypertension Aldosterone Steroid hormone (adrenal cortex) that increases renal Na\u207a reabsorption in the collecting duct ADH (Vasopressin) Regulates water reabsorption in proportion to sodium concentration Atrial Natriuretic Peptide (ANP) Released by atria in response to high ECF volume; promotes renal Na\u207a excretion Renin-Angiotensin system Renin \u2192 angiotensin I \u2192 angiotensin II \u2192 stimulates aldosterone; major BP-sodium control system"},{"location":"minerals/sodium/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Nearly 100% absorbed \u2014 active (Na\u207a-coupled) and passive throughout the GI tract Distribution ~55% ECF (plasma + interstitial); ~40% bone; ~10% ICF Regulation RAAS, aldosterone, ADH, ANP/BNP, renal pressure-natriuresis Excretion Primarily renal (~90% of intake); sweat and faeces for remainder; kidneys can excrete as little as 1\u20135 mmol/day under sodium restriction Sweat loss 10\u201370 mmol/L depending on acclimatisation; significant in heavy exercise"},{"location":"minerals/sodium/#effects-of-deficiency-hyponatraemia","title":"Effects of Deficiency (Hyponatraemia)","text":"<p>Serum Na\u207a &lt;135 mmol/L. The most common electrolyte disorder in hospitalised patients.</p> <p>Causes: - Hypovolaemic hyponatraemia: Fluid loss with hypotonic replacement (diarrhoea, vomiting, diuretics) - Euvolaemic hyponatraemia: SIADH, hypothyroidism, Addison's disease, psychogenic polydipsia - Hypervolaemic hyponatraemia: Heart failure, cirrhosis, nephrotic syndrome \u2014 dilutional</p> <p>Symptoms (severity correlates with rate of fall): - Mild: Nausea, headache, malaise, confusion - Moderate: Disorientation, lethargy, muscle cramps - Severe: Seizures, coma, brainstem herniation, respiratory arrest</p> <p>Critical: Rapid correction of chronic hyponatraemia risks osmotic demyelination syndrome (ODS / central pontine myelinolysis) \u2014 do not raise Na\u207a by more than 8\u201310 mmol/L per 24 hours in chronic cases.</p>"},{"location":"minerals/sodium/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Acute severe symptomatic hyponatraemia 3% hypertonic saline 100\u2013150 ml IV over 20 minutes; repeat if needed; target 5 mmol/L rise in first hour Chronic hyponatraemia Fluid restriction \u00b1 oral sodium; treat underlying cause; max correction 8\u201310 mmol/L/24hr SIADH Fluid restriction (500\u20131,000 ml/day); vasopressin receptor antagonists (tolvaptan, conivaptan) Hypovolaemic hyponatraemia IV isotonic saline (0.9% NaCl) to restore volume Exercise-induced hyponatraemia Hypertonic saline if symptomatic; avoid hypotonic fluids during prolonged exercise"},{"location":"minerals/sodium/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Thiazide diuretics Impair renal Na\u207a excretion at DCT but increase urinary dilution \u2192 hyponatraemia (most common drug cause) Loop diuretics Natriuresis \u2192 volume depletion hyponatraemia SSRIs Cause SIADH \u2192 hyponatraemia (especially in elderly) Carbamazepine / oxcarbazepine Cause SIADH NSAIDs Promote sodium and water retention \u2192 oedema and exacerbate hypertension ACE inhibitors / ARBs Block angiotensin II \u2192 reduce aldosterone \u2192 mild natriuresis; appropriate for hypertension Amiloride / spironolactone Block aldosterone / ENaC \u2192 promote Na\u207a excretion; potassium-sparing"},{"location":"minerals/sodium/#food-sources","title":"Food Sources","text":"<p>Most sodium intake comes from processed, packaged, or restaurant foods \u2014 not from the salt shaker.</p> Food Serving Sodium (mg) Table salt 1 tsp (5.7g) ~2,325 mg Canned chicken soup 240 ml ~870 mg Soy sauce 1 tbsp ~900 mg Deli ham 85g ~1,000 mg Canned tomato sauce 120 ml ~650 mg Hard cheese (parmesan) 28g ~449 mg Pickles (dill) 1 large ~1,000 mg Bread (white, commercial) 1 slice ~150 mg Whole milk 240 ml ~105 mg Fresh chicken breast (unprocessed) 85g ~55 mg"},{"location":"minerals/sodium/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Sodium is an element \u2014 it is not degraded by cooking or storage.</li> <li>Significant sodium is added during food processing and preservation; the food matrix (not intrinsic sodium) drives most intake.</li> </ul>"},{"location":"minerals/sodium/#toxicity-hypernatraemia","title":"Toxicity (Hypernatraemia)","text":"<p>Serum Na\u207a &gt;145 mmol/L. Most commonly from water deficit rather than sodium excess.</p> <p>Causes: Insufficient fluid intake, diabetes insipidus, excessive sweating, osmotic diuresis, hypertonic fluid administration.</p> <p>Symptoms: Thirst, restlessness, irritability \u2192 lethargy, weakness, twitching \u2192 seizures, coma, intracranial haemorrhage (from cerebral shrinkage).</p> <p>Treatment: Gradual correction with hypotonic fluids (0.45% saline or D5W); do not correct faster than 0.5 mmol/L/hour to avoid cerebral oedema.</p> <p>Chronic high sodium: Strong independent risk factor for hypertension, stroke, left ventricular hypertrophy, kidney disease, and gastric cancer (via H. pylori-mediated inflammation at high salt concentrations). No UL is set as a true toxicity threshold, but the CDRR provides a clinical target.</p>"},{"location":"minerals/sulfur/","title":"Sulfur (S)","text":""},{"location":"minerals/sulfur/#overview","title":"Overview","text":"<p>Sulfur is the third most abundant mineral in the body by mass. Unlike other minerals, sulfur does not exist as a free ion in biological systems \u2014 it functions almost entirely within organic molecules: the amino acids methionine (Met) and cysteine (Cys) are its primary biological vehicles, along with several vitamins (B1, B7, B5) and metabolites (glutathione, taurine, coenzyme A). Sulfur is essential for protein structure, detoxification, and redox chemistry.</p> <ul> <li>Atomic number: 16; biologically active primarily as organosulfur (thiols \u2013SH, disulfides S\u2013S, sulfate \u2013SO\u2084\u00b2\u207b)</li> <li>Category: Macromineral</li> <li>Body content: ~140 g in average adult</li> <li>No dietary requirement established: Sulfur is obtained via sulfur-containing amino acids (methionine, cysteine); no separate RDA or AI exists for elemental sulfur intake.</li> </ul>"},{"location":"minerals/sulfur/#requirements","title":"Requirements","text":"<p>No Recommended Dietary Allowance (RDA) for sulfur as an element. Requirements are met by adequate intake of sulfur-containing amino acids: - Methionine: Essential amino acid (cannot be synthesised) \u2014 must be consumed in diet - Cysteine: Conditionally essential \u2014 synthesised from methionine via the transsulfuration pathway</p> Parameter Value Combined methionine + cysteine requirement ~15 mg/kg/day (adult) From protein perspective Met + Cys should total ~1.7 g/day for 70 kg adult <p>Additional sulfur also comes from vitamins B1 (thiamine), B5 (pantothenic acid), and B7 (biotin), as well as taurine and various food-derived organosulfur compounds.</p>"},{"location":"minerals/sulfur/#functions","title":"Functions","text":"<ul> <li>Protein Tertiary Structure: Cysteine \u2013SH groups form disulfide bonds (\u2013S\u2013S\u2013) in extracellular proteins, antibodies (immunoglobulins), insulin, keratin, albumin, and enzymes \u2014 critical for 3D structure and stability.</li> <li>Glutathione Synthesis: \u03b3-Glu-Cys-Gly (glutathione, GSH) is the major intracellular antioxidant. Cysteine provides the reactive \u2013SH group required for free radical scavenging and detoxification.</li> <li>Coenzyme A (CoA): Pantothenic acid + cysteine-derived phosphopantetheine forms CoA \u2014 the universal acyl carrier in fatty acid metabolism, acetyl-CoA, and the citric acid cycle.</li> <li>Iron-Sulfur Clusters: Fe-S cluster proteins (in ETC Complexes I, II, III and many other enzymes) use cysteine-ligated iron and sulfur for electron transfer.</li> <li>Phase II Detoxification (Sulfation): Sulfate (from cysteine/methionine catabolism) conjugates to drugs, hormones (oestrogens, DHEA), and xenobiotics via SULT enzymes \u2192 increases water-solubility for renal excretion.</li> <li>Taurine: Cysteine-derived; used for bile acid conjugation (taurocholate), osmoregulation, retinal function, neurological development, and cardiac contractility.</li> <li>Collagen and Keratin: Cysteine is the most abundant amino acid in keratin (hair, nails, skin); disulfide bonds give keratin its rigidity.</li> <li>B Vitamins: Thiamine (B1) contains a thiazole ring with sulfur \u2014 essential for its function; biotin (B7) and pantothenic acid (B5) also contain sulfur in their active structures.</li> <li>Methionine Cycle: Methionine donates its methyl group as S-adenosylmethionine (SAM) \u2014 the universal methylation cosubstrate for DNA methylation, histone modification, neurotransmitter synthesis, and more.</li> </ul>"},{"location":"minerals/sulfur/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Vitamin B6 (PLP) Required for cystathionine synthase and cystathionine lyase in the transsulfuration pathway (Met \u2192 Cys) Vitamin B12 Required for methionine synthase \u2014 regenerates methionine from homocysteine Folate Provides 5-methyl-THF to regenerate methionine; integrated with sulfur metabolism Zinc Zinc-finger proteins use Cys thiol groups for metal coordination Iron Fe-S clusters require both iron and cysteine-derived sulfide"},{"location":"minerals/sulfur/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Intake form Dietary proteins (methionine, cysteine); sulfur-containing vitamins; alliums (garlic, onion organosulfurs) Absorption Methionine and cysteine absorbed in small intestine as free amino acids or dipeptides via active transporters Metabolism Methionine \u2192 (SAM \u2192 SAH \u2192 homocysteine) \u2192 cysteine (transsulfuration) \u2192 taurine, sulfate, or glutathione Excretion As inorganic sulfate in urine (main route); taurine in urine; glutathione metabolites in urine and bile Sulfur balance Closely tied to protein (nitrogen) balance; high-protein diets generate significant acid load via sulfate excretion"},{"location":"minerals/sulfur/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>True isolated sulfur (as element) deficiency does not occur in practice \u2014 deficiency manifests as methionine or cysteine deficiency, typically as part of broader protein-energy malnutrition.</p> <p>Key manifestations in protein-sulfur deficiency: - Kwashiorkor: Oedema, muscle wasting, fatty liver, impaired immune function \u2014 glutathione depletion plays a role - Glutathione depletion: Increased oxidative stress, impaired detoxification, susceptibility to infection and drug toxicity - Impaired collagen crosslinking: Poor wound healing, weakened connective tissue - Taurine deficiency: Rare, but can affect retinal function, cardiac contractility, and bile acid conjugation; seen in long-term exclusively vegan parenteral nutrition without taurine supplementation - Hair and nail fragility: Keratin synthesis impaired in severe protein deficiency</p>"},{"location":"minerals/sulfur/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Protein-energy malnutrition Gradual refeeding with protein-complete diet; include animal or complementary plant proteins Acetaminophen/paracetamol overdose N-acetylcysteine (NAC) \u2014 replenishes glutathione depleted by toxic NAPQI metabolite; 150 mg/kg IV loading dose Glutathione depletion (oxidative stress) NAC 600\u20131,200 mg/day oral; cysteine/whey protein supplementation Homocystinuria (CBS deficiency) High-dose B6 if responsive; methionine-restricted diet; betaine supplementation Mucous plugging in cystic fibrosis Inhaled N-acetylcysteine (mucolytic \u2014 breaks disulfide bonds in mucus)"},{"location":"minerals/sulfur/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect N-acetylcysteine (NAC) Reduces efficacy of nitrates (tolerance mechanism); mucolytic/antidote use High-protein diet + sulfur amino acids Acid load (sulfate) can increase calcium urinary excretion \u2192 potential bone effects Warfarin + garlic/organosulfur supplements High-dose garlic may enhance anticoagulant effect Cisplatin Competes with Cys-thiol groups; NAC may reduce nephrotoxicity but could reduce efficacy Disulfiram (Antabuse) Contains Cys-reactive organosulfur that inhibits aldehyde dehydrogenase Penicillamine Contains sulfur; chelates copper and other metals; depletes vitamin B6"},{"location":"minerals/sulfur/#food-sources","title":"Food Sources","text":"<p>Sulfur is obtained from protein foods (methionine/cysteine) and allium/cruciferous vegetables (organosulfur compounds):</p> Food Key Sulfur Compounds Eggs (especially whites and yolks) High methionine, high cysteine Meat and poultry High methionine and cysteine Fish and seafood High methionine; taurine-rich Dairy (whey protein) Cysteine-rich (excellent glutathione precursor) Garlic and onions Allicin, alliin, diallyl disulfide Broccoli, Brussels sprouts, kale Glucosinolates (sulforaphane precursors \u2014 potent phase II enzyme inducers) Legumes Moderate methionine; complementary with grains (which are cysteine-rich) Whole grains Cysteine-containing proteins"},{"location":"minerals/sulfur/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Sulfur-containing amino acids in foods are generally heat-stable.</li> <li>Allicin (from garlic) is generated enzymatically when plant tissue is crushed \u2014 degraded by cooking; raw garlic provides most organosulfur benefits.</li> <li>Glucosinolates in cruciferous vegetables are converted to sulforaphane by myrosinase (enzyme in the plant) when chewed or crushed; light steaming is preferable to boiling for preserving activity.</li> </ul>"},{"location":"minerals/sulfur/#toxicity","title":"Toxicity","text":"<p>Elemental sulfur and dietary organic sulfur from food have very low toxicity in humans with normal kidney function.</p> Form Toxicity Details Dietary sulfur amino acids No UL established; high methionine may theoretically raise homocysteine if B12/folate are deficient Inorganic sulfate Osmotic diarrhoea at high doses (sulfate salts used as laxatives); tolerated in normal renal function Organosulfur supplements (garlic, MSM) Generally safe; MSM (methylsulfonylmethane) up to 3 g/day well-tolerated Sulfur dioxide (SO\u2082 food preservative) Can trigger asthma in sensitive individuals; regulated in food labelling H\u2082S (hydrogen sulfide) Toxic gas \u2014 not a dietary concern; relevant in industrial/environmental exposure"},{"location":"minerals/zinc/","title":"Zinc (Zn)","text":""},{"location":"minerals/zinc/#overview","title":"Overview","text":"<p>Zinc is the second most abundant trace mineral in the human body (after iron), with approximately 2\u20133 g in adults. It is present in every cell and is a structural or functional component of over 300 enzymes and more than 1,000 transcription factors. Unlike iron, zinc has no direct redox activity (it stays as Zn\u00b2\u207a) \u2014 it functions as a structural or Lewis acid (electron acceptor) catalyst in enzymes and as a stabiliser of protein-folding domains (zinc fingers).</p> <ul> <li>Atomic number: 30; always exists as Zn\u00b2\u207a (no redox cycling)</li> <li>Category: Trace mineral</li> <li>Body content: ~2\u20133 g, distributed in muscle (60%), bone (30%), skin, liver, prostate, and brain</li> <li>Key fact: No dedicated zinc storage pool exists \u2014 the body is highly sensitive to inadequate daily intake.</li> </ul>"},{"location":"minerals/zinc/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 2 mg/day (AI) Infants 7\u201312 months 3 mg/day Children 1\u20133 years 3 mg/day Children 4\u20138 years 5 mg/day Children 9\u201313 years 8 mg/day Adolescents 14\u201318 (male) 11 mg/day Adolescents 14\u201318 (female) 9 mg/day Adult Men 19+ 11 mg/day Adult Women 19+ 8 mg/day Pregnant Women 11\u201313 mg/day Breastfeeding Women 12\u201313 mg/day <p>Tolerable Upper Intake Level (UL): 40 mg/day for adults.</p>"},{"location":"minerals/zinc/#functions","title":"Functions","text":"<ul> <li>Catalytic Role: Zinc is a cofactor for ~300 enzymes across all six enzyme classes (oxidoreductases, transferases, hydrolases, lyases, isomerases, ligases). Key examples:</li> <li>Carbonic anhydrase \u2014 CO\u2082/HCO\u2083\u207b interconversion; critical for acid-base balance and CO\u2082 transport</li> <li>Alcohol dehydrogenase \u2014 ethanol oxidation in liver</li> <li>Alkaline phosphatase \u2014 bone mineralisation</li> <li>Carboxypeptidases \u2014 protein digestion</li> <li>DNA/RNA polymerases \u2014 replication and transcription</li> <li>Structural Role (Zinc Fingers): ~1,000 transcription factors contain zinc finger domains (Cys\u2082His\u2082, Cys\u2084 motifs) \u2014 regulate gene expression; critical for development, differentiation, and proliferation.</li> <li>Wound Healing: Zinc deficiency profoundly impairs wound healing \u2014 required for collagen synthesis, keratinocyte proliferation, and inflammatory cell function.</li> <li>Immune Function: Essential for thymulin (thymic hormone maturation), T-cell development, NK cell activity, and neutrophil function. Zinc is a master regulator of NF-\u03baB signalling.</li> <li>Antioxidant: Structural component of Cu/Zn-superoxide dismutase (SOD1), which dismutates O\u2082\u207b radicals.</li> <li>Cell Differentiation and Apoptosis: Zinc signals regulate mTOR, p53 activation, and apoptotic pathways.</li> <li>Taste and Smell: Required for gustin (carbonic anhydrase VI) \u2014 mediates taste perception; deficiency causes ageusia/dysgeusia.</li> <li>Reproduction: Required for spermatogenesis, testosterone production, sperm motility, and oocyte maturation.</li> <li>Vision: Component of retinal dehydrogenase (retinol metabolism) and high concentration in the choroid and RPE of the eye.</li> <li>Insulin Storage: Zinc forms hexameric crystals of insulin in pancreatic beta cell granules, enabling dense storage.</li> </ul>"},{"location":"minerals/zinc/#cofactors-needed","title":"Cofactors Needed","text":"Cofactor Role Protein intake Provides ligands (His, Cys, Glu, Asp) for zinc coordination in metalloenzymes Albumin (carrier) Transports ~60% of plasma zinc; hypoalbuminaemia can cause apparent hypozincaemia Metallothioneins Cysteine-rich intracellular proteins that buffer and store zinc; induced by excess zinc Vitamin A Zinc required for retinol-binding protein synthesis \u2014 deficiency of either impairs the other"},{"location":"minerals/zinc/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption 20\u201340% dietary zinc absorbed; primarily in jejunum via ZIP4 transporter Enhancers Animal protein (partially overcomes phytate inhibition via digestion), citrate Inhibitors Phytate (major), high copper, high calcium, iron (competitive at very high doses), fibre Distribution Intracellular (90%); ~60% muscle, ~30% bone; minimal plasma fraction (~0.1%) Regulation Metallothionein induction and ZIP/ZnT transporter expression; no dedicated storage; body adapts via reduced excretion Excretion Primarily faecal (endogenous intestinal zinc); urinary excretion minor (~0.5 mg/day) Half-life (plasma) ~2\u20133 hours; pool turnover ~13 days"},{"location":"minerals/zinc/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Zinc deficiency is common globally, particularly in populations relying on unfortified plant-based diets (high phytate). No single reliable biomarker \u2014 plasma zinc is used but is insensitive.</p> <p>Symptoms: - Growth retardation (most sensitive indicator in children) - Immune dysfunction: Lymphopenia, reduced NK cell activity, increased susceptibility to infection (diarrhoea, pneumonia, malaria) - Hypogonadism and delayed sexual maturation (males especially) - Dermatitis: Perioral, perineal, and acral vesiculobullous rash (particularly in acrodermatitis enteropathica \u2014 hereditary Zn malabsorption) - Alopecia (hair loss) - Ageusia/anosmia \u2014 loss of taste and smell - Poor wound healing - Diarrhoea (in severe deficiency) - Night blindness (secondary to vitamin A metabolism impairment) - Cognitive impairment and irritability</p>"},{"location":"minerals/zinc/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild-moderate deficiency Zinc gluconate or zinc acetate 25\u201350 mg elemental Zn/day orally Acrodermatitis enteropathica Lifelong zinc supplementation 1\u20133 mg/kg/day Diarrhoeal disease (children, WHO protocol) Zinc sulfate 10\u201320 mg/day for 10\u201314 days \u2014 proven to reduce severity and duration Childhood growth faltering 5\u201310 mg/day supplemental zinc Wound healing (chronic wounds) 25\u201350 mg elemental Zn/day orally (if deficient) Common cold (within 24 hrs onset) Zinc acetate lozenges (75\u201380 mg/day) \u2014 reduces duration by ~1 day"},{"location":"minerals/zinc/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Tetracyclines / fluoroquinolones Zinc chelates drug \u2192 reduced antibiotic absorption \u2014 separate by \u22652 hours Penicillamine Drug chelates zinc \u2192 zinc depletion Thiazide diuretics Increase urinary zinc excretion Copper supplements High zinc blocks copper absorption (used therapeutically in Wilson's disease \u2014 50 mg elemental Zn TID inhibits Cu uptake) Iron supplements (&gt;25 mg elemental) Compete with zinc at DMT1 \u2014 separate if possible Antacids / PPIs Reduce gastric acid \u2192 impair zinc absorption marginally"},{"location":"minerals/zinc/#food-sources","title":"Food Sources","text":"Food Serving Zinc (mg) Oysters (cooked) 85g ~74 mg Beef (chuck, cooked) 85g ~7.0 mg Alaskan king crab 85g ~6.5 mg Lobster 85g ~3.4 mg Pork loin (cooked) 85g ~2.9 mg Baked beans (canned) 90g ~2.9 mg Pumpkin seeds 28g ~2.2 mg Fortified breakfast cereal 1 cup 2.8\u201311 mg Cashews 28g ~1.6 mg Yogurt 245g ~1.7 mg"},{"location":"minerals/zinc/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Zinc as a mineral is stable to cooking. Bioavailability from plant foods can be improved by soaking, fermenting, or sprouting legumes and grains (reduces phytate content).</li> </ul>"},{"location":"minerals/zinc/#toxicity","title":"Toxicity","text":"Dose Effect &gt;40 mg/day (UL) chronically Impairs copper absorption \u2192 copper deficiency (sideroblastic anaemia, neuropathy) &gt;150 mg/day Nausea, vomiting, abdominal pain, headache, reduced HDL cholesterol Acute toxicity GI distress; metallic taste; reported from accidental exposure to high-dose supplements Anti-denture cream case reports Prolonged use of zinc-containing denture cream \u2192 severe copper deficiency neuropathy"},{"location":"misc/COMT/","title":"COMT \u2014 Catechol-O-Methyltransferase","text":"<p>COMT is a Phase II biotransformation enzyme that inactivates catecholamines and catechol-containing compounds by transferring a methyl group (\u2013CH\u2083) from SAM (S-Adenosylmethionine) onto the catechol ring. It is the primary route of catecholamine clearance in the prefrontal cortex and a key regulator of mood, motivation, pain, and stress response.</p>"},{"location":"misc/COMT/#biochemistry-overview","title":"\ud83d\udd2c Biochemistry Overview","text":"Property Detail Full name Catechol-O-Methyltransferase Gene COMT (chromosome 22q11.21) EC number EC 2.1.1.6 Reaction type O-methylation (methyl group transferred from SAM to catechol \u2013OH) Cofactors required SAM (methyl donor), Mg\u00b2\u207a (structural/catalytic) Products of SAM consumption SAH (S-Adenosylhomocysteine) \u2192 Homocysteine Isoforms MB-COMT (membrane-bound, brain-dominant) \u00b7 S-COMT (soluble, liver/kidney/erythrocytes) Location Neuronal cytoplasm &amp; membranes; liver; adrenal gland; kidney"},{"location":"misc/COMT/#what-comt-methylates","title":"\u2699\ufe0f What COMT Methylates","text":"<p>COMT acts on any molecule with a catechol ring (two adjacent \u2013OH groups on a benzene ring):</p> Substrate Product Significance Dopamine (DA) 3-Methoxytyramine (3-MT) Primary PFC clearance route Norepinephrine (NE) Normetanephrine (NMN) Sympathetic downregulation Epinephrine (EPI) Metanephrine (MN) Adrenal hormone clearance L-DOPA 3-O-Methyldopa Reduces therapeutic L-DOPA availability 2-Hydroxyestradiol (2-OHE2) 2-Methoxyestradiol Detoxifies catechol-oestrogens; anti-cancer 4-Hydroxyestradiol (4-OHE2) 4-Methoxyestradiol Reduces genotoxic quinone formation Catechol drugs Methylated metabolites e.g. catechin, isoproterenol, methyldopa <p>Note: COMT works in parallel with MAO. In the periphery &amp; liver, MAO is dominant; in the prefrontal cortex, COMT is the primary catecholamine inactivator.</p>"},{"location":"misc/COMT/#dopamine-catabolism-full-pathway","title":"\ud83e\udde0 Dopamine Catabolism \u2014 Full Pathway","text":"<pre><code>Dopamine\n  \u2502\n  \u251c\u2500\u2500\u25ba MAO-B \u2500\u2500\u25ba DOPAL (DOPALD)\n  \u2502                 \u2502\n  \u2502                 \u2514\u2500\u2500\u25ba ALDH + NAD\u207a \u2500\u2500\u25ba DOPAC\n  \u2502                            \u2502\n  \u2502                            \u2514\u2500\u2500\u25ba COMT + SAM, Mg\u00b2\u207a \u2500\u2500\u25ba HVA (homovanillic acid) [excreted in urine]\n  \u2502\n  \u2514\u2500\u2500\u25ba COMT + SAM, Mg\u00b2\u207a \u2500\u2500\u25ba 3-Methoxytyramine (3-MT)\n                                  \u2502\n                                  \u2514\u2500\u2500\u25ba MAO-B \u2500\u2500\u25ba MOPEGAL\n                                                    \u2502\n                                                    \u2514\u2500\u2500\u25ba ALDH + NAD\u207a \u2500\u2500\u25ba HVA [excreted]\n</code></pre> <p>HVA (Homovanillic Acid) is the primary urinary end-product of dopamine metabolism.</p>"},{"location":"misc/COMT/#key-snps","title":"\ud83e\uddec Key SNPs","text":""},{"location":"misc/COMT/#val158met-rs4680-the-warrior-worrier-snp","title":"Val158Met (rs4680) \u2014 The \"Warrior / Worrier\" SNP","text":"<p>This is one of the most studied pharmacogenomic variants:</p> Genotype Enzyme Activity Prefrontal DA level Phenotype Val/Val High (3\u20134\u00d7 baseline) Lower PFC dopamine \"Warrior\" \u2014 better stress resilience, lower baseline cognition Val/Met Intermediate Intermediate Moderate profile Met/Met Low (~25\u201340% of Val/Val) Higher PFC dopamine \"Worrier\" \u2014 better baseline cognition, impaired stress response, \u2191 pain sensitivity <p>Clinical implications: - Met/Met carriers: greater risk of anxiety, PTSD, fibromyalgia, opioid dependence, depression under stress. Higher dopamine allows better working memory in calm states. - Val/Val carriers: more resilient to stress, but lower tonic dopamine \u2192 risk of impulse control issues, ADHD-like traits. Benefit more from dopamine-raising interventions. - L-DOPA therapy in Parkinson's: COMT inhibitors (entacapone, tolcapone) are used to prevent peripheral L-DOPA degradation before it reaches the brain.</p>"},{"location":"misc/COMT/#other-notable-snps","title":"Other Notable SNPs","text":"SNP Effect rs4633 Linked to altered psychiatric risk rs6269 Affects expression levels rs4818 Alters mRNA stability and COMT activity Haplotypes combining the above Define \"COMT haplotype\" more precisely than Val158Met alone"},{"location":"misc/COMT/#cofactors-nutritional-dependencies","title":"\ud83e\uddea Cofactors &amp; Nutritional Dependencies","text":"<p>COMT requires two essential inputs:</p>"},{"location":"misc/COMT/#1-sam-s-adenosylmethionine-methyl-donor","title":"1. SAM (S-Adenosylmethionine) \u2014 Methyl Donor","text":"<p>SAM is depleted every time COMT runs (SAM \u2192 SAH). SAM supply depends on:</p> Nutrient Role Deficiency Effect Methionine (diet) SAM precursor \u2193 SAM \u2192 impaired COMT Folate (5-MTHF / B9) Regenerates methionine via MTR \u2193 SAM Vitamin B12 (methylcobalamin) MTR cofactor \u2193 SAM Riboflavin (B2 / FAD) MTHFR cofactor (activates folate) \u2193 Active folate \u2192 \u2193 SAM Betaine (TMG) Alternative methyl donor via BHMT Spares SAM when folate/B12 low Choline Converted to betaine Spares SAM"},{"location":"misc/COMT/#2-magnesium-mg2-structural-cofactor","title":"2. Magnesium (Mg\u00b2\u207a) \u2014 Structural Cofactor","text":"<p>Mg\u00b2\u207a is required in the COMT active site \u2014 it coordinates the SAM methyl transfer:</p> Deficiency State Effect on COMT Low dietary Mg \u2193 COMT activity \u2192 elevated catecholamines Stress (cortisol depletes Mg) Chronic stress \u2192 chronic Mg loss \u2192 impaired COMT Alcohol use Mg wasting \u2192 \u2193 COMT \u2192 catecholamine excess <p>Combined deficiency: Low SAM (from B12/folate deficiency) + Low Mg = severe COMT impairment even in Val/Val carriers.</p>"},{"location":"misc/COMT/#effects-of-nutritional-deficiencies-on-comt","title":"\ud83d\udea8 Effects of Nutritional Deficiencies on COMT","text":"<p>Since COMT depends entirely on SAM (methyl donor) and Mg\u00b2\u207a (active site metal), deficiencies in the nutrients that feed these two inputs have cascading effects on catecholamine and oestrogen clearance.</p>"},{"location":"misc/COMT/#summary-table","title":"Summary Table","text":"Deficient Nutrient Effect on COMT Downstream Consequences Folate (B9 / 5-MTHF) \u2193 SAM regeneration \u2192 \u2193 COMT activity \u2191 Dopamine, NE, EPI \u00b7 \u2191 Catechol-oestrogens \u2192 genotoxic quinones Vitamin B12 (methylcobalamin) \u2193 Methionine synthase activity \u2192 \u2193 SAM Same as folate deficiency; elevated homocysteine Riboflavin (B2 / FAD) \u2193 MTHFR activity \u2192 \u2193 active folate \u2192 \u2193 SAM Cascade \u2193 COMT; also impairs MAO (double catecholamine burden) Magnesium (Mg\u00b2\u207a) Direct loss of active site metal \u2192 \u2193 enzyme catalysis \u2191 Catecholamines even with adequate SAM (enzyme cannot bind substrate) Methionine \u2193 SAM precursor \u2192 \u2193 COMT Generalised methylation failure across all methyltransferases Choline \u2193 Betaine \u2192 \u2193 BHMT \u2192 \u2193 SAM backup Worsens methylation when folate/B12 are borderline Zinc (Zn\u00b2\u207a) Indirect \u2014 \u2193 PEMT \u2192 \u2193 phosphatidylcholine \u2192 \u2193 membrane fluidity for MB-COMT Reduced membrane-bound COMT activity"},{"location":"misc/COMT/#individual-deficiency-detail","title":"Individual Deficiency Detail","text":""},{"location":"misc/COMT/#folate-deficiency","title":"\ud83d\udfe1 Folate Deficiency","text":"<ul> <li>MTHFR cannot produce 5-MTHF \u2192 methionine synthase (MTR) stalls \u2192 homocysteine accumulates \u2192 methionine and SAM drop.</li> <li>With \u2193 SAM, COMT cannot transfer methyl groups \u2192 dopamine, NE, EPI accumulate in the synapse and periphery.</li> <li>Oestrogen risk: 4-OHE2 is not methylated \u2192 4-OHE2-o-quinones form \u2192 DNA adducts \u2192 \u2191 breast/endometrial cancer risk.</li> <li>Neuropsychiatric signs: hyper-dopaminergic state \u2192 agitation, anxiety, insomnia, hypertension; in Met/Met individuals (already slow COMT) this is dramatically amplified.</li> <li>Elevated homocysteine itself is injurious: endothelial dysfunction, thrombosis, neurodegeneration.</li> </ul>"},{"location":"misc/COMT/#vitamin-b12-deficiency","title":"\ud83d\udd34 Vitamin B12 Deficiency","text":"<ul> <li>MTR (methionine synthase) requires methylcobalamin \u2192 B12 deficiency causes identical SAM depletion to folate deficiency.</li> <li>Unlike folate deficiency, B12 deficiency also causes methylmalonic acid (MMA) accumulation \u2192 mitochondrial toxicity, demyelination.</li> <li>COMT impairment from B12 deficiency thus overlaps with neurological damage: poor catecholamine clearance plus nerve damage.</li> <li>Common in vegans, elderly (poor intrinsic factor), and MTRR SNP carriers.</li> </ul>"},{"location":"misc/COMT/#riboflavin-b2-deficiency","title":"\ud83d\udfe0 Riboflavin (B2) Deficiency","text":"<ul> <li>FAD is required by MTHFR (the enzyme that activates folate). B2 deficiency \u2192 \u2193 MTHFR activity \u2192 \u2193 5-MTHF \u2192 \u2193 SAM \u2192 \u2193 COMT.</li> <li>B2 deficiency simultaneously impairs MAO-A and MAO-B (FAD is their direct cofactor).</li> <li>Double hit: both oxidative and methylation catecholamine disposal fail \u2192 large spike in synaptic dopamine, serotonin, and NE.</li> <li>B2 deficiency is underappreciated \u2014 subclinical in migraine patients, alcoholics, and MTHFR C677T homozygotes (who have higher FAD demand).</li> </ul>"},{"location":"misc/COMT/#magnesium-deficiency","title":"\ud83d\udd35 Magnesium Deficiency","text":"<ul> <li>Mg\u00b2\u207a is physically required in the COMT catalytic site for methyl transfer. Even with abundant SAM, COMT cannot function without Mg.</li> <li>Modern diet provides ~250 mg/day versus the RDA of 310\u2013420 mg \u2014 chronic subclinical deficiency is common.</li> <li>Stress connection: cortisol directly causes renal Mg wasting \u2192 chronic stress \u2192 chronic Mg loss \u2192 chronic COMT impairment \u2192 elevated catecholamines \u2192 worsening anxiety/stress \u2192 more cortisol. This is a self-reinforcing cycle.</li> <li>Alcohol, caffeine, and high sugar intake further deplete Mg.</li> <li>Signs: hypertension, palpitations, anxiety, muscle cramps, insomnia \u2014 all consistent with catecholamine excess from impaired COMT.</li> </ul>"},{"location":"misc/COMT/#methionine-deficiency","title":"\u26aa Methionine Deficiency","text":"<ul> <li>SAM is synthesised directly from methionine + ATP. Low dietary methionine (rare in omnivores, possible in very low-protein diets) reduces SAM synthesis at the source.</li> <li>Generalised methylation failure: COMT, HNMT, ASMT (melatonin), DNMT (DNA methylation) all impaired simultaneously.</li> <li>Combined methionine + B12 + folate deficiency represents the most severe methylation collapse.</li> </ul>"},{"location":"misc/COMT/#combined-deficiency-scenarios","title":"Combined Deficiency Scenarios","text":"Scenario Nutrients Impaired COMT Status Clinical Picture Veganism without supplementation B12 (often), possibly B2, methionine \u2193\u2193 COMT Elevated homocysteine, anxiety, poor oestrogen clearance Chronic stress / alcoholism Mg (wasted), B2, folate \u2193\u2193\u2193 COMT Hypertension, catecholamine excess, sleep failure MTHFR C677T + low B2 Folate activation, SAM \u2193\u2193 COMT Amplified psychiatric risk, elevated 4-OHE2 Elderly / poor diet B12, Mg, folate \u2193\u2193 COMT Cognitive decline, Alzheimer's risk, hypertension Met/Met genotype + any of above SAM or Mg Near-zero COMT Severe anxiety, pain, oestrogen dominance"},{"location":"misc/COMT/#oestrogen-detoxification-role","title":"\ud83d\udee1\ufe0f Oestrogen Detoxification Role","text":"<p>COMT methylates catechol-oestrogens, which are oxidised forms of oestrogen that can bind DNA and generate reactive quinones:</p> <pre><code>Oestradiol (E2)\n  \u2502\n  \u251c\u2500\u2500\u25ba CYP1A1/CYP3A4 \u2192 2-OHE2 \u2500\u2500\u25ba COMT + SAM \u2500\u2500\u25ba 2-MeOE2 (protective, anti-angiogenic)\n  \u2502\n  \u2514\u2500\u2500\u25ba CYP1B1 \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u25ba 4-OHE2 \u2500\u2500\u25ba COMT + SAM \u2500\u2500\u25ba 4-MeOE2 (less reactive)\n                               \u2502\n                        \u2193 if COMT slow/low SAM\n                               \u2502\n                               \u2514\u2500\u2500\u25ba 4-OHE2-o-quinones \u2192 DNA adducts \u2192 \u2191 cancer risk\n</code></pre> <p>COMT is thus a cancer-protective enzyme particularly relevant in oestrogen-driven cancers (breast, endometrial). Met/Met carriers with low methylation nutrients are at elevated risk.</p>"},{"location":"misc/COMT/#pharmacological-relevance","title":"\ud83d\udc8a Pharmacological Relevance","text":"Drug Class Interaction with COMT COMT inhibitors (entacapone, tolcapone) Used in Parkinson's to extend L-DOPA half-life L-DOPA ~80% is methylated by peripheral COMT before reaching brain Catecholamine drugs (dobutamine, isoprenaline) Substrates for COMT; dosing affected by COMT activity Tolcapone Also inhibits hepatic COMT; risk of hepatotoxicity Methyldopa Antihypertensive; metabolised first by COMT"},{"location":"misc/COMT/#dietary-modulators","title":"\ud83c\udf7d\ufe0f Dietary Modulators","text":"Food / Compound Effect on COMT Green tea (EGCG) COMT inhibitor \u2014 raises catecholamine levels; slows oestrogen clearance Quercetin Weak COMT inhibitor Luteolin, fisetin Mild COMT inhibition Methionine-rich diet (meat, eggs) \u2191 SAM \u2192 supports COMT Cruciferous vegetables \u2191 Substrate (catechol-oestrogens) via CYP1B1 + protects via COMT support Magnesium-rich foods Supports COMT active site <p>Practical note: In Met/Met individuals (already low COMT activity), excessive EGCG (e.g. high-dose green tea extract) may worsen dopamine/oestrogen accumulation.</p>"},{"location":"misc/COMT/#mental-health-neuroscience","title":"\ud83e\udde0 Mental Health &amp; Neuroscience","text":"Condition COMT Relevance Schizophrenia Val158Met strongly implicated; 22q11 deletion syndrome (COMT gene deleted) doubles schizophrenia risk ADHD Low COMT activity (Met/Met) + adequate DA \u2192 fewer ADHD symptoms; but stress worsens PTSD Met/Met \u2192 exaggerated fear extinction deficits; Val/Val more resilient Bipolar disorder COMT haplotypes linked to mood cycling Chronic pain / fibromyalgia Met/Met \u2192 elevated DA/NE \u2192 paradoxically lower \u03bc-opioid receptor binding \u2192 \u2191 pain OCD Val/Val associated (lower PFC DA \u2192 compulsive circuits more active) Anxiety Met/Met \u2192 higher PFC DA \u2192 rumination, worry, hypervigilance"},{"location":"misc/COMT/#signs-of-high-vs-low-comt-activity","title":"\u26a0\ufe0f Signs of High vs. Low COMT Activity","text":"COMT Activity Downstream Effect Clinical Pattern High (Val/Val) Rapid DA clearance in PFC Low working memory, impulsivity, stress resilience, low anxiety baseline Low (Met/Met) Slow DA clearance in PFC High working memory, anxiety, worry, pain sensitivity, poor stress resilience Combined with low SAM or Mg COMT further impaired Elevated catecholamines, high BP, anxiety, insomnia"},{"location":"misc/COMT/#clinical-testing","title":"\ud83d\udcca Clinical Testing","text":"Test What It Shows COMT Val158Met genotyping Genetic activity level Plasma/urine catecholamines Functional output (DA, NE, EPI) Urinary HVA, VMA, normetanephrine Downstream metabolite ratios Plasma homocysteine SAM/methylation adequacy SAM : SAH ratio Direct methylation status Serum/RBC magnesium Cofactor availability"},{"location":"misc/COMT/#summary","title":"Summary","text":"<p>COMT is a methylation-dependent enzyme that inactivates dopamine, norepinephrine, epinephrine, and catechol-oestrogens. Its activity is genetically modulated by the Val158Met SNP, nutritionally dependent on SAM (B12, folate, B2, methionine) and Magnesium, and pharmacologically inhibited by EGCG and COMT inhibitor drugs. Optimising COMT function \u2014 through adequate methylation nutrients and Mg \u2014 is clinically relevant for mood disorders, pain, hormone balance, and neurodegenerative disease.</p>"},{"location":"misc/MAO/","title":"MAO \u2014 Monoamine Oxidase","text":"<p>MAO (Monoamine Oxidase) is a mitochondria-bound flavoenzyme that oxidatively deaminates monoamine neurotransmitters and dietary amines. It is the primary degradation enzyme for serotonin, norepinephrine, dopamine, and tyramine. MAO exists in two isoforms \u2014 MAO-A and MAO-B \u2014 with distinct but overlapping substrate specificity.</p>"},{"location":"misc/MAO/#biochemistry-overview","title":"\ud83d\udd2c Biochemistry Overview","text":"Property MAO-A MAO-B Gene MAOA (Xp11.3) MAOB (Xp11.23) Chromosome X chromosome X chromosome EC number EC 1.4.3.4 EC 1.4.3.4 Cofactor FAD (Flavin Adenine Dinucleotide) \u2014 covalently bound FAD \u2014 covalently bound Location Outer mitochondrial membrane (neurons, gut enterocytes, liver, placenta) Outer mitochondrial membrane (neurons, glial cells, liver, platelets) Primary substrates Serotonin, Norepinephrine, Epinephrine, Tyramine, Dopamine Dopamine, \u03b2-PEA, Benzylamine, N-methyl histamine, Tyramine Inhibitor selectivity Moclobemide, Clorgyline (reversible/irreversible selective) Selegiline, Rasagiline (irreversible selective) Clinical focus Depression, anxiety, panic disorder, PTSD Parkinson's disease, cognitive decline"},{"location":"misc/MAO/#the-mao-reaction","title":"\u2699\ufe0f The MAO Reaction","text":"<pre><code>R-CH\u2082-NH\u2082  +  O\u2082  +  H\u2082O  \u2500\u2500\u25ba R-CHO  +  NH\u2083  +  H\u2082O\u2082\n  (amine)                       (aldehyde)        (reactive oxygen species)\n</code></pre>"},{"location":"misc/MAO/#key-consequences","title":"Key Consequences:","text":"<ol> <li>Aldehyde intermediate \u2014 toxic; rapidly converted by ALDH (requires NAD\u207a/B3) to an acid, or by AR to an alcohol</li> <li>H\u2082O\u2082 generation \u2014 a source of oxidative stress in neurons (relevant in neurodegeneration)</li> <li>NH\u2083 generation \u2014 minor contribution to ammonia pool</li> </ol>"},{"location":"misc/MAO/#substrate-specificity-full-degradation-pathways","title":"\ud83e\udde0 Substrate Specificity &amp; Full Degradation Pathways","text":""},{"location":"misc/MAO/#mao-a-pathways","title":"MAO-A Pathways","text":""},{"location":"misc/MAO/#serotonin-5-ht-catabolism","title":"Serotonin (5-HT) Catabolism","text":"<pre><code>Serotonin (5-HT)\n  \u2502\n  \u2514\u2500\u2500\u25ba MAO-A + FAD \u2500\u2500\u25ba 5-Hydroxyindoleacetaldehyde (5-HIAL)\n                              \u2502\n                              \u251c\u2500\u2500\u25ba ALDH + NAD\u207a \u2500\u2500\u25ba 5-HIAA (5-Hydroxyindoleacetic acid) \u2190 [Primary urinary metabolite]\n                              \u2502\n                              \u2514\u2500\u2500\u25ba AR + NADPH \u2500\u2500\u25ba 5-HIOL (minor)\n</code></pre>"},{"location":"misc/MAO/#norepinephrine-ne-catabolism","title":"Norepinephrine (NE) Catabolism","text":"<pre><code>Norepinephrine\n  \u2502\n  \u251c\u2500\u2500\u25ba MAO-A + FAD \u2500\u2500\u25ba DHPGAL (3,4-Dihydroxyphenylglycolaldehyde)\n  \u2502                          \u2502\n  \u2502                          \u2514\u2500\u2500\u25ba ALDH + NAD\u207a \u2500\u2500\u25ba DHPGA\n  \u2502                                   \u2502\n  \u2502                                   \u2514\u2500\u2500\u25ba COMT + SAM \u2500\u2500\u25ba VMA (Vanillylmandelic acid) [primary urinary end-product]\n  \u2502\n  \u2514\u2500\u2500\u25ba COMT + SAM \u2500\u2500\u25ba Normetanephrine \u2500\u2500\u25ba MAO-A \u2500\u2500\u25ba VMA\n</code></pre>"},{"location":"misc/MAO/#mao-b-pathways","title":"MAO-B Pathways","text":""},{"location":"misc/MAO/#dopamine-da-catabolism","title":"Dopamine (DA) Catabolism","text":"<pre><code>Dopamine\n  \u2502\n  \u251c\u2500\u2500\u25ba MAO-B + FAD \u2500\u2500\u25ba DOPAL (3,4-Dihydroxyphenylacetaldehyde) \u2190 [neurotoxic intermediate]\n  \u2502                          \u2502\n  \u2502                          \u251c\u2500\u2500\u25ba ALDH + NAD\u207a \u2500\u2500\u25ba DOPAC (3,4-Dihydroxyphenylacetic acid)\n  \u2502                          \u2502                          \u2502\n  \u2502                          \u2502                          \u2514\u2500\u2500\u25ba COMT + SAM, Mg\u00b2\u207a \u2500\u2500\u25ba HVA [urinary end-product]\n  \u2502                          \u2502\n  \u2502                          \u2514\u2500\u2500\u25ba AR + NADPH \u2500\u2500\u25ba DOPET (minor)\n  \u2502\n  \u2514\u2500\u2500\u25ba COMT + SAM \u2500\u2500\u25ba 3-MT \u2500\u2500\u25ba MAO-B \u2500\u2500\u25ba MOPEGAL \u2500\u2500\u25ba ALDH \u2500\u2500\u25ba HVA\n</code></pre> <p>DOPAL (aldehyde intermediate of dopamine) is directly neurotoxic \u2014 it cross-links \u03b1-synuclein and contributes to Lewy body formation in Parkinson's disease. ALDH efficiency (NAD\u207a/B3 dependent) is critical for its rapid clearance.</p>"},{"location":"misc/MAO/#-phenylethylamine-pea-catabolism","title":"\u03b2-Phenylethylamine (\u03b2-PEA) Catabolism","text":"<p><pre><code>\u03b2-PEA \u2500\u2500\u25ba MAO-B + FAD \u2500\u2500\u25ba Phenylacetaldehyde \u2500\u2500\u25ba ALDH \u2500\u2500\u25ba Phenylacetic acid\n</code></pre> \u03b2-PEA is an endogenous neuromodulator (the \"love molecule\" \u2014 released during excitement/attraction). It has a very short half-life because MAO-B is highly efficient at degrading it.</p>"},{"location":"misc/MAO/#cofactor-fad-riboflavin-vitamin-b2","title":"\ud83e\uddea Cofactor: FAD (Riboflavin / Vitamin B2)","text":"<p>FAD is the sole enzymatic cofactor of MAO-A and MAO-B. It is covalently bonded to the enzyme (unlike many FAD enzymes where it is loosely bound):</p> FAD Availability Effect on MAO Downstream Effect Normal riboflavin (B2) status Full MAO-A + MAO-B activity Normal monoamine turnover B2 deficiency \u2193 FAD \u2192 \u2193 MAO-A activity \u2191 Serotonin, NE half-life \u2192 mood effects B2 deficiency (MAO-B) \u2193 FAD \u2192 \u2193 MAO-B activity \u2191 Dopamine, \u03b2-PEA levels High-dose riboflavin May restore MAO activity in deficiency Normalizes monoamine catabolism <p>Because FAD is covalently bound, MAO protein synthesis (and thus dietary B2 for de novo enzyme production) matters more than just repletion of free FAD.</p>"},{"location":"misc/MAO/#key-snps","title":"\ud83e\uddec Key SNPs","text":""},{"location":"misc/MAO/#mao-a-the-warrior-gene","title":"MAO-A \u2014 The \"Warrior Gene\"","text":"<p>The most famous variable number tandem repeat (VNTR) polymorphism:</p> VNTR Allele Expression Level Phenotype 3-repeat (3R) Lower MAO-A expression \u2191 Serotonin/NE \u2192 impulsivity, aggression under stress 4-repeat (4R) Higher MAO-A expression Normal/faster serotonin clearance 3.5R / 5R Intermediate\u2013high Variable <p>Why \"Warrior Gene\"? - Low MAO-A (3R, especially in males given X-linkage) \u2192 higher baseline serotonin and NE \u2192 associated with increased aggression, impulsivity, antisocial behavior under adversity, but also resilience in some contexts. - The effect is strongly modified by early childhood environment (abuse, neglect). Low MAO-A men who experienced maltreatment have significantly higher rates of conduct disorder \u2014 one of the strongest gene \u00d7 environment interactions in psychiatry.</p> <p>X-linkage: - Males have only one X chromosome \u2192 one copy of MAOA. Effect is more direct. - Females have two X chromosomes \u2192 usually one allele is more expressed, but protection from homozygosity effect is partial.</p>"},{"location":"misc/MAO/#mao-b-snps","title":"MAO-B SNPs","text":"SNP Location Effect rs1799836 (A/G) Intron 13 Lower activity (A allele) \u2192 higher DA/\u03b2-PEA \u2192 Parkinson's protection, but different psychiatric risk rs6651806 Promoter Affects MAO-B expression"},{"location":"misc/MAO/#mao-inhibitors-maois-clinical-pharmacology","title":"\ud83d\udc8a MAO Inhibitors (MAOIs) \u2014 Clinical Pharmacology","text":"<p>MAOIs are among the oldest and most powerful psychiatric drugs. They work by blocking MAO-A, MAO-B, or both, increasing synaptic monoamine levels.</p>"},{"location":"misc/MAO/#classification","title":"Classification","text":"Type Examples Selectivity Reversibility Non-selective irreversible Phenelzine, Tranylcypromine, Isocarboxazid MAO-A + MAO-B Irreversible Selective MAO-A reversible (RIMA) Moclobemide MAO-A Reversible Selective MAO-B irreversible Selegiline (low-dose), Rasagiline MAO-B Irreversible (low dose) Selective MAO-B (high-dose selegiline) Selegiline patch / high oral dose Both MAO-A + B \u2014"},{"location":"misc/MAO/#clinical-uses","title":"Clinical Uses","text":"Indication MAO Inhibitor Used Rationale Treatment-resistant depression Phenelzine, Tranylcypromine Non-selective; massive \u2191 serotonin + NE + DA Social anxiety disorder Phenelzine, Moclobemide MAO-A inhibition \u2192 \u2191 NE, serotonin PTSD Phenelzine Strong evidence for re-experiencing symptoms Atypical depression Phenelzine &gt; SSRIs in RCTs Unique efficacy profile Parkinson's disease Selegiline, Rasagiline MAO-B inhibition \u2192 \u2191 DA, neuroprotection Cognitive decline prevention Selegiline MAO-B inhibition reduces oxidative stress"},{"location":"misc/MAO/#the-tyramine-effect-cheese-reaction","title":"\u26a0\ufe0f The Tyramine Effect (Cheese Reaction)","text":"<p>This is the most critical clinical safety issue with MAOIs:</p>"},{"location":"misc/MAO/#mechanism","title":"Mechanism","text":"<pre><code>Dietary tyramine (cheese, wine, cured meats, fermented foods)\n  \u2502\n  Normally: MAO-A (gut/liver) degrades tyramine before systemic absorption\n  \u2502\n  If MAO-A inhibited:\n  \u2502\n  \u2514\u2500\u2500\u25ba Tyramine enters circulation \u2192 displaces catecholamines from vesicles\n                                        \u2192 massive NE/EPI release\n                                        \u2192 Hypertensive crisis (headache, chest pain, stroke risk)\n</code></pre>"},{"location":"misc/MAO/#foods-to-avoid-with-non-selective-irreversible-mao-a-inhibitors","title":"Foods to Avoid with Non-Selective / Irreversible MAO-A Inhibitors","text":"Food Category High Tyramine Examples Aged cheeses Old cheddar, brie, blue cheese, Camembert Fermented/cured meats Salami, pepperoni, fermented sausage Fermented beverages Tap beer, red wine, aged spirits Fermented foods Sauerkraut, kimchi, soy sauce, miso Aged/smoked fish Smoked salmon, pickled herring Overripe fruit Overripe bananas, avocados <p>Moclobemide (RIMA) has much lower tyramine liability because inhibition is reversible \u2014 tyramine can displace it from MAO-A.</p>"},{"location":"misc/MAO/#serotonin-syndrome-risk","title":"Serotonin Syndrome Risk","text":"<p>MAOIs + serotonergic drugs = potentially fatal: - MAOIs + SSRIs/SNRIs \u2192 serotonin syndrome - MAOIs + tramadol, meperidine, linezolid, methylene blue \u2192 dangerous interactions - Washout period: 2 weeks after stopping irreversible MAOI before starting serotonergic drug; 5 weeks after fluoxetine (long half-life) before starting MAOI</p>"},{"location":"misc/MAO/#nutritional-regulators-of-mao-activity","title":"\ud83c\udf7d\ufe0f Nutritional Regulators of MAO Activity","text":"Nutrient / Compound Effect Mechanism Riboflavin (B2) Required cofactor FAD supplies oxidative capacity Curcumin MAO-A + MAO-B inhibitor Competitive inhibition (mild) Quercetin MAO-A inhibitor Flavonoid-based inhibition Epigallocatechin (EGCG) MAO-B inhibitor Also inhibits COMT Resveratrol MAO-A + MAO-B inhibitor Stilbene polyphenol Piperine (black pepper) Weak MAO inhibitor May raise monoamine levels Harmine, harmaline (\u03b2-carbolines) Potent MAO-A inhibitors Found in passionflower, ayahuasca St. John's Wort (Hyperforin) MAO inhibitor + reuptake inhibitor Significant drug interactions Alcohol (chronic) \u2191 MAO-B activity Platelet MAO-B used as alcoholism biomarker"},{"location":"misc/MAO/#effects-of-nutritional-deficiencies-on-mao","title":"\ud83d\udea8 Effects of Nutritional Deficiencies on MAO","text":"<p>MAO-A and MAO-B each carry FAD covalently bound to the enzyme protein. Unlike enzymes with loosely-bound cofactors that can be immediately replenished, MAO activity depends on de-novo enzyme synthesis incorporating FAD \u2014 meaning riboflavin (B2) deficiency has sustained, not easily reversible, effects on MAO activity.</p>"},{"location":"misc/MAO/#summary-table","title":"Summary Table","text":"Deficient Nutrient Effect on MAO Downstream Consequences Riboflavin (B2 / FAD) \u2193 FAD \u2192 \u2193 MAO-A + \u2193 MAO-B enzyme activity \u2191 Serotonin, NE, Dopamine half-life; \u2191 \u03b2-PEA; \u2191 tyramine sensitivity Niacin (B3 / NAD\u207a) \u2193 ALDH activity \u2192 toxic aldehyde accumulation DOPAL accumulates \u2192 \u03b1-synuclein aggregation; 5-HIAL and GLYALD build up \u2192 neurotoxicity Iron (Fe\u00b2\u207a) Indirect \u2014 MAO-A/B are not themselves iron-enzymes, but iron deficiency \u2193 mitochondrial ETC \u2192 impaired MAO (mitochondria-bound) Blunted overall mitochondrial function; altered monoamine homeostasis Copper (Cu\u00b2\u207a) DAO (distinct from MAO) impaired; indirect effect on redox environment \u2191 Peripheral histamine; altered oxidative state affecting MAO microenvironment Folate / B12 / B2 (SAM pathway) Reduced COMT activity \u2192 shifts substrate load onto MAO MAO becomes the sole catecholamine disposal route \u2192 overloaded, depleting FAD faster Protein / Tryptophan Not a direct cofactor; \u2193 serotonin synthesis shifts balance Less substrate for MAO-A; serotonin economy disturbed upstream of MAO"},{"location":"misc/MAO/#individual-deficiency-detail","title":"Individual Deficiency Detail","text":""},{"location":"misc/MAO/#riboflavin-b2-deficiency-primary-and-most-critical","title":"\ud83d\udfe0 Riboflavin (B2) Deficiency \u2014 Primary and Most Critical","text":"<p>Riboflavin is the rate-limiting nutrient for MAO function:</p> <ul> <li>FAD is covalently attached to a histidine residue in both MAO-A and MAO-B. When cells are riboflavin-deficient, newly synthesised MAO apoenzyme cannot acquire FAD and is functionally inactive or degraded.</li> <li>Unlike non-covalent FAD enzymes, repletion of B2 requires new protein synthesis \u2014 the effect persists until the body turns over existing enzyme stock (days to weeks).</li> <li>MAO-A implications: Serotonin and NE accumulate \u2192 paradoxically, B2 deficiency mimics a mild MAOI effect. This may transiently elevate mood but eventually disrupts serotonin rhythm, sleep architecture, and autonomic tone.</li> <li>MAO-B implications: Dopamine accumulates; \u03b2-PEA (phenylethylamine) surges. \u03b2-PEA has a half-life of seconds under normal MAO-B \u2014 deficiency allows it to linger, producing brief amphetamine-like effects and potentially anxiety or perceptual disturbances.</li> <li>Tyramine risk (dietary): Even without MAOI drugs, severe B2 deficiency reduces MAO-A in the gut wall and liver \u2192 reduced first-pass tyramine metabolism \u2192 \u2191 tyramine systemic absorption \u2192 \u2191 blood pressure risk after tyramine-rich meals.</li> <li>Who is at risk: Vegans (B2 is highest in dairy, meat, eggs), alcoholics (poor absorption + increased demand), women on oral contraceptives (B2 depletion), MTHFR C677T homozygotes (higher FAD demand), RLS patients using riboflavin-depleting drugs, and the elderly.</li> </ul>"},{"location":"misc/MAO/#niacin-b3-nad-deficiency-toxic-aldehyde-crisis","title":"\ud83d\udfe1 Niacin (B3 / NAD\u207a) Deficiency \u2014 Toxic Aldehyde Crisis","text":"<p>MAO generates toxic aldehydes as intermediate products: - DOPAL (from dopamine) \u2014 highly reactive; covalently cross-links \u03b1-synuclein \u2192 oligomer formation \u2192 Lewy bodies - 5-HIAL (from serotonin) \u2014 reacts with proteins and DNA - MOPEGAL (from 3-MT) \u2014 reactive aldehyde</p> <p>These are normally instantly detoxified by ALDH (aldehyde dehydrogenase), which requires NAD\u207a. Niacin deficiency \u2192 \u2193 NAD\u207a \u2192 \u2193 ALDH \u2192 DOPAL and 5-HIAL accumulate.</p> Aldehyde Source Consequence of Accumulation DOPAL Dopamine via MAO-B \u03b1-Synuclein aggregation, mitochondrial toxicity, dopaminergic cell death (Parkinson's pathomechanism) 5-HIAL Serotonin via MAO-A Protein adducts, possible neurodegeneration DHPGAL NE via MAO-A Adrenergic neuron stress <p>This is a compelling reason why pellagra (niacin deficiency) presents with neuropsychiatric symptoms (dementia, psychosis) \u2014 not just dermatitis and diarrhoea. DOPAL-mediated dopaminergic damage may contribute.</p> <p>Alcohol + MAO + Niacin deficiency is a particularly destructive triad: alcohol upregulates MAO-B (\u2191 DOPAL generation) while simultaneously depleting NAD\u207a via the ALDH/ADH detox load \u2192 DOPAL accumulates \u2192 accelerated dopaminergic neurodegeneration.</p>"},{"location":"misc/MAO/#iron-deficiency-indirect-mitochondrial-effect","title":"\ud83d\udd35 Iron Deficiency \u2014 Indirect Mitochondrial Effect","text":"<ul> <li>MAO is embedded in the outer mitochondrial membrane and, while not an iron enzyme itself, relies on the mitochondrial environment (membrane potential, electron transport capacity) for normal function.</li> <li>Severe iron deficiency impairs the electron transport chain \u2192 altered mitochondrial membrane dynamics \u2192 reduced MAO integration and activity.</li> <li>More importantly, iron deficiency severely \u2193 tyrosine hydroxylase (TH) \u2192 \u2193 dopamine synthesis \u2192 MAO-B has less substrate; but simultaneously monoamine clearance may also be impaired, creating an unpredictable altered monoamine state.</li> <li>Iron deficiency anaemia is strongly associated with restless legs syndrome \u2014 a dopamine circuit disorder that reflects both impaired synthesis and altered MAO/COMT catabolism.</li> </ul>"},{"location":"misc/MAO/#combined-sammethylation-deficiency-mao-overload","title":"\u26aa Combined SAM/Methylation Deficiency \u2192 MAO Overload","text":"<p>When COMT is impaired (B12, folate, Mg, B2 deficiency \u2014 see COMT.md), catecholamines that should be methylated now flow almost entirely through the MAO pathway: - MAO-B handles more dopamine \u2192 more DOPAL generated \u2192 higher ALDH demand (needs NAD\u207a/B3) - If NAD\u207a is also borderline \u2192 DOPAL accumulates - Combined COMT + MAO impairment (from B2 and Mg + B12/folate deficiency together) = severely impaired catecholamine disposal from both routes simultaneously</p>"},{"location":"misc/MAO/#combined-deficiency-scenarios","title":"Combined Deficiency Scenarios","text":"Scenario Nutrients Impaired MAO Status Clinical Picture Vegan + low B2 + no supplements B2 (riboflavin), B12 \u2193 MAO-A + \u2193 MAO-B Monoamine rhythm disruption, sleep disturbance, tyramine sensitivity Alcoholism B2, B3, B1, Mg \u2193 MAO-A/B acutely; \u2191 MAO-B chronically DOPAL accumulation \u2192 neurodegeneration; psychiatric instability Pellagra / severe B3 deficiency NAD\u207a MAO runs but ALDH fails DOPAL crisis \u2192 Parkinson's-like neurodegeneration; psychosis Elderly + low protein + low B2 B2, methionine \u2193 MAO-A + \u2193 COMT Catecholamine excess, hypertension, cognitive decline MAOA 3R + B2 deficiency B2 (on already-low activity gene) Near-zero MAO-A Very elevated serotonin + NE \u2192 impulsivity, sleep loss, aggression risk"},{"location":"misc/MAO/#neurological-psychiatric-relevance","title":"\ud83e\udde0 Neurological &amp; Psychiatric Relevance","text":"Condition MAO Connection Depression Low MAO-A VNTR \u2192 \u2191 serotonin (paradoxically doesn't protect \u2014 see environment); MAOIs most effective antidepressants in some subtypes Aggression / antisocial behaviour Low MAO-A + adverse childhood \u2192 strongest G\u00d7E interaction in psychiatry PTSD MAO-A VNTR + trauma exposure \u2192 fear circuit sensitisation Parkinson's disease MAO-B oxidizes MPTP \u2192 MPP\u207a (neurotoxin); MAO-B also generates H\u2082O\u2082 \u2192 dopaminergic neuron death Alzheimer's disease MAO-B markedly increased in astrocytes near amyloid plaques \u2192 \u2191 oxidative stress Autism spectrum MAOA VNTR implicated in some ASD subgroups ADHD MAO-A regulation intersects with dopamine/NE tone Fibromyalgia Lower MAO activity \u2192 higher pain-modulating monoamines (serotonin) paradoxically impairs pain perception context"},{"location":"misc/MAO/#mao-vs-comt-complementary-degradation","title":"\ud83d\udd01 MAO vs. COMT \u2014 Complementary Degradation","text":"Feature MAO COMT Reaction type Oxidative deamination O-methylation Cofactor FAD (B2) SAM (B12, folate, B2, Mg) Location emphasis Presynaptic mitochondria, gut, liver Postsynaptic PFC neurons, liver, erythrocytes Primary role Intraneuronal catabolism Extraneuronal / synaptic cleft clearance Key substrate Serotonin (MAO-A), Dopamine (MAO-B) Dopamine, NE, EPI, catechol-oestrogens Toxic intermediate Aldehydes (DOPAL, 5-HIAL) + H\u2082O\u2082 SAH \u2192 Homocysteine (if cycle impaired) Genetic SNP MAOA VNTR (3R/4R) Val158Met Drug inhibitors Phenelzine, selegiline, rasagiline Entacapone, tolcapone"},{"location":"misc/MAO/#clinical-testing","title":"\ud83d\udcca Clinical Testing","text":"Test What It Measures Platelet MAO-B activity Surrogate for CNS MAO-B; used in research; elevated in alcoholism Urinary 5-HIAA Serotonin turnover (MAO-A output) \u2014 elevated in carcinoid syndrome Urinary HVA Dopamine turnover (MAO-B + COMT output) Urinary VMA NE/EPI turnover (MAO-A + COMT output) \u2014 elevated in phaeochromocytoma Plasma metanephrines NE/EPI degradation rate (COMT &gt; MAO) MAOA VNTR genotyping Genetic promoter activity assessment Serum riboflavin / EGRAC FAD sufficiency (MAO cofactor)"},{"location":"misc/MAO/#summary","title":"Summary","text":"<p>MAO-A and MAO-B are mitochondria-bound, FAD-dependent enzymes that are the first line of monoamine degradation, working in concert with COMT and ALDH. MAO-A primarily handles serotonin and norepinephrine; MAO-B handles dopamine and \u03b2-PEA. Their activity is genetically modulated (MAOA VNTR \"warrior gene\" polymorphism), nutritionally governed by riboflavin (B2), and pharmacologically inhibited by MAOIs \u2014 a class of drugs with powerful antidepressant and antiparkinsonian applications but serious tyramine and serotonin syndrome risks. MAO-B overactivation in the aging brain contributes to oxidative stress and neurodegeneration via H\u2082O\u2082 and toxic aldehyde accumulation (particularly DOPAL in Parkinson's disease).</p>"},{"location":"misc/krebs_cycle/","title":"Krebs Cycle (Citric Acid Cycle / TCA Cycle)","text":"<p>The Krebs cycle \u2014 also called the Citric Acid Cycle or Tricarboxylic Acid (TCA) Cycle \u2014 is the central metabolic hub of aerobic energy production. It occurs in the mitochondrial matrix and functions as the convergence point for carbohydrate, fat, and protein catabolism, feeding electrons into the electron transport chain (ETC) to generate ATP.</p>"},{"location":"misc/krebs_cycle/#overview","title":"\ud83d\udd2c Overview","text":"Property Detail Location Mitochondrial matrix Net inputs (per turn) 1 Acetyl-CoA, 3 NAD\u207a, 1 FAD, 1 ADP/GDP, 1 H\u2082O Net outputs (per turn) 2 CO\u2082, 3 NADH, 1 FADH\u2082, 1 GTP (or ATP), 1 CoA-SH Turns per glucose 2 (one per pyruvate \u2192 acetyl-CoA) Total ATP per glucose (via ETC) ~20\u201324 ATP from NADH/FADH\u2082 generated by TCA Regulation type Substrate availability + allosteric + product inhibition"},{"location":"misc/krebs_cycle/#the-pyruvate-acetyl-coa-bridge-pyruvate-dehydrogenase-complex","title":"\u2699\ufe0f The Pyruvate \u2192 Acetyl-CoA Bridge (Pyruvate Dehydrogenase Complex)","text":"<p>Before entering the Krebs cycle, pyruvate (from glycolysis) must be converted to Acetyl-CoA. This irreversible step is performed by the Pyruvate Dehydrogenase Complex (PDC).</p> <pre><code>Pyruvate + CoA + NAD\u207a  \u2500\u2500[PDC]\u2500\u2500\u25ba  Acetyl-CoA + CO\u2082 + NADH\n</code></pre>"},{"location":"misc/krebs_cycle/#pdc-cofactor-requirements","title":"PDC Cofactor Requirements","text":"Cofactor Vitamin Source Role TPP (Thiamine pyrophosphate) Vitamin B1 (Thiamine) Decarboxylation of pyruvate Lipoic acid Synthesised endogenously; diet Electron/acyl carrier (oxidised/reduced cycle) CoA (Coenzyme A) Vitamin B5 (Pantothenate) Acetyl group acceptor FAD Vitamin B2 (Riboflavin) Reoxidises dihydrolipoamide (E3 subunit) NAD\u207a Vitamin B3 (Niacin) Final electron acceptor \u2192 NADH <p>Clinical note: B1 (thiamine) deficiency blocks PDC \u2192 pyruvate cannot enter Krebs \u2192 ATP production fails \u2192 Wernicke's encephalopathy, lactic acidosis, cardiac failure.</p>"},{"location":"misc/krebs_cycle/#the-8-steps-of-the-krebs-cycle","title":"\ud83d\udd04 The 8 Steps of the Krebs Cycle","text":""},{"location":"misc/krebs_cycle/#complete-reaction-map","title":"Complete Reaction Map","text":"<pre><code>                     Acetyl-CoA (2C)\n                          \u2502\n                          \u25bc\nOxaloacetate (4C) \u2500\u2500[1: Citrate synthase]\u2500\u2500\u25ba Citrate (6C)\n                                                    \u2502\n                                      [2: Aconitase]\u25bc\n                                            Isocitrate (6C)\n                                                    \u2502\n                               [3: Isocitrate dehydrogenase]\u25bc\n                                      \u03b1-Ketoglutarate (5C) + CO\u2082 + NADH\n                                                    \u2502\n                           [4: \u03b1-KG dehydrogenase complex]\u25bc\n                                     Succinyl-CoA (4C) + CO\u2082 + NADH\n                                                    \u2502\n                               [5: Succinyl-CoA synthetase]\u25bc\n                                       Succinate (4C) + GTP\n                                                    \u2502\n                                     [6: Succinate dehydrogenase]\u25bc\n                                          Fumarate (4C) + FADH\u2082\n                                                    \u2502\n                                           [7: Fumarase]\u25bc\n                                             Malate (4C) + H\u2082O\n                                                    \u2502\n                                     [8: Malate dehydrogenase]\u25bc\n                                      Oxaloacetate (4C) + NADH\n                                           \u2502\n                                     \u25c4\u2500\u2500\u2500 cycle repeats\n</code></pre>"},{"location":"misc/krebs_cycle/#step-by-step-detail","title":"Step-by-Step Detail","text":"Step Enzyme Reaction Cofactors Output Regulation 1 Citrate synthase Oxaloacetate (4C) + Acetyl-CoA (2C) \u2192 Citrate (6C) + CoA CoA-SH Citrate Inhibited by ATP, NADH, succinyl-CoA, citrate 2 Aconitase Citrate \u21cc Isocitrate (via cis-aconitate) Fe-S cluster (non-haem iron) Isocitrate Inhibited by fluorocitrate (aconite toxin) 3 Isocitrate dehydrogenase Isocitrate \u2192 \u03b1-Ketoglutarate + CO\u2082 + NADH NAD\u207a, Mn\u00b2\u207a or Mg\u00b2\u207a NADH, CO\u2082 Activated by ADP, Ca\u00b2\u207a; inhibited by ATP, NADH 4 \u03b1-Ketoglutarate (\u03b1-KG) dehydrogenase complex \u03b1-KG \u2192 Succinyl-CoA + CO\u2082 + NADH TPP (B1), Lipoic acid, CoA (B5), FAD (B2), NAD\u207a (B3) NADH, CO\u2082 Inhibited by succinyl-CoA, NADH, ATP; activated by Ca\u00b2\u207a 5 Succinyl-CoA synthetase Succinyl-CoA \u2192 Succinate + GTP Mg\u00b2\u207a, GDP/ADP + P\u1d62 GTP (or ATP) Substrate-level phosphorylation 6 Succinate dehydrogenase (Complex II) Succinate \u2192 Fumarate + FADH\u2082 FAD (B2), Fe-S clusters, CoQ10 FADH\u2082 Inhibited by oxaloacetate, malonate 7 Fumarase (Fumarate hydratase) Fumarate + H\u2082O \u2192 L-Malate None Malate Minor; product inhibition 8 Malate dehydrogenase L-Malate \u2192 Oxaloacetate + NADH NAD\u207a NADH Equilibrium strongly favours malate; pulled by citrate synthase"},{"location":"misc/krebs_cycle/#net-yield-per-acetyl-coa-1-turn","title":"\ud83d\udcca Net Yield Per Acetyl-CoA (1 Turn)","text":"Product Quantity Energy contribution NADH 3 ~7.5 ATP each via Complex I \u2192 ~22.5 ATP FADH\u2082 1 ~1.5 ATP via Complex II \u2192 ~1.5 ATP GTP 1 \u2248 1 ATP (directly) CO\u2082 2 Waste (excreted via respiration) Net ATP per turn ~25 ATP (theoretical maximum) <p>Per glucose (2 turns): ~20\u201324 ATP from TCA products (accounting for proton leak and efficiency losses in vivo).</p>"},{"location":"misc/krebs_cycle/#cofactor-dependencies-full-reference","title":"\ud83e\uddec Cofactor Dependencies \u2014 Full Reference","text":"Cofactor Vitamin / Mineral Steps Required Deficiency Consequence NAD\u207a B3 (Niacin) Steps 3, 4, 8 (\u00d73 NADH) \u2193 TCA flux \u2192 \u2193 ATP \u2192 Pellagra; lactic acidosis FAD B2 (Riboflavin) Step 4 (\u03b1-KG DH), Step 6 (SDH) \u2193 FADH\u2082 \u2192 \u2193 ETC Complex II input CoA (Coenzyme A) B5 (Pantothenate) PDC bridge + Step 4 + Step 5 \u2193 Acetyl-CoA entry; impaired fatty acid oxidation TPP (Thiamine pyrophosphate) B1 (Thiamine) PDC bridge, Step 4 (\u03b1-KG DH) Wernicke's, lactic acidosis, \u2193 \u03b1-KG \u2192 \u2193 glutamate/GABA Lipoic acid Endogenous / diet PDC bridge, Step 4 Impaired PDC and \u03b1-KG DH function Fe-S clusters (aconitase) Iron (Fe\u00b2\u207a) Step 2 \u2193 Citrate \u2192 isocitrate conversion; TCA block Mg\u00b2\u207a Magnesium Steps 3, 5 (enzyme cofactors) \u2193 Isocitrate DH, succinyl-CoA synthetase activity Mn\u00b2\u207a Manganese Step 3 (Isocitrate DH in some species) Minor; usually Mg\u00b2\u207a is primary in humans Ca\u00b2\u207a Calcium Activation of Steps 3, 4 (mitochondrial) \u2193 TCA activation during muscle contraction/signalling CoQ10 (Ubiquinone) Endogenous; diet/supplements Step 6 (SDH \u2192 ETC handoff) \u2193 FADH\u2082 \u2192 ETC transfer; statin-induced CoQ10 depletion"},{"location":"misc/krebs_cycle/#connections-to-neurotransmitter-synthesis","title":"\ud83d\udd17 Connections to Neurotransmitter Synthesis","text":"<p>The Krebs cycle is directly upstream of several neurotransmitter pathways:</p> Krebs Intermediate NT Pathway Connection \u03b1-Ketoglutarate (\u03b1-KG) Transaminated \u2192 Glutamate (\u2192 GABA via GAD); major excitatory NT precursor Oxaloacetate (OAA) Transaminated \u2192 Aspartate (precursor to pyrimidines and asparagine; excitatory NT) Succinyl-CoA Required for haem synthesis (haemoglobin, cytochromes, myoglobin) Acetyl-CoA (entry point) Also substrate for Acetylcholine synthesis (via ChAT: Acetyl-CoA + Choline \u2192 ACh) GTP (Step 5) Substrate for BH4 synthesis (GCH1 step) \u2192 BH4 is cofactor for TPH (serotonin) and TH (dopamine) NADH / NADPH Powers BH4 recycling (DHPR uses NADH; DHFR uses NADPH) <pre><code>Krebs Cycle\n    \u2502\n    \u251c\u2500\u2500 \u03b1-KG \u2500\u2500\u25ba Glutamate \u2500\u2500\u25ba GABA\n    \u2502                       \u2514\u2500\u2500\u25ba Glutamine\n    \u2502\n    \u251c\u2500\u2500 GTP \u2500\u2500\u2500\u2500\u25ba BH4 \u2500\u2500\u25ba Serotonin (TPH), Dopamine (TH), NE, EPI\n    \u2502\n    \u251c\u2500\u2500 Acetyl-CoA \u2500\u2500\u25ba Acetylcholine (ChAT)\n    \u2502\n    \u2514\u2500\u2500 NADH \u2500\u2500\u25ba ETC \u2500\u2500\u25ba ATP (powers all NT synthesis, vesicle loading, axonal transport)\n</code></pre>"},{"location":"misc/krebs_cycle/#anaplerosis-replenishing-the-cycle","title":"\ud83d\udd00 Anaplerosis \u2014 Replenishing the Cycle","text":"<p>Since intermediates are constantly drained for biosynthesis (glutamate, aspartate, haem, etc.), they must be replenished. This is called anaplerosis:</p> Anaplerotic Reaction Enzyme Source Pyruvate + CO\u2082 \u2192 Oxaloacetate Pyruvate carboxylase (requires Biotin/B7) Gluconeogenesis, lactate Amino acids \u2192 \u03b1-KG (e.g. Glutamate \u2192 \u03b1-KG) Glutamate dehydrogenase, aminotransferases Protein catabolism Propionyl-CoA \u2192 Succinyl-CoA Methylmalonyl-CoA mutase (requires B12) Odd-chain fatty acids, valine, isoleucine, methionine Aspartate \u2192 OAA Aspartate aminotransferase Amino acid catabolism Fatty acids (even-chain) \u03b2-oxidation \u2192 Acetyl-CoA Fat catabolism (not strictly anaplerotic) <p>Note: B7 (Biotin) deficiency impairs pyruvate carboxylase \u2192 OAA cannot be replenished \u2192 TCA cycle slows \u2192 \u2193 gluconeogenesis and \u2193 energy. B12 deficiency impairs propionyl-CoA \u2192 succinyl-CoA \u2192 odd-chain fat catabolism blocked (methylmalonic aciduria).</p>"},{"location":"misc/krebs_cycle/#cataplerosis-draining-intermediates-for-biosynthesis","title":"\ud83e\uddea Cataplerosis \u2014 Draining Intermediates for Biosynthesis","text":"Intermediate Drained Used For Acetyl-CoA Fatty acid synthesis, cholesterol, ketone bodies, Acetylcholine \u03b1-Ketoglutarate Glutamate, Glutamine, GABA, proline, arginine synthesis Oxaloacetate Gluconeogenesis (via PEP carboxykinase), aspartate Succinyl-CoA Haem/porphyrin synthesis; ketone body activation Citrate Fatty acid synthesis (exported to cytoplasm \u2192 ATP citrate lyase \u2192 Acetyl-CoA) Malate Gluconeogenesis; NADPH production (via malic enzyme)"},{"location":"misc/krebs_cycle/#regulation","title":"\ud83d\udea6 Regulation","text":"<p>The Krebs cycle is tightly regulated by energy charge (ATP:ADP:AMP ratio) and redox state (NADH:NAD\u207a):</p>"},{"location":"misc/krebs_cycle/#key-regulatory-points","title":"Key Regulatory Points","text":"Enzyme Activated By Inhibited By Citrate synthase ADP, substrate availability ATP, NADH, succinyl-CoA, citrate Isocitrate dehydrogenase ADP, Ca\u00b2\u207a (mitochondrial) ATP, NADH \u03b1-KG dehydrogenase complex Ca\u00b2\u207a, ADP ATP, NADH, succinyl-CoA PDC (upstream bridge) Ca\u00b2\u207a, insulin (activates PDC phosphatase) ATP, NADH, acetyl-CoA (product inhibition); PDC kinase (phosphorylation inactivates) <p>Ca\u00b2\u207a as activator: During muscle contraction or neuronal firing, intracellular Ca\u00b2\u207a rises \u2192 activates isocitrate DH and \u03b1-KG DH \u2192 accelerates TCA \u2192 more ATP produced to meet demand. This is a direct link between neuronal activity and mitochondrial energy production.</p>"},{"location":"misc/krebs_cycle/#feedback-summary","title":"Feedback Summary","text":"<pre><code>High ATP/NADH (energy replete)\n    \u2502\n    \u251c\u2500\u2500 Inhibits Citrate synthase \u2192 \u2193 cycle entry\n    \u251c\u2500\u2500 Inhibits Isocitrate DH \u2192 \u2193 Step 3\n    \u2514\u2500\u2500 Inhibits \u03b1-KG DH \u2192 \u2193 Step 4\n          \u2192 TCA slows \u2192 NADH/ATP production drops \u2192 cycle resumes when demand rises\n</code></pre>"},{"location":"misc/krebs_cycle/#clinical-consequences-of-krebs-cycle-disruption","title":"\ud83d\udea8 Clinical Consequences of Krebs Cycle Disruption","text":"Deficiency / Condition Primary Block Consequence Thiamine (B1) deficiency PDC + \u03b1-KG DH paralysed Lactic acidosis, \u2193 ATP, \u2193 glutamate/GABA; Wernicke's encephalopathy (neuronal ATP failure) Riboflavin (B2) deficiency \u2193 FAD \u2192 \u2193 \u03b1-KG DH + \u2193 SDH Reduced TCA throughput; impaired ETC Complex II Niacin (B3) deficiency \u2193 NAD\u207a \u2192 Steps 3, 4, 8 blocked Pellagra (dermatitis, diarrhoea, dementia); mitochondrial failure Pantothenate (B5) deficiency \u2193 CoA \u2192 \u2193 Acetyl-CoA entry + Step 4 Burning feet syndrome; \u2193 ACh synthesis; global energy failure Biotin (B7) deficiency \u2193 Pyruvate carboxylase \u2192 \u2193 OAA anaplerosis Ketoacidosis, \u2193 gluconeogenesis, TCA intermediate depletion Vitamin B12 deficiency \u2193 Methylmalonyl-CoA mutase \u2192 propionyl-CoA accumulates Methylmalonic aciduria; odd-chain fatty acid accumulation (neurotoxic); succinyl-CoA depletion Iron deficiency \u2193 Aconitase (Fe-S clusters) + \u2193 haem Impaired isocitrate \u2192 \u03b1-KG; \u2193 cytochrome c \u2192 ETC block Magnesium deficiency \u2193 Isocitrate DH, succinyl-CoA synthetase Reduced TCA flux; impaired ATP synthesis Arsenic poisoning Inhibits lipoic acid (blocks PDC + \u03b1-KG DH) Severe lactic acidosis; multi-organ failure Fluoroacetate (rat poison) Converted to fluorocitrate \u2192 inhibits aconitase Citrate accumulation; TCA block; fatal SDHB/SDHC/SDHD mutations Succinate dehydrogenase deficiency Hereditary paraganglioma/phaeochromocytoma; succinate accumulates (oncometabolite) Mitochondrial disease (mtDNA) ETC complex defects \u2192 \u2191 NADH:NAD\u207a \u2192 TCA product inhibition Lactic acidosis, Leigh syndrome, MELAS"},{"location":"misc/krebs_cycle/#krebs-cycle-and-the-brain","title":"\ud83e\udde0 Krebs Cycle and the Brain","text":"<p>The brain is almost entirely dependent on oxidative phosphorylation (fuelled by TCA), consuming ~20% of total body oxygen despite being 2% of body weight. Neurons have very limited glycolytic reserve.</p> Neurological Connection Mechanism Energy for all neurotransmitter synthesis ATP powers amino acid uptake, enzymatic synthesis, vesicle packaging Glutamate/GABA homeostasis \u03b1-KG \u2194 Glutamate \u2194 GABA; Krebs intermediates feed this directly Acetylcholine synthesis Acetyl-CoA (TCA entry metabolite) is the direct substrate for ChAT BH4 production (\u2192 dopamine, serotonin) GTP produced at Step 5 is substrate for GCH1 (BH4 synthesis) BH4 recycling NADPH (via malic enzyme from malate) and NADH (DHPR) are TCA-linked Nitric oxide (NO) nNOS requires BH4; impaired TCA \u2192 \u2193 GTP \u2192 \u2193 BH4 \u2192 \u2193 NO + NOS uncoupling Axonal transport Kinesin/dynein motors require ATP; TCA failure \u2192 transport arrest \u2192 neurodegeneration Calcium signalling Ca\u00b2\u207a activates TCA (Steps 3, 4); reciprocally, TCA failure \u2192 dysregulated Ca\u00b2\u207a"},{"location":"misc/krebs_cycle/#pharmacological-and-supplementation-relevance","title":"\ud83d\udc8a Pharmacological and Supplementation Relevance","text":"Supplement / Drug Mechanism Krebs Relevance CoQ10 ETC electron carrier (FADH\u2082 \u2192 Complex III) Supports SDH (Step 6) \u2192 ETC handoff; statin-depleted Alpha-Lipoic Acid (ALA) Cofactor for PDC + \u03b1-KG DH; antioxidant Supports 2 critical TCA entry/flow steps B-complex vitamins B1/B2/B3/B5 are direct TCA cofactors Comprehensive Krebs support Magnesium glycinate Mg\u00b2\u207a for isocitrate DH + succinyl-CoA synthetase Removes rate-limiting factor in many depleted individuals N-Acetyl Cysteine (NAC) Antioxidant; protects mitochondrial proteins Prevents oxidative inactivation of Fe-S enzymes (aconitase) Creatine Phosphocreatine \u2194 ATP buffer; spares TCA demand Reduces acute ATP deficit during TCA insufficiency L-Carnitine Fatty acid transport into mitochondria Maximises Acetyl-CoA supply for TCA cycle Succinic acid TCA intermediate; directly enters at Step 6 Experimental in mitochondrial disease; bypasses upstream blocks Metformin Inhibits Complex I \u2192 \u2191 NADH:NAD\u207a \u2192 TCA slowdown Reduces hepatic gluconeogenesis (OAA diverted less) Statins Deplete CoQ10 (via mevalonate pathway) Impairs SDH \u2192 ETC electron transfer; myopathy risk"},{"location":"misc/krebs_cycle/#dietary-sources-of-krebs-cofactors","title":"\ud83c\udf7d\ufe0f Dietary Sources of Krebs Cofactors","text":"Nutrient Food Sources RDA (Adult) B1 (Thiamine) Pork, legumes, fortified cereals, sunflower seeds 1.1\u20131.2 mg/day B2 (Riboflavin) Liver, dairy, eggs, almonds, mushrooms 1.1\u20131.3 mg/day B3 (Niacin / NAD\u207a) Liver, chicken, tuna, peanuts, mushrooms 14\u201316 mg NE/day B5 (Pantothenate / CoA) Liver, sunflower seeds, mushrooms, avocado 5 mg/day (AI) B7 (Biotin) Eggs (cooked), liver, nuts, seeds 30 \u00b5g/day (AI) B12 Meat, fish, shellfish, dairy, eggs 2.4 \u00b5g/day Lipoic acid Red meat, liver, spinach, broccoli No formal RDA (endogenous synthesis + diet) CoQ10 Organ meats, fatty fish, peanuts, soybeans No RDA; 100\u2013300 mg therapeutic Iron (Fe\u00b2\u207a) Red meat, shellfish, legumes, spinach 8 mg (M) / 18 mg (F premenopausal) Magnesium Nuts, seeds, legumes, dark leafy greens 310\u2013420 mg/day"},{"location":"misc/krebs_cycle/#integration-with-other-metabolic-pathways","title":"\ud83d\udcca Integration with Other Metabolic Pathways","text":"<pre><code>Glycolysis \u2192 Pyruvate \u2500\u2500[PDC: B1, B2, B3, B5, Lipoate]\u2500\u2500\u25ba Acetyl-CoA \u2500\u2500\u25ba TCA Cycle\n                                                                                 \u2502\n                          \u03b2-Oxidation (Fatty acids) \u2500\u2500\u25ba Acetyl-CoA \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n                                                                                 \u2502\n                    Amino acid catabolism \u2500\u2500\u25ba \u03b1-KG, OAA, Succinyl-CoA \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u25ba\u2518\n                                                                                 \u2502\n                                                                              TCA Cycle\n                                                                                 \u2502\n                                          \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2524\n                                          \u2502                                       \u2502\n                                       3 NADH                                 1 FADH\u2082\n                                       1 GTP                                       \u2502\n                                          \u2502                                        \u2502\n                              Electron Transport Chain (ETC)                      ETC\n                                          \u2502\n                                       ~25\u201330 ATP per glucose equivalent\n                                          \u2502\n                         \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n                         \u2502                                   \u2502\n                    ATP for synthesis              Biosynthetic drains\n                    (NT synthesis,                 (Glutamate, GABA, haem,\n                     vesicle transport,             acetyl-CoA for lipids,\n                     ion pumps)                     BH4 via GTP, ACholine)\n</code></pre>"},{"location":"misc/krebs_cycle/#signs-of-impaired-krebs-cycle-function","title":"\u26a0\ufe0f Signs of Impaired Krebs Cycle Function","text":"Symptom Pattern Likely Block Key Missing Nutrient Chronic fatigue + brain fog + lactic acidosis PDC block B1 (Thiamine) Fatigue + neuropathy + methylmalonic acid\u2191 Anaplerosis (propionyl-CoA \u2192 succinyl-CoA) B12 Pellagra (dermatitis, dementia, diarrhoea) NAD\u207a depletion (Steps 3, 4, 8) B3 (Niacin) Muscle weakness + myopathy (especially statin users) CoQ10 depletion \u2192 SDH/ETC block CoQ10 Burning feet + fatigue + neurological symptoms CoA depletion B5 (Pantothenate) Anaemia + fatigue + iron-deficiency neuropathy Aconitase (Fe-S cluster loss) Iron Fatigue + hypertension + insulin resistance Mg\u00b2\u207a depletion \u2192 multiple TCA enzyme failure Magnesium Depression + anxiety + low dopamine AND serotonin \u2193 GTP (Step 5) \u2192 \u2193 BH4 \u2192 \u2193 TPH + TH Mitochondrial health (B1, B2, B3, CoQ10)"},{"location":"misc/krebs_cycle/#summary","title":"Summary","text":"<p>The Krebs cycle is the metabolic engine of the cell. It requires B1, B2, B3, B5, B7, B12, Iron, Magnesium, CoQ10, and Lipoic acid as direct cofactors. Its outputs \u2014 NADH, FADH\u2082, and GTP \u2014 power the ETC (for ATP), BH4 synthesis (for serotonin and dopamine), and acetylcholine production. Impaired TCA function therefore cascades into energy failure, neurotransmitter depletion, and metabolic disease.</p>"},{"location":"misc/methylation/","title":"Methylation: A Comprehensive Overview","text":"<p>Methylation is one of the most fundamental biochemical processes in the body \u2014 it's essentially the transfer of a methyl group (\u2013CH\u2083) from one molecule to another. This simple reaction, happening billions of times per second, governs gene expression, neurotransmitter synthesis, detoxification, immune function, and much more.</p>"},{"location":"misc/methylation/#the-core-chemistry","title":"\ud83d\udd2c The Core Chemistry","text":"<p>A methyl group is just one carbon atom bonded to three hydrogen atoms (\u2013CH\u2083). Methylation is the act of adding this group to a substrate \u2014 a DNA base, a protein, a neurotransmitter, a toxin, etc.</p> <p>The universal methyl donor in the body is SAM (S-Adenosylmethionine), which is synthesized from methionine (an essential amino acid) and ATP.</p> <pre><code>Methionine + ATP \u2192 SAM \u2192 (donates \u2013CH\u2083) \u2192 SAH (S-Adenosylhomocysteine)\n                                                  \u2193\n                                           Homocysteine\n                                                  \u2193\n                          (via B12/folate/B6) \u2192 Methionine (recycled)\n</code></pre> <p>When SAM donates its methyl group, it becomes SAH, then homocysteine. Homocysteine is either: - Re-methylated back to methionine (requires B12 + methylfolate/5-MTHF), or - Transsulfurated to cysteine \u2192 glutathione (requires B6)</p> <p>Elevated homocysteine is a marker of impaired methylation and is associated with cardiovascular disease, neurodegeneration, and inflammation.</p>"},{"location":"misc/methylation/#1-dna-methylation-epigenetics","title":"\ud83e\uddec 1. DNA Methylation (Epigenetics)","text":"<p>This is the most studied form. DNA methylation silences gene expression without altering the DNA sequence \u2014 this is epigenetics.</p>"},{"location":"misc/methylation/#mechanism","title":"Mechanism","text":"<ul> <li>A DNA methyltransferase (DNMT) enzyme adds a methyl group to the 5-position of cytosine (5-methylcytosine, or 5mC), almost always at CpG dinucleotides (cytosine next to guanine).</li> <li>Methylated CpG islands in a gene's promoter region \u2192 gene is silenced.</li> <li>Unmethylated promoters \u2192 gene is expressed.</li> </ul>"},{"location":"misc/methylation/#why-it-matters","title":"Why It Matters","text":"State Effect Hypermethylation of tumor suppressor genes Cancer risk \u2191 Hypomethylation of oncogenes Cancer risk \u2191 Appropriate methylation of imprinted genes Normal development Methylation of viral DNA sequences Immune defense Loss of methylation patterns Aging, Alzheimer's"},{"location":"misc/methylation/#inheritance","title":"Inheritance","text":"<p>Methylation patterns can be passed to daughter cells during cell division (mitotic inheritance) and in some cases across generations (transgenerational epigenetics).</p>"},{"location":"misc/methylation/#2-neurotransmitter-synthesis-breakdown","title":"\ud83e\udde0 2. Neurotransmitter Synthesis &amp; Breakdown","text":"<p>Methylation is critical for brain chemistry:</p> Reaction Enzyme Cofactor Norepinephrine \u2192 Epinephrine PNMT SAM Serotonin \u2192 Melatonin ASMT SAM Dopamine breakdown COMT SAM, Mg\u00b2\u207a Histamine breakdown HNMT SAM <p>COMT (Catechol-O-Methyltransferase) is particularly important \u2014 it methylates and inactivates catecholamines (dopamine, epinephrine, norepinephrine). The common COMT Val158Met SNP slows this enzyme, leading to higher dopamine/norepinephrine levels, which can affect mood, stress response, and pain sensitivity.</p>"},{"location":"misc/methylation/#3-detoxification","title":"\ud83d\udee1\ufe0f 3. Detoxification","text":"<p>The liver uses methylation in Phase II detoxification to neutralize and excrete:</p> <ul> <li>Estrogens \u2014 methylation converts 2-OHE1 (less harmful) to 2-methoxyestrone (excreted). Impaired methylation \u2192 accumulation of 16\u03b1-OHE1 (more carcinogenic)</li> <li>Heavy metals \u2014 arsenic is methylated for urinary excretion</li> <li>Drugs &amp; xenobiotics \u2014 many medications are methylated for clearance</li> <li>Toxins \u2014 various environmental chemicals</li> </ul>"},{"location":"misc/methylation/#4-phospholipid-membrane-synthesis","title":"\ud83d\udc8a 4. Phospholipid &amp; Membrane Synthesis","text":"<p>Methylation is required to synthesize phosphatidylcholine (PC), a key component of every cell membrane, via the PEMT pathway:</p> <pre><code>Phosphatidylethanolamine \u2192 (3\u00d7 methylation via PEMT + SAM) \u2192 Phosphatidylcholine\n</code></pre> <p>This is why choline is so important \u2014 it spares the methylation demand. Low choline intake increases the methylation burden on SAM.</p>"},{"location":"misc/methylation/#5-the-folate-cycle-one-carbon-metabolism","title":"\ud83d\udd01 5. The Folate Cycle &amp; One-Carbon Metabolism","text":"<p>Methylation doesn't work in isolation \u2014 it's part of the one-carbon metabolism network, which includes:</p> <pre><code>\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n\u2502                  FOLATE CYCLE                           \u2502\n\u2502  Dietary Folate \u2192 DHF \u2192 THF \u2192 5,10-MTHF \u2192 5-MTHF      \u2502\n\u2502                                    \u2195             \u2193      \u2502\n\u2502              (via MTHFR enzyme)          Homocysteine   \u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n                                                 \u2193\n\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n\u2502               METHIONINE CYCLE                          \u2502\n\u2502   Homocysteine \u2192 (B12 + 5-MTHF) \u2192 Methionine \u2192 SAM    \u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n</code></pre>"},{"location":"misc/methylation/#key-enzyme-mthfr","title":"Key Enzyme: MTHFR","text":"<p>Methylenetetrahydrofolate reductase converts 5,10-MTHF \u2192 5-MTHF (active methylfolate), which then donates its methyl group to convert homocysteine \u2192 methionine.</p> <p>The MTHFR C677T SNP (very common \u2014 ~40% of people have one copy) reduces enzyme efficiency by 30\u201370%, impairing the folate \u2192 methylation pathway. These individuals often benefit from 5-MTHF (methylfolate) supplementation rather than folic acid.</p>"},{"location":"misc/methylation/#6-protein-methylation-histones","title":"\u2699\ufe0f 6. Protein Methylation (Histones)","text":"<p>Beyond DNA, methylation occurs on histone proteins (which DNA wraps around):</p> <ul> <li>Histone methyltransferases (HMTs) add methyl groups to specific lysine or arginine residues on histone tails</li> <li>Effect depends on which residue is methylated and how many methyl groups:</li> <li>H3K4me3 \u2192 gene activation</li> <li>H3K27me3 \u2192 gene repression</li> <li>H3K9me3 \u2192 heterochromatin formation</li> </ul> <p>This is another major layer of epigenetic control.</p>"},{"location":"misc/methylation/#7-rna-methylation-epitranscriptomics","title":"\ud83e\uddea 7. RNA Methylation (Epitranscriptomics)","text":"<p>A newer, rapidly emerging field \u2014 methylation of RNA:</p> <ul> <li>m6A (N6-methyladenosine) \u2014 the most common RNA modification; regulates mRNA stability, translation, and splicing</li> <li>Written by \"writers\" (METTL3/14), read by \"readers\" (YTHDF proteins), erased by \"erasers\" (FTO, ALKBH5)</li> <li>Dysregulated in cancers, metabolic disease, and neurological conditions</li> </ul>"},{"location":"misc/methylation/#key-nutrients-for-methylation","title":"\ud83c\udf7d\ufe0f Key Nutrients for Methylation","text":"Nutrient Role Methionine Precursor to SAM Folate (5-MTHF) Regenerates methionine from homocysteine Vitamin B12 (methylcobalamin) Cofactor for methionine synthase Vitamin B6 (P5P) Cofactor for transsulfuration (homocysteine \u2192 cysteine) Riboflavin (B2) Cofactor for MTHFR enzyme Choline Spares SAM via the PEMT pathway Betaine (TMG) Alternative methyl donor via BHMT enzyme Zinc, Magnesium Cofactors for methyltransferase enzymes Glycine Buffers excess methyl groups"},{"location":"misc/methylation/#common-snps-affecting-methylation","title":"\ud83e\uddec Common SNPs Affecting Methylation","text":"SNP Gene Impact C677T MTHFR \u2193 folate \u2192 methylation conversion A1298C MTHFR \u2193 BH4, affects neurotransmitters Val158Met COMT \u2193 catecholamine breakdown A2756G MTR \u2193 methionine synthase activity A66G MTRR \u2193 B12 recycling"},{"location":"misc/methylation/#consequences-of-methylation-dysfunction","title":"\u26a0\ufe0f Consequences of Methylation Dysfunction","text":"<p>Undermethylation (too little): - Depression, OCD, anxiety (low serotonin) - Autoimmune conditions - Elevated homocysteine \u2192 cardiovascular risk, blood clots, stroke - Impaired detoxification \u2192 toxin accumulation</p> <p>Overmethylation (too much): - Anxiety, paranoia, low motivation - Histamine intolerance - Can suppress genes that should be active</p>"},{"location":"misc/methylation/#clinical-testing","title":"\ud83d\udcca Clinical Testing","text":"Test What It Measures Plasma homocysteine Overall methylation capacity MTHFR genotyping Genetic methylation risk Whole blood histamine Methylation status (low = overmethylator) SAM:SAH ratio Direct methylation adequacy Methylmalonic acid Functional B12 status Organic acids Folate/B12 functional deficiency"},{"location":"misc/methylation/#summary","title":"Summary","text":"<p>Methylation is a master regulator of biology \u2014 it controls which genes are on or off, how your brain chemicals are balanced, how efficiently you detoxify, and how resilient your cells are. It's not a single pathway but a metabolic network interconnected through the methionine cycle, folate cycle, and transsulfuration pathway. Nutrients (B12, folate, B6, choline), genetics (MTHFR, COMT), and lifestyle (diet, stress, toxins) all profoundly influence methylation capacity.</p>"},{"location":"neuroscience/hpa_axis/","title":"HPA Axis (Hypothalamic\u2013Pituitary\u2013Adrenal Axis)","text":""},{"location":"neuroscience/hpa_axis/#overview","title":"Overview","text":"<p>The HPA axis is the central neuroendocrine stress-response system, coordinating the brain's perception of threat with the body's hormonal readiness to cope. Its primary output \u2014 cortisol \u2014 affects virtually every organ system: metabolism, immune function, memory, mood, and inflammation.</p> <p>Key insight \u2014 Cortisol is not inherently harmful. Short pulses are essential for survival. It is chronic, tonically elevated cortisol that depletes nutrients, shrinks the hippocampus, suppresses immunity, and dysregulates mood.</p>"},{"location":"neuroscience/hpa_axis/#the-axis-and-its-hormones","title":"The Axis and Its Hormones","text":"<pre><code>Hypothalamus\n    \u2502\n    \u2502 [CRH] Corticotropin-Releasing Hormone (pulsatile; peaks 08:00)\n    \u25bc\nAnterior Pituitary\n    \u2502\n    \u2502 [ACTH] Adrenocorticotropic Hormone\n    \u25bc\nAdrenal Cortex (zona fasciculata)\n    \u2502\n    \u2502 Cholesterol \u2192 Pregnenolone \u2192 Progesterone \u2192 11-Deoxycortisol \u2192 Cortisol\n    \u25bc\nCortisol (hydrocortisone)  \u2500\u2500\u2500\u2500\u25ba systemic effects\n    \u2502\n    \u2514\u2500\u2500\u25ba Negative feedback:\n         \u251c\u2500 Hypothalamus (suppresses CRH)\n         \u2514\u2500 Pituitary (suppresses ACTH)\n</code></pre>"},{"location":"neuroscience/hpa_axis/#diurnal-cortisol-rhythm","title":"Diurnal Cortisol Rhythm","text":"Time Cortisol Level Function 06:00\u201308:00 Peak (CAR \u2014 Cortisol Awakening Response) Mobilises glucose; primes immune system 08:00\u201312:00 Declining plateau Supports alertness, focus 12:00\u201320:00 Gradual fall Activity tolerance 20:00\u201302:00 Nadir Tissue repair; immune surveillance 02:00\u201306:00 Rising (pre-dawn surge) Preparation for awakening"},{"location":"neuroscience/hpa_axis/#cortisol-synthesis-nutrient-requirements","title":"Cortisol Synthesis \u2014 Nutrient Requirements","text":"<p>Cortisol is a steroid derived from cholesterol through a multi-enzyme cascade in the adrenal cortex.</p> Step Enzyme Nutrient Cofactor Notes Cholesterol \u2192 Pregnenolone StAR + CYP11A1 (P450scc) Vitamin C, Fe\u00b2\u207a Rate-limiting; mitochondrial Pregnenolone \u2192 Progesterone 3\u03b2-HSD DHEA as substrate side-product \u2014 Progesterone \u2192 17-OH-Progesterone CYP17A1 \u2014 Also makes androgens \u2192 11-Deoxycortisol CYP21A2 \u2014 \u2014 11-Deoxycortisol \u2192 Cortisol CYP11B1 Vitamin C (essential for adrenal CYP enzymes), Fe\u00b2\u207a Highest Vitamin C concentration in body is in adrenal glands"},{"location":"neuroscience/hpa_axis/#vitamin-c-and-the-adrenals","title":"Vitamin C and the Adrenals","text":"<p>The adrenal gland has the highest concentration of vitamin C in the body (~30\u00d7 plasma). Vitamin C: - Protects adrenal CYP450 enzymes from oxidative damage - Required for catecholamine synthesis (DBH: dopamine \u2192 norepinephrine \u2192 epinephrine) - Depleted rapidly during acute stress (ACTH stimulates Vit C release from adrenals)</p>"},{"location":"neuroscience/hpa_axis/#cortisols-systemic-effects","title":"Cortisol's Systemic Effects","text":"System Acute Effect (adaptive) Chronic Effect (pathological) Metabolism Gluconeogenesis \u2191, lipolysis \u2191 Insulin resistance, visceral fat accumulation, muscle wasting Immune Anti-inflammatory (transient) Immunosuppression; impaired NK cells and TH1 response Brain Hippocampal LTP (memory consolidation) Hippocampal dendrite retraction; BDNF \u2193; memory impairment Cardiovascular BP \u2191, HR \u2191 Hypertension, endothelial damage Gut Reduces gut motility IBS, intestinal permeability \u2191 (leaky gut) Reproductive \u2014 Suppresses LH/FSH \u2192 low testosterone/estrogen"},{"location":"neuroscience/hpa_axis/#stress-induced-nutrient-depletion","title":"Stress-Induced Nutrient Depletion","text":"<p>Chronic HPA activation creates a vicious nutritional cycle: stress depletes nutrients \u2192 nutrient depletion worsens stress resilience \u2192 amplified HPA response.</p> Nutrient Mechanism of Depletion Consequence of Deficiency Vitamin C Rapid adrenal release during ACTH stimulation Impaired cortisol synthesis; collagen breakdown Magnesium Excreted by kidneys under adrenergic stimulation; also COMT is Mg-dependent Hyperexcitability, poor sleep, COMT impairment Zinc Stress-induced metallothionein = sequesters Zn away from immune/enzymatic functions Immune suppression, reduced BDNF, impaired 5\u03b1-reductase B5 (Pantothenate) Direct precursor to CoA (required for acetyl-CoA in adrenal steroidogenesis) Adrenal fatigue, impaired cortisol synthesis; also required for melatonin production B6 (Pyridoxal-5\u2032-phosphate) Cortisol degrades PLP; glucocorticoids inhibit PLP-dependent enzymes Serotonin/dopamine synthesis impaired (AADC requires PLP) Vitamin D Stress-induced inflammation reduces VDR expression; also dietary neglect Immune dysregulation, reduced serotonin synthesis Iron Chronic inflammation sequesters iron (hepcidin \u2191) Fatigue, cognitive impairment, reduced CYP activity B12 and Folate Methylation demand increases under stress (cortisol \u2192 epinephrine conversion via PNMT requires SAM) Elevated homocysteine, impaired methylation"},{"location":"neuroscience/hpa_axis/#adrenal-recovery-nutritional-protocols","title":"Adrenal Recovery \u2014 Nutritional Protocols","text":"<p>Note on \"Adrenal Fatigue\": Not a validated medical diagnosis, but HPA axis dysregulation (attenuated cortisol rhythm, blunted CAR, raised basal evening cortisol) is documented in burnout and chronic stress. Treatment centres on reducing allostatic load and restoring depleted nutrients.</p>"},{"location":"neuroscience/hpa_axis/#priority-nutrients","title":"Priority Nutrients","text":"Nutrient Dose Range (therapeutic) Rationale Vitamin C 500\u20132000 mg/day (divided) Adrenal support; antioxidant; blunts cortisol response to exercise in studies Pantothenic Acid (B5) 500\u20131500 mg/day CoA synthesis; required for ALL steroid hormone production Magnesium glycinate / threonate 200\u2013400 mg elemental/day HPA dampening; sleep quality; COMT support Ashwagandha (KSM-66) 300\u2013600 mg/day (extract) Cortisol reduction in RCTs; adaptogen acting on HPA feedback Rhodiola rosea 200\u2013400 mg/day (standardised) Mild MAO inhibition; cortisol blunting; reduces adrenal sensitisation Phosphatidylserine 400\u2013800 mg/day Blunts ACTH and cortisol response to exercise stress (consistent RCT data) Zinc 15\u201330 mg/day Restores thymulin, BDNF; supports CYP enzyme stability Vitamin D3 + K2 2000\u20135000 IU/day Restores VDR; anti-inflammatory; adrenal cortex VDR binding Adaptogenic B-complex Full spectrum (B1\u2013B12) Restore PLP; support methylation; catecholamine synthesis"},{"location":"neuroscience/hpa_axis/#key-hormones-and-distinctions","title":"Key Hormones and Distinctions","text":"Hormone Source Primary Trigger Half-life Key Function CRH Hypothalamus (PVN) Perceived threat, inflammation, hypoglycaemia ~90 min Releases ACTH ACTH Anterior pituitary CRH ~10 min Stimulates cortisol synthesis Cortisol Adrenal cortex (zona fasciculata) ACTH ~60\u2013100 min Glucocorticoid effector DHEA / DHEA-S Adrenal cortex (zona reticularis) ACTH 7\u201310 hrs (DHEA-S) Counter-regulates cortisol; neurosteroid; androgen precursor Aldosterone Adrenal cortex (zona glomerulosa) Angiotensin II, low Na\u207a ~20 min Na\u207a/K\u207a balance; BP regulation Adrenaline (Epinephrine) Adrenal medulla Sympathetic (fast) ~2\u20133 min Acute fight-or-flight; heart rate"},{"location":"neuroscience/hpa_axis/#hpa-axis-and-neurotransmitters","title":"HPA Axis and Neurotransmitters","text":"<p>The HPA axis does not operate in isolation \u2014 it is tightly modulated by key neurotransmitter systems:</p> Neurotransmitter Effect on HPA Serotonin 5-HT\u2081A \u2192 inhibits CRH; 5-HT\u2082 \u2192 stimulates. Net: tonic inhibitory. Low serotonin = disinhibited HPA GABA Inhibitory tone on hypothalamic CRH neurons; reduced GABA \u2192 amplified stress response Dopamine Inhibits ACTH release; low dopamine states \u2192 dysregulated cortisol Norepinephrine Stimulates CRH (\u03b1\u2081 receptor); locus coeruleus \u2192 HPA activation in acute stress Glutamate / NMDA Activates PVN CRH neurons; excitotoxic loop in chronic stress Acetylcholine Muscarinic \u2192 stimulates CRH; nicotine chronically dysregulates HPA rhythm"},{"location":"neuroscience/hpa_axis/#negative-feedback-failure","title":"Negative Feedback Failure","text":"<p>In chronic stress, the negative feedback loop deteriorates due to:</p> <ol> <li>Glucocorticoid Receptor (GR) downregulation \u2014 prolonged cortisol reduces GR expression in hippocampus and hypothalamus \u2192 less feedback sensitivity</li> <li>Hippocampal atrophy \u2014 hippocampus normally suppresses PVN; dendrite retraction = loss of inhibitory tone</li> <li>CRH hypersecretion \u2014 CRH neurons in bed nucleus of stria terminalis (BNST) bypass normal feedback circuits</li> </ol> <p>Restoration requires both nutrient repletion (above) and stimulus removal \u2014 sleep, down-regulation of perceived threat (CBT, mindfulness have demonstrated GR normalisation in studies).</p>"},{"location":"neuroscience/hpa_axis/#clinical-relevance","title":"Clinical Relevance","text":"Condition HPA Status Key Features Anxiety / panic disorder Hyperactive HPA Elevated baseline CRH; morning cortisol spike during panic attacks Major depression Hyperactive HPA (melancholic) or blunted (atypical) Dexamethasone non-suppression test classically positive in melancholic type PTSD Blunted HPA + hypersensitive amygdala Low cortisol paradox; glucocorticoid receptor hypersensitivity Burnout / chronic fatigue Hypocortisol (HPA exhaustion) Flat diurnal curve; poor CAR; depleted B5, Mg, C Cushing's syndrome Chronic hypercortisolaemia Central obesity, muscle wasting, immunosuppression, osteoporosis Addison's disease Adrenal insufficiency Low cortisol + aldosterone; medical emergency Metabolic syndrome Elevated cortisol \u2192 insulin resistance Visceral fat, dyslipidaemia, hyperglycaemia"},{"location":"neuroscience/kynurenine_pathway/","title":"Kynurenine Pathway","text":""},{"location":"neuroscience/kynurenine_pathway/#overview","title":"Overview","text":"<p>Under normal conditions, dietary tryptophan feeds primarily into serotonin and melatonin synthesis. However, in the presence of inflammation, the kynurenine pathway competitively diverts up to 95% of tryptophan away from serotonin \u2014 producing neuroactive and neurotoxic metabolites that directly modulate mood, cognition, and neurodegeneration.</p> <p>The kynurenine pathway is the biochemical bridge between inflammation and depression.</p> <p>Key insight \u2014 Depression in the context of chronic illness, autoimmune disease, or post-infection is often not a serotonin deficiency per se, but a tryptophan diversion problem: inflammation has shunted tryptophan into the kynurenine pathway, starving serotonin synthesis while simultaneously generating neurotoxic quinolinic acid.</p>"},{"location":"neuroscience/kynurenine_pathway/#pathway-overview","title":"Pathway Overview","text":"<pre><code>Dietary Tryptophan (Trp)\n         \u2502\n         \u251c\u2500\u2500\u25ba [TPH1/2]  \u2192  Serotonin \u2192 Melatonin        \u2190 Normal route (~1\u20135% Trp)\n         \u2502\n         \u2514\u2500\u2500\u25ba [IDO / TDO]  \u2190 INFLAMED route (~95% Trp under inflammation)\n                  \u2502\n                  \u25bc\n            Kynurenine (KYN)\n                  \u2502\n       \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u253c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n       \u2502          \u2502                      \u2502\n       \u25bc          \u25bc                      \u25bc\n [KAT I\u2013IV]  [KMO]                  [KMO blocked]\n + Vit B6     + FAD (B2)\n       \u2502          \u2502                      \u2502\n       \u25bc          \u25bc                      \u25bc\n Kynurenic    3-Hydroxykynurenine   Anthranilic Acid\n  Acid (KA)        \u2502\n(neuroprotective)  \u2502 [HAAO]\n                   \u2502  + Fe\u00b2\u207a\n                   \u25bc\n            3-Hydroxyanthranilic Acid (3-HAA)\n                   \u2502\n                   \u2502 [ACMSD]  \u2190 can divert away from neurotoxic route\n                   \u25bc\n           Quinolinic Acid (QUIN)  \u2190 NEUROTOXIC\n                   \u2502\n                   \u2502 [QPRT]\n                   \u25bc\n              NAD\u207a  \u2190 end product\n</code></pre>"},{"location":"neuroscience/kynurenine_pathway/#key-enzymes","title":"Key Enzymes","text":""},{"location":"neuroscience/kynurenine_pathway/#ido-indoleamine-23-dioxygenase-the-inflammation-gate","title":"IDO (Indoleamine 2,3-Dioxygenase) \u2014 The Inflammation Gate","text":"<p>IDO is the primary rate-limiting enzyme of the kynurenine pathway. It is expressed in: - Dendritic cells and macrophages (strongly) - Microglia (brain immune cells) - Liver (minor role, TDO predominates here) - Placenta, tumour cells</p> <p>IDO is powerfully induced by:</p> Inducer Source Interferon-gamma (IFN-\u03b3) T cells, NK cells \u2014 THE primary IDO inducer LPS (lipopolysaccharide) Gram-negative bacteria / gut permeability TNF-\u03b1 Macrophages IL-6 Broad inflammatory states Cortisol Stress (via HPA axis) Reactive oxygen species Oxidative stress conditions"},{"location":"neuroscience/kynurenine_pathway/#tdo-tryptophan-23-dioxygenase-the-hepatic-gate","title":"TDO (Tryptophan 2,3-Dioxygenase) \u2014 The Hepatic Gate","text":"<p>TDO is constitutively expressed in the liver and is the dominant enzyme for tryptophan catabolism under non-inflammatory conditions. It is induced by: - Tryptophan itself (substrate induction) - Glucocorticoids (cortisol) \u2014 stress further potentiates tryptophan diversion via TDO</p>"},{"location":"neuroscience/kynurenine_pathway/#neuroactive-metabolites-the-kynurenine-balance","title":"Neuroactive Metabolites \u2014 The Kynurenine Balance","text":"<p>The pathway branches into neuroprotective and neurotoxic arms. The balance between these arms determines neurological outcome.</p> Metabolite Effect NMDA Receptor Produced by Kynurenic Acid (KA) NEUROPROTECTIVE Antagonist (blocks) Astrocytes (via KAT) Quinolinic Acid (QUIN) NEUROTOXIC Agonist (activates) Microglia, macrophages 3-Hydroxykynurenine (3-HK) PRO-OXIDANT \u2014 Macrophages (KMO) Picolinic Acid Mildly neuroprotective Chelates Zn, inhibits QUIN Peripheral tissues NAD\u207a Mitochondrial co-enzyme \u2014 All tissues (via QPRT)"},{"location":"neuroscience/kynurenine_pathway/#the-kynurenic-acid-quinolinic-acid-ratio","title":"The Kynurenic Acid / Quinolinic Acid Ratio","text":"<p>This ratio is a critical clinical marker: - High KA / low QUIN \u2192 neuroprotective state (astrocyte-dominant) - Low KA / high QUIN \u2192 neurotoxic state (microglia-dominant) = seen in depression, Alzheimer's, HIV encephalopathy</p>"},{"location":"neuroscience/kynurenine_pathway/#quinolinic-acid-mechanism-of-neurotoxicity","title":"Quinolinic Acid \u2014 Mechanism of Neurotoxicity","text":"<p>Quinolinic acid (QUIN) is an endogenous NMDA receptor agonist and the principal neurotoxin of the kynurenine pathway.</p>"},{"location":"neuroscience/kynurenine_pathway/#mechanisms-of-quin-toxicity","title":"Mechanisms of QUIN Toxicity","text":"<pre><code>QUIN\n  \u2502\n  \u251c\u2500\u2500\u25ba NMDA receptor over-activation \u2192 Ca\u00b2\u207a influx\n  \u2502         \u2502\n  \u2502         \u251c\u2500\u2500\u25ba Mitochondrial dysfunction (cytochrome c release)\n  \u2502         \u251c\u2500\u2500\u25ba ROS generation (nitric oxide via nNOS)\n  \u2502         \u2514\u2500\u2500\u25ba Excitotoxic neuronal death\n  \u2502\n  \u251c\u2500\u2500\u25ba Glutamate transporter inhibition \u2192 Glutamate accumulates \u2192 Compound excitotoxicity\n  \u2502\n  \u251c\u2500\u2500\u25ba Oxidative stress \u2192 lipid peroxidation, DNA damage\n  \u2502\n  \u251c\u2500\u2500\u25ba Inhibits complex II and III of ETC (mitochondrial impairment)\n  \u2502\n  \u2514\u2500\u2500\u25ba Suppresses BDNF \u2192 impairs hippocampal neuroplasticity\n</code></pre> <p>Brain regions most vulnerable: - Hippocampus (CA1, CA3) \u2014 memory - Striatum \u2014 movement, reward - Cortex \u2014 cognition, executive function</p>"},{"location":"neuroscience/kynurenine_pathway/#the-inflammation-depression-link","title":"The Inflammation \u2192 Depression Link","text":"<p>The kynurenine pathway explains the cytokine-induced depression model (also called the inflammatory sickness model of depression):</p> <pre><code>Infection / Chronic illness / Gut dysbiosis / Autoimmune disease\n       \u2502\n       \u25bc\nElevated IFN-\u03b3, IL-6, TNF-\u03b1, LPS\n       \u2502\n       \u25bc\nIDO induction in brain MICROGLIA\n       \u2502\n       \u251c\u2500\u2500\u25ba Tryptophan diverted \u2192 Serotonin \u2193 \u2192 Melatonin \u2193\n       \u2502\n       \u251c\u2500\u2500\u25ba QUIN \u2191 \u2192 NMDA excitotoxicity \u2192 Hippocampal damage\n       \u2502\n       \u251c\u2500\u2500\u25ba BDNF \u2193 \u2192 Reduced neuroplasticity\n       \u2502\n       \u2514\u2500\u2500\u25ba KA \u2193 (KMO &gt; KAT) \u2192 Loss of neuroprotective buffer\n               \u2502\n               \u25bc\n           Depression / Cognitive impairment / Psychosis risk\n</code></pre> <p>This model explains: - Depression associated with cancer, HIV, multiple sclerosis, and post-COVID - Elevated QUIN in CSF of suicidal patients - Why SSRIs (which purely raise serotonin) fail in inflammatory depression - Why anti-inflammatory interventions (omega-3, curcumin, low-dose naltrexone) show antidepressant effects</p>"},{"location":"neuroscience/kynurenine_pathway/#cofactor-requirements-along-the-pathway","title":"Cofactor Requirements Along the Pathway","text":"Enzyme Cofactor Required Deficiency Effect TPH1/2 (Trp \u2192 5-HTP) BH4, Fe\u00b2\u207a, O\u2082 \u2193 Serotonin synthesis IDO Fe\u00b2\u207a (haem), O\u2082 IDO is less active when Fe\u00b2\u207a limited \u2014 may limit kynurenine production KMO (Kyn \u2192 3-HK) FAD (Riboflavin / B2) B2 deficiency \u2192 KYN accumulates or shunts to KA \u2192 neuroprotective shift KAT I/II/III/IV (Kyn \u2192 KA) PLP (Vitamin B6) B6 deficiency \u2192 KA impaired \u2192 reduced neuroprotection HAAO (3-HK \u2192 3-HAA) Fe\u00b2\u207a \u2014 QPRT (QUIN \u2192 NAD\u207a) Mg\u00b2\u207a, Phosphoribosyl-PP Reduced when cellular NAD\u207a demand exceeds QPRT; QUIN builds up"},{"location":"neuroscience/kynurenine_pathway/#nutritional-implication","title":"Nutritional Implication","text":"<p>Vitamin B6 (PLP) is critical for the KAT branch (neuroprotective arm). B6 deficiency blunts kynurenic acid production, shifting the balance toward quinolinic acid toxicity.</p>"},{"location":"neuroscience/kynurenine_pathway/#nutritional-modulation-of-the-kynurenine-pathway","title":"Nutritional Modulation of the Kynurenine Pathway","text":"Nutrient / Compound Effect on Pathway Mechanism Omega-3 (EPA especially) \u2193 IDO induction Reduces IFN-\u03b3, IL-6, TNF-\u03b1; reduces NF-\u03baB \u2192 less IDO transcription Vitamin B6 (PLP) \u2191 KA production (neuroprotective) KAT cofactor; improves kyn \u2192 KA ratio Vitamin B3 (Niacin / Nicotinamide) Reduces IDO activity (via NAD\u207a feedback) Niacin supplies NAD\u207a independently \u2192 reduces metabolic pressure on QPRT path Curcumin \u2193 IDO expression; \u2193 NF-\u03baB Anti-inflammatory; also chelates Fe (reduces IDO haem availability as secondary effect) Resveratrol \u2193 IDO; \u2193 SIRT1-mediated kynurenine flux SIRT1 pathway, reduces TDO under liver stress Tryptophan restriction \u2193 TDO activity (substrate withdrawal) Exploited in tumour immunology Melatonin \u2193 IDO induction; direct ROS quenching Anti-inflammatory; also has scavenging effect on QUIN-generated ROS NAC (N-Acetylcysteine) Reduces QUIN-driven oxidative stress Glutathione precursor; direct ROS scavenging Zinc Competes with QUIN at NMDA site (picolinic acid chelates Zn \u2014 supplementing Zn counteracts) Reduces QUIN-driven excitotoxicity Magnesium NMDA receptor Mg\u00b2\u207a block \u2192 reduces QUIN's excitotoxic access Voltage-dependent NMDA block"},{"location":"neuroscience/kynurenine_pathway/#nad-production-via-the-kynurenine-pathway","title":"NAD\u207a Production via the Kynurenine Pathway","text":"<p>The kynurenine pathway is the de novo route for NAD\u207a synthesis in humans. This has significant implications:</p> <ul> <li>Under high IDO activity (chronic inflammation): QUIN \u2192 NAD\u207a via QPRT is the primary NAD\u207a source</li> <li>Niacin (vitamin B3) provides the salvage pathway \u2014 maintaining NAD\u207a without requiring tryptophan flux through QUIN</li> <li>NMN and NR (NAD\u207a precursors) similarly bypass QUIN toxicity</li> </ul> <p>Clinical pearl: In conditions with chronic inflammation (HIV, lupus, IBD), NAD\u207a supplementation (niacin, NMN, NR) may serve the dual role of restoring NAD\u207a AND reducing pressure on the QUIN arm of the kynurenine pathway.</p>"},{"location":"neuroscience/kynurenine_pathway/#clinical-relevance","title":"Clinical Relevance","text":"Condition Kynurenine Pathway Status Clinical Implication Major Depression (inflammatory subtype) \u2191 IDO, \u2191 QUIN, \u2193 KA, \u2193 serotonin IDO inhibitors (experimental); omega-3; B6; anti-inflammatory diet Schizophrenia \u2191 KA (over-blocks NMDA \u2192 negative symptoms) High KA = NMDA hypofunction; KMO inhibitors investigated Alzheimer's disease \u2191 QUIN in plaques; IDO active in microglia Tryptophan \u2192 QUIN may contribute to A\u03b2-associated neurodegeneration Post-COVID (neurological) \u2191 IDO (IFN-\u03b3 surge); \u2193 tryptophan; \u2191 kynurenine Explains fatigue, cognitive fog; omega-3 + B6 + NAD\u207a support Cancer (tumour immune evasion) Tumours express IDO to deplete Trp in tumour microenvironment \u2192 suppresses T cells IDO1 inhibitors (epacadostat etc.) in clinical trials HIV encephalopathy Elevated QUIN in CSF QUIN from activated macrophages drives CNS damage Sepsis Massive IDO induction \u2192 tryptophan collapse Nutritional tryptophan matters; reduces serotonergic depression post-sepsis IBD / Gut dysbiosis Gut IDO1 activation; LPS \u2192 systemic IDO Probiotic restoration reduces LPS \u2192 reduces IDO \u2192 improves kynurenine balance"},{"location":"neuroscience/neuroplasticity/","title":"Neuroplasticity","text":""},{"location":"neuroscience/neuroplasticity/#overview","title":"Overview","text":"<p>Neuroplasticity is the brain's capacity to reorganise its structure, connections, and function in response to experience, learning, injury, or environmental change. It underlies all learning and memory, and is the therapeutic target in depression, PTSD, addiction recovery, and cognitive decline.</p> <p>The two major forms:</p> Form Mechanism Timescale Synaptic plasticity Strength changes between existing synapses Seconds \u2192 days Structural plasticity Axon sprouting, dendritic remodelling, neurogenesis Days \u2192 weeks"},{"location":"neuroscience/neuroplasticity/#brain-derived-neurotrophic-factor-bdnf","title":"Brain-Derived Neurotrophic Factor (BDNF)","text":"<p>BDNF is the master regulator of neuroplasticity. It binds TrkB receptors, activating downstream cascades (MAPK/ERK, PI3K/Akt, PLC\u03b3) that promote neuronal survival, synaptic strengthening, and new synapse formation.</p>"},{"location":"neuroscience/neuroplasticity/#bdnf-and-the-creb-pathway","title":"BDNF and the CREB Pathway","text":"<pre><code>Stimulus (exercise, novelty, learning)\n       \u2502\n       \u25bc\n[Neuronal activity] \u2192 Ca\u00b2\u207a influx \u2192 CaM-kinase activation\n       \u2502\n       \u25bc\nCREB phosphorylation (pCREB) \u2500\u2500\u25ba BDNF gene transcription\n       \u2502\n       \u25bc\nBDNF protein \u2192 secreted \u2192 binds TrkB (pre/post-synaptically)\n       \u2502\n       \u251c\u2500\u2500\u25ba MAPK/ERK \u2192 synaptic protein synthesis (LTP consolidation)\n       \u251c\u2500\u2500\u25ba PI3K/Akt \u2192 neuronal survival (anti-apoptotic)\n       \u2514\u2500\u2500\u25ba PLC\u03b3 \u2192 DAG + IP3 \u2192 PKC \u2192 AMPA receptor insertion\n</code></pre>"},{"location":"neuroscience/neuroplasticity/#key-insight","title":"Key Insight","text":"<p>Low BDNF is consistently found in depression, Alzheimer's, and chronic stress. Most antidepressants (SSRIs, exercise, ketamine) exert effects at least partly by raising BDNF.</p>"},{"location":"neuroscience/neuroplasticity/#long-term-potentiation-ltp","title":"Long-Term Potentiation (LTP)","text":"<p>LTP is the cellular mechanism of memory formation: repeated stimulation of a synapse makes it more efficient at transmitting future signals.</p>"},{"location":"neuroscience/neuroplasticity/#mechanism","title":"Mechanism","text":"<pre><code>Weak stimulation \u2192 AMPA receptors open \u2192 Na\u207a influx \u2192 small EPSP\n\nRepeated / strong stimulation:\n       \u2502\n       \u25bc\nLarge Na\u207a influx \u2192 EPSP depolarises membrane\n       \u2502\n       \u25bc\nMg\u00b2\u207a block of NMDA receptor removed (voltage-gated)\n       \u2502\n       \u25bc\nGlutamate + Glycine bind NMDA receptor \u2192 Ca\u00b2\u207a + Na\u207a influx\n       \u2502\n       \u2502                        \u250c\u2500\u2500\u2500 CaM-Kinase II (CaMKII) \u2192 AMPA phosphorylation\n       \u25bc                        \u2502\nLarge Ca\u00b2\u207a signal \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u25ba\u2502\u2500\u2500\u2500 PKC \u2192 AMPA receptor trafficking (\u2191surface AMPAs)\n                                \u2502\n                                \u2514\u2500\u2500\u2500 CREB activation \u2192 BDNF \u2192 structural changes\n</code></pre>"},{"location":"neuroscience/neuroplasticity/#phases-of-ltp","title":"Phases of LTP","text":"Phase Duration Mechanism Sensitive To E-LTP (early) &lt; 3 hrs AMPA phosphorylation, existing proteins Protein kinase inhibitors L-LTP (late) &gt; 3 hrs / days New protein synthesis, structural remodelling BDNF antibodies, transcription inhibitors"},{"location":"neuroscience/neuroplasticity/#nmda-dependent-plasticity","title":"NMDA-Dependent Plasticity","text":"<p>The NMDA receptor (NMDAr) is the co-incidence detector of the brain \u2014 it only opens when the synapse is active (glutamate present) AND the neuron is already depolarised (Mg\u00b2\u207a block removed). This requirement enforces Hebbian learning: \"neurons that fire together, wire together.\"</p>"},{"location":"neuroscience/neuroplasticity/#nmda-receptor-subunits-and-nutrition","title":"NMDA Receptor Subunits and Nutrition","text":"Subunit Role in plasticity Nutritional relevance GluN1 Obligatory; binds glycine (co-agonist) Glycine sufficiency required for activation GluN2A Synaptic; short deactivation Zinc modulates (inhibitory at high conc.) GluN2B Extrasynaptic; long open time; key for LTP induction Magnesium (Mg-L-threonate increases brain Mg\u00b2\u207a; reduces Mg\u00b2\u207a block) GluN2D Hippocampus; slow deactivation \u2014"},{"location":"neuroscience/neuroplasticity/#co-agonist-site","title":"Co-agonist Site","text":"<p>The NMDAr requires both glutamate and a co-agonist (glycine or D-serine) for full activation: - Glycine (dietary; synthesised from serine) \u2014 binds GluN1 - D-Serine (synthesised by neuronal/astrocytic serine racemase) \u2014 predominates in cortex and hippocampus</p> <p>Deficiency note: Low glycine or impaired serine racemase (e.g., folate-deficiency affecting one-carbon metabolism and serine synthesis) can impair NMDA-dependent LTP.</p>"},{"location":"neuroscience/neuroplasticity/#neurogenesis","title":"Neurogenesis","text":"<p>Adult neurogenesis occurs primarily in: - Dentate gyrus (hippocampus) \u2014 spatial memory, pattern separation, emotional regulation - Olfactory bulb (via subventricular zone)</p> <p>Regulated by: - \u2191: Exercise (\u2191 BDNF, \u2191 VEGF), caloric restriction, omega-3, curcumin, low stress - \u2193: Chronic stress (elevated cortisol), sleep deprivation, alcohol, neuroinflammation</p>"},{"location":"neuroscience/neuroplasticity/#nutrients-that-upregulate-bdnf-and-neuroplasticity","title":"Nutrients That Upregulate BDNF and Neuroplasticity","text":"Nutrient / Compound Mechanism Evidence Level Omega-3 (DHA) DHA is incorporated into neuronal membranes \u2192 increases TrkB density; reduces neuroinflammation (prostaglandin E2 \u2193) Strong (human RCTs) Magnesium (Mg-L-threonate) Raises synaptic Mg\u00b2\u207a \u2192 enhances NMDA function at optimal levels; activates CREB Moderate (animal model; human trials ongoing) Zinc TrkB \u2192 BDNF signalling modulator; regulates NMDA GluN2 subunit sensitivity Moderate Curcumin Activates CREB; inhibits NF-\u03baB (reduces BDNF-suppressing inflammation); inhibits MAO Moderate (poor bioavailability unless with piperine) Vitamin D VDR (vitamin D receptor) upregulates NGF and NT-3 (similar to BDNF); modulates synaptic plasticity genes Moderate Resveratrol SIRT1 activation \u2192 PGC-1\u03b1 \u2192 mitochondrial biogenesis; increases BDNF indirectly Moderate Lion's Mane (Hericium erinaceus) Hericenones / erinacines stimulate NGF synthesis via same CREB pathway Moderate (human trials small) Exercise (exerkines) FNDC5/irisin \u2192 PGC-1\u03b1 \u2192 BDNF mRNA; also VEGF, IGF-1 (crosses BBB) Very strong Caloric restriction / fasting AMPK activation; \u2191 BDNF via ketone body \u03b2-OHB signalling Moderate B vitamins (B6, B9, B12) Homocysteine control (elevated Hcy is NMDA hyper-activator \u2192 excitotoxicity, damages synapses) Strong"},{"location":"neuroscience/neuroplasticity/#factors-that-suppress-neuroplasticity","title":"Factors That Suppress Neuroplasticity","text":"Factor Mechanism Chronic cortisol Dendrite retraction in hippocampus; suppresses BDNF gene transcription Neuroinflammation (IL-6, TNF-\u03b1) IDO activation \u2192 tryptophan \u2192 quinolinate (NMDA agonist toxicity); \u2193 BDNF High homocysteine Excitotoxic NMDA over-activation; DNA damage in neurons; B9/B12 deficiency Alcohol Acutely inhibits NMDA (anaesthetic effect); chronic \u2192 NMDA upregulation + withdrawal excitotoxicity Sleep deprivation Impairs synaptic homeostasis (SHY hypothesis); reduces hippocampal BDNF Oxidative stress Oxidises BDNF, damages TrkB receptors; depletes Mg, Zn, Se"},{"location":"neuroscience/neuroplasticity/#synaptic-homeostasis-hypothesis-shy","title":"Synaptic Homeostasis Hypothesis (SHY)","text":"<p>Sleep is not merely restorative \u2014 it is a mandatory downscaling of synaptic strength. During wakefulness, LTP-like processes build up synaptic weights throughout the day; sleep (especially slow-wave sleep) globally downscales synapses via LTD (long-term depression), restoring signal-to-noise ratio and energy efficiency.</p> <p>Nutritional relevance: Glycine supplementation (3 g before sleep) promotes deep SWS in human trials \u2014 proposed mechanism involves hypothermic effect (vasodilation) and NMDA receptor modulation in the suprachiasmatic nucleus.</p>"},{"location":"neuroscience/neuroplasticity/#clinical-relevance","title":"Clinical Relevance","text":"Condition Plasticity Mechanism Nutritional Application Depression Reduced BDNF (blunted hippocampal neurogenesis) DHA, Mg, Zn, curcumin, exercise Alzheimer's disease Tau-disrupted BDNF transport; A\u03b2 inhibits TrkB DHA, curcumin, Lion's Mane (NGF), vitamin D PTSD Over-consolidated fear memories (amygdala LTP); reduced hippocampal BDNF MDMA-assisted therapy increases BDNF; omega-3 Addiction Pathological LTP in reward circuits (NAc, PFC) Curcumin (blunts \u0394FosB), Mg (modulates NMDA craving circuits) Stroke / TBI Reduced BDNF in peri-lesion cortex DHA (neuroprotective), Mg (reduces excitotoxicity acutely) Cognitive ageing Declining BDNF, synaptic loss, reduced neurogenesis Multimodal: exercise + DHA + Mg + sleep optimisation"},{"location":"neuroscience/sleep_architecture/","title":"Sleep Architecture","text":""},{"location":"neuroscience/sleep_architecture/#overview","title":"Overview","text":"<p>Sleep is a dynamically structured biological process governed by two interacting systems:</p> <ol> <li>Process S (Sleep Pressure) \u2014 homeostatic drive that accumulates with wakefulness (adenosine build-up); discharged during sleep</li> <li>Process C (Circadian Clock) \u2014 24-hour endogenous oscillation in the suprachiasmatic nucleus (SCN) that times sleep onset, depth, and awakening</li> </ol> <p>Together these systems orchestrate a predictable sequence of sleep stages that perform critical functions: memory consolidation, cellular repair, immune surveillance, and metabolic regulation.</p>"},{"location":"neuroscience/sleep_architecture/#sleep-stage-architecture","title":"Sleep Stage Architecture","text":"<p>A normal night consists of 4\u20136 cycles of ~90 minutes each, with NREM stages predominating early and REM increasing toward morning.</p> <pre><code>Awake \u2500\u2500\u25ba NREM N1 \u2500\u2500\u25ba NREM N2 \u2500\u2500\u25ba NREM N3 (SWS) \u2500\u2500\u2510\n                                                     \u2502\n                                        \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n                                        \u25bc\n                                   REM Sleep \u2500\u2500\u25ba (repeat cycle)\n</code></pre> Stage EEG Pattern Duration per night Primary Function Vulnerable To N1 (light NREM) Theta (4\u20138 Hz) 5\u201310 mins per cycle Hypnic jerk; transition Noise, light N2 (intermediate) Sleep spindles, K-complexes 20\u201330 mins per cycle Memory tagging; cardiovascular restoration Stimulants, alcohol later N3 (SWS) Delta (0.5\u20134 Hz); slow-wave 20\u201340 mins first cycle Physical repair, GH release, immune, deep memory consolidation Stress, blue light, caffeine REM Theta + beta; low amplitude 10\u201360 mins (grows across night) Emotional processing, dreaming, procedural memory, creative association Alcohol, antidepressants"},{"location":"neuroscience/sleep_architecture/#adenosine-the-sleep-pressure-molecule","title":"Adenosine \u2014 The Sleep Pressure Molecule","text":"<p>Adenosine is a by-product of neuronal ATP consumption. As neurons fire during wakefulness, adenosine accumulates in the extracellular space (especially the basal forebrain), progressively inhibiting wake-promoting neurons \u2192 building sleep pressure.</p>"},{"location":"neuroscience/sleep_architecture/#adenosine-receptor-subtypes","title":"Adenosine Receptor Subtypes","text":"Receptor Location Effect of adenosine binding A1 Cortex, hippocampus, basal forebrain Inhibits neuronal firing; reduces cholinergic wake drive A2A Striatum, olfactory tubercle Promotes sleep; also reduces dopaminergic activity"},{"location":"neuroscience/sleep_architecture/#caffeine-mechanism","title":"Caffeine Mechanism","text":"<p>Caffeine is a competitive antagonist at A1 and A2A receptors. It does not destroy adenosine \u2014 it blocks its receptors. Adenosine accumulates behind the block, and when caffeine is metabolised (t\u00bd ~5 hrs), the \"adenosine debt\" is suddenly experienced \u2192 caffeine crash.</p> <p>Half-life note: CYP1A2 genotype determines caffeine metabolism speed (fast vs slow metabolisers). Late caffeine intake (~after 14:00) delays sleep onset and suppresses SWS.</p>"},{"location":"neuroscience/sleep_architecture/#adenosine-and-nutrition","title":"Adenosine and Nutrition","text":"Nutrient / Compound Effect on Adenosine System Magnesium Required for ATP synthesis; optimised ATP turnover maintains healthy adenosine dynamics Theanine (L-theanine) Adenosine A1 partial agonist; promotes alpha-wave relaxation without sedation Quercetin Inhibits adenosine kinase \u2192 reduces adenosine phosphorylation \u2192 increases adenosine availability Alcohol Increases adenosine initially (promotes sleep onset) \u2192 rebound awakening in second half; fragments SWS/REM"},{"location":"neuroscience/sleep_architecture/#circadian-clock-scn-and-molecular-mechanism","title":"Circadian Clock \u2014 SCN and Molecular Mechanism","text":"<p>The suprachiasmatic nucleus (SCN) in the hypothalamus is the master clock, running on a ~24.2-hour cycle entrained to light/dark via the retinohypothalamic tract.</p>"},{"location":"neuroscience/sleep_architecture/#molecular-feedback-loop","title":"Molecular Feedback Loop","text":"<pre><code>Clock proteins: CLOCK + BMAL1 (activators)\n       \u2502\n       \u25bc\nTranscription of: PER1/2/3, CRY1/2, Rev-erb\u03b1, ROR\u03b1\n       \u2502\n       \u25bc\nPER:CRY complex \u2192 accumulates in cytoplasm \u2192 enters nucleus\n       \u2502\n       \u25bc\nInhibits CLOCK:BMAL1 \u2192 stops its own transcription (negative feedback)\n       \u2502\n       \u25bc\nPER:CRY degraded (after ~12 hrs) \u2192 CLOCK:BMAL1 activity resumes\n       \u2514\u2500\u2500\u25ba ~24-hr cycle\n</code></pre>"},{"location":"neuroscience/sleep_architecture/#light-entrainment","title":"Light Entrainment","text":"<ul> <li>Melanopsin-containing ipRGCs (intrinsically photosensitive retinal ganglion cells) send light signals to the SCN</li> <li>Blue light (480 nm peak) \u2192 suppresses melatonin most powerfully</li> <li>Morning bright light \u2192 advances circadian phase; evening bright light \u2192 delays phase</li> </ul>"},{"location":"neuroscience/sleep_architecture/#melatonin-the-darkness-signal","title":"Melatonin \u2014 The Darkness Signal","text":"<p>Melatonin is synthesised in the pineal gland from serotonin (itself derived from tryptophan). It is the chemical signal of darkness, not directly of sleep \u2014 it gates the timing of sleep but does not induce sedation directly.</p>"},{"location":"neuroscience/sleep_architecture/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>Tryptophan (dietary essential)\n       \u2502\n       \u2502 [TPH1/2]  Cofactors: BH4, Fe\u00b2\u207a, O\u2082\n       \u25bc\n5-HTP (5-Hydroxytryptophan)\n       \u2502\n       \u2502 [AADC]    Cofactor: PLP (Vitamin B6)\n       \u25bc\nSerotonin (5-HT)\n       \u2502\n       \u2502 [AANAT \u2014 Arylalkylamine N-acetyltransferase]\n       \u2502  Cofactor: Acetyl-CoA (from B5 / CoA)\n       \u2502  \u26a0 Rate-limiting step; activated by darkness/NE signal from SCN\n       \u25bc\nN-Acetylserotonin\n       \u2502\n       \u2502 [ASMT / HIOMT]   Cofactor: SAM (S-adenosylmethionine \u2192 needs B12, folate, B2, Mg)\n       \u25bc\nMelatonin (N-acetyl-5-methoxytryptamine)\n</code></pre>"},{"location":"neuroscience/sleep_architecture/#cofactor-requirements-for-melatonin","title":"Cofactor Requirements for Melatonin","text":"Step Enzyme Required Nutrient Tryptophan \u2192 5-HTP TPH2 BH4, Iron (Fe\u00b2\u207a) 5-HTP \u2192 Serotonin AADC Vitamin B6 (PLP) Serotonin \u2192 N-Acetylserotonin AANAT Acetyl-CoA (Vitamin B5 \u2192 CoA) N-Acetylserotonin \u2192 Melatonin ASMT SAM (requires B12, Folate, B2, Magnesium)"},{"location":"neuroscience/sleep_architecture/#nutrients-affecting-each-sleep-stage","title":"Nutrients Affecting Each Sleep Stage","text":""},{"location":"neuroscience/sleep_architecture/#slow-wave-sleep-n3-enhancers","title":"Slow-Wave Sleep (N3) Enhancers","text":"Nutrient Mechanism Evidence Glycine Hypothermic effect (vasodilation \u2192 core temp \u2193); NMDA co-agonist in SCN neurons; 3 g at bedtime \u2192 \u2191 SWS RCT evidence (Inagawa et al.) Magnesium NMDA receptor modulation; activates GABA-A receptors; reduces cortisol Moderate RCT evidence Zinc Synergistic with Mg for SWS; required for melatonin receptor sensitivity Moderate Phosphatidylserine Blunts evening cortisol \u2192 removes cortisol suppression of SWS Some RCT evidence Valerian root Mild GABA-A positive modulation; weak MAO inhibition Inconsistent; mild effect"},{"location":"neuroscience/sleep_architecture/#rem-sleep-modifiers","title":"REM Sleep Modifiers","text":"Nutrient / Drug Effect Vitamin B6 (high dose, &gt;100 mg) Vivid REM dreams; increases P5P availability for tryptophan \u2192 serotonin \u2192 acetylcholine balance in REM Choline / CDP-choline Increases acetylcholine \u2192 acetylcholine drives REM cycling; excess may increase REM quantity 5-HTP Increases serotonin \u2192 initially \u2191 REM, but very high serotonin can suppress REM (like SSRIs) Alcohol Suppresses REM in the first half; REM rebound (intense dreams) in second half SSRIs / SNRIs Strongly suppress REM; used in narcolepsy (cataplexy)"},{"location":"neuroscience/sleep_architecture/#sleep-onset-n1n2-transitions","title":"Sleep Onset (N1/N2 transitions)","text":"Nutrient Mechanism L-Tryptophan Precursor to serotonin and melatonin; competes for BBB transport with large neutral amino acids Melatonin (exogenous) 0.3\u20131 mg dose most physiological; useful for phase shifts (jet lag, shift work); does not significantly increase total sleep time at low doses L-Theanine Alpha-wave promotion; mild GABAergic; anxiety reduction \u2192 easier sleep onset Inositol Second-messenger in 5-HT2 signalling; some evidence for reduced sleep latency"},{"location":"neuroscience/sleep_architecture/#growth-hormone-and-sws","title":"Growth Hormone and SWS","text":"<p>Growth hormone (GH) is released in large pulses within the first 90-minute SWS block of the night. It is the primary driver of: - Protein synthesis and muscle repair - Lipolysis (fat mobilisation overnight) - IGF-1 production (anabolic)</p> <p>Nutrients that support GH release: - Arginine (2\u20135 g before sleep) \u2014 GHRH stimulation; reduced GH at high doses/older adults - Lysine \u2014 synergistic with arginine - Low carbohydrate before sleep \u2014 insulin suppresses GH; ketogenic state favours GH pulsatility - Melatonin \u2014 may augment nocturnal GH via GABA interaction in GHRH neurons</p>"},{"location":"neuroscience/sleep_architecture/#circadian-disruption-consequences","title":"Circadian Disruption \u2014 Consequences","text":"Disruption Mechanism Nutritional Implication Shift work Melatonin suppressed by evening light; food timing misaligned with clocks in liver/gut Metabolic syndrome risk; vitamin D deficiency (indoor exposure) Blue-light exposure (evening) Melanopsin-mediated melatonin suppression 2 hrs before bedtime: \u2193 melatonin 50%; tryptophan intake becomes ineffective Social jet lag Weekend sleep timing shifts reset clocks \u2192 perpetual mini-jet lag Mood dysregulation; cortisol rhythm disrupts Chronic sleep restriction Glymphatic clearance impaired (A\u03b2, tau accumulates); gut microbiome dysbiosis Omega-3 may reduce A\u03b2-associated inflammation Eating at night Peripheral clocks (liver, gut) uncoupled from SCN Impairs insulin sensitivity; raises triglycerides"},{"location":"neuroscience/sleep_architecture/#glymphatic-system","title":"Glymphatic System","text":"<p>The glymphatic system (brain's lymphatic equivalent) clears metabolic waste \u2014 including Alzheimer's-associated proteins A\u03b2 (amyloid-beta) and tau \u2014 during sleep, specifically during SWS when the system is most active. CSF flushes through perivascular spaces around arteries.</p> <p>Nutritional relevance: AQP4 water channels (glymphatic conduit) may be influenced by omega-3 fatty acid membrane composition; Mg deficiency impairs neurovascular coupling.</p>"},{"location":"neuroscience/sleep_architecture/#clinical-relevance","title":"Clinical Relevance","text":"Condition Sleep Stage Disruption Nutritional Approach Insomnia Delayed N3; prolonged sleep latency Mg, Glycine, L-Theanine, Tryptophan timing Depression Reduced SWS; shortened REM latency 5-HTP (with B6); light therapy; normalise Mg Alzheimer's disease Reduced SWS \u2192 impaired glymphatic A\u03b2 clearance DHA, Glycine, Mg-L-threonate ADHD Delayed sleep phase; poor SWS Mg, Zn, melatonin (phase-shift); reduce caffeine Anxiety Frequent arousals; reduced SWS GABA-supportive: Mg, Theanine, Inositol, B6 Shift work disorder Circadian misalignment Melatonin (timed); vitamin D supplementation; circadian-appropriate nutrition timing"},{"location":"neurotransmitters/acetylcholine/","title":"Acetylcholine (ACh)","text":""},{"location":"neurotransmitters/acetylcholine/#overview","title":"Overview","text":"<p>Acetylcholine is a quaternary ammonium neurotransmitter synthesised from choline and acetyl-CoA. It is the predominant neurotransmitter at the neuromuscular junction (voluntary muscle control), in the autonomic nervous system (all parasympathetic, all preganglionic sympathetic), and in multiple CNS circuits governing attention, memory encoding, and REM sleep. The cholinergic system is one of the first to degenerate in Alzheimer's disease.</p> <p>Key insight \u2014 Unlike most neurotransmitters, the rate-limiting factor for ACh synthesis is typically choline availability, not the enzyme. Choline must come from diet or phosphatidylcholine breakdown; de novo synthesis in the liver is inadequate for high neuronal demand.</p>"},{"location":"neurotransmitters/acetylcholine/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>Dietary Choline / Phosphatidylcholine (PC)\n      \u2502\n      \u2502 PC hydrolysis by phospholipase D \u2192 Choline released\n      \u2502 Choline actively transported into presynaptic terminal via CHT1\n      \u2502 (Na\u207a-dependent high-affinity choline transporter)\n      \u2502\n      \u2502 [Choline Acetyltransferase \u2014 ChAT]\n      \u2502  + Acetyl-CoA (from mitochondria / pyruvate \u2192 PDH complex)\n      \u2502  Cofactor: CoA (Pantothenate / Vitamin B5-derived)\n      \u2502  \u26a0 Choline availability is rate-limiting in most contexts\n      \u25bc\nAcetylcholine (ACh)\n      \u2502\n      \u2502 Loaded into synaptic vesicles by VAChT (vesicular ACh transporter)\n      \u25bc\nStored \u2192 Released by exocytosis\n</code></pre>"},{"location":"neurotransmitters/acetylcholine/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme / Transporter Required Cofactors / Nutrients Choline uptake CHT1 Na\u207a gradient (ATP-dependent); adequate plasma choline Pyruvate \u2192 Acetyl-CoA PDH complex Thiamine (B1), Riboflavin (B2), Niacin (B3), Lipoic acid, Pantothenate (B5), Mg\u00b2\u207a Choline + Acetyl-CoA \u2192 ACh \u26a0 ChAT No vitamin cofactor per se \u2014 rate determined by choline and acetyl-CoA availability Vesicular loading VAChT Mg\u00b2\u207a, ATP (proton gradient)"},{"location":"neurotransmitters/acetylcholine/#acetyl-coa-the-cholinergic-bottleneck-under-energy-stress","title":"Acetyl-CoA: The Cholinergic Bottleneck Under Energy Stress","text":"<p>Acetyl-CoA is produced primarily from: - Pyruvate (via PDH \u2014 requires B1, B2, B3, B5, lipoic acid) - \u03b2-oxidation of fatty acids - Ketone body metabolism (acetoacetate \u2192 acetyl-CoA)</p> <p>In hypoglycaemia or mitochondrial dysfunction, acetyl-CoA availability drops \u2192 ACh synthesis falls \u2192 cognitive impairment precedes energy-related symptoms.</p>"},{"location":"neurotransmitters/acetylcholine/#degradation-pathway","title":"Degradation Pathway","text":"<p>Acetylcholine degradation is entirely enzymatic (no reuptake of intact ACh):</p> <pre><code>Acetylcholine (synaptic cleft)\n      \u2502\n      \u2502 [Acetylcholinesterase \u2014 AChE]\n      \u2502  Location: synaptic cleft (membrane-anchored), red blood cells\n      \u2502  This is one of the fastest enzymes in the body (~25,000 ACh/sec)\n      \u2502  No cofactor required (serine esterase \u2014 uses catalytic triad)\n      \u25bc\nCholine  +  Acetate\n      \u2502\n      \u2502 Choline recycled via CHT1 \u2192 re-used for synthesis\n      \u2502 Acetate \u2192 converted to Acetyl-CoA in mitochondria\n</code></pre> <p>Pseudocholinesterase (BuChE): - In plasma, liver, and glial cells - Broader substrate specificity (also hydrolyses drugs like succinylcholine, cocaine) - Not essential for ACh signalling but provides backup at NMJ when AChE is impaired</p>"},{"location":"neurotransmitters/acetylcholine/#choline-sources-dietary-endogenous","title":"Choline Sources (Dietary &amp; Endogenous)","text":"Source Choline Content Beef liver (85g) ~356 mg Eggs (1 large, hard boiled) ~147 mg Salmon (85g cooked) ~187 mg Chicken breast (85g cooked) ~72 mg Soybeans (cooked, 180g) ~214 mg Brussels sprouts (80g cooked) ~32 mg AI (Adequate Intake) Men: 550 mg/day; Women: 425 mg/day; Pregnancy: 450 mg/day <p>Endogenous PEMT pathway: - Phosphatidylethanolamine (PE) \u2192 Phosphatidylcholine (PC) via PEMT enzyme - Requires: 3 SAM molecules (high methylation demand \u2014 needs B12, folate, B2, Mg\u00b2\u207a) - Accounts for ~15\u201325% of hepatic choline; insufficient for total body needs</p>"},{"location":"neurotransmitters/acetylcholine/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency Choline Immediate ACh precursor; rate-limiting Low ACh synthesis; memory impairment; fatty liver Pantothenate (B5) CoA synthesis \u2192 Acetyl-CoA Reduced ACh synthesis capacity Thiamine (B1) PDH complex \u2192 Acetyl-CoA Wernicke's encephalopathy; impaired ACh synthesis Riboflavin (B2) PDH complex Reduced Acetyl-CoA generation Niacin (B3) NAD\u207a for PDH complex Energy and ACh synthesis impaired Lipoic acid PDH complex cofactor Impairs Acetyl-CoA production Folate (5-MTHF) + B12 PEMT pathway (SAM) for choline synthesis Reduced endogenous choline Magnesium VAChT vesicular loading Impaired vesicular storage and release"},{"location":"neurotransmitters/acetylcholine/#acetylcholine-receptors","title":"Acetylcholine Receptors","text":"Receptor Type Location Function Nicotinic (nAChR) \u2014 muscle type Ionotropic (Na\u207a/K\u207a/Ca\u00b2\u207a) Neuromuscular junction Voluntary muscle contraction Nicotinic \u2014 neuronal type (\u03b14\u03b22, \u03b17) Ionotropic CNS, autonomic ganglia Attention, memory, nicotine targets Muscarinic M1 Gq-coupled Cortex, hippocampus Cognitive function, memory; blocked by atropine Muscarinic M2 Gi-coupled Heart (SA node) Slows heart rate (vagal tone) Muscarinic M3 Gq-coupled Smooth muscle, glands Bronchoconstriction, salivation, GI motility Muscarinic M4/M5 Gi/Gq Striatum, CNS Dopamine interaction; reward"},{"location":"neurotransmitters/acetylcholine/#clinical-relevance","title":"Clinical Relevance","text":"Condition ACh Status Mechanism Alzheimer's disease Severe cholinergic deficit Loss of basal forebrain cholinergic neurons (nucleus basalis of Meynert) Myasthenia gravis ACh normal; receptors blocked Autoantibodies against nAChR \u2192 NMJ transmission failure Lambert-Eaton syndrome Reduced ACh release Autoantibodies against presynaptic Ca\u00b2\u207a channels \u2192 impaired exocytosis Organophosphate poisoning ACh excess (AChE blocked) AChE irreversibly inhibited \u2192 SLUDGE (Salivation, Lacrimation, Urination, Defaecation, GI cramping, Emesis) + bradycardia Soman/Sarin (nerve agents) AChE irreversibly inhibited Convulsions; death Dry mouth / cognitive fog Low ACh (drug-induced) Anticholinergic drugs (promethazine, diphenhydramine, oxybutynin) \u2014 cumulative ACh burden"},{"location":"neurotransmitters/acetylcholine/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Donepezil, Rivastigmine AChE inhibitors \u2014 increase synaptic ACh (Alzheimer's) Galantamine AChE inhibitor + nAChR allosteric potentiator Atropine Competitive Muscarinic antagonist \u2014 blocks M1-M5 Scopolamine M-antagonist \u2014 motion sickness; amnesia Ipratropium M3 antagonist \u2014 bronchodilator (COPD) Pyridostigmine Reversible AChE inhibitor \u2014 myasthenia gravis Pralidoxime (2-PAM) Reactivates AChE before ageing \u2014 organophosphate antidote Succinylcholine Depolarising muscle relaxant; hydrolysed by pseudocholinesterase Nicotine nAChR agonist \u2014 CNS stimulation"},{"location":"neurotransmitters/cofactors_summary/","title":"Neurotransmitters \u2014 Cofactors Master Reference","text":""},{"location":"neurotransmitters/cofactors_summary/#overview","title":"Overview","text":"<p>This document provides a unified reference table for every vitamin, mineral, and cofactor involved in neurotransmitter synthesis, activation, and degradation across all major pathways. Use this alongside the individual neurotransmitter files for a complete picture.</p>"},{"location":"neurotransmitters/cofactors_summary/#master-synthesis-cofactor-table","title":"Master Synthesis Cofactor Table","text":"Vitamin / Mineral / Cofactor Neurotransmitter Pathway Step Enzyme Consequence of Deficiency Vitamin B6 (PLP) Serotonin: 5-HTP \u2192 5-HT AADC \u2193 Serotonin Dopamine: L-DOPA \u2192 Dopamine AADC \u2193 Dopamine, \u2191 L-DOPA in neurons NE/EPI: L-DOPA \u2192 Dopamine (prerequisite) AADC \u2193 NE, EPI GABA: Glutamate \u2192 GABA GAD65/67 \u2193 GABA \u2192 seizure risk, anxiety GABA: GABA degradation GABA-T Dysregulated catabolism Histamine: Histidine \u2192 Histamine HDC \u2193 Histamine synthesis Histamine: Gut degradation DAO \u2193 DAO \u2192 histamine intolerance BH4 (Tetrahydrobiopterin) Serotonin: Tryptophan \u2192 5-HTP TPH1/TPH2 Severe \u2193 serotonin and dopamine Dopamine: Tyrosine \u2192 L-DOPA Tyrosine hydroxylase (TH) Severe \u2193 dopamine; NE/EPI collapse NE/EPI: Tyrosine \u2192 L-DOPA (shared) TH Same collapse Folate (5-MTHF / B9) BH4 regeneration (\u2192 serotonin, dopamine) DHFR, DHPR \u2193 BH4 \u2192 \u2193 5-HT, DA SAM cycle \u2192 ASMT (melatonin) MTR/MTHFR \u2193 Melatonin SAM cycle \u2192 COMT (catecholamine clearance) COMT Impaired catecholamine degradation SAM cycle \u2192 HNMT (histamine) HNMT Impaired CNS histamine clearance Vitamin B12 (Methylcobalamin) SAM regeneration (methionine synthase) MTR \u2193 Melatonin; impaired COMT, HNMT Methyl-B12 \u2192 SAM \u2192 ASMT (melatonin NAS \u2192 melatonin) ASMT \u2193 Melatonin Riboflavin (B2 / FAD) MAO-A degradation of serotonin, NE MAO-A Dysregulated monoamine catabolism MAO-B degradation of dopamine MAO-B Extended DA half-life BH4 synthesis (MTHFR needs FAD) MTHFR \u2193 BH4 \u2192 \u2193 serotonin, dopamine SAM cycle (MTRR needs FAD) MTRR SAM depletion Niacin (B3 / NAD\u207a) Serotonin aldehyde \u2192 5-HIAA ALDH Reduced terminal catabolism Dopamine aldehyde \u2192 DOPAC ALDH Dysregulated dopamine turnover Histamine aldehyde \u2192 imidazole acetaldehyde ALDH Minor histamine catabolism impairment GABA shunt: SSA \u2192 Succinate SSADH Elevated GABA; SSADH deficiency Glutamate synthesis (\u03b1-KG \u2192 Glu) GDH \u2193 Glutamate synthesis Tryptophan competes with NAD\u207a synthesis IDO/ACMSD \u2193 Serotonin (tryptophan diverted) Pantothenate (B5) Acetyl-CoA synthesis (\u2192 ACh, \u2192 AANAT for melatonin) PDH complex \u2193 ACh; \u2193 Melatonin (NAS \u2192 NAS remains) Thiamine (B1) Pyruvate \u2192 Acetyl-CoA PDH complex \u2193 ACh; \u2193 GABA substrate (\u03b1-KG); Wernicke's Vitamin C (Ascorbate) NE: Dopamine \u2192 Norepinephrine DBH \u2193 NE; excess DA BH4 stabilisation (antioxidant) Nonenzymatic Lower effective BH4 PAM (peptide C-terminal amidation) PAM \u2193 Enkephalin potency; \u2193 neuropeptide activity DAO upregulation (anti-inflammatory) AOC1 gene expression \u2193 DAO \u2192 histamine intolerance Vitamin D TH gene expression (dopamine synthesis) TH transcription \u2193 DA TPH2 gene expression (brain serotonin) TPH2 transcription \u2193 Serotonin Iron (Fe\u00b2\u207a) Serotonin: TPH1/TPH2 cofactor TPH1/TPH2 \u2193 Serotonin; restless legs syndrome Dopamine: TH cofactor TH \u2193 Dopamine \u2192 ADHD, RLS NE/EPI: TH cofactor (shared) TH \u2193 NE, EPI Melatonin: TPH1 cofactor TPH1 \u2193 Melatonin Copper (Cu\u00b2\u207a) NE: Dopamine \u2192 Norepinephrine DBH (active site metal) \u2193 NE (Menkes disease extreme) Histamine degradation (gut) DAO (TPQ formation) \u2193 DAO \u2192 histamine intolerance Enkephalin amidation PAM \u2193 Neuropeptide potency Zinc (Zn\u00b2\u207a) Serotonin: AADC stabilisation AADC \u2193 5-HT Dopamine: AADC AADC \u2193 DA GABA: GAD enzyme stability GAD65/67 \u2193 GABA GABA-A receptor modulation Allosteric Reduced inhibitory tone Glutamate: NMDA allosteric inhibition NMDA receptor Increased excitotoxic risk Glutamate: GDH allosteric GDH \u2193 Glutamate synthesis Enkephalin degradation APN, NEP Metalloprotease cofactor Prohormone processing (POMC, proenkephalin) PC1, PC2 Impaired opioid peptide cleavage Magnesium (Mg\u00b2\u207a) NMDA receptor Mg\u00b2\u207a-pore block NMDA channel Excitotoxicity COMT function COMT Impaired catecholamine clearance GS cofactor (glutamate \u2192 glutamine) Glutamine synthetase \u2193 Glutamine \u2192 \u2193 GABA and Glu supply SAM cycle (MAT cofactor) MAT \u2193 SAM \u2192 \u2193 ASMT, COMT, HNMT Calcium (Ca\u00b2\u207a) Prohormone convertase activation PC1, PC2 \u2193 \u03b2-Endorphin, enkephalin processing Vesicular exocytosis of all neurotransmitters SNARE complex Global NT release failure Manganese (Mn\u00b2\u207a) Glutamine synthetase (astrocytes) GS \u2193 Glutamine \u2192 \u2193 GABA and Glu SAM Melatonin: NAS \u2192 Melatonin ASMT \u2193 Melatonin; NAS accumulation Catecholamine inactivation COMT Excess DA, NE, EPI Histamine inactivation (CNS) HNMT Elevated CNS histamine DHA (Omega-3) 5-HT2A receptor density (serotonin) Membrane effect Reduced serotonin signalling D2 receptor density (dopamine) Membrane effect Altered dopaminergic tone NMDA receptor efficiency (glutamate) Membrane effect Reduced LTP Lipoic acid Acetyl-CoA synthesis \u2192 ACh PDH complex \u2193 ACh Tryptophan Serotonin precursor TPH1/TPH2 \u2193 Serotonin, Melatonin Tyrosine Dopamine, NE, EPI precursor TH \u2193 All catecholamines Histidine Histamine precursor HDC \u2193 Histamine Glutamate GABA precursor GAD \u2193 GABA Choline Acetylcholine precursor (rate-limiting) ChAT \u2193 ACh; memory impairment Methionine SAM precursor MAT \u2193 Methylation capacity"},{"location":"neurotransmitters/cofactors_summary/#quick-reference-which-nutrients-affect-the-most-pathways","title":"Quick Reference: Which Nutrients Affect the Most Pathways","text":"Nutrient Pathways Affected (count) Primary Impact Vitamin B6 (PLP) Serotonin, Dopamine, NE/EPI, GABA, GABA-T, Histamine, DAO 7 Folate (5-MTHF) BH4 regeneration (5-HT+DA), SAM (Melatonin, COMT, HNMT) 5+ Vitamin B12 SAM \u2192 ASMT, COMT, HNMT 5 Riboflavin (B2 / FAD) MAO-A (5-HT+NE), MAO-B (DA), BH4, SAM cycle 5 Iron (Fe\u00b2\u207a) TPH (serotonin, melatonin), TH (DA, NE, EPI) 5 Magnesium NMDA, COMT, GS, MAT (SAM) 4 Zinc AADC (5-HT, DA), GAD (GABA), NMDA, GDH, enkephalins 5+ Vitamin C DBH (NE), BH4 stability, PAM (neuropeptides), DAO 4 Copper DBH (NE), DAO (histamine), PAM (neuropeptides) 3 Niacin (B3 / NAD\u207a) ALDH (5-HT, DA, NE catabolism), SSADH (GABA), GDH 4"},{"location":"neurotransmitters/cofactors_summary/#degradation-enzyme-cofactor-reference","title":"Degradation Enzyme Cofactor Reference","text":"Enzyme Neurotransmitter Catabolised Cofactor Required MAO-A Serotonin, NE (primary), Dopamine FAD (Riboflavin / B2) MAO-B Dopamine (primary), N-methylhistamine FAD (Riboflavin / B2) COMT Dopamine, NE, EPI, catechol-oestrogens SAM (B12, Folate, B2, Mg\u00b2\u207a) HNMT Histamine (CNS/intracellular) SAM (B12, Folate, B2, Mg\u00b2\u207a) DAO (AOC1) Histamine (gut/plasma) Cu\u00b2\u207a, PLP (B6), NAD\u207a (B3) AChE Acetylcholine None (serine esterase) BuChE Acetylcholine (backup), drugs None GABA-T GABA PLP (Vitamin B6) SSADH Succinic semialdehyde (GABA catabolism) NAD\u207a (Niacin / B3) ALDH All monoamine aldehydes (5-HT, DA, NE intermediates) NAD\u207a (Niacin / B3) NEP (neprilysin) Enkephalins, substance P, \u03b2-amyloid Zn\u00b2\u207a APN (aminopeptidase N) Enkephalins (N-terminus) Zn\u00b2\u207a Carboxypeptidase E \u03b2-Endorphin C-terminus Zn\u00b2\u207a"},{"location":"neurotransmitters/cofactors_summary/#bh4-tetrahydrobiopterin-detailed-reference","title":"BH4 (Tetrahydrobiopterin) \u2014 Detailed Reference","text":""},{"location":"neurotransmitters/cofactors_summary/#what-is-bh4","title":"What Is BH4?","text":"<p>BH4 is a pteridine cofactor synthesised endogenously from GTP. It is the essential electron donor for the aromatic amino acid hydroxylases \u2014 the rate-limiting enzymes in catecholamine and indoleamine synthesis \u2014 and for all three nitric oxide synthase (NOS) isoforms.</p>"},{"location":"neurotransmitters/cofactors_summary/#role-in-neurotransmitter-synthesis","title":"Role in Neurotransmitter Synthesis","text":"Enzyme Reaction NT Produced Tryptophan hydroxylase (TPH1/2) Tryptophan \u2192 5-HTP Serotonin (\u2192 Melatonin) Tyrosine hydroxylase (TH) Tyrosine \u2192 L-DOPA Dopamine, NE, EPI Phenylalanine hydroxylase (PAH) Phenylalanine \u2192 Tyrosine Precursor supply for TH step Nitric oxide synthase (eNOS, nNOS, iNOS) L-Arg \u2192 Nitric oxide Vascular + neuronal signalling <p>Note: BH4 is consumed (oxidised to BH2) during each catalytic cycle and must be continuously regenerated.</p>"},{"location":"neurotransmitters/cofactors_summary/#bh4-synthesis-pathway","title":"BH4 Synthesis Pathway","text":"<pre><code>GTP\n \u2502\n \u25bc  GCH1 (GTP cyclohydrolase 1) \u2190 rate-limiting step\n \u2502\n7,8-Dihydroneopterin triphosphate\n \u2502\n \u25bc  PTPS (6-pyruvoyltetrahydropterin synthase)\n \u2502\n6-Pyruvoyltetrahydropterin\n \u2502\n \u25bc  SR (sepiapterin reductase) + NADPH\n \u2502\nBH4 \u25c4\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 active cofactor\n</code></pre>"},{"location":"neurotransmitters/cofactors_summary/#bh4-recycling-pathway","title":"BH4 Recycling Pathway","text":"<p>BH4 is oxidised to quinonoid-BH2 (q-BH2) during hydroxylase reactions, then recycled:</p> <pre><code>BH4 \u2500\u2500[TPH / TH / PAH]\u2500\u2500\u25ba q-BH2 (quinonoid BH2)\n                                \u2502\n                                \u25bc  DHPR (dihydropteridine reductase) + NADH\n                               BH4  \u25c4\u2500\u2500 recycled\n\nBH2 (oxidised, lost pool) \u2500\u2500\u25ba BH4  via  DHFR (dihydrofolate reductase) + NADPH\n                                        \u2191\n                                   Requires active folate (5-MTHF / B9)\n</code></pre>"},{"location":"neurotransmitters/cofactors_summary/#cofactors-required-for-bh4-function","title":"Cofactors Required for BH4 Function","text":"Cofactor / Nutrient Role GTP Primary substrate for BH4 de-novo synthesis (GCH1 step) NADPH Electron donor for sepiapterin reductase (SR) and DHFR NADH Electron donor for DHPR (recycling of q-BH2 \u2192 BH4) Folate (5-MTHF / B9) Required by DHFR to convert BH2 \u2192 BH4; MTHFR deficiency impairs this Riboflavin (B2 / FAD) MTHFR requires FAD; FAD depletion reduces folate-mediated BH4 recycling Vitamin C (Ascorbate) Protects BH4 from oxidative degradation; stabilises the active pool Iron (Fe\u00b2\u207a) Non-haem iron is a cofactor for TPH and TH (alongside BH4)"},{"location":"neurotransmitters/cofactors_summary/#what-depletes-bh4","title":"What Depletes BH4?","text":"Factor Mechanism Oxidative stress ROS oxidise BH4 directly \u2192 BH2 accumulation; uncouples NOS Folate / B9 deficiency Impairs DHFR-mediated BH2 \u2192 BH4 recycling B2 / FAD deficiency Reduces MTHFR activity \u2192 less 5-MTHF \u2192 less DHFR substrate MTHFR polymorphisms (C677T) Reduced MTHFR efficiency \u2192 folate insufficiency \u2192 \u2193 BH4 recycling GCH1 mutations Rare; directly impairs de-novo BH4 synthesis (Dopa-responsive dystonia) Inflammation / cytokines Upregulate IDO (tryptophan \u2192 kynurenine), divert substrate away from serotonin; also promote BH4 oxidation"},{"location":"neurotransmitters/cofactors_summary/#clinical-consequences-of-bh4-deficiency","title":"Clinical Consequences of BH4 Deficiency","text":"System Effect Serotonin \u2193 TPH activity \u2192 \u2193 5-HT \u2192 depression, anxiety, poor sleep Dopamine \u2193 TH activity \u2192 \u2193 L-DOPA \u2192 dopamine/NE/EPI collapse Nitric oxide NOS uncoupling \u2192 superoxide production instead of NO \u2192 endothelial dysfunction PKU BH4 deficiency (or unresponsiveness) \u2192 phenylalanine accumulation \u2192 neurotoxicity Dopa-responsive dystonia GCH1 mutations \u2192 severe BH4 deficiency \u2192 movement disorder responsive to L-DOPA"},{"location":"neurotransmitters/cofactors_summary/#therapeutic-supplementation-notes","title":"Therapeutic / Supplementation Notes","text":"<ul> <li>Sapropterin (Kuvan) \u2014 synthetic BH4; FDA-approved for BH4-responsive PKU</li> <li>Folate + B12 \u2014 first-line indirect support; ensure DHFR/MTHFR adequacy</li> <li>Riboflavin (B2) \u2014 improves folate recycling; especially important in MTHFR C677T carriers</li> <li>Vitamin C \u2014 antioxidant preservation of BH4 pool; 500\u20131000 mg/day commonly used adjunctively</li> <li>NAC / Glutathione precursors \u2014 reduce oxidative BH4 depletion</li> <li>5-MTHF (methylfolate) \u2014 bypasses MTHFR; preferred over folic acid when BH4 recycling is a concern</li> </ul>"},{"location":"neurotransmitters/cofactors_summary/#pathway-interaction-map","title":"Pathway Interaction Map","text":"<pre><code>Tryptophan \u2500\u2500\u25ba Serotonin \u2500\u2500\u25ba Melatonin\n                 \u2191               \u2191\n               [B6, Fe, BH4]   [SAM, B12, B9, B2, B5]\n\nPhenylalanine \u2192 Tyrosine \u2500\u2500\u25ba L-DOPA \u2500\u2500\u25ba Dopamine \u2500\u2500\u25ba NE \u2500\u2500\u25ba EPI\n                  \u2191              \u2191          \u2191        \u2191      \u2191\n               [BH4, Fe]     [BH4, Fe]   [B6]  [Vit C, Cu] [SAM]\n\nHistidine \u2500\u2500\u25ba Histamine \u2500\u2500\u25ba [HNMT: SAM] \u2192 CNS clearance\n                          \u2514\u2500\u2500\u25ba [DAO: Cu, B6] \u2192 Gut clearance\n\nGlutamate \u2500\u2500\u25ba [GAD: B6, Zn] \u2500\u2500\u25ba GABA \u2500\u2500\u25ba [GABA-T: B6] \u2500\u2500\u25ba Krebs\n     \u2191\n[\u03b1-KG via Krebs: B1, B2, B3, lipoic acid]\n\nCholine + Acetyl-CoA \u2500\u2500\u25ba [ChAT: B5\u2192CoA] \u2500\u2500\u25ba ACh \u2500\u2500\u25ba [AChE] \u2500\u2500\u25ba Choline (recycled)\n\nPOMC/Proenkephalin \u2500\u2500\u25ba [PC1/PC2: Ca, Zn] \u2500\u2500\u25ba Endorphins/Enkephalins\n                                          \u2500\u2500\u25ba [PAM: Vit C, Cu] \u2500\u2500\u25ba Amidated peptides\n</code></pre>"},{"location":"neurotransmitters/cofactors_summary/#supplementation-strategy-by-deficiency-pattern","title":"Supplementation Strategy by Deficiency Pattern","text":"Clinical Picture Suspected Deficiency First-Line Support Depression + fatigue + poor cold tolerance Low serotonin + NE B6, iron, folate, B12, Tryptophan Anxiety + muscle tension + poor sleep Low GABA + Mg Mg glycinate, B6, zinc, L-theanine Brain fog + poor memory Low ACh Choline (eggs, lecithin), B5, B1 Low motivation + apathy Low dopamine Tyrosine, iron, B6, folate, Vit D Histamine sensitivity + flushing Low DAO Copper, B6, Vit C; reduce alcohol Delayed sleep onset Low melatonin Tryptophan, B6, B12, folate, light hygiene Chronic pain + poor exercise tolerance Low endorphins Zinc, Vit C, protein, exercise Restless legs + impulse control Low DA (iron-related) Iron assessment, Mg, B6 Hypertension + anxiety + panic Excess NE/EPI Mg, relaxation; COMT support (B12, folate) Low serotonin + low dopamine simultaneously \u2193 BH4 (upstream of both TPH &amp; TH) 5-MTHF, B2, Vit C, NAC; rule out MTHFR C677T"},{"location":"neurotransmitters/dopamine/","title":"Dopamine","text":""},{"location":"neurotransmitters/dopamine/#overview","title":"Overview","text":"<p>Dopamine is a catecholamine neurotransmitter serving as the chemical currency of reward, motivation, movement, and executive function. It is synthesised primarily in the substantia nigra (pars compacta, for motor control), ventral tegmental area (VTA, for reward and motivation), and the hypothalamus (for prolactin inhibition). Dopamine is also produced in the adrenal medulla as a precursor to norepinephrine, and in the gut and kidneys as a local paracrine signal.</p> <p>Key insight \u2014 Dopamine is not simply the \"pleasure molecule.\" It encodes reward prediction error \u2014 the gap between expected and actual outcomes. It is critical for motivation to seek, not merely for pleasure upon receiving.</p>"},{"location":"neurotransmitters/dopamine/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>L-Phenylalanine  (dietary essential)\n      \u2502\n      \u2502 [Phenylalanine hydroxylase \u2014 PAH]\n      \u2502  Cofactor: BH4 (tetrahydrobiopterin), Fe\u00b2\u207a, O\u2082\n      \u25bc\nL-Tyrosine  (conditionally essential; also dietary)\n      \u2502\n      \u2502 [Tyrosine hydroxylase \u2014 TH]\n      \u2502  Cofactors: BH4, Fe\u00b2\u207a, O\u2082, NADPH\n      \u2502  \u26a0 Rate-limiting step for ALL catecholamines\n      \u25bc\nL-DOPA (L-3,4-dihydroxyphenylalanine)\n      \u2502\n      \u2502 [Aromatic L-amino acid decarboxylase \u2014 AADC / DOPA decarboxylase]\n      \u2502  Cofactor: Pyridoxal-5\u2032-phosphate (PLP / Vitamin B6)\n      \u25bc\nDopamine (DA)\n      \u2502\n      \u251c\u2500\u2500\u25ba Dopaminergic neurons: stored in vesicles \u2192 released\n      \u2502\n      \u2514\u2500\u2500\u25ba Noradrenergic neurons:\n           \u2502 [Dopamine-\u03b2-hydroxylase \u2014 DBH]\n           \u2502  Cofactors: Vitamin C (ascorbate), Cu\u00b2\u207a, O\u2082\n           \u25bc\n           Norepinephrine (\u2192 Epinephrine)\n</code></pre>"},{"location":"neurotransmitters/dopamine/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme Required Cofactors / Nutrients 1. Phe \u2192 Tyrosine PAH BH4, Fe\u00b2\u207a, O\u2082, NADPH 2. Tyrosine \u2192 L-DOPA \u26a0 Tyrosine hydroxylase (TH) BH4, Fe\u00b2\u207a, O\u2082, NADPH; regulated by PKA (cAMP) 3. L-DOPA \u2192 Dopamine AADC PLP (Vitamin B6), Zn\u00b2\u207a BH4 synthesis GTP cyclohydrolase I Folate (5-MTHF), Riboflavin (FAD) BH4 recycling DHPR NADPH, Vitamin C (antioxidant)"},{"location":"neurotransmitters/dopamine/#bh4-the-critical-gatekeeper","title":"BH4 \u2014 The Critical Gatekeeper","text":"<p>Tetrahydrobiopterin (BH4) is co-substrate for both TH (dopamine) and TPH (serotonin). Low BH4 simultaneously collapses both pathways.</p> <p>Causes of low BH4: - Oxidative stress (BH4 is oxidised to BH2 and biopterin) - Inflammation (cytokines suppress GCH1 \u2014 BH4 synthesis enzyme) - Folate / B12 / riboflavin deficiency (impair BH4 regeneration) - Genetic GCH1 mutations (Dopa-responsive dystonia)</p> <p>Consequences: Simultaneous dopamine + serotonin deficiency \u2192 depression + movement disorder.</p>"},{"location":"neurotransmitters/dopamine/#degradation-pathway","title":"Degradation Pathway","text":"<pre><code>Dopamine\n      \u2502\n      \u251c\u2500\u2500\u25ba [MAO-A or MAO-B]          \u251c\u2500\u2500\u25ba [COMT]\n      \u2502     Cofactor: FAD (B2)        \u2502     Cofactor: SAM (needs B12/folate/B2/Mg)\n      \u25bc                               \u25bc\n3,4-Dihydroxyphenylacetaldehyde    3-Methoxytyramine (3-MT)\n      \u2502                               \u2502\n      \u2502 [ALDH]   Cofactor: NAD\u207a (B3) \u2502 [MAO-B]\n      \u25bc                               \u25bc\n3,4-Dihydroxyphenylacetic acid      Homovanillic acid (HVA)\n(DOPAC)\n      \u2502\n      \u2502 [COMT] Cofactor: SAM\n      \u25bc\nHomovanillic acid (HVA)  \u2500\u2500\u25ba urine (primary urinary dopamine metabolite)\n</code></pre>"},{"location":"neurotransmitters/dopamine/#degradation-enzymes","title":"Degradation Enzymes","text":"Enzyme Location Cofactor Notes MAO-A Neurons, liver, gut FAD (Riboflavin / B2) Predominates in dopaminergic neurons MAO-B Platelets, glia, serotonin neurons FAD (B2) Major role in peripheral DA catabolism; target in Parkinson's COMT Postsynaptic neurons, liver, kidney SAM \u2192 requires B12, folate, B2, Mg\u00b2\u207a COMT V158M SNP (val/val = high activity, low DA; met/met = low activity, high DA) ALDH Cytosol/mitochondria NAD\u207a (B3) Converts aldehyde intermediate to acid"},{"location":"neurotransmitters/dopamine/#comt-polymorphism-rs4680","title":"COMT Polymorphism (rs4680)","text":"Genotype COMT Activity Dopamine Level Trait Tendency Val/Val High Low (fast breakdown) Better stress tolerance; lower working memory Val/Met Intermediate Moderate Balanced Met/Met Low High (slow breakdown) Better cognitive performance; higher anxiety/pain sensitivity <p>Nutrient support for Met/Met: Avoid excessive SAM supplementation (over-methylation). Magnesium and B2 are key for balancing COMT activity.</p>"},{"location":"neurotransmitters/dopamine/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency L-Tyrosine Immediate dopamine precursor Reduced DA synthesis capacity L-Phenylalanine PAH \u2192 tyrosine (in phenylketonuria, PAH fails) PKU causes dopamine deficiency Vitamin B6 (PLP) AADC \u2014 decarboxylation of L-DOPA \u2192 dopamine Reduced conversion efficiency Iron (Fe\u00b2\u207a) TH cofactor (rate-limiting step) Impaired DA synthesis; RLS, ADHD, fatigue BH4 TH cofactor Severe DA deficiency Folate (5-MTHF / B9) BH4 regeneration + SAM for COMT Dual hit: synthesis + degradation impaired Vitamin B12 SAM maintenance (COMT/methylation) COMT impairment; elevated catecholamine half-life Riboflavin (B2) FAD for MAO-A/B; BH4 synthesis Dysregulated catabolism Vitamin C DBH cofactor; BH4 stabilisation Reduced NE synthesis from DA Copper (Cu\u00b2\u207a) DBH cofactor Excess DA, low NE (Menkes disease extreme) Magnesium COMT function; downstream receptor signalling COMT impairment Zinc AADC activity; D2 receptor modulation Reduced decarboxylation Vitamin D Upregulates TH gene expression Low DA synthesis linked to mood disorders"},{"location":"neurotransmitters/dopamine/#dopamine-receptors","title":"Dopamine Receptors","text":"Receptor Signalling Location Function D1 Gs \u2192 cAMP \u2191 Striatum, PFC, cortex Reward, working memory, movement initiation D2 Gi \u2192 cAMP \u2193 Striatum, limbic, pituitary Autoreceptor (inhibits DA release); antipsychotic target D3 Gi Limbic Reward, motivation; addiction pharmacology D4 Gi Cortex, limbic Attention (ADHD association); novelty-seeking D5 Gs Hippocampus, hypothalamus Memory; motor learning"},{"location":"neurotransmitters/dopamine/#reuptake","title":"Reuptake","text":"<p>After synaptic release, dopamine is recycled via: - DAT (dopamine transporter) \u2014 primary reuptake in striatum, meso-limbic - NET (norepinephrine transporter) \u2014 in prefrontal cortex (low DAT density) - Vesicular repackaging by VMAT2, or - Degradation by MAO-B (mitochondria) or COMT (cytosol/extrasynaptic)</p>"},{"location":"neurotransmitters/dopamine/#clinical-relevance","title":"Clinical Relevance","text":"Condition Dopamine Status Mechanism Parkinson's disease Low (nigrostriatal) Loss of substantia nigra dopaminergic neurons ADHD Low (PFC) Impaired DAT + reduced prefrontal DA signalling Schizophrenia Excess (mesolimbic) + low (PFC) Dopamine dysregulation hypothesis Addiction Phasic hyper-release \u2192 tonic depletion Reward pathway sensitisation Restless Legs Syndrome Low (spinal cord) Iron/BH4 deficiency depleting DA Hyperprolactinaemia Low (tuberoinfundibular) DA normally inhibits prolactin; DA deficiency \u2192 elevated prolactin"},{"location":"neurotransmitters/dopamine/#drug-interactions","title":"Drug Interactions","text":"Drug Effect L-DOPA (levodopa) Bypasses TH rate-limit; exogenous L-DOPA \u2192 dopamine Carbidopa Inhibits peripheral AADC \u2014 keeps L-DOPA in blood for CNS entry MAO-B inhibitors (selegiline) Block DA degradation \u2192 extend action COMT inhibitors (entacapone) Block peripheral COMT \u2192 extend L-DOPA bioavailability Antipsychotics D2 receptor antagonists Methylphenidate / Amphetamines Block DAT / reverse transport \u2192 increased synaptic DA Cocaine DAT blocker Tyramine (diet + MAOIs) Dietary tyramine (aged cheese) + MAOI \u2192 hypertensive crisis"},{"location":"neurotransmitters/endorphins_enkephalins/","title":"Endorphins &amp; Enkephalins (Endogenous Opioid Peptides)","text":""},{"location":"neurotransmitters/endorphins_enkephalins/#overview","title":"Overview","text":"<p>Endogenous opioid peptides are neuropeptides that mimic the effects of opioid drugs by binding to opioid receptors (\u03bc, \u03ba, \u03b4). They modulate pain, reward, stress responses, thermoregulation, immune function, and mood. Unlike small-molecule neurotransmitters, they are synthesised as large precursor proteins that are enzymatically cleaved into active fragments.</p> Peptide Family Precursor Key Active Peptides Primary Receptor Endorphins POMC (pro-opiomelanocortin) \u03b2-Endorphin, \u03b1-endorphin, \u03b3-endorphin \u03bc (mu) &gt; \u03b4 Enkephalins Proenkephalin A Met-enkephalin, Leu-enkephalin \u03b4 (delta) &gt; \u03bc Dynorphins Prodynorphin Dynorphin A, Dynorphin B, \u03b1-neoendorphin \u03ba (kappa) Endomorphins Unknown precursor Endomorphin-1, Endomorphin-2 \u03bc (high selectivity) Nociceptin (OFQ) Pronociceptin Nociceptin/Orphanin FQ NOP (opioid-related) <p>Key insight \u2014 Endorphins and enkephalins are not stored awaiting release like dopamine or serotonin. They are synthesised on demand by gene expression and precursor protein processing. This makes them highly dependent on adequate nutritional co-factors for transcription, translation, and post-translational processing.</p>"},{"location":"neurotransmitters/endorphins_enkephalins/#synthesis-pathway-endorphin-pomc-pathway","title":"Synthesis Pathway: \u03b2-Endorphin (POMC Pathway)","text":"<pre><code>Dietary Amino Acids (protein \u2192 translation)\n      \u2502\n      \u2502 [POMC gene transcription \u2192 mRNA]\n      \u2502  Regulated by: CRH (corticotropin-releasing hormone), IL-6, insulin, dopamine\n      \u2502  Co-activators: zinc-finger transcription factors \u2014 require Zn\u00b2\u207a\n      \u25bc\nPOMC (pro-opiomelanocortin) \u2014 267 amino acids\n      \u2502\n      \u2502 [PC1 (Proprotein convertase 1/3)]\n      \u2502  Requires: Ca\u00b2\u207a; zinc metalloprotease activity; Vitamin C (for some PCs)\n      \u2502  Cut sites: dibasic residues (Arg-Lys / Lys-Arg pairs)\n      \u25bc\n\u03b2-Lipotropin (\u03b2-LPH)  +  ACTH\n      \u2502\n      \u2502 [PC2]  Requires: Ca\u00b2\u207a, alkaline pH (secretory vesicle)\n      \u25bc\n\u03b2-Endorphin (31 amino acids)  \u2190\u2500\u2500 major analgesic opioid\n\u03b3-MSH / \u03b1-MSH / CLIP (ACTH fragments)\n\nAlso from POMC: \u03b1-MSH (melanocyte stimulating), \u03b2-MSH, \u03b3-MSH\n</code></pre>"},{"location":"neurotransmitters/endorphins_enkephalins/#key-pomc-expression-sites","title":"Key POMC Expression Sites","text":"Site Primary products Function Anterior pituitary (corticotrophs) ACTH + \u03b2-LPH Stress axis (HPA); cortisol release Arcuate nucleus (hypothalamus) \u03b2-Endorphin Analgesia, reward, feeding behaviour Nucleus tractus solitarius \u03b2-Endorphin Autonomic pain modulation Immune cells (lymphocytes, monocytes) \u03b2-Endorphin Peripheral analgesia; immunomodulation"},{"location":"neurotransmitters/endorphins_enkephalins/#synthesis-pathway-enkephalins-proenkephalin-pathway","title":"Synthesis Pathway: Enkephalins (Proenkephalin Pathway)","text":"<pre><code>Dietary Amino Acids \u2192 Translation\n      \u2502\n      \u2502 [Proenkephalin A gene \u2192 mRNA \u2192 protein]\n      \u2502  Contains 4\u00d7 Met-enkephalin, 1\u00d7 Leu-enkephalin, 2\u00d7 extended forms\n      \u25bc\nProenkephalin A (267 amino acids)\n      \u2502\n      \u2502 [PC1 / PC2] \u2014 Cleavage at dibasic sites\n      \u2502  Cofactors: Ca\u00b2\u207a, active vesicular pH, Zn\u00b2\u207a\n      \u25bc\nMet-enkephalin (Tyr-Gly-Gly-Phe-Met)\nLeu-enkephalin (Tyr-Gly-Gly-Phe-Leu)\n      \u2502\n      \u2502 C-terminal amidation (some extended forms):\n      \u2502 [PAM \u2014 Peptidylglycine \u03b1-amidating monooxygenase]\n      \u2502  Cofactors: Vitamin C, Cu\u00b2\u207a, O\u2082\n      \u25bc\nAmidated enkephalin (more potent/stable)\n</code></pre>"},{"location":"neurotransmitters/endorphins_enkephalins/#post-translational-processing-cofactors","title":"Post-Translational Processing Cofactors","text":"<p>All endogenous opioid peptides require extensive post-translational processing:</p> Step Enzyme Cofactors Required Signal peptide cleavage Signal peptidase \u2014 (ER membrane process) Proprotein cleavage PC1, PC2 Ca\u00b2\u207a, Zn\u00b2\u207a, appropriate pH C-terminal amidation PAM (PHM + PAL domains) Vitamin C (ascorbate), Cu\u00b2\u207a, O\u2082 N-terminal acetylation NAT Acetyl-CoA (Pantothenate / B5) Tyrosine hydroxylation (Tyr in peptide) Prolyl hydroxylase Vitamin C, Fe\u00b2\u207a, O\u2082, \u03b1-KG Disulfide bond formation PDI (ER) Oxidising environment; no specific vitamin <p>Vitamin C note \u2014 PAM is required for C-terminal amidation of ~50% of known neuropeptides (including enkephalins, substance P, oxytocin, CRH). Each catalytic cycle consumes 1 ascorbate. This makes Vitamin C critically important for the activity of the entire neuropeptide signalling system.</p>"},{"location":"neurotransmitters/endorphins_enkephalins/#degradation-pathway","title":"Degradation Pathway","text":"<p>Enkephalins and endorphins are rapidly degraded (half-life seconds to minutes in synapse):</p> <pre><code>Met/Leu-Enkephalin\n      \u2502\n      \u251c\u2500\u2500\u25ba [APN \u2014 Aminopeptidase N / CD13]\n      \u2502     Cleaves N-terminal Tyr residue\n      \u2502     Cofactor: Zn\u00b2\u207a (zinc metalloprotease)\n      \u2502\n      \u251c\u2500\u2500\u25ba [NEP \u2014 Neutral Endopeptidase / Neprilysin / CD10]\n      \u2502     Cleaves Gly3-Phe4 bond\n      \u2502     Cofactor: Zn\u00b2\u207a, Ca\u00b2\u207a\n      \u2502\n      \u251c\u2500\u2500\u25ba [ECE \u2014 Endothelin-converting enzyme]\n      \u2502     Also degrades enkephalins\n      \u2502\n      \u2514\u2500\u2500\u25ba [DPP \u2014 Dipeptidyl peptidase IV]\n           Cleaves Pro-containing enkephalins\n\nAll generate: amino acid fragments \u2192 recycled into protein pool\n</code></pre> <p>\u03b2-Endorphin degradation: - Longer peptide \u2192 slower degradation (minutes\u2013hours) - Carboxypeptidase E (CPE) removes C-terminal amino acids - Aminopeptidases degrade from N-terminus after carboxypeptidase action</p>"},{"location":"neurotransmitters/endorphins_enkephalins/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency Protein / Amino acids POMC and proenkephalin precursor synthesis Insufficient substrate; reduced opioid peptide production Zinc (Zn\u00b2\u207a) PC1/PC2 (prohormone cleavage); APN, NEP degradation enzymes Impaired processing AND degradation Calcium (Ca\u00b2\u207a) PC1, PC2 activity; vesicular secretion Impaired peptide processing Vitamin C (Ascorbate) PAM \u2014 C-terminal amidation of neuropeptides Reduced potency/stability of &gt;50% neuropeptides Copper (Cu\u00b2\u207a) PAM cofactor Same as Vitamin C deficiency Pantothenate (B5) Acetyl-CoA for N-terminal acetylation of some opioid peptides Reduced acetylation of some peptides Iron (Fe\u00b2\u207a) Prolyl hydroxylase (peptide maturation) Impaired hydroxylation Folate / B12 Protein synthesis, one-carbon metabolism General protein synthesis impairment Magnesium Ribosomal protein synthesis; downstream signalling General protein synthesis; opioid receptor coupling"},{"location":"neurotransmitters/endorphins_enkephalins/#opioid-receptors","title":"Opioid Receptors","text":"Receptor Primary Ligands Signalling Key Functions \u03bc (mu) \u2014 OPRM1 \u03b2-Endorphin, Endomorphins Gi \u2192 cAMP \u2193, K\u207a \u2191, Ca\u00b2\u207a \u2193 Analgesia, euphoria, respiratory depression, constipation \u03b4 (delta) \u2014 OPRD1 Enkephalins Gi \u2192 cAMP \u2193 Analgesia (spinal), mood, immune modulation \u03ba (kappa) \u2014 OPRK1 Dynorphins Gi \u2192 cAMP \u2193 Analgesia, dysphoria, sedation, anti-reward NOP \u2014 OPRL1 Nociceptin Gi \u2192 cAMP \u2193 Anti-analgesia at supraspinal; pain modulation"},{"location":"neurotransmitters/endorphins_enkephalins/#physiological-triggers-for-endorphin-release","title":"Physiological Triggers for Endorphin Release","text":"Trigger Mechanism Exercise (aerobic, moderate-high intensity) Hypothalamic \u03b2-endorphin + peripheral; \u03bc and \u03b4 receptor activation Laughter, social bonding \u03bc-opioid activation in limbic system Pain / injury Spinal cord enkephalin release (DNIC \u2014 diffuse noxious inhibitory control) Acupuncture Met-enkephalin, \u03b2-endorphin release (clinical evidence) Sexual activity / orgasm Massive endorphin surge \u2192 mesolimbic reward Capsaicin consumption TRPV1 activation \u2192 spinal endorphin release"},{"location":"neurotransmitters/endorphins_enkephalins/#clinical-relevance","title":"Clinical Relevance","text":"Condition Opioid Peptide Status Mechanism Chronic pain Low enkephalin (spinal) Downregulation of DRG proenkephalin expression Depression Low \u03b2-endorphin; \u03bc-opioid hyposensitivity HPA dysregulation; reduced \u03bc-receptor binding Opioid use disorder Desensitised \u03bc-receptors Exogenous opioids downregulate POMC system Fibromyalgia Low CSF \u03b2-endorphin Central sensitisation; opioid system dysfunction POMC mutations Absent \u03b2-endorphin + ACTH Extreme obesity + red hair (PC1/POMC mutations) Stress (acute) \u03b2-Endorphin surge HPA axis co-release of ACTH + \u03b2-endorphin from pituitary"},{"location":"neurotransmitters/endorphins_enkephalins/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Morphine, Codeine, Oxycodone \u03bc-opioid agonists \u2014 mimic endorphins Naloxone / Naltrexone Opioid antagonists \u2014 block \u03bc, \u03ba, \u03b4; reverse overdose Low-dose naltrexone (LDN) Transient block \u2192 rebound endorphin upregulation (fibromyalgia, autoimmune) Buprenorphine Partial \u03bc agonist + \u03ba antagonist Tramadol Weak \u03bc agonist + SERT/NET inhibitor NSAIDs Potentiate endogenous opioid analgesia at spinal level"},{"location":"neurotransmitters/gaba/","title":"GABA (Gamma-Aminobutyric Acid)","text":""},{"location":"neurotransmitters/gaba/#overview","title":"Overview","text":"<p>GABA is the primary inhibitory neurotransmitter in the mammalian central nervous system. It counterbalances glutamate (the principal excitatory transmitter), regulating neuronal excitability throughout the brain and spinal cord. GABA mediates anxiolysis, sedation, anticonvulsant effects, and muscle relaxation. Approximately 30\u201340% of all synapses in the brain are GABAergic.</p> <p>Key insight \u2014 GABA cannot cross the blood-brain barrier in meaningful quantities. Oral GABA supplementation has limited direct CNS impact unless the gut-brain axis or very specific transport mechanisms are involved. Precursor and cofactor support (glutamate + B6) is physiologically more relevant.</p>"},{"location":"neurotransmitters/gaba/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>Glucose  \u2192  Krebs cycle\n                \u2502\n                \u25bc\n         \u03b1-Ketoglutarate\n                \u2502\n          [Transamination]\n                \u25bc\n         L-Glutamate  \u2190\u2500\u2500 also from dietary glutamine via GLS\n                \u2502\n                \u2502 [Glutamic acid decarboxylase \u2014 GAD65 / GAD67]\n                \u2502  Cofactor: Pyridoxal-5\u2032-phosphate (PLP / Vitamin B6)\n                \u2502  \u26a0 Rate-limiting step\n                \u2502  Zn\u00b2\u207a enhances GAD stability\n                \u25bc\n         GABA\n                \u2502\n                \u251c\u2500\u2500\u25ba Stored in vesicles \u2192 released synaptically\n                \u2502\n                \u2514\u2500\u2500\u25ba GABA shunt (see below)\n</code></pre>"},{"location":"neurotransmitters/gaba/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme Required Cofactors / Nutrients Glucose \u2192 \u03b1-KG Krebs cycle (multiple enzymes) Thiamine (B1), Riboflavin (B2), Niacin (B3), Lipoic acid, Mg\u00b2\u207a, Mn\u00b2\u207a \u03b1-KG \u2192 Glutamate GABA-T (reverse) / Aminotransferases PLP (B6), Zn\u00b2\u207a Glutamate \u2192 GABA \u26a0 GAD65 / GAD67 PLP (Vitamin B6), Zn\u00b2\u207a, adequate glutamate substrate Glutamine \u2192 Glutamate (glial supply) Glutaminase (GLS) \u2014 (Pi-activated)"},{"location":"neurotransmitters/gaba/#the-gaba-shunt-gabakrebs-cycle-link","title":"The GABA Shunt (GABA\u2013Krebs Cycle Link)","text":"<p>The GABA shunt is a metabolic bypass through which GABA re-enters the Krebs cycle:</p> <pre><code>GABA\n  \u2502\n  \u2502 [GABA-T \u2014 GABA transaminase]\n  \u2502  Cofactor: PLP (Vitamin B6)\n  \u2502  (Zn\u00b2\u207a activates; Mg\u00b2\u207a stabilises)\n  \u25bc\nSuccinic semialdehyde (SSA)\n  \u2502\n  \u2502 [SSADH \u2014 succinic semialdehyde dehydrogenase]\n  \u2502  Cofactor: NAD\u207a (Niacin / B3)\n  \u25bc\nSuccinate  \u2192  Krebs cycle (succinyl-CoA \u2192 ATP)\n</code></pre> <p>The shunt ensures GABA is not purely wasted \u2014 it feeds ~8\u201310% of Krebs cycle flux in the brain.</p>"},{"location":"neurotransmitters/gaba/#glutamateglutamine-cycle-astrocyteneuron","title":"Glutamate\u2013Glutamine Cycle (Astrocyte\u2013Neuron)","text":"<p>GABA synthesis depends on a continuous astrocytic glutamate supply:</p> <pre><code>Glutamatergic neuron releases glutamate \u2192 astrocyte uptake\nAstrocyte: Glutamate \u2192[GS]\u2192 Glutamine  (GS cofactor: Mg\u00b2\u207a, ATP)\nGlutamine released \u2192 taken up by GABAergic neuron\nNeuron: Glutamine \u2192[GLS]\u2192 Glutamate  \u2192 [GAD + B6] \u2192 GABA\n</code></pre>"},{"location":"neurotransmitters/gaba/#degradation-catabolism","title":"Degradation / Catabolism","text":"<pre><code>GABA (synaptic)\n      \u2502\n      \u2502 Reuptake via GAT-1/3 (GABA transporters)\n      \u25bc\nPresynaptic terminal or astrocyte\n      \u2502\n      \u2502 [GABA-T]  Cofactor: PLP (B6)\n      \u25bc\nSuccinic semialdehyde\n      \u2502\n      \u2502 [SSADH]  Cofactor: NAD\u207a (B3)\n      \u25bc\nSuccinate \u2192 Krebs cycle\n</code></pre> Enzyme Location Cofactor Inhibited By GABA-T Mitochondria (neurons + astrocytes) PLP (B6) Vigabatrin (anticonvulsant \u2014 irreversible GABA-T inhibitor) SSADH Mitochondria NAD\u207a (B3) GHB (endogenous/exogenous) competes"},{"location":"neurotransmitters/gaba/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency Vitamin B6 (PLP) GAD cofactor (glutamate \u2192 GABA); GABA-T (catabolism) Low GABA \u2192 anxiety, seizures; B6 deficiency seizures in infants Zinc Enhances GAD isoform stability; modulates GABA-A receptor Reduced GABA synthesis; anxiety Magnesium GABA-A receptor allosteric modulation; GS cofactor for glutamine Hypomagnesaemia \u2192 anxiety, muscle spasms Thiamine (B1) ATP production for Krebs cycle \u2192 glutamate supply Reduced GABA substrate Niacin (B3) NAD\u207a for SSADH (GABA catabolism); Krebs cycle Dysregulated GABA turnover Glutamate (glutamine) Direct GABA precursor Substrate limitation Taurine GABA-A receptor agonist; inhibitory co-transmitter Reduced inhibitory tone L-Theanine Increases GABA and reduces glutamate signalling N/A (supplemental)"},{"location":"neurotransmitters/gaba/#gaba-receptors","title":"GABA Receptors","text":"Receptor Type Mechanism Key Features GABA-A Ligand-gated Cl\u207b channel (ionotropic) Increases Cl\u207b influx \u2192 hyperpolarisation Benzodiazepine site; alcohol; barbiturate site; neurosteroid site GABA-B Gi-coupled GPCR (metabotropic) Decreases cAMP; opens K\u207a channels Baclofen target; pre- and post-synaptic GABA-C (now GABA-A \u03c1) Cl\u207b channel Similar to GABA-A; slower kinetics Retinal cells <p>Key allosteric modulators of GABA-A: - Benzodiazepines \u2014 increase frequency of Cl\u207b channel opening (anxiolytic, sedative) - Barbiturates \u2014 increase duration of channel opening (anticonvulsant) - Alcohol (ethanol) \u2014 positive modulator of GABA-A (also inhibits NMDA) - Neurosteroids (allopregnanolone, THDOC) \u2014 endogenous ligands; fluctuate with menstrual cycle, stress, and pregnancy - Magnesium \u2014 modulates receptor sensitivity</p>"},{"location":"neurotransmitters/gaba/#clinical-relevance","title":"Clinical Relevance","text":"Condition GABA Status Mechanism Epilepsy Low GABA GAD deficiency; GABA-T excess; channelopathies Anxiety disorders Low GABA tone Reduced GAD67 expression; chronic stress PTSD Low GABA (amygdala) HPA activation depletes GABA; BZ receptor downregulation Alcohol use disorder GABA-A tolerance Chronic alcohol \u2192 GABA-A downregulation \u2192 withdrawal seizures SSADH deficiency Elevated GABA Rare metabolic disorder (NAD+ enzyme failure) Huntington's disease Loss of GABAergic striatal neurons Disinhibition of thalamus \u2192 choreiform movements"},{"location":"neurotransmitters/gaba/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Benzodiazepines (diazepam, lorazepam) Positive GABA-A modulator \u2014 potentiate Cl\u207b influx Barbiturates (phenobarbitone) GABA-A positive allosteric modulator \u2014 higher abuse risk Vigabatrin Irreversible GABA-T inhibitor \u2192 raises brain GABA Baclofen GABA-B agonist \u2014 muscle relaxant, alcohol craving reduction Sodium valproate GABA-T inhibitor + GAD activator + Na\u207a channel block Gabapentin / Pregabalin Bind \u03b12\u03b4 subunit of voltage-gated Ca\u00b2\u207a channels; reduce glutamate (indirect GABA enhancement) Alcohol GABA-A agonist + NMDA antagonist (acute); reverse on withdrawal Flumazenil Benzodiazepine receptor antagonist (reversal agent)"},{"location":"neurotransmitters/glutamate/","title":"Glutamate","text":""},{"location":"neurotransmitters/glutamate/#overview","title":"Overview","text":"<p>Glutamate is the primary excitatory neurotransmitter in the mammalian CNS, involved in the majority of fast excitatory synaptic transmission. It is not only a neurotransmitter but also a central metabolite \u2014 participating in the Krebs cycle, amino acid transamination, and as the direct precursor to GABA and glutathione. Far from being a simple \"one-way\" stimulant, glutamate signalling follows a carefully regulated astrocyte\u2013neuron recycling cycle.</p> <p>Key insight \u2014 Glutamate excess (excitotoxicity) kills neurons via NMDA receptor-mediated calcium overload and mitochondrial failure. Zinc and magnesium are critical physiological blockers of the NMDA receptor channel pore. Nutritional deficits in these minerals increase vulnerability to excitotoxic damage.</p>"},{"location":"neurotransmitters/glutamate/#synthesis-pathway","title":"Synthesis Pathway","text":"<p>Glutamate is not a single-precursor molecule \u2014 it is synthesised via multiple routes:</p> <pre><code>Route 1: Krebs Cycle (primary)\n\u03b1-Ketoglutarate (from citric acid cycle)\n      \u2502\n      \u2502 [Glutamate dehydrogenase \u2014 GDH]\n      \u2502  Cofactors: NAD\u207a / NADH (Niacin / B3), NADP\u207a / NADPH\n      \u2502  Allosteric: Zn\u00b2\u207a, Mg\u00b2\u207a, ADP, leucine\n      \u25bc\nL-Glutamate\n\nRoute 2: Transamination\n\u03b1-Ketoglutarate + amino acid donor (e.g., aspartate, alanine)\n      \u2502\n      \u2502 [Aminotransferases \u2014 AST, ALT]\n      \u2502  Cofactor: PLP (Vitamin B6)\n      \u25bc\nL-Glutamate\n\nRoute 3: Glutamine Hydrolysis (major in neurons)\nGlutamine (from astrocytes)\n      \u2502\n      \u2502 [Glutaminase \u2014 GLS]\n      \u2502  Activated by: phosphate (Pi), NH\u2084\u207a\n      \u2502  Inhibited by: glutamate itself\n      \u25bc\nL-Glutamate  +  NH\u2083\n</code></pre>"},{"location":"neurotransmitters/glutamate/#astrocyteneuron-glutamateglutamine-cycle","title":"Astrocyte\u2013Neuron Glutamate\u2013Glutamine Cycle","text":"<pre><code>Glutamatergic Neuron                    Astrocyte\n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\nGlutamate released into synapse\n      \u2502\n      \u2502 Postsynaptic action (AMPA, NMDA)\n      \u2502\n      \u2502 Excess taken up by astrocyte via EAAT (GLAST / GLT-1)\n      \u2502                              \u25bc\n      \u2502                   [Glutamine synthetase \u2014 GS]\n      \u2502                    Cofactors: Mg\u00b2\u207a, ATP, Mn\u00b2\u207a\n      \u2502                              \u25bc\n      \u2502                          Glutamine\n      \u2502\n      \u2502 Released by astrocyte \u2192 taken up by neuron (SNAT transporters)\n      \u2502\n      \u2502 [Glutaminase \u2014 GLS]\n      \u25bc\n  Glutamate (re-packaged into vesicles by VGLUT1/2/3)\n</code></pre>"},{"location":"neurotransmitters/glutamate/#cofactor-requirements-for-synthesis","title":"Cofactor Requirements for Synthesis","text":"Step Enzyme Required Cofactors / Nutrients \u03b1-KG \u2192 Glutamate GDH NAD\u207a (B3), NADP\u207a; Zn\u00b2\u207a (allosteric); Mg\u00b2\u207a Transamination AST, ALT PLP (Vitamin B6) Glutamine \u2192 Glutamate Glutaminase Phosphate; no specific vitamin cofactor Glutamate \u2192 Glutamine (astrocyte) Glutamine synthetase (GS) Mg\u00b2\u207a, Mn\u00b2\u207a, ATP VGLUT loading (vesicular) VGLUT1/2/3 H\u207a-ATPase ATP (indirect \u2014 oxidative phosphorylation)"},{"location":"neurotransmitters/glutamate/#degradation-termination-of-signalling","title":"Degradation / Termination of Signalling","text":"<p>Glutamate signalling is terminated primarily by reuptake, not enzymatic degradation:</p> <pre><code>Synaptic Glutamate\n      \u2502\n      \u251c\u2500\u2500\u25ba Astrocyte reuptake via EAAT1 (GLAST) / EAAT2 (GLT-1)\n      \u2502           \u2192 Glutamine synthesis (GS, Mg\u00b2\u207a-dependent)\n      \u2502           \u2192 Released back to neurons\n      \u2502\n      \u251c\u2500\u2500\u25ba Presynaptic reuptake via EAAT3 (EAAC1)\n      \u2502           \u2192 Glutamine synthesis or Krebs cycle\n      \u2502\n      \u2514\u2500\u2500\u25ba Metabolism:\n              Glutamate\n                \u2502\n                \u251c\u2500\u2500[GAD + B6]\u2192 GABA (in inhibitory neurons)\n                \u2502\n                \u251c\u2500\u2500[GDH]\u2192 \u03b1-KG \u2192 Krebs cycle (energy)\n                \u2502\n                \u2514\u2500\u2500[\u03b3-glutamylcysteine synthetase]\u2192 Glutathione synthesis\n</code></pre>"},{"location":"neurotransmitters/glutamate/#excitotoxicity-the-dark-side","title":"Excitotoxicity \u2014 The Dark Side","text":"<p>Glutamate overactivation of NMDA and AMPA receptors leads to excitotoxic cell death:</p> <pre><code>Excessive glutamate release or reuptake failure\n      \u2502\n      \u25bc\nSustained NMDA activation \u2192 Ca\u00b2\u207a influx\n      \u2502\n      \u25bc\nMitochondrial Ca\u00b2\u207a overload\n      \u2502\n      \u251c\u2500\u2500\u25ba Excessive ROS production\n      \u251c\u2500\u2500\u25ba Cytochrome c release \u2192 apoptosis\n      \u2514\u2500\u2500\u25ba calpain / caspase activation \u2192 neuronal death\n</code></pre> <p>Physiological NMDA channel blockers (prevent excitotoxicity): - Magnesium (Mg\u00b2\u207a) \u2014 voltage-dependent pore block (removed during depolarisation) - Zinc (Zn\u00b2\u207a) \u2014 allosteric inhibition of NR2B-containing NMDA receptors - D-Serine \u2014 co-agonist at glycine site (required for NMDA activation \u2014 not a blocker, but regulates gating)</p>"},{"location":"neurotransmitters/glutamate/#glutamate-receptors","title":"Glutamate Receptors","text":"Receptor Family Type Mechanism Main Role AMPA (GluA1-4) Ionotropic \u2014 Na\u207a/K\u207a channel Fast depolarisation Fast excitation; LTP induction NMDA (GluN1/2/3) Ionotropic \u2014 Na\u207a/K\u207a/Ca\u00b2\u207a channel Slow, voltage-gated LTP; memory; excitotoxicity; Mg\u00b2\u207a-blocked at rest Kainate (GluK1-5) Ionotropic Moderate kinetics Presynaptic modulation; epilepsy mGluR Group I (mGluR1,5) Gq-coupled GPCR Enhances excitability Synaptic plasticity mGluR Group II/III (mGluR2-4,6-8) Gi-coupled GPCR Reduces glutamate release Autoreceptors; presynaptic inhibition"},{"location":"neurotransmitters/glutamate/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency Magnesium (Mg\u00b2\u207a) NMDA receptor Mg\u00b2\u207a-block (channel pore); GS cofactor NMDA hyperactivation \u2192 anxiety, seizures, excitotoxicity Zinc (Zn\u00b2\u207a) NMDA NR2B allosteric inhibition; GDH allosteric Increased excitotoxicity risk Vitamin B6 (PLP) Transamination for glutamate synthesis; GAD for GABA Altered Glu/GABA balance Niacin (B3) / NAD\u207a GDH cofactor for glutamate synthesis Reduced synthesis capacity Thiamine (B1) Krebs cycle \u2192 \u03b1-KG supply Reduced glutamate synthesis (Wernicke's encephalopathy) Manganese (Mn\u00b2\u207a) GS cofactor in astrocytes Impaired glutamine synthesis (Mn\u00b2\u207a toxicity also impairs GS \u2192 glutamate accumulation) DHA (Omega-3) Maintains NMDA receptor density and membrane fluidity Reduced NMDA signalling efficiency Taurine Modulates GABA-A and NMDA (indirect protection) Reduced neuroprotection"},{"location":"neurotransmitters/glutamate/#clinical-relevance","title":"Clinical Relevance","text":"Condition Glutamate Status Mechanism Stroke Massive excitotoxic release Ischemia \u2192 ATP failure \u2192 reversal of EAAT \u2192 glutamate surge Epilepsy Local excess GAD/GABA-T imbalance; reduced Mg\u00b2\u207a block ALS Reduced EAAT2 Impaired astrocyte reuptake \u2192 motor neuron excitotoxicity Alzheimer's NMDA dysregulation Memantine (NMDA antagonist) approved treatment Depression Glutamate excess (PFC/hippocampus) Ketamine (NMDA antagonist) \u2014 rapid-acting antidepressant Schizophrenia NMDA hypofunction (GABA interneuron loss) NMDA antagonists (PCP, ketamine) mimic symptoms Glutamate sensitivity (dietary) MSG sensitivity claims Evidence limited; DAO/HNMT co-involvement"},{"location":"neurotransmitters/glutamate/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Memantine Uncompetitive NMDA antagonist \u2014 Alzheimer's disease Ketamine / Esketamine NMDA antagonist \u2014 rapid antidepressant; dissociative PCP (phencyclidine) NMDA antagonist \u2014 abuse/psychosis Riluzole Reduces glutamate release; ALS treatment Lamotrigine Blocks Na\u207a channels \u2192 reduces glutamate release Topiramate AMPA/kainate antagonist + GABA-A enhancement; anticonvulsant Alcohol NMDA antagonist (acute); NMDA upregulation on withdrawal \u2192 seizures Mg\u00b2\u207a supplementation Physiological NMDA modulation; reduces excitotoxicity"},{"location":"neurotransmitters/histamine/","title":"Histamine","text":""},{"location":"neurotransmitters/histamine/#overview","title":"Overview","text":"<p>Histamine is a biogenic amine derived from L-histidine via a single decarboxylation step. It functions as a neurotransmitter in the CNS (wakefulness, attention, feeding), a peripheral hormone/mediator in immune responses (allergy, anaphylaxis), and a paracrine signal in the gastric mucosa (acid secretion). The CNS histaminergic system originates almost exclusively from the tuberomammillary nucleus (TMN) of the posterior hypothalamus.</p> <p>Key insight \u2014 Histamine has two separate degradation enzymes: HNMT (intracellular, CNS) and DAO (extracellular, gut/plasma). DAO is the critical first line of defence against dietary histamine. DAO is nutritionally sensitive \u2014 it requires B6, copper, B12, and folate for optimal activity.</p>"},{"location":"neurotransmitters/histamine/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>L-Histidine  (dietary; also from muscle protein turnover)\n      \u2502\n      \u2502 [L-Histidine Decarboxylase \u2014 HDC]\n      \u2502  Cofactor: Pyridoxal-5\u2032-phosphate (PLP / Vitamin B6)\n      \u2502  \u26a0 Rate-limiting step (product inhibition by histamine itself)\n      \u2502  Expressed in: mast cells, basophils, enterochromaffin-like (ECL) cells, TMN neurons\n      \u25bc\nHistamine\n      \u2502\n      \u251c\u2500\u2500\u25ba CNS: released from TMN neurons \u2192 wakefulness, attention\n      \u251c\u2500\u2500\u25ba Mast cells / Basophils: stored in granules \u2192 released in allergy/injury\n      \u2514\u2500\u2500\u25ba Gastric ECL cells: released \u2192 stimulates parietal cell H2 receptor \u2192 HCl secretion\n</code></pre>"},{"location":"neurotransmitters/histamine/#cofactor-requirements","title":"Cofactor Requirements","text":"Step Enzyme Required Cofactors / Nutrients Histidine \u2192 Histamine \u26a0 HDC PLP (Vitamin B6), L-Histidine substrate Bacterial HDC (gut) Bacterial HDC B6 (from microbiome environment) \u2014 Lactobacillus, Clostridium species"},{"location":"neurotransmitters/histamine/#degradation-pathways","title":"Degradation Pathways","text":"<p>Histamine is degraded by two distinct pathways depending on tissue location:</p>"},{"location":"neurotransmitters/histamine/#pathway-1-hnmt-histamine-n-methyltransferase-cns-and-intracellular","title":"Pathway 1: HNMT (Histamine N-Methyltransferase) \u2014 CNS and Intracellular","text":"<pre><code>Histamine (intracellular / CNS)\n      \u2502\n      \u2502 [HNMT \u2014 Histamine N-methyltransferase]\n      \u2502  Cofactor: SAM (S-adenosylmethionine)\n      \u2502           \u2192 requires B12, Folate (5-MTHF), Riboflavin (B2), Mg\u00b2\u207a\n      \u25bc\nN-Methylhistamine\n      \u2502\n      \u2502 [MAO-B]  Cofactor: FAD (Riboflavin / B2)\n      \u25bc\nMethyl-imidazoleacetic acid  \u2192  urine\n</code></pre>"},{"location":"neurotransmitters/histamine/#pathway-2-dao-diamine-oxidase-gut-and-plasma","title":"Pathway 2: DAO (Diamine Oxidase) \u2014 Gut and Plasma","text":"<pre><code>Histamine (extracellular / gut lumen / plasma)\n      \u2502\n      \u2502 [DAO \u2014 Diamine Oxidase / AOC1]\n      \u2502  Cofactors: Cu\u00b2\u207a (copper), PLP (B6)\n      \u2502  Post-translational: requires topaquinone (TPQ) \u2014 derived from Cu\u00b2\u207a + tyrosine\n      \u2502  Inhibited by: alcohol, metformin, certain drugs\n      \u25bc\nImidazole acetaldehyde\n      \u2502\n      \u2502 [ALDH]  Cofactor: NAD\u207a (Niacin / B3)\n      \u25bc\nImidazoleacetic acid  \u2192  urine\n</code></pre>"},{"location":"neurotransmitters/histamine/#degradation-summary","title":"Degradation Summary","text":"Enzyme Location Cofactors Clinically inhibited by HNMT CNS neurons, lung, liver, kidneys SAM (B12, folate, B2, Mg\u00b2\u207a) SKF 91488 (research); SAM depletion DAO (AOC1) Intestinal epithelium, placenta, kidney Cu\u00b2\u207a, PLP (B6), NAD\u207a (B3) Alcohol, isoniazid, metformin, verapamil, histamine blockers MAO-B Glia, platelets FAD (B2) Selegiline, rasagiline"},{"location":"neurotransmitters/histamine/#histamine-intolerance","title":"Histamine Intolerance","text":"<p>Histamine intolerance arises when dietary histamine accumulation exceeds the body's ability to degrade it (primarily via DAO):</p> <p>Causes of reduced DAO activity: - Genetic variants in AOC1 gene (reduced DAO expression) - Alcohol (competitive DAO inhibitor) - Copper deficiency (DAO active site Cu\u00b2\u207a) - Vitamin B6 deficiency (DAO cofactor) - Folate / B12 deficiency (indirect \u2014 HNMT pathway impaired) - Gut inflammation (IBD, celiac) \u2014 damages DAO-expressing enterocytes - Certain drugs (isoniazid, metformin, some ACE inhibitors)</p> <p>Symptoms of histamine intolerance: headache, flushing, hives, nasal congestion, GI cramping, tachycardia, hypotension</p> <p>High-histamine foods: fermented foods (wine, cheese, sauerkraut, soy sauce, vinegar), tinned fish, aged meat, spinach, tomatoes, alcohol</p>"},{"location":"neurotransmitters/histamine/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency Vitamin B6 (PLP) HDC cofactor (histamine synthesis); DAO cofactor (degradation) Dual: reduces synthesis AND degradation capacity Copper (Cu\u00b2\u207a) DAO active site (TPQ formation and catalysis) Severely impaired DAO \u2192 histamine intolerance SAM (B12 + Folate + B2 + Mg\u00b2\u207a) HNMT cofactor (CNS and systemic methylation) Impaired CNS histamine clearance Riboflavin (B2) FAD for MAO-B (downstream N-methylhistamine catabolism); BH4/SAM pathway Reduced histamine degradation Niacin (B3) / NAD\u207a ALDH (imidazole acetaldehyde \u2192 acid) Minor impairment of terminal step Zinc Supports DAO enzyme stability Reduced DAO activity Vitamin C Upregulates DAO activity (anti-inflammatory); reduces mast cell degranulation Increased mast cell reactivity and lower DAO"},{"location":"neurotransmitters/histamine/#histamine-receptors","title":"Histamine Receptors","text":"Receptor Signalling Location Function H1 Gq \u2192 PLC \u2192 IP\u2083/DAG Smooth muscle, endothelium, CNS Bronchoconstriction; itch; wakefulness; allergy H2 Gs \u2192 cAMP \u2191 Gastric parietal cells, heart Gastric acid secretion; positive chronotropy H3 Gi (autoreceptor) CNS (presynaptic) Inhibits histamine release; modulates DA, ACh, 5-HT H4 Gi Mast cells, eosinophils, gut Immune cell chemotaxis; gut inflammation"},{"location":"neurotransmitters/histamine/#clinical-relevance","title":"Clinical Relevance","text":"Condition Histamine Status Mechanism Allergic rhinitis / Asthma Elevated (mast cell release) IgE-mediated mast cell degranulation Anaphylaxis Massively elevated Systemic mast cell + basophil degranulation Carcinoid / ECL tumour Elevated (persistent) Tumour histidine decarboxylase overexpression Histamine intolerance Relative elevation DAO insufficiency (see above) Narcolepsy Low CNS histamine TMN neuronal loss; hypocretin/orexin system failure \u2192 H1 recruitment lost Peptic ulcer disease H2 stimulation excess H. pylori \u2192 gastrin \u2192 ECL \u2192 histamine \u2192 acid hypersecretion Mastocytosis Chronic excess Clonal mast cell proliferation"},{"location":"neurotransmitters/histamine/#drug-interactions","title":"Drug Interactions","text":"Drug Mechanism H1 antihistamines (loratadine, cetirizine, diphenhydramine) H1 receptor antagonists \u2014 allergy treatment H2 blockers (ranitidine, famotidine) H2 antagonists \u2014 acid suppression MAOI drugs Block MAO-B \u2192 impair N-methylhistamine catabolism Alcohol Inhibits DAO; promotes mast cell degranulation Isoniazid (TB drug) DAO inhibitor + HDC inhibitor \u2014 histamine toxicity (scombroid fish risk) Metformin Weak DAO inhibitor Proton pump inhibitors Indirect: reduce acid-suppressed bacterial histamine production"},{"location":"neurotransmitters/melatonin/","title":"Melatonin","text":""},{"location":"neurotransmitters/melatonin/#overview","title":"Overview","text":"<p>Melatonin (N-acetyl-5-methoxytryptamine) is an indolamine hormone and neuromodulator synthesised primarily by the pineal gland from serotonin. It is the principal signal of circadian night, communicating darkness to the body and regulating sleep onset, immune modulation, antioxidant defence, and reproductive seasonality. Because melatonin is made from serotonin, it sits at the downstream end of the tryptophan cascade and is directly affected by all the upstream cofactors that govern serotonin synthesis.</p> <p>Key insight \u2014 Melatonin synthesis is controlled almost entirely by light exposure, not by substrate availability alone. Blue-light exposure at night (480 nm) suppresses melatonin via retino-hypothalamic tract \u2192 suprachiasmatic nucleus (SCN) \u2192 paraventricular nucleus \u2192 superior cervical ganglion \u2192 pineal gland. Nutritional support is necessary but insufficient without circadian light hygiene.</p>"},{"location":"neurotransmitters/melatonin/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>L-Tryptophan  (dietary essential amino acid)\n      \u2502\n      \u2502 [Tryptophan hydroxylase 1 \u2014 TPH1 (pineal)]\n      \u2502  Cofactors: BH4, Fe\u00b2\u207a, O\u2082, NADPH\n      \u25bc\n5-HTP (5-Hydroxytryptophan)\n      \u2502\n      \u2502 [AADC \u2014 Aromatic amino acid decarboxylase]\n      \u2502  Cofactor: PLP (Vitamin B6)\n      \u25bc\nSerotonin (5-HT)\n      \u2502\n      \u2502  Nighttime: NE released from SCG (from SCN entrainment)\n      \u2502  NE activates \u03b2/\u03b11-adrenoceptors \u2192 cAMP \u2191 \u2192 PKA \u2192 AANAT transcription\n      \u2502\n      \u2502 [AANAT \u2014 Arylalkylamine N-acetyltransferase]\n      \u2502  Cofactor: Acetyl-CoA (requires B5/pantothenate chain)\n      \u2502  \u26a0 Rate-limiting step for melatonin (controlled by circadian clock)\n      \u25bc\nN-Acetylserotonin (NAS)\n      \u2502\n      \u2502 [ASMT \u2014 Acetylserotonin O-methyltransferase]\n      \u2502  Cofactor: SAM (S-adenosylmethionine)\n      \u2502            \u2192 requires B12, Folate (5-MTHF), Riboflavin (B2), Mg\u00b2\u207a, Methionine\n      \u25bc\nMelatonin (N-acetyl-5-methoxytryptamine)\n      \u2502\n      \u25bc\nReleased directly into blood and CSF (no vesicle storage \u2014 lipid soluble)\n</code></pre>"},{"location":"neurotransmitters/melatonin/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme Required Cofactors / Nutrients Tryptophan \u2192 5-HTP TPH1 BH4, Fe\u00b2\u207a, O\u2082, NADPH 5-HTP \u2192 Serotonin AADC PLP (Vitamin B6), Zn\u00b2\u207a Serotonin \u2192 NAS \u26a0 AANAT Acetyl-CoA (from B5, B1, B2, B3, lipoic acid) NAS \u2192 Melatonin ASMT SAM (methionine + B12 + 5-MTHF + B2 + Mg\u00b2\u207a) BH4 regeneration DHFR, DHPR Folate (B9), Riboflavin (B2), NADPH"},{"location":"neurotransmitters/melatonin/#light-regulation-circadian-control-of-aanat","title":"Light Regulation (Circadian Control of AANAT)","text":"<pre><code>Light (daytime) \u2192 Retina \u2192 Retino-hypothalamic tract \u2192 SCN\n      \u2502\n      \u2514\u2500\u2500\u25ba SCN inhibits PVN \u2192 inhibits SCG \u2192 inhibits pineal\n           \u2192 AANAT is low \u2192 no melatonin\n\nDark (nighttime) \u2192 SCN disinhibits PVN \u2192 SCG activated\n      \u2502\n      \u2514\u2500\u2500\u25ba Norepinephrine released onto pinealocytes\n           \u2192 \u03b21 + \u03b11 adrenoceptors \u2192 cAMP + PKC \u2191\n           \u2192 AANAT transcription + post-translational stabilisation\n           \u2192 Melatonin surge (peaks ~2\u20134 am)\n</code></pre> <p>Blue light (480 nm) is the most potent melatonin suppressor \u2014 targets melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGC).</p>"},{"location":"neurotransmitters/melatonin/#degradation-pathway","title":"Degradation Pathway","text":"<pre><code>Melatonin (blood, tissues)\n      \u2502\n      \u251c\u2500\u2500\u25ba Liver (major route):\n      \u2502    [CYP1A2, CYP1A1, CYP1B1]\n      \u2502     \u2192 6-Hydroxymelatonin\n      \u2502         \u2502\n      \u2502         \u2502 [SULT / UGT Phase II conjugation]\n      \u2502         \u25bc\n      \u2502     6-Sulphatoxymelatonin (aMT6s) \u2192 urine (principal metabolite, standard biomarker)\n      \u2502\n      \u2514\u2500\u2500\u25ba Brain:\n           [AFMK pathway \u2014 enzymatic + non-enzymatic]\n           Melatonin \u2192 AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine)\n                     \u2192 AMK (N1-acetyl-5-methoxykynuramine)\n                     (antioxidant metabolites \u2014 free radical cascade)\n</code></pre> Route Enzyme Cofactor Product Significance Hepatic hydroxylation CYP1A2 Haem, O\u2082, NADPH 6-OH-Melatonin Primary metabolic route Phase II conjugation SULT1A/UGT PAPS (sulfotransfer) / UDPGA 6-sulphatoxymelatonin Urinary biomarker (nighttime peak) Free-radical neutralisation Non-enzymatic None AFMK, AMK Antioxidant cascade (each melatonin \u2192 10+ ROS scavenged)"},{"location":"neurotransmitters/melatonin/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency L-Tryptophan Serotonin (and thus melatonin) precursor Reduced substrate; low serotonin and melatonin Vitamin B6 (PLP) AADC cofactor (5-HTP \u2192 serotonin) Reduced melatonin upstream Pantothenate (B5) Acetyl-CoA for AANAT (serotonin \u2192 NAS) Reduced rate-limiting step SAM (Methionine + B12 + Folate + B2 + Mg\u00b2\u207a) ASMT cofactor \u2014 methyl group transfer (NAS \u2192 melatonin) NAS accumulates; melatonin reduced Vitamin B12 (methylcobalamin) SAM regeneration (ASMT) Impaired melatonin methylation Folate (5-MTHF/B9) BH4 regeneration (TPH1) + SAM cycle Upstream and methylation impairment Riboflavin (B2) FAD for BH4 synthesis; SAM cycle Impairs TPH1 and ASMT indirectly Iron (Fe\u00b2\u207a) TPH1 cofactor Reduced 5-HTP production Magnesium No direct melatonin enzyme; binds to melatonin receptors; regulates ASMT cycle Sleep complaints; low melatonin receptor sensitivity Zinc AADC activity Reduced serotonin \u2192 melatonin Vitamin D Upregulates TPH1 expression in pineal Low melatonin linked to vitamin D deficiency"},{"location":"neurotransmitters/melatonin/#melatonin-receptors","title":"Melatonin Receptors","text":"Receptor Signalling Location Function MT1 (MTNR1A) Gi \u2192 cAMP \u2193 SCN, pituitary, peripheral tissues Acute sleep signal; reproductive regulation MT2 (MTNR1B) Gi \u2192 cAMP \u2193 Retina, SCN Phase shifting (circadian reset); type 2 diabetes association MT3 NRH quinone oxidoreductase Peripheral tissues Physiological role unclear; may be quinone reductase"},{"location":"neurotransmitters/melatonin/#melatonin-as-an-antioxidant","title":"Melatonin as an Antioxidant","text":"<p>Melatonin is a potent free radical scavenger \u2014 via two mechanisms: 1. Direct \u2014 scavenges \u00b7OH, ONOO\u207b, H\u2082O\u2082 (no receptor required) 2. Indirect \u2014 ASMT metabolites (AFMK, AMK) continue scavenging downstream</p> <p>One melatonin molecule can neutralise up to 10 reactive oxygen species through this cascade \u2014 far exceeding Vitamin C or E.</p> <p>Additionally, melatonin upregulates antioxidant enzymes: SOD, GPx, GR, catalase.</p>"},{"location":"neurotransmitters/melatonin/#clinical-relevance","title":"Clinical Relevance","text":"Condition Melatonin Status Notes Insomnia / delayed sleep phase Low or phase-shifted Exogenous melatonin (0.5\u20135 mg) advances phase Jet lag Arrhythmic Timed melatonin administration resets SCN Night shift workers Suppressed (light exposure) Blackout environment + timed supplementation Autism spectrum disorder Low (some individuals) ASMT mutations found in cohort studies Breast / prostate cancer Epidemiologically low Night shift \u2192 suppressed melatonin \u2192 MT1 loss of oncostatic signalling Type 2 diabetes MT2 variant (MTNR1B rs10830963) Associated with elevated fasting glucose Mitochondrial disorders Depleted Oxidative stress consumes melatonin non-regeneratively"},{"location":"neurotransmitters/melatonin/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Fluvoxamine (SSRI) Potent CYP1A2 inhibitor \u2192 raises melatonin 10-fold Ramelteon / Tasimelteon MT1/MT2 agonists \u2014 approved for insomnia and non-24 disorder Agomelatine MT1/MT2 agonist + 5-HT2C antagonist \u2014 antidepressant Beta-blockers (propranolol) Block \u03b21 adrenoceptors in pineal \u2192 suppress AANAT \u2192 reduce melatonin NSAIDs (aspirin, ibuprofen) PGE\u2082 inhibition \u2192 may reduce melatonin (mechanism unclear) Caffeine CYP1A2 competitor \u2192 may marginally raise melatonin Alcohol Suppresses melatonin secretion acutely; disrupts circadian rhythm Corticosteroids Suppress melatonin secretion"},{"location":"neurotransmitters/norepinephrine_epinephrine/","title":"Norepinephrine &amp; Epinephrine (Catecholamines)","text":""},{"location":"neurotransmitters/norepinephrine_epinephrine/#overview","title":"Overview","text":"<p>Norepinephrine (noradrenaline / NE) and epinephrine (adrenaline / EPI) are catecholamines synthesised sequentially from dopamine. They are the principal mediators of the sympathetic nervous system (fight-or-flight) and regulate arousal, focus, cardiovascular tone, blood glucose, and the stress response.</p> Norepinephrine Epinephrine Primary site Locus coeruleus (CNS); adrenal medulla; sympathetic ganglia Adrenal medulla (chromaffin cells, ~80% of output) CNS role Arousal, attention, fight-or-flight, mood Peripheral stress response; some central (minor) Peripheral role Vasoconstriction, cardiac output Bronchodilation, glycogenolysis, lipolysis"},{"location":"neurotransmitters/norepinephrine_epinephrine/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>L-Tyrosine\n      \u2502\n      \u2502 [Tyrosine hydroxylase \u2014 TH]  \u2190 rate-limiting for all catecholamines\n      \u2502  Cofactors: BH4, Fe\u00b2\u207a, O\u2082, NADPH\n      \u25bc\nL-DOPA\n      \u2502\n      \u2502 [AADC / Dopa decarboxylase]\n      \u2502  Cofactor: PLP (Vitamin B6)\n      \u25bc\nDopamine\n      \u2502\n      \u2502 [Dopamine-\u03b2-hydroxylase \u2014 DBH]  \u2190 occurs inside vesicles\n      \u2502  Cofactors: Vitamin C (ascorbate), Cu\u00b2\u207a, O\u2082\n      \u2502  \u26a0 Key step: Vitamin C is consumed stoichiometrically\n      \u25bc\nNorepinephrine (NE)\n      \u2502\n      \u2502 [Phenylethanolamine N-methyltransferase \u2014 PNMT]\n      \u2502  Cofactor: SAM (S-adenosylmethionine)\n      \u2502  Only in adrenal medulla and a few CNS nuclei\n      \u2502  PNMT is induced by glucocorticoids (cortisol)\n      \u25bc\nEpinephrine (EPI)\n</code></pre>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme Required Cofactors / Nutrients 1. Tyrosine \u2192 L-DOPA \u26a0 Tyrosine hydroxylase (TH) BH4, Fe\u00b2\u207a, O\u2082, NADPH (see dopamine.md) 2. L-DOPA \u2192 Dopamine AADC PLP (Vitamin B6), Zn\u00b2\u207a 3. Dopamine \u2192 NE Dopamine-\u03b2-hydroxylase (DBH) Vitamin C (ascorbate), Cu\u00b2\u207a (copper), O\u2082 4. NE \u2192 Epinephrine PNMT SAM (needs methionine, B9, B12, B2, Mg\u00b2\u207a) Cortisol induction of PNMT Adrenal cortex \u2192 medulla Cortisol upregulates PNMT gene expression"},{"location":"neurotransmitters/norepinephrine_epinephrine/#dbh-vitamin-c-dependency","title":"DBH \u2014 Vitamin C Dependency","text":"<p>Dopamine-\u03b2-hydroxylase (DBH) is unique in requiring ascorbate (Vitamin C) as an actual electron donor \u2014 not just a cofactor. Each catalytic cycle oxidises ascorbate to semi-dehydroascorbate.</p> <ul> <li>DBH is located inside synaptic vesicles \u2014 ascorbate must be actively transported into chromaffin granules</li> <li>Scurvy (severe Vitamin C deficiency) substantially impairs NE synthesis \u2192 fatigue, hypotension, mood changes</li> <li>Ascorbate transport into vesicles is mediated by SVCT2 transporter</li> <li>Copper is the prosthetic metal at the DBH active site \u2014 copper deficiency impairs DBH regardless of ascorbate status</li> </ul>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#pnmt-sam-and-cortisol-regulation","title":"PNMT \u2014 SAM and Cortisol Regulation","text":"<p>Phenylethanolamine N-methyltransferase (PNMT) transfers a methyl group from SAM onto norepinephrine: - Exclusive to adrenal chromaffin cells and a small number of brain stem neurons - Gene expression requires glucocorticoid (cortisol) signalling via a GRE (glucocorticoid response element) - Chronic stress \u2192 sustained cortisol \u2192 PNMT upregulation \u2192 excess EPI synthesis \u2192 adrenal exhaustion if prolonged - SAM depletion (B12/folate/B2/Mg deficiency) \u2192 impaired PNMT \u2192 reduced epinephrine</p>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#degradation-pathways","title":"Degradation Pathways","text":"<p>Both NE and EPI are degraded by the same enzymatic machinery:</p> <pre><code>Norepinephrine / Epinephrine\n         \u2502\n    \u250c\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n    \u2502               \u2502\n[MAO-A]          [COMT]\n FAD (B2)         SAM (B12/folate/B2/Mg)\n    \u2502               \u2502\n3,4-dihydroxymandelic     Normetanephrine / Metanephrine\nacid (DHMA)              (major plasma/urine metabolite)\n    \u2502               \u2502\n    \u2514\u2500\u2500\u2500\u2500 COMT \u2500\u2500\u2500\u2500\u2500\u2518\n              \u2502\n              \u25bc\n    3-Methoxy-4-hydroxymandelic acid\n    = Vanillylmandelic acid (VMA)  \u2500\u2500\u25ba urine\n    (also called Normetanephrine/Metanephrine intermediate)\n\n[Additional route via MHPG \u2192 in CNS]\nCentral NE \u2192 3-Methoxy-4-hydroxyphenylglycol (MHPG) \u2192 urine/CSF\n</code></pre>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#degradation-enzymes","title":"Degradation Enzymes","text":"Enzyme Action Cofactor Notes MAO-A Oxidises NE/EPI to aldehyde FAD (B2) Primary neuronal route COMT O-methylation SAM (B12/folate/B2/Mg) Primary extraneuronal/hepatic route ALDH Aldehyde \u2192 acid NAD\u207a (B3) Converts DHMA; also handles acetaldehyde <p>Urine biomarkers: - VMA (vanillylmandelic acid) \u2014 elevated in pheochromocytoma - Normetanephrine / Metanephrine \u2014 highly sensitive for pheo - MHPG \u2014 central NE catabolism marker (low in depression correlating with NE deficiency)</p>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role Effect of Deficiency L-Tyrosine Dopamine (and thus NE/EPI) precursor Reduced catecholamine synthesis under stress Vitamin C (Ascorbate) DBH electron donor (dopamine \u2192 NE) Impaired NE synthesis; fatigue, hypotension Copper (Cu\u00b2\u207a) DBH active site metal Impaired NE synthesis (Menkes disease) Vitamin B6 (PLP) AADC cofactor (L-DOPA \u2192 DA) Reduced dopamine for NE synthesis Iron (Fe\u00b2\u207a) TH cofactor (rate-limiting) Rate-limited synthesis BH4 TH cofactor Collapse of all catecholamine synthesis Folate (5-MTHF) BH4 regeneration + SAM (PNMT) Dual impairment Vitamin B12 SAM maintenance PNMT impaired; catecholamine methylation reduced Riboflavin (B2) FAD for MAO-A; BH4 synthesis Dysregulated catabolism Magnesium COMT function; adrenal regulation Exaggerated catecholamine half-life Pantothenate (B5) Acetyl-CoA \u2192 adrenal steroid synthesis (cortisol induces PNMT) Indirect impairment of EPI Vitamin D Regulates TH and catecholamine pathway gene expression Reduced catecholamine synthesis Zinc AADC activity; adrenal function Indirectly reduces DA substrate"},{"location":"neurotransmitters/norepinephrine_epinephrine/#norepinephrine-reuptake","title":"Norepinephrine Reuptake","text":"<ul> <li>NET (norepinephrine transporter) is the primary reuptake mechanism</li> <li>NET is expressed densely in sympathetic nerve terminals and locus coeruleus neurons</li> <li>In PFC, NET also clears dopamine (low DAT density \u2192 NET is primary dopamine transporter here)</li> <li>SNRIs (venlafaxine, duloxetine) and TCAs block NET \u2192 raised synaptic NE</li> <li>Atomoxetine (ADHD) is a selective NET inhibitor</li> </ul>"},{"location":"neurotransmitters/norepinephrine_epinephrine/#adrenoceptors","title":"Adrenoceptors","text":"Receptor Signalling Location Function \u03b11 Gq \u2192 IP\u2083 Vasculature, iris Vasoconstriction, pupil dilation \u03b12 Gi \u2192 cAMP \u2193 Presynaptic (autoreceptor), PFC Inhibits NE release; PFC attention \u03b21 Gs \u2192 cAMP \u2191 Heart Increased heart rate and contractility \u03b22 Gs \u2192 cAMP \u2191 Bronchioles, skeletal muscle vasculature Bronchodilation, vasodilation \u03b23 Gs Adipocytes Lipolysis"},{"location":"neurotransmitters/norepinephrine_epinephrine/#clinical-relevance","title":"Clinical Relevance","text":"Condition NE/EPI Status Mechanism Depression Low NE (noradrenergic deficiency) Reduced locus coeruleus output; fatigue, anhedonia ADHD Low NE in PFC Impaired \u03b12A-adrenergic signalling \u2192 poor attention PTSD Chronic NE excess Hyperactivated locus coeruleus; amygdala hyperreactivity Pheochromocytoma Massive NE/EPI excess Adrenal tumour; hypertensive crisis Orthostatic hypotension Insufficient NE Impaired vasoconstriction on standing (e.g., DBH deficiency) Heart failure Chronic NE excess Cardiac remodelling; \u03b21 downregulation"},{"location":"neurotransmitters/norepinephrine_epinephrine/#drug-interactions","title":"Drug Interactions","text":"Drug Effect SNRIs (venlafaxine, duloxetine) NET blocker \u2192 increased synaptic NE TCAs (amitriptyline, nortriptyline) NET + SERT blocker Atomoxetine Selective NET inhibitor (ADHD) Guanfacine / Clonidine \u03b12A agonist \u2192 reduced NE release; ADHD/PTSD Propranolol \u03b2-blocker \u2192 reduces cardiovascular NE effects Phentolamine \u03b1-blocker; used in pheo hypertensive crisis Cocaine / Amphetamines NET blocker / reverse transport MAOIs Prevent NE degradation \u2192 excess accumulation Tyramine (cheese effect) Tyramine displaces NE from vesicles; dangerous with MAOIs"},{"location":"neurotransmitters/overview/","title":"Neurotransmitters \u2014 Overview","text":""},{"location":"neurotransmitters/overview/#what-are-neurotransmitters","title":"What Are Neurotransmitters?","text":"<p>Neurotransmitters are endogenous chemical messengers synthesised and released by neurons (and some glial cells) to transmit signals across synapses to target cells. They govern virtually every physiological and psychological function: mood, cognition, sleep, appetite, pain, motor control, and autonomic regulation.</p> <p>Key insight \u2014 Most neurotransmitters are derived from common dietary amino acids. Their synthesis, release, and degradation are tightly regulated by enzymes that critically depend on vitamins, minerals, and cofactors. Nutritional status directly sets the ceiling for neurotransmitter output.</p>"},{"location":"neurotransmitters/overview/#classification-of-neurotransmitters","title":"Classification of Neurotransmitters","text":"Class Examples Primary Precursor Monoamines \u2014 Catecholamines Dopamine, Norepinephrine, Epinephrine L-Tyrosine Monoamines \u2014 Indolamines Serotonin, Melatonin L-Tryptophan Monoamines \u2014 Imidazolamines Histamine L-Histidine Amino Acids (inhibitory) GABA, Glycine Glutamate, Serine Amino Acids (excitatory) Glutamate, Aspartate Glutamine, \u03b1-ketoglutarate Cholinergic Acetylcholine Choline + Acetyl-CoA Opioid Peptides Endorphins, Enkephalins, Dynorphins POMC, Proenkephalin Neuropeptides Substance P, NPY, CRH, Oxytocin Varied protein precursors Gaseous Nitric Oxide (NO), CO, H\u2082S Arginine, Haem, Cysteine"},{"location":"neurotransmitters/overview/#the-synthesisreleasedegradation-cycle","title":"The Synthesis\u2013Release\u2013Degradation Cycle","text":"<p>All neurotransmitters share a common functional lifecycle:</p> <pre><code>Dietary Precursor (amino acid / choline / etc.)\n        \u2502\n        \u25bc [Rate-limiting synthesis step \u2014 enzyme + cofactors]\nNeurotransmitter (stored in vesicles)\n        \u2502\n        \u25bc [Action potential \u2192 vesicle fusion \u2192 exocytosis]\nSynapse (binds post-synaptic receptors)\n        \u2502\n        \u251c\u2500\u25ba Reuptake (transporter proteins \u2014 SERT, DAT, NET, GAT)\n        \u2502          \u2192 recycled or degraded in presynaptic terminal\n        \u2502\n        \u2514\u2500\u25ba Enzymatic Degradation\n                   \u2192 MAO-A, MAO-B, COMT, AChE, GABA-T\n                   \u2192 inactive metabolites \u2192 urine / faeces\n</code></pre>"},{"location":"neurotransmitters/overview/#rate-limiting-enzymes","title":"Rate-Limiting Enzymes","text":"Neurotransmitter Rate-Limiting Enzyme Key Cofactors Serotonin Tryptophan hydroxylase (TPH1/2) Tetrahydrobiopterin (BH4), Fe\u00b2\u207a, O\u2082 Dopamine Tyrosine hydroxylase (TH) BH4, Fe\u00b2\u207a, O\u2082 Norepinephrine Dopamine-\u03b2-hydroxylase (DBH) Vitamin C, Cu\u00b2\u207a, O\u2082 GABA Glutamic acid decarboxylase (GAD) Pyridoxal-5\u2032-phosphate (PLP / B6) Acetylcholine Choline acetyltransferase (ChAT) Acetyl-CoA (B5/pantothenate chain) Histamine Histidine decarboxylase (HDC) Pyridoxal-5\u2032-phosphate (PLP / B6) Melatonin Acetylserotonin methyltransferase (ASMT) SAM (methylation \u2014 requires B12, folate, B2)"},{"location":"neurotransmitters/overview/#shared-cofactors-and-nutrient-dependencies","title":"Shared Cofactors and Nutrient Dependencies","text":"Nutrient Role in Neurotransmitter Metabolism Vitamin B6 (PLP) Essential cofactor for DOPA decarboxylase (serotonin, dopamine, GABA, histamine synthesis) Vitamin B9 (Folate / 5-MTHF) Regenerates BH4; provides methyl groups for catecholamine methylation via SAM Vitamin B12 (methylcobalamin) SAM regeneration; methionine synthase; myelin maintenance Vitamin B3 (Niacin) Tryptophan competes with NAD\u207a synthesis \u2014 deficiency diverts tryptophan away from serotonin Vitamin B5 (Pantothenate) Acetyl-CoA synthesis for acetylcholine production Vitamin C (Ascorbate) DBH cofactor (norepinephrine synthesis); antioxidant protection of BH4 Vitamin D Regulates tyrosine hydroxylase and tryptophan hydroxylase gene expression Iron (Fe\u00b2\u207a) TH and TPH enzyme cofactor; also required for BH4 recycling Zinc Co-factor for DOPA decarboxylase; modulates NMDA receptor; required for MAO activity Magnesium NMDA receptor blocker (prevents excitotoxicity); cofactor for many kinases in signalling Copper (Cu\u00b2\u207a) DBH cofactor (dopamine \u2192 norepinephrine) Tetrahydrobiopterin (BH4) Essential cofactor for TH (dopamine) and TPH (serotonin); regenerated by folate/B12 SAM (S-adenosylmethionine) Methyl donor for COMT (catecholamine inactivation), HNMT (histamine), ASMT (melatonin) Omega-3 fatty acids (DHA) Modulate receptor density (5-HT, D2, NMDA); membrane fluidity for synaptic vesicle release"},{"location":"neurotransmitters/overview/#degradation-pathways-summary","title":"Degradation Pathways Summary","text":"Enzyme Substrates Products Inhibited By MAO-A Serotonin, Norepinephrine, Dopamine 5-HIAA, MHPG, HVA Moclobemide, phenelzine, some SSRIs MAO-B Dopamine, Phenylethylamine, Histamine HVA, imidazole acetaldehyde Selegiline, rasagiline; reversibly by curcumin COMT Dopamine, Norepinephrine, Epinephrine, catechol-oestrogens 3-MT, normetanephrine, metanephrine Entacapone, tolcapone (Parkinson's drugs) AChE Acetylcholine Choline + Acetate Donepezil, galantamine (Alzheimer's drugs) GABA-T GABA Succinic semialdehyde Vigabatrin (anticonvulsant) HNMT Histamine (CNS) N-methylhistamine SKF 91488 (research compound) DAO (diamine oxidase) Histamine (gut/plasma) Imidazole acetaldehyde Alcohol, metformin; B6/copper deficiency"},{"location":"neurotransmitters/overview/#contents-of-this-folder","title":"Contents of This Folder","text":"File Topic <code>serotonin.md</code> Tryptophan \u2192 5-HTP \u2192 serotonin pathway; MAO-A catabolism; cofactors <code>dopamine.md</code> Tyrosine \u2192 L-DOPA \u2192 dopamine; MAO/COMT catabolism; BH4 cycle <code>norepinephrine_epinephrine.md</code> Dopamine \u2192 norepinephrine \u2192 epinephrine; DBH, PNMT; adrenal synthesis <code>gaba.md</code> Glutamate \u2192 GABA (GAD); GABA shunt; GABA-T degradation <code>glutamate.md</code> Glutamine \u2192 glutamate; GS/GDH; glutamate\u2013glutamine cycle; NMDA <code>acetylcholine.md</code> Choline + Acetyl-CoA \u2192 ACh (ChAT); AChE degradation; choline sources <code>histamine.md</code> Histidine \u2192 histamine (HDC); HNMT and DAO degradation pathways <code>melatonin.md</code> Serotonin \u2192 NAS \u2192 melatonin; AANAT, ASMT; light regulation; SAM <code>endorphins_enkephalins.md</code> POMC, proenkephalin precursors; opioid peptide processing; enkephalinase <code>cofactors_summary.md</code> Master reference: all vitamins, minerals, cofactors across all pathways"},{"location":"neurotransmitters/serotonin/","title":"Serotonin (5-Hydroxytryptamine / 5-HT)","text":""},{"location":"neurotransmitters/serotonin/#overview","title":"Overview","text":"<p>Serotonin is a monoamine indolamine neurotransmitter synthesised primarily in the enterochromaffin cells of the gut (~90\u201395%) and in the raphe nuclei of the brainstem (~5\u201310%). Despite most serotonin being peripheral, central serotonin drives mood, cognition, appetite, sleep onset, and pain modulation. Serotonin also serves as the obligate precursor to melatonin.</p> <p>Key insight \u2014 Serotonin cannot cross the blood-brain barrier. Central serotonin is synthesised entirely within the brainstem from dietary tryptophan that enters the CNS. Gut serotonin regulates intestinal motility; it does not influence mood directly.</p>"},{"location":"neurotransmitters/serotonin/#synthesis-pathway","title":"Synthesis Pathway","text":"<pre><code>L-Tryptophan  (dietary essential amino acid)\n      \u2502\n      \u2502 [Tryptophan hydroxylase \u2014 TPH1 (gut/pineal) / TPH2 (brain)]\n      \u2502  Cofactors: Tetrahydrobiopterin (BH4), Fe\u00b2\u207a, O\u2082, NADPH\n      \u2502  \u26a0 Rate-limiting step\n      \u25bc\n5-Hydroxytryptophan (5-HTP)\n      \u2502\n      \u2502 [Aromatic L-amino acid decarboxylase \u2014 AADC / DOPA decarboxylase]\n      \u2502  Cofactor: Pyridoxal-5\u2032-phosphate (PLP / Vitamin B6)\n      \u25bc\nSerotonin (5-HT)\n      \u2502\n      \u251c\u2500\u2500\u25ba Stored in vesicles (with chromogranins)\n      \u2502\n      \u2514\u2500\u2500\u25ba In pinealocytes:\n           \u2502 [AANAT \u2014 arylalkylamine N-acetyltransferase]\n           \u2502  Cofactor: Acetyl-CoA\n           \u25bc\n           N-Acetylserotonin (NAS)\n           \u2502\n           \u2502 [ASMT \u2014 acetylserotonin O-methyltransferase]\n           \u2502  Cofactor: SAM (S-adenosylmethionine)\n           \u25bc\n           Melatonin\n</code></pre>"},{"location":"neurotransmitters/serotonin/#step-by-step-cofactor-requirements","title":"Step-by-Step Cofactor Requirements","text":"Step Enzyme Cofactors / Nutrients Required 1. Tryptophan \u2192 5-HTP Tryptophan hydroxylase (TPH1/TPH2) BH4 (tetrahydrobiopterin), Fe\u00b2\u207a (iron), O\u2082, NADPH 2. 5-HTP \u2192 Serotonin AADC (aromatic amino acid decarboxylase) PLP (Vitamin B6 active form), Zn\u00b2\u207a BH4 regeneration DHFR, DHPR Folate (B9), Vitamin C, NADPH SAM availability (for melatonin) MAT \u2192 MTHFR \u2192 MTR Methionine, Folate (B9), B12, Riboflavin (B2), Mg\u00b2\u207a"},{"location":"neurotransmitters/serotonin/#rate-limiting-step-in-detail-bh4-and-tryptophan-availability","title":"Rate-Limiting Step in Detail: BH4 and Tryptophan Availability","text":"<p>Two factors most commonly limit serotonin synthesis:</p>"},{"location":"neurotransmitters/serotonin/#1-bh4-tetrahydrobiopterin","title":"1. BH4 (Tetrahydrobiopterin)","text":"<ul> <li>BH4 is an essential electron carrier for TPH</li> <li>BH4 is depleted by oxidative stress; regenerated by dihydrobiopterin reductase (DHPR) using NADPH</li> <li>BH4 synthesis requires folate (5-MTHF), B12, and riboflavin (B2) via the methyl cycle</li> <li>Inflammatory cytokines (IL-6, TNF-\u03b1) suppress BH4 synthesis, reducing serotonin</li> </ul>"},{"location":"neurotransmitters/serotonin/#2-tryptophan-competition-the-idokynurenine-pathway","title":"2. Tryptophan Competition \u2014 The IDO/Kynurenine Pathway","text":"<ul> <li>Inflammation activates indoleamine 2,3-dioxygenase (IDO), diverting tryptophan away from serotonin \u2192 toward kynurenine pathway</li> <li>This is a key mechanism linking chronic inflammation \u2192 depression</li> <li>Kynurenine accumulation can itself produce neuroinflammatory quinolinic acid (NMDA agonist)</li> </ul> <pre><code>L-Tryptophan\n     \u251c\u2500\u2500\u25ba TPH pathway \u2192 Serotonin  (brain/gut)\n     \u2514\u2500\u2500\u25ba IDO pathway \u2192 Kynurenine \u2192 NAD\u207a or Quinolinic acid (neurotoxic)\n              \u2191\n        Activated by: LPS, IFN-\u03b3, IL-6, chronic stress\n</code></pre> <p>Niacin (B3) note: Tryptophan is also the precursor to NAD\u207a. In B3 deficiency (pellagra), tryptophan is diverted to niacin synthesis at the expense of serotonin.</p>"},{"location":"neurotransmitters/serotonin/#degradation-pathway","title":"Degradation Pathway","text":"<pre><code>Serotonin (5-HT)\n      \u2502\n      \u2502 [MAO-A \u2014 Monoamine Oxidase A]\n      \u2502  Located: mitochondrial outer membrane (neurons, gut, liver)\n      \u2502  Cofactor: FAD (Riboflavin / Vitamin B2)\n      \u25bc\n5-Hydroxyindoleacetaldehyde\n      \u2502\n      \u2502 [Aldehyde dehydrogenase \u2014 ALDH]\n      \u2502  Cofactor: NAD\u207a (Niacin / Vitamin B3)\n      \u25bc\n5-Hydroxyindoleacetic acid (5-HIAA)\n      \u2502\n      \u25bc\nExcreted in urine\n</code></pre>"},{"location":"neurotransmitters/serotonin/#degradation-key-points","title":"Degradation \u2014 Key Points","text":"Enzyme Location Cofactor Notes MAO-A Neurons, gut enterocytes, liver, placenta FAD (B2) Primary route of serotonin catabolism; inhibited by SSRIs, SNRIs, and MAOIs Aldehyde dehydrogenase Liver, brain NAD\u207a (B3) Minor route; also handles acetaldehyde from alcohol <ul> <li>5-HIAA in urine is the primary biomarker of serotonin turnover (elevated in carcinoid tumour; low in brain serotonin deficiency)</li> <li>Alcohol suppresses MAO-A \u2192 transiently raises serotonin \u2192 then rebounds lower</li> <li>Oestrogen upregulates TPH2 expression and downregulates MAO-A \u2192 explains premenstrual serotonin dynamics</li> </ul>"},{"location":"neurotransmitters/serotonin/#cofactors-and-nutritional-support-summary","title":"Cofactors and Nutritional Support \u2014 Summary","text":"Nutrient Role in Serotonin Metabolism Effect of Deficiency L-Tryptophan Dietary precursor Low serotonin (Trp is essential \u2014 cannot be made) Vitamin B6 (PLP) AADC cofactor (5-HTP \u2192 serotonin) Reduced conversion even with adequate Trp Iron (Fe\u00b2\u207a) TPH cofactor Impaired hydroxylation step; anaemia linked to serotonin dysfunction Tetrahydrobiopterin (BH4) TPH cofactor Severe serotonin deficiency (e.g., PKU, DHPR deficiency) Folate (5-MTHF / B9) BH4 regeneration; SAM for melatonin Reduces serotonin + melatonin; linked to depression Vitamin B12 SAM regeneration (BH4 + melatonin pathway) Downstream serotonin effects; depression risk Riboflavin (B2) FAD for MAO-A; BH4 synthesis Dysregulated degradation; reduced enzyme activity Zinc AADC activity; modulates 5-HT3 receptor Impaired decarboxylation Magnesium 5-HT2 receptor sensitivity; cofactor in SAM cycle Anxiety, sleep issues (serotonin-related) Vitamin C BH4 stabilisation (antioxidant); reduces IDO activation via anti-inflammatory Serotonin synthesis indirectly impaired Vitamin D Upregulates TPH2 in the brain; downregulates TPH1 in gut Low central serotonin in deficiency Omega-3 DHA Maintains 5-HT2A receptor density; modulates IDO indirectly Reduced serotonin signalling efficiency"},{"location":"neurotransmitters/serotonin/#serotonin-reuptake-recycling","title":"Serotonin Reuptake (Recycling)","text":"<p>After release, serotonin is:</p> <ol> <li>Taken back up via SERT (serotonin reuptake transporter) into the presynaptic terminal</li> <li>Repackaged into vesicles (by VMAT2) for re-release, OR</li> <li>Degraded by MAO-A in the mitochondria</li> </ol> <p>SSRIs (selective serotonin reuptake inhibitors) block the SERT transporter, increasing synaptic serotonin concentration. They do not increase serotonin synthesis \u2014 nutritional precursor support (tryptophan, B6, iron) is still necessary for efficacy.</p>"},{"location":"neurotransmitters/serotonin/#serotonin-receptors","title":"Serotonin Receptors","text":"Receptor Family Type Key Functions 5-HT1 (A, B, D, F) Gi-coupled (inhibitory) Autoreceptors; migraine; anxiety 5-HT2 (A, B, C) Gq-coupled (excitatory) Mood, cognition, appetite, psychedelics 5-HT3 Ion channel Nausea/vomiting (gut); anxiety 5-HT4 Gs-coupled Gut motility; memory 5-HT6 Gs-coupled Cognition; antipsychotic target 5-HT7 Gs-coupled Circadian rhythm; depression"},{"location":"neurotransmitters/serotonin/#clinical-relevance","title":"Clinical Relevance","text":"Condition Serotonin Status Key Mechanism Depression Low central 5-HT Reduced TPH activity, IDO activation, B6/folate deficiency Anxiety Variable (often low 5-HT1A tone) Reduced autoreceptor inhibition IBS Dysregulated gut 5-HT Altered enterochromaffin cell signalling Carcinoid tumour Dramatically elevated (peripheral) Tumour-secreted 5-HT \u2192 flushing, diarrhoea Serotonin syndrome Excessive (iatrogenic) MAOIs + SSRIs + tryptophan \u2192 hyperthermia, clonus, agitation Premenstrual dysphoria Cyclic low 5-HT Oestrogen/progesterone modulate MAO-A and 5-HT2A"},{"location":"neurotransmitters/serotonin/#drug-interactions","title":"Drug Interactions","text":"Drug Effect on Serotonin Pathway SSRIs (fluoxetine, sertraline) Block SERT reuptake \u2014 raise synaptic 5-HT SNRIs (venlafaxine) Block SERT + NET MAOIs (phenelzine) Inhibit MAO-A \u2192 prevent serotonin degradation Triptans (sumatriptan) 5-HT1B/1D agonists \u2014 vasoconstriction; migraine relief Ondansetron 5-HT3 antagonist \u2014 antiemetic LSD, Psilocybin 5-HT2A partial agonists Tramadol Weak SERT inhibitor + \u03bc-opioid agonist \u2014 serotonin syndrome risk Methylene blue MAO inhibitor at high doses \u2014 serotonin syndrome risk St John's Wort Weak SERT inhibitor (hyperforin); interactions with SSRIs"},{"location":"performance/beta_alanine/","title":"Beta-Alanine","text":""},{"location":"performance/beta_alanine/#overview","title":"Overview","text":"<p>Beta-alanine (\u03b2-alanine) is a non-proteinogenic \u03b2-amino acid \u2014 meaning it is not used in protein synthesis \u2014 produced endogenously in the liver from the catabolism of carnosine, anserine, and \u03b2-aminoisobutyrate. It is the rate-limiting precursor for the synthesis of carnosine (\u03b2-alanyl-L-histidine) in skeletal muscle. Carnosine acts as an intramuscular pH buffer, hydrogen ion sink, and ROS scavenger, and is directly responsible for \u03b2-alanine's ergogenic effects. Beta-alanine is consistently recognised as one of the few sports supplements with a credible evidence base, particularly for sustained high-intensity exercise lasting 1\u201310 minutes.</p> <ul> <li>Molecular formula: C\u2083H\u2087NO\u2082 (MW = 89.09 g/mol)</li> <li>Endogenous synthesis: Small amount from pyrimidine catabolism (uracil \u2192 dihydrouracil \u2192 \u03b2-alanine) and from microbial fermentation in the gut</li> <li>Rate-limiting step: Carnosine synthase (CARNS1) condenses \u03b2-alanine + L-histidine \u2192 carnosine in muscle; \u03b2-alanine supply is the limiting factor (histidine is abundant)</li> <li>Muscle carnosine: Type II (fast-twitch) fibres have 2\u00d7 higher carnosine than type I; men typically have 30\u201340% higher carnosine than women; sprint athletes have higher levels than endurance athletes</li> </ul>"},{"location":"performance/beta_alanine/#mechanism-of-action","title":"Mechanism of Action","text":""},{"location":"performance/beta_alanine/#carnosine-as-ph-buffer","title":"Carnosine as pH Buffer","text":"<ul> <li>During intense exercise, anaerobic glycolysis produces H\u207a (lactic acid dissociates to lactate\u207b + H\u207a); intracellular pH drops from ~7.1 to ~6.6 at fatigue</li> <li>Muscle acidosis inhibits phosphofructokinase (PFK), actin-myosin cross-bridge cycling, and Ca\u00b2\u207a sensitivity of troponin \u2192 force production decreases</li> <li>Carnosine has a pKa of ~6.83 \u2014 optimally positioned to buffer H\u207a in the physiological exercise pH range</li> <li>At typical carnosine concentrations (20\u201340 mmol/kg dw), carnosine contributes ~7\u201316% of total intramuscular buffering capacity</li> </ul>"},{"location":"performance/beta_alanine/#additional-roles-of-carnosine","title":"Additional Roles of Carnosine","text":"Role Details Anti-glycation Carnosine reacts with reactive carbonyl species (methylglyoxal, acrolein) \u2192 prevents AGE (advanced glycation end product) formation \u2192 anti-senescent; lens carnosine (N-acetylcarnosine eye drops \u2014 cataracts) Ca\u00b2\u207a sensitivity Carnosine increases myofibrillar Ca\u00b2\u207a sensitivity at acidic pH \u2192 partially counteracts acidosis-induced desensitisation Zinc chelation Carnosine chelates Zn\u00b2\u207a \u2192 zinc-carnosine complex (polaprezinc) used clinically for gastric ulcer treatment and gut inflammation Antioxidant Scavenges ROS (\u2022OH, HOCl, \u00b9O\u2082) in vitro; in vivo significance debated"},{"location":"performance/beta_alanine/#ergogenic-evidence","title":"Ergogenic Evidence","text":"Exercise Type Effect Duration Showing Benefit High-intensity cycling Increased time-to-exhaustion, higher peak power 1\u201310 min Repeated sprint ability Reduced sprint time decay across multiple bouts 30 s\u20134 min bouts Swimming Improved 200 m time performance ~2 min Rowing Improved 2000 m time (\u22486.5 min) Sustained HIIT efforts Strength training (volume) Small increase in total volume-load at high rep ranges (15\u201325 rep sets) Moderate intensity, high reps &lt; 60-second efforts Minimal benefit (PCr/ATP system dominates before carnosine buffering relevant) Insufficient duration Endurance (&gt; 25 min) No significant benefit (aerobic metabolism; pH largely maintained) Not indicated <p>Meta-analysis (Hobson et al., 2012; Saunders et al., 2017): \u03b2-alanine supplementation increases muscle carnosine by 40\u201380% over 4 weeks; ergogenic effects are small-to-moderate for exercises of 1\u201310 minutes (SMD \u2248 0.18\u20130.35).</p>"},{"location":"performance/beta_alanine/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Well absorbed from small intestine via beta-amino acid transporter (PAT1, SLC36A1) Peak plasma 30\u201360 minutes post-dose Muscle uptake SLC6A6 (taurine transporter) imports \u03b2-alanine into muscle; rate-limited by transporter kinetics Loading duration Minimum 4 weeks for significant carnosine elevation; 10\u201312 weeks for maximum (+80%) Washout Carnosine returns to baseline over ~15 weeks after stopping; washout slower than loading Dose\u2013response 3.2 g/day vs. 6.4 g/day: both elevate carnosine; higher dose elevates faster but equal final levels at 24 weeks Paresthesia (tingling) Most common side effect \u2014 dose-dependent peripheral tingling (face, hands, extremities) caused by \u03b2-alanine binding MRGPRD receptors on cutaneous sensory neurons; harmless but bothersome"},{"location":"performance/beta_alanine/#managing-paresthesia","title":"Managing Paresthesia","text":"<ul> <li>Use sustained-release (SR) formulations \u2014 most effective approach; reduces peak plasma levels \u2192 eliminates or greatly reduces tingling</li> <li>Split dosing (4 \u00d7 0.8 g throughout day) achieves similar result</li> <li>No health risk from paresthesia; fully resolves within 60\u201390 minutes</li> </ul>"},{"location":"performance/beta_alanine/#dietary-sources","title":"Dietary Sources","text":"Source \u03b2-Alanine Content Chicken breast (cooked) ~350 mg/100 g (from carnosine hydrolysis in cooked meat) Beef (lean) ~300 mg/100 g Pork ~250 mg/100 g Tuna ~200 mg/100 g Vegetables / plant foods Negligible <p>Note: Dietary carnosine (from meat) is hydrolysed in the GI tract to \u03b2-alanine + histidine \u2192 \u03b2-alanine absorbed and remade into carnosine in muscle. Vegetarians have significantly lower muscle carnosine (~20\u201330% lower) and respond better to supplementation.</p>"},{"location":"performance/beta_alanine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"performance/beta_alanine/#exercise-capacity-in-elderly","title":"Exercise Capacity in Elderly","text":"<ul> <li>Older adults have ~30\u201340% lower muscle carnosine than young adults; associated with reduced buffering capacity and exercise tolerance</li> <li>\u03b2-Alanine (3.2 g/day \u00d7 12 weeks) increases carnosine and improves exercise performance in adults &gt;55 years (ISSN recommendation)</li> </ul>"},{"location":"performance/beta_alanine/#type-2-diabetes-insulin-resistance","title":"Type 2 Diabetes / Insulin Resistance","text":"<ul> <li>Carnosine has anti-glycation and anti-AGE properties \u2014 preliminary human data show reduced HbA1c with carnosine supplementation; \u03b2-alanine as precursor under investigation</li> <li>Polaprezinc (Zn-carnosine) improves gut permeability in T2DM patients</li> </ul>"},{"location":"performance/beta_alanine/#psychiatric-conditions","title":"Psychiatric Conditions","text":"<ul> <li>Carnosine as dipeptide crosses the BBB; zinc-carnosine combinations studied in autism (carnosine supplementation improved autism severity scales in pilot RCT, Sokol et al., 2001) \u2014 results not convincingly replicated</li> </ul>"},{"location":"performance/beta_alanine/#interactions","title":"Interactions","text":"Factor Interaction Creatine Complementary, not competing; creatine targets PCr system (0\u201315 s); \u03b2-alanine targets H\u207a buffering (1\u201310 min); commonly combined in pre-workout formulations Histidine High histidine intake does not further increase carnosine (\u03b2-alanine is rate-limiting, not histidine, in normal diet); excess histidine can even competitively inhibit CARNS1 Taurine Both \u03b2-alanine and taurine use SLC6A6 for transport; very high \u03b2-alanine supplementation may reduce taurine uptake into tissues; clinical significance unknown at typical supplement doses Training volume Training increases carnosine synthesis and turnover; trained athletes have higher baseline carnosine and greater response rate to supplementation"},{"location":"performance/beta_alanine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dose: 3.2\u20136.4 g/day; sustained-release preferred; 4 weeks minimum, 10\u201312 weeks for full effect</li> <li>Form: Sustained-release tablets (e.g., CarnoSyn SR) best for paresthesia management; powder in split doses acceptable</li> <li>Timing: Not time-sensitive; any time of day; taking with food reduces GI discomfort</li> <li>Combination: Often combined with creatine monohydrate \u2014 complementary energy system coverage; creatine + \u03b2-alanine RCTs show additive lean mass and performance benefits (Hoffman et al., 2006)</li> <li>Who benefits most: Athletes competing in 1\u201310 minute events (800 m\u20133 km running, 100\u2013400 m swimming, cycling time trials, wrestling, rowing); team sport athletes with repeated high-intensity bouts</li> <li>Safety: No adverse effects beyond paresthesia; no long-term safety concerns identified; WADA-permitted</li> </ul>"},{"location":"performance/caffeine/","title":"Caffeine","text":""},{"location":"performance/caffeine/#overview","title":"Overview","text":"<p>Caffeine (1,3,7-trimethylxanthine) is the world's most widely consumed psychoactive substance and one of the most rigorously studied ergogenic aids in sports nutrition. It is a naturally occurring methylxanthine alkaloid found in coffee, tea, cocoa, guaran\u00e1, and yerba mat\u00e9. Caffeine acts primarily as a competitive antagonist of adenosine receptors (A\u2081 and A\u2082A subtypes) in the CNS and peripheral tissues, blunting adenosine's inhibitory/fatigue-promoting effects. It is effective across virtually all exercise modalities \u2014 endurance, strength, power, team sports \u2014 and remains one of the only legal ergogenic aids with performance benefits across a broad dose range (3\u20136 mg/kg).</p> <ul> <li>Molecular formula: C\u2088H\u2081\u2080N\u2084O\u2082 (MW = 194.19 g/mol)</li> <li>Classification: Methylxanthine; mild CNS stimulant; A\u2081/A\u2082A adenosine receptor antagonist</li> <li>Natural sources: Coffee, tea, cocoa, guaran\u00e1 seeds, yerba mat\u00e9, kola nuts</li> <li>Regulatory status: Removed from WADA prohibited list in 2004 (previously banned at &gt;12 \u03bcg/mL urinary); currently WADA-permitted but on monitoring program; legal worldwide</li> </ul>"},{"location":"performance/caffeine/#mechanisms-of-action","title":"Mechanisms of Action","text":"Mechanism Details Adenosine receptor antagonism Adenosine accumulates during exercise \u2192 binds A\u2081 (inhibits cAMP \u2192 reduces alertness, increases sleep drive) and A\u2082A receptors \u2192 fatigue, sedation; caffeine blocks both non-competitively \u2192 increases neuronal firing, reduces pain perception (RPE), promotes wakefulness Catecholamine release A\u2081 antagonism in sympathetic ganglia \u2192 enhanced epinephrine and norepinephrine release \u2192 increased heart rate, cardiac output, lipolysis, glycogenolysis Phosphodiesterase inhibition At high concentrations (&gt;100 \u03bcmol/L, well above typical supplementation), inhibits PDE \u2192 prevents cAMP degradation \u2192 amplified cAMP signalling; minor contribution at normal doses Ryanodine receptor sensitisation Caffeine sensitises RyR1/RyR2 \u2192 enhanced Ca\u00b2\u207a release from SR \u2192 increased myofibrillar Ca\u00b2\u207a availability \u2192 enhanced muscle force production (seen in isolated muscle; less certain in vivo) Fat oxidation Epinephrine-mediated activation of HSL (hormone-sensitive lipase) \u2192 increased FFA mobilisation \u2192 spares muscle glycogen (particularly at moderate intensities); most relevant in fasted state Pain/RPE reduction Central A\u2081 antagonism in pain circuits \u2192 reduced ratings of perceived exertion \u2192 athletes can sustain higher intensities subjectively; \u03bc-opioid pathway interaction"},{"location":"performance/caffeine/#ergogenic-evidence","title":"Ergogenic Evidence","text":"Performance Domain Effect Effect Size Endurance (cycling, running TT) ~2\u20134% improvement in time trial performance Moderate (SMD ~0.4) Muscular strength (1-RM) ~1\u20133% increase in 1-RM strength Small Muscular endurance (reps to failure) ~10\u201320% more reps at submaximal loads Moderate Sprint power ~3\u20135% increase in peak power output Moderate Team sport performance Improved sprint speed, jumping, skill accuracy under fatigue Moderate Cognitive performance Significant improvement in sustained attention, reaction time, vigilance \u2014 most robust effect Large Grip strength Small but significant increases Small Sleep deprivation compensation Largely restores cognitive and physical performance lost to 24h sleep deprivation Large <p>Meta-analysis (Grgic et al., 2019; Southward et al., 2018): Effect size for endurance performance: ES = 0.40 (95% CI 0.26\u20130.55); strongest effects in aerobic events lasting 5\u201360 minutes.</p>"},{"location":"performance/caffeine/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Rapidly absorbed from GI tract; F \u2248 99%; peak plasma at 30\u201360 min (tablets/powder); energy drinks 45\u201360 min Half-life 3\u20135 hours (adults); highly variable \u2014 CYP1A2 rapid metabolisers (smokers, CYP1A2*1F AA) clear caffeine ~2\u00d7 faster; slow metabolisers (CY1A2 AC or CC) clear more slowly Distribution V_d \u2248 0.6 L/kg; crosses BBB and placenta; ~25\u201336% plasma protein bound Metabolism Hepatic CYP1A2 \u2192 paraxanthine (84%, active), theobromine (12%), theophylline (4%) Elimination Renal; caffeine found in urine at detectable levels 10+ hours after ingestion Habitual consumption Adenosine receptor upregulation with chronic caffeine use \u2192 tolerance of stimulant and ergogenic effects; acute abstinence (3\u20134 day washout) before competition maximises ergogenic response"},{"location":"performance/caffeine/#dietary-sources","title":"Dietary Sources","text":"Source Caffeine Content Espresso (30 mL) 60\u2013120 mg Drip coffee (240 mL) 70\u2013140 mg Black tea (240 mL) 30\u201360 mg Green tea (240 mL) 20\u201350 mg Energy drink (250 mL) 80\u2013150 mg Pre-workout supplement 150\u2013400 mg per serving Dark chocolate (30 g) 20\u201330 mg Guaran\u00e1 supplement Variable; ~40\u201380 mg per capsule Caffeine anhydrous tablet (200 mg) Most precise and rapidly absorbed form"},{"location":"performance/caffeine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"performance/caffeine/#cyp1a2-pharmacogenomics-and-cardiovascular-risk","title":"CYP1A2 Pharmacogenomics and Cardiovascular Risk","text":"<ul> <li>NEJM 2006 (Cornelis et al.): CYP1A2 slow metabolisers (AC/CC) homozygous \u2192 slower caffeine clearance \u2192 elevated plasma levels \u2192 increased MI risk with &gt;4 cups/day coffee; fast metabolisers (AA) showed no increased risk and even reduced MI risk at moderate intake</li> <li>Clinical importance: Genetic testing for CYP1A2 alleles may personalise caffeine recommendations for high-risk cardiac patients and athletes</li> </ul>"},{"location":"performance/caffeine/#anxiogenic-effects","title":"Anxiogenic Effects","text":"<ul> <li>Caffeine increases amygdala activity and sympathetic arousal; at doses &gt;400 mg, can precipitate or worsen generalized anxiety disorder (GAD), panic attacks, and tachyarrhythmias in susceptible individuals</li> <li>Vulnerability increased with ADORA2A (adenosine A\u2082A receptor) genetic variants (affecting anxiogenic response)</li> </ul>"},{"location":"performance/caffeine/#bone-mineral-density","title":"Bone Mineral Density","text":"<ul> <li>Very high caffeine intake (&gt;800 mg/day) associated with marginally reduced calcium absorption (~5 mg Ca per 150 mg caffeine); compensated by adequate calcium intake; not clinically significant at normal intake</li> </ul>"},{"location":"performance/caffeine/#pregnancy","title":"Pregnancy","text":"<ul> <li>Current guidelines: limit to &lt;200 mg/day during pregnancy (WHO, ACOG); caffeine crosses placenta; fetal CYP1A2 absent \u2192 accumulates; associated with low birth weight at high intake</li> </ul>"},{"location":"performance/caffeine/#interactions","title":"Interactions","text":"Factor Interaction Creatine No confirmed antagonism; early concern based on one study not replicated; safe to combine Beta-alanine No pharmacokinetic interaction; often combined in pre-workout (different mechanisms, complementary) Alcohol Caffeine masks alcohol's sedative effects but does not reduce impairment of psychomotor skills \u2192 false sense of sobriety \u2192 dangerous combination Adenosine agonists (adenosine infusion, regadenoson) Caffeine blocks adenosine cardiac vasodilation during myocardial perfusion imaging \u2192 false negative stress test; must stop caffeine 12\u201324 h before Oral contraceptives / fluvoxamine CYP1A2 inhibition \u2192 elevated caffeine levels \u2192 increased side effects; consider dose reduction Fluoroquinolone antibiotics (ciprofloxacin) CYP1A2 inhibitor \u2192 significantly raises caffeine plasma levels \u2014 caution with concurrent use Nicotine CYP1A2 inducer; smokers metabolise caffeine ~2\u00d7 faster \u2192 lower plasma levels per dose"},{"location":"performance/caffeine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Optimal dose: 3\u20136 mg/kg body weight (typically 200\u2013400 mg); doses above 9 mg/kg produce no additional ergogenic benefit but significantly more side effects</li> <li>Timing: Consume 45\u201360 minutes before exercise to align peak plasma level with effort; some ultra-endurance athletes use caffeine later in events (mid-race supplementation) to offset central fatigue</li> <li>Tolerance management: Cycle caffeine; use 3\u20135 day washout before key competitions to maximise effect; avoid daily supplemental doses if competition performance is the goal</li> <li>Form: Caffeine anhydrous (tablet/capsule/powder) = most consistent and reliable pharmacokinetics; coffee is effective but variable; energy drinks are effective but often contain other ingredients</li> <li>Sensitive individuals: Start with 100 mg to assess tolerance; avoid within 8 hours of sleep (half-life 5h \u2192 10% remains at 16h)</li> <li>Rhabdomyolysis risk: Rare but documented cases with very high-dose caffeine powder ingestion (&gt;5 g) \u2014 avoid bulk caffeine powder (tablespoon = potentially lethal dose); use pre-measured capsules</li> </ul>"},{"location":"performance/creatine/","title":"Creatine","text":""},{"location":"performance/creatine/#overview","title":"Overview","text":"<p>Creatine is a naturally occurring nitrogenous compound synthesised endogenously in the liver and kidneys from the amino acids arginine, glycine, and methionine (~1 g/day). It is also obtained from dietary meat and fish (~1\u20132 g/day from an omnivorous diet). As creatine phosphate (phosphocreatine, PCr), it serves as the primary high-energy phosphate buffer in muscle cells, rapidly regenerating ATP during high-intensity, short-duration efforts. Creatine is the most researched and evidence-backed performance supplement in sports nutrition, with a 30+ year safety record and hundreds of RCTs.</p> <ul> <li>Molecular formula: C\u2084H\u2089N\u2083O\u2082 (MW = 131.13 g/mol)</li> <li>Endogenous synthesis: Arg + Gly \u2192 guanidinoacetate (kidney) + Met \u2192 creatine (liver); rate-limited by AGAT enzyme</li> <li>Storage: ~95% in skeletal muscle (60\u201370% as PCr); ~5% in brain, heart, testes; total body pool \u2248 120 g (70 kg male); replenished ~2 g/day</li> <li>Half-life: Creatine t\u00bd in blood \u2248 3 hours; muscle creatine stores turnover ~1\u20132% per day (\u2192 creatinine excreted via kidneys)</li> </ul>"},{"location":"performance/creatine/#functions","title":"Functions","text":"Function Details ATP regeneration (PCr system) PCr + ADP \u2192 Cr + ATP (catalysed by creatine kinase, CK); provides immediate ATP during the first 5\u201315 seconds of maximal effort; dominates the ATP-PCr energy system Intracellular pH buffering Anaerobic PCr hydrolysis consumes H\u207a \u2192 buffers acidosis during high-intensity exercise \u2192 delays fatigue Satellite cell activation Creatine supplementation increases IGF-1 expression and Akt phosphorylation \u2192 promotes satellite cell differentiation \u2192 enhanced muscle hypertrophy signalling Myosin heavy chain isoform Shifts myosin heavy chain (MHC) expression toward type IIa fibres post-loading \u2192 power-oriented muscle remodelling Brain creatine Phosphocreatine serves a cognitive reserve function in the brain; supplementation raises brain [Cr] ~8% (MRS studies); neuroprotective in TBI, hypoxia, epilepsy animal models Osmoprotective Creatine is an osmolyte; cellular uptake increases intracellular water \u2192 increased cell volume \u2192 anabolic signalling (mTOR, MAP kinase)"},{"location":"performance/creatine/#ergogenic-evidence","title":"Ergogenic Evidence","text":"Performance Type Effect Effect Size Maximal sprint power ~5\u201315% increase in peak power output (Wingate test) Large Strength (1-RM squat, bench) ~5\u201315% increase in 1-RM over 4\u20138 weeks combined with resistance training Large Resistance training volume ~15\u201325% more total reps per set before fatigue Large Hypertrophy ~0.3\u20132 kg extra lean mass gain vs. placebo over 4\u201312 weeks (meta-analysis, Lanhers 2017) Moderate High-intensity interval bouts Improved performance in repeated 10\u201330 second efforts; attenuates fatigue across bouts Moderate Endurance Minimal direct effect; potential indirect benefit through enhanced training volume Small/None Cognitive function Beneficial in sleep-deprived or cognitively fatigued states; task-specific (Rawson &amp; Venezia, 2011) Small-Moderate"},{"location":"performance/creatine/#pharmacokinetics-and-loading","title":"Pharmacokinetics and Loading","text":"Parameter Details Absorption Rapidly absorbed from small intestine via SLC6A8 (sodium/chloride-dependent creatine transporter) Loading phase 20 g/day (4 \u00d7 5 g doses) \u00d7 5\u20137 days \u2192 saturates muscle stores (~20% increase) to ~160 mmol/kg dw; then maintain with 3\u20135 g/day Maintenance without loading 3\u20135 g/day \u2192 reaches same muscle saturation after ~28 days; preferred for GI tolerance Washout time ~4\u20136 weeks after cessation to return to baseline muscle Cr levels Creatine monohydrate Gold standard form; ~88% creatine by weight; most studied; cheapest; bioavailability ~99% Response variability ~25\u201330% of users are \"non-responders\" (already near-maximal muscle Cr saturation from diet; often higher baseline Cr levels, more type I muscle fibres)"},{"location":"performance/creatine/#dietary-sources","title":"Dietary Sources","text":"Source Creatine Content Raw beef ~4\u20135 g/kg Raw pork ~3\u20134 g/kg Herring ~6\u201310 g/kg (highest natural source) Salmon ~4.5 g/kg Tuna ~4 g/kg Cod ~3 g/kg Vegetarians/vegans Essentially no dietary creatine \u2192 lower baseline muscle Cr \u2192 larger ergogenic response to supplementation <p>Note: Cooking denatures creatine \u2192 cooked meat contains creatine + creatinine; dietary intake from normal servings = ~1\u20132 g/day in meat-eaters.</p>"},{"location":"performance/creatine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"performance/creatine/#muscular-dystrophy-and-neuromuscular-disease","title":"Muscular Dystrophy and Neuromuscular Disease","text":"<ul> <li>Cochrane review: creatine supplementation increases strength and reduces fatigue in Duchenne MD, Becker MD, and other muscular dystrophies; modest but consistent benefit</li> <li>Mechanism: PCr supplementation bypasses impaired muscle energy metabolism</li> </ul>"},{"location":"performance/creatine/#creatine-transporter-deficiency-ctd","title":"Creatine Transporter Deficiency (CTD)","text":"<ul> <li>X-linked disorder (SLC6A8 mutation) \u2192 no creatine in brain \u2192 severe intellectual disability, autism-like features, seizures</li> <li>Treatment: creatine arginine glycoside and cyclocreatine analogues under investigation; dietary creatine ineffective due to transport defect</li> </ul>"},{"location":"performance/creatine/#traumatic-brain-injury-tbi","title":"Traumatic Brain Injury (TBI)","text":"<ul> <li>Pre-treatment with creatine reduces severity of TBI outcomes in children (RCT series from Ames, Italy); post-TBI use also under investigation</li> </ul>"},{"location":"performance/creatine/#sarcopenia-and-elderly-populations","title":"Sarcopenia and Elderly Populations","text":"<ul> <li>Creatine + resistance training most evidence-backed combination for improving strength and lean mass in adults &gt;70 years; recommended by International Society of Sports Nutrition (ISSN)</li> </ul>"},{"location":"performance/creatine/#interactions","title":"Interactions","text":"Factor Interaction Carbohydrates Co-ingestion with CHO (~70\u2013100 g) increases insulin \u2192 enhances muscle creatine uptake by ~60%; practically: take with fruit juice or high-GI meal Caffeine Early studies suggested antagonism of creatine's ergogenic effects; more recent data do not confirm this interaction; combined use appears safe NSAIDs Both creatine and NSAIDs cleared by kidney; theoretical but unconfirmed concern for renal load; creatine alone does not impair renal function in healthy individuals Metformin Metformin inhibits CK indirectly; theoretical interaction; not clinically established Creatinine (serum biomarker) Supplementation raises serum creatinine (breakdown product of creatine) \u2192 can falsely suggest reduced GFR; eGFR equations (MDRD, CKD-EPI) assume normal creatinine baseline \u2014 creatine users should inform physician"},{"location":"performance/creatine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Form: Creatine monohydrate is preferred \u2014 most studied, cheapest, most effective; no credible evidence that creatine ethyl ester, buffered creatine, or creatine HCl is superior</li> <li>Dose: 3\u20135 g/day (maintenance); loading protocol only shortens time-to-saturation, not final effect</li> <li>Timing: Post-workout may have marginal advantage (Cribb &amp; Hayes, 2006) but total daily dose is more important than timing</li> <li>Hydration: Increase water intake ~500 mL/day during loading phase (osmotic water retention in muscle)</li> <li>Safety: No adverse effects in healthy individuals at 3\u20135 g/day for up to 5 years (extensive safety data); only concern is in pre-existing renal disease (avoid or use with monitoring)</li> <li>Vegans: Higher response expected; even more beneficial to supplement given zero dietary intake</li> <li>Regulatory status: Not a controlled substance; legal in all sports; WADA-permitted; sold OTC worldwide</li> </ul>"},{"location":"performance/l_carnitine/","title":"L-Carnitine","text":""},{"location":"performance/l_carnitine/#overview","title":"Overview","text":"<p>L-Carnitine is a naturally occurring amino acid derivative synthesised endogenously in the liver and kidneys predominantly from lysine and methionine, with ascorbate (Vitamin C), niacin (Vitamin B3), pyridoxine (Vitamin B6), and iron as essential cofactors. Its primary biological role is the transport of long-chain fatty acids (LCFA) across the inner mitochondrial membrane for \u03b2-oxidation \u2014 an essential step because LCFA cannot cross this membrane freely. Approximately 95\u201398% of body carnitine is found in skeletal and cardiac muscle. While carnitine occupies a central role in fat metabolism, evidence for ergogenic effects in athletes with normal carnitine status is considerably more nuanced than its popularity suggests.</p> <ul> <li>Molecular formula: C\u2087H\u2081\u2085NO\u2083 (MW = 161.20 g/mol)</li> <li>Classification: Amino acid derivative / conditionally essential nutrient (essential in preterm neonates, and conditionally in certain metabolic disorders)</li> <li>Endogenous synthesis rate: ~1.2 \u03bcmol/kg/day; adequate in healthy adults; dependent on adequate lysine, methionine, Fe, ascorbate, niacin, B6</li> <li>Body pool: ~25 g (70 kg male); 97\u201398% in skeletal muscle (&gt;3000:1 concentration ratio muscle:plasma)</li> <li>Forms: Free carnitine (FC) + acylcarnitines; short, medium, and long-chain acylcarnitines serve as metabolite buffers and overflow valves</li> </ul>"},{"location":"performance/l_carnitine/#functions","title":"Functions","text":"Function Details Long-chain fatty acid transport Carnitine palmitoyltransferase I (CPT-I, outer membrane) + translocase + CPT-II (inner membrane): converts LCFA-CoA \u2192 acylcarnitine \u2192 transports across inner mitochondrial membrane \u2192 regenerates LCFA-CoA inside for \u03b2-oxidation Acetyl-CoA buffering Acetylcarnitine transfers acetyl groups out of mitochondria \u2192 free CoA recycled \u2192 maintains mitochondrial CoA availability during high metabolic rate; \"CoA sink\" hypothesis Reducing acylcarnitine overflow When \u03b2-oxidation is overwhelmed (T2DM, VLCAD deficiency), acylcarnitines accumulate \u2192 carnitine supplementation buffers excess acyl groups \u2192 reduces toxic accumulation Modulates glucose oxidation By controlling acetyl-CoA flux and PDC activity via acetylcarnitine, carnitine affects the balance of fat vs. glucose oxidation Antioxidant role Acetyl-L-carnitine (ALCAR) specifically: reduces mitochondrial ROS production, maintains electron transport chain efficiency, reduces lipid peroxidation in ageing neurons"},{"location":"performance/l_carnitine/#forms-of-carnitine","title":"Forms of Carnitine","text":"Form Key Uses / Properties L-Carnitine tartrate Preferred for exercise performance; fast absorption; most studied athletic form Acetyl-L-carnitine (ALCAR) Crosses BBB; primarily used for cognitive function, neuroprotection, peripheral neuropathy; acetyl group donated to acetylcholine synthesis Propionyl-L-carnitine (PLC) Studied in peripheral artery disease and heart failure; improves exercise tolerance in cardiovascular disease L-Carnitine L-tartrate (LCLT) Reduces exercise-induced muscle damage markers; preferred in acute exercise damage protocols Glycine propionyl-L-carnitine (GPLC) Increases nitric oxide bioavailability \u2192 potential vasodilatory effect; emerging data in intermittent claudication"},{"location":"performance/l_carnitine/#ergogenic-evidence","title":"Ergogenic Evidence","text":"Performance Outcome Effect Evidence Quality Fat oxidation (trained athletes) No significant increase at physiological oral doses without insulin manipulation; muscle carnitine does not increase with standard oral supplementation alone Well-established Fat oxidation (with insulin) Wall et al., 2011 (JPhysiol): 24 weeks of L-carnitine + CHO (80 g insulin spike before dose) \u2192 ~21% increase in muscle carnitine \u2192 significantly spared glycogen and reduced lactate at submaximal exercise Strong (mechanistic RCT) Exercise capacity in PAD Propionyl-L-carnitine: Cochrane review confirms improved walking performance in peripheral artery disease Moderate Heart failure exercise tolerance Carnitine reduces symptoms and improves VO\u2082max in heart failure patients Moderate Muscle damage/recovery LCLT (2 g/day): reduces exercise-induced DOMS, plasma myoglobin, creatine kinase, and MDA in multiple RCTs Moderate Weight loss/body composition Modest evidence; meta-analysis (Pooyandjoo et al., 2016): \u22121.33 kg body weight vs. placebo; effect strongest with concomitant caloric restriction Small Healthy athletes fat oxidation No meaningful effect at oral doses without insulin co-ingestion Well established (null)"},{"location":"performance/l_carnitine/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Oral bioavailability ~14\u201318% in omnivores (extensive colonic microbial competition and degradation); ~68\u201386% in vegans (gut microbiome less adapted to carnitine metabolism, less TMAO production) TMAO production Colonic bacteria (Acinetobacter, Pseudomonas) convert carnitine \u2192 TMA \u2192 hepatic FMO3 \u2192 trimethylamine N-oxide (TMAO); elevated TMAO associated with increased CVD risk in some epidemiological studies (Hall et al.); causality debated Absorption route Active transport via OCTN2 (SLC22A5) transporter in small intestine IV vs. oral IV carnitine achieves rapid plasma elevation; oral doses primarily raise plasma, not muscle, unless combined with insulin elevation Insulin dependency for muscle uptake OCTN2 in muscle is insulin-sensitive \u2192 chronic hyperinsulinaemia needed for prolonged muscle carnitine accumulation (explains Wall et al. protocol)"},{"location":"performance/l_carnitine/#dietary-sources","title":"Dietary Sources","text":"Source L-Carnitine Content Beef steak (raw, 100 g) 56\u2013162 mg Pork (cooked, 85 g) 24\u201335 mg Chicken breast (85 g) 3\u20135 mg Whole milk (240 mL) 8 mg Cod fish (85 g) 4\u20137 mg Avocado (100 g) 2 mg Plant foods generally &lt;1 mg \u2014 vegans have 50\u201370% lower plasma carnitine than omnivores"},{"location":"performance/l_carnitine/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"performance/l_carnitine/#primary-carnitine-deficiency-pcd","title":"Primary Carnitine Deficiency (PCD)","text":"<ul> <li>Autosomal recessive OCTN2 loss-of-function mutation (SLC22A5 gene) \u2192 carnitine not reabsorbed by kidneys \u2192 urinary wasting \u2192 profound plasma and tissue carnitine depletion</li> <li>Presents as: dilated cardiomyopathy, skeletal myopathy, hypoketotic hypoglycaemia in infants/children</li> <li>Treatment: L-carnitine supplementation 100\u2013300 mg/kg/day; dramatic clinical response; lifelong treatment required</li> </ul>"},{"location":"performance/l_carnitine/#secondary-carnitine-deficiency","title":"Secondary Carnitine Deficiency","text":"<ul> <li>Causes: renal failure (dialysis removes carnitine), valproate therapy (anti-epileptic binds carnitine \u2192 increased urinary loss, hepatotoxicity), HIV treatment (NRTI drugs), preterm neonates (insufficient endogenous synthesis)</li> <li>Treatment: L-carnitine supplementation; renally tailored dosing</li> </ul>"},{"location":"performance/l_carnitine/#cognitive-function-alcar","title":"Cognitive Function (ALCAR)","text":"<ul> <li>ALCAR (1.5\u20133 g/day) improves mild cognitive impairment and early Alzheimer's disease in multiple trials; modest but consistent effect on cognitive speed and attention</li> <li>Reduces carnitine deficiency in aging neurons; improves mitochondrial function</li> </ul>"},{"location":"performance/l_carnitine/#peripheral-neuropathy","title":"Peripheral Neuropathy","text":"<ul> <li>ALCAR (500\u20131000 mg \u00d7 3/day): reduces neuropathic pain and improves nerve conduction in diabetic, HIV, and cisplatin-induced neuropathy \u2014 meta-analysis confirms analgesic effect</li> <li>FDA has not approved for neuropathy, but commonly recommended by integrative medicine specialists</li> </ul>"},{"location":"performance/l_carnitine/#interactions","title":"Interactions","text":"Factor Interaction Valproate/Valproic acid Significantly increases urinary carnitine excretion \u2192 symptomatic deficiency in some patients; supplement L-carnitine when on long-term valproate (50\u2013100 mg/kg/day) Thyroid hormones Carnitine antagonises thyroid hormone action (possibly by blocking nuclear receptor entry) \u2192 useful in hyperthyroidism-induced bone loss Anticoagulants (acenocoumarol) Case reports of elevated INR with carnitine supplementation; warfarin interaction less well-documented; monitor INR Insulin Required for muscle carnitine uptake; low insulin states (fasting, T1DM) impair muscle carnitine accumulation from oral supplements TMAO / gut microbiome Carnitine \u2192 TMA \u2192 TMAO via gut bacteria; high TMAO associated with CVD events in some studies; vegan gut microbiome produces far less TMAO from same carnitine dose"},{"location":"performance/l_carnitine/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Standard dose: 1\u20133 g/day (as free carnitine or L-carnitine tartrate)</li> <li>For fat oxidation in athletes: Combine with 80 g simple carbohydratesto trigger insulin; 24-week loading required for muscle accumulation (Wall et al. protocol)</li> <li>For cognitive function: Acetyl-L-carnitine (ALCAR) 1.5\u20132 g/day; crosses BBB effectively</li> <li>For muscle damage/recovery: L-Carnitine L-Tartrate (LCLT) 2\u20134 g/day peri-workout</li> <li>Timing: With meals; fat vs. glucose meal may not matter significantly for plasma absorption</li> <li>Vegans: Lower baseline \u2192 higher bioavailability per dose \u2192 potentially better candidates for ergogenic protocols; supplementation 500\u20132000 mg/day commonly recommended</li> <li>Safety: Generally very safe; GI upset (nausea, diarrhoea) at &gt;3 g/day; fishy body odour from TMA in some individuals; TMAO concern theoretically but clinical significance of supplementation-dose TMAO unclear</li> </ul>"},{"location":"performance/workout_nutrition/","title":"Pre / Intra / Post-Workout Nutrition","text":""},{"location":"performance/workout_nutrition/#overview","title":"Overview","text":"<p>Workout nutrition timing \u2014 often called nutrient timing \u2014 refers to the strategic consumption of macronutrients and micronutrients before, during, and after exercise to optimise performance, recovery, and adaptation. While total daily food intake remains the most important nutritional variable for long-term body composition and performance, nutrient timing provides a meaningful \"second-order\" benefit for athletes training at high volumes and intensities. The theoretical basis is that exercise acutely alters insulin sensitivity, muscle protein synthesis (MPS) rates, glycogen storage kinetics, and hormonal milieu \u2014 all of which can be leveraged by appropriate nutrient delivery.</p> <p>Context: The relative importance of timing decreases as dietary quality and total intake improve. For recreational athletes eating adequate total protein and carbohydrates, precise timing is less critical than often marketed.</p>"},{"location":"performance/workout_nutrition/#pre-workout-nutrition","title":"Pre-Workout Nutrition","text":""},{"location":"performance/workout_nutrition/#goals","title":"Goals","text":"<ol> <li>Maximise glycogen stores for the session</li> <li>Provide pre-exercise amino acids to reduce net protein catabolism</li> <li>Enhance performance via ergogenic compounds (caffeine, creatine)</li> <li>Prevent GI distress during training</li> </ol>"},{"location":"performance/workout_nutrition/#macronutrient-guidelines","title":"Macronutrient Guidelines","text":"Timing Before Exercise Carbohydrates Protein Fat Fluid 3\u20134 hours 3\u20134 g/kg body weight (full meal) 0.3\u20130.5 g/kg Moderate (20\u201340 g) 5\u20137 mL/kg 1\u20132 hours 1\u20132 g/kg (moderate meal/snack) 0.2\u20130.3 g/kg Low (&lt;15 g) 3\u20135 mL/kg &lt;1 hour 0.5\u20131 g/kg (small snack) 10\u201320 g Low (&lt;5 g) 3\u20135 mL/kg"},{"location":"performance/workout_nutrition/#carbohydrate-type-pre-exercise","title":"Carbohydrate Type Pre-Exercise","text":"<ul> <li>High-GI vs. low-GI: High-GI carbohydrates 30\u201360 min before exercise deliver rapid glucose \u2192 slight reactive hypoglycaemia possible in sensitive individuals; most athletes are unaffected</li> <li>Low-GI meals 3\u20134 hours before sustain energy better and are recommended for endurance events</li> <li>Glycogen full state: Requires adequate carbohydrate intake over 24\u201348 hours preceding competition \u2014 single pre-race meal cannot rescue depleted glycogen</li> </ul>"},{"location":"performance/workout_nutrition/#ergogenic-compounds","title":"Ergogenic Compounds","text":"Compound Optimal Pre-Exercise Timing Dose Caffeine (anhydrous tablet) 45\u201360 min before 3\u20136 mg/kg Creatine Timing flexible; daily dose can be pre- or post-workout 3\u20135 g Beta-alanine Not time-sensitive; any time pre- or non-workout 3.2\u20136.4 g/day total Sodium bicarbonate 60\u201390 min before (with 1.5 L water to minimise GI distress) 0.3 g/kg Beetroot juice (nitrates) 2\u20132.5 hours before (for peak nitrite conversion) 400\u2013500 mg nitrates"},{"location":"performance/workout_nutrition/#practical-pre-workout-meal-examples","title":"Practical Pre-Workout Meal Examples","text":"<ul> <li>3 hours before: Oats + banana + eggs + orange juice (CHO: ~80 g, Protein: ~25 g)</li> <li>1.5 hours before: Greek yogurt + berries + granola (CHO: ~40 g, Protein: ~20 g)</li> <li>&lt;1 hour before: Banana + 200 mL skimmed milk or rice cakes with honey (CHO: ~25 g, Protein: ~5 g)</li> </ul>"},{"location":"performance/workout_nutrition/#intra-workout-nutrition","title":"Intra-Workout Nutrition","text":""},{"location":"performance/workout_nutrition/#when-is-it-necessary","title":"When Is It Necessary?","text":"<ul> <li>Sessions &lt;60 minutes, moderate intensity: Water only \u2014 no additional carbohydrates needed</li> <li>Sessions 60\u201390 minutes, high intensity: Small CHO intake enhances performance (mouth rinse effect also works)</li> <li>Sessions &gt;90 minutes: Exogenous carbohydrates become performance-critical</li> <li>Multi-event days / twice-daily training: Intra-workout CHO + protein for rapid recovery between sessions</li> </ul>"},{"location":"performance/workout_nutrition/#carbohydrate-intake-guidelines-during-exercise","title":"Carbohydrate Intake Guidelines During Exercise","text":"Session Duration Intra-Workout CHO Recommendation &lt;60 min Not required; optional mouth rinse 60\u201375 min 30 g/hour (1 gel \u2248 22 g) 75\u201390 min 30\u201360 g/hour &gt;90 min 60 g/hour (glucose alone, via SGLT1 transporter saturable at 60 g/hour) &gt;2.5 hours (high intensity) 60\u201390 g/hour using multiple transportable carbohydrates (MTC) \u2014 glucose:fructose 2:1 ratio (or maltodextrin:fructose) avoids SGLT1 saturation via combined SGLT1 (glucose) + GLUT5 (fructose) uptake"},{"location":"performance/workout_nutrition/#multiple-transportable-carbohydrates-mtc-concept","title":"Multiple Transportable Carbohydrates (MTC) Concept","text":"<ul> <li>Glucose/maltodextrin uses SGLT1 transporter (saturates at ~60 g/hour)</li> <li>Fructose uses GLUT5 (separate transporter, additional 30 g/hour capacity)</li> <li>2:1 glucose:fructose ratio at 90 g/hour \u2192 ~20% better performance than glucose alone in &gt;3-hour events (Currell &amp; Jeukendrup, 2008)</li> <li>Products: SiS Beta Fuel, Maurten 320, GU Liquid Energy</li> </ul>"},{"location":"performance/workout_nutrition/#fluid-requirements-during-exercise","title":"Fluid Requirements During Exercise","text":"Condition Sweat Rate Estimate Fluid Strategy Moderate exercise, cool temp 500\u20131000 mL/hour Drink to thirst; water usually sufficient High intensity, warm weather 1000\u20132000 mL/hour 400\u2013800 mL/hour with electrolytes; avoid overdrinking (hyponatraemia risk) Ultra-endurance events 500\u20131500 mL/hour Individualised; Na\u207a supplementation essential (500\u20131000 mg Na\u207a/hour)"},{"location":"performance/workout_nutrition/#electrolyte-considerations","title":"Electrolyte Considerations","text":"<ul> <li>Sodium (Na\u207a): 500\u20131000 mg/hour in prolonged exercise (&gt;2 hours) prevents hyponatraemia; lost in sweat at ~460\u20131840 mg/L depending on individual</li> <li>Potassium (K\u207a): 150\u2013300 mg/hour (lost in sweat: 120\u2013225 mg/L)</li> <li>Magnesium: Modest losses; usually replaced by post-exercise food</li> <li>Sports drinks typically contain: 400\u2013800 mg Na\u207a/L + 78\u2013195 mg K\u207a/L + 6\u20138% CHO</li> </ul>"},{"location":"performance/workout_nutrition/#protein-during-exercise","title":"Protein During Exercise","text":"<ul> <li>Only relevant for ultra-endurance events (&gt;4 hours) or back-to-back sessions</li> <li>Addition of protein (0.25 g/kg/hour) to CHO drink in events &gt;4 hours may reduce muscle damage and improve subsequent performance; minimal GI effect if well-tolerated protein source used</li> </ul>"},{"location":"performance/workout_nutrition/#post-workout-nutrition","title":"Post-Workout Nutrition","text":""},{"location":"performance/workout_nutrition/#the-anabolic-window-reality-vs-myth","title":"The Anabolic Window \u2014 Reality vs. Myth","text":"<ul> <li>Traditional view: narrow 30-minute \"anabolic window\" post-exercise requires immediate protein/CHO</li> <li>Current evidence: The window is 2\u20134 hours wide; urgency depends on time since last meal and session type</li> <li>If training fasted or last meal &gt;5 hours ago \u2192 post-workout meal timing is important</li> <li>If training 2\u20133 hours after a normal meal \u2192 urgency is low; next meal within 2\u20134 hours is adequate</li> <li>Protein timing matters more than carbohydrate timing for muscle protein synthesis (MPS)</li> </ul>"},{"location":"performance/workout_nutrition/#protein-the-priority","title":"Protein \u2014 The Priority","text":"Parameter Recommendation Amount 0.25\u20130.4 g/kg immediately post-exercise (typically 20\u201340 g for most athletes); meta-analysis (Morton et al., 2015) shows &gt;0.4 g/kg shows no additional MPS benefit per dose Quality Fast-digesting, leucine-rich sources preferred (whey &gt; casein &gt; soy &gt; rice for acute MPS stimulus); leucine threshold (~2\u20133 g leucine per dose) is the key trigger of mTORC1 activation Leucine content as guide: Whey protein 25 g = ~2.7 g leucine; casein 25 g = ~2.3 g; soy 25 g = ~1.9 g Sources Whey protein isolate/concentrate, milk, eggs, chicken breast; plant-athltes: pea + rice protein blend (matched leucine) Frequency 4\u20135 protein feedings of 20\u201340 g throughout the day (including pre-sleep dose) &gt; 2 large meals for daily MPS maximisation"},{"location":"performance/workout_nutrition/#carbohydrates-post-exercise","title":"Carbohydrates Post-Exercise","text":"Goal CHO Recommendation Glycogen replenishment (endurance athlete) 1.0\u20131.2 g/kg/hour for first 4 hours post-training (urgent for athletes training &gt;2\u00d7/day); adding protein (0.3 g/kg) may enhance glycogen synthesis when CHO is below optimal Strength/power athlete 0.5\u20131.0 g/kg post-workout; less critical than for endurance; total daily CHO intake more important Type High-GI (dextrose, maltodextrin, glucose polymers) most effective for rapid glycogen resynthesis; mixed meals acceptable for sessions &gt;6 hours before next training"},{"location":"performance/workout_nutrition/#post-workout-meal-examples","title":"Post-Workout Meal Examples","text":"<ul> <li>Endurance athlete, 2-hour session: 500 mL chocolate milk (~30 g CHO + 16 g protein) immediately \u2192 full meal 1\u20132 hours later (pasta + lean meat + vegetables)</li> <li>Strength athlete: Whey shake (25\u201335 g protein) within 2 hours \u2192 balanced meal 2 hours later</li> <li>Whole food first approach: 3 eggs + 2 slices toast + banana (~55 g CHO, ~22 g protein) \u2014 highly effective without supplements</li> </ul>"},{"location":"performance/workout_nutrition/#sleep-time-nutrition","title":"Sleep-Time Nutrition","text":"<ul> <li>Pre-sleep protein: 40 g casein protein 30\u201345 min before bed \u2192 sustained overnight MPS (~25\u201330% higher overnight MPS than placebo); no impact on fat mass in energy-balanced individuals</li> <li>Evidence: Res et al., 2012 (Medicine &amp; Science landmark trial); Snijders et al., 2015 (resistance training + casein before sleep = greater muscle hypertrophy over 12 weeks)</li> <li>Sources: cottage cheese (~30 g/250 mL), Greek yogurt, casein protein powder, milk</li> </ul>"},{"location":"performance/workout_nutrition/#special-situations","title":"Special Situations","text":""},{"location":"performance/workout_nutrition/#fasted-training","title":"Fasted Training","text":"<ul> <li>Common for recreational athletes training first thing in the morning</li> <li>Fat oxidation is higher fasted (increased lipolysis via elevated catecholamines, low insulin)</li> <li>Performance is reduced above lactate threshold (CHO-dependent efforts)</li> <li>Muscle protein breakdown is elevated; post-fast workout protein is urgent</li> <li>Recommendation: If performance is not the priority and session is moderate-intensity, fasted is acceptable; high-intensity sessions should include at least a small CHO snack pre-training</li> </ul>"},{"location":"performance/workout_nutrition/#weight-category-sports-cutting","title":"Weight-Category Sports (Cutting)","text":"<ul> <li>Rapid weight loss (fluid): Avoid; severe dehydration (\u22652% BW loss) significantly impairs strength and endurance; heat illness risk</li> <li>Gradual cut: 0.5%\u20131% BW per week; maintain protein at \u22652.3 g/kg/LBM; prioritise training performance even in caloric deficit</li> <li>Rehydration strategy: After weigh-in \u2192 1.5 mL per mL of sweat loss over 2\u20133 hours; 60\u201390 g/hour CHO to rapidly restore glycogen</li> </ul>"},{"location":"performance/workout_nutrition/#vegan-athletes","title":"Vegan Athletes","text":"<ul> <li>Higher risk of: B12 deficiency, creatine depletion, carnitine deficiency, carnosine (and \u03b2-alanine) under-supply, iron insufficiency, omega-3 (EPA/DHA) inadequacy</li> <li>Post-workout: pea + rice protein blend (1.5\u00d7 dose vs. whey, ~0.6 g/kg, to match leucine delivery); fortified plant milks for Ca + D</li> <li>Creatine supplementation particularly important for vegans (25\u201350% higher ergogenic response vs. omnivores)</li> </ul>"},{"location":"performance/workout_nutrition/#summary-table-golden-rules","title":"Summary Table: Golden Rules","text":"Timing Primary Priority Secondary Pre-workout (2\u20133 h) CHO in proportion to session duration/intensity Protein + low fat/fibre Pre-workout (30\u201360 min) Caffeine + small fast CHO Avoid high fat/fibre Intra-workout (&gt;90 min) Exogenous CHO 60\u201390 g/hour Electrolytes (Na\u207a, K\u207a) + fluid Post-workout 20\u201340 g leucine-rich protein within 2 hours CHO to restore glycogen Pre-sleep 40 g slow-releasing protein (casein) Tart cherry, magnesium for sleep quality"},{"location":"phytonutrients/carotenoids/","title":"Carotenoids","text":""},{"location":"phytonutrients/carotenoids/#overview","title":"Overview","text":"<p>Carotenoids are a family of over 700 naturally occurring fat-soluble pigments synthesised by plants, algae, and photosynthetic bacteria \u2014 responsible for the red, orange, and yellow colours of many fruits and vegetables. Humans cannot synthesise carotenoids de novo; all carotenoids must be obtained from the diet. They are divided into two major groups: carotenes (pure hydrocarbons: \u03b1-carotene, \u03b2-carotene, lycopene) and xanthophylls (oxygenated carotenoids: lutein, zeaxanthin, astaxanthin, \u03b2-cryptoxanthin, canthaxanthin). A subset \u2014 the provitamin A carotenoids (\u03b2-carotene, \u03b1-carotene, \u03b2-cryptoxanthin) \u2014 can be cleaved by intestinal BCMO1 (\u03b2-carotene 15,15\u02b9-monooxygenase) to yield retinal \u2192 retinol (Vitamin A). Non-provitamin A carotenoids (lycopene, lutein, zeaxanthin, astaxanthin) have independent antioxidant and signalling roles.</p> <ul> <li>Type: Fat-soluble phytonutrients (terpenoids; 8 isoprene units = C\u2084\u2080 skeleton)</li> <li>Key members: \u03b2-carotene, \u03b1-carotene, lycopene, lutein, zeaxanthin, \u03b2-cryptoxanthin, astaxanthin</li> <li>Tissue accumulation: Stored in adipose tissue, liver, adrenal glands; lutein/zeaxanthin concentrate in the retinal macula; lycopene concentrates in prostate, testes, adrenal glands</li> <li>Absorption factor: Must be consumed with fat \u2014 micellar formation is required; absorption ranges from 5\u201365% depending on food matrix, fat co-ingestion, and cooking</li> </ul>"},{"location":"phytonutrients/carotenoids/#functions","title":"Functions","text":"Function Details Provitamin A activity \u03b2-Carotene, \u03b1-carotene, \u03b2-cryptoxanthin \u2192 cleaved to retinal by BCMO1; retinal \u2192 retinol (Vit A) or retinoic acid; essential for vision, immunity, epithelial integrity, embryogenesis Singlet oxygen quenching Carotenoids are uniquely efficient at quenching singlet oxygen (\u00b9O\u2082) \u2014 the characteristic excited-state ROS produced by UV radiation in skin and retina; they dissipate singlet oxygen energy as heat via their conjugated double-bond system Peroxyl radical scavenging Act as chain-breaking antioxidants in lipid bilayers \u2014 particularly effective at low partial pressures of oxygen (tissues, not blood) Blue light filtration Lutein and zeaxanthin form the macular pigment optical density (MPOD) \u2014 physically absorbs blue light (400\u2013500 nm) before it reaches photoreceptors, reducing photodamage Cell signalling Carotenoid metabolites (apo-carotenoids, retinoids) bind nuclear receptors (RXR, RAR) \u2192 regulate gene expression; independent of provitamin A activity Gap junction communication \u03b2-Carotene and lycopene upregulate connexin-43 expression \u2192 increase gap junction intercellular communication (GJIC) \u2192 associated with anti-cancer effects in cell studies Immune modulation Enhance NK cell activity, lymphocyte proliferation; \u03b2-carotene supplementation in deficiency states improves cell-mediated immunity"},{"location":"phytonutrients/carotenoids/#absorption-and-metabolism","title":"Absorption and Metabolism","text":"Step Details Digestion Carotenoids are released from food matrix by chewing and cooking; heat and mechanical disruption break protein-carotenoid complexes \u2192 improves bioavailability (cooked tomato &gt; raw for lycopene) Micellar incorporation Require dietary fat for incorporation into mixed micelles in the small intestine; SR-BI and CD36 are the primary intestinal uptake transporters Intestinal conversion BCMO1 cleaves provitamin A carotenoids symmetrically \u2192 2\u00d7 retinal; BCDO2 catalyses eccentric cleavage \u2192 apo-carotenals (less studied) Transport Packaged into chylomicrons \u2192 thoracic duct \u2192 systemic circulation \u2192 LDL and HDL; transferred to peripheral tissues via lipoprotein lipase Storage Accumulate in adipose, liver; lutein/zeaxanthin selectively transported and concentrated in the retina by the GSTP1 protein (zeaxanthin-binding protein) BCMO1 polymorphisms Up to 45% of people carry BCMO1 variants (e.g., R267S, A379V) reducing conversion efficiency by 30\u201370% \u2192 higher dietary requirement for preformed Vitamin A"},{"location":"phytonutrients/carotenoids/#dietary-sources","title":"Dietary Sources","text":"Carotenoid Best Food Sources \u03b2-Carotene Sweet potato, carrots, pumpkin, butternut squash, cantaloupe, kale, spinach \u03b1-Carotene Carrots, pumpkin, butternut squash Lycopene Cooked tomatoes (tomato paste, sauce), watermelon, guava, pink grapefruit, papaya Lutein Kale, spinach, collard greens, Swiss chard, egg yolk Zeaxanthin Corn, kale, orange peppers, egg yolk \u03b2-Cryptoxanthin Papaya, tangerines, orange peppers, pumpkin Astaxanthin Wild salmon, krill, shrimp, microalgae (Haematococcus pluvialis) <p>Key principle: Bioavailability from cooked and processed foods is often greater than from raw foods; fat co-ingestion (even small amounts) is essential.</p>"},{"location":"phytonutrients/carotenoids/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"phytonutrients/carotenoids/#age-related-macular-degeneration-amd","title":"Age-Related Macular Degeneration (AMD)","text":"<ul> <li>AREDS and AREDS2 trials: Lutein (10 mg) + Zeaxanthin (2 mg) supplementation reduced progression from intermediate to advanced AMD by ~25%; replaced \u03b2-carotene in AREDS2 after smokers on supplemental \u03b2-carotene showed increased lung cancer risk</li> <li>Macular pigment (lutein + zeaxanthin) correlates with MPOD, which is protective against photodamage-driven AMD</li> </ul>"},{"location":"phytonutrients/carotenoids/#carotenoids-and-cancer-prevention","title":"Carotenoids and Cancer Prevention","text":"<ul> <li>Lycopene: Epidemiological association with reduced prostate cancer risk; inhibits IGF-1 signalling and induces cell cycle arrest in vitro; RCTs have not consistently confirmed benefit</li> <li>\u03b2-Carotene and lung cancer (smokers): ATBC and CARET trials showed high-dose supplemental \u03b2-carotene (20\u201330 mg/day) increased lung cancer risk in heavy smokers \u2014 likely due to pro-oxidant metabolites (\u03b2-carotene + smoke oxidants \u2192 reactive breakdown products); dietary carotenoids are not associated with this risk</li> <li>General diet: High dietary carotenoid intake consistently associated with reduced cancer risk across cohort studies; confounding with overall diet quality is a concern</li> </ul>"},{"location":"phytonutrients/carotenoids/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Higher red blood cell / plasma carotenoid levels associated with lower CVD risk and all-cause mortality in large epidemiological studies</li> <li>Mechanistically: antioxidant protection of LDL, reducing LDL oxidation; anti-inflammatory effects via NF-\u03baB suppression (lycopene, astaxanthin)</li> </ul>"},{"location":"phytonutrients/carotenoids/#vitamin-a-deficiency","title":"Vitamin A Deficiency","text":"<ul> <li>In resource-limited settings, dietary carotenoids (especially \u03b2-carotene from orange and yellow vegetables) are the primary vitamin A source</li> <li>WHO recommendation: high-dose vitamin A supplementation for deficient children; \u03b2-carotene supplements are NOT equivalent to preformed Vitamin A due to conversion variability</li> </ul>"},{"location":"phytonutrients/carotenoids/#interactions","title":"Interactions","text":"Factor Interaction Dietary fat Essential for absorption; avocado, olive oil, or eggs as co-ingested fat significantly increases carotenoid bioavailability from salads Vitamin E Synergistic antioxidant; vitamin E regenerates oxidised carotenoids in lipid membranes; carotenoids spare vitamin E Vitamin C Water-soluble cycle: vitamin C reduces carotenoid-derived radicals; carotenoids protect lipid phases Iron \u03b2-Carotene from food may enhance iron absorption in some studies; likely modest effect Colestyramine / Orlistat Fat absorption inhibitors reduce carotenoid absorption (fat soluble) Tobacco smoke Pro-oxidant environment converts \u03b2-carotene to reactive cleavage products \u2014 supplemental \u03b2-carotene is contraindicated in smokers Statin drugs No significant interaction; carotenoids may have additive LDL-oxidation protection BCMO1 variants SNPs in BCMO1 reduce provitamin A conversion \u2192 poor converters need preformed retinol from animal foods"},{"location":"phytonutrients/carotenoids/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Dietary carotenoids are the preferred and safest source \u2014 consistently associated with health benefits; supplemental forms have a more mixed evidence base</li> <li>Lutein (10 mg/day) + Zeaxanthin (2 mg/day): Well-supported for AMD risk reduction (AREDS2); widely available; generally safe; no established UL</li> <li>Lycopene (15\u201330 mg/day): Commonly studied dose; primarily from food (tomato products); supplements have inconsistent evidence</li> <li>\u03b2-Carotene supplements: Avoid high-dose supplementation in smokers or asbestos-exposed individuals; dietary sources are entirely safe</li> <li>Astaxanthin (4\u201312 mg/day): Potent antioxidant; emerging evidence for exercise recovery, skin photoprotection, and metabolic health; well-tolerated; GRAS status</li> <li>Carotenodermia: High dietary intake of \u03b2-carotene/lycopene \u2192 orange-yellow skin discolouration (palms, soles), especially with carrot/tomato juice overconsumption \u2014 benign and reversible; not a sign of Vitamin A toxicity</li> </ul>"},{"location":"phytonutrients/flavonoids/","title":"Flavonoids","text":""},{"location":"phytonutrients/flavonoids/#overview","title":"Overview","text":"<p>Flavonoids are the largest and most studied class of plant polyphenols, with over 6,000 identified compounds. They share a common C\u2086\u2013C\u2083\u2013C\u2086 diphenylpropane skeleton consisting of two aromatic rings (A and B) connected by a three-carbon bridge that forms an oxygenated heterocyclic ring (C ring). Minor variations in the C ring structure, hydroxylation pattern, and glycosylation determine which of the six main subclasses a compound belongs to. Flavonoids are ubiquitous in plant foods and are a major component of the average human diet \u2014 estimated dietary intake ranges from ~200 mg/day to &gt;1 g/day depending on diet composition. They exert their effects primarily via antioxidant activity, enzymatic inhibition, receptor modulation, and modulation of the gut microbiome.</p> <p>Six major subclasses:</p> Subclass Characteristic Key Examples Flavonols Most widely distributed; C3-OH (3-hydroxyflavone backbone) Quercetin, Kaempferol, Myricetin, Fisetin Flavones Lack C3-OH; often methylated or polymethoxylated Luteolin, Apigenin, Chrysin, Tangeretin Flavanones Saturated C2\u2013C3 bond; characteristic of citrus Hesperidin, Naringenin, Eriocitrin Flavan-3-ols No C4 ketone; most complex structural diversity Catechin, Epicatechin, EGCG (green tea), Proanthocyanidins Anthocyanins Water-soluble pigments (red/purple/blue); pH-sensitive Cyanidin, Delphinidin, Pelargonidin Isoflavones B ring attached at C3 (isomeric to flavones); phytoestrogenic Genistein, Daidzein, Glycitein, Puerarin"},{"location":"phytonutrients/flavonoids/#functions","title":"Functions","text":"<ul> <li>Antioxidant and radical scavenging: Donate hydrogen atoms (HAT mechanism) or electrons (SET mechanism) to neutralise ROS; chelate transition metals (Fe\u00b2\u207a, Cu\u00b2\u207a) to prevent Fenton reaction; inhibit xanthine oxidase and NADPH oxidase (superoxide sources)</li> <li>Anti-inflammatory: Inhibit NF-\u03baB \u2192 reduce TNF-\u03b1, IL-6, IL-1\u03b2; inhibit COX-1/COX-2 and 5-LOX \u2192 reduce prostaglandin and leukotriene synthesis; luteolin, quercetin, and apigenin are particularly potent NF-\u03baB inhibitors</li> <li>Estrogenic / anti-estrogenic (isoflavones): Genistein and daidzein bind ER\u03b1 and ER\u03b2 with weak affinity (~1/100\u20131/1000 vs oestradiol); preferential ER\u03b2 agonism \u2192 tissue-selective effects (bone and brain protective, breast anti-proliferative); act as SERMs (selective oestrogen receptor modulators)</li> <li>Cardiovascular protection: Improve endothelial function (via eNOS activation and NO production \u2014 quercetin, EGCG, epicatechin); inhibit platelet aggregation; reduce LDL oxidation; reduce blood pressure (flavanol-rich cocoa is among the best-evidenced)</li> <li>Enzyme inhibition: Inhibit CYP enzymes (grapefruit flavanones \u2014 naringenin/bergamottin inhibit CYP3A4); inhibit aromatase (chrysin, quercetin); inhibit \u03b1-glucosidase (quercetin \u2014 relevant for blood glucose)</li> <li>Microbiome modulation: Most dietary flavonoids reach the colon unabsorbed; colonic bacteria catabolise flavonoids \u2192 phenolic acids (e.g., urolithins from ellagitannins, equol from daidzein) with independent bioactivity; quercetin \u2192 3,4-dihydroxyphenylacetic acid; gut microbiome composition determines individual flavonoid metabolism substantially</li> <li>Autophagy and senescence: Quercetin and fisetin identified as senolytics in preclinical studies \u2014 selectively clear senescent cells; EGCG and quercetin activate autophagy via AMPK/mTOR pathway</li> <li>Neuroprotection: Cross blood-brain barrier (lipophilic aglycones); reduce neuroinflammation; apigenin and luteolin studied in Alzheimer's and anxiety models; flavanol supplementation improves memory in older adults (COSMOS-mind trial)</li> </ul>"},{"location":"phytonutrients/flavonoids/#absorption-and-metabolism","title":"Absorption and Metabolism","text":"Step Details Dietary forms Mainly as glycosides (sugar conjugates) in food; aglycones less common (except in processed foods) Small intestinal absorption Aglycones and some glycosides absorbed in small intestine; lactase phlorizin hydrolase (LPH) and cytosolic \u03b2-glucosidase (CBG) cleave glucose-conjugated flavonoids in enterocytes Colonic fermentation The majority of dietary flavonoids (particularly flavonols, flavones, flavan-3-ols) reach the colon \u2192 catabolised by Lactobacillus, Bifidobacterium, Clostridium \u2192 phenolic acids, valerolactones, equol Equol from isoflavones Daidzein \u2192 equol (by gut bacteria in ~30\u201350% of people, primarily those with specific Lactobacillus and Bifidobacterium populations); equol has higher ER\u03b2 affinity than the parent compound; equol-producer status substantially determines soy health benefits Phase I/II metabolism Absorbed flavonoids \u2192 methylation (COMT), sulfation (SULT), glucuronidation (UGT) \u2192 circulate as conjugates; deconjugation may occur in tissues Bioavailability range Highly variable: flavanols from green tea \u2014 up to 30%; quercetin from food \u2014 ~0.4\u201317% depending on matrix; isoflavones \u2014 ~15\u201340% depending on equol-producer status"},{"location":"phytonutrients/flavonoids/#dietary-sources-by-subclass","title":"Dietary Sources by Subclass","text":"Subclass Primary Food Sources Flavonols Onions (quercetin), kale, broccoli, apples, berries, capers, shallots, green tea Flavones Parsley, celery, chamomile tea, thyme, sweet red peppers, honey Flavanones Citrus: oranges, lemons, grapefruit, tangerines (hesperidin, naringenin) Flavan-3-ols Green tea (EGCG), black tea, dark chocolate/cocoa, apples, grapes, red wine Anthocyanins Blueberries, blackcurrants, blackberries, raspberries, red cabbage, red grapes, blood oranges Isoflavones Soy beans (edamame), tofu, tempeh, miso, soy milk"},{"location":"phytonutrients/flavonoids/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"phytonutrients/flavonoids/#cardiovascular-disease","title":"Cardiovascular Disease","text":"<ul> <li>Flavanol-rich cocoa: Multiple RCTs demonstrate reductions in blood pressure, improved FMD (flow-mediated dilation), reduced platelet aggregation; COSMOS trial found cocoa extract (500 mg flavanols/day) associated with 27% reduction in cardiovascular death</li> <li>Quercetin: Meta-analyses show modest antihypertensive effect (~3\u20135 mmHg systolic reduction); reduces CRP and LDL oxidation in clinical trials</li> <li>Anthocyanins: Strong epidemiological association between berry consumption and reduced CVD risk; NHANES and UK Biobank data support; RCTs show BP and insulin sensitivity improvements</li> </ul>"},{"location":"phytonutrients/flavonoids/#type-2-diabetes","title":"Type 2 Diabetes","text":"<ul> <li>Flavonoids inhibit \u03b1-glucosidase and \u03b1-amylase \u2192 blunted postprandial glucose; quercetin, EGCG, berberine-like flavonoids activate AMPK \u2192 improve insulin sensitivity</li> <li>Higher flavonoid intake consistently associated with lower T2D risk in prospective cohorts (Harvard NHS, EPIC)</li> </ul>"},{"location":"phytonutrients/flavonoids/#cancer-prevention","title":"Cancer Prevention","text":"<ul> <li>Epidemiological data: High isoflavone intake associated with lower breast cancer risk in Asian populations; mechanistically, ER\u03b2 agonism may oppose ER\u03b1-driven proliferation; evidence in Western populations is mixed</li> <li>EGCG inhibits DNMT1 (DNA methyltransferase) \u2192 epigenetic reactivation of tumour suppressor genes; inhibits cancer cell proliferation in multiple in vitro models; human RCT data limited</li> <li>Apigenin and luteolin: pro-apoptotic in multiple cancer cell lines; anti-angiogenic via VEGF inhibition; being studied as sensitisers for chemotherapy</li> </ul>"},{"location":"phytonutrients/flavonoids/#gut-microbiome","title":"Gut Microbiome","text":"<ul> <li>Flavonoids act as prebiotics: selectively stimulate Bifidobacterium and Lactobacillus; reduce pathogenic Firmicutes; increase butyrate production</li> <li>Proanthocyanidins (grape seed, cranberry) associated with reduced UTI recurrence \u2014 inhibit E. coli adhesion to uroepithelium (A-type proanthocyanidins)</li> </ul>"},{"location":"phytonutrients/flavonoids/#bone-health","title":"Bone Health","text":"<ul> <li>Isoflavones: genistein supplementation (54 mg/day) reduces bone resorption markers and improves BMD in postmenopausal women in several RCTs; particularly effective in equol producers; endorsed by some European menopause guidelines as an alternative to HRT for bone support</li> <li>Quercetin and kaempferol: stimulate osteoblast differentiation in cell models; associated with higher hip BMD in epidemiological studies</li> </ul>"},{"location":"phytonutrients/flavonoids/#interactions","title":"Interactions","text":"Factor Interaction CYP3A4 (grapefruit effect) Furanocoumarins and flavanones in grapefruit irreversibly inhibit intestinal CYP3A4 \u2192 dramatically increase bioavailability of statins, calcium channel blockers, immunosuppressants, benzodiazepines, and many other drugs \u2014 potentially dangerous Iron absorption Quercetin and other flavonols chelate non-haem iron \u2192 reduce iron absorption (relevant in iron-deficient individuals); black tea reduces iron absorption by up to 60% at a meal Thyroid hormones (isoflavones) Genistein inhibits thyroid peroxidase \u2192 may impair thyroid hormone synthesis; clinically significant mainly in iodine deficiency or hypothyroid patients taking levothyroxine (separate dosing by 4 hours recommended) HRT / SERM drugs Isoflavones have weak estrogenic activity \u2192 theoretical additive effect with HRT; clinically mild but worth noting in hormone-sensitive conditions Warfarin Quercetin is a CYP2C9 inhibitor \u2192 may raise warfarin levels; high-dose quercetin supplements warrant INR monitoring; dietary levels unlikely to be significant Equol producer status Microbiome composition determines conversion of daidzein \u2192 equol; this status significantly affects health outcomes of soy-based isoflavones Biotin (high-dose EGCG) High-dose EGCG can falsely lower biotin lab values in immunoassay-based tests (cross-reactivity)"},{"location":"phytonutrients/flavonoids/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Quercetin (500\u20131,000 mg/day): Most studied flavonoid supplement; poor oral bioavailability \u2014 phytosome (quercetin-lecithin) or quercetin with bromelain improves absorption; used for immunomodulation, antihypertensive and anti-inflammatory effects; senolytic protocols use 1,000 mg/day pulsed with dasatinib (experimental)</li> <li>EGCG / Green tea extract (400\u2013800 mg EGCG/day): Evidence for LDL reduction, modest weight loss, and insulin sensitivity; high doses (&gt;800 mg EGCG/day) associated with rare hepatotoxicity \u2014 do not take on an empty stomach; adulterated products have caused liver injury</li> <li>Isoflavones (40\u2013100 mg/day total isoflavones from soy): Support for menopausal symptom relief (modest hot flush reduction vs placebo) and bone density in postmenopausal women; response varies by equol-producer status</li> <li>Anthocyanins (from blueberry extract or standardised berry concentrates): Doses around 320 mg/day studied for cognition and cardiovascular outcomes; well-tolerated; limited standardisation of commercial products</li> <li>Proanthocyanidins / OPC (grape seed extract 100\u2013300 mg/day): Used for venous insufficiency, capillary fragility, oedema; evidence for blood pressure reduction; well-tolerated</li> <li>Fisetin (100\u2013500 mg/day): Emerging senolytic; accumulates in brain after oral dosing; studied in preclinical models of neurodegeneration and longevity; limited but promising human data</li> </ul>"},{"location":"phytonutrients/glucosinolates/","title":"Glucosinolates","text":""},{"location":"phytonutrients/glucosinolates/#overview","title":"Overview","text":"<p>Glucosinolates are a class of sulphur- and nitrogen-containing secondary metabolites found almost exclusively in the order Brassicales, which includes the cruciferous vegetables: broccoli, cabbage, cauliflower, Brussels sprouts, kale, watercress, rocket (arugula), radishes, and mustard. Over 130 individual glucosinolates have been characterised, all sharing a core \u03b2-D-glucopyranose moiety linked via S\u2013C bond to a sulfonated oxime, plus a highly variable R side chain derived from amino acids (methionine, phenylalanine, tryptophan, or other amino acids). Glucosinolates are biologically inert in intact plant cells. However, upon cell damage (chopping, chewing, cooking), they are hydrolysed by the plant enzyme myrosinase (\u03b2-thioglucoside glucohydrolase) \u2014 which is stored separately \u2014 releasing a suite of bioactive breakdown products: isothiocyanates, nitriles, indoles, and epithionitriles, depending on pH and cofactors. The primary health-linked compounds are the isothiocyanates (especially sulforaphane) and indole-3-carbinol (I3C) / 3,3\u02b9-diindolylmethane (DIM).</p> <ul> <li>Type: Thioglucosides (non-nutrient, non-essential phytonutrient)</li> <li>Bioactive breakdown products: Isothiocyanates (ITCs), Indoles (I3C, DIM), Nitriles</li> <li>Key compound: Sulforaphane (SFN) \u2014 derived from glucoraphanin (via myrosinase) \u2014 the most studied ITC; highest concentrations in broccoli sprouts (50\u2013100\u00d7 more glucoraphanin per gram than mature broccoli)</li> <li>Myrosinase compartmentalisation: Plant myrosinase is destroyed by cooking; gut bacterial myrosinase (e.g., Bacteroides, Lactobacillus) converts glucosinolates \u2192 ITCs in the colon; the host's individual gut microbiome significantly affects ITC bioavailability from cooked vegetables</li> </ul>"},{"location":"phytonutrients/glucosinolates/#functions","title":"Functions","text":"Function Details Nrf2 pathway activation Sulforaphane and other ITCs alkylate Keap1's cysteine residues \u2192 release Nrf2 from Keap1 \u2192 Nrf2 translocates to nucleus \u2192 binds ARE \u2192 upregulates Phase II detoxification enzymes (NQO1, HO-1, GSTs, GCL, thioredoxin) and antioxidant proteins \u2014 the master anticancer and cytoprotective enzyme induction pathway Phase II detoxification ITCs induce NQO1 (quinone reductase), glutathione S-transferases, UDP-glucuronosyltransferases \u2192 conjugation of carcinogens, mutagens, and reactive intermediates \u2192 enhanced excretion; key mechanism for cancer prevention in epidemiological studies Oestrogen metabolism modulation I3C \u2192 DIM (acid-catalysed dimerisation in the stomach); DIM modulates CYP1A1 and CYP1B1 \u2192 shifts oestradiol metabolism from 16\u03b1-hydroxyestradiol (more proliferative) to 2-hydroxyestradiol (less proliferative); used therapeutically in oestrogen-sensitive conditions Anti-inflammatory (NF-\u03baB inhibition) Sulforaphane inhibits NF-\u03baB activation \u2192 reduces COX-2 expression, TNF-\u03b1, IL-1\u03b2, IL-6 production in macrophages and epithelial cells; relevant in inflammatory bowel disease and chronic inflammation Histone deacetylase (HDAC) inhibition Sulforaphane and other ITCs inhibit class I and II HDACs \u2192 epigenetic gene reactivation; tumour suppressor genes silenced by HDAC-mediated chromatin compaction are reactivated \u2014 mechanistic basis for anti-cancer and anti-ageing epigenetic effects Autophagy induction Sulforaphane induces autophagy via AMPK activation and mTOR inhibition \u2192 cellular quality control; relevant for neurodegeneration and cancer prevention H. pylori suppression Sulforaphane has direct bactericidal activity against Helicobacter pylori (including clarithromycin-resistant strains) \u2014 small clinical trials in Japan show broccoli sprout consumption reduces H. pylori colonisation and gastric mucosal inflammation Blood glucose regulation Sulforaphane activates AMPK \u2192 improves insulin sensitivity; also inhibits glucose-6-phosphatase in hepatocytes \u2192 reduces hepatic glucose output; a 2017 RCT (Axelsson et al.) showed sulforaphane reduced fasting glucose in obese T2D patients"},{"location":"phytonutrients/glucosinolates/#metabolism","title":"Metabolism","text":"Step Details Hydrolysis by myrosinase On cell damage, plant myrosinase cleaves the \u03b2-thioglucosidic bond \u2192 releases an unstable aglycone that spontaneously rearranges (Lossen rearrangement) \u2192 isothiocyanate (or nitrile if epithiospecifier protein is active) pH and ESP influence Neutral pH favours ITC production; acidic pH and epithiospecifier protein (ESP) favour nitrile formation (less bioactive) - young broccoli has less ESP \u2192 more ITCs Fate of cooked glucosinolates Myrosinase is heat-sensitive; lightly steamed broccoli (3 min) substantially retains bioavailability; boiling/microwaving &gt;5 min destroys most myrosinase; cooked glucosinolates hydrolysed in colon by bacterial myrosinase Mercapturic acid pathway Absorbed ITCs are conjugated to glutathione (by GSTs) \u2192 cysteinylglycine conjugate \u2192 cysteine conjugate \u2192 N-acetylcysteine conjugate (mercapturic acid) \u2192 excreted in urine; urinary dithiocarbamates are validated biomarkers of ITC intake DIM formation I3C (from indole glucosinolates: glucobrassicin) \u2192 acid-catalysed trimerisation and dimerisation in the stomach \u2192 DIM + other oligomers; I3C itself is unstable but DIM is stable; DIM is the primary circulating metabolite Half-life ITCs: relatively short plasma half-life (~2\u20134 hours); daily or twice-daily intake recommended for sustained tissue levels"},{"location":"phytonutrients/glucosinolates/#dietary-sources","title":"Dietary Sources","text":"Vegetable Key Glucosinolates Notes Broccoli sprouts Glucoraphanin (sulforaphane precursor) 50\u2013100\u00d7 higher glucoraphanin than mature broccoli; best source Broccoli (mature) Glucoraphanin, glucobrassicin (indoles) Lightly steamed preferred; raw also good Brussels sprouts Sinigrin, glucobrassicin High total glucosinolate content Kale Gluconapoleiferin, glucobrassicin Also rich in carotenoids Cabbage Sinigrin, progoitrin Both green and red; red cabbage also rich in anthocyanins Cauliflower Glucoraphanin, glucobrassicin White variety lower carotenoids but similar glucosinolates Watercress Gluconasturtiin (\u2192 phenethyl ITC) Strong ITC profile; richest PEITC source Radish Glucoraphasatin, glucoerucin Raw; myrosinase intact Rocket (arugula) Glucoerucin (\u2192 erucin) Mild but consistent ITC source Mustard seeds Sinigrin, sinalbin Used as condiment; high ITC potential <p>Cooking tip: Chop broccoli 40 minutes before cooking to allow myrosinase to act while the enzyme is still active; lightly steam (3 min) rather than boil. Alternatively, add raw mustard seeds to cooked broccoli to provide exogenous myrosinase.</p>"},{"location":"phytonutrients/glucosinolates/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"phytonutrients/glucosinolates/#cancer-prevention","title":"Cancer Prevention","text":"<ul> <li>Epidemiology: High cruciferous vegetable intake consistently associated with reduced risk of bladder, lung, colorectal, and prostate cancers in prospective cohort studies (Harvard Health Professionals, EPIC); associations are among the strongest in the plant food\u2013cancer literature</li> <li>Mechanism (multi-target): Carcinogen detoxification (Phase II induction), DNA damage prevention, cell cycle arrest, pro-apoptotic effects in transformed cells, HDAC inhibition \u2192 reactivation of tumour suppressors, anti-angiogenic effects</li> <li>Phase II ITC supplementation trials (ongoing): Sulforaphane-rich broccoli sprout extracts in prostate cancer (EPOC trial), bladder cancer, colon polyp recurrence</li> <li>Prostate cancer: Broccoli-enriched diet RCT showed changes in gene expression in prostate tissue (GSTP1 pathway) favouring anti-cancer microenvironment; SFN delays progression in TRAMP mouse model</li> </ul>"},{"location":"phytonutrients/glucosinolates/#breast-cancer-and-oestrogen-metabolism","title":"Breast Cancer and Oestrogen Metabolism","text":"<ul> <li>DIM (3,3\u02b9-Diindolylmethane): Phase I/II trials show DIM (150\u2013300 mg/day) shifts urinary oestrogen metabolite ratios toward 2-OHE\u2081 and away from 16\u03b1-OHE\u2081; being studied in women at high breast cancer risk; sold as a supplement for \"oestrogen detox\"</li> <li>Women on tamoxifen: I3C/DIM may interact with oestrogen metabolism; caution warranted; discuss with oncologist</li> </ul>"},{"location":"phytonutrients/glucosinolates/#thyroid-function-goitrogens","title":"Thyroid Function \u2014 Goitrogens","text":"<ul> <li>Progoitrin (in cabbage, Brussels sprouts, kale) \u2192 goitrin (upon hydrolysis) \u2014 inhibits thyroid peroxidase \u2192 can reduce thyroid hormone synthesis \u2192 goitre in extreme intake or iodine deficiency</li> <li>Clinical significance: Requires very high intake (typically &gt;several hundred grams raw daily); cooking reduces goitrogen activity; adequate iodine intake protects; no concern for normal mixed dietary intake</li> <li>Patients with hypothyroidism taking medication: cook cruciferous vegetables and do not consume in extreme amounts, especially raw juices</li> </ul>"},{"location":"phytonutrients/glucosinolates/#type-2-diabetes","title":"Type 2 Diabetes","text":"<ul> <li>2017 RCT (Axelsson, Science Translational Medicine): Concentrated broccoli sprout extract (providing ~40 \u00b5mol/day sulforaphane) in obese subjects with T2D showed significant reduction in fasting blood glucose and HbA1c; hepatic glucose production suppressed (via AMPK/G6Pase inhibition); promising but requires replication</li> </ul>"},{"location":"phytonutrients/glucosinolates/#autism-spectrum-disorder","title":"Autism Spectrum Disorder","text":"<ul> <li>Pilot RCT (Singh 2014, PNAS): Sulforaphane (50\u2013150 \u00b5mol/day, 18 weeks) improved social interaction, communication, and aberrant behaviour scores in young men with ASD on standardised scales; proposed mechanism: fever-response simulation via Nrf2 activation; a larger Phase 2 trial is ongoing</li> </ul>"},{"location":"phytonutrients/glucosinolates/#interactions","title":"Interactions","text":"Factor Interaction Thyroid medication (levothyroxine) Goitrogens in raw cruciferous vegetables may impair thyroid hormone synthesis; separate large raw doses from medication; cooking largely eliminates concern CYP1A2 induction ITCs may induce CYP1A2 \u2192 accelerate metabolism of caffeine, clozapine, olanzapine, and other CYP1A2 substrates \u2192 potential for reduced drug levels Warfarin (Vitamin K content) Cruciferous vegetables are high in Vitamin K\u2081 \u2192 may reduce warfarin effectiveness if intake varies; encourage consistent intake rather than avoidance Iodine Goitrogens compete with iodine uptake at the thyroid; adequate iodine intake greatly attenuates goitrogenic effect Myrosinase sources Adding mustard seed to cooked cruciferous veg restores myrosinase activity \u2192 increases ITC production from cooked food Gut microbiome Bacteroides thetaiotaomicron, Lactobacillus agilis, and other bacteria express bacterial myrosinase \u2192 convert intact glucosinolates to ITCs in the colon; probiotic-rich gut \u2192 better ITC bioavailability from cooked cruciferous veg"},{"location":"phytonutrients/glucosinolates/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Broccoli sprout powder / extract (standardised for glucoraphanin or sulforaphane): Most common supplement form; doses providing 10\u201340 \u00b5mol sulforaphane studied; quality varies widely \u2014 look for products that include active myrosinase or add a myrosinase activator; \"SGS\" (sulforaphane glucosinolate) is a standardised extract from broccoli sprout</li> <li>Stabilised sulforaphane (Avmacol\u00ae and similar): Provides both glucoraphanin and myrosinase in separate layers to prevent premature conversion; better conversion than non-standardised extracts</li> <li>DIM (Diindolylmethane; 150\u2013300 mg/day): Stable, bioavailable form of the I3C metabolite; used for oestrogen metabolism support, PMS, fibrocystic breast disease, and used in integrative oncology; well-tolerated; may cause headache or transient GI effects at high doses</li> <li>I3C (Indole-3-carbinol; 200\u2013400 mg/day): Less stable than DIM; converted to DIM and other oligomers in the acidic stomach; often preferring DIM for consistent dosing</li> <li>Best dietary approach: Daily consumption of 200\u2013300 g of diverse cruciferous vegetables (broccoli, kale, Brussels sprouts, cabbage), with a mix of raw and lightly cooked, provides meaningful glucosinolate and ITC exposure without the need for supplementation for most purposes</li> </ul>"},{"location":"phytonutrients/phytosterols/","title":"Phytosterols","text":""},{"location":"phytonutrients/phytosterols/#overview","title":"Overview","text":"<p>Phytosterols (plant sterols and stanols) are structural analogues of cholesterol found in plant cell membranes \u2014 they fulfil the same membrane-stabilising and fluidity-regulating role in plants that cholesterol does in animal cells. Over 250 types have been identified; the most abundant in the human diet are \u03b2-sitosterol (the most common), campesterol, and stigmasterol, which are sterols; \u03b2-sitostanol and campestanol are the corresponding saturated stanols. Daily intake in omnivorous Western diets is approximately 200\u2013400 mg/day; vegetarian and vegan diets provide ~400\u2013700 mg/day. Phytosterols are the most evidence-based plant compound for LDL cholesterol reduction: at intakes of 2 g/day, they reduce LDL cholesterol by 8\u201310% on average through competitive inhibition of intestinal cholesterol absorption. This effect is robust, mechanistically well-understood, and forms the basis for their inclusion in functional foods (sterol-enriched margarines, yoghurt drinks, orange juice) and the guidelines of European, US, and Australian lipid bodies.</p> <ul> <li>Type: Triterpenoids (C\u2082\u2087\u2013C\u2082\u2089); structural analogues of cholesterol with extra methyl or ethyl group at C24 of the side chain</li> <li>Absorption: Very poorly absorbed \u2014 physiological absorption of \u03b2-sitosterol is 0.4\u20134% (vs ~60% for cholesterol); stanols are even less absorbed (&lt;0.1%); absorbed phytosterols are actively transported back into the intestinal lumen by ABCG5/ABCG8 half-transporters (the same efflux pumps that limit their accumulation)</li> <li>Relationship to cholesterol: Compete for incorporation into mixed bile acid micelles in the small intestine \u2192 displace cholesterol \u2192 less cholesterol absorbed; partially offsetting increase in endogenous cholesterol synthesis occurs but net LDL reduction is consistent</li> </ul>"},{"location":"phytonutrients/phytosterols/#functions","title":"Functions","text":"Function Details LDL cholesterol reduction Inhibit cholesterol absorption by displacing cholesterol from intestinal mixed micelles \u2192 reduced cholesterol availability for chylomicron incorporation \u2192 lower LDL; 2 g/day lowers LDL by ~0.3\u20130.5 mmol/L (8\u201310%); additive to statins and dietary saturated fat reduction Anti-inflammatory activity \u03b2-Sitosterol inhibits NF-\u03baB activation, reduces TNF-\u03b1 and IL-6 production from macrophages; immunomodulatory effects studied in infectious disease models (\u03b2-sitosterol + sitosterolin) Immune modulation \u03b2-Sitosterol/sitosterolin combination: studied for enhancement of delayed-type hypersensitivity (DTH) responses and NK cell activity; evidence from HIV and TB patient trials in South Africa Androgen pathway inhibition (BPH) \u03b2-Sitosterol inhibits 5\u03b1-reductase (reduces DHT) and anti-proliferative effect on prostate epithelial cells; meta-analysis of saw palmetto (rich in phytosterols) shows small but significant improvements in urinary symptoms in BPH Anticancer (preclinical) \u03b2-Sitosterol induces apoptosis in breast, colon, and prostate cancer cell lines via caspase-3 activation and Bcl-2 downregulation; inhibits tumour proliferation in animal models; human trial data are limited ABCG5/ABCG8 efflux Phytosterols are actively pumped back from enterocytes into the gut lumen by ABCG5/ABCG8 transporters \u2192 limits their own accumulation; loss-of-function mutations in these genes \u2192 sitosterolaemia (plant sterol accumulation disease)"},{"location":"phytonutrients/phytosterols/#metabolism","title":"Metabolism","text":"Step Details Dietary digestion Phytosterols released from food matrix; esterified forms (in functional foods) hydrolysed by pancreatic cholesterol esterase in the small intestine \u2192 free sterols Micellar competition Free phytosterols compete with cholesterol for incorporation into mixed bile acid micelles; higher phytosterol \u2192 less micellar cholesterol \u2192 reduced mucosal uptake Intestinal uptake Minimal absorption via NPC1L1 (the same transporter as cholesterol); absorbed phytosterols immediately effluxed back by ABCG5/ABCG8 at the apical membrane or at the basolateral membrane back into the portal circulation and recycled to the gut Hepatic processing Trace amounts of absorbed phytosterols enter portal circulation \u2192 liver; ABCG5/ABCG8 in hepatocyte canalicular membranes secrete phytosterols directly into bile \u2192 excreted in faeces Sitosterolaemia Rare autosomal recessive disorder (ABCG5 or ABCG8 mutations): phytosterol absorption rises to 15\u201360% \u2192 plasma phytosterol accumulation \u2192 premature atherosclerosis, xanthomas, haemolytic anaemia; treatment: low-plant-sterol diet + ezetimibe No systemic conversion Unlike cholesterol, phytosterols are not converted to steroid hormones or bile acids in humans"},{"location":"phytonutrients/phytosterols/#dietary-sources","title":"Dietary Sources","text":"Food Category Phytosterol Content Notes Vegetable oils Corn oil: ~950 mg/100 g; rapeseed: ~600 mg; sesame: ~720 mg; palm: ~49 mg Highest concentration sources Nuts Pistachios: ~280 mg/100 g; sesame seeds: ~700 mg; sunflower seeds: ~270 mg Good everyday sources Legumes Lentils: ~70 mg/100 g; chickpeas: ~90 mg; kidney beans: ~75 mg Whole grains Wheat germ: ~300 mg/100 g; whole wheat: ~65 mg; rye bread: ~37 mg Vegetables and fruit Broadly ~10\u201330 mg/100 g; minor contributors at typical serving sizes Functional foods Flora ProActiv, Benecol margarines, enriched yoghurt drinks: 2 g phytosterols per serving Specifically fortified to provide therapeutic LDL-lowering doses <p>To achieve the 2 g/day threshold needed for LDL benefit, regular dietary sources alone are usually insufficient \u2014 fortified foods or supplements are typically required.</p>"},{"location":"phytonutrients/phytosterols/#clinical-relevance","title":"Clinical Relevance","text":""},{"location":"phytonutrients/phytosterols/#ldl-cholesterol-reduction","title":"LDL Cholesterol Reduction","text":"<ul> <li>Mechanism: Confirmed via multiple RCTs; dose-response relationship: ~0.6 mmol/L LDL reduction per gram of phytosterol (effect diminishes above 2\u20133 g/day); effect size similar in normo- and hypercholesterolaemic individuals</li> <li>Guideline endorsement: European Society of Cardiology (2019 guidelines), National Lipid Association (USA), Heart Foundation (Australia) recommend phytosterol-enriched foods (2\u20133 g/day) as part of dietary management of hypercholesterolaemia, particularly for patients who cannot or will not take statins and as an adjunct to statin therapy</li> <li>Potent additive effect: Phytosterols + statin reduces LDL by an additional 8\u201310% beyond statin alone; mechanism is complementary (statins reduce synthesis, phytosterols reduce absorption)</li> <li>Do not affect HDL or triglycerides significantly at standard doses</li> </ul>"},{"location":"phytonutrients/phytosterols/#cardiovascular-risk-reduction-surrogate-vs-hard-outcomes","title":"Cardiovascular Risk Reduction \u2014 Surrogate vs Hard Outcomes","text":"<ul> <li>LDL reduction is a validated surrogate endpoint; large RCTs with hard cardiovascular endpoints (myocardial infarction, stroke) for phytosterols specifically are lacking; extrapolation from statin trials and LDL-lowering evidence supports efficacy</li> <li>Epidemiological data: higher plasma phytosterol levels associated with better cardiovascular outcomes in some studies, but also paradoxically with increased CVD risk in others (potentially reflecting impaired ABCG5/ABCG8 function in high-absorbers); this area remains controversial</li> </ul>"},{"location":"phytonutrients/phytosterols/#benign-prostatic-hyperplasia-bph","title":"Benign Prostatic Hyperplasia (BPH)","text":"<ul> <li>Meta-analysis (Cochrane, 1998): \u03b2-Sitosterol modestly improves urinary flow rate and symptom scores (IPSS) in men with BPH; mechanism includes 5\u03b1-reductase inhibition (reducing DHT) and anti-inflammatory effects on prostate epithelium</li> <li>Saw palmetto extract (Serenoa repens) \u2014 rich in phytosterols including \u03b2-sitosterol \u2014 has inconsistent evidence in larger, more rigorous RCTs (Wilt et al., Cochrane Review); European Medicines Agency (EMA) recognises it as a \"traditional herbal medicinal product\" for mild-to-moderate BPH</li> </ul>"},{"location":"phytonutrients/phytosterols/#fat-soluble-vitamin-caution","title":"Fat-Soluble Vitamin Caution","text":"<ul> <li>High phytosterol intake (&gt;3 g/day) may reduce absorption of fat-soluble vitamins (A, D, E, K) and carotenoids (\u03b2-carotene, lycopene): some studies show 10\u201320% reductions in plasma \u03b2-carotene and \u03b1-tocopherol</li> <li>Functional foods with phytosterols are sometimes enriched with vitamins A and D to compensate</li> <li>Clinical significance of this interaction at recommended doses (2\u20133 g/day) is debated but monitoring/compensation is prudent</li> </ul>"},{"location":"phytonutrients/phytosterols/#interactions","title":"Interactions","text":"Factor Interaction Statins Additive LDL reduction (~additional 8\u201310%); complementary mechanisms (HMGCR inhibition + reduced absorption); widely recommended combination Ezetimibe Both phytosterols and ezetimibe (NPC1L1 inhibitor) reduce cholesterol absorption; effects partially additive; ezetimibe also reduces phytosterol absorption (useful in sitosterolaemia) Fat-soluble vitamins (A, D, E, K) Phytosterols reduce micellar solubilisation of fat-soluble vitamins \u2192 modest reduction in absorption; consume phytosterol-enriched foods with meals containing carotenoid-rich vegetables Dietary fat Phytosterols must be consumed with food (specifically with fat) for efficacy \u2014 they act in the intestinal lumen during fat digestion; fat-free phytosterol supplements taken away from meals are significantly less effective Bile acid sequestrants (cholestyramine, colesevelam) Additive cholesterol lowering; independent mechanism; may be combined; both reduce cholesterol absorption/recirculation Orlistat Reduces fat absorption \u2192 may reduce phytosterol absorption as well; avoid high-dose phytosterol supplements with orlistat due to reduced efficacy Anticoagulants (Warfarin) Phytosterols may modestly reduce vitamin K absorption \u2192 theoretical effect on warfarin sensitivity; evidence is weak but INR monitoring appropriate during initiation"},{"location":"phytonutrients/phytosterols/#supplementation-notes","title":"Supplementation Notes","text":"<ul> <li>Functional food approach (preferred): Spreads (e.g., Flora ProActiv, Benecol), yoghurt drinks, orange juice fortified to provide 2 g phytosterols/day; most RCTs used this delivery form; phytosterols must be consumed WITH fat-containing meals to work</li> <li>Phytosterol supplements (capsules/tablets): Available; efficacy less robustly studied than functional food forms; standardised products providing 2 g/day phytosterols are clinically reasonable; ensure fat co-ingestion</li> <li>Recommended dose: 2 g/day of free plant sterols or stanols consistently supported; no additional LDL benefit above 3 g/day; doses above 3 g/day increase risk of carotenoid/fat-soluble vitamin reduction</li> <li>Who benefits most: Patients with mild-to-moderate hypercholesterolaemia; as an adjunct to statins; patients intolerant of or unwilling to start statins; familial hypercholesterolaemia as adjunct therapy</li> <li>Who should avoid: Children under 5 (no safety data); pregnant or breastfeeding women (avoid routine supplementation); patients with sitosterolaemia (absolute contraindication \u2014 use ezetimibe instead)</li> <li>Stanols vs sterols: Stanols (saturated form, e.g., Benecol's sitostanol) are absorbed even less than sterols and do not accumulate; both show equivalent LDL reduction at equivalent doses; stanols may be preferred in patients with high phytosterol absorption (sitosterolaemia trait carriers)</li> </ul>"},{"location":"vitamins/vitamin_a/","title":"Vitamin A (Retinol)","text":""},{"location":"vitamins/vitamin_a/#overview","title":"Overview","text":"<p>Vitamin A is a fat-soluble vitamin essential for vision, immune function, cell growth, and reproduction. It exists in two primary dietary forms: - Preformed Vitamin A (Retinol): Found in animal products; directly bioavailable. - Provitamin A Carotenoids (e.g., Beta-Carotene): Found in plants; converted by the body to retinol with variable efficiency (5\u201365%).</p> <p>First isolated in 1913, it was one of the first vitamins to be discovered. It is stored extensively in the liver and can accumulate to toxic levels.</p>"},{"location":"vitamins/vitamin_a/#requirements-rda","title":"Requirements (RDA)","text":"<p>Expressed as Retinol Activity Equivalents (RAE):</p> Age / Group RDA Infants 0\u20136 months 400 mcg RAE/day (AI) Infants 7\u201312 months 500 mcg RAE/day (AI) Children 1\u20133 years 300 mcg RAE/day Children 4\u20138 years 400 mcg RAE/day Children 9\u201313 years 600 mcg RAE/day Adolescents (males 14\u201318) 900 mcg RAE/day Adolescents (females 14\u201318) 700 mcg RAE/day Adult Men (19+) 900 mcg RAE/day Adult Women (19+) 700 mcg RAE/day Pregnant Women 770 mcg RAE/day Breastfeeding Women 1,300 mcg RAE/day <p>Tolerable Upper Intake Level (UL): 3,000 mcg RAE/day of preformed vitamin A for adults. No UL for provitamin A carotenoids.</p>"},{"location":"vitamins/vitamin_a/#functions","title":"Functions","text":"<ul> <li>Vision: Combines with opsin to form rhodopsin in the retina \u2014 essential for night (scotopic) vision.</li> <li>Gene Regulation: Retinoic acid (active metabolite) binds to nuclear receptors (RAR/RXR) to regulate gene expression for cell differentiation.</li> <li>Immune Defence: Maintains integrity of skin and mucosal barriers; enhances white blood cell function.</li> <li>Cell Growth &amp; Differentiation: Regulates development of virtually all cell types; critical for organogenesis in the embryo.</li> <li>Reproduction: Supports spermatogenesis and fetal development.</li> <li>Skin Health: Promotes keratinocyte turnover, collagen synthesis, and sebum regulation.</li> <li>Antioxidant (via beta-carotene): Provitamin A carotenoids scavenge reactive oxygen species.</li> </ul>"},{"location":"vitamins/vitamin_a/#cofactors-needed","title":"Cofactors Needed","text":"<p>Vitamin A's metabolism depends on several nutrients: | Cofactor | Role | |---|---| | Zinc | Required for retinol-binding protein (RBP) synthesis and retinol \u2192 retinal conversion | | Vitamin C | Supports antioxidant function of carotenoids | | Vitamin E | Protects vitamin A from oxidation in storage | | Dietary Fat | Required for absorption (fat-soluble vitamin) |</p>"},{"location":"vitamins/vitamin_a/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Preformed (retinol): 70\u201390% absorbed; Provitamin A: 5\u201365% (highly variable) Distribution 90% stored in liver as retinyl esters; smaller amounts in lungs and kidneys Active Form Retinol \u2192 retinal (reversible) \u2192 retinoic acid (irreversible) Liver Storage Half-Life 200\u2013300 days (well-nourished individuals) Plasma Half-Life (retinyl palmitate) ~2.2 hours (initial phase) Retinoic Acid Half-Life ~2 minutes (rapid turnover) Excretion Metabolites excreted in urine and feces; small amounts via breath"},{"location":"vitamins/vitamin_a/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Vitamin A deficiency (VAD) is the leading cause of preventable blindness in children worldwide, common in developing countries.</p> <p>Symptoms: - Ocular: Night blindness (earliest sign), xerophthalmia (dry eyes), Bitot's spots, corneal ulceration/keratomalacia \u2192 permanent blindness - Skin: Follicular hyperkeratosis (rough, bumpy skin) - Immune: Increased susceptibility to infections (especially measles, respiratory, GI) - Growth: Stunted growth in children</p> <p>At-Risk Groups: - Populations with maize/rice-dominant diets - Those with fat malabsorption (Crohn's, celiac, cystic fibrosis) - Individuals taking Orlistat - Patients with liver disease</p>"},{"location":"vitamins/vitamin_a/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild deficiency Dietary improvement; low-dose retinol supplementation Moderate/severe deficiency 200,000 IU oral retinol for 2 days + repeat after 2 weeks Night blindness 10,000\u201320,000 IU/day for 2 weeks VAD in pre-school children (WHO) 200,000 IU every 4\u20136 months Toxicity cessation Stop all supplements immediately; symptoms usually resolve"},{"location":"vitamins/vitamin_a/#drug-interactions","title":"Drug Interactions","text":"Drug / Class Effect Oral retinoids (isotretinoin, tretinoin) Additive toxicity; avoid concurrent high-dose vitamin A Orlistat Reduces absorption of vitamin A Warfarin High-dose vitamin A increases bleeding risk Tetracycline antibiotics Combined use may increase intracranial pressure Oral contraceptives May increase circulating vitamin A levels Alcohol (chronic) Depletes liver stores; enhances hepatotoxicity"},{"location":"vitamins/vitamin_a/#food-sources","title":"Food Sources","text":"Food Serving Vitamin A (mcg RAE) Beef liver (cooked) 85g ~6,582 mcg Sweet potato (cooked) 1 medium ~1,403 mcg Carrot (raw) 1 medium ~509 mcg Spinach (cooked) 90g ~472 mcg Fortified milk 240 ml ~149 mcg Egg (whole) 1 large ~80 mcg Salmon 85g ~59 mcg Mango 1 fruit ~181 mcg"},{"location":"vitamins/vitamin_a/#toxicity-hypervitaminosis-a","title":"Toxicity (Hypervitaminosis A)","text":"<p>Toxicity only occurs from preformed vitamin A, NOT beta-carotene.</p> Type Cause Symptoms Acute Single large dose (&gt;660,000 IU) Nausea, vomiting, headache, blurred vision, dizziness Chronic Prolonged intake &gt;3,000 mcg RAE/day Liver damage, hair loss, dry skin, bone pain, headaches, intracranial hypertension Teratogenic High doses during pregnancy Birth defects (cardiovascular, CNS malformations) <p>Treatment: Stop all vitamin A supplementation immediately. Liver damage, if severe, may be irreversible.</p>"},{"location":"vitamins/vitamin_a/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Light-sensitive: Degrades in strong UV light.</li> <li>Heat-stable: Cooking does not significantly destroy retinol.</li> <li>Fat-soluble: Found predominantly in fatty foods; not destroyed by cooking.</li> </ul>"},{"location":"vitamins/vitamin_b1/","title":"Vitamin B1 (Thiamine)","text":""},{"location":"vitamins/vitamin_b1/#overview","title":"Overview","text":"<p>Vitamin B1, also known as thiamine, is a water-soluble B-group vitamin essential for energy metabolism, neurological function, and muscle contraction. It was the first B vitamin to be discovered (isolated in 1926 by Jansen and Donath). The body stores only approximately 25\u201350 mg, primarily in the liver, heart, brain, and skeletal muscle \u2014 with a tissue half-life of only 9\u201318 days, making daily intake critical.</p>"},{"location":"vitamins/vitamin_b1/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 0.2 mg/day (AI) Infants 7\u201312 months 0.3 mg/day (AI) Children 1\u20133 years 0.5 mg/day Children 4\u20138 years 0.6 mg/day Children 9\u201313 years 0.9 mg/day Adolescent Males 14\u201318 1.2 mg/day Adolescent Females 14\u201318 1.0 mg/day Adult Men (19+) 1.2 mg/day Adult Women (19+) 1.1 mg/day Pregnant Women 1.4 mg/day Breastfeeding Women 1.4 mg/day <p>Tolerable Upper Intake Level (UL): None established \u2014 no adverse effects from high oral intakes reported.</p>"},{"location":"vitamins/vitamin_b1/#functions","title":"Functions","text":"<ul> <li>Carbohydrate Metabolism: Essential cofactor for pyruvate dehydrogenase (PDC) \u2014 the gateway enzyme converting pyruvate to acetyl-CoA for the citric acid cycle.</li> <li>Energy Production: Cofactor for alpha-ketoglutarate dehydrogenase in the Krebs cycle.</li> <li>Branched-Chain Amino Acid Metabolism: Cofactor for branched-chain alpha-ketoacid dehydrogenase.</li> <li>Pentose Phosphate Pathway: Cofactor for transketolase \u2014 critical for nucleic acid synthesis and NADPH production.</li> <li>Neural Signalling: Involved in acetylcholine synthesis and nerve conduction.</li> <li>Fatty Acid Synthesis: Participates in mitochondrial energy and lipid biosynthesis pathways.</li> </ul>"},{"location":"vitamins/vitamin_b1/#cofactors-needed","title":"Cofactors Needed","text":"<p>The active form of thiamine is Thiamine Pyrophosphate (TPP), also called thiamine diphosphate. Its synthesis requires:</p> Cofactor Role Magnesium (Mg\u00b2\u207a) Required cofactor for thiamine pyrophosphokinase (the enzyme that phosphorylates thiamine to TPP) ATP Donates phosphate groups to activate thiamine to TPP <p>Enzymes requiring TPP: 1. Pyruvate dehydrogenase 2. Alpha-ketoglutarate dehydrogenase 3. Branched-chain alpha-ketoacid dehydrogenase 4. Transketolase 5. 2-hydroxyphytanoyl-CoA lyase</p>"},{"location":"vitamins/vitamin_b1/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Active transport at physiological doses; passive diffusion at pharmacological doses; inhibited by alcohol Distribution Liver, heart, brain, kidneys, skeletal muscle Bioavailability 3.7\u20135.3% (thiamine hydrochloride); saturability limits high-dose oral benefit Tissue Half-Life 9\u201318 days Blood Half-Life 1\u201312 hours at high doses Metabolism Phosphorylated in the liver to TPP; excess excreted renally unchanged Excretion Primarily renal"},{"location":"vitamins/vitamin_b1/#effects-of-deficiency-beriberi","title":"Effects of Deficiency (Beriberi)","text":"<p>Thiamine deficiency is called beriberi (Sinhalese: \"I cannot, I cannot\") and presents in distinct clinical forms.</p> <p>Dry Beriberi (Neurological): - Peripheral neuropathy (numbness, tingling, burning in extremities) - Muscle weakness, wasting, and pain - Loss of deep tendon reflexes</p> <p>Wet Beriberi (Cardiovascular): - High-output heart failure - Tachycardia, peripheral oedema, dyspnoea</p> <p>Wernicke Encephalopathy (acute): - Classic triad: ophthalmoplegia, ataxia, confusion - Medical emergency; can progress to Korsakoff Syndrome (permanent memory impairment)</p> <p>Infantile Beriberi: - Occurs in breastfed infants of thiamine-deficient mothers - Dyspnoea, cyanosis, vomiting, cardiac failure</p> <p>At-Risk Groups: - Chronic alcohol use disorder (impaired absorption + poor diet) - Patients on dialysis - Post-bariatric surgery patients - Diets based heavily on white rice (polished) - Prolonged high-dose diuretic use</p> <p>Lab Diagnosis: - Erythrocyte transketolase activity coefficient (ETK-AC) \u2014 gold standard - Whole blood or serum thiamine levels</p>"},{"location":"vitamins/vitamin_b1/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild deficiency 10 mg/day oral for 1 week, then 3\u20135 mg/day for \u22656 weeks Moderate clinical beriberi 50\u2013100 mg IM or IV followed by oral maintenance Wernicke encephalopathy 500 mg IV three times daily for 2\u20133 days, then 250 mg/day IV/IM for 3\u20135 days, then oral Prophylaxis (alcoholics in hospital) 100\u2013200 mg IV before any glucose administration <p>Critical Note: Always administer thiamine BEFORE glucose/dextrose in at-risk patients \u2014 glucose infusion without thiamine can precipitate or worsen Wernicke encephalopathy.</p>"},{"location":"vitamins/vitamin_b1/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Alcohol (ethanol) Inhibits intestinal thiamine transport and phosphorylation to TPP Furosemide (loop diuretic) Increases urinary thiamine excretion Fluorouracil (5-FU) Blocks thiamine phosphorylation Patiromer Binds oral thiamine; separate administration by \u22653 hours Trimethoprim May alter cellular thiamine uptake Certain antibiotics (fleroxacin, fosfomycin) May reduce thiamine via altered gut flora"},{"location":"vitamins/vitamin_b1/#food-sources","title":"Food Sources","text":"Food Serving Thiamine (mg) Nutritional yeast 1 tbsp ~1.4 mg Pork loin (cooked) 85g ~0.96 mg Fortified breakfast cereal 1 cup 1.1\u20131.5 mg Navy beans (cooked) 180g ~0.42 mg Sunflower seeds 28g ~0.41 mg Brown rice (cooked) 195g ~0.19 mg Asparagus (cooked) 180g ~0.22 mg Salmon (cooked) 85g ~0.26 mg <p>Food processing note: Milling/polishing of grains removes thiamine-rich bran and germ. White rice retains 10\u201330% of original thiamine vs. brown rice unless enriched.</p>"},{"location":"vitamins/vitamin_b1/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Heat-sensitive: Cooking at high temperatures destroys significant thiamine (up to 50%).</li> <li>Water-soluble: Leaches into cooking water.</li> <li>Alkaline-sensitive: Destroyed rapidly in alkaline conditions (e.g., baking soda).</li> <li>Raw fish/shellfish hazard: Contain thiaminase enzymes that destroy thiamine; problem with diets high in raw fish.</li> </ul>"},{"location":"vitamins/vitamin_b1/#toxicity","title":"Toxicity","text":"<p>No known toxicity from dietary or supplemental thiamine by oral route. No UL established. At very high intravenous doses, rare anaphylactic reactions have been reported; IV administration should be done with caution.</p>"},{"location":"vitamins/vitamin_b12/","title":"Vitamin B12 (Cobalamin)","text":""},{"location":"vitamins/vitamin_b12/#overview","title":"Overview","text":"<p>Vitamin B12, known as cobalamin, is the largest and most structurally complex of all vitamins. It contains a cobalt atom at its centre (giving it the \"cobalt\" in the name) within a corrin ring structure. It is unique among vitamins in that: - It is only found naturally in animal products (synthesised by bacteria) - It requires intrinsic factor (IF) for physiological absorption - The body can store it for 3\u20135 years in the liver - It functions as a cofactor for just two human enzymes, but these are essential reactions</p> <p>Active coenzyme forms: - Methylcobalamin \u2014 functions in the cytoplasm (methionine synthase) - Adenosylcobalamin \u2014 functions in the mitochondria (methylmalonyl-CoA mutase)</p>"},{"location":"vitamins/vitamin_b12/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 0.4 mcg/day (AI) Infants 7\u201312 months 0.5 mcg/day (AI) Children 1\u20133 years 0.9 mcg/day Children 4\u20138 years 1.2 mcg/day Children 9\u201313 years 1.8 mcg/day Adolescents 14\u201318 years 2.4 mcg/day Adults (19+) 2.4 mcg/day Pregnant Women 2.6 mcg/day Breastfeeding Women 2.8 mcg/day <p>Tolerable Upper Intake Level (UL): None established \u2014 no adverse effects reported from high intakes.</p> <p>Special note for older adults (&gt;50): 10\u201330% cannot absorb B12 from food due to reduced gastric acid; should obtain B12 from supplements or fortified foods (crystalline B12 does not require IF for absorption at high doses).</p>"},{"location":"vitamins/vitamin_b12/#functions","title":"Functions","text":"<ul> <li>DNA Synthesis: As methylcobalamin, activates folate cycle \u2014 essential for nucleotide synthesis and cell division.</li> <li>Myelin Synthesis: Critical for synthesis and maintenance of the myelin sheath around neurons; deficiency causes subacute combined degeneration of the spinal cord.</li> <li>Red Blood Cell Maturation: Works with folate in erythropoiesis; deficiency causes megaloblastic anaemia.</li> <li>Homocysteine \u2192 Methionine Conversion: Methionine synthase converts homocysteine to methionine \u2014 reducing cardiovascular risk and providing methyl groups via SAM (S-adenosylmethionine).</li> <li>Methylmalonyl-CoA \u2192 Succinyl-CoA: Adenosylcobalamin enables this mitochondrial conversion \u2014 vital for fatty acid and amino acid catabolism. Impaired reaction leads to methylmalonic aciduria (MMA).</li> <li>Energy Metabolism: Succinyl-CoA enters the citric acid cycle.</li> </ul>"},{"location":"vitamins/vitamin_b12/#cofactors-needed","title":"Cofactors Needed","text":"<p>B12 functions as a cofactor for two enzymes:</p> Enzyme Coenzyme Form Reaction Methionine Synthase Methylcobalamin Homocysteine + 5-MTHF \u2192 Methionine + THF Methylmalonyl-CoA Mutase Adenosylcobalamin L-methylmalonyl-CoA \u2192 Succinyl-CoA <p>B12 metabolism also requires: | Cofactor | Role | |---|---| | Folate (B9 / 5-MTHF) | Provides the methyl group in the methionine synthase reaction | | Riboflavin (B2) | MTHFR reaction (folate \u2192 5-MTHF) | | Intrinsic Factor (IF) | Glycoprotein from gastric parietal cells \u2014 essential for ileal absorption | | Transcobalamin II (TCII) | Plasma transport protein for newly absorbed B12 |</p>"},{"location":"vitamins/vitamin_b12/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption (food-bound B12) Released by gastric acid and pepsin; binds R-proteins then intrinsic factor; absorbed in distal ileum Absorption (crystalline B12) ~1\u20133% absorbed passively (without IF) at high supplemental doses Peak Plasma (IM injection) Within 1 hour Plasma Half-Life ~6 days Body Stores 2\u20135 mg total; 50\u201390% stored in liver Hepatic Storage Years (3\u20135 years supply) Excretion Bile (enterohepatic recycling); urine (excess, especially after IM) IM half-life (cyanocobalamin) 20\u201350 minutes; 50\u201390% excreted in urine within 48h Hydroxocobalamin Retained longer than cyanocobalamin"},{"location":"vitamins/vitamin_b12/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Pathophysiology: Deficiency impairs both methylcobalamin-dependent and adenosylcobalamin-dependent enzymes: - Homocysteine accumulates (cardiovascular risk) - Methylmalonic acid accumulates (neurotoxic) - Folate becomes trapped as 5-MTHF (\"folate trap\") \u2192 functional folate deficiency</p> <p>Early Symptoms: - Fatigue, weakness - Pale or yellowish skin - Palpitations, shortness of breath (anaemia)</p> <p>Haematological: - Megaloblastic/macrocytic anaemia - Hypersegmented neutrophils</p> <p>Neurological (Subacute Combined Degeneration \u2014 SCD): - Progressive demyelination of dorsal and lateral spinal columns - Paraesthesia, proprioception loss \u2192 ataxia \u2192 spastic paraparesis - Cognitive decline, memory impairment, depression - Can be irreversible if untreated</p> <p>At-Risk Groups: - Vegans and strict vegetarians - Elderly (reduced IF and gastric acid) - Gastric bypass / gastrectomy patients - Pernicious anaemia (autoimmune destruction of parietal cells \u2192 no IF) - Long-term metformin and PPI users - Patients with ileal resection/Crohn's disease</p> <p>Lab Diagnosis: - Serum B12 &lt;200 pg/mL = probable deficiency - Elevated serum methylmalonic acid (MMA) \u2014 most sensitive functional marker - Elevated homocysteine (non-specific) - Schilling test (rarely used now)</p>"},{"location":"vitamins/vitamin_b12/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary deficiency (normal absorption) 1,000\u20132,000 mcg/day oral cyanocobalamin or methylcobalamin Malabsorption (no IF) Hydroxocobalamin 1 mg IM on alternate days \u00d7 2 weeks, then monthly lifelong Pernicious anaemia (UK protocol) Hydroxocobalamin 1 mg IM, 3\u00d7 weekly \u00d7 2 weeks; then every 2\u20133 months lifelong Neurological deficiency Hydroxocobalamin IM alternate days until no further improvement, then every 2 months Vegan / vegetarian prophylaxis 250\u2013500 mcg/day oral supplementation or fortified foods <p>\u26a0\ufe0f Never treat folate-deficiency anaemia with folic acid alone without ruling out B12 deficiency \u2014 doing so corrects the blood picture but allows neurological deterioration to continue.</p>"},{"location":"vitamins/vitamin_b12/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Proton pump inhibitors (omeprazole, etc.) Reduce gastric acid \u2192 impair B12 liberation from food H2 blockers (ranitidine, famotidine) Same mechanism as PPIs Metformin Reduces B12 absorption (mechanism involves calcium-dependent transport) Cholestyramine Reduces absorption by binding cobalamins Colchicine Interferes with B12 absorption Aminosalicylic acid Impairs B12 absorption Alcohol (chronic) Reduces B12 absorption and storage Chloramphenicol Inhibits erythrocyte B12 uptake"},{"location":"vitamins/vitamin_b12/#food-sources","title":"Food Sources","text":"Food Serving Vitamin B12 (mcg) Clams (cooked) 85g ~84 mcg Beef liver (cooked) 85g ~70 mcg Oysters (cooked) 85g ~24 mcg Salmon (cooked) 85g ~4.9 mcg Beef (cooked) 85g ~2.4 mcg Milk (whole) 240 ml ~1.2 mcg Yogurt (plain) 245g ~1.1 mcg Egg (whole) 1 large ~0.6 mcg Nutritional yeast (fortified) 2 tbsp ~2.4 mcg"},{"location":"vitamins/vitamin_b12/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Relatively stable during cooking when heated</li> <li>Sensitive to strong alkali and strong acid</li> <li>Also sensitive to UV light</li> <li>Stored well in the body \u2014 deficiency takes years to develop from dietary insufficiency alone</li> </ul>"},{"location":"vitamins/vitamin_b12/#toxicity","title":"Toxicity","text":"<p>No known toxicity from dietary or supplemental vitamin B12. No UL established. Excess B12 is renally excreted. Rare allergic reactions to cobalt (component of B12) have been reported.</p>"},{"location":"vitamins/vitamin_b2/","title":"Vitamin B2 (Riboflavin)","text":""},{"location":"vitamins/vitamin_b2/#overview","title":"Overview","text":"<p>Vitamin B2, also known as riboflavin, is a water-soluble B-group vitamin essential for energy production, cellular function, and the metabolism of fats, carbohydrates, and proteins. It was first isolated in the 1920s and chemically characterized in 1934.</p> <ul> <li>Chemical nature: It contains an isoalloxazine ring fused to a ribitol side chain, giving it a characteristic yellow-orange fluorescence.</li> <li>Solubility: Soluble in water; not retained in body fat. Intestinal absorption is saturable (~27 mg per dose maximum), limiting efficacy of very high oral doses.</li> <li>Storage: Not stored in large quantities in the body \u2014 daily intake is essential.</li> </ul>"},{"location":"vitamins/vitamin_b2/#requirements-rda","title":"Requirements (RDA)","text":"<p>The Recommended Dietary Allowance (RDA) for riboflavin by age and sex:</p> Age / Group RDA Infants 0\u20136 months 0.3 mg/day (AI) Infants 7\u201312 months 0.4 mg/day (AI) Children 1\u20133 years 0.5 mg/day Children 4\u20138 years 0.6 mg/day Children 9\u201313 years 0.9 mg/day Adolescents 14\u201318 (male) 1.3 mg/day Adolescents 14\u201318 (female) 1.0 mg/day Adult Men (19+) 1.3 mg/day Adult Women (19+) 1.1 mg/day Pregnant Women 1.4 mg/day Breastfeeding Women 1.6 mg/day <p>Tolerable Upper Intake Level (UL): None established \u2014 riboflavin has very low toxicity due to limited intestinal absorption and rapid renal excretion.</p>"},{"location":"vitamins/vitamin_b2/#functions","title":"Functions","text":"<p>Riboflavin's roles span energy metabolism, antioxidant defence, and nutrient activation:</p> <ul> <li>Energy Production: Integral to the metabolism of carbohydrates, fats, and proteins. FADH\u2082 donates electrons at Complex II of the mitochondrial electron transport chain (ETC).</li> <li>Fatty Acid Beta-Oxidation: FAD is required by acyl-CoA dehydrogenase enzymes that break down fatty acids in the mitochondrial matrix.</li> <li>Antioxidant Defence: Cofactor for glutathione reductase, regenerating reduced glutathione to neutralise reactive oxygen species (ROS).</li> <li>Nutrient Activation: Converts:</li> <li>Vitamin B6 \u2192 pyridoxal phosphate (active coenzyme form)</li> <li>Tryptophan \u2192 Niacin (Vitamin B3)</li> <li>Folate \u2192 active tetrahydrofolate derivatives</li> <li>Iron Mobilisation: Required by xanthine oxidase to mobilise iron from ferritin storage.</li> <li>Homocysteine Regulation: Riboflavin-dependent MTHFR enzyme helps reduce plasma homocysteine, lowering cardiovascular risk.</li> <li>Drug Metabolism: CYP450 enzymes (cytochrome P450 system) are flavoproteins dependent on FAD/FMN.</li> <li>Thyroid Hormone Synthesis: Riboflavin-dependent enzymes are involved in thyroid hormone production.</li> <li>Cellular Growth &amp; Development: Supports skin integrity, ocular health, neurological function, and fetal development.</li> <li>Migraine Prophylaxis: High-dose riboflavin (400 mg/day) reduces migraine frequency \u2014 proposed mechanism is correction of mitochondrial energy deficits in susceptible neurons.</li> </ul>"},{"location":"vitamins/vitamin_b2/#cofactors-needed","title":"Cofactors Needed","text":"<p>Riboflavin is the precursor to two essential coenzymes (collectively called flavocoenzymes):</p> <ol> <li>Flavin Mononucleotide (FMN) \u2014 riboflavin-5'-phosphate; first phosphorylation step.</li> <li>Flavin Adenine Dinucleotide (FAD) \u2014 the more abundant form; FAD is synthesised from FMN + AMP.</li> </ol> <p>Biochemical role: Both FAD and FMN accept and donate 2 electrons + 2 protons, cycling between oxidised (FAD/FMN) and reduced (FADH\u2082/FMNH\u2082) states \u2014 central to all redox reactions.</p> <p>Enzyme classes dependent on flavocoenzymes: - Oxidases (e.g., xanthine oxidase, monoamine oxidase) - Dehydrogenases (e.g., succinate dehydrogenase in the citric acid cycle) - Monooxygenases (e.g., CYP450 enzymes)</p> <p>Note: In some enzymes, FAD/FMN is covalently bound and cannot be recycled or recovered by the body, making riboflavin status critical.</p>"},{"location":"vitamins/vitamin_b2/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Active carrier-mediated transport in the small intestine; saturable at ~27 mg/dose; bile salts enhance absorption Distribution Primarily liver, kidneys, and cardiac muscle; circulates bound to plasma proteins Metabolism Riboflavin \u2192 FMN (via riboflavin kinase) \u2192 FAD (via FAD synthetase) Elimination half-life ~66\u201384 minutes after a single oral/IM dose Absorption half-life ~1.1 hours Excretion Renally excreted; urine turns bright yellow at high doses (riboflavinuria \u2014 harmless and expected) Bioavailability Up to ~95% from food; significantly reduced by alcohol use"},{"location":"vitamins/vitamin_b2/#effects-of-deficiency-ariboflavinosis","title":"Effects of Deficiency (Ariboflavinosis)","text":"<p>Deficiency is rare in isolation and usually occurs alongside deficiencies of other B vitamins.</p> <p>Symptoms include: - Oral: Angular stomatitis (sores at mouth corners), cheilosis (cracked lips), glossitis (swollen magenta tongue), pharyngitis (sore throat) - Ocular: Photophobia, excessive tearing, corneal vascularisation; cataracts in severe/prolonged cases - Skin: Seborrhoeic dermatitis, especially around the nose, ears, and genitalia - Haematological: Normochromic normocytic anaemia - Neurological: Peripheral neuropathy (rare)</p> <p>At-Risk Populations: - Vegans and strict vegetarians (limited animal product intake) - Individuals with alcohol use disorder (impaired absorption and utilisation) - Athletes (increased metabolic demand) - Elderly adults (reduced intake and absorption) - Patients with anorexia, malabsorption syndromes (e.g., IBD, coeliac disease) - Those on certain medications (see Drug Interactions) - Neonates under prolonged phototherapy (riboflavin is photodegraded)</p> <p>Laboratory Diagnosis: - Erythrocyte Glutathione Reductase Activation Coefficient (EGR-AC): Gold standard \u2014 values &gt;1.4 indicate deficiency - Urinary riboflavin excretion: &lt;27 \u00b5g/day suggests deficiency</p>"},{"location":"vitamins/vitamin_b2/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild dietary deficiency 5\u201310 mg/day oral, plus dietary correction Clinical ariboflavinosis 10\u201330 mg/day oral in divided doses until symptoms resolve Migraine prophylaxis 400 mg/day oral (evidence-based, under medical supervision) Severe deficiency / malabsorption IV or IM riboflavin as part of a multi-B complex Neonatal jaundice (phototherapy) IV supplementation as B2 is degraded by phototherapy light <ul> <li>Supplements are most effective when taken with food (enhances absorption).</li> <li>Treatment of co-existing B-vitamin deficiencies is essential since they commonly co-occur.</li> </ul>"},{"location":"vitamins/vitamin_b2/#drug-interactions","title":"Drug Interactions","text":"<p>Certain drugs reduce riboflavin absorption, excretion, or efficacy:</p> Drug / Class Effect Tricyclic antidepressants (e.g., amitriptyline) Inhibit riboflavin incorporation into flavocoenzymes Phenothiazines (e.g., chlorpromazine) Reduce FAD synthesis Antimalarials (e.g., probenecid) Block renal tubular reabsorption \u2192 increased urinary loss Metformin May interfere with riboflavin metabolism Doxorubicin (chemotherapy) Competes with riboflavin at cellular binding sites Alcohol Impairs both absorption and conversion to active coenzymes"},{"location":"vitamins/vitamin_b2/#food-sources","title":"Food Sources","text":"<p>Riboflavin is found in both animal and plant foods. Key note: riboflavin is highly sensitive to UV light \u2014 milk in clear bottles can lose up to 50% of its riboflavin content within 2 hours of light exposure.</p> Food Serving Riboflavin (mg) Beef liver (cooked) 85g ~2.9 mg Fortified breakfast cereal 1 cup 1.3\u20132.3 mg Milk (whole, cow) 240 ml ~0.4 mg Yogurt (plain, low-fat) 245g ~0.6 mg Chicken breast (cooked) 85g ~0.2 mg Salmon (cooked) 85g ~0.2 mg Eggs (whole, large) 1 egg ~0.2 mg Almonds 28g (1 oz) ~0.3 mg Mushrooms (cooked) 86g (\u00bd cup) ~0.2 mg Spinach (cooked) 90g (\u00bd cup) ~0.2 mg"},{"location":"vitamins/vitamin_b2/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Light-sensitive: Destroyed rapidly by UV/visible light \u2014 store foods in opaque or non-transparent packaging.</li> <li>Heat-stable: Cooking losses are generally low; does not degrade significantly at normal cooking temperatures.</li> <li>Water-soluble: Can leach into boiling water \u2014 using cooking water in soups can recover nutrients.</li> </ul>"},{"location":"vitamins/vitamin_b2/#toxicity","title":"Toxicity","text":"<p>No toxicity has been established from food or supplement sources. Because intestinal absorption is saturable and excess is rapidly excreted renally, risk of toxicity is extremely low. No Tolerable Upper Intake Level (UL) has been set by any major dietary authority.</p>"},{"location":"vitamins/vitamin_b3/","title":"Vitamin B3 (Niacin)","text":""},{"location":"vitamins/vitamin_b3/#overview","title":"Overview","text":"<p>Vitamin B3, commonly called niacin, is a water-soluble B vitamin that exists in three main forms: - Nicotinic acid \u2014 dietary form; causes \"niacin flush\" at pharmacological doses - Nicotinamide (Niacinamide) \u2014 preferred for supplementation; no flushing - Nicotinamide Riboside (NR) \u2014 emerging form, a direct NAD+ precursor</p> <p>Niacin can also be synthesized endogenously from the amino acid tryptophan (60 mg tryptophan \u2192 1 mg niacin). Hence, requirements are expressed as Niacin Equivalents (NE).</p>"},{"location":"vitamins/vitamin_b3/#requirements-rda","title":"Requirements (RDA)","text":"<p>Expressed in milligrams of Niacin Equivalents (NE):</p> Age / Group RDA Infants 0\u20136 months 2 mg NE/day (AI) Infants 7\u201312 months 4 mg NE/day (AI) Children 1\u20133 years 6 mg NE/day Children 4\u20138 years 8 mg NE/day Children 9\u201313 years 12 mg NE/day Adult Men (19+) 16 mg NE/day Adult Women (19+) 14 mg NE/day Pregnant Women 18 mg NE/day Breastfeeding Women 17 mg NE/day <p>Tolerable Upper Intake Level (UL): 35 mg/day of niacin (as nicotinic acid or nicotinamide) for adults from all sources combined.</p>"},{"location":"vitamins/vitamin_b3/#functions","title":"Functions","text":"<p>Niacin's primary role is as precursor to the coenzymes NAD and NADP, which participate in &gt;400 biochemical reactions:</p> <ul> <li>Energy Metabolism: NAD/NADH are central electron carriers in glycolysis, the citric acid cycle, and beta-oxidation.</li> <li>Oxidative Phosphorylation: NADH feeds electrons into Complex I of the mitochondrial ETC.</li> <li>DNA Repair: NAD\u207a is the substrate for PARP (poly-ADP-ribose polymerase) and sirtuins \u2014 DNA damage response enzymes.</li> <li>Anabolic Pathways: NADPH drives reductive biosynthesis of fatty acids, cholesterol, and steroid hormones.</li> <li>Antioxidant: NADPH maintains reduced glutathione and is consumed by glutathione reductase.</li> <li>Cellular Signalling: NAD/NADP regulate sirtuins (longevity-associated deacetylases) and cADPR (calcium signalling).</li> <li>Cardiovascular (pharmacological): High-dose nicotinic acid raises HDL-C, lowers LDL-C and triglycerides.</li> <li>Skin Health: Protects against UV-induced DNA damage; reduces inflammatory conditions.</li> <li>Neurological: Neuroprotective; maintains brain energy metabolism via NAD+.</li> </ul>"},{"location":"vitamins/vitamin_b3/#cofactors-needed","title":"Cofactors Needed","text":"<p>Niacin is itself converted to the coenzymes: 1. NAD\u207a (Nicotinamide Adenine Dinucleotide) \u2014 oxidized form; accepts electrons 2. NADH \u2014 reduced form; donates electrons in ETC 3. NADP\u207a (Nicotinamide Adenine Dinucleotide Phosphate) \u2014 anabolic reactions 4. NADPH \u2014 reduced form; essential for reductive biosynthesis and antioxidant defence</p> <p>Riboflavin (B2) is needed for the tryptophan \u2192 niacin metabolic pathway.</p>"},{"location":"vitamins/vitamin_b3/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Facilitated diffusion; up to 90% for nicotinic acid, ~100% for nicotinamide Distribution ~20% plasma protein bound; adipose tissue, liver, kidneys First-pass metabolism Extensive and dose-dependent Plasma Half-Life 20\u201345 minutes (nicotinic acid) Metabolite Half-Lives Nicotinuric acid: 1.3 h; N-methylnicotinamide: 12.6 h Excretion 60\u201376% in urine; up to 12% excreted unchanged"},{"location":"vitamins/vitamin_b3/#effects-of-deficiency-pellagra","title":"Effects of Deficiency (Pellagra)","text":"<p>Severe deficiency causes pellagra, the disease of the \"4 Ds\":</p> Symptom Details Dermatitis Dark pigmented rash on sun-exposed skin (\"Casal's necklace\"); photosensitive Diarrhoea Often bloody; GI mucosal atrophy Dementia Headache, fatigue, memory loss, disorientation, hallucinations; psychosis Death If untreated <p>Other symptoms: glossitis (bright red tongue), stomatitis, vomiting, constipation.</p> <p>Causes: Maize-dominated diets without nixtamalization (niacin is bound), alcoholism, carcinoid syndrome (tryptophan diverted), Hartnup disease (tryptophan malabsorption), isoniazid therapy.</p>"},{"location":"vitamins/vitamin_b3/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Pellagra (WHO recommendation) 300 mg/day nicotinamide orally in divided doses, or 100 mg/day parenterally for 3\u20134 weeks Dietary deficiency Nicotinamide 50\u2013100 mg/day + balanced diet Dyslipidemia (pharmacological) Nicotinic acid 1\u20133 g/day (extended release); medical supervision required Migraine prevention (limited evidence) 400\u2013500 mg/day <p>Nicotinamide is preferred for deficiency treatment \u2014 it corrects the deficiency without causing flushing.</p>"},{"location":"vitamins/vitamin_b3/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Statins Combined use increases muscle damage risk (myopathy/rhabdomyolysis) Anticoagulants (Warfarin) Niacin may impair clotting \u2192 increased bleeding risk Blood pressure medications Niacin lowers BP; additive hypotension risk Diabetes medications Niacin raises blood glucose; may require dose adjustment Allopurinol Niacin raises uric acid \u2192 worsens gout Alcohol Increases flushing; raises risk of hepatotoxicity Aspirin (low-dose) Reduces niacin flush; high-dose may slow niacin clearance Zinc Worsens flushing and itching Chromium May lower blood glucose additively"},{"location":"vitamins/vitamin_b3/#food-sources","title":"Food Sources","text":"Food Serving Niacin (mg NE) Beef liver (cooked) 85g ~14.7 mg Chicken breast (cooked) 85g ~11.8 mg Tuna (canned in water) 85g ~11.3 mg Pork loin (cooked) 85g ~6.6 mg Fortified breakfast cereal 1 cup 5\u201327 mg Salmon (cooked) 85g ~8.6 mg Peanuts (dry roasted) 28g ~4.2 mg Brown rice (cooked) 195g ~3.0 mg Mushrooms (cooked) 86g ~3.8 mg <p>Note: Corn's niacin is largely in a bound (niacytin) form unavailable to the body unless treated with alkali \u2014 the process of nixtamalization (used in traditional tortilla-making) releases the niacin.</p>"},{"location":"vitamins/vitamin_b3/#toxicity","title":"Toxicity","text":"Type Threshold Symptoms Niacin Flush \u226530 mg nicotinic acid Flushing, warmth, pruritus (face/neck) \u2014 harmless but uncomfortable GI Toxicity &gt;1 g/day Nausea, vomiting, abdominal pain, peptic ulcers Hepatotoxicity &gt;2\u20136 g/day (especially sustained-release) Elevated liver enzymes \u2192 liver failure (rare) Hyperglycaemia &gt;1 g/day Impaired insulin sensitivity Hyperuricaemia &gt;1 g/day Can precipitate gout attacks Hypotension Any dose Rapid heart rate, dizziness"},{"location":"vitamins/vitamin_b3/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Relatively stable to heat and light compared to other B vitamins</li> <li>Water-soluble; can leach into cooking water</li> <li>Nicotinamide is more stable than nicotinic acid in solution</li> </ul>"},{"location":"vitamins/vitamin_b5/","title":"Vitamin B5 (Pantothenic Acid)","text":""},{"location":"vitamins/vitamin_b5/#overview","title":"Overview","text":"<p>Vitamin B5, known as pantothenic acid (from Greek \"pantos\" = \"everywhere\"), is a water-soluble B vitamin found in virtually all foods. It is the precursor to Coenzyme A (CoA) \u2014 one of the most central molecules in metabolism, involved in over 70 enzymatic reactions. Despite its ubiquity, it is often overlooked in nutritional science due to the rarity of isolated deficiency.</p>"},{"location":"vitamins/vitamin_b5/#requirements-rda","title":"Requirements (RDA)","text":"<p>No formal RDA has been established for pantothenic acid due to insufficient evidence. An Adequate Intake (AI) is used instead:</p> Age / Group AI Infants 0\u20136 months 1.7 mg/day Infants 7\u201312 months 1.8 mg/day Children 1\u20133 years 2 mg/day Children 4\u20138 years 3 mg/day Children 9\u201313 years 4 mg/day Adolescents 14\u201318 years 5 mg/day Adults (19+) 5 mg/day Pregnant Women 6 mg/day Breastfeeding Women 7 mg/day <p>Tolerable Upper Intake Level (UL): None established \u2014 no adverse effects reported from high oral intakes.</p>"},{"location":"vitamins/vitamin_b5/#functions","title":"Functions","text":"<ul> <li>Coenzyme A (CoA) Synthesis: Primary function \u2014 CoA is essential for:</li> <li>Acetyl-CoA production (central to citric acid cycle and ATP generation)</li> <li>Fatty acid synthesis and beta-oxidation</li> <li>Amino acid catabolism</li> <li>Synthesis of steroid hormones, bile acids, and heme</li> <li>Acetylation reactions (e.g., acetylation of histones and proteins)</li> <li>Acyl Carrier Protein (ACP): Pantothenic acid is also a component of ACP, critical for de novo fatty acid synthesis.</li> <li>Neurotransmitter Synthesis: Acetyl-CoA is needed for synthesis of acetylcholine.</li> <li>Gluconeogenesis: CoA participates in conversion of non-carbohydrate precursors to glucose.</li> <li>Adrenal Function: High CoA concentrations in adrenal glands support steroid hormone synthesis.</li> <li>Skin, Hair, Nails: Supports epithelial integrity via fatty acid synthesis.</li> <li>Immune Function: Supports production of antibodies and immune cell proliferation.</li> <li>Stress Response: Involved in synthesis of cortisol (a stress hormone).</li> </ul>"},{"location":"vitamins/vitamin_b5/#cofactors-needed","title":"Cofactors Needed","text":"<p>Pantothenic acid is the precursor; its active forms are:</p> <ol> <li>Coenzyme A (CoA) \u2014 synthesised in a 5-step pathway from pantothenic acid</li> <li>Acyl Carrier Protein (ACP) \u2014 the phosphopantetheine group from CoA is transferred to an acyl carrier protein</li> </ol> <p>The CoA synthesis pathway requires: | Cofactor | Role | |---|---| | ATP | Required for phosphorylation steps | | Cysteine | Incorporated during pantothenate kinase step | | Vitamin C | Indirectly supports CoA-dependent enzyme reactions |</p>"},{"location":"vitamins/vitamin_b5/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Dietary CoA/phosphopantetheine hydrolysed to free pantothenate in gut; absorbed via sodium-dependent active transport (saturable) + passive diffusion at high doses Bioavailability 40\u201361% from dietary sources Peak Concentration ~1 hour after ingestion (fasted); delayed ~2 hours when taken with food Distribution Liver (highest), adrenal glands, kidneys, brain, heart, testes Metabolism Incorporated into CoA and ACP within tissues Terminal Half-Life ~225 hours (based on calcium pantothenate studies) Steady State Achieved ~day 14 with multiple daily doses Excretion Excreted intact in urine; amount proportional to intake"},{"location":"vitamins/vitamin_b5/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Pantothenic acid deficiency is extremely rare in free-living individuals due to its presence in virtually all foods. Isolated deficiency typically only occurs in severe malnutrition or specific genetic conditions.</p> <p>Symptoms of Deficiency: - Fatigue and weakness - GI disturbances: nausea, vomiting, stomach cramps - Neurological: burning feet syndrome (paraesthesia), irritability, sleep disturbances, restlessness - Headache, impaired coordination</p> <p>\"Burning Feet Syndrome\": A well-documented symptom during periods of wartime deprivation \u2014 painful paresthesia in feet believed to involve pantothenic acid deficiency.</p> <p>At-Risk Groups: - Severely malnourished individuals - Patients with inherited pantothenate kinase deficiency (PANK2 mutations \u2192 neurodegeneration) - Patients on total parenteral nutrition without supplementation</p>"},{"location":"vitamins/vitamin_b5/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild deficiency 5\u201310 mg/day oral pantothenic acid Severe deficiency / malnutrition Higher doses; IV supplementation as part of multi-vitamin preparation Pantothenate kinase-associated neurodegeneration Specialised care; pantothenate supplementation under investigation <p>Note: No high-dose therapeutic use has been established for pantothenic acid in the way that exists for other B vitamins.</p>"},{"location":"vitamins/vitamin_b5/#drug-interactions","title":"Drug Interactions","text":"<p>Interactions are rare. However: | Drug | Effect | |---|---| | Oral contraceptives | May increase pantothenic acid requirements | | Antibiotics (prolonged use) | May alter gut flora and reduce intestinal pantothenate production | | Salicylates (aspirin, high dose) | May interfere with pantothenic acid utilisation |</p>"},{"location":"vitamins/vitamin_b5/#food-sources","title":"Food Sources","text":"Food Serving Pantothenic Acid (mg) Beef liver (cooked) 85g ~5.9 mg Sunflower seeds 28g ~2.0 mg Chicken breast (cooked) 85g ~1.3 mg Avocado \u00bd fruit ~1.0 mg Portobello mushroom (cooked) 86g ~1.5 mg Sweet potato (cooked) 1 medium ~1.0 mg Fortified cereal 1 cup 5 mg (variable) Milk (whole) 240 ml ~0.9 mg Egg (whole) 1 large ~0.7 mg <p>Stability note: Food processing (canning, refrigerating, freezing, and grain refining) can destroy 20\u201380% of pantothenic acid content.</p>"},{"location":"vitamins/vitamin_b5/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Susceptible to heat \u2014 significant losses in boiling and canning</li> <li>Water-soluble; leaches into cooking liquid</li> <li>Relatively stable at neutral pH but degraded in acidic and alkaline conditions</li> <li>Protect supplements from moisture and light</li> </ul>"},{"location":"vitamins/vitamin_b5/#toxicity","title":"Toxicity","text":"<p>No known toxicity from oral intake. Very high doses (e.g., 10\u201320 g/day) may occasionally cause mild GI upset or diarrhoea. No Tolerable Upper Intake Level has been set.</p>"},{"location":"vitamins/vitamin_b6/","title":"Vitamin B6 (Pyridoxine)","text":""},{"location":"vitamins/vitamin_b6/#overview","title":"Overview","text":"<p>Vitamin B6 exists in six interconvertible forms: pyridoxine, pyridoxal, pyridoxamine, and their 5'-phosphate esters. The biologically active coenzyme form is Pyridoxal-5'-Phosphate (PLP), which participates in over 100 enzyme reactions \u2014 predominantly in amino acid metabolism. Vitamin B6 has significance in neurotransmitter synthesis, immune function, haemoglobin production, and homocysteine regulation.</p>"},{"location":"vitamins/vitamin_b6/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 0.1 mg/day (AI) Infants 7\u201312 months 0.3 mg/day (AI) Children 1\u20133 years 0.5 mg/day Children 4\u20138 years 0.6 mg/day Children 9\u201313 years 1.0 mg/day Adult Men 19\u201350 1.3 mg/day Adult Men 51+ 1.7 mg/day Adult Women 19\u201350 1.3 mg/day Adult Women 51+ 1.5 mg/day Pregnant Women 1.9 mg/day Breastfeeding Women 2.0 mg/day <p>Tolerable Upper Intake Level (UL): 100 mg/day for adults \u2014 exceeded primarily via supplementation.</p>"},{"location":"vitamins/vitamin_b6/#functions","title":"Functions","text":"<p>PLP acts as a coenzyme in a wide range of critical metabolic processes: - Amino Acid Metabolism: Transamination, deamination, decarboxylation reactions for all amino acids. - Neurotransmitter Synthesis:   - Serotonin (from tryptophan)   - Dopamine, norepinephrine, epinephrine (from tyrosine)   - GABA (from glutamate)   - Histamine (from histidine) - Haemoglobin Synthesis: Required for delta-aminolevulinic acid synthase \u2014 the first step in porphyrin (haem) synthesis. - Glycogen Phosphorylase: Required for glycogen breakdown to release glucose. - Homocysteine Regulation: Cystathionine beta-synthase (PLP-dependent) converts homocysteine to cysteine. - Gene Expression: PLP modulates steroid hormone receptor activity. - Immune Function: Supports lymphocyte proliferation and IL-2 production. - Lipid Metabolism: Participates in sphingolipid synthesis.</p>"},{"location":"vitamins/vitamin_b6/#cofactors-needed","title":"Cofactors Needed","text":"<p>The conversion of dietary B6 to its active PLP form requires:</p> Cofactor Role Riboflavin (B2) Required for pyridoxine-5'-phosphate oxidase (key step in PLP synthesis) Magnesium Activates pyridoxal kinase; enhances PLP membrane transport Zinc Supports PLP-dependent enzyme function ATP Phosphorylation of pyridoxine/pyridoxal to phosphorylated coenzyme forms"},{"location":"vitamins/vitamin_b6/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Primarily in the jejunum via passive diffusion First-Pass Metabolism Converted to PLP in the liver and intestinal mucosa Distribution Liver (major storage), brain, muscles; PLP is ~90% protein-bound in plasma Half-Life (pyridoxine) 15\u201320 days Half-Life (PLP, active form) 36\u201395 hours Excretion Via urine as 4-pyridoxic acid (main metabolite)"},{"location":"vitamins/vitamin_b6/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Isolated B6 deficiency is rare but secondary deficiency due to medications is common.</p> <p>Symptoms: - Microcytic hypochromic anaemia (due to impaired haem synthesis) - Peripheral neuropathy (numbness, tingling) - Pellagra-like dermatitis - Glossitis, stomatitis - Depression, confusion, irritability - Impaired immune function - Seizures (especially in infants \u2014 B6-dependency syndrome)</p> <p>At-Risk Groups: - Individuals taking isoniazid, hydralazine, penicillamine, oral contraceptives - Patients with renal failure - Alcohol use disorder - Autoimmune conditions (IBD, rheumatoid arthritis)</p>"},{"location":"vitamins/vitamin_b6/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary deficiency 50\u2013100 mg/day oral for 1\u20132 weeks, then multivitamin with 2\u20135 mg/day Drug-induced deficiency (e.g., isoniazid) 10\u201350 mg/day prophylaxis; 100 mg/day therapeutic B6-dependency seizures (infants) 100 mg IV initially; may repeat up to 500 mg total Premenstrual syndrome (modest evidence) 50\u2013100 mg/day Pregnancy nausea/vomiting 10\u201325 mg every 8 hours (often combined with doxylamine)"},{"location":"vitamins/vitamin_b6/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Isoniazid Acts as a vitamin B6 antagonist; causes peripheral neuropathy Hydralazine Forms inactive complex with PLP Penicillamine Inactivates PLP Cycloserine Inhibits kynurenine aminotransferase (B6-dependent) Corticosteroids Increase B6 requirements Levodopa (without carbidopa) B6 accelerates peripheral conversion of levodopa to dopamine, reducing CNS efficacy Oral contraceptives Increase B6 requirements via altered tryptophan metabolism Theophylline May lower B6 levels Altretamine/cisplatin chemotherapy B6 co-administration may reduce their efficacy"},{"location":"vitamins/vitamin_b6/#food-sources","title":"Food Sources","text":"Food Serving Vitamin B6 (mg) Chickpeas (canned) 240g ~1.1 mg Beef liver (cooked) 85g ~0.9 mg Tuna (canned in water) 85g ~0.9 mg Salmon (cooked) 85g ~0.6 mg Chicken breast (cooked) 85g ~0.5 mg Banana 1 medium ~0.4 mg Potato (with skin, cooked) 1 medium ~0.4 mg Fortified breakfast cereal 1 cup 0.5\u20132.5 mg Spinach (cooked) 90g ~0.25 mg"},{"location":"vitamins/vitamin_b6/#toxicity","title":"Toxicity","text":"<p>Unique among water-soluble vitamins \u2014 B6 has a defined UL due to well-documented neurotoxicity.</p> Dose Risk &gt;500 mg/day (some reports at lower doses) Sensory peripheral neuropathy Chronic high dose Progressive numbness, tingling, burning; loss of proprioception; ataxia Recovery Stop supplementation \u2014 recovery is slow (months to years); may be incomplete"},{"location":"vitamins/vitamin_b6/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Sensitive to light (especially UV)</li> <li>Relatively heat-stable in neutral and acidic environments</li> <li>Water-soluble; leaches into cooking water</li> </ul>"},{"location":"vitamins/vitamin_b7/","title":"Vitamin B7 (Biotin)","text":""},{"location":"vitamins/vitamin_b7/#overview","title":"Overview","text":"<p>Vitamin B7, also known as biotin (or formerly vitamin H, from the German \"Haar und Haut\" \u2014 hair and skin), is a water-soluble B vitamin. Unlike other B vitamins, biotin does not function as a simple coenzyme \u2014 it is covalently bound (as a prosthetic group) to five crucial carboxylase enzymes. Biotin deficiency is rare but significant in special clinical populations, and it has unique interactions with laboratory diagnostics.</p>"},{"location":"vitamins/vitamin_b7/#requirements-ai","title":"Requirements (AI)","text":"<p>A formal RDA has not been established for biotin due to insufficient evidence. An Adequate Intake (AI) is used:</p> Age / Group AI Infants 0\u20136 months 5 mcg/day Infants 7\u201312 months 6 mcg/day Children 1\u20133 years 8 mcg/day Children 4\u20138 years 12 mcg/day Children 9\u201313 years 20 mcg/day Adolescents 14\u201318 years 25 mcg/day Adults (19+) 30 mcg/day Pregnant Women 30 mcg/day Breastfeeding Women 35 mcg/day <p>Tolerable Upper Intake Level (UL): None established \u2014 no adverse effects reported from high oral doses, but biotin interferes with lab tests (see Drug Interactions).</p>"},{"location":"vitamins/vitamin_b7/#functions","title":"Functions","text":"<p>Biotin serves as a prosthetic group covalently attached to five mammalian carboxylase enzymes:</p> Enzyme Pathway Pyruvate Carboxylase (PC) Gluconeogenesis (converts pyruvate \u2192 oxaloacetate) Acetyl-CoA Carboxylase 1 (ACC1) Fatty acid synthesis (acetyl-CoA \u2192 malonyl-CoA) Acetyl-CoA Carboxylase 2 (ACC2) Regulates mitochondrial fatty acid oxidation Methylcrotonyl-CoA Carboxylase (MCC) Leucine metabolism Propionyl-CoA Carboxylase (PCC) Metabolism of odd-chain fatty acids and certain amino acids <p>Additional roles: - Gene Expression: Biotin regulates gene expression via histone biotinylation (epigenetic control) - Cell Signalling: Participates in activation of soluble guanylate cyclase - Skin, Hair, Nail Health: Supports keratin infrastructure (widely marketed but evidence for supplementation in non-deficient individuals is limited) - Neurological Function: Supports CNS myelination and neurotransmitter activity</p>"},{"location":"vitamins/vitamin_b7/#cofactors-needed","title":"Cofactors Needed","text":"<p>Biotin is itself a cofactor, covalently attached to enzymes by: | Enzyme | Role | |---|---| | Holocarboxylase Synthetase (HCS) | Attaches biotin to apocarboxylase proteins to form active holoenyzmes | | Biotinidase | Recycles biotin by releasing it from biotinylated histones and degraded holocarboxylase products |</p>"},{"location":"vitamins/vitamin_b7/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Active carrier-mediated transport in small intestine; also passively diffused at high doses Gut Bacteria Intestinal microflora produce some biotin, though contribution to human requirements is unclear Peak Plasma Concentration 1\u20132 hours after oral intake Distribution Widely distributed; highest concentrations in liver Elimination Half-Life 1.8\u201318.8 hours (dose-dependent) Metabolism Metabolised to bisnorbiotin and biotin sulfoxide Excretion Primarily renal Clearance Rapid; high doses clear within ~1 week"},{"location":"vitamins/vitamin_b7/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Biotin deficiency is rare in healthy individuals consuming a balanced diet. Symptomatic deficiency typically follows prolonged raw egg white consumption, total parenteral nutrition, or genetic disorders.</p> <p>Symptoms: - Skin: Seborrhoeic dermatitis; scaly, erythematous rash around the eyes, nose, mouth, and perianal region (\"biotin-deficient facies\") - Hair: Alopecia (hair thinning/loss) - Neurological: Lethargy, depression, hallucinations, paraesthesia, ataxia, seizures - Ocular: Conjunctivitis - Other: Brittle nails, fatigue, muscle pain</p> <p>At-Risk Groups: - Individuals consuming large quantities of raw egg whites (avidin protein binds biotin irreversibly) - Long-term antibiotic use (disrupts gut bacteria biotin production) - Biotinidase deficiency (autosomal recessive; neonatal screening recommended) - Holocarboxylase synthetase deficiency - Prolonged total parenteral nutrition (TPN) without biotin supplementation - Smokers (increased biotin catabolism) - Pregnant women (sub-marginal biotin status is common)</p>"},{"location":"vitamins/vitamin_b7/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary biotin deficiency 5\u201310 mg/day oral biotin; correct diet Biotinidase deficiency 5\u201310 mg/day oral (lifelong) Holocarboxylase synthetase deficiency 10\u201340 mg/day or higher (titrated to response) Biotin\u2013thiamin-responsive basal ganglia disease Lifelong biotin 5\u201310 mg/kg/day + thiamine 300 mg/day"},{"location":"vitamins/vitamin_b7/#drug-interactions","title":"Drug Interactions","text":"Drug / Substance Effect Anticonvulsants (carbamazepine, phenytoin, phenobarbital, primidone) Increase biotin catabolism; reduce intestinal absorption \u2192 deficiency risk Antibiotics (prolonged use) Reduce gut bacteria biotin production Raw egg whites (avidin) Binds biotin in gut, preventing absorption Smoking Accelerates biotin catabolism \u26a0\ufe0f Lab Test Interference High-dose biotin interferes with biotin-streptavidin immunoassays used in clinical diagnostics \u2014 can cause falsely HIGH or LOW results for: thyroid hormones (TSH, T3, T4), cardiac troponin, Vitamin D, testosterone, FSH, LH, cortisol, prolactin <p>Clinical Alert: Patients taking &gt;5 mg/day of biotin supplements should stop supplementation at least 72 hours before blood tests to prevent diagnostic interference.</p>"},{"location":"vitamins/vitamin_b7/#food-sources","title":"Food Sources","text":"Food Serving Biotin (mcg) Beef liver (cooked) 75g ~33 mcg Egg (whole, cooked) 1 large ~10 mcg Salmon (cooked) 85g ~5 mcg Pork (cooked) 85g ~3.8 mcg Sunflower seeds 28g ~2.6 mcg Sweet potato (cooked) 1 medium ~2.5 mcg Almonds 28g ~1.5 mcg Spinach (cooked) 90g ~0.5 mcg <p>Note: Cooking eggs denatures avidin and restores biotin bioavailability. Raw egg consumption regularly should be avoided.</p>"},{"location":"vitamins/vitamin_b7/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Sensitive to heat at high temperatures; some losses in cooking</li> <li>Water-soluble; can leach into cooking liquid</li> <li>Sensitive to oxidation</li> </ul>"},{"location":"vitamins/vitamin_b7/#toxicity","title":"Toxicity","text":"<p>No known toxicity from oral or IV administration. No Tolerable Upper Intake Level (UL) established. The primary concern at high doses is laboratory test interference (see Drug Interactions), not physiological toxicity.</p>"},{"location":"vitamins/vitamin_b9/","title":"Vitamin B9 (Folate / Folic Acid)","text":""},{"location":"vitamins/vitamin_b9/#overview","title":"Overview","text":"<p>Vitamin B9 is a water-soluble B vitamin that exists in two primary forms: - Folate: Naturally occurring form in food; a family of compounds with different one-carbon substituents. - Folic Acid: Synthetic oxidised form used in supplements and food fortification; more stable and more bioavailable (~85% vs ~50% for dietary folate).</p> <p>Folate is critical for DNA synthesis, cell division, and amino acid metabolism. Its role in neural tube defect (NTD) prevention during early pregnancy is one of the most well-established nutritional findings in medicine.</p> <p>Requirement is expressed in Dietary Folate Equivalents (DFE): - 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid (supplement with food) = 0.5 mcg folic acid (supplement on empty stomach)</p>"},{"location":"vitamins/vitamin_b9/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 65 mcg DFE/day (AI) Infants 7\u201312 months 80 mcg DFE/day (AI) Children 1\u20133 years 150 mcg DFE/day Children 4\u20138 years 200 mcg DFE/day Children 9\u201313 years 300 mcg DFE/day Adults (19+) 400 mcg DFE/day Pregnant Women 600 mcg DFE/day Breastfeeding Women 500 mcg DFE/day Women planning pregnancy 400\u2013800 mcg folic acid/day (before conception) <p>Tolerable Upper Intake Level (UL): 1,000 mcg/day (as folic acid from supplements/fortified food) \u2014 higher doses can mask B12 deficiency.</p>"},{"location":"vitamins/vitamin_b9/#functions","title":"Functions","text":"<ul> <li>DNA &amp; RNA Synthesis: Folate coenzymes are one-carbon donors essential for purine and pyrimidine synthesis \u2014 the building blocks of DNA and RNA.</li> <li>Cell Division: Essential for rapidly dividing cells (bone marrow, GI epithelium, embryonic tissue).</li> <li>Amino Acid Metabolism: Converts homocysteine \u2192 methionine (1-carbon transfer via 5-MTHF and B12); serine \u2194 glycine interconversion.</li> <li>Erythropoiesis: Required for maturation of red blood cells; deficiency causes megaloblastic anaemia.</li> <li>Neural Tube Development: Periconceptional folate reduces NTD risk (spina bifida, anencephaly) by 50\u201370%.</li> <li>Methylation Reactions: Methionine produced via folate-B12 metabolism is converted to SAM (S-adenosylmethionine) \u2014 the universal methyl donor for DNA methylation and gene regulation.</li> <li>Cognitive Health: Lower folate is associated with cognitive decline and depression in older adults.</li> </ul>"},{"location":"vitamins/vitamin_b9/#cofactors-needed","title":"Cofactors Needed","text":"<p>Folate requires conversion to its active metabolic form by dihydrofolate reductase (DHFR): - Folic acid \u2192 Dihydrofolate (DHF) \u2192 Tetrahydrofolate (THF) \u2192 5,10-methyleneTHF \u2192 5-methylTHF (5-MTHF) [the main circulating form]</p> <p>Key co-factors in folate metabolism:</p> Cofactor Role Vitamin B12 Required by methionine synthase to accept methyl group from 5-MTHF \u2192 regenerates THF Vitamin B6 Metabolises homocysteine to cysteine (cystathionine pathway) NADPH Required by DHFR for folate reduction Zinc Essential cofactor for folate conjugase (GCPII) in the gut, required for the absorption of dietary polyglutamates <p>\u26a0\ufe0f Methylenetetrahydrofolate Reductase (MTHFR) genetic variants (especially C677T) reduce conversion efficiency, increasing cardiovascular risk and NTD risk. Supplementation with 5-MTHF (pre-methylated form) bypasses this step.</p>"},{"location":"vitamins/vitamin_b9/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Dietary polyglutamate folates hydrolysed to monoglutamate in gut, then absorbed in jejunum; folic acid is better absorbed (~85% vs ~50%) Circulating Form 5-methyltetrahydrofolate (5-MTHF) Plasma Half-Life ~1.5 hours (folic acid IM) RBC Folate Half-Life ~8 weeks Steady State (RBC) ~40 weeks Body Stores 15\u201330 mg total; ~50% in liver Excretion Urine; also bile and enterohepatic circulation"},{"location":"vitamins/vitamin_b9/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Early Signs: - Megaloblastic anaemia: large, immature red blood cells; fatigue, pallor, weakness, dyspnoea - Hypersegmented neutrophils on peripheral blood smear</p> <p>Advanced Signs: - Glossitis (sore, smooth tongue) - Mouth ulcers - GI disturbances - Poor growth in children</p> <p>Pregnancy: - Neural tube defects (spina bifida, anencephaly) - Placental abruption, miscarriage, low birth weight</p> <p>Neuropsychiatric (chronic): - Depression, cognitive impairment, dementia (overlapping with B12)</p> <p>At-Risk Groups: - Pregnant women - Alcohol use disorder - Patients with malabsorption disorders (celiac, Crohn's IBD) - Those on methotrexate, anticonvulsants, or sulfasalazine - MTHFR variant carriers</p>"},{"location":"vitamins/vitamin_b9/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary folate deficiency 5 mg/day oral folic acid for \u22654 months Megaloblastic anaemia (folate-related) 5 mg/day oral; rule out and treat B12 deficiency FIRST Neural tube defect prevention 400\u2013800 mcg folic acid/day before conception and through the first trimester High-risk pregnancy (prior NTD) 5 mg/day folic acid from pre-conception through week 12 Methotrexate-induced folate depletion 1\u20135 mg/day folic acid (not on methotrexate administration day) <p>\u26a0\ufe0f Critical: Folic acid supplementation can mask vitamin B12 deficiency \u2014 always check and treat B12 status before or alongside folate treatment to prevent irreversible neurological damage.</p>"},{"location":"vitamins/vitamin_b9/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Methotrexate Folate pathway antagonist \u2014 B9 can reduce side effects but may alter anti-cancer efficacy Anticonvulsants (phenytoin, carbamazepine, valproate, phenobarbital) Reduce folate absorption; folic acid can lower their plasma levels and increase seizure risk Pyrimethamine (antimalarial) Inhibits dihydrofolate reductase Sulfasalazine Inhibits folate absorption Proton pump inhibitors / H2 blockers Reduce folate absorption over long-term use Antacids (Al/Mg) Impair folic acid absorption; separate by \u22652 hours Zinc supplements High-dose folic acid may reduce zinc absorption Trimethoprim/sulfamethoxazole Inhibits DHFR \u2192 functional folate deficiency"},{"location":"vitamins/vitamin_b9/#food-sources","title":"Food Sources","text":"Food Serving Folate (mcg DFE) Beef liver (cooked) 85g ~215 mcg Spinach (cooked) 180g (1 cup) ~263 mcg Black-eyed peas (cooked) 180g ~358 mcg Asparagus (cooked) 4 spears ~89 mcg Brussels sprouts (cooked) 90g ~78 mcg Fortified breakfast cereal 1 cup 100\u2013400 mcg Orange (fresh) 1 medium ~48 mcg Peanuts (dry roasted) 28g ~27 mcg <p>Folate stability: Very sensitive to heat, light, and oxygen. Prolonged cooking significantly reduces folate content. Eating raw or lightly-cooked vegetables preserves folate better.</p>"},{"location":"vitamins/vitamin_b9/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Highly sensitive to heat \u2014 up to 50\u201390% can be lost through cooking</li> <li>Sensitive to UV light and oxygen</li> <li>Folic acid (synthetic) is more stable than naturally occurring food folates</li> <li>Store leafy vegetables in a dark, cool environment</li> </ul>"},{"location":"vitamins/vitamin_b9/#toxicity","title":"Toxicity","text":"<p>No known toxicity from folate in food. The Tolerable Upper Intake Level (UL) of 1,000 mcg/day applies specifically to synthetic folic acid due to concern about masking B12 neurological deficiency \u2014 not due to direct folate toxicity.</p>"},{"location":"vitamins/vitamin_c/","title":"Vitamin C (Ascorbic Acid)","text":""},{"location":"vitamins/vitamin_c/#overview","title":"Overview","text":"<p>Vitamin C, chemically known as L-ascorbic acid, is a water-soluble vitamin and powerful antioxidant. It is unique in that most mammals synthesise their own vitamin C (from glucose via the gulonolactone oxidase enzyme), but humans, other primates, guinea pigs, and some other species have lost this ability due to mutation of the GULO gene \u2014 making dietary intake essential.</p> <p>Vitamin C first gained clinical recognition in the 18th century through James Lind's work on scurvy in sailors, and was isolated in 1928 by Albert Szent-Gy\u00f6rgyi.</p>"},{"location":"vitamins/vitamin_c/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 40 mg/day (AI) Infants 7\u201312 months 50 mg/day (AI) Children 1\u20133 years 15 mg/day Children 4\u20138 years 25 mg/day Children 9\u201313 years 45 mg/day Adolescent Males 14\u201318 75 mg/day Adolescent Females 14\u201318 65 mg/day Adult Men (19+) 90 mg/day Adult Women (19+) 75 mg/day Pregnant Women 85 mg/day Breastfeeding Women 120 mg/day Smokers +35 mg/day above RDA (increased oxidative stress) <p>Tolerable Upper Intake Level (UL): 2,000 mg/day for adults.</p>"},{"location":"vitamins/vitamin_c/#functions","title":"Functions","text":"<ul> <li>Collagen Biosynthesis: Cofactor for prolyl and lysyl hydroxylases \u2014 enzymes that hydroxylate proline and lysine in procollagen, essential for the triple-helix collagen structure. Without vitamin C, collagen is unstable \u2192 scurvy.</li> <li>Antioxidant: Directly neutralises reactive oxygen species (superoxide, hydroxyl radicals, hypochlorous acid) and regenerates oxidised vitamin E (tocopheryl radical \u2192 alpha-tocopherol).</li> <li>Non-Haem Iron Absorption: Reduces Fe\u00b3\u207a to Fe\u00b2\u207a in the gut, making non-haem iron 2\u20133x more bioavailable.</li> <li>Carnitine Synthesis: Required for two hydroxylation steps in carnitine synthesis \u2014 carnitine transports fatty acids into mitochondria for beta-oxidation.</li> <li>Catecholamine Synthesis: Cofactor for dopamine beta-hydroxylase (dopamine \u2192 norepinephrine).</li> <li>Immune Function: Stimulates proliferation of T- and B-lymphocytes; supports neutrophil function; enhances NK cell activity; reduces duration/severity of colds in high-risk groups.</li> <li>Wound Healing: Via collagen synthesis and immune support.</li> <li>Drug Metabolism: Modulates CYP450 oxidase activity.</li> <li>Epigenetic Regulation: Cofactor for TET enzymes that demethylate DNA \u2014 implications in cancer prevention and stem cell function.</li> </ul>"},{"location":"vitamins/vitamin_c/#cofactors-needed","title":"Cofactors Needed","text":"<p>Vitamin C itself IS a cofactor for: | Enzyme | Function | |---|---| | Prolyl hydroxylase | Collagen hydroxylation | | Lysyl hydroxylase | Collagen hydroxylation | | Dopamine beta-hydroxylase | Catecholamine synthesis | | Peptidylglycine alpha-amidating monooxygenase | Neuropeptide maturation | | HIF prolyl hydroxylase | Hypoxia signalling regulation | | TET enzymes | DNA demethylation (epigenetic regulation) |</p> <p>All these enzymes require vitamin C to maintain their metal centres (iron or copper) in the reduced (active) state.</p>"},{"location":"vitamins/vitamin_c/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption Active sodium-dependent cotransport (SVCT1/SVCT2) + passive diffusion; absorption decreases at higher oral doses (saturable) Absorption rate at low doses &gt;90% Absorption rate at 1,250 mg ~33% Peak plasma concentration Plateaus at ~70\u201380 \u00b5M with oral intake; up to 30\u201370\u00d7 higher with IV administration Distribution Brain, adrenal glands, and eye concentrated highly; white blood cells carry 50\u2013100\u00d7 plasma levels Plasma Half-Life 10\u201320 days (normal stores); ~2 hours at high IV doses Excretion Kidneys; as ascorbic acid, dehydroascorbic acid, and oxalate Renal threshold Plasma &gt;0.8 mg/dL; excess excreted in urine"},{"location":"vitamins/vitamin_c/#effects-of-deficiency-scurvy","title":"Effects of Deficiency (Scurvy)","text":"<p>Scurvy develops after 4\u201312 weeks of severe vitamin C deprivation (&lt;10 mg/day). Historically a disease of sailors, it remains relevant in the elderly, homeless, and those with food insecurity.</p> <p>Symptoms: - Connective Tissue (earliest signs): Corkscrew hair, perifollicular haemorrhages - Gingival: Spongy, bleeding, swollen gums \u2192 tooth loss (perimyolysis) - Skin: Petechiae, purpura, large bruises - Musculoskeletal: Subperiosteal haemorrhages, bone pain, arthralgia - Anaemia: Due to impaired iron absorption + capillary fragility - Wound Healing Failure: Old wounds may reopen - Mood: Depression, fatigue, irritability</p> <p>At-Risk Groups: - Those with poor fruit/vegetable intake (poverty, eating disorders) - Older adults living alone - Alcohol use disorder - Patients on dialysis - Those with malabsorption syndromes</p>"},{"location":"vitamins/vitamin_c/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild deficiency Increase fruit/vegetable intake; 200\u2013500 mg/day Scurvy 500\u20131,000 mg/day oral for 1\u20132 weeks, then nutritious diet Severe/hospitalised patients IV ascorbic acid as needed Iron absorption enhancement 100\u2013200 mg vitamin C with iron-rich meals High-dose IV (oncology/sepsis) 10\u201325 g IV (investigational; not standard of care)"},{"location":"vitamins/vitamin_c/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Warfarin High-dose vitamin C may reduce warfarin efficacy (disputed) Statins + Niacin Vitamin C may reduce HDL-raising effect of niacin-statin combo Chemotherapy drugs May reduce cell-damaging effects (pro-oxidant suppression); controversial \u2014 avoid during certain chemotherapy Aluminium antacids Vitamin C increases aluminium absorption Protease inhibitors (indinavir, saquinavir) May reduce drug levels Estrogens (OCP/HRT) Vitamin C may increase oestrogen bioavailability Iron supplements Vitamin C significantly increases non-haem iron absorption"},{"location":"vitamins/vitamin_c/#food-sources","title":"Food Sources","text":"Food Serving Vitamin C (mg) Red bell pepper (raw) \u00bd cup ~95 mg Kiwi 1 medium ~71 mg Orange (fresh) 1 medium ~70 mg Broccoli (cooked) \u00bd cup ~51 mg Strawberries \u00bd cup ~49 mg Brussels sprouts (cooked) \u00bd cup ~48 mg Grapefruit \u00bd fruit ~39 mg Potato (baked) 1 medium ~17 mg <p>Stability note: Vitamin C is the most sensitive of all vitamins. It is destroyed by heat, oxygen, light, and alkaline conditions. Prefer raw or lightly steamed vegetables. Cooking water contains leached vitamin C \u2014 use for soups.</p>"},{"location":"vitamins/vitamin_c/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Very sensitive to heat, oxygen, and light</li> <li>Rapidly degraded in alkaline conditions</li> <li>Use fresh produce promptly; refrigeration slows degradation</li> <li>Avoid copper cookware (catalyses oxidation)</li> </ul>"},{"location":"vitamins/vitamin_c/#toxicity","title":"Toxicity","text":"Dose Risk &gt; 2,000 mg/day GI upset, diarrhoea, nausea, abdominal cramps High doses (chronic) Oxalate kidney stones (increased oxalate excretion) \u2014 especially in those with kidney disease or history of stones Very high IV doses Pro-oxidant effects; haemolytic anaemia in G6PD-deficient patients <p>Rebound scurvy: Rapid withdrawal from very high-dose supplementation may cause rebound deficiency in newborns of mothers supplementing heavily.</p>"},{"location":"vitamins/vitamin_d/","title":"Vitamin D (Calciferol)","text":""},{"location":"vitamins/vitamin_d/#overview","title":"Overview","text":"<p>Vitamin D is a fat-soluble, prohormone that the human body can synthesise when the skin is exposed to ultraviolet B (UVB) radiation. Unlike most vitamins, vitamin D functions more like a steroid hormone \u2014 it is activated in the kidneys and binds to nuclear receptors throughout the body, regulating thousands of genes. It exists in two main dietary forms:</p> <ul> <li>Vitamin D2 (Ergocalciferol): Synthesised by plants/fungi exposed to UV light</li> <li>Vitamin D3 (Cholecalciferol): Synthesised in human skin from 7-dehydrocholesterol; also from animal foods; generally more potent than D2 at raising serum 25(OH)D</li> </ul> <p>Vitamin D deficiency is one of the most prevalent nutritional deficiencies globally, affecting an estimated 1 billion people.</p>"},{"location":"vitamins/vitamin_d/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u201312 months 400 IU (10 mcg)/day (AI) Children 1\u201313 years 600 IU (15 mcg)/day Adolescents 14\u201318 years 600 IU (15 mcg)/day Adults 19\u201370 years 600 IU (15 mcg)/day Adults &gt;70 years 800 IU (20 mcg)/day Pregnant Women 600 IU (15 mcg)/day Breastfeeding Women 600 IU (15 mcg)/day <p>Tolerable Upper Intake Level (UL): 4,000 IU (100 mcg)/day for adults (conservative). Some non-government experts place the practical upper safe limit at 10,000 IU/day.</p>"},{"location":"vitamins/vitamin_d/#functions","title":"Functions","text":"<ul> <li>Calcium &amp; Phosphate Homeostasis: Upregulates intestinal calcium absorption (via calbindin) and renal calcium reabsorption; stimulates osteoblast activity.</li> <li>Bone Mineralisation: Works with calcium and phosphate \u2014 essential for rickets prevention (children) and osteomalacia/osteoporosis prevention (adults).</li> <li>Cell Growth &amp; Differentiation: Calcitriol inhibits proliferation and promotes differentiation of multiple cell types \u2014 anti-cancer activity mechanisms under investigation.</li> <li>Immune Modulation: Promotes innate immunity (macrophage and dendritic cell function); reduces excessive adaptive immune responses (autoimmune disease association).</li> <li>Neuromuscular Function: Required for muscle contraction and neuromuscular coordination; low levels associated with falls in elderly.</li> <li>Insulin Secretion: Supports pancreatic beta-cell function.</li> <li>Cardiovascular: Vitamin D receptors expressed in cardiac muscle and vascular smooth muscle; deficiency linked to hypertension and cardiomyopathy.</li> <li>Gene Regulation: Calcitriol (active form) binds vitamin D receptor (VDR) \u2014 a nuclear transcription factor regulating &gt;200 genes.</li> </ul>"},{"location":"vitamins/vitamin_d/#cofactors-needed","title":"Cofactors Needed","text":"<p>Vitamin D requires several cofactors for activation and function:</p> Cofactor Role Magnesium Required by EVERY enzyme that metabolises vitamin D (CYP2R1, CYP27B1, CYP24A1); deficiency impairs vitamin D activation Vitamin K2 Directs calcium to bones and teeth; prevents calcium deposition in soft tissues/arteries; mitigates some risks of high-dose vitamin D Vitamin A Coordinates with VDR and RXR receptors for gene regulation; A and D work together Zinc Required for VDR (vitamin D receptor) synthesis Omega-3 fatty acids May enhance vitamin D efficacy, especially in individuals with liver/kidney dysfunction <p>Important: Supplementing vitamin D without ensuring adequate magnesium can be ineffective \u2014 magnesium is consumed in the hydroxylation steps.</p>"},{"location":"vitamins/vitamin_d/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Skin Synthesis UVB (290\u2013315 nm) converts 7-dehydrocholesterol \u2192 pre-D3 \u2192 cholecalciferol (D3) Absorption (dietary) Absorbed in the small intestine with dietary fat; incorporated into chylomicrons First hydroxylation (liver) D3 \u2192 25-hydroxyvitamin D [25(OH)D] = \"calcidiol\" by CYP2R1/CYP27A1; main circulating and measured form Second hydroxylation (kidney) 25(OH)D \u2192 1,25-dihydroxyvitamin D [calcitriol] by CYP27B1; biologically active form Calcitriol half-life 4\u20136 hours 25(OH)D half-life 2\u20133 weeks (15\u201321 days) D3 half-life ~2 days Storage Adipose tissue (fat-soluble); can be released slowly over months Catabolism CYP24A1 inactivates calcitriol; regulated by PTH and blood calcium/phosphate"},{"location":"vitamins/vitamin_d/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Serum 25(OH)D status: - Deficient: &lt;20 ng/mL (&lt;50 nmol/L) - Insufficient: 20\u201329 ng/mL - Sufficient: \u226530 ng/mL</p> <p>Symptoms &amp; Associated Conditions: - Children: Rickets \u2014 softening of bones, bowed legs, delayed dentition, muscle weakness, seizures (hypocalcaemia) - Adults: Osteomalacia \u2014 diffuse bone pain, weakness, stress fractures; long-term \u2192 osteoporosis - Elderly: Falls and fractures; muscle weakness; compromised immune function - Fatigue, depression, chronic pain, frequent infections</p> <p>At-Risk Groups: - Dark-skinned individuals (melanin reduces UV-mediated D3 synthesis) - Older adults (reduced skin synthesis; reduced renal activation) - Those with limited sun exposure (office workers, northern latitudes, veiled women) - Infants exclusively breastfed (breast milk low in vitamin D) - Obese individuals (D3 sequestered in fat) - Patients with fat malabsorption disorders - Kidney or liver disease patients</p>"},{"location":"vitamins/vitamin_d/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Mild insufficiency (20\u201330 ng/mL) 1,000\u20132,000 IU/day; dietary improvement + sun exposure Deficiency (&lt;20 ng/mL) 2,000\u20134,000 IU/day \u00d7 8\u201312 weeks, then maintenance 1,500\u20132,000 IU/day Severe deficiency (clinical) Loading dose: 50,000 IU weekly \u00d7 8 weeks, then maintenance Rickets (children) High-dose vitamin D + calcium supplementation; specialist supervision Hypoparathyroidism Calcitriol (1,25-dihydroxyvitamin D) \u2014 bypasses renal hydroxylation step Familial hypophosphatemia Calcitriol or dihydrotachysterol under specialist supervision"},{"location":"vitamins/vitamin_d/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Statins (atorvastatin) Vitamin D may reduce statin levels via CYP3A4 induction Thiazide diuretics Increase the risk of hypercalcaemia when combined with vitamin D Digoxin Vitamin D enhances digoxin's effects on the heart Aluminium antacids Vitamin D increases aluminium absorption Calcium channel blockers Vitamin D enhances calcium absorption, potentially countering channel blockade Anticonvulsants (phenytoin, carbamazepine) Accelerate vitamin D breakdown \u2192 deficiency risk Corticosteroids (long-term) Impair vitamin D activation and calcium absorption \u2192 osteoporosis risk Orlistat Reduces absorption of fat-soluble vitamins including D"},{"location":"vitamins/vitamin_d/#food-sources","title":"Food Sources","text":"Food Serving Vitamin D (IU) Cod liver oil 1 tbsp ~1,360 IU Rainbow trout (cooked) 85g ~645 IU Salmon (cooked) 85g ~570 IU Sardines (canned) 85g ~164 IU Tuna (canned in water) 85g ~68 IU Egg yolk 1 large ~44 IU UV-treated mushrooms 85g ~400 IU Fortified milk 240 ml ~120 IU Fortified orange juice 240 ml ~100 IU"},{"location":"vitamins/vitamin_d/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Fat-soluble \u2014 stable to heat in most cooking conditions</li> <li>Sensitive to UV light; store in opaque/dark containers</li> <li>Absorbed best when taken with a fatty meal</li> </ul>"},{"location":"vitamins/vitamin_d/#toxicity-hypervitaminosis-d","title":"Toxicity (Hypervitaminosis D)","text":"<p>Vitamin D toxicity results almost exclusively from excessive supplementation, NOT sun exposure (skin synthesis is self-regulating).</p> <p>Mechanism: Excess calcitriol increases intestinal calcium absorption \u2192 hypercalcaemia</p> Severity Symptoms Mild Nausea, vomiting, fatigue, polyuria, polydipsia Moderate Constipation, muscle weakness, bone pain, confusion Severe Kidney stones, nephrocalcinosis, arrhythmias, kidney failure <p>Treatment: Discontinue supplements; hydration; dietary calcium restriction; corticosteroids or bisphosphonates in severe cases.</p>"},{"location":"vitamins/vitamin_e/","title":"Vitamin E (Tocopherol)","text":""},{"location":"vitamins/vitamin_e/#overview","title":"Overview","text":"<p>Vitamin E is a fat-soluble antioxidant that exists in eight natural forms: - Four tocopherols: alpha (\u03b1), beta (\u03b2), gamma (\u03b3), delta (\u03b4) - Four tocotrienols: alpha, beta, gamma, delta</p> <p>Alpha-tocopherol (\u03b1-tocopherol) is the only form recognised to meet human requirements and is the form maintained and preferentially distributed by the body. It is the most potent biological form and the only one that reliably raises serum vitamin E levels.</p> <p>Vitamin E was discovered in 1922 by Evans and Bishop. Its name derives from the Greek \"tocos\" (childbirth) + \"phero\" (to carry), reflecting early research on reproductive function in rats.</p>"},{"location":"vitamins/vitamin_e/#requirements-rda","title":"Requirements (RDA)","text":"Age / Group RDA Infants 0\u20136 months 4 mg (6 IU)/day (AI) Infants 7\u201312 months 5 mg (7.5 IU)/day (AI) Children 1\u20133 years 6 mg (9 IU)/day Children 4\u20138 years 7 mg (10.4 IU)/day Children 9\u201313 years 11 mg (16.4 IU)/day Adolescents 14\u201318 years 15 mg (22.4 IU)/day Adults (19+) 15 mg (22.4 IU)/day Pregnant Women 15 mg/day Breastfeeding Women 19 mg (28 IU)/day <p>Tolerable Upper Intake Level (UL): 1,000 mg/day of alpha-tocopherol (synthetic or natural) for adults \u2014 primarily due to bleeding risk.</p>"},{"location":"vitamins/vitamin_e/#functions","title":"Functions","text":"<ul> <li>Primary Antioxidant: Protects polyunsaturated fatty acids (PUFAs) in cell membranes from lipid peroxidation by free radicals. Particularly important because cell membranes are rich in PUFAs.</li> <li>Chain-Breaking Antioxidant: Intercepts lipid radical chain reactions \u2014 donates hydrogen to a lipid radical, stops peroxidation cascade.</li> <li>Vitamin E\u2013Vitamin C Cycle: Oxidised vitamin E (tocopheroxyl radical) is regenerated by vitamin C \u2014 the two antioxidants work synergistically.</li> <li>Immune Function: Enhances T-cell proliferation and cytokine production; supports NK cell activity; anti-inflammatory via inhibition of protein kinase C and NF-\u03baB.</li> <li>Platelet Aggregation: Inhibits platelet adhesion and aggregation \u2014 reduces thrombus formation.</li> <li>Gene Regulation: Tocopherols and tocotrienols modulate gene expression related to inflammation and cell cycle.</li> <li>Vascular Health: Inhibits smooth muscle proliferation; reduces LDL oxidation \u2014 atherosclerosis prevention (under investigation).</li> <li>Skin Health: Photoprotection; reduces UV-induced skin damage.</li> <li>Nervous System: Protects neuronal membranes; peripheral neuropathy hallmark of severe deficiency.</li> </ul>"},{"location":"vitamins/vitamin_e/#cofactors-needed","title":"Cofactors Needed","text":"<p>Unlike B vitamins, vitamin E does not function as an enzyme cofactor in the classical sense. However, it works synergistically with:</p> Nutrient Role Vitamin C (Ascorbic Acid) Regenerates oxidised \u03b1-tocopherol (tocopheroxyl radical) back to active form Selenium Works with vitamin E in glutathione peroxidase system to protect membranes from oxidative damage Coenzyme Q10 (Ubiquinol) Another fat-soluble antioxidant that works alongside vitamin E in membranes"},{"location":"vitamins/vitamin_e/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter Details Absorption ~55% of oral alpha-tocopherol absorbed; requires dietary fat and bile; absorbed in small intestine Chylomicron transport Packaged into chylomicrons \u2192 delivered to liver Preferential retention Liver uses alpha-tocopherol transfer protein (\u03b1-TTP) to preferentially select alpha-tocopherol for VLDL assembly; other forms are metabolised Distribution Adipose tissue (largest reservoir), liver, muscle, cell membranes Elimination Half-Life ~20 hours (alpha-tocopherol); tocotrienols: 2\u20134 hours Metabolism Hepatic CYP450 side-chain oxidation \u2192 beta-oxidation \u2192 CEHC metabolites Excretion Bile/feces (major); urine (minor, as CEHC)"},{"location":"vitamins/vitamin_e/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Vitamin E deficiency is rare in healthy adults but significant in populations with fat malabsorption or genetic metabolic abnormalities.</p> <p>Causes: - Fat malabsorption disorders (abetalipoproteinaemia, cystic fibrosis, Crohn's, celiac, liver disease) - Mutations in alpha-TTP gene (rare ataxia with vitamin E deficiency \u2014 AVED) - Severely premature infants</p> <p>Symptoms: - Neurological (primary manifestation):   - Peripheral neuropathy: sensory loss in hands/feet, absent deep tendon reflexes   - Spinocerebellar ataxia (loss of coordination)   - Ophthalmoplegia (weakness of eye muscles)   - Retinopathy - Haematological:   - Haemolytic anaemia (especially in premature infants \u2014 oxidative damage to RBC membranes) - Immune:   - Impaired immune cell function</p> <p>At-Risk Groups: - People with fat malabsorption conditions - Premature infants - Individuals with AVED (genetic TTP mutation) - Severe protein-energy malnutrition</p>"},{"location":"vitamins/vitamin_e/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Dietary deficiency Increase dietary vitamin E; 15\u2013200 mg/day supplemental alpha-tocopherol Neurological deficiency (moderate) High-dose oral: 100\u2013400 mg/day (monitor response) Abetalipoproteinaemia 1,000\u20132,000 mg/day or higher; specialist management AVED (genetic) 800\u20131,200 mg/day; lifelong supplementation Premature infants Prophylactic 25 IU/day to prevent haemolytic anaemia and retinopathy"},{"location":"vitamins/vitamin_e/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Warfarin / other anticoagulants Vitamin E inhibits platelet aggregation \u2192 additive bleeding risk at &gt;300 mg/day; monitor INR Aspirin Additive antiplatelet effects Cyclosporine (immunosuppressant) High-dose vitamin E may increase cyclosporine levels Statins + Niacin Vitamin E may blunt the HDL-raising effect of niacin-statin combination Chemotherapy / radiotherapy May reduce oxidative cell-killing effect \u2014 avoid supplementation during treatment unless specified Fat-soluble vitamin interference Very high vitamin E can impair absorption of vitamins A, D, K"},{"location":"vitamins/vitamin_e/#food-sources","title":"Food Sources","text":"Food Serving Vitamin E (mg alpha-tocopherol) Wheat germ oil 1 tbsp ~20.3 mg Sunflower seeds (dry roasted) 28g ~7.4 mg Almonds (dry roasted) 28g ~6.8 mg Sunflower oil 1 tbsp ~5.6 mg Hazelnuts (dry roasted) 28g ~4.3 mg Peanut butter 2 tbsp ~2.9 mg Spinach (cooked) 90g ~3.7 mg Avocado \u00bd fruit ~2.1 mg Mango \u00bd cup ~1.5 mg"},{"location":"vitamins/vitamin_e/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Stable to heat in absence of oxygen \u2014 cooking at moderate temperatures usually does not substantially reduce vitamin E</li> <li>Sensitive to oxygen and UV light \u2014 oils stored in dark, airtight containers preserve vitamin E longer</li> <li>Destroyed by high-heat frying and industrial refining of vegetable oils</li> </ul>"},{"location":"vitamins/vitamin_e/#toxicity","title":"Toxicity","text":"<p>Vitamin E has low toxicity from food sources. The UL applies to supplemental alpha-tocopherol:</p> Risk Details Haemorrhagic risk &gt;1,000 mg/day \u2014 impairs platelet aggregation; increases bleeding, especially with anticoagulants GI symptoms High doses: nausea, diarrhoea, fatigue, headache Prostate cancer risk (possible) SELECT trial suggested increased prostate cancer risk in healthy men taking 400 IU/day \u2014 findings controversial All-cause mortality Some meta-analyses suggest &gt;400 IU/day associated with small increase in all-cause mortality \u2014 avoid supraphysiological doses without indication"},{"location":"vitamins/vitamin_k/","title":"Vitamin K (Phylloquinone / Menaquinone)","text":""},{"location":"vitamins/vitamin_k/#overview","title":"Overview","text":"<p>Vitamin K is a fat-soluble vitamin that exists in two main naturally-occurring forms:</p> <ul> <li>Vitamin K1 (Phylloquinone): Found in green leafy plants; the primary dietary form.</li> <li>Vitamin K2 (Menaquinones, MK-4 to MK-13): Produced by bacteria in fermented foods and the gut; also produced in tissues from K1. Sub-types differ by length of their isoprenoid side chain.</li> <li>MK-4: Short-chain, found in animal products; rapidly converted from K1 in the body</li> <li>MK-7: Long-chain, from natto (fermented soybeans); has longest half-life and greatest bone/vascular effect per dose</li> </ul> <p>A synthetic form, Vitamin K3 (Menadione), is no longer used due to toxicity.</p> <p>Vitamin K was named from the German \"Koagulationsvitamin\" \u2014 its essential role in coagulation.</p>"},{"location":"vitamins/vitamin_k/#requirements-adequate-intake","title":"Requirements (Adequate Intake)","text":"<p>The RDA for vitamin K has not been formally established. An Adequate Intake (AI) is used:</p> Age / Group AI Infants 0\u20136 months 2 mcg/day Infants 7\u201312 months 2.5 mcg/day Children 1\u20133 years 30 mcg/day Children 4\u20138 years 55 mcg/day Children 9\u201313 years 60 mcg/day Adolescents 14\u201318 years 75 mcg/day Adult Men (19+) 120 mcg/day Adult Women (19+) 90 mcg/day Pregnant Women 90 mcg/day Breastfeeding Women 90 mcg/day <p>Tolerable Upper Intake Level (UL): None established for K1 or K2 \u2014 no adverse effects from high dietary or supplemental intake. (K3/menadione is restricted due to toxicity.)</p>"},{"location":"vitamins/vitamin_k/#functions","title":"Functions","text":"<p>Vitamin K functions as a cofactor for gamma-glutamyl carboxylase \u2014 an enzyme that activates vitamin K-dependent (VKD) proteins by carboxylating their glutamic acid residues (Gla), enabling them to bind calcium.</p> <p>Haemostasis (Blood Clotting): Activates clotting factors II (prothrombin), VII, IX, X, and anticoagulant proteins C, S, and Z.</p> Protein Role Prothrombin (Factor II) Converted to thrombin \u2192 activates fibrin clot formation Factor VII Extrinsic pathway protease Factor IX Intrinsic pathway protease Factor X Common pathway protease Protein C + S Natural anticoagulants; prevent excessive clotting Protein Z Inhibits Factor Xa <p>Bone Metabolism: - Osteocalcin (BGP): Binds calcium in bone mineral; promotes bone formation and quality. - Matrix Gla-Protein (MGP): Inhibits arterial calcification \u2014 inhibits calcium crystal formation in vascular tissue.</p> <p>Vascular Health: K2 in particular is critical for preventing arterial stiffness by activating MGP \u2014 carboxylated MGP inhibits calcium deposition in arterial walls.</p>"},{"location":"vitamins/vitamin_k/#cofactors-needed","title":"Cofactors Needed","text":"<p>Vitamin K itself acts as a cofactor. The vitamin K cycle requires:</p> Component Role Gamma-glutamyl carboxylase The enzyme activated by vitamin K; carboxylates VKD proteins Vitamin K epoxide reductase (VKOR) Regenerates active vitamin K from its epoxide form \u2014 target of warfarin CO\u2082 and O\u2082 Co-substrates for the carboxylation reaction Vitamin D Works synergistically \u2014 D induces osteocalcin expression; K activates it Calcium Carboxylated Gla proteins bind calcium; mineral needed for function"},{"location":"vitamins/vitamin_k/#pharmacokinetics","title":"Pharmacokinetics","text":"Parameter K1 (Phylloquinone) K2 / MK-7 Sources Green leafy vegetables Fermented foods, gut bacteria, animal products Absorption 4\u201317% from vegetables; much better from oils/supplements; requires fat + bile Higher from fermented foods Distribution Liver (short-term); cleared rapidly Widely distributed including blood vessels, bone Half-Life ~1\u20132 hours (very short) MK-7: ~3 days; MK-9: ~60 hours Metabolism Converted to inactive urinary metabolites Similar pathway, but slower clearance of long-chain MKs Excretion ~20% urine, 40\u201350% feces via bile Similar Body Stores Very limited; rapid turnover Stored longer due to longer half-life <p>Note: Because K1 has such a short half-life, daily intake is more important. K2 (especially MK-7) has a longer half-life and accumulates over time \u2014 closer to a single weekly dose being effective.</p>"},{"location":"vitamins/vitamin_k/#effects-of-deficiency","title":"Effects of Deficiency","text":"<p>Vitamin K deficiency is rare in healthy adults but can be clinically significant in certain groups.</p> <p>Primary Risk: Haemorrhage - Easy bruising, petechiae (tiny blood spots) - Prolonged bleeding from cuts - Heavy menstrual bleeding - Blood in urine (haematuria) or dark, tarry stools (GI bleeding)</p> <p>Neonatal (Vitamin K Deficiency Bleeding \u2014 VKDB): - Severity ranges from mild bruising to life-threatening intracranial haemorrhage - Newborns are at high risk due to: low transplacental transfer, low breast milk K content, sterile/immature gut (no bacterial K2 synthesis) - Treatment: Single IM injection of vitamin K at birth is standard worldwide</p> <p>Bone Effects (Chronic/Subclinical): - Uncarboxylated osteocalcin impairs bone mineral density - Associated with increased fracture risk</p> <p>At-Risk Groups: - Newborns (not given IM vitamin K at birth) - Patients on long-term antibiotic therapy (reduces gut bacteria K2 production) - Individuals with fat malabsorption disorders (celiac, cystic fibrosis, Crohn's, liver disease) - Patients on warfarin or other vitamin K antagonists</p> <p>Lab Diagnosis: - Prothrombin Time (PT) / INR \u2014 elevated in deficiency - PIVKA-II (Protein Induced by Vitamin K Absence) \u2014 sensitive marker</p>"},{"location":"vitamins/vitamin_k/#treatment-protocols","title":"Treatment Protocols","text":"Condition Protocol Neonatal VKDB prevention (everywhere) 1 mg IM vitamin K at birth Acute K deficiency bleeding 10 mg IV phytomenadione; repeat in 4\u20138 hours if needed Warfarin reversal (urgent) IV vitamin K 1\u20135 mg (slow infusion) + fresh frozen plasma or prothrombin complex concentrate Warfarin reversal (non-urgent) Oral vitamin K 1\u20135 mg; hold warfarin doses Dietary deficiency 90\u2013120 mcg/day oral phylloquinone; dietary improvements Bone health (adjunct) K2 (MK-7) 100\u2013300 mcg/day combined with vitamin D3 and calcium"},{"location":"vitamins/vitamin_k/#drug-interactions","title":"Drug Interactions","text":"Drug Effect Warfarin (Coumadin) Most critical interaction \u2014 warfarin inhibits VKOR, blocking vitamin K recycling. Changes in K intake alter warfarin's anticoagulant effect \u2014 maintain consistent K intake Antibiotics (prolonged) Destroy gut bacteria \u2192 reduced K2 synthesis \u2192 coagulation risk Orlistat Reduces absorption of fat-soluble vitamins including K Cholestyramine / Colestipol Bile acid sequestrants reduce K absorption Mineral oil Reduces K absorption NSAIDs (ibuprofen, naproxen) Unclear anticoagulation interactions; exercise caution Anticonvulsants May induce K catabolism"},{"location":"vitamins/vitamin_k/#food-sources","title":"Food Sources","text":"<p>Vitamin K1 (Phylloquinone):</p> Food Serving Vitamin K1 (mcg) Kale (cooked) 90g ~1,062 mcg Spinach (cooked) 90g ~888 mcg Collard greens (cooked) 90g ~773 mcg Swiss chard 90g ~830 mcg Broccoli (cooked) 90g ~220 mcg Brussels sprouts (cooked) 90g ~219 mcg Cabbage (cooked) 90g ~163 mcg Soybean oil 1 tbsp ~25 mcg <p>Vitamin K2 (Menaquinones):</p> Food Serving Vitamin K2 (mcg) Natto (fermented soybeans) 85g ~850 mcg (MK-7) Hard cheese (e.g., Gouda) 28g ~76 mcg (MK-8/MK-9) Soft cheese (e.g., Brie) 28g ~39 mcg Chicken liver 85g ~12 mcg (MK-4) Egg yolk 1 large ~5 mcg (MK-4)"},{"location":"vitamins/vitamin_k/#storage-stability","title":"Storage &amp; Stability","text":"<ul> <li>Relatively stable to heat \u2014 cooking does not appreciably destroy K1 in vegetables</li> <li>Sensitive to light and UV radiation \u2014 store in opaque containers</li> <li>Keep oils away from light and air to prevent vitamin K degradation</li> <li>Absorption enhanced when consumed with dietary fat (fat-soluble)</li> </ul>"},{"location":"vitamins/vitamin_k/#toxicity","title":"Toxicity","text":"<p>Vitamin K1 and K2 have an extremely low toxicity profile. No Tolerable Upper Intake Level (UL) has been established by the FDA or EFSA for K1 or K2.</p> <ul> <li>High intake from green vegetables or supplements has no reported adverse effects</li> <li>Historical toxicity involved only synthetic Vitamin K3 (Menadione) \u2014 now banned due to haemolytic anaemia and kernicterus in neonates</li> </ul> <p>Cautions: - Patients on warfarin: Large changes in vitamin K intake can destabilise anticoagulation (do not avoid; maintain consistency) - Patients with severe liver disease: Impaired clotting may worsen even with K administration \u2014 specialist management required - Dialysis patients: Should discuss supplementation with their care team</p>"}]}